FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Burton, EA Fink, DJ Glorioso, JC AF Burton, EA Fink, DJ Glorioso, JC TI Gene delivery using herpes simplex virus vectors SO DNA AND CELL BIOLOGY LA English DT Review ID LATENCY-ASSOCIATED TRANSCRIPT; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE RECEPTORS; HOST SHUTOFF FUNCTION; RAT SPINAL-CORD; HEPARAN-SULFATE PROTEOGLYCANS; VESICULAR STOMATITIS-VIRUS; HUMAN TRIGEMINAL GANGLIA; IMMEDIATE-EARLY PROTEINS AB Herpes simplex virus (HSV) is a neurotropic DNA virus with many favorable properties as a gene delivery vector. HSV is highly infectious, so HSV vectors are efficient vehicles for the delivery of exogenous genetic material to cells. Viral replication is readily disrupted by null mutations in immediate early genes that in vitro can be complemented in trans, enabling straightforward production of high-titre pure preparations of nonpathogenic vector. The genome is large (152 Kb) and many of the viral genes are dispensable for replication in vitro, allowing their replacement with large or multiple transgenes. Latent infection with wild-type virus results in episomal viral persistence in sensory neuronal nuclei for the duration of the host lifetime. Transduction with replication-defective vectors causes a latent-like infection in both neural and non-neural tissue; the vectors are non-pathogenic, unable to reactivate and persist long-term. The latency active promoter complex can be exploited in vector design to achieve long-term stable transgene expression in the nervous system. HSV vectors transduce a broad range of tissues because of the wide expression pattern of the cellular receptors recognized by the virus. Increasing understanding of the processes involved in cellular entry has allowed preliminary steps to be taken towards targeting the tropism of HSV vectors. Using replication-defective HSV vectors, highly encouraging results have emerged from recent pre-clinical studies on models of neurological disease, including glioma, peripheral neuropathy, chronic pain and neurodegeneration. Consequently, HSV vectors encoding appropriate transgenes to tackle these pathogenic processes are poised to enter clinical trials. C1 Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Oxford, Dept Clin Neurol, Oxford OX1 2JD, England. VA Pittsburgh Healthcare Syst, CRECC, Pittsburgh, PA USA. RP Glorioso, JC (reprint author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA. OI Burton, Edward/0000-0002-8072-4636 NR 236 TC 55 Z9 56 U1 1 U2 6 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1044-5498 J9 DNA CELL BIOL JI DNA Cell Biol. PD DEC PY 2002 VL 21 IS 12 BP 915 EP 936 DI 10.1089/104454902762053864 PG 22 WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity GA 632NR UT WOS:000180229900006 PM 12573050 ER PT J AU Shimizu, S Maegawa, H Egawa, K Shi, K Bryer-Ash, M Kashiwagi, A AF Shimizu, S Maegawa, H Egawa, K Shi, K Bryer-Ash, M Kashiwagi, A TI Mechanism for differential effect of protein-tyrosine phosphatase 1B on Akt versus mitogen-activated protein kinase in 3T3-L1 adipocytes SO ENDOCRINOLOGY LA English DT Article ID INSULIN SENSITIVITY; RESISTANCE; OBESITY; OVEREXPRESSION; RECEPTOR; TISSUE; PTP-1B; MICE AB We investigated the effect of overexpression of protein-tyrosine phosphatase 1B (PTP1B) on insulin signaling in 3T3-L1 adipocytes. Overexpression of a wild-type PTP1B in L1 adipocytes as well as in L6 myocytes, led to a profound decrease in insulin-stimulated phosphorylation of MAPK. Even though the decrease in insulin receptor substrate protein-1 (IRS-1) phosphorylation was identical with that seen in L6 myocytes, overexpression of wild-type PTP1B in L1 adipocytes was associated with modest impairment of insulin-stimulated AM phosphorylation in addition to a small, but significant, attenuation in insulin-stimulated glucose uptake, when compared with a phosphatase-negative mutant. Regarding the relatively small effect on Akt phosphorylation, we obtained identical results in rat 1 fibroblasts overexpressing human insulin receptor, suggesting that the higher expression levels of insulin receptor and IRS-1 might be responsible. With regard to the large effect on MAPK phosphorylation, we found that PTP1B overexpression led to the impaired phosphorylation of both IRS-1 and Shc, resulting in a decrease in their association with Grb2. Furthermore, phosphorylation of Shc stimulated by platelet-derived growth factor was also attenuated, without any change in its receptors, suggesting that PTP1B directly regulates Shc phosphorylation. These data demonstrate that PTP1B negatively regulates insulin signaling in the MAPK cascade to a much greater extent than the Akt pathway in some cell lines, especially in L1 adipocytes. C1 Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan. Univ Calif Los Angeles, Dept Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA 90095 USA. RP Maegawa, H (reprint author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan. NR 23 TC 19 Z9 19 U1 0 U2 2 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2002 VL 143 IS 12 BP 4563 EP 4569 DI 10.1210/en.2002-220517 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 620QK UT WOS:000179543900011 PM 12446583 ER PT J AU Manetta, J Franz, LH Moon, C Perell, KL Fang, MK AF Manetta, J Franz, LH Moon, C Perell, KL Fang, MK TI Comparison of hip and knee muscle moments in subjects with and without knee pain SO GAIT & POSTURE LA English DT Article DE gait; osteoarthritis; kinetics ID OSTEO-ARTHRITIS; NHANES-I; OSTEOARTHRITIS; GAIT; OBESITY; DISEASE; AGE AB Elderly subjects with and without knee pain walked at a comfortable pace during gait analysis. Comparison of peak hip and knee internal extensor generalized muscle moments (GMMs) during loading response was made between groups. Walking velocity, peak hip internal extensor GMM, and knee range of motion (ROM) were significantly less for the group with knee pain than for the group without pain. Peak hip internal extensor GMM was strongly correlated with velocity, but peak knee internal extensor GMM was not. Knee ROM limitations may account for the increased peak knee internal extensor GMM in the knee pain group. (C) 2002 Published by Elsevier Science B.V. C1 Mt St Marys Coll, Dept Phys Therapy, Los Angeles, CA 90049 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Perell, KL (reprint author), VA Greater Los Angeles Healthcare Syst, Phys Med & Rehabil Dept 117, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 22 TC 12 Z9 12 U1 1 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD DEC PY 2002 VL 16 IS 3 BP 249 EP 254 AR PII S0966-6362(02)00009-7 DI 10.1016/S0966-6362(02)00009-7 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 630RR UT WOS:000180123100004 PM 12443949 ER PT J AU Hwang, IR Kodama, T Kikuchi, S Sakai, K Peterson, LE Graham, DY Yamaoka, Y AF Hwang, IR Kodama, T Kikuchi, S Sakai, K Peterson, LE Graham, DY Yamaoka, Y TI Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1 beta production in Helicobacter pylori infection SO GASTROENTEROLOGY LA English DT Article ID RECEPTOR ANTAGONIST GENE; NECROSIS-FACTOR-ALPHA; ACID-SECRETION; INCREASED RISK; PLASMA-LEVELS; IL-1RA GENE; IL-1-BETA; CANCER; ASSOCIATION; DISEASE AB Background & Aims: Although epidemiological studies suggest that interleukin (IL)-1 genetic polymorphisms are involved in Helicobacter pylori-related gastric carcinogenesis, the data are conflicting regarding the effects of these polymorphisms on IL-1beta production. Methods: IL-1B-511 polymorphism was genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism, and IL-1RN variable number of tandem repeats was determined by PCR. Mucosal IL-1beta levels were measured by enzyme-linked immunosorbent assay. To determine which factors influence mucosal IL-1beta levels, gastric inflammation, and atrophy, multiple regression analyses were performed. Results: We studied 117 H. pylori-infected Japanese patients. Carriers of the IL-1B-511T/T genotype or IL-1RN*2 allele had higher mucosal IL-1beta levels than noncarriers (partial regression coefficient [PRC] SE), TT versus CC: 37.6 +/- 6 [antrum] and 32.1 +/- 6 [corpus] pg/mg protein (P < 0.001 for each), *1/*2 versus *1/*1: 24 < 8 [antrum] (P < 0.01) and 36.5 +/- 7 [corpus] (P < 0.001). Simultaneous carriers of IL-1B-511T/T genotype and IL-1RN*2 allele had the highest IL-1(3 levels (82.9 +/- 12 [antrum] and 87.2 +/- 11 [corpus]) and showed a synergistic effect between 2 loci. The *1/*2 carriers were closely related to atrophy (PRC SE; 0.87 +/- 0.4 [antrum] and 0.93 +/- 0.4 [corpus], P < 0.05), whereas being a carrier of the -511T/T genotype was related to severe gastric inflammation. Conclusions: IL-1 genetic polymorphisms influenced H. pylori-related gastric mucosal IL-1beta levels and were related to gastric inflammation and atrophy, factors thought to be important in gastric carcinogenesis. C1 Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 602, Japan. Aichi Med Univ, Sch Med, Dept Publ Hlth, Aichi, Japan. Baylor Coll Med, Dept Med Mol & Human Genet, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Vet Affairs Med Ctr 111D, Room 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIDDK NIH HHS [DK-53659, DK56338] NR 48 TC 242 Z9 266 U1 0 U2 6 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2002 VL 123 IS 6 BP 1793 EP 1803 DI 10.1053/gast.2002.37043 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 620RA UT WOS:000179545300010 PM 12454835 ER PT J AU Ko, CW Lee, SP AF Ko, CW Lee, SP TI Epidemiology and natural history of common bile duct stones and prediction of disease SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT NIH State-of-the-Science Conference - ERCP for Diagnosis and Therapy CY JAN 14-16, 2002 CL BETHESDA, MARYLAND ID GALLSTONE FORMATION; GALLBLADDER-DISEASE; MR CHOLANGIOGRAPHY; PHYSICAL-ACTIVITY; CHOLESTEROL; CHOLECYSTECTOMY; CHOLELITHIASIS; RISK; CHOLEDOCHOLITHIASIS; WOMEN C1 Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Lee, SP (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. NR 41 TC 34 Z9 40 U1 0 U2 4 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD DEC PY 2002 VL 56 IS 6 SU S BP S165 EP S169 DI 10.1067/mge.2002.129005 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 623WN UT WOS:000179726000005 PM 12447261 ER PT J AU Perell, KL AF Perell, KL TI Assessing the risk of falls: Guidelines for selecting appropriate measures for clinical practice settings SO GENERATIONS-JOURNAL OF THE AMERICAN SOCIETY ON AGING LA English DT Article ID ELDERLY PATIENTS; FUNCTIONAL ASSESSMENT; PREVENTION; PROBABILITY; POPULATION; MOBILITY; INDEX; GAIT; GO C1 Calif State Univ Fullerton, Div Kinesiol & Hlth Promot, Fullerton, CA 92634 USA. VA Greater Los Angeles Healthcare Syst, Dept Med Phys, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Rehabil & Res, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Phys Med & Rehabil, Los Angeles, CA 90024 USA. RP Perell, KL (reprint author), Calif State Univ Fullerton, Div Kinesiol & Hlth Promot, Fullerton, CA 92634 USA. NR 19 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC AGING PI SAN FRANCISCO PA 833 MARKET ST, STE 511, SAN FRANCISCO, CA 94103-1824 USA SN 0738-7806 J9 GENERATIONS JI Generations-J. Am. Soc. Aging PD WIN PY 2002 VL 26 IS 4 BP 66 EP 68 PG 3 WC Gerontology SC Geriatrics & Gerontology GA 725AN UT WOS:000185520600013 ER PT J AU Kercher, BJ Rubenstein, LZ AF Kercher, BJ Rubenstein, LZ TI Home-safety checklists for elders in print and on the Internet SO GENERATIONS-JOURNAL OF THE AMERICAN SOCIETY ON AGING LA English DT Article C1 Los Angeles Cty Dept Hlth Serv, Los Angeles, CA 90012 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. RP Kercher, BJ (reprint author), Los Angeles Cty Dept Hlth Serv, Los Angeles, CA 90012 USA. NR 5 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC AGING PI SAN FRANCISCO PA 833 MARKET ST, STE 511, SAN FRANCISCO, CA 94103-1824 USA SN 0738-7806 J9 GENERATIONS JI Generations-J. Am. Soc. Aging PD WIN PY 2002 VL 26 IS 4 BP 69 EP 74 PG 6 WC Gerontology SC Geriatrics & Gerontology GA 725AN UT WOS:000185520600014 ER PT J AU Foo, NC Ahn, BY Ma, XH Hyun, W Yen, TSB AF Foo, NC Ahn, BY Ma, XH Hyun, W Yen, TSB TI Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein SO HEPATOLOGY LA English DT Article ID FIBROSING CHOLESTATIC HEPATITIS; LARGE ENVELOPE POLYPEPTIDE; ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; BREFELDIN-A; EXPRESSION; ACTIVATION; INFECTION; SECRETION; ANTIGEN AB Fibrosing cholestatic hepatitis (FCH) is a rapidly progressive form of viral hepatitis B that occurs in severely immunosuppressed patients. Pathologically, the liver in FCH is characterized by widespread hepatocyte vacuolization and apoptosis, which, in contrast to more common forms of hepatitis B, is only rarely associated with significant inflammation. Therefore, it has been proposed that, in FCH, hepatocytes may be injured by a direct cytopathic effect of the virus rather than by the host immune response. In support of this hypothesis, we present evidence that cultured hepatoma cells that had been transfected with a plasmid selectively expressing the viral large surface protein form numerous large vacuoles and undergo apoptosis. The similarity of the cytopathology in FCH in vivo and in these transfected cells in vitro strongly implicates the large surface protein as the direct cause of this acute liver disease. This conclusion is further supported by the published demonstration that hepatocytes tend to accumulate large surface protein in FCH, which may reflect its overexpression by the virus. In conclusion, our data implicate the large surface protein as a major cause of hepatocyte injury in fibrosing cholestatic hepatitis. C1 San Francisco VA Med Ctr, Pathol Serv, San Francisco, CA USA. Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA. Korea Univ, Dept Life Sci, Seoul 136701, South Korea. RP Yen, TSB (reprint author), Pathol 113B,4150 Clement St, San Francisco, CA 94121 USA. FU NCI NIH HHS [R01CA55578]; NIDDK NIH HHS [P30DK26743] NR 34 TC 49 Z9 66 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD DEC PY 2002 VL 36 IS 6 BP 1400 EP 1407 DI 10.1053/jhep.2002.36819 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 620MC UT WOS:000179536300013 PM 12447865 ER PT J AU El-Serag, HB Hampel, H Yeh, C Rabeneck, L AF El-Serag, HB Hampel, H Yeh, C Rabeneck, L TI Extrahepatic manifestations of hepatitis C among United States male veterans SO HEPATOLOGY LA English DT Article ID PORPHYRIA-CUTANEA-TARDA; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; ESSENTIAL MIXED CRYOGLOBULINEMIA; ORAL LICHEN-PLANUS; VIRUS-INFECTION; DIABETES-MELLITUS; LYMPHOPROLIFERATIVE DISEASES; PREVALENCE; ASSOCIATION AB Hepatitis C virus (HCV) has been associated with several extrahepatic conditions. To date, most studies assessing these associations involved small numbers of patients and lacked a control group. Using the computerized databases of the Department of Veterans Affairs, we carried out a hospital-based case-control study that examined all cases of HCV-infected patients hospitalized during 1992 to 1999 (n = 34,204) and randomly chosen control subjects without HCV (n = 136,816) matched with cases on the year of admission. The inpatient and outpatient files were searched for several disorders involving the skin (porphyria cutanea tarda [PCT], vitiligo, and lichen planus); renal (membranous glomerulonephritis [GN] and membranoproliferative glomerulonephritis); hematologic (cryoglobulin, Hodgkin's and non-Hodgkin's lymphoma [NHL]); endocrine (diabetes, thyroiditis); and rheumatologic (Sjogren's syndrome). The association between HCV and these disorders was examined in multivariate analyses that controlled for age, gender, ethnicity, and period of military service. Patients in the case group were younger in age (45 vs. 57 years), were more frequently nonwhite (39.6% vs. 26.3%), and were more frequently male (98.1 % vs. 97.0%). A significantly greater proportion of HCV-infected patients had PCT, vitiligo, lichen planus, and cryoglobulinemia. There was a greater prevalence of membranoproliferative GN among patients with HCV but not membranous GN. There was no significant difference in the prevalence of thyroiditis, Sjogren's syndrome, or Hodgkin's or NHL. However, NHL became significant after age adjustment. Diabetes was more prevalent in controls than cases, but no statistically significant association was found after adjustment for age. In conclusion, we found a significant association between HCV infection and PCT, lichen planus, vitiligo, cryoglobulinemia, membranoproliferative GN, and NHL. Patients presenting with these disorders should be tested for HCV infection. C1 Houston Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr, Gastroenterol Sect, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIDDK NIH HHS [K24 DK259318] NR 50 TC 150 Z9 154 U1 2 U2 5 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD DEC PY 2002 VL 36 IS 6 BP 1439 EP 1445 DI 10.1053/jhep.2002.37191 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 620MC UT WOS:000179536300018 PM 12447870 ER PT J AU Acar, B Beaulieu, CF Gokturk, SB Tomasi, C Paik, DS Jeffrey, RB Yee, J Napel, S AF Acar, B Beaulieu, CF Gokturk, SB Tomasi, C Paik, DS Jeffrey, RB Yee, J Napel, S TI Edge displacement field-based classification for improved detection of polyps in CT colonography SO IEEE TRANSACTIONS ON MEDICAL IMAGING LA English DT Article DE computed tomographic colonography (CTC); computer-aided diagnosis; edge displacement fields (EDFs); fiber-optic colonoscopy (FOC) ID COLORECTAL POLYPS; VIRTUAL COLONOSCOPY; SPIRAL CT; COLON; COLOGRAPHY; VISUALIZATION; FEASIBILITY; IMAGES; ENDOSCOPY; DISPLAY AB Colorectal cancer can easily be prevented provided that the precursors to tumors, small colonic polyps, are detected and removed. Currently, the only definitive examination of the colon is fiber-optic colonoscopy, which is invasive and expensive. Computed tomographic colonography (CTC) is potentially a less costly and less invasive alternative to FOC. It would be desirable to have computer-aided detection (CAD) algorithms to examine the large amount of data CTC provides. Most current CAD algorithms have high false positive rates at the required sensitivity levels. We developed and evaluated a postprocessing algorithm to decrease the false positive rate of such a CAD method without sacrificing sensitivity. Our method attempts to model the way a radiologist recognizes a polyp while scrolling a cross-sectional plane through three-dimensional computed tomography data by classification of the changes in the location of the edges in the two-dimensional plane. We performed a tenfold cross-validation study to assess its performance using sensitivity/specificity analysis on data from 48 patients. The mean specificity over all experiments increased from 0.19 (0.35) to 0.47 (0.56) for a sensitivity of 1.00 (0.95). C1 Stanford Univ, LUCAS MRS Ctr, Dept Radiol, Lab 3D, Stanford, CA 94305 USA. Stanford Univ, Dept Elect Engn & Comp Sci, Stanford, CA 94305 USA. Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Acar, B (reprint author), Stanford Univ, LUCAS MRS Ctr, Dept Radiol, Lab 3D, Stanford, CA 94305 USA. RI Acar, Burak/C-7904-2009 OI Acar, Burak/0000-0003-4818-9378 FU NCI NIH HHS [1R01 CA72023] NR 35 TC 63 Z9 66 U1 0 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017-2394 USA SN 0278-0062 J9 IEEE T MED IMAGING JI IEEE Trans. Med. Imaging PD DEC PY 2002 VL 21 IS 12 BP 1461 EP 1467 DI 10.1109/TMI.2002.806405 PG 7 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA 643QC UT WOS:000180871100003 PM 12588030 ER PT J AU Carabello, BA AF Carabello, BA TI Concentric versus eccentric remodeling SO JOURNAL OF CARDIAC FAILURE LA English DT Article; Proceedings Paper CT 17th World Congress of the International-Society-for-Heart-Research CY JUL 12-14, 2001 CL MINNEAPOLIS, MINNESOTA SP Int Soc Heart Res DE hypertrophy; valvular heart disease; and ventricular function ID CHRONIC MITRAL REGURGITATION; HUMAN LEFT-VENTRICLE; AORTIC-STENOSIS; EJECTION PERFORMANCE; WALL STRESS; DETERMINANTS; HYPERTROPHY; AFTERLOAD; PRESSURE; OVERLOAD AB Cardiac hypertrophy has long been recognized as one of the heart's mechanisms for compensating a pressure or volume overload. This compensation has often been viewed as a feedback loop in which the concentric hypertrophy, which develops in pressure overload, normalizes wall stress while the eccentric hypertrophy, which develops in volume overload, allows for an increase in total stroke volume to compensate that which is lost from regulation. While the concentric hypertrophy of pressure overload often is compensatory, many examples are noted where either too little hypertrophy occurs to normalize stress or in other cases, in which hypertrophy exceeds the amount needed for normalization. These observations invoke nonmechanical mechanisms which modulate the degree to which the mechanical signal of pressure overload is translated into an increase in myocardial mass. Hypertrophy develops when the rate of myocardial protein synthesis exceeds that of protein degradation. It now appears that in pressure overload this imbalance is created as synthesis rate increases while in volume overload hypertrophy appears to accrue because degradation rate decreases. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. RP Carabello, BA (reprint author), 2002 Holcombe Blvd,111MCL, Houston, TX 77030 USA. NR 18 TC 49 Z9 52 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2002 VL 8 IS 6 SU S BP S258 EP S263 DI 10.1054/jcaf.2002.129250 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 633DF UT WOS:000180263400004 PM 12555129 ER PT J AU Dorn, GW Mann, DL AF Dorn, GW Mann, DL TI Signaling pathways involved in left ventricular remodeling: Summation SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material C1 Houston Vet Adm Med Ctr, Winters Ctr Heart Failure Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Cincinnati, Dept Med, Cardiol Sect, Cincinnati, OH 45221 USA. RP Mann, DL (reprint author), VA Med Ctr, Cardiol Res, 151C,2002 Holcombe Blvd, Houston, TX 77030 USA. OI Mann, Douglas /0000-0002-2516-0145 NR 0 TC 0 Z9 0 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2002 VL 8 IS 6 SU S BP S387 EP S388 DI 10.1054/jcaf.2002.129266 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 633DF UT WOS:000180263400025 PM 12555150 ER PT J AU Mann, DL AF Mann, DL TI Tumor necrosis factor-induced signal transduction and left ventricular remodeling SO JOURNAL OF CARDIAC FAILURE LA English DT Article; Proceedings Paper CT 17th World Congress of the International-Society-for-Heart-Research CY JUL 12-14, 2001 CL MINNEAPOLIS, MINNESOTA SP Int Soc Heart Res DE tumor necrosis factor; hypertrophy; remodeling; signal transduction ID NF-KAPPA-B; INDUCED CELL-DEATH; MAMMALIAN CARDIAC MYOCYTE; P55 TNF-RECEPTOR; FACTOR-ALPHA; INDUCED APOPTOSIS; TRANSGENIC MICE; CYTOCHROME-C; DILATED CARDIOMYOPATHY; INSULIN ACTION AB Recent studies have identified the importance of biologically active molecules such as neurohormones in disease progression in heart failure. More recently, it has become apparent that in addition to neurohormones another portfolio of biologically active molecules termed cytokines are also expressed in the setting of heart failure. This article will review the role of tumor necrosis factor-induced signal transduction and the process of left ventricular remodeling. C1 Houston Vet Adm Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Mann, DL (reprint author), VA Med Ctr, Cardiol Res, 151C,2002 Holcombe Blvd, Houston, TX 77030 USA. OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [R01 HL58081-01, HL-42250-10/10, P50 HL-O6H, R01 HL61543-01] NR 77 TC 26 Z9 27 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2002 VL 8 IS 6 SU S BP S379 EP S386 DI 10.1054/jcaf.2002.129253 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 633DF UT WOS:000180263400024 PM 12555149 ER PT J AU Teerlink, JR AF Teerlink, JR TI Reversal of left ventricular remodeling: Role of the endothelin pathway SO JOURNAL OF CARDIAC FAILURE LA English DT Article; Proceedings Paper CT 17th World Congress of the International-Society-for-Heart-Research CY JUL 12-14, 2001 CL MINNEAPOLIS, MINNESOTA SP Int Soc Heart Res DE endothelin; heart failure; endothelin antagonists; ventricular volumes; ventricular remodeling ID EXPERIMENTAL HEART-FAILURE; REDUCES INFARCT SIZE; A RECEPTOR BLOCKADE; MYOCARDIAL-INFARCTION; ANGIOTENSIN-II; ETA-RECEPTOR; CARDIAC-FUNCTION; RAT-HEART; ANTAGONIST; BOSENTAN AB Left ventricular remodeling is the result of multiple interrelated processes that evolve through time. The contribution of neurohormones to these processes has been recognized and has lead to important therapeutic advances. Endothelin is a recently discovered neurohormone that has many properties that suggest an important role in the pathophysiology of ventricular remodeling. This review discusses this role of the endothelin pathway in the development of left ventricular remodeling and the evidence that endothelin antagonists can reverse this deleterious process. C1 San Francisco VA Med Ctr, Heart Failure Clin, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Heart Failure Clin, 111C,4150 Clement St, San Francisco, CA 94121 USA. RI Teerlink, John/D-2986-2012 NR 39 TC 6 Z9 6 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2002 VL 8 IS 6 SU S BP S494 EP S499 DI 10.1054/jcaf.2002.129288 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 633DF UT WOS:000180263400039 PM 12555164 ER PT J AU Zile, MR AF Zile, MR TI Structural components of cardiomyocyte remodeling: Summation SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material ID ACTIVATION; HEART C1 Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Zile, MR (reprint author), Med Univ S Carolina, Div Cardiol, Dept Med, Gazes Cardiac Res Inst, 96 Jonathan Lucas St,Suite 816,POB 250623, Charleston, SC 29425 USA. NR 11 TC 1 Z9 1 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD DEC PY 2002 VL 8 IS 6 SU S BP S311 EP S313 DI 10.1054/jcaf.2002.129273 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 633DF UT WOS:000180263400012 PM 12555137 ER PT J AU Goldstein, G Allen, DN Sanders, RD AF Goldstein, G Allen, DN Sanders, RD TI Sensory-perceptual dysfunction in patients with schizophrenia and comorbid alcoholism SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID NEUROLOGIC EXAMINATION ABNORMALITIES; PREVALENCE; ABUSE AB We studied the effects of aging and comorbid alcoholism on sensory-perceptual dysfunction in patients with schizophrenia. Using sensory-perceptual tests from the Halstead-Reitan Neuropsychological Battery included in the Russell, Neuringer, and Goldstein (1970) Perceptual Disorders Index, samples were compared of 54 patients with comorbid schizophrenia and alcoholism. 234 patients with schizophrenia but no history of alcoholism. 132 patients with chronic alcoholism and 171 patient controls. Data were analyzed by one-way analyses of variance followed by Scheffe multiple comparison tests. Numerous significant differences were found among groups. with the comorbid schizophrenia group doing more poorly than the other groups on measures of touch perception and suppression. finger agnosia, and fingertip number writing. Multiple regression analyses using the sensory-perceptual test, its predictor variables and age its the dependent variable indicated that the strength of association between age and the multivariate set of sensory-perceptual test scores was greater in the comorbid schizophrenia group than the noncomorbid schizophrenia, alcoholism and patient control groups. The preponderance of age-related deficits was left-sided, suggesting accelerated decline in right hemispheric function, A comparison of groups across ages on a single Perceptual Disorders Index score showed a substantially larger age effect in the comorbid schizophrenia group relative to the other groups. C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Nevada, Las Vegas, NV 89154 USA. RP Goldstein, G (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, 151R,7180 Highland Dr, Pittsburgh, PA 15206 USA. NR 20 TC 3 Z9 4 U1 1 U2 4 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD DEC PY 2002 VL 24 IS 8 BP 1010 EP 1016 DI 10.1076/jcen.24.8.1010.8378 PG 7 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 642HA UT WOS:000180797100003 PM 12650227 ER PT J AU Tew, JD Mulsant, BH Haskett, RF Dolata, D Hixson, L Mann, JJ AF Tew, JD Mulsant, BH Haskett, RF Dolata, D Hixson, L Mann, JJ TI A randomized comparison of high-charge right unilateral electroconvulsive therapy and bilateral electroconvulsive therapy in older depressed patients who failed to respond to 5 to 8 moderate-charge right unilateral treatments SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ELECTRODE PLACEMENT; MAJOR DEPRESSION; EFFICACY; ECT; ANTIDEPRESSANT AB Background: Electroconvulsive therapy (ECT) is the treatment of choice in some older patients with severe depression. When compared with younger depressed patients, older patients have been shown to be as likely to respond to ECT but more likely to develop cognitive impairment. This study addresses whether adults aged 50 years and over who have already failed to respond to at least 5 moderate-charge right unilateral (RUL) ECT treatments (150% above seizure threshold) are more likely to benefit from a switch to high-charge RUL ECT (450% above threshold) or to bilateral (BL) ECT. Method: Twenty-four patients who were treated with 5 to 8 moderate-charge RUL ECT treatments and who failed to improve sufficiently were randomly assigned to receive either BL ECT (N = 11) or high-charge RUL ECT (N = 13). Depressive (24-item Hamilton Rating Scale for Depression) and cognitive scores (Mini-Mental State Examination [MMSE]) were compared under double-blind conditions at 3 phases of treatment. Results: Patients in the BL ECT group exhibited significantly greater cognitive impairment (mean MMSE score decrease of 1.13) than those receiving high-charge RUL ECT (mean MMSE increase of 1.71). There were no statistically significant differences in clinical response to BL or high-charge RUL ECT (63.6% and 61.5%, respectively) or in depressive symptom remission (18.1% and 46.2%). Conclusion: These results suggest that older patients who fail to respond to moderate-charge RUL ECT may benefit from a switch to high-charge RUL ECT rather than BL ECT. Larger future studies will be needed to compare clinical response in patients switched from moderate-dose RUL ECT to higher-dose RUL or to BL ECT. C1 Univ Pittsburgh, Sch Med, WPIC, Dept Psychiat, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA. RP Mulsant, BH (reprint author), Univ Pittsburgh, Sch Med, WPIC, Dept Psychiat, E837,3811 O Hara St, Pittsburgh, PA 15213 USA. FU NIMH NIH HHS [MH48512, MH01613, MH30915, MH52247, MH61591] NR 13 TC 15 Z9 18 U1 1 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2002 VL 63 IS 12 BP 1102 EP 1105 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 635QK UT WOS:000180410200003 PM 12523868 ER PT J AU Tsuang, J Marder, SR Han, A Hsieh, W AF Tsuang, J Marder, SR Han, A Hsieh, W TI Olanzapine treatment for patients with schizophrenia and cocaine abuse SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID CLOZAPINE; DISORDERS; ALCOHOL C1 Harbor UCLA Med Ctr, Torrance, CA 90509 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Calif Sch Profess Psychol, Los Angeles, CA USA. RP Tsuang, J (reprint author), Harbor UCLA Med Ctr, Torrance, CA 90509 USA. NR 6 TC 28 Z9 29 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2002 VL 63 IS 12 BP 1180 EP 1181 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 635QK UT WOS:000180410200016 PM 12530415 ER PT J AU Heber, R Kellner, M Yehuda, R AF Heber, R Kellner, M Yehuda, R TI Salivary cortisol levels and the cortisol response to dexamethasone before and after EMDR: A case report SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE EMDR; dexamethasone suppression test; cortisol; posttraumatic stress disorder; neuroendocrine ID EYE-MOVEMENT DESENSITIZATION; POSTTRAUMATIC-STRESS-DISORDER; SUPPRESSION; WOMEN AB Trauma survivors with posttraumatic stress disorder (PTSD) have been shown to have lower basal cortisol levels in the urine, plasma, and saliva than in trauma survivors without PTSD, nontraurnatized mentally ill. or healthy subjects. We report on a case study in which we measured pre and post-Eye Movement Desensitization and Reprocessing (EMDR) treatment salivary cortisol levels and salivary cortisol response to 0.50 mg of dexamethasone in a 41-year-old female with chronic PTSD symptoms. Our goal was to determine whether symptom improvement following trauma-focused treatment (EMDR) is associated with changes in basal salivary cortisol or in the cortisol response to dexamethasone administration. Our findings show moderate symptom improvement, an increase in basal cortisol levels, and a more attenuated cortisol hypersuppression in response to the dexamethasone suppression test following EMDR treatment. These results suggest the potential utility of including neuroendocrine measures in the assessment of treatment outcome in PTSD. (C) 2002 Wiley Periodicals, Inc. J Clin Psychol 58: 1521-1530, 2002. C1 CUNY Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Univ Hamburg, Hosp Eppendorf, D-20246 Hamburg, Germany. RP Heber, R (reprint author), 200 E 33rd St,Apt 4-I, New York, NY 10016 USA. FU PHS HHS [R01 49536, R01 49555] NR 27 TC 14 Z9 14 U1 1 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD DEC PY 2002 VL 58 IS 12 BP 1521 EP 1530 DI 10.1002/jclp.10102 PG 10 WC Psychology, Clinical SC Psychology GA 622EH UT WOS:000179633200006 PM 12455019 ER PT J AU Tsuang, JW Eckman, T Marder, S Tucker, D AF Tsuang, JW Eckman, T Marder, S Tucker, D TI Can risperidone reduce cocaine use in substance abusing schizophrenic patients? SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Letter C1 Harbor UCLA Med Ctr, Harbor UCLA Sch Med, Dept Psychiat, Dual Diag Treatment Program, Torrance, CA 90509 USA. W Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Tsuang, JW (reprint author), Harbor UCLA Med Ctr, Harbor UCLA Sch Med, Dept Psychiat, Dual Diag Treatment Program, Torrance, CA 90509 USA. NR 8 TC 23 Z9 23 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2002 VL 22 IS 6 BP 629 EP 630 DI 10.1097/00004714-200212000-00017 PG 2 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 622GW UT WOS:000179639500017 PM 12454567 ER PT J AU Venkataraman, R Kellum, JA Palevsky, P AF Venkataraman, R Kellum, JA Palevsky, P TI Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States SO JOURNAL OF CRITICAL CARE LA English DT Article ID CONTINUOUS HEMOFILTRATION; DELIVERED DIALYSIS; FAILURE; HEMODIALYSIS; MEMBRANES; MULTICENTER; OUTCOMES; CHOICE; TRIAL AB Purpose: We sought to retrospectively review the dosing patterns of continuous renal replacement therapy (CRRT) in patients with acute renal failure (ARF) and determine their actual delivered dosage of CRRT. Materials and Methods: Computerized records of patients (n = 115) who received CRRT for ARF at a single, large, academic, tertiary care hospital from September 1, 1999 through August 31, 2000 were reviewed. The delivered dose of CRRT for each patient/day was calculated from the hourly effluent flow rate, the patient's weight, and the duration (in hours) of CRRT for that day. A mean effluent flow rate (in L/h) for each patient was then calculated. Results: The average number of hours/day on CRRT was 16.1 +/- 3.53 (mean +/- SD), with a mean flow rate (averaged over 24 h) of 1.36 +/- 0.31 L/h. The mean CRRT dose prescribed for these patients was 24.46 +/- 6.13 mL/Kg/h, but the mean dose delivered was only 16.55 +/- 5.41 mL/Kg/h (68% of the prescribed dose, P < .000001). Conclusions: Many patients are prescribed low doses of CRRT Furthermore, the dose delivered is considerably lower than that prescribed. Methods and procedures to extend CRRT system life may improve the dose delivery. Copyright 2002, Elsevier Science (USA). All rights reserved. C1 Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Lab, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Lab, 3550 Terrace St, Pittsburgh, PA 15261 USA. OI Palevsky, Paul/0000-0002-7334-5400 NR 28 TC 59 Z9 63 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD DEC PY 2002 VL 17 IS 4 BP 246 EP 250 DI 10.1053/jcrc.2002.36757 PG 5 WC Critical Care Medicine SC General & Internal Medicine GA 627UB UT WOS:000179953600006 PM 12501152 ER PT J AU George, MS Nahas, Z Kozel, FA Li, XB Denslow, S Yamanaka, K Mishory, A Foust, MJ Bohning, DE AF George, MS Nahas, Z Kozel, FA Li, XB Denslow, S Yamanaka, K Mishory, A Foust, MJ Bohning, DE TI Mechanisms and state of the art of transcranial magnetic stimulation SO JOURNAL OF ECT LA English DT Review DE transcranial; magnetic; stimulation; TMS; therapeutics ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; HUMAN CEREBRAL-CORTEX; LONG-TERM DEPRESSION; MAJOR DEPRESSION; MOTOR CORTEX; ELECTROCONVULSIVE-THERAPY; ELECTRICAL-STIMULATION; PARKINSONS-DISEASE; PREFRONTAL CORTEX AB In 1985, Barker et al. built a transcranial magnetic stimulation (TMS) device with enough power to stimulate dorsal roots in the spine. They quickly realized that this machine could likely also noninvasively stimulate the superficial cortex in humans. They waited a while before using their device over a human head, fearing that the TMS pulse might magnetically "erase the hard-drive" of the human brain. Almost 10 years later, in 1994, an editorial in this journal concerned whether TMS might evolve into a potential antidepressant treatment. In the intervening years, there has been an explosion of basic and clinical research with and about TMS. Studies are now uncovering the mechanisms by which TMS affects the brain. It does not "erase the hard-drive" of the brain, and it has many demonstrated research and clinical uses. This article reviews the major recent advances with this interesting noninvasive technique for stimulating the brain, critically reviewing the data on whether TMS has anticonvulsant effects or modulates cortical-limbic loops. C1 Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St,502 N,IOP, Charleston, SC 29425 USA. RI Kozel, Frank/I-5366-2012 FU NIA NIH HHS [R01-AG40956] NR 139 TC 54 Z9 59 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1095-0680 J9 J ECT JI J. ECT PD DEC PY 2002 VL 18 IS 4 BP 170 EP 181 DI 10.1097/00124509-200212000-00002 PG 12 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA 626DH UT WOS:000179856700002 PM 12468991 ER PT J AU Covinsky, KE AF Covinsky, KE TI Malnutrition and bad outcomes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID PROTEIN-ENERGY UNDERNUTRITION; MEDICAL PATIENTS C1 Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Covinsky, KE (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. NR 14 TC 8 Z9 10 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2002 VL 17 IS 12 BP 956 EP 957 DI 10.1046/j.1525-1497.2002.21011.x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 624ZH UT WOS:000179791800009 PM 12472933 ER PT J AU Boulis, A Goold, S Ubel, PA AF Boulis, A Goold, S Ubel, PA TI Responding to the immunoglobulin shortage: A case study SO JOURNAL OF HEALTH POLITICS POLICY AND LAW LA English DT Article ID GLOBULIN THERAPY AB In fall 1997, a shortage of intravenous immunoglobulin (IVIG) developed in the United States because of increased demand for the product, reduced supply, and product recalls. This shortage is a useful model for understanding how our health care system responds to scarcity. Although the U.S. government took steps to inform the medical community of the shortage, with few exceptions, the government did not respond to the shortage in a timely or effective manner. Instead, it took a relatively passive role, leaving IVIG manufacturers and distributors, health care institutions, and clinicians to fend for themselves. The shortage likely had an uneven impact on patients, based on the relative market strength of the health care institutions in which they received care and the individual patient's ability to absorb the increasing out-of-pocket costs of scarce IVIG. Market mechanisms have now largely alleviated the shortage and significantly reduced its detrimental impact on patients. However, future shortages of IVIG or other scarce medical products, such as vaccines and antibiotics, would benefit from more immediate and coordinated efforts not only to make sure that scarce health care resources are distributed in a just manner but also to identify and remedy the sources of health product supply problems. C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Michigan, Ann Arbor, MI 48109 USA. RP Boulis, A (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. OI Goold, Susan Dorr/0000-0002-0258-9774 FU NCI NIH HHS [R01 CA 78052-01] NR 20 TC 20 Z9 21 U1 1 U2 1 PU DUKE UNIV PRESS PI DURHAM PA 905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA SN 0361-6878 J9 J HEALTH POLIT POLIC JI J. Health Polit. Policy Law PD DEC PY 2002 VL 27 IS 6 BP 977 EP 999 DI 10.1215/03616878-27-6-977 PG 23 WC Health Care Sciences & Services; Health Policy & Services; Medicine, Legal; Social Issues; Social Sciences, Biomedical SC Health Care Sciences & Services; Legal Medicine; Social Issues; Biomedical Social Sciences GA 636TW UT WOS:000180474000004 PM 12556024 ER PT J AU Werth, VP Berlin, JA Callen, JP Mick, R Sullivan, KE AF Werth, VP Berlin, JA Callen, JP Mick, R Sullivan, KE TI Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article; Proceedings Paper CT Annual Scientific Sessions of the Society-for-Investigative-Dermatology CY 2002 CL LOS ANGELES, CALIFORNIA SP Soc Investigat Dermatol DE TNF alpha; apoptosis; lupus; autoimmunity; photosensitivity ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; NECROSIS-FACTOR-ALPHA; CUTANEOUS LUPUS; PROTEIN GENE; RHEUMATOID-ARTHRITIS; KERATINOCYTE APOPTOSIS; COMPLEMENT DEFICIENCY; C1Q; TOXOPLASMOSIS; CELLS AB One theory for the pathophysiology of photosensitive autoimmune skin diseases is that photoinduction of tumor necrosis factor alpha (TNFalpha) secretion leads to keratinocyte apoptosis and translocation of previously sequestered cellular antigens that then activate the immune system. We previously found an association of the overproducing TNFalpha-308 A variant with adult dermatomyositis and with subacute cutaneous lupus erythematosus. Here we focused on mannose binding lectin (MBL), which is one of several proteins involved in clearance of apoptotic cells and could thereby lessen photosensitive autoimmunity. We examined three variant MBL polymorphisms associated with decreased MBL protein (Asp(54) , Glu(57) , and the LX promoter polymorphism) in adult dermatomyositis, subacute cutaneous lupus erythematosus, and discoid lupus, and controls. The variant Asp(54) allele was positively associated with adult dermatomyositis in a dose-responsive fashion (p=0.0004), as was the Glu(57) allele (p=0.004). None of the three variant MBL alleles considered individually was significantly associated with either subacute cutaneous lupus erythematosus or discoid lupus. In adult dermatomyositis patients homozygous for the wild-type TNFalpha-308G allele (GG), i.e., presumably without elevated TNFalpha production, 69% had at least two of the MBL polymorphisms, versus 20% of healthy GG controls (p=0.0011). Combinations of low-producing MBL variants were over-represented in adult dermatomyositis in a dose-responsive fashion (p=0.0002). In adult dermatomyositis patients with one variant TNFalpha-308 A allele (GA), 46% had at least two MBL polymorphisms, versus 7% of GA controls (p=0.0077). Thus, low-producing MBL genes are very strongly associated with adult dermatomyositis. Our model is that genetic polymorphisms leading to overproduction of apoptotic keratinocytes and then impaired clearance of these cells contribute to the pathogenesis of adult dermatomyositis, a photoinduced autoimmune skin disease. C1 Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Louisville, Dept Dermatol, Louisville, KY 40292 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, 2 Rhoads Pavil,36th & Spruce Sts, Philadelphia, PA 19104 USA. OI Sullivan, Kathleen/0000-0003-4018-1646 FU NIAMS NIH HHS [1K24AR002207-01] NR 58 TC 30 Z9 31 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD DEC PY 2002 VL 119 IS 6 BP 1394 EP 1399 DI 10.1046/j.1523-1747.2002.19608.x PG 6 WC Dermatology SC Dermatology GA 625ED UT WOS:000179803200027 PM 12485445 ER PT J AU Antezana, MA Sullivan, SR Usui, ML Gibran, NS Spenny, ML Larsen, JA Ansel, JC Bunnett, NW Olerud, JE AF Antezana, MA Sullivan, SR Usui, ML Gibran, NS Spenny, ML Larsen, JA Ansel, JC Bunnett, NW Olerud, JE TI Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE inflammation; nerves; neuropeptides; substanceP; wound healing ID SUBSTANCE-P; NERVE-FIBERS; ENDOTHELIAL-CELLS; NEUROPEPTIDES; INFLAMMATION; EXPRESSION; MELLITUS; GROWTH; PROLIFERATION; NEUTROPHILS AB Cutaneous sensory nerves mediate inflammation and wound healing by releasing neuropeptides, such as substance P , which stimulates pro-inflammatory responses by keratinocytes, fibroblasts, and endothelial cells. The cell surface enzyme, neutral endopeptidase, degrades substance P , thereby regulating its biologic actions. We hypothesized that neutral endopeptidase enzymatic activity is increased in chronic wounds and skin from subjects with diabetes. We compared cutaneous neutral endopeptidase expression and enzymatic activity between normal controls and diabetic subjects with neuropathy and chronic wounds. Skin samples from subjects with diabetes were taken at the time of amputation for nonhealing ulcers. Skin taken from the ulcer margin, 1 cm from the ulcer (adjacent), and from the most proximal region of the amputated leg were studied. Skin biopsies from the leg of healthy control subjects were also studied. Neutral endopeptidase was localized by immunohistochemistry in all tissue sections. Neutral endopeptidase activity was measured using a fluorimetric assay. The median neutral endopeptidase activity of the ulcer margin was 1.21 x higher (p>0.2) than adjacent skin, 5.26 x higher (p<0.001) than proximal skin, and 15.22 x higher (p<0.001) than control skin. Adjacent skin had a median neutral endopeptidase activity 4.34 x higher (p<0.001) than proximal skin and 12.58 x higher (p<0.001) than control skin. The median neutral endopeptidase activity of proximal skin was 2.90 x higher (p<0.001) than control skin. This elevated neutral endopeptidase activity in the skin and chronic ulcers of subjects with diabetes combined with peripheral neuropathy may contribute to deficient neuroinflammatory signaling and may impair wound healing in subjects with diabetes. C1 Univ Washington, Dept Med Dermatol, Seattle, WA 98195 USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Orthopaed, Seattle, WA USA. Emory Univ, Dept Dermatol, Atlanta, GA 30322 USA. UCSF, Dept Physiol, San Francisco, CA USA. UCSF, Dept Surg, San Francisco, CA USA. RP Olerud, JE (reprint author), Univ Washington, Dept Med Dermatol, 1959 NE Pacific St,Box 356524, Seattle, WA 98195 USA. RI Sullivan, Stephen/C-6389-2013 NR 38 TC 37 Z9 38 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD DEC PY 2002 VL 119 IS 6 BP 1400 EP 1404 DI 10.1046/j.1523-1747.2002.19618.x PG 5 WC Dermatology SC Dermatology GA 625ED UT WOS:000179803200028 PM 12485446 ER PT J AU Small, GW Agdeppa, ED Kepe, V Satyamurthy, N Huang, SC Barrio, JR AF Small, GW Agdeppa, ED Kepe, V Satyamurthy, N Huang, SC Barrio, JR TI In vivo brain imaging of tangle burden in humans SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Alzheimer's disease; positron emission tomography; cerebral glucose metabolism; neurofibrillary tangles ID POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; DIAGNOSIS; PLAQUES; ALLELE; RISK; PET AB Cerebral neurofibrillary tangles (NFTs) accumulate in a predictable sequence decades before the clinical symptoms of Alzheimer's disease emerge, and the degree of tangle degeneration correlates with the severity of cognitive impairment. A valid in vivo marker of tangle burden, therefore, would be useful for presymptomatic and symptomatic disease detection and treatment monitoring. Recent advances using positron emission tomography (PET) indicate the feasibility of in vivo imaging that provides a combined signal of both neurofibrillary tangles and senile plaques. Such results are encouraging that a tangle-specific marker will be found; however, several methodological issues first need to be addressed, including scanner spatial resolution in the relatively small brain regions where tangles accumulate. NFT-specific imaging probes will need to be lipophilic in order to cross the blood-brain barrier and neuronal membranes and have a high binding affinity to NFTs with minimal nonspecific binding, which would result in a high signal-to-background ratio in PET images. C1 Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Aging, Sch Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Small, GW (reprint author), Univ Calif Los Angeles, Inst Neuropsychiat, Dept Psychiat & Biobehav Sci, Sch Med, 760 Westwood Plaza, Los Angeles, CA 90024 USA. FU NIA NIH HHS [AG10123, AG13308]; NIMH NIH HHS [MH52453] NR 27 TC 32 Z9 34 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD DEC PY 2002 VL 19 IS 3 BP 323 EP 327 PG 5 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 633BT UT WOS:000180259900011 PM 12540059 ER PT J AU Kinney, GA Spain, WJ AF Kinney, GA Spain, WJ TI Synaptically evoked GABA transporter currents in neocortical glia SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article ID GAMMA-AMINOBUTYRIC-ACID; PLASMA-MEMBRANE TRANSPORTER; NA+CL COTRANSPORT FUNCTION; CEREBELLAR GRANULE CELLS; HIPPOCAMPAL CA1 NEURONS; RAT CEREBRAL-CORTEX; GLUTAMATE TRANSPORTERS; HORIZONTAL CELLS; PHARMACOLOGICAL CHARACTERIZATION; EXTRASYNAPTIC GLUTAMATE AB The presence, magnitude, and time course of GABA transporter currents were investigated in electrophysiologically characterized neocortical astrocytes in an in vitro slice preparation. On stimulation with a bipolar-tungsten stimulating electrode placed nearby, the majority of cells tested displayed long-lasting GABA transporter currents using both single and repetitive stimulation protocols. Using subtype-specific GABA transporter antagonists, long-lasting GABA transporter cur-rents were identified in neocortical astrocytes that originated from at least two subtypes of GABA transporters: GAT-1 and GAT-2/3. These transporter currents displayed slow rise times and long decay times, contrasting the time course observed for glutamate transporter currents, and are indicative of a long extracellular time course of GABA as well as a role for glial GABA transporters during synaptic transmission. C1 Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98104 USA. Univ Washington, Dept Physiol & Biophys, Sch Med, Seattle, WA 98104 USA. RP Kinney, GA (reprint author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA. FU BLRD VA [I01 BX000386]; NINDS NIH HHS [NS-07395] NR 82 TC 32 Z9 34 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2002 VL 88 IS 6 BP 2899 EP 2908 DI 10.1152/jn.00037.2002 PG 10 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 626HK UT WOS:000179865600002 PM 12466416 ER PT J AU Taylor, AN Romeo, HE Beylin, AV Tio, DL Rahman, SU Hovda, DA AF Taylor, AN Romeo, HE Beylin, AV Tio, DL Rahman, SU Hovda, DA TI Alcohol consumption in traumatic brain injury: Attenuation of TBI-induced hyperthermia and neurocognitive deficits SO JOURNAL OF NEUROTRAUMA LA English DT Article DE alcohol; brain temperature; core body temperature; hyperthermia; neuroprotection; spatial learning; traumatic brain injury ID ACUTE-PHASE RESPONSE; HEAD-INJURY; MODERATE HYPOTHERMIA; CORTICAL CONTUSION; ETHANOL; RATS; INTERLEUKIN-6; TEMPERATURE; INTOXICATION; PROTECTION AB Clinical and animal studies indicate that hyperthermia during or after traumatic brain injury (TBI) is associated with poor outcome. Alcohol intoxication, a complicating risk factor in many cases of head injury, has been found to both worsen or attenuate posttraumatic neural damage and outcome. The purpose of the present study was to determine whether chronic ethanol consumption would affect TBI-induced hyperthermia and deficits in spatial learning. TBI was produced by cortical contusion injury in adult male rats. We first characterized the TBI-induced febrile response using probes implanted intraperitoneally (ip) or intracerebroventricularly for continuous biotelemetric recording of core body and brain temperatures and locomotor activity. In another experiment, rats, implanted with ip probes, were fed a liquid diet containing ethanol (5% w/v, 35% ethano/derived calories); control rats were pair-fed the isocaloric liquid diet (P-P). At 14 days after commencement of diet feeding, TBI or sham surgery was performed, and the ethanol-fed rats were divided into two groups: half were transferred to the isocaloric diet (E-P) and the other half remained on the ethanol-containing diet (E-E). TBI produced a significant febrile response in all rats, that persisted for at least 6 days in the E-P and P-P groups but lasted for only 2 days in the E-E group. When tested at 3-4 weeks after TBI, E-E rats required significantly fewer trials than E-P rats to reach criterion in the Morris water maze. In sum, continuous consumption of ethanol before and after TBI attenuated TBI-induced hyperthermia and deficits in spatial learning. Whereas the results suggest that this ethanol regimen may be neuroprotective, a causal relationship between the two outcomes remains to be determined. C1 Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Taylor, AN (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurobiol, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA. FU NIAAA NIH HHS [AA09850] NR 50 TC 26 Z9 27 U1 1 U2 6 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD DEC PY 2002 VL 19 IS 12 BP 1597 EP 1608 DI 10.1089/089771502762300256 PG 12 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 629UY UT WOS:000180070700007 PM 12542860 ER PT J AU Bolchoz, LJC Gelasco, AK Jollow, DJ McMillan, DC AF Bolchoz, LJC Gelasco, AK Jollow, DJ McMillan, DC TI Primaquine-induced hemolytic anemia: Formation of free radicals in rat erythrocytes exposed to 6-methoxy-8-hydroxylaminoquinoline SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID LIPID-PEROXIDATION; IRON RELEASE; ACTIVATED METMYOGLOBIN; DAPSONE HYDROXYLAMINE; ANILINE METABOLITES; HYDROGEN-PEROXIDE; RED-CELLS; SUPEROXIDE; HEMOGLOBIN; PHENYLHYDROXYLAMINE AB Primaquine is an important antimalarial drug that is often dose-limited in therapy by the onset of hemolytic anemia. We have shown recently that an N-hydroxy metabolite of primaquine, 6-methoxy-8-hydroxylaminoquinoline (MAQ-NOH), is a direct-acting hemolytic agent in rat red cells and that the hemolytic activity of this metabolite is associated with GSH oxidation and oxidative damage to both membrane lipids and skeletal proteins. To determine whether the formation of free radicals may be involved in this process, rat red cells (40% suspensions) were incubated with hemolytic concentrations of MAQ-NOH (150-750 muM) and examined by EPR spectroscopy using 2-ethoxycarbonyl-2-methyl-3,4-dihydro-2H-pyrrole-1-oxide (EMPO) as a spin trap. Addition of MAQ-NOH to red cell suspensions containing 10 mM EMPO gave rise to an EPR spectrum with hyperfine constants consistent with those of an EMPO-hydroxyl radical adduct standard. Of interest, formation of EMPO-OH was constant for up to 20 min and dependent on the presence of erythrocytic GSH. Although no other radical adduct signals were detected in the cells by EPR, spectrophotometric analysis revealed the presence of ferrylhemoglobin, which indicates that hydrogen peroxide is generated under these experimental conditions. The data support the hypothesis that oxygen-derived and possibly other free radicals are involved in the mechanism underlying MAQ-NOH-induced hemolytic anemia. C1 Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA. Med Univ S Carolina, Div Nephrol, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Dept Vet Affairs, Res Serv, Charleston, SC USA. RP McMillan, DC (reprint author), Med Univ S Carolina, Dept Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA. FU NIAID NIH HHS [AI46424]; NIDDK NIH HHS [DK59950] NR 39 TC 18 Z9 20 U1 0 U2 2 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD DEC PY 2002 VL 303 IS 3 BP 1121 EP 1129 DI 10.1124/jpet.102.041459 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 616EN UT WOS:000179290500030 PM 12438535 ER PT J AU Pullman-Mooar, S Mooar, P Sieck, M Clayburne, G Schumacher, HR AF Pullman-Mooar, S Mooar, P Sieck, M Clayburne, G Schumacher, HR TI Are there distinctive inflammatory flares after hylan G-F 20 intraarticular injections? SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE hyaluronic acid injections; viscosupplementation; crystals; osteoarthritis inflammation; hylan G-F 20 ID KNEE OSTEOARTHRITIS; HYALURONAN; VISCOSUPPLEMENTATION; HYALGAN(R); TRIAL AB Objective. This survey was designed to examine features of a group of patients with acute painful joint effusions following hylan G-F 20 (Synvisc(C)) knee injections. Methods. Eight patients with painful local reactions after intraarticular hylan G-F 20 injections for knee ostcoarthritis were evaluated clinically, with detailed synovial fluid analysis, and followed for outcome. Results. Leukocyte counts ranged from 3150 to 103,000/mm(3). Crystals were seen in one patient. Inflammatory knee effusions occurred from I to 48 h after injections, but never with first injections. Synovial fluid volumes were 30 to 71 mm(3). Three patients had shiny clumps (not further characterized) that were noted in leukocytes on Wright stained smears. Most patients were treated with aspiration and depot steroids. Five of the,8 patients had moderate or greater improvement at 6 months. Conclusion. The majority of the occasional dramatic episodes of inflammation after hylan G-F 20 injection do not seem to be related to crystals. No detrimental lasting results were noted. The absence of post-hylan flares following the first intraarticular injection in this small series suggests that sensitization to or accumulation of hylan G-F 20 or its breakdown products may play an etiologic role in these flares. C1 Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Med Coll Penn & Hahnemann Univ, Sch Med, Philadelphia, PA 19102 USA. RP Pullman-Mooar, S (reprint author), Vet Affairs Med Ctr, 151,Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 15 TC 34 Z9 34 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2002 VL 29 IS 12 BP 2611 EP 2614 PG 4 WC Rheumatology SC Rheumatology GA 621YK UT WOS:000179618400025 PM 12465161 ER PT J AU Karlawish, JHT Casarett, DJ James, BD AF Karlawish, JHT Casarett, DJ James, BD TI Alzheimer's disease patients' and caregivers' capacity, competency, and reasons to enroll in an early-phase Alzheimer's disease clinical trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Alzheimer's disease; research ethics; informed consent; decision-making capacity; competency ID INFORMED CONSENT; DEMENTIA; SAFETY AB OBJECTIVES: To examine the capacity, competency, and reasons for enrolling of patients with Alzheimer's disease (AD) and of their caregivers in an early phase AD clinical trial. DESIGN: Interviews were conducted with patients with AD, nondemented older persons, and caregivers. SETTING: Participants' homes. PARTICIPANTS: Fifteen patients with mild to moderate AD, 15 age- and education-matched nondemented older persons, and 15 patient caregivers. MEASUREMENTS: Capacity was measured using the MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR); a study coordinator who reviewed audiotapes of the capacity interviews judged competency, and the reasons for a decision were determined by coding the capacity interviews. RESULTS: On all measures except the ability to make a choice, patients performed worse than controls (understanding: z = 3.2, P = .001; appreciation: z = 2.8, P = .005; reasoning: z = 3.5, P = .0005), and caregivers (understanding: z = 3.8, P = .0002; appreciation: z = 3.0, P = .003; reasoning: z = 3.6, P = .0003). Using the controls' performance to set psychometric criteria to define capacity, the proportions of patients with adequate understanding, appreciation, and reasoning were six of 15 (40%), three of 15 (20%), and five of 15 (33%). All caregivers and nine of the 15 (60%) patients were competent. Reasons for enrolling typically featured the potential benefit to the patients' health or well-being and altruism that was expressed as a desire to help other patients and their families or a desire to contribute to scientific knowledge. CONCLUSIONS: The MacCAT-CR, in particular its understanding scale, is a reliable and valid way to assess patient capacity and competency to enroll in an early-phase clinical trial. Although many patients have significant impairments in their capacity, some mild-stage patients are competent. Reasons for enrolling in an early-phase trial blend an expectation of therapeutic benefit and a desire to help others. C1 Univ Penn, Dept Med, Div Geriatr, Philadelphia, PA 19104 USA. Alzheimers Dis Ctr, Philadelphia, PA USA. Ctr Bioeth, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Karlawish, JHT (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. FU NIA NIH HHS [K01-AG00931, P30-AG01024] NR 28 TC 67 Z9 67 U1 0 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2002 VL 50 IS 12 BP 2019 EP 2024 DI 10.1046/j.1532-5415.2002.50615.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 624EM UT WOS:000179747400015 PM 12473015 ER PT J AU Casarett, DJ Hirschman, KB Miller, ER Farrar, JT AF Casarett, DJ Hirschman, KB Miller, ER Farrar, JT TI Is satisfaction with pain management a valid and reliable quality indicator for use in nursing homes? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain management; satisfaction; nursing homes ID GERIATRIC DEPRESSION SCALE; PATIENT SATISFACTION; RESIDENTS; PREVALENCE; ADULTS; SAMPLE; CARE AB OBJECTIVES: To determine whether satisfaction with pain management can be measured reliably in nursing homes and to gather preliminary data about the validity of satisfaction assessments in this population. DESIGN: Cross-sectional interview study. SETTING: Two urban nursing homes. PARTICIPANTS: Sixty-six nursing home residents with pain. MEASUREMENTS: Overall satisfaction with pain management, satisfaction with pain medication, experiences related to pain management, cognitive function, depressive symptoms, and retest reliability of overall satisfaction rating. RESULTS: Most residents (60/66; 91%) could rate their overall satisfaction with pain management. Overall satisfaction was weakly correlated with pain severity at the time of the interview (Spearman correlation coefficient = -0.28; P = .033) and over the past week (-0.27; P = .038). Overall satisfaction was also negatively associated with the Geriatric Depression Scale score (-0.50; P < .001). Satisfaction with pain medication was associated with several ratings of the medication's beneficial effects, including improved activity, sleep, and speed of relief, but not with the frequency with which it caused side effects. Ratings of overall satisfaction showed good reliability overall (kappa = 0.62; P < .001) and for those with Mini-Mental State Examination scores greater than 21 (kappa = 0.70; P < .001) and 21 or less (kappa = 0.54; P = .004). CONCLUSION: These results suggest that satisfaction with pain management can be measured reliably when residents are able to report their pain, but further research is needed before satisfaction with pain management can be incorporated into routine assessments in nursing homes. C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Social Work, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Casarett, DJ (reprint author), 3615 Chestnut St, Philadelphia, PA 19104 USA. RI Farrar, John/A-1037-2007 OI Farrar, John/0000-0001-8656-5157 NR 27 TC 7 Z9 7 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2002 VL 50 IS 12 BP 2029 EP 2034 DI 10.1046/j.1532-5415.2002.50617.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 624EM UT WOS:000179747400017 PM 12473017 ER PT J AU Hazzard, WR AF Hazzard, WR TI Geriatrics at the crossroads - or simply early in the journey? SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material C1 Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP Hazzard, WR (reprint author), Univ Washington, VA Puget Sound Healthcare Syst, S-GEC-182,4660 S Columbian Way, Seattle, WA 98108 USA. NR 2 TC 6 Z9 6 U1 2 U2 2 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2002 VL 57 IS 12 BP M806 EP M806 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 625JL UT WOS:000179813300012 PM 12456742 ER PT J AU Warshaw, G AF Warshaw, G TI Geriatrics at the crossroads - or simply early in the journey? Commentary SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material C1 Univ Washington, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. RP Warshaw, G (reprint author), Univ Cincinnati, Med Ctr, Off Geriatr Med, 231 Albert Sabin Way,POB 670504, Cincinnati, OH 45267 USA. NR 2 TC 6 Z9 6 U1 1 U2 2 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2002 VL 57 IS 12 BP M806 EP M807 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 625JL UT WOS:000179813300013 PM 12456741 ER PT J AU Rincon-Choles, H Kasinath, BS Gorin, Y Abboud, HE AF Rincon-Choles, H Kasinath, BS Gorin, Y Abboud, HE TI Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy SO KIDNEY INTERNATIONAL LA English DT Article; Proceedings Paper CT 3rd International Conference on Hypertension and the Kidney CY FEB, 2002 CL MADRID, SPAIN SP Hosp Gen, Dept Nephrol, Univ Gregorio Maranon, Spanish Soc Nephrol, Spanish Soc Hypertens, European Renal Assoc, European Dialysis & Transplant Assoc, European Soc Hypertens DE renin-angiotensin system; progressive renal disease; capillary permeability; hemodynamics; fibrosis; AGEs; transforming growth factor-beta ID FACTOR-BETA; GLOMERULAR NEPHRIN; CONVERTING ENZYME; RENAL EXPRESSION; RATS; SYSTEM; RECEPTORS; KIDNEY; KINASE AB The renin-angiotensin system (RAS) and growth factors mediate structural and functional changes during the course of diabetic nephropathy (DN). Studies in humans and experimental models with DN suggest their involvement in the development and progression of DN. Activation of renal tissue RAS and increased expression of growth factors have been demonstrated at early stages of the disease. Angiotensin II and growth factors alter renal hemodynamics and exert trophic changes in renal cells that eventually result in fibrosis through direct mechanisms or through the release of other mediators. Their effects are likely modulated by metabolic changes including high glucose and free fatty acids. While blockade of the RAS ameliorates DN in humans, such evidence for blockade of growth factors is still lacking. It is likely that susceptibility to the development of DN and therapeutic efficacy are modulated by genetic polymorphisms in components of the RAS and growth factors including their receptors and other target molecules. Approaches to understand the intricate relationship between these systems and the mechanism(s) by which they alter capillary permeability and result in structural changes are areas of fruitful investigation. C1 Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Div Nephrol, Dept Med, San Antonio, TX USA. RP Rincon-Choles, H (reprint author), Univ Texas, Hlth Sci Ctr, Div Nephrol, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 33 TC 11 Z9 12 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2002 VL 62 SU 82 BP S8 EP S11 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 613AC UT WOS:000179106800003 ER PT J AU Glassman, PA Simon, B Belperio, P Lanto, A AF Glassman, PA Simon, B Belperio, P Lanto, A TI Improving recognition of drug interactions - Benefits and barriers to using automated drug alerts SO MEDICAL CARE LA English DT Article; Proceedings Paper CT Annual Meeting of the VA HSR&D CY FEB, 2002 CL WASHINGTON, D.C. DE drug therapy; computer assisted; medication errors; attitude of health personnel; attitude toward computers; medical record systems; computerized ID DECISION-SUPPORT SYSTEMS; PHYSICIAN ORDER ENTRY; MEDICATION ERRORS; COMPUTER; CARE; EVENTS; INTERVENTION; IMPLEMENTATION; SATISFACTION; KNOWLEDGE AB BACKGROUND. Clinicians' perceptions about decision support systems may impact the effectiveness of these technologies. OBJECTIVE. To explore clinicians' baseline knowledge of common drug interactions and experiences with automated drug alerts within a provider order entry system as a means to better understand the potential benefits and barriers to using this technology. RESEARCH DESIGN. Cross-sectional survey. SUBJECTS. The study population comprised 263 clinicians practicing within a Southern California Veterans Affairs health care system that used VA's Computerized Patient Record System (CPRS). Response rate was 64%. MEASURES. A 67-item survey (19 questions) was developed to elicit information including: (1) computer use for patient-related activities; (2) recognition of drug interactions; and (3) benefits and barriers to using automated drug alerts. RESULTS. Clinicians correctly categorized 44% (range 11-64%) of all drug-drug pairs, 53% of interacting combinations, and 54% of contraindicated pairs. Providers also correctly categorized 55% (range 24-87%) of 11 drug-disease pairs and 62% of interacting combinations, and 53% of contraindicated pairs. Nearly 90% of clinicians thought drug alerts would be helpful to identify interactions yet 55% of clinicians perceived that the most significant barrier to utilizing existing alerts was poor signal to noise ratio, meaning too many nonrelevant warnings. CONCLUSIONS. Automated drug interaction alerts have the potential to dramatically increase clinicians' recognition of selected drug interactions. However, perceived poor specificity of drug alerts may be an important obstacle to efficient utilization of information and may impede the ability of such alerts to improve patient safety. C1 VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med 111G, VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, VA HSR&D Ctr Excellence Study Healthcare Provider, Sepulveda, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Glassman, PA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med 111G, VA HSR&D Ctr Excellence Study Healthcare Provider, W Los Angeles Campus,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 40 TC 151 Z9 155 U1 4 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2002 VL 40 IS 12 BP 1161 EP 1171 DI 10.1097/01.MLR.0000036429.31445.E0 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 621ZM UT WOS:000179621500004 PM 12458299 ER PT J AU Swarztrauber, K Vickrey, BG Mittman, BS AF Swarztrauber, K Vickrey, BG Mittman, BS TI Physicians' preferences for specialty involvement in the care of patients with neurological conditions SO MEDICAL CARE LA English DT Article DE physician's practice patterns; referral and consultation; knowledge ID PARKINSONS-DISEASE; CAROTID ENDARTERECTOMY; REFERRAL RATES; UNITED-STATES; MANAGED-CARE; FINANCIAL INCENTIVES; MEDICAL OUTCOMES; STROKE PATIENTS; CONSULTATION; PATTERNS AB BACKGROUND. Recent changes in the US health care system have produced questions about the appropriate roles and responsibilities of generalist and specialist physicians within a primary care-centered health care delivery system. OBJECTIVES. To determine neurologists' and primary care physicians' preferences for specialist involvement in the management of common neurologic conditions and the factors influencing these preferences. RESEARCH DESIGN AND SUBJECTS. A self administered questionnaire was developed with the assistance of a multispecialty Advisory Board and sent to a stratified probability sample of 608 family physicians, 624 general internists, and 492 neurologists. MEASURES. The questionnaire contained three clinical scenarios, each followed by questions regarding respondent preferences for the primary care physician to manage alone, curb-side, or refer to a specialist. The questionnaire also contained knowledge questions corresponding to each scenario and physician and practice characteristics questions. RESULTS. Response rate was 60%. For all three scenarios, primary care physicians' preferences to involve a specialist differed substantially from neurologists' preferences, with nearly all neurologists preferring involvement of a specialist. Primary care physicians with less knowledge were more likely to prefer assistance from a neurologist. Physician age and practice setting influenced the type of assistance preferred (curbside vs. referral). Utilization management techniques and financial incentives had little influence on physician preferences to involve a specialist. CONCLUSIONS. The extensive disagreement between primary care physicians' and specialists' preferences for specialty involvement represents cause for considerable concern, supporting further efforts to identify where inappropriate referral processes are occurring and to implement mechanisms for improving the coordination and quality of primary and specialty care. C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Neurol, Portland, OR USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Alzheimers Dis Res Ctr, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. RP Swarztrauber, K (reprint author), Oregon Hlth Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L-226, Portland, OR 97201 USA. NR 71 TC 17 Z9 17 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2002 VL 40 IS 12 BP 1196 EP 1209 DI 10.1097/01.MLR.0000036601.97980.7C PG 14 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 621ZM UT WOS:000179621500007 PM 12458302 ER PT J AU Korthuis, PT Asch, S Mancewicz, M Shapiro, MF Mathews, WC Cunningham, WE McCutchan, JA Gifford, A Lee, ML Bozzette, SA AF Korthuis, PT Asch, S Mancewicz, M Shapiro, MF Mathews, WC Cunningham, WE McCutchan, JA Gifford, A Lee, ML Bozzette, SA TI Measuring medication - Do interviews agree with medical record and pharmacy data? SO MEDICAL CARE LA English DT Article DE HIV disease/AIDS; medications; cohort studies; methodology; epidemiology ID NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; SERVICES UTILIZATION; UNITED-STATES; HIV COST; ANTIRETROVIRAL THERAPY; ENDOMETRIAL CANCER; PRIMARY-CARE; LOW KAPPA; INFORMATION AB BACKGROUND. Medication measurement is crucial in assessing quality for chronic conditions yet agreement of alternate data sources remains uncertain. OBJECTIVES. To evaluate medication agreement between interviews, medical records, and pharmacy data; to assess data source contribution to attributing medication exposure; and to describe the impact of combining data sources on models that predict medication use. RESEARCH DESIGN. Prospective cohort study. SUBJECTS. Probability sample of HIV infected participants in the HIV Cost and Services Utilization Study. MEASURES. Medications reported in 2267 interviews, 1936 medical records, and 457 pharmacy records were compared using crude agreement, kappa, and the proportion of average positive and negative agreement. The percent of medications reported in each source alone was used to assess their relative contri- bution to attributing exposure status. We performed weighted logistic regression in alternate data sources. RESULTS. Kappa varied from 0.38 for nucleoside reverse transcriptase inhibitors to 0.70 for protease inhibitors, when comparing drug classes in interview versus medical record, interview versus pharmacy data, and medical record versus pharmacy data. The percentage of medications reported in medical records was greater than that reported in interviews or pharmacy data. Pharmacy data contributed little to the attribution of medication exposure. Adding medication data to interview data did not appreciably change analytic models predicting medication use. combining data sources does not change the results of analytic models predicting appropriate medication use.CONCLUSIONS. For specific medications, agreement between alternative data sources is fair to substantial, but is lower for key drug classes. Relying on one data source may lead to misclassification of drug exposure status, but combining data sources does not change the results of analytic models predicting appropriate medication use. C1 Univ Calif Los Angeles, Greater Los Angeles VA Syst, Los Angeles, CA 90073 USA. RAND Corp, Hlth Program, Santa Monica, CA 90407 USA. Univ Calif San Diego, San Diego, CA 92103 USA. San Diego VA Hlth Care Syst, San Diego, CA USA. Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. RP Korthuis, PT (reprint author), Univ Calif Los Angeles, Greater Los Angeles VA Syst, Bldg 500,Room 3233,11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. RI Mathews, William/E-4451-2010 OI Mathews, William/0000-0002-2352-0725 FU AHRQ HHS [U01 HS 08578] NR 33 TC 19 Z9 19 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2002 VL 40 IS 12 BP 1270 EP 1282 DI 10.1097/01.MLR.0000036406.61316.B5 PG 13 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 621ZM UT WOS:000179621500013 PM 12458308 ER PT J AU Cooper, RA Spaeth, DM Jones, DK Boninger, ML Fitzgerald, SG Guo, SF AF Cooper, RA Spaeth, DM Jones, DK Boninger, ML Fitzgerald, SG Guo, SF TI Comparison of virtual and real electric powered wheelchair driving using a position sensing joystick and an isometric joystick SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE wheelchair; controls; human-machine interface; human performance; virtual reality AB There are limited interface options for electric powered wheelchairs, which results in the inability of some individuals to drive independently. In addition, the development of new interface technologies will necessitate the development of alternative training methods. This study compares a conventional position sensing joystick to a novel isometric joystick during a driving task in a virtual environment and a real environment. The results revealed that there were few differences in task completion time and rootmean-square error (RMSE) between the two types of joysticks. There were significant correlations between the RMSE in the virtual environment and the real environment for both types of joysticks. The data indicate that performance in the virtual environment was representative of driving ability in the real environment, and the isometric joystick performed comparably to the position sensing joystick. (C) 2002 IPEM. Published by Elsevier Science Ltd. All rights reserved. C1 Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Bioengn & Phys Med & Rehabil, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. Cent Michigan Univ, Dept Ind & Engn Technol, Mt Pleasant, MI 48859 USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, 5044 Forbes Tower, Pittsburgh, PA 15261 USA. OI Boninger, Michael/0000-0001-6966-919X NR 15 TC 30 Z9 30 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 J9 MED ENG PHYS JI Med. Eng. Phys. PD DEC PY 2002 VL 24 IS 10 BP 703 EP 708 AR PII S1350-4533(02)00111-X DI 10.1016/S1350-4533(02)00111-X PG 6 WC Engineering, Biomedical SC Engineering GA 623TE UT WOS:000179718300008 PM 12460730 ER PT J AU Prokunina, L Castillejo-Lopez, C Oberg, F Gunnarsson, I Berg, L Magnusson, V Brookes, AJ Tentler, D Kristjansdottir, H Grondal, G Bolstad, AI Svenungsson, E Lundberg, I Sturfelt, G Jonssen, A Truedsson, L Lima, G Alcocer-Varela, J Jonsson, R Gyllensten, UB Harley, JB Alarcon-Segovia, D Steinsson, K Alarcon-Riquelme, ME AF Prokunina, L Castillejo-Lopez, C Oberg, F Gunnarsson, I Berg, L Magnusson, V Brookes, AJ Tentler, D Kristjansdottir, H Grondal, G Bolstad, AI Svenungsson, E Lundberg, I Sturfelt, G Jonssen, A Truedsson, L Lima, G Alcocer-Varela, J Jonsson, R Gyllensten, UB Harley, JB Alarcon-Segovia, D Steinsson, K Alarcon-Riquelme, ME TI A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans SO NATURE GENETICS LA English DT Article ID ALLELE-SPECIFIC HYBRIDIZATION; SIB-PAIR FAMILIES; HUMAN PD-1 GENE; AUTOIMMUNE-DISEASES; CROHNS-DISEASE; T-LYMPHOCYTES; EXPRESSION; IMMUNORECEPTOR; TOLERANCE; PEDIGREES AB Systemic lupus erythematosus (SLE, OMIM 152700) is a complex autoimmune disease that affects 0.05% of the Western population, predominantly women(1-4). A number of susceptibility loci for SLE have been suggested in different populations, but the nature of the susceptibility genes and mutations is yet to be identified(5-9). We previously reported a susceptibility locus (SLEB2) for Nordic multi-case families(9,10). Within this locus, the programmed cell death 1 gene (PDCD1, also called PD-1) was considered the strongest candidate for association with the disease(11-14). Here, we analyzed 2,510 individuals, including members of five independent sets of families as well as unrelated individuals affected with SLE, for single-nucleotide polymorphisms (SNPs) that we identified in PDCD1. We show that one intronic SNP in PDCD1 is associated with development of SLE in Europeans (found in 12% of affected individuals versus 5% of controls; P=0.00001, r.r. (relative risk)=2.6) and Mexicans (found in 7% of affected individuals versus 2% of controls; P=0.0009, r.r.=3.5). The associated allele of this SNP alters a binding site for the runt-related transcription factor 1 (RUNX1, also called AML1) located in an intronic enhancer, suggesting a mechanism through which it can contribute to the development of SLE in humans. C1 Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Med Genet Sect, S-75185 Uppsala, Sweden. Everygene AB, Uppsala, Sweden. Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Sect Pathol, S-75185 Uppsala, Sweden. Univ Uppsala, Evolut Biol Ctr, Dept Comparat Physiol, S-75185 Uppsala, Sweden. Karolinska Inst, Rheumatol Unit, Stockholm, Sweden. Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden. Karolinska Inst, Ctr Genom & Bioinformat, Stockholm, Sweden. Labdpitalinn, Dept Rheumatol, Reykjavik, Iceland. Labdpitalinn, Ctr Rheumatol Res, Reykjavik, Iceland. Univ Bergen, Broegelmann Res Lab, Bergen, Norway. Haukeland Univ Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway. Univ Lund Hosp, Dept Clin Immunol, S-22185 Lund, Sweden. Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden. Inst Nacl Ciencias Med & Nutr Salvador Zubirdan, Dept Immunol & Rheumatol, Mexico City, DF, Mexico. Univ Oklahoma, Dept Med, Arthrit & Immunol Program, Oklahoma Med Res Fdn, Oklahoma City, OK USA. US Dept Vet Affairs, Oklahoma City, OK USA. RP Alarcon-Riquelme, ME (reprint author), Univ Uppsala, Rudbeck Labs, Inst Genet & Pathol, Med Genet Sect, Dag Hammarsjolds Vag 20, S-75185 Uppsala, Sweden. RI Hoiom, Veronica/F-4153-2012 OI Prokunina-Olsson, Ludmila/0000-0002-9622-2091; Svenungsson, Elisabet/0000-0003-3396-3244; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154 NR 29 TC 469 Z9 488 U1 3 U2 21 PU NATURE AMERICA INC PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD DEC PY 2002 VL 32 IS 4 BP 666 EP 669 DI 10.1038/ng1020 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA 621MH UT WOS:000179593000022 PM 12402038 ER PT J AU Jara, A Chacon, C Felsenfeld, AJ AF Jara, A Chacon, C Felsenfeld, AJ TI Hyperphosphatemia modestly retards parathyroid hormone suppression during calcitriol-induced hypercalcemia in normal and azotemic rats SO NEPHRON LA English DT Article DE calcitriol; hyperparathyroidism; parathyroid hormone; phosphate; renal failure ID VITAMIN-D METABOLITES; TISSUE IN-VITRO; SECONDARY HYPERPARATHYROIDISM; GENE-EXPRESSION; SENSING RECEPTOR; CALCIUM RECEPTOR; PTH SECRETION; RENAL-FAILURE; UREMIC RATS; PHOSPHATE AB Background/Aims: In in vitro studies, a high phosphate concentration has been shown to directly stimulate parathyroid hormone (PTH) secretion in a normal calcium concentration and to reduce PTH suppression in a high calcium concentration. In hemodialysis patients during dialysis-induced hypercalcemia, the effect of hyperphosphatemia on PTH secretion was less than in vitro studies. Our goal was to determine whether hyperphosphatemia retards PTH suppression during calcitriol-induced hypercalcemia in azotemic rats with hyperparathyroidism. Methods: Rats underwent a two-stage 5/6 nephrectomy or sham operations. After surgery, rats received a high phosphate diet (P 1.2%, Ca 0.6%) for 4 weeks to induce hyperparathyroidism and then were placed on a normal diet (P 0.6%, Ca 0.6%) for two additional weeks to normalize serum calcium values in azotemic rats. At week 7, rats were divided into five groups and before sacrifice received at 24-hour intervals, three doses of calcitriol (CTR) or its vehicle. The five groups and dietary phosphate content were: group 1 - normal renal function (NRF) + 0.6% P + vehicle; group 2 - NRF + 0.6% P + CTR; group 3 - renal failure (RF) + 0.6% P + vehicle; group 4 RF + 1.2% P + CTR; and group 5 - RF + 0.6% P + CTR. Results: In the two CTR-treated groups with marked hypercalcemia (groups 2 and 5), 15.52 +/- 0.26 and 15.12 +/- 0.13 mg/dl, respectively, stepwise regression showed that hyperphosphatemia retarded PTH suppression. When the two azotemic groups treated with CTR (groups 4 and 5) were combined to expand the range of serum calcium values, stepwise regression showed that hypercalcemia suppressed and hyperphosphatemia modestly retarded PTH suppression. Similarly, in groups 4 and 5 combined, correlations were present between PTH and both serum calcium (r = -0.70, p < 0.001) and serum phosphate (r = 0.64, p = 0.001). Conclusions: Hypercalcemia and high doses of calcitriol markedly reduced PTH secretion in azotemic rats despite severe hyperphosphatemia. Even though hyperphosphatemia did retard PTH suppression during hypercalcemia, its effect was small. Copyright (C) 2002 S. Karger AG, Basel. C1 Pontificia Univ Catolica Chile, Dept Nephrol, Santiago, Chile. W Los Angeles VA Med Ctr, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Jara, A (reprint author), Pontificia Univ Catolica Chile, Dept Nephrol, Marcoleta 345, Santiago, Chile. NR 35 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-2766 J9 NEPHRON JI Nephron PD DEC PY 2002 VL 92 IS 4 BP 883 EP 888 DI 10.1159/000065454 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 611FZ UT WOS:000179006900019 PM 12399635 ER PT J AU Pekary, AE Senanayake, S Sattin, A AF Pekary, AE Senanayake, S Sattin, A TI Cocaine regulates TRH-related peptides in rat brain SO NEUROCHEMISTRY INTERNATIONAL LA English DT Article DE limbic system; cocaine; TRH-like peptides; HPLC; radioimmunoassay ID THYROTROPIN-RELEASING-HORMONE; MONKEY PREFRONTAL CORTEX; SEIZURES INCREASE LEVELS; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-BLOOD-FLOW; NUCLEUS-ACCUMBENS; MICE LACKING; NORMAL WOMEN; SUBSTANCE-P; DOPAMINE AB Cocaine administration has previously been reported to alter the levels of prepro-TRH mRNA and TRH (pGlu-His-Pro-NH2) in the limbic system of rats (J. Neurochem. 60 (1993) 115 1). We have now demonstrated that a previously unrecognized family of TRH-like peptides is involved in the actions of cocaine. We treated young adult male Sprague-Dawley rats (five per group, 250 g body weight at sacrifice) for 2 weeks with either twice daily injections of saline (control group), twice daily injections of 15 mg/kg cocaine until sacrifice (chronic group), single injection of 15 mg/kg cocaine 2 h prior to sacrifice (acute group) or chronic cocaine injections replaced by saline injections 72 h prior to sacrifice (withdrawal group (WD)). Twelve different brain regions were dissected and immunoreactivity for TRH (TRH-IR), EEP (pGlu-Glu-Pro-NH2; EEP-IR) and related peptides were measured by radioimmunoassay (RIA). High pressure liquid chromatography (HPLC) revealed that in many brain regions EEP-IR and TRH-IR consisted of a mixture of TRH, and other TRH-like peptides including EEP, pGlu-Val-Pro-NH2) (Val(2)-TRH), pGlu-Tyr-Pro-NH2 (Tyr(2)-TRH), pGlu-Leu-Pro-NH2 (Leu(2)-TRH), and pGlu-Phe-Pro-NH2 (Phe(2)-TRH). Following i.p. injection, these TRH-like peptides readily crossed the blood-brain barrier but cleared very slowly from brain tissues. Acute cocaine produced a 4.1-fold increase in Val(2)-TRH level in medulla while Val(2)-TRH and Tyr(2)-TRH, increased 6.2- and 2.9-fold, respectively in pyriform cortex PYR. TRH and Leu(2)-TRH, decreased 47 and 93%, respectively in the nucleus accumbens (AM) while other EEP-IR peaks decreased 50-100% consistent with the significant decrease in total EEP-IR in the AMs following acute cocaine treatment. Because 2 h is too short a time to alter levels of neuropeptides via changes in the rate of biosynthesis, the acute cocaine-induced elevation or reduction in TRH and related peptides is most likely due to suppression or stimulation, respectively, of the corresponding peptide secretion rate. Because TRH and TRH-like peptides have antidepressant, analeptic and euphorigenic properties, we conclude that these endogenous substances are potential mediators of both the cocaine "high" and withdrawal symptoms. Published by Elsevier Science Ltd. C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Biobehav Sci & Brain Res Inst, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv, Bldg 114,Room 229,111301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM epekary@ucla.edu NR 75 TC 13 Z9 13 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0197-0186 EI 1872-9754 J9 NEUROCHEM INT JI Neurochem. Int. PD DEC PY 2002 VL 41 IS 6 BP 415 EP 428 AR PII S0197-0186(02)00022-0 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 598VR UT WOS:000178297600006 ER PT J AU Walker, RH Friedman, J Wiener, J Hobler, R Gwinn-Hardy, K Adam, A DeWolfe, J Gibbs, R Baker, M Farrer, M Hutton, M Hardy, J AF Walker, RH Friedman, J Wiener, J Hobler, R Gwinn-Hardy, K Adam, A DeWolfe, J Gibbs, R Baker, M Farrer, M Hutton, M Hardy, J TI A family with a tau P301L mutation presenting with parkinsonism SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE genetics; parkinsonism; progressive supranuclear palsy; dementia; tau ID FRONTOTEMPORAL DEMENTIA; EXTENDED HAPLOTYPE; GENE; DISEASE; CHROMOSOME-17; ASSOCIATION; POLYMORPHISMS; PHENOTYPE; MISSENSE; INSOMNIA AB We report a sib-pair with a tau P301L mutation. Unlike most previous cases with this mutation, parkinsonism, rather than dementing features were the predominant and presenting feature. We have also observed that the P301L mutation has occurred on the HI tau haplotype background. The haplotype background may influence the disease phenotype since in many previous Caucasian families with the P301L mutation, the haplotype background has been H2. (C) 2002 Elsevier Science Ltd. All rights reserved. C1 Mayo Clin Jacksonville, Labs Neurogenet, Dept Neurosci, Jacksonville, FL 32224 USA. Bronx Vet Adm Med Ctr, Dept Neurol, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Brown Univ, Sch Med, Dept Clin Neurosci, Providence, RI 02912 USA. Mem Hosp Rhode Isl, Div Neurol, Pawtucket, RI 02860 USA. VA Hudson Valley Healthcare Syst, Dept Psychol, Castle Point, NY 12511 USA. NINDS, Neurogenet Lab, Bethesda, MD 20892 USA. RP Hardy, J (reprint author), Mayo Clin Jacksonville, Labs Neurogenet, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. RI Gwinn, Katrina/C-2508-2009; Hardy, John/C-2451-2009 NR 20 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD DEC PY 2002 VL 9 IS 2 BP 121 EP 123 AR PII S1353-8020(02)00003-2 DI 10.1016/S1353-8020(02)00003-2 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 619LM UT WOS:000179477500010 PM 12473404 ER PT J AU Sipols, AJ Bayer, J Bennett, R Figlewicz, DP AF Sipols, AJ Bayer, J Bennett, R Figlewicz, DP TI Intraventricular insulin decreases kappa opioid-mediated sucrose intake in rats SO PEPTIDES LA English DT Article DE insulin; kappa opioid; palatability; food intake ID FOOD-INTAKE; SELF-STIMULATION; MESSENGER-RNA; PALATABILITY; BRAIN; DYNORPHIN-(1-13); SENSITIZATION; HYPERPHAGIA; SELECTION; AGONISTS AB The hormone insulin acts in the central nervous system (CNS) as a regulator of body adiposity and food intake. Recent work from our laboratory has provided evidence that one way by which insulin may decrease food intake is by decreasing the rewarding properties of food. Evidence from others suggests that endogenous opioids may mediate the palatable properties of foods, and insulin may decrease nonfood-related reward via interaction with some CNS kappa opioid systems. In the present study we examined the ability of insulin to interact with exogenous or endogenous kappa opioids to modulate feeding of palatable sucrose pellets by nondeprived rats. Insulin (5 mU intracerebroventricular (i.c.v.), t = -3 h) completely reversed the ability of the exogenous kappa agonist U50,488 (26 mug, i.c.v., t = -15 min) to stimulate 90-min sucrose feeding (211 +/- 32% reduced to 125 +/- 23% of 90-min baseline intake). Further, i.c.v. insulin (5 mU, t = -3 h) interacted with a subthreshold dose of the kappa receptor antagonist norbinaltorphimine (5 mug, i.c.v., t = -15 min) to decrease the 90-min sucrose intake baseline (77 +/- 11% versus 109 +/- 10% of 90 min baseline intake, insulin/norbinaltorphimine versus norbinaltorphimine). Together these studies provide new evidence that insulin in the CNS may decrease the action of CNS kappa opioid system(s) that mediate palatable feeding. (C) 2002 Elsevier Science Inc. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Seattle, WA 98108 USA. Univ Latvia, Inst Clin & Expt Med, Riga, Latvia. Univ Latvia, Fac Med, Riga, Latvia. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, 1660 So Columbian Way,Seattle Div, Seattle, WA 98108 USA. FU NIDDK NIH HHS [R01 DK40963] NR 34 TC 26 Z9 30 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD DEC PY 2002 VL 23 IS 12 BP 2181 EP 2187 AR PII S0196-9781(02)00246-2 DI 10.1016/S0196-9781(02)00246-2 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 641WJ UT WOS:000180769800013 PM 12535697 ER PT J AU Mata, M Glorioso, JC Fink, DJ AF Mata, M Glorioso, JC Fink, DJ TI Targeted gene delivery to the nervous system using herpes simplex virus vectors SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE gene therapy; herpes simplex virus; neurotrophic factor; neuropathy; pain; enkephalin ID MEDIATED EXPRESSION; DELETION MUTANTS; MOTOR-NEURONS; TYPE-1 ICP27; DEGENERATION; BCL-2; PROTEINS AB Neurotrophic factors are highly potent macromolecules with protean effects. Although they are highly effective in vitro and in animal models in vivo, they have not been successfully applied to the treatment of human disease. Our laboratories have developed recombinant herpes simplex virus (HSV)-based vectors, that we have demonstrated may be used to deliver and express neurotrophic factor genes in dorsal root ganglion neurons to protect against the development of neuropathy in animal models, without causing systemic side effects. In a similar fashion, we have demonstrated that a vector expressing proenkephalin to mediate the release of opioid peptides from afferent nerve terminals in the spinal cord can be used to produce a localized antinociceptive effect in animal models of pain. Targeted gene delivery using HSV-based vectors offers a means to utilize short-lived peptides to produce specific effects in the nervous system. (C) 2002 Elsevier Science Inc. All rights reserved. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, GREC, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Biochem & Mol Genet, Pittsburgh, PA 15261 USA. RP Fink, DJ (reprint author), S-520 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. NR 21 TC 11 Z9 12 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD DEC PY 2002 VL 77 IS 4-5 BP 483 EP 488 AR PII S0031-9384(02)00908-3 DI 10.1016/S0031-9384(02)00908-3 PG 6 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 638TZ UT WOS:000180588400006 PM 12526987 ER PT J AU Koepsell, T Reiber, G Simmons, KW AF Koepsell, T Reiber, G Simmons, KW TI Behavioral risk factors and use of preventive services among veterans in Washington State SO PREVENTIVE MEDICINE LA English DT Article DE medicine; preventive; veterans; health behavior ID SMOKING AB Background. Little is known about the special preventive health needs of U.S. veterans and the 3.6 million users of VA health care. Methods. The Washington State version of the 1999 Behavioral Risk Factor Survey included three new questions about veteran status and use of VA health care. Data on this population-based sample of 3,608 adults were used to compare sociodemographic, health, and behavioral characteristics between veterans and non-veterans and between VA users and nonusers. Results. Veterans were nearly 13 years older than nonveterans. VA users were socioeconomically worse off and had poorer health status than nonusers. Current smoking among males was more common among veterans than among nonveterans (24% vs 18%). This difference persisted after controlling for age, race, education, and income and held across all age groups. Use of several screening tests varied little in relation to veteran or VA user status. Conclusions. The BRFSS has become a rich source of data on veteran health. Veterans and VA users have distinct sociodemographic profiles that must be considered when comparing health-related characteristics. Cigarette smoking is especially prevalent among veterans-an excess unexplained by sociodemographic differences. (C) 2002 American Health Foundation and Elsevier Science (USA). C1 US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Washington State Dept Hlth, Ctr Hlth Stat, Olympia, WA 98504 USA. RP Koepsell, T (reprint author), VAPSHCS, Seattle Epidemiol Res & Informat Ctr, Box 152E,1660 S Columbia Way, Seattle, WA 98108 USA. NR 8 TC 24 Z9 24 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD DEC PY 2002 VL 35 IS 6 BP 557 EP 562 DI 10.1006/pmed.2002.1121 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 621ZJ UT WOS:000179621100004 PM 12460523 ER PT J AU Thompson, R Kane, VR Sayers, SL Brown, GK Coyne, JC Katz, IR AF Thompson, R Kane, VR Sayers, SL Brown, GK Coyne, JC Katz, IR TI An assessment of suicide in an urban VA Medical Center SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID OF-VETERANS-AFFAIRS; COMPLETED SUICIDE; PSYCHIATRIC-PATIENTS; AFFECTIVE-DISORDERS; PREVENTION CENTERS; YOUNG MEN; AGE; DEPRESSION; POPULATION; PREDICTION AB This study characterizes those patients of an urban VA Medical Center (VAMC) who had committed suicide. A cause-of-death search of the 1,075 veterans from the VAMCs case rolls who died during 1998 was conducted. For confirmed and suspected suicides, a chart review was conducted, noting psychiatric history and recent contact with the VAMC. Nineteen patients were either confirmed or suspected suicides. Few of these patients had made recent contact with the VAMC, although the majority of them had received psychiatric services from the VA at some time. The proportion of deaths due to suicide was similar in African American and White patients. Rates of suicide were elevated, primarily because of the high proportion of patients receiving psychiatric treatment. Elderly suicides were less likely to have had psychiatric services or previous psychiatric diagnoses than were younger suicides. Patients with past contact with psychiatric services may be especially at risk of suicide, particularly as contact with these services diminishes. Elderly patients in medical settings with undiagnosed or undertreated psychiatric disorders are also likely to have elevated risk for suicide. These findings demonstrate the importance of acknowledging that risk factors for suicide are specific to sites or populations; this information can be used in allocating resources for developing site-specific strategies for prevention. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Mental Illnes Res Educ & Clin Ctr, Philadelphia, PA USA. RP Thompson, R (reprint author), Univ Penn, Dept Psychiat, 11 Gates HUP,3400 Spruce St, Philadelphia, PA 19104 USA. RI Thompson, Richard/G-5408-2011 OI Thompson, Richard/0000-0003-0127-513X NR 36 TC 5 Z9 5 U1 1 U2 1 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PD WIN PY 2002 VL 65 IS 4 BP 326 EP 337 DI 10.1521/psyc.65.4.326.20234 PG 12 WC Psychiatry SC Psychiatry GA 631AU UT WOS:000180145100008 ER PT J AU Monga, TN AF Monga, TN TI Special issue: Sexuality and cancer - Introduction SO SEXUALITY AND DISABILITY LA English DT Editorial Material C1 Houston VA Med Ctr, Rehabil Care Line Execut RCL117, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Monga, TN (reprint author), Houston VA Med Ctr, Rehabil Care Line Execut RCL117, 2002 Holcomb Blvd, Houston, TX 77030 USA. NR 6 TC 0 Z9 0 U1 0 U2 1 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD WIN PY 2002 VL 20 IS 4 BP 235 EP 237 DI 10.1023/A:1021653312501 PG 3 WC Rehabilitation SC Rehabilitation GA 639EA UT WOS:000180613600002 ER PT J AU Henson, HK AF Henson, HK TI Breast cancer and sexuality SO SEXUALITY AND DISABILITY LA English DT Article DE breast cancer; sexuality; quality of life; female self-concept ID QUALITY-OF-LIFE; BODY-IMAGE; PSYCHOSOCIAL-ASPECTS; OVARIAN FAILURE; FOLLOW-UP; MASTECTOMY; THERAPY; SURGERY; IMPACT; RECONSTRUCTION AB Breast cancer is the most common form of cancer among women today. With early detection and advanced treatment options, survival rates are continuing to improve, but not without some long-term physical and emotional side effects. This article reviews the eftects. of breast cancer in general and breast cancer treatment specifically on sexuality in cancer survivors. How the cancer and its treatment may affect women at different ages is discussed. The psychological impact of cancer therapy on both the patient and her spouse are noted; and options for treatment interventions are reviewed. C1 Houston VA Med Ctr, Rehabil Care Line RCL117, Houston, TX 77030 USA. Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. RP Henson, HK (reprint author), Houston VA Med Ctr, Rehabil Care Line RCL117, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 90 TC 47 Z9 48 U1 5 U2 10 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD WIN PY 2002 VL 20 IS 4 BP 261 EP 275 DI 10.1023/A:1021657413409 PG 15 WC Rehabilitation SC Rehabilitation GA 639EA UT WOS:000180613600004 ER PT J AU Monga, U AF Monga, U TI Sexual functioning in cancer patients SO SEXUALITY AND DISABILITY LA English DT Review DE cancer; sexual functioning; infertility; pregnancy ID SILDENAFIL CITRATE VIAGRA; INDUCED OVARIAN FAILURE; TESTICULAR CANCER; HODGKINS-DISEASE; SEMEN CRYOPRESERVATION; ERECTILE DYSFUNCTION; RADIATION-THERAPY; PROSTATE-CANCER; RETROPERITONEAL LYMPHADENECTOMY; CYCLOPHOSPHAMIDE THERAPY AB Controversy exists regarding the extent and nature of sexual problems in cancer patients. The incidence of sexual problems varies in published studies irrespective of the cancer site. Most of the studies are retrospective and descriptive in design and many do not take into account the preexisting physical, psychosocial, sexual, and marital problems. However, it is clear that sexual problems are common in cancer patients and may be caused by all the available treatment options. Management of sexual problems in this patient population has not been systematically studied. This article reviews prevalence of sexual problems that result from various treatment modalities (such as surgery, radiotherapy, and chemotherapy) and describes guidelines for management of sexuality related issues in cancer survivors. C1 Houston VA Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. RP Monga, U (reprint author), Radiotherapy Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 126 TC 11 Z9 12 U1 5 U2 7 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD WIN PY 2002 VL 20 IS 4 BP 277 EP 295 DI 10.1023/A:1021609530248 PG 19 WC Rehabilitation SC Rehabilitation GA 639EA UT WOS:000180613600005 ER PT J AU Tan, G Waldman, K Bostick, R AF Tan, G Waldman, K Bostick, R TI Psychosocial issues, sexuality, and cancer SO SEXUALITY AND DISABILITY LA English DT Article DE psychological; sexuality; cancer ID LONG-TERM SURVIVORS; QUALITY-OF-LIFE; BREAST-CANCER; PROSTATE-CANCER; GYNECOLOGIC CANCER; SELF-SCHEMA; DEPRESSION; WOMEN; MEN; DYSFUNCTION AB It is well-documented in the literature that psychosocial factors play a significant role in the development and progress of, adaptation to, and survival from cancer Cancer and its treatment often lead to psychiatric co-morbidity, precipitate spiritual crisis, compel lifestyle changes, and disrupt family and social relationships. One area most affected by cancer is quality of life, including sexual functioning. Cancer treatment may increase risk of infertility, difficulty with intimacy and sexuality, employment discrimination, increased general distress, and fear of recurrence. In addition to describing the psychosocial impact of cancer and its treatment, and discussing how psychosocial factors affect sexuality and sexual functioning, this paper concludes with options available to manage the sexual problems and related psychosocial issues in order to restore optimal sexual functioning. C1 Houston VA Med Ctr, Mental Hlth Care Line, Houston, TX 77030 USA. Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA. RP Tan, G (reprint author), Houston VA Med Ctr, Mental Hlth Care Line, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 96 TC 21 Z9 22 U1 3 U2 6 PU KLUWER ACADEMIC-HUMAN SCIENCES PRESS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0146-1044 J9 SEX DISABIL JI Sex. Disabil. PD WIN PY 2002 VL 20 IS 4 BP 297 EP 318 DI 10.1023/A:1021661614318 PG 22 WC Rehabilitation SC Rehabilitation GA 639EA UT WOS:000180613600006 ER PT J AU Mandelkern, M Raines, J AF Mandelkern, Mark Raines, Jonathan TI Positron Emission Tomography in Cancer Research and Treatment SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT LA English DT Article AB Positron emission tomography (PET), the imaging of pharmaceuticals labeled with positron-emitting radionuclides, is a rapidly growing modality for the diagnosis and management of cancer. PET yields high-quality images characterizing substrate metabolism, cellular proliferation, receptor density, and other parameters that can be used to identify cancer and evaluate its response to therapies. The technique mainly utilized in cancer management is FOG-PET, which exploits the abnormal glucose metabolism of cancer cells first characterized by Warburg. We discuss the principles of PET, the currently available instrumentation and radiopharmaceuticals, the efficacy of FOG-PET in the management of cancer, and the prospects for near-term advances in cancer using PET. C1 [Mandelkern, Mark] Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA. [Mandelkern, Mark; Raines, Jonathan] Greater Los Angeles VA Healthcare Syst, Dept Imaging, Los Angeles, CA USA. RP Mandelkern, M (reprint author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA. EM markm@uci.edu NR 97 TC 9 Z9 10 U1 0 U2 0 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA SN 1533-0346 J9 TECHNOL CANCER RES T JI Technol. Cancer Res. Treat. PD DEC PY 2002 VL 1 IS 6 BP 423 EP 439 PG 17 WC Oncology SC Oncology GA V28FZ UT WOS:000208668000003 PM 12625770 ER PT J AU Krieger, JN Ross, SO Penson, DF Riley, DE AF Krieger, JN Ross, SO Penson, DF Riley, DE TI Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome SO UROLOGY LA English DT Article ID NONBACTERIAL PROSTATITIS; PROSTATODYNIA; MEN; CLASSIFICATION; OBSTRUCTION; VALIDATION AB Objectives. To evaluate the possibility that patients with inflammatory and noninflammatory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) might present with different symptoms. Patients with CP/CPPS present with characteristic symptoms without bacteriuria. The new National Institutes of Health consensus suggests that CP/CPPS can be divided into inflammatory and noninflammatory categories. Methods. Standardized symptom surveys were completed by 130 subjects who met the criteria for CP/CPPS after clinical examination and urethral, urine, expressed prostatic secretion (EPS), and seminal fluid analysis evaluations. Results. When classified by either EPS or postprostatic massage urine (VB3) findings, subjects with and without inflammation had similar symptoms. However, when classified using the combination of EPS, VB3, and seminal fluid analysis, subjects with inflammatory CP/CPPS had more severe (P <0.02) and more frequent symptoms, in particular, difficulty reaching erection (P <0.01), weak urinary stream (P <0.01), urinary frequency (P = 0.03), and penile pain (P = 0.04). Conclusions. The increased severity and frequency of symptoms among patients with inflammatory CP/ CPPS provide empirical support for the new consensus classification on the basis of the combination of EPS, VB3, and seminal fluid analysis findings. (C) 2002, Elsevier Science Inc. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA 98108 USA. Univ Washington, Dept Urol, Sch Med, Seattle, WA 98108 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Pathobiol, Seattle, WA 98108 USA. RP Krieger, JN (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Urol Sect, 112 GU,1660 S Columbian Way,Campus Mail Box 35828, Seattle, WA 98108 USA. FU NIDDK NIH HHS [R01 DK38955] NR 25 TC 14 Z9 14 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD DEC PY 2002 VL 60 IS 6 BP 959 EP + AR PII S0090-4295(02)01963-5 DI 10.1016/S0090-4295(02)01963-5 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 626TC UT WOS:000179888500004 PM 12475649 ER PT J AU Vaughan, D Imperato-Mcginley, J McConnell, J Matsumoto, AM Bracken, B Roy, J Sullivan, M Pappas, F Cook, T Daurio, C Meehan, A Stoner, E Waldstreicher, J AF Vaughan, D Imperato-Mcginley, J McConnell, J Matsumoto, AM Bracken, B Roy, J Sullivan, M Pappas, F Cook, T Daurio, C Meehan, A Stoner, E Waldstreicher, J TI Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia SO UROLOGY LA English DT Article ID ACUTE URINARY RETENTION; EFFICACY; SAFETY; NEED AB Objectives. To evaluate the effects of finasteride, a specific type II 5-alpha-reductase inhibitor, on symptoms of benign prostatic hyperplasia, prostate volume, and urinary flow during a 7 to 8-year period. Methods. A total of 190 men with symptomatic benign prostatic hyperplasia and enlarged prostates entered one of two Phase II double-blind 3 to 6-month studies. Of these, 156 patients continued taking open-label finasteride, and more than 70 patients completed 7 to 8 years of treatment. The symptoms were scored using a patient self-administered modified Boyarsky symptom questionnaire. Prostate volume was measured by magnetic resonance imaging or ultrasonography, and the maximal urinary flow rate was assessed noninvasively. Results. Treatment with finasteride for 7 to 8 years led to sustained improvement in symptoms, reduction in prostate volume (28% from baseline), and increased urinary flow (median 2.5 mL/s from baseline). Decreases in dihydrotestosterone (86%) and prostate-specific antigen (54%) levels were also maintained. Long-term finasteride treatment was safe and generally well tolerated. Conclusions. Long-term treatment with finasteride was well tolerated and resulted in durable symptom relief and improvement in prostate volume and urinary flow. (C) 2002, Elsevier Science Inc. C1 Merck Res Labs, Rahway, NJ 07065 USA. Cornell Univ, Ctr Med, New York, NY USA. Univ Texas, Dallas, TX 75230 USA. Univ Washington, Sch Med, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. Univ Cincinnati, Edmond, OK USA. Mercy Res Clin, San Diego, CA USA. RP Waldstreicher, J (reprint author), Merck Res Labs, RY34-A212,126 E Lincoln Ave, Rahway, NJ 07065 USA. NR 17 TC 43 Z9 49 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD DEC PY 2002 VL 60 IS 6 BP 1040 EP 1044 AR PII S0090-4295(02)01971-4 DI 10.1016/S0090-4295(02)01971-4 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 626TC UT WOS:000179888500021 PM 12475666 ER PT J AU Stanislaus, R Gilg, AG Singh, AK Singh, I AF Stanislaus, R Gilg, AG Singh, AK Singh, I TI Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin SO NEUROSCIENCE LETTERS LA English DT Article DE Lovastatin; statins; autoimmunity; Th1; Th2; experimental autoimmune encephalomyelitis; multiple sclerosis; splenocytes ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; MULTIPLE-SCLEROSIS; MICE; CELLS; CYTOKINES; IL-6 AB Previous studies; have demonstrated the immunomodulatory potential of Lovastatin, a hydroxy methyl glutaryl-CoA reductase inhibitor, in lessening the clinical and histological manifestations in the neuroinflammatory animal model experimental autoimmune encephalomyelitis (EAE) (Neurosci. Lett., 269 (1999) 71, and J. Neurosci. Res., 66 (2001) 155). To determine the mechanism behind the observed amelioration of EAE by Lovastatin, we examined the cytokine profile of stimulated splenocytes from control, EAE and Lovastatin treated EAE rats. Splenocytes from Lovastatin-treated EAE rats showed decreased levels of interferon-gamma, a Th1 type cytokine, while interleukin (IL)-10, a Th2 type cytokine, was markedly increased as compared to untreated EAE animals. In addition, we also observed reduced levels of IL-6 and nitric oxide production in lipopolysaccharide-stimulated splenocytes isolated from Lovastatin-treated animals. This study documents for the first time that Lovastatin induces a bias towards Th2 cytokines ex vivo, and as a result may be of therapeutic value for cell-mediated diseases such as multiple sclerosis. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. FU NINDS NIH HHS [NS-34741, NS-40810, NS-22576, NS-37766] NR 17 TC 52 Z9 60 U1 0 U2 0 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 29 PY 2002 VL 333 IS 3 BP 167 EP 170 AR PII S0304-3940(02)00943-6 DI 10.1016/S0304-3940(02)00943-6 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 619MR UT WOS:000179480200004 PM 12429374 ER PT J AU Mann, MA Tyler, KL Knipe, DM Fields, BN AF Mann, MA Tyler, KL Knipe, DM Fields, BN TI Type 3 reovirus neuroinvasion after intramuscular inoculation: Viral genetic determinants of lethality and spinal cord infection SO VIROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; MOLECULAR-BASIS; MAMMALIAN REOVIRUSES; SIGMA-1 PROTEIN; M1 GENE; VIRULENCE; GROWTH; MICE; PATHOGENESIS; PARTICLES AB To better understand the mechanisms by which neurotropic viruses invade peripheral nerve pathways and produce CNS disease, we defined the type 3 (T3) reovirus genes that are determinants of the capacity of reovirus T3 strain Dearing (T3D) and T3 clone 9 (C9) to infect the spinal cord and kill mice after hindlimb injection. T3D and C9 viruses are both highly virulent (LD50 < 10(1) PFU) after intracranial injection of neonatal mice. However, C9 is significantly more lethal than T3D after either intramuscular injection (LD50 < 10(1) vs LD50 10(4) PFU) or peroral injection (LD50 10(3.4) vs LD50 > 10(8.3) PFU). Using reassortant viruses containing different combinations of genes derived from T3D and C9, we found that the S1 gene, encoding the cell attachment protein sigma 1 and the nonstructural protein sigma 1 s, and the L3 gene, encoding the core shell protein lambda 1 were the primary determinants of lethality after intramuscular injection. The L3 gene and the L2 gene encoding spike protein, lambda 2, determined differences in spinal cord titer after intramuscular injection. A C9 x T3D mono-reassortant containing all T3D genes except for the C9-derived L3 was lethal after peroral injection. These studies indicate that the S1, L2, and L3 genes all play a potential role in neuroinvasiveness and provide the first identification of a role in pathogenesis for the L3 gene. (C) 2002 Elsevier Science (USA). C1 Northeastern Univ, Dept Biol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Denver VA Med Ctr, Neurol Serv, Denver, CO 80262 USA. RP Mann, MA (reprint author), Columbia Univ Coll Phys & Surg, 630 W 168th St,11-519, New York, NY 10032 USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NINDS NIH HHS [P50 NS16998, P01 NS35138] NR 37 TC 3 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 25 PY 2002 VL 303 IS 2 BP 213 EP 221 DI 10.1006/viro.2002.1698 PG 9 WC Virology SC Virology GA 628GL UT WOS:000179984700001 PM 12490384 ER PT J AU Wray, NP Moseley, JB O'Malley, K AF Wray, NP Moseley, JB O'Malley, K TI Arthroscopic surgery for osteoarthritis of the knee - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Wray, NP (reprint author), Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 4 TC 2 Z9 2 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC/NEJM PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 21 PY 2002 VL 347 IS 21 BP 1718 EP 1719 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 617BL UT WOS:000179339900021 ER PT J AU Rumsfeld, JS Plomondon, ME Peterson, ED Shlipak, MG Maynard, C Grunwald, GK Grover, FL Shroyer, ALW AF Rumsfeld, JS Plomondon, ME Peterson, ED Shlipak, MG Maynard, C Grunwald, GK Grover, FL Shroyer, ALW TI The impact of ethnicity on outcomes following coronary artery bypass graft surgery in the Veterans Health Administration SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID LEFT-VENTRICULAR HYPERTROPHY; ACUTE MYOCARDIAL-INFARCTION; INVASIVE CARDIAC PROCEDURES; RACIAL-DIFFERENCES; REVASCULARIZATION PROCEDURES; OPERATIVE MORTALITY; CARDIOVASCULAR PROCEDURES; AFFAIRS; RACE; IDENTIFICATION AB OBJECTIVES We evaluated the effect of African American (AA) and Hispanic American (HA) ethnicity on mortality and complications following coronary artery bypass graft (CABG) surgery in the Veterans Health Administration (VHA). BACKGROUND Few studies have examined the impact of ethnicity on outcomes following cardiovascular procedures. METHODS This study included all 29,333 Caucasian, 2,570 AA, and 1,525 HA patients who underwent CABG surgery at any one of the 43 VHA cardiac surgery centers from January 1995 through March 2001. We evaluated the relationship between ethnicity, (AA vs. Caucasian and HA vs. Caucasian) and 30-day mortality, 6-month mortality, and 30-day complications, adjusting for a wide array of demographic, cardiac, and noncardiac variables. RESULTS After adjustment for baseline characteristics, AA and Caucasian patients had similar 30-day (AA/Caucasian odds ratio [OR] 1.07; 95% confidence interval [CI] 0,84 to 1.35; p = 0.59) and 6-month mortality, risk (AA/Caucasian OR 1.10; 95% CI 0.91 to 1.34; p = 0.31). However, among patients with low surgical risk, AA ethnicity was associated with higher mortality (OR 1.52, CI 1.10 to 2.11, p = 0.01), and AA patients were more likely to experience complications following surgery (OR 1.28; 95% CI 1.14 to 1.45; p < 0.01). In contrast, HA patients had lower 30-day (HA/Caucasian OR 0.70; 95% CI 0.49 to 0.98; p = 0.04) and 6-month mortality risk (HA/Caucasian OR 0.66; 95% CI 0.50 to 0.88; p < 0.01) than Caucasian patients. CONCLUSIONS Ethnicity does not appear to be a strong risk factor for adverse outcomes following CABG surgery in the VHA. Future studies are needed to determine why AA patients have more complications, but ethnicity should not affect the decision to offer the operation. (C) 2002 by the American College of Cardiology Foundation. C1 Vet Adm Med Ctr, Denver, CO USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Vet Adm Med Ctr, San Francisco, CA 94121 USA. Duke Univ, Durham, NC 27706 USA. RP Rumsfeld, JS (reprint author), Vet Adm Med Ctr, Cardiol 111B,1055 Clermont St, Denver, CO USA. RI Shroyer, Annie Laurie/B-8836-2016; Maynard, Charles/N-3906-2015 OI Shroyer, Annie Laurie/0000-0001-6461-0623; Maynard, Charles/0000-0002-1644-7814 NR 43 TC 20 Z9 21 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 20 PY 2002 VL 40 IS 10 BP 1786 EP 1793 AR PII S0735-1097(02)02485-3 DI 10.1016/S0735-1097(02)02485-3 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 616MY UT WOS:000179308600010 PM 12446062 ER PT J AU Gupta, S Knowlton, AA AF Gupta, S Knowlton, AA TI Cytosolic heat shock protein 60, hypoxia, and apoptosis SO CIRCULATION LA English DT Article DE apoptosis; hypoxia; ischemia; myocytes ID CYTOCHROME-C RELEASE; DILATED CARDIOMYOPATHY; CELLS; BAX; REOXYGENATION; EXPRESSION; TRANSLOCATION; MITOCHONDRIA; LOCALIZATION; ACTIVATION AB Background-Heat shock protein (HSP)60 is an abundant protein found primarily in the mitochondria, though 15% to 20% is found in the cytosol. Previously we observed that HSP60 complexes with bax in the cytosol. Reduction in HSP60 precipitates translocation of bax to the mitochondria and apoptosis. We hypothesized that HSP60 would decrease with hypoxia/reoxygenation and that this would precipitate bax translocation to the mitochondria and release of cytochrome c. Methods and Results-Adult rat cardiac myocytes were studied at end-hypoxia and at 10 and 24 hours of reoxygenation. HSP60 levels were unchanged at end-hypoxia and decreased 33% and 40% at 10 and 24 hours of reoxygenation, whereas HSP72 increased 80% and 110%. Bax and bcl-2 decreased during reoxygenation. However, cytochrome c release occurred at end-hypoxia, before reoxygenation. Cell fractionation was done to analyze this further. In normal myocytes, bax and HSP60 were present in the cytosol, and bax coimmunoprecipitated with cytosolic HSP60. At end-hypoxia, mitochondrial HSP60 was unchanged, but cytosolic HSP60 had disappeared and was now in the plasma membrane fraction. Concurrently, bax was no longer in the cytosol but now in the mitochondria. Thus, although total HSP60 remained the same, it no longer complexed with bax, and bax was free to translocate to the mitochondria and precipitate apoptosis. Reduction in ATP had a similar effect. Conclusions-These studies show that hypoxia results in disassociation of the HSP60-bax complex with translocation of cytosolic HSP60 to the plasma membrane and bax to the mitochondria. This is sufficient to trigger apoptosis. C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. RP Univ Calif Davis, Div Cardiovasc, TB172,1 Shields Ave, Davis, CA 95616 USA. EM aaknowlton@ucdavis.edu FU NHLBI NIH HHS [HL58515, R01 HL058515]; NIA NIH HHS [AG19327, R01 AG019327] NR 27 TC 102 Z9 108 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 19 PY 2002 VL 106 IS 21 BP 2727 EP 2733 DI 10.1061/01.CIR.0000038112.64503.6E PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 618LX UT WOS:000179420500019 PM 12438300 ER PT J AU Prommer, EE AF Prommer, EE TI Hematologic aspects of Wilson's disease (hepatolenticular degeneration) SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 W Los Angeles VA, Div Hematol Oncol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 3464 BP 4B EP 4B PN 2 PG 1 WC Hematology SC Hematology GA 614JL UT WOS:000179184800007 ER PT J AU Sansores-Garcia, L Nigam, R Agrawal, A Siddiqi, T Adachi, R AF Sansores-Garcia, L Nigam, R Agrawal, A Siddiqi, T Adachi, R TI Localization, interaction and function of Munc-18 proteins and Syntaxins in mast cell exocytosis. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 Baylor Coll Med, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX USA. RI Agrawal, Anurag/A-7312-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 926 BP 245A EP 245A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184700927 ER PT J AU Kroll, MH Resendiz, JC Ji, GL Berndt, MC Feng, SJ AF Kroll, MH Resendiz, JC Ji, GL Berndt, MC Feng, SJ TI Purinergic P2Y(12) receptor blockade inhibits shear-induced platelet aggregation by inhibiting phosphatidylinositol 3-kinase. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Rice Univ, Houston, TX 77251 USA. Wihuri Res Inst, SF-00140 Helsinki, Finland. Monash Univ, Clayton, Vic 3168, Australia. RI Berndt, Michael/D-5580-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 959 BP 252A EP 252A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184700960 ER PT J AU Speckhart, SA Christianson, TA Lensch, MW Bagby, GC AF Speckhart, SA Christianson, TA Lensch, MW Bagby, GC TI Screening for Fanconi pathway dysfunction using low numbers of CD34+ cells. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA. Portland VA Med Ctr, Mol Hematopoiesis Lab, Portland, OR USA. MIT, Whitehead Inst Biomed Res, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 1255 BP 324A EP 324A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184701255 ER PT J AU Feng, SJ Xin, L Kroll, MH AF Feng, SJ Xin, L Kroll, MH TI Pathological shear stress stimulates alpha IIb beta 3-dependent tyrosine kinase signaling. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Rice Univ, Houston, TX 77251 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 1841 BP 474A EP 475A PN 1 PG 2 WC Hematology SC Hematology GA 614JK UT WOS:000179184701842 ER PT J AU Feng, SJ Xin, L Kroll, MH AF Feng, SJ Xin, L Kroll, MH TI Peptide from the filamin A binding domain of platelet glycoprotein Ib alpha inhibits ristocetin- and shear-induced platelet aggregation. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Rice Univ, Houston, TX 77251 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 1842 BP 475A EP 475A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184701843 ER PT J AU Kroll, MH Resendiz, JC Feng, SJ Ji, GL AF Kroll, MH Resendiz, JC Feng, SJ Ji, GL TI von Willebrand factor binding to platelet glycoprotein Ib-IX-V stimulates the assembly of an alpha-actinin based signaling complex. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Rice Univ, Houston, TX 77251 USA. Wihuri Res Inst, SF-00140 Helsinki, Finland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 1843 BP 475A EP 475A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184701844 ER PT J AU Yee, KWH O'Farrell, AM Town, AR Cherrington, JM Heinrich, MC AF Yee, KWH O'Farrell, AM Town, AR Cherrington, JM Heinrich, MC TI FLT3 inbibitor SU11248 displays synergistic effects with cytarabine and daunorubicin on FLT3 ITD leukemia cell lines. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. SUGEN Inc, Dept Preclin & Translat Med, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 2129 BP 542A EP 542A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184702130 ER PT J AU Hong, W Pastore, Y Pool, L Schafer, AI Prchal, J AF Hong, W Pastore, Y Pool, L Schafer, AI Prchal, J TI Gain-of function mutation of human erythropoietin receptor in mice decreases neointimal formation. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 Baylor Coll Med, VA Med Ctr, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Texas Childrens Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 2681 BP 680A EP 681A PN 1 PG 2 WC Hematology SC Hematology GA 614JK UT WOS:000179184702683 ER PT J AU Yee, KWH Braziel, RM O'Farrell, AM McGreevey, LS Haley, A Town, AR Griffith, DJ Cherrington, JM Heinrich, MC AF Yee, KWH Braziel, RM O'Farrell, AM McGreevey, LS Haley, A Town, AR Griffith, DJ Cherrington, JM Heinrich, MC TI SU11248 inhibits activation loop mutants of FLT3. SO BLOOD LA English DT Meeting Abstract CT 44th Annual Meeting of the American-Society-of-Hematology CY DEC 06-10, 2002 CL PHILADELPHIA, PENNSYLVANIA SP Amer Soc Hematol C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. SUGEN Inc, Dept Preclin & Translat Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2002 VL 100 IS 11 MA 2922 BP 739A EP 739A PN 1 PG 1 WC Hematology SC Hematology GA 614JK UT WOS:000179184702924 ER PT J AU Montanez, S Daws, LC Gould, GG Gerhardt, GA Frazer, A AF Montanez, S Daws, LC Gould, GG Gerhardt, GA Frazer, A TI Differential in vivo clearance of serotonin in rat dorsal raphe nucleus and CA3 region SO BRAIN RESEARCH LA English DT Article DE serotonin transporter; dorsal raphe nucleus; CA3; chronoamperometry; rat ID NOREPINEPHRINE UPTAKE SITES; IN-VIVO; QUANTITATIVE AUTORADIOGRAPHY; EXTRACELLULAR SEROTONIN; DOPAMINE UPTAKE; ELECTRON-MICROSCOPY; REUPTAKE INHIBITORS; PREFRONTAL CORTEX; SUBSTANTIA-NIGRA; MESSENGER-RNA AB In vivo chronoamperometric recordings were used to determine if the majority of serotonin transporters (SERTs) in the dorsal raphe nucleus (DRN) are functionally active. This was achieved by comparing the clearance of exogenously applied serotonin (5-HT) from the extracellular fluid (ECF) of the DRN to that in the CA3 region of the hippocampus, an area with lower SERT density. Serotonin was pressure ejected into these regions in anesthetized rats and reproducible electrochemical signals measured by carbon fiber microelectrodes were recorded. Consistent with SERT density as measured by [H-3]cyanoimipramine binding in these brain regions (DRN>>CA3), clearance of 5-HT was significantly faster in DRN compared to that in the CA3 region. The selective serotonin reuptake inhibitor, fluvoxamine, prolonged 5-HT clearance in both CA3 and DRN. It is known that the norepinephrine transporter (NET) contributes to clearance of 5-HT in the dentate gyrus (DG) but not in CA3. Given that the DRN receives noradrenergic innervation, it was also determined if the NET contributes to 5-HT clearance in the DRN. Destruction of the NET with the neurotoxin 6-hydroxydopamine failed to alter 5-HT clearance parameters in the DRN. These data support the hypothesis that serotonin transporters are functionally active in the DRN, that serotonin clearance is mediated primarily by the SERT in the DRN and that the faster clearance of 5-HT from this region is related to its greater density of functional SERTs. (C) 2002 Elsevier Science B.V. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Alcohol & Drug Addict, Dept Psychiat, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. Univ Kentucky, Dept Anat & Neurobiol, Ctr Sensor Technol, Lexington, KY 40536 USA. RP Montanez, S (reprint author), Univ Texas, Hlth Sci Ctr, Div Alcohol & Drug Addict, Dept Psychiat, 7703 Floyd Curl Dr,MS 7792, San Antonio, TX 78229 USA. OI Gould, Georgianna/0000-0002-5470-8763 FU NIMH NIH HHS [MH01245, MH57001] NR 45 TC 16 Z9 16 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD NOV 15 PY 2002 VL 955 IS 1-2 BP 236 EP 244 AR PII S0006-8993(02)03470-4 DI 10.1016/S0006-8993(02)03470-4 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 618NU UT WOS:000179424800028 PM 12419542 ER PT J AU Hare, CB Vu, MP Grunfeld, C Lampiris, HW AF Hare, CB Vu, MP Grunfeld, C Lampiris, HW TI Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COA REDUCTASE INHIBITORS; PROTEASE INHIBITORS; DISEASE AB We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction. C1 Univ Calif San Francisco, Div Infect Dis, Posit Hlth Program, San Francisco, CA 94110 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. San Francisco Vet Adm Med Ctr, Serv Pharm, San Francisco, CA USA. San Francisco Vet Adm Med Ctr, Metab Sect, San Francisco, CA USA. San Francisco Vet Adm Med Ctr, Div Infect Dis, San Francisco, CA USA. RP Hare, CB (reprint author), Univ Calif San Francisco, Div Infect Dis, Posit Hlth Program, 3180 18th St,Ste 305, San Francisco, CA 94110 USA. NR 14 TC 44 Z9 49 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2002 VL 35 IS 10 BP E111 EP E112 DI 10.1086/344179 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 611PM UT WOS:000179027000024 PM 12410494 ER PT J AU Elbert, T Sterr, A Rockstroh, B Pantev, C Muller, MM Taub, E AF Elbert, T Sterr, A Rockstroh, B Pantev, C Muller, MM Taub, E TI Expansion of the tonotopic area in the auditory cortex of the blind SO JOURNAL OF NEUROSCIENCE LA English DT Article DE tonotopic map; auditory cortex; reorganization; blind; MEG ID EVENT-RELATED POTENTIALS; CROSS-MODAL PLASTICITY; ADULT OWL MONKEYS; CONGENITALLY BLIND; BRAILLE READERS; FREQUENCY REPRESENTATION; CORTICAL REPRESENTATION; SOMATOSENSORY CORTEX; ACTIVATION PATTERNS; SIGHTED SUBJECTS AB A part of the core area of the auditory cortex was examined in nine blind and10 sighted individuals by magnetic source imaging and was found to be enlarged by a factor of 1.8 in the blind compared with the sighted humans. Moreover, the latency of the N1m component of the auditory-evoked magnetic response was significantly decreased in the blind. The development of use-dependent cortical reorganization may be a consequence of the absence of visual input in combination with enhanced auditory activity generated by the long-term concentration by blind individuals on nonvisual cues to interact appropriately with the environment. It is consistent with and well suited to mediate the demonstrated increased ability of the blind to accurately localize acoustic sources in peripheral auditory fields and to decode speech. C1 Univ Konstanz, Dept Psychol, D-78457 Constance, Germany. Univ Liverpool, Dept Psychol, Liverpool L69 7ZA, Merseyside, England. Rotman Res Inst Neurosci, Toronto, ON M6A 2E1, Canada. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Elbert, T (reprint author), Univ Konstanz, Dept Psychol, POB D25, D-78457 Constance, Germany. RI Elbert, Thomas/C-8556-2009 NR 44 TC 84 Z9 86 U1 1 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 15 PY 2002 VL 22 IS 22 BP 9941 EP 9944 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 613TF UT WOS:000179147000033 PM 12427851 ER PT J AU Le, SV Yamaguchi, DJ McArdle, CA Tachiki, K Pisegna, JR Germano, P AF Le, SV Yamaguchi, DJ McArdle, CA Tachiki, K Pisegna, JR Germano, P TI PAC1 and PACAP expression, signaling, and effect on the growth of HCT8, human colonic tumor cells SO REGULATORY PEPTIDES LA English DT Article DE pituitary adenylate cyclase-activating polypeptide; pituitary adenylate cyclase-activating polypeptide type 1 receptor; HCT8 cells; colon cancer growth ID CYCLASE-ACTIVATING POLYPEPTIDE; GASTRIC-ACID SECRETION; LUNG-CANCER CELLS; ADENYLATE-CYCLASE; FAS-LIGAND; I RECEPTOR; HYPOTHALAMIC POLYPEPTIDE; MOLECULAR-CLONING; SPLICE VARIANTS; T-LYMPHOCYTES AB The pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1) is a heptahelical, G protein-coupled receptor that has been shown to be expressed by non-squamous lung cancer and breast cancer cell lines, and to be coupled to the growth of these tumors. We have previously shown that PACAP and its receptor, PAC1, are expressed in rat colonic tissue. In this study, we used polyclonal antibodies directed against the COOH terminal of PAC1, as well as fluorescently labeled PACAP, Fluor-PACAP, to demonstrate the expression of PAC1 on HCT8 human colonic tumor cells, using FACS analysis and confocal laser scanning microscopy. Similarly, anti-PACAP polyclonal antibodies were used to confirm the expression of PACAP hormone by this cell line. We then investigated the signal transduction properties of PAC1 in these tumor cells. PACAP-38 elevated intracellular cAMP levels in a dose-dependent manner, with a half-maximal (EC50) stimulation of approximately 3 nM. In addition, PACAP-38 stimulation caused an increase in cytosolic Ca2+ concentration [Ca2+](i), which was partially inhibited by the PACAP antagonist, PACAP-(6-38). Finally, we studied the potential role of PACAP upon the growth of these tumor cells. We found that PACAP-38, but not VIP, increased the number of viable HCT8 cells, as measured by MTT activity. We also demonstrated that HCT8 cells expressed the Fas receptor (Fas-R/CD95), which was subsequently down-regulated upon activation with PACAP-38, further suggesting a possible role for PACAP in the growth and survival of these tumor cells. These data indicate that HCT8 human colon tumor cells express PAC1 and produce PACAP hormone. Furthermore, PAC1 activation is coupled to adenylate cyclase, increase cytosolic [Ca2+](i), and cellular proliferation. Therefore, PACAP is capable of increasing the number of viable cells and regulating Fas-R expression in a human colonic cancer cell line, suggesting that PACAP might play a role in the regulation of colon cancer growth and modulation of T lymphocyte anti-tumoral response via the Fas-R/Fas-L apoptotic pathway. (C) 2002 Published by Elsevier Science B.V. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. Univ Bristol, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England. RP Germano, P (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, CURE, Bldg 115,Room 313,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 48 TC 23 Z9 24 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-0115 J9 REGUL PEPTIDES JI Regul. Pept. PD NOV 15 PY 2002 VL 109 IS 1-3 BP 115 EP 125 AR PII S0167-0115(02)00194-5 DI 10.1016/S0167-0115(02)00194-5 PG 11 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 614WA UT WOS:000179213400017 PM 12409223 ER PT J AU Burgio, KL Goode, PS Locher, JL Umlauf, MG Roth, DL Richter, HE Varner, RE Lloyd, LK AF Burgio, KL Goode, PS Locher, JL Umlauf, MG Roth, DL Richter, HE Varner, RE Lloyd, LK TI Behavioral training with and without biofeedback in the treatment of urge incontinence in older women - A Randomized controlled trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID URINARY-INCONTINENCE; BLADDER; EFFICACY AB Context Previous research on urge urinary incontinence has demonstrated that multicomponent behavioral training with biofeedback is safe and effective, yet it has not been established whether biofeedback is an essential component that heightens therapeutic efficacy. Objective To examine the role of biofeedback in a multicomponent behavioral training program for urge incontinence in community-dwelling older women. Design Prospective, randomized controlled trial conducted from April 1, 1995, to March 30, 2001. Setting University-based outpatient continence clinic in the United States. Patients A volunteer sample of 222 ambulatory, nondemented, community-dwelling women aged 55 to 92 years with urge incontinence or mixed incontinence with urge as the predominant pattern. Patients were stratified by race, type of incontinence (urge only vs mixed), and severity (frequency of accidents). Interventions Patients were randomly assigned to receive 8 weeks (4 visits) of bio-feedback-assisted behavioral training (n=73), 8 weeks (4 visits) of behavioral training fee without biofeedback (verbal feedback based on vaginal palpation; n=74), or 8 weeks, of self-administered behavioral treatment using a self-help booklet (control condition; n=75). Main Outcome Measures Reduction in the number of incontinence episodes as documented in bladder diaries, patients' perceptions and satisfaction, and changes in quality of life. Results Intention-to-treat analysis showed that behavioral training with biofeedback yielded a mean 63.1% reduction (SD, 42.7%) in incontinence, verbal feedback a mean 69.4% reduction (SD; 32.7%), and the self-help booklet a mean 58.6% reduction (SD, 38.8%). The 3 groups were not significantly different from each other (P=.23). The groups differed significantly regarding patient satisfaction: 75.0% of the biofeedback group, 85.5% of the verbal feedback group, and 55.7% of the self-help booklet group reported being completely satisfied with treatment (P=.001). Significant improvements were seen across all 3 groups on 3 quality-of-life instruments, with no significant between-group differences. Conclusions Biofeedback to teach pelvic floor muscle control, verbal feedback based on vaginal palpation, and a self-help booklet in a first-line behavioral training program all;achieved comparable improvements in urge incontinence in community-dwelling older women. Patients' perceptions of treatment were significantly better for the 2 behavioral training interventions. C1 Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. Univ Alabama, Sch Med, Birmingham, AL USA. Univ Alabama, Ctr Aging, Birmingham, AL USA. Univ Alabama, Sch Nursing, Birmingham, AL USA. Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA. RP Burgio, KL (reprint author), Birmingham Vet Affairs Med Ctr, GRECC-11G,700 19th St S, Birmingham, AL 35233 USA. RI Umlauf, Mary/A-5021-2015 FU NIA NIH HHS [AG R0108010] NR 24 TC 135 Z9 137 U1 4 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 13 PY 2002 VL 288 IS 18 BP 2293 EP 2299 DI 10.1001/jama.288.18.2293 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 614JZ UT WOS:000179186400028 PM 12425706 ER PT J AU Rollins, YD Filley, CM McNutt, JT Chahal, S Kleinschmidt-DeMasters, BK AF Rollins, YD Filley, CM McNutt, JT Chahal, S Kleinschmidt-DeMasters, BK TI Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion SO NEUROLOGY LA English DT Article; Proceedings Paper CT 78th Annual Meeting of the American-Association-of-Neuropathologists CY JUN 20-23, 2002 CL DENVER, COLORADO SP Amer Assoc Neuropathol ID CHILDREN; EPIDEMIC AB The authors report a 57-year-old man who survived 18 days after swallowing an 8-oz. can of Sterno in a suicide attempt. Two days after ingestion, he developed confusion and acute renal failure requiring hemodialysis, followed on day 8 by a delayed but rapidly evolving ascending paralysis. Pathologic examination showed severe demyelination, with lesser axonal damage, of virtually all cranial and peripheral nerves sampled and sparing of central myelin. The diethylene glycol in the Sterno was considered responsible for this intoxication. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kleinschmidt-DeMasters, BK (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. NR 10 TC 20 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 12 PY 2002 VL 59 IS 9 BP 1460 EP 1463 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 613LT UT WOS:000179134300038 PM 12427908 ER PT J AU Zandi, PP Carlson, MC Plassman, BL Welsh-Bohmer, KA Mayer, LS Steffens, DC Breitner, JCS AF Zandi, PP Carlson, MC Plassman, BL Welsh-Bohmer, KA Mayer, LS Steffens, DC Breitner, JCS CA Cache County Memory Study Investig TI Hormone replacement therapy and incidence of Alzheimer disease in older women - The Cache County Study SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID COGNITIVE DECLINE; CONTROLLED TRIAL; ESTROGEN; RISK; DEMENTIA; AD; POPULATION; PREVALENCE; AGE AB Context Previous studies have shown a sex-specific increased risk of Alzheimer disease (AD) in women older than 80 years. Basic neuroscience findings suggest that hormone replacement therapy (HRT) could reduce a woman's risk of AD. Epidemiologic findings on AD and HRT are mixed. Objective To examine the relationship between use of HRT and risk of AD among elderly women. Design, Setting, and Participants Prospective study of incident dementia among 1357 men (mean age, 73.2 years) and 1889 women (mean age, 74.5 years) residing in a single county in Utah. Participants were first assessed in 1995-1997, with follow-up conducted in 1998-2000. History of women's current and former use of HRT, as well as of calcium and multivitamin supplements, was ascertained at the initial contact. Main Outcome Measure Diagnosis of incident AD. Results Thirty-five men (2.6%) and 88 women (4.7%) developed AD between the initial interview and time of the follow-up Q years). Incidence among women increased after age 80 years and exceeded the risk among men of similar age (adjusted hazard ratio [HR], 2.11.; 95% confidence interval [CI], 1.22-3.86). Women who used HRT had a reduced risk of AD (26 cases among 1066 women) compared with non-HRT users (58 cases among 800 women) (adjusted HR, 0.59; 95% CI, 0.36-0.96). Risk varied with duration of HRT use, so that a woman's sex-specific increase in risk disappeared entirely with more than 10 years of treatment Q cases among 427 women). Adjusted HRs were 0.41 (95% CI, 0.17-0.86) for HRT users compared with non users and 0.77 (95% CI, 0.31-1.67) compared with men. No similar effect was seen with calcium or multivitamin use. Almost all of the HRT-related reduction in incidence reflected former use of HRT (9 cases among 490 women; adjusted HR, 0.33 [95% CI, 0.15-0.65]). There was no effect with current HRT use (17 cases among 576 women; adjusted HR, 1.08 [95% CI, 0.59-1.91]) unless duration of treatment exceeded 10 years (6 cases among 344 women; adjusted HR, 0.55 [95% CI, 0.21-1.23]). Conclusions Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years. C1 VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA 98108 USA. Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Ment Hyg, Baltimore, MD USA. Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC USA. Banner Hlth Syst, Phoenix, AZ USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Breitner, JCS (reprint author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIA NIH HHS [R01-AG-11380] NR 32 TC 547 Z9 560 U1 5 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 6 PY 2002 VL 288 IS 17 BP 2123 EP 2129 DI 10.1001/jama.288.17.2123 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 611ZJ UT WOS:000179048100022 PM 12413371 ER PT J AU Sedlis, SP Morrison, DA Lorin, JD Esposito, R Sethi, G Sacks, J Henderson, W Grover, F Ramanathan, KB Weiman, D Saucedo, J Antakli, T Paramesh, V Pett, S Vernon, S Blrjiniuk, V Welt, F Krucoff, M Wolfe, W Lucke, JC Mediratta, S Booth, D Murphy, E Ward, H Miller, L Kiesz, S Barbiere, C Lewis, D AF Sedlis, SP Morrison, DA Lorin, JD Esposito, R Sethi, G Sacks, J Henderson, W Grover, F Ramanathan, KB Weiman, D Saucedo, J Antakli, T Paramesh, V Pett, S Vernon, S Blrjiniuk, V Welt, F Krucoff, M Wolfe, W Lucke, JC Mediratta, S Booth, D Murphy, E Ward, H Miller, L Kiesz, S Barbiere, C Lewis, D CA Investigators Dept Vet Affairs Stu Angina Extremely Serious Operative TI Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass - Outcome of diabetic patients in the AWESOME randomized trial and registry SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article; Proceedings Paper CT 50th Annual Scientific Session of the American College of Cardiology CY MAR 18-20, 2001 CL ORLANDO, FLORIDA SP Amer Coll Cardiol ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; REVASCULARIZATION-INVESTIGATION BARI; HOSPITAL RESOURCE UTILIZATION; ARTERY BYPASS; ECONOMIC-IMPACT; CARDIAC-SURGERY; DISEASE ERACI; FOLLOW-UP; ANGIOPLASTY AB OBJECTIVES This study compared survival after percutaneous coronary intervention (PCI) with survival after coronary artery bypass graft surgery (CABG) among diabetics in the Veterans Affairs AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) study randomized trial and registry of high-risk patients. BACKGROUND Previous studies indicate that CABG may be superior to PCI for diabetics, but no comparisons have been made for diabetics at high risk for surgery. METHODS Over five years (1995 to 2000), 2,431 patients with medically refractory myocardial ischemia and at least one of five risk factors (prior CABG, myocardial infarction within seven days, left ventricular ejection fraction <0.35, age >70 years, or an intra-aortic balloon being required to stabilize) were identified. A total of 781 were acceptable for CABG and PCI, and 454 consented to be randomized. The 1,650 patients not acceptable for both CABG and PCI constitute the physician-directed registry, and the 327 who were acceptable but refused to be randomized constitute the patient-choice registry. Diabetes prevalence was 32% (144) among randomized patients, 27% (89) in the patient-choice registry, and 32% (525) in the physician-directed registry. The CABG and PCI survival rates were compared using Kaplan-Meier curves and log-rank tests. RESULTS The respective CABG and PCI 36-month survival rates for diabetic patients were 72% and 81% for randomized patients, 85% and 89% for patient-choice registry patients, and 73% and 71% for the physician-directed registry patients. None of the differences was statistically significant. CONCLUSIONS We conclude that PCI is a relatively safe alternative to CABG for diabetic patients with medically refractory unstable angina who are at high risk for CABG. (C) 2002 by the American College of Cardiology Foundation. C1 Vet Adm Med Ctr, Cardiol Sect, New York, NY 10010 USA. Tucson VA Med Ctr, Tucson, AZ USA. Edward Hines Jr Vet Adm Hosp, CSPCC, Hines, IL 60141 USA. Denver VA Med Ctr, Denver, CO USA. Memphis VA Med Ctr, Memphis, TN USA. Little Rock VA Med Ctr, Little Rock, AR USA. Albuquerque VA Med Ctr, Albuquerque, NM USA. W Roxbury VA Med Ctr, W Roxbury, MA USA. Durham VA Med Ctr, Durham, NC USA. Asheville VA Med Ctr, Asheville, NC USA. Lexington VA Med Ctr, Lexington, KY USA. Portland VA Med Ctr, Portland, OR USA. Minneapolis VA Med Ctr, Minneapolis, MN USA. San Antonio VA Med Ctr, San Antonio, TX USA. Kansas City VA Med Ctr, Kansas City, KS USA. RP Sedlis, SP (reprint author), Vet Adm Med Ctr, Cardiol Sect, 12W,423 E 23rd St, New York, NY 10010 USA. NR 50 TC 62 Z9 64 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 6 PY 2002 VL 40 IS 9 BP 1555 EP 1566 AR PII S0735-1097(02)02346-X DI 10.1016/S0735-1097(02)02346-X PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 610DY UT WOS:000178946500003 PM 12427406 ER PT J AU Washington, DL Stevens, CD Shekelle, PG Henneman, PL Brook, RH AF Washington, DL Stevens, CD Shekelle, PG Henneman, PL Brook, RH TI Next-day care for emergency department users with nonacute conditions - A randomized, controlled trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PUBLIC HOSPITAL EMERGENCY; DEPARTMENTS; CONSEQUENCES; PHYSICIAN; QUALITY; LEAVE; LIFE AB Background: Because of overcrowding and cost-control efforts, emergency departments are under pressure to refer patients with nonacute conditions to other settings. However, no validated systematic methods exist for safely performing such referrals. Objective: To determine the effects on health status and access to care of systematically referring patients with nonacute conditions to next-day primary care. Design: Randomized, controlled trial. Setting: An emergency department in a public hospital. Patients: 156 adults who used the emergency department on weekdays from 7:00 a.m. to 3:00 p.m. and met criteria for deferred care. The criteria applied to three symptom complexes that account for 33% of U.S. emergency department visits by adults. Intervention: Next-day care at the study site's primary care center or usual same-day care. Measurements: Self-reported health status and use of health services during 1-week follow-up. Results: Patients assigned to next-day care did not demonstrate clinically important disadvantages in health status or physician visits compared with usual care patients. In each group, more than 95% of patients were evaluated at least once by a physician, 4% sought health services after their initial evaluation, and no patients were hospitalized or died. At follow-up, both groups reported improved health status and fewer days in bed or with disability, although the deferred care group reported less improvement on all three measures. The 95% Cls were sufficiently narrow to exclude a clinically significant difference in self-reported health status. However, the possibility of 1 additional day in bed or with disability in the deferred care group could not be excluded. Conclusions: Clinically detailed standardized screening criteria can safely identify patients at public hospital emergency departments for referral to next-day care. However, larger studies are needed to assess the possibility of adverse effects. C1 Vet Affairs Greater Los Angeles Healthcare syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. RAND Hlth, Santa Monica, CA USA. Baystate Med Ctr, Springfield, MA USA. Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Washington, DL (reprint author), Vet Affairs Greater Los Angeles Healthcare syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. NR 30 TC 39 Z9 40 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 5 PY 2002 VL 137 IS 9 BP 707 EP 714 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 612BA UT WOS:000179052400001 PM 12416944 ER PT J AU Oboler, SK Prochazka, AV Anderson, RJ AF Oboler, SK Prochazka, AV Anderson, RJ TI Public expectation for annual physical examinations - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA. RP Oboler, SK (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 5 PY 2002 VL 137 IS 9 BP 774 EP 774 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 612BA UT WOS:000179052400014 ER PT J AU Aikawa, K Retzlaff, B Fish, B Levitz, M Walden, C Khan, SE Knopp, RH AF Aikawa, K Retzlaff, B Fish, B Levitz, M Walden, C Khan, SE Knopp, RH TI Dyslipidemia of insulin resistance and obesity: Gender differences SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Washington, NW Lipid Res Clin, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 377 BP 75 EP 75 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142700419 ER PT J AU Nemoto, S Diwan, A DeFrietas, G Shi, SP Sivasubramanian, N AF Nemoto, S Diwan, A DeFrietas, G Shi, SP Sivasubramanian, N TI Mice deficient in the NF kappa B1 p50 subunit exhibit cardiac hypertrophy and altered function in the unstressed state SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 807 BP 160 EP 161 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142700849 ER PT J AU Nemoto, S Diwan, A DeFreitas, G Carabello, BA Mann, DL AF Nemoto, S Diwan, A DeFreitas, G Carabello, BA Mann, DL TI Post-translational processing of tumor necrosis factor (TNF) modulates LV function in transgenic mice with cardiac restricted overexpression of TNF SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 VA Med Ctr, Baylor Coll Med, Houston, TX USA. Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 1297 BP 258 EP 258 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142701336 ER PT J AU Nemoto, S Razeghi, P Young, ME DeFreitas, G Taegtmeyer, H Carabello, BA AF Nemoto, S Razeghi, P Young, ME DeFreitas, G Taegtmeyer, H Carabello, BA TI Peroxisome proliferator-activated receptor (PPAR) agonists ameliorate LV dysfunction in experimental chronic mitral regurgitation (MR) SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 VA Med Ctr, Baylor Coll Med, Houston, TX USA. Univ Texas, Sch Med, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 1320 BP 263 EP 263 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142701359 ER PT J AU Masoudi, FA Plomondon, ME Magid, DJ Sales, AE Rumsfeld, JS AF Masoudi, FA Plomondon, ME Magid, DJ Sales, AE Rumsfeld, JS TI Renal dysfunction and mortality after acute coronary syndromes SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Denver Hlth Med Ctr, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. Colorado Permanente Med Grp, Denver, CO USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 1991 BP 401 EP 401 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702029 ER PT J AU Mozaffarian, D Nye, RG AF Mozaffarian, D Nye, RG TI Statin therapy is associated with lower mortality in severe heart failure SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 VA Puget Sound Healthcare Syst, Seattle, WA USA. Pfizer, New London, CT USA. Univ Washington, Seattle, WA 98195 USA. RI Mozaffarian, Dariush/B-2276-2008 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2329 BP 470 EP 471 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702367 ER PT J AU Rumsfeld, JS Havranek, E Masoudi, FA Tooley, JF Peterson, ED Jones, P Spertus, JA AF Rumsfeld, JS Havranek, E Masoudi, FA Tooley, JF Peterson, ED Jones, P Spertus, JA TI Depressive symptoms are the strongest predictor of decline in health status in patients with heart failure SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Pharmacia Co, Skokie, IL USA. Duke Univ, Med Ctr, Durham, NC USA. UMKC, Mid Amer Heart Inst, Kansas City, MO USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2338 BP 472 EP 473 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702376 ER PT J AU Ix, JH Mercado, N Shlipak, MG Boersma, E Lemos, PA Lindenboom, W O'Neill, WW Wijns, W Serruys, PW AF Ix, JH Mercado, N Shlipak, MG Boersma, E Lemos, PA Lindenboom, W O'Neill, WW Wijns, W Serruys, PW TI The effect of renal insufficiency on clinical outcomes after coronary revascularization in patients with multivessel disease: The Arterial Revascularization Therapies Study (ARTS) SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Erasmus Univ, Ctr Thorax, NL-3000 DR Rotterdam, Netherlands. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Univ Hosp Digest & Cardialysis, Rotterdam, Netherlands. William Beaumont Hosp, Royal Oak, MI 48072 USA. Onze Lieve Vrouw Hosp, CV Ctr, Aalst, Belgium. RI Lemos, Pedro/G-5758-2013 OI Lemos, Pedro/0000-0002-6782-750X NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2428 BP 492 EP 492 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702466 ER PT J AU Wong, ML Staszewsky, L Anand, I Feliciano, N Hester, A Cohn, JN AF Wong, ML Staszewsky, L Anand, I Feliciano, N Hester, A Cohn, JN TI Stratification of baseline left ventricular dimension and ejection fraction determines response to valsartan in heart failure. Val-HeFT echocardiography study SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Inst Mario Negri, Milan, Italy. Univ Minnesota, Minneapolis, MN USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2526 BP 511 EP 512 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702564 ER PT J AU Cai, JM Hatsukami, TS Ferguson, MS Yuan, C AF Cai, JM Hatsukami, TS Ferguson, MS Yuan, C TI The differentiation of stable and unstable carotid atherosclerotic plaque by in vivo high-resolution MR imaging SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Surg Serv 112, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2590 BP 525 EP 525 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702628 ER PT J AU Xu, Y Lu, L Lee, J Greyson, C Kinugawa, K Long, C Schwartz, GG AF Xu, Y Lu, L Lee, J Greyson, C Kinugawa, K Long, C Schwartz, GG TI Acute treatment with a PPAR-gamma activator increases susceptibility to ventricular fibrillation in myocardial ischemia and reperfusion in pigs SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2776 BP 562 EP 562 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702814 ER PT J AU Agoston, I Urbauer, D Deswal, A AF Agoston, I Urbauer, D Deswal, A TI Outcomes of diastolic heart failure in a racially balanced cohort SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 2801 BP 567 EP 567 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142702839 ER PT J AU Olshansky, B Warner, A Solomon, A Sharma, A Platia, E O'Neill, G Feld, G Rosenfeld, L Akiyama, T Brodsky, M Ingalls, S Greene, HL AF Olshansky, B Warner, A Solomon, A Sharma, A Platia, E O'Neill, G Feld, G Rosenfeld, L Akiyama, T Brodsky, M Ingalls, S Greene, HL CA NHLBI AFFIRM Investigators TI Rate control in atrial fibrillation: A substudy of the AFFIRM trial SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Iowa, Iowa City, IA USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Georgetown Univ, Med Ctr, Washington, DC 20007 USA. Reg Cardiol Assoc, Med Grp, Sacramento, CA USA. Washington Hosp Ctr, Washington, DC 20010 USA. Univ Calif Davis, Sacramento, CA 95817 USA. Univ Calif Davis, Sacramento, CA 95817 USA. Mercy Gen Hosp, Sacramento, CA USA. Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA. Axio Res Corp, Seattle, WA USA. NHLBI, AFFIRM Investigators, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 3125 BP 633 EP 634 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142703164 ER PT J AU Baruch, L Heywood, T Krum, H Anand, I Glazer, R Cohn, JN AF Baruch, L Heywood, T Krum, H Anand, I Glazer, R Cohn, JN TI Efficacy of valsartan in elderly heart failure patients in Val-HeFT SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Loma Linda Univ, Med Ctr, Loma Linda, CA USA. Monash Univ, Sch Med, Melbourne, Vic 3004, Australia. VA Med Ctr Cardiol, Minneapolis, MN USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 3379 BP 685 EP 685 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142703417 ER PT J AU Chen, EW Canto, JG Parsons, LS Every, NR Barron, HV AF Chen, EW Canto, JG Parsons, LS Every, NR Barron, HV TI Hospital variation of short term mortality following acute ST elevation myocardial infarction in the United States SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Alabama, Birmingham, AL USA. Ovat Res Grp, Seattle, WA USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif San Francisco, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 3701 BP 753 EP 753 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142703737 ER PT J AU Chen, EW Canto, JG Parsons, LS Littrell, KA Every, NR Hochman, JS Ohman, EM Cheeks, M Barron, HV AF Chen, EW Canto, JG Parsons, LS Littrell, KA Every, NR Hochman, JS Ohman, EM Cheeks, M Barron, HV TI High hospital intra-aortic balloon counterpulsation volume is associated with lower mortality in acute myocardial infarction complicated by cardiogenic shook SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Alabama, Birmingham, AL USA. Ovat Res Grp, Seattle, WA USA. Genentech Inc, San Francisco, CA 94080 USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. St Lukes Roosevelt Hosp, New York, NY USA. Columbia Univ, New York, NY USA. Univ N Carolina, Chapel Hill, NC USA. Univ Calif San Francisco, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 3742 BP 762 EP 762 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142703778 ER PT J AU Sonel, AF Good, CB Kelley, ME Wall, L Whittle, J AF Sonel, AF Good, CB Kelley, ME Wall, L Whittle, J TI What do borderline troponin elevations imply and do we listen? SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Kansas, Kansas City, KS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S MA 3740 BP 762 EP 762 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142703776 ER PT J AU Chen, EW Canto, JG Parsons, LS Every, NR Barron, HV AF Chen, EW Canto, JG Parsons, LS Every, NR Barron, HV TI Hospital variation of short-term mortality after acute ST-segment elevation myocardial infarction in the United States SO CIRCULATION LA English DT Meeting Abstract CT American-Heart-Association Abstracts From Scientific Sessions CY NOV 17-20, 2002 CL CHICAGO, ILLINOIS SP Amer Heart Assoc C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Alabama, Birmingham, AL USA. Ovat Res Grp, Seattle, WA USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Genentech Inc, San Francisco, CA 94080 USA. Univ Calif San Francisco, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 5 PY 2002 VL 106 IS 19 SU S BP R EP R PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 613QJ UT WOS:000179142700028 ER PT J AU Magid, DJ Rhodes, KV Asplin, BR Steiner, JF Rumsfeld, JS AF Magid, DJ Rhodes, KV Asplin, BR Steiner, JF Rumsfeld, JS TI Designing a research agenda to improve the quality of emergency care SO ACADEMIC EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT AEM Consensus Conference on Assuring Quality CY MAY, 2002 CL ST LOUIS, MISSOURI DE quality; emergency medicine; research ID ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; ADVERSE EVENTS; PROSPECTIVE VALIDATION; IMMEDIATE ANGIOPLASTY; HOSPITALIZED-PATIENTS; CORONARY ANGIOPLASTY; MEDICARE PATIENTS; CLINICAL-TRIAL; RULE AB A systematic approach to develop a research agenda for improving the quality of emergency care is presented. This approach is based on the six domains of quality outlined by the Institute of Medicine (effective, timely, efficient, safe, patient-centered, and equitable care) and a sequence of four research steps (evidence, synthesis, assessment, and intervention). Examples related to the care of patients with acute myocardial infarction are used to illustrate the proposed approach. Examples of other emergency medicine research topics relevant to the Institute of Medicine quality domains are also presented. Research to improve the quality of emergency care can benefit from a more systematic consideration of the domains of quality and the research steps necessary to generate evidence and inform quality improvement efforts in practice. C1 Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. Univ Chicago, Chicago, IL 60637 USA. Reg Hosp, St Paul, MN USA. Hlth Partners Res Fdn, St Paul, MN USA. Colorado Hlth Outcomes Program, Denver, CO USA. Denver VA Med Ctr, Denver, CO USA. RP Magid, DJ (reprint author), Colorado Permanente Clin Res Unit, POB 378066, Denver, CO 80237 USA. NR 63 TC 6 Z9 6 U1 0 U2 1 PU HANLEY & BELFUS INC PI PHILADELPHIA PA 210 S 13TH ST, PHILADELPHIA, PA 19107 USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD NOV PY 2002 VL 9 IS 11 BP 1124 EP 1130 DI 10.1111/j.1553-2712.2002.tb01566.x PG 7 WC Emergency Medicine SC Emergency Medicine GA 614RC UT WOS:000179203100011 PM 12414460 ER PT J AU Rumsfeld, JS Magid, DJ Plomondon, ME Spertus, JA O'Brien, MM Every, NR Sales, AE AF Rumsfeld, JS Magid, DJ Plomondon, ME Spertus, JA O'Brien, MM Every, NR Sales, AE TI Depression is associated with anginal frequency, anginal stability, physical limitation, and quality of life after acute coronary syndromes SO AMERICAN HEART JOURNAL LA English DT Meeting Abstract CT 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY SEP 30-OCT 01, 2001 CL WASHINGTON, D.C. C1 Vet Adm Med Ctr, Denver, CO USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD NOV PY 2002 VL 144 IS 5 MA 31 BP 894 EP 894 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 615NJ UT WOS:000179252400053 ER PT J AU Samaha, FF Kimmel, SE Kizer, JR Goyal, A Wade, M Boden, WE AF Samaha, FF Kimmel, SE Kizer, JR Goyal, A Wade, M Boden, WE TI Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave myocardial Infarction Strategies, In-Hospital (VANQWISH) Trial SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CONSERVATIVE MANAGEMENT STRATEGY; CORONARY SYNDROMES AB We sought to test the validity and clinical, utility of the Thrombolysis in Myocardial Infarction (TIMI) risk,score for patients who have non-O-wave myocardial infarction. A post hoc analysis of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) Trial was performed, wherein patients were assigned a TIMI risk score from which both 30-day and 12-month Outcomes (death, nonfatal myocardial infarction, or urgent revascularization) were assessed. At 30 days, the TIMI risk score showed a close match between observed and predicted probabilities of events after adjustment for overall event rates. The event rate at 30 days was 6%, for a score of 0 to 2, 10% for a score of 3, 13% for a score of 4, and 14% for a score of 5 to 7 (p = 0.003 and c statistic 0.59). Discriminative ability of the score was greater, in the conservative group at 30 days'(p = 0.0004, c statistic 0.67). The score remained modestly predictive of events at 1 year (c statistic 0.66). Conservative strategy. patients had better 30-day outcomes than the invasive strategy patients if their score was 0 to 2 (odds ratio 0.24, 95% confidence interval 0.08 to 0.76). No significant difference in outcomes between strategies was. detected for a score greater than or equal to3. The TIMI risk score provides moderate incremental prognostic information in high-risk patients, during both short- and long-term follow-up. (C) 2002 by Excerpta Medica, Inc. C1 Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Cornell Univ, Dept Med, Weill Coll, New York, NY USA. Cornell Univ, Dept Publ Hlth, Weill Coll, New York, NY USA. Vet Affairs Med Ctr, Syracuse, NY USA. Univ Connecticut, Div Cardiol, Hartford Hosp, Dept Med, Hartford, CT 06112 USA. RP Samaha, FF (reprint author), Vet Affairs Med Ctr, MC 111C,Univ & Woodland Ave, Philadelphia, PA 19104 USA. RI Goyal, Abhinav/J-5086-2012 OI Goyal, Abhinav/0000-0002-6286-2349 NR 12 TC 20 Z9 22 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 1 PY 2002 VL 90 IS 9 BP 922 EP 926 AR PII S0002-9149(02)02654-1 DI 10.1016/S0002-9149(02)02654-1 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 610ZC UT WOS:000178991100003 PM 12398955 ER PT J AU Gallik, DM Singer, I Meissner, MD Molnar, J Somberg, JC AF Gallik, DM Singer, I Meissner, MD Molnar, J Somberg, JC TI Hemodynamic and surface electrocardiographic effects of a now aqueous formulation of intravenous amiodarone SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID POLYSORBATE-80; HEART; DOG AB Intravenous amiodarone is an effective antiarrhythmic agent. However, the standard formulation (Cordarone IV) frequently causes hypotension. Hemodynamic studies have attributed this adverse effect to the solvents employed. A newly developed aqueous formulation (Amio-Aqueous) lacks solvents and thus may not causes hypotension. This study evaluated the hemodynamic effects in a cardiac catheterization laboratory. Two boluses of 150-mg aqueous amiodarone were administered via a peripheral vein to 32 hemodynamically stable patients who underwent cardiac catheterization. Boluses were administered initially over 2 to 5 minutes and in the lost 9 patients over 2 minutes. Hemodynamic evaluation was performed and 12-lead electrocardiograms were obtained at baseline, immediately after each bolus, and following 30 minutes of observation. No patient developed hypotension. There were no significant changes in systolic and diastolic blood pressure (BP) following the boluses. Compared with baseline, heart rate (HR) significantly decreased 5 minutes after the second bolus (73 +/- 12 vs 67 +/- 11 beats/min, p < 0.05). Mean arterial BP increased (90 +/- 14 vs 100 +/- 16 mm Hg, p <0.05) and dp/dt decreased (1,599 +/- 645 vs 1,294 +/- 531 mm Hg/s p <0.05), whereas the PR, QT, and JT intervals increased (174 30 vs 182 331402 +/- 32 vs 424 +/- 35; 317 +/- 37 vs 336 +/- 32 ms, p <0.05, respectively) by the end of the 30-minute observation period. Amio-Aqueous possesses pharmacodynamic effects that have been attributed to amiodarone, whereas it lacks the hypotensive effect of the standard intravenous amiodarone formulation. Amio-Aqueous appears to be a safer alternative to Cordarone IV when rapid administration is indicated. (C) 2002 by Excerpta Medica, Inc. C1 W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ Louisville, Louisville, KY 40292 USA. Sinai Grace Hosp, Detroit, MI USA. Acad Pharmaceut, Lake Bluff, IL USA. Rush Univ, Chicago, IL 60612 USA. RP Somberg, JC (reprint author), 21 N Skokie Valley Hwy,Suite G-3, Lake Bluff, IL 60044 USA. NR 17 TC 19 Z9 20 U1 1 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 1 PY 2002 VL 90 IS 9 BP 964 EP 968 AR PII S0002-9149(02)02662-0 DI 10.1016/S0002-9149(02)02662-0 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 610ZC UT WOS:000178991100011 PM 12398963 ER PT J AU Lieber, CS Packer, L AF Lieber, CS Packer, L TI S-adenosylmethionine: molecular, biological, and clinical aspects - an introduction SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article; Proceedings Paper CT Symposium on S-Adenosylmethionine (SAMe) - From Molecular Mechanism to Clinical Implications CY MAR 07-10, 2001 CL SANTA BARBARA, CALIFORNIA SP Abbott Labs, Ross Prod Div DE homocysteine; membranes; methionine; methionine adenosyltransferase; nucleic acids; polyamines; S-adenosylmethionine ID METABOLISM; HOMOCYSTEINE; METHIONINE; LIVER AB In clinical research, a novel approach has emerged: some of the essential nutrients are being used to treat pathologic conditions. Many of these nutrients, including methionine, must first be activated in the liver or in other tissues before they can exert their key functions. However, this activating process is impaired in disease states and, as a consequence, nutritional requirements change. For instance, for methionine to act as the main cellular methyl donor, it must first be activated to S-adenosylmethionine (SAMe; also known as ademethionine). SAMe is required and is of fundamental importance for the metabolism of nucleic acids and polyamines, the structure and function of membranes, and as a precursor of glutathione. These processes are often seriously altered in various pathologic states addressed in this symposium, but they cannot be restored by simply administering methionine. For instance, in liver disease associated with impairment of the enzyme that activates methionine to SAMe, supplementation with methionine is useless and may even become toxic as it accumulates because it is not used. Accordingly, one must correct the lack of SAMe by bypassing the deficiency in enzyme activation; this is done by providing the product of the defective reaction, namely SAMe. Under these pathologic conditions, SAMe becomes crucial for the functioning of the cell. Thus SAMe, which is found in all living organisms, becomes the essential nutrient instead of methionine. This symposium reviewed the biological and corresponding molecular aspects of SAMe metabolism and the clinical consequences of its deficiency or supplementation in various tissues. C1 Bronx Vet Adm Med Ctr, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Bronx, NY USA. Univ So Calif, Dept Mol Pharmacol & Toxicol, Sch Pharm, Los Angeles, CA USA. RP Lieber, CS (reprint author), Bronx Vet Adm Med Ctr, Sect Liver Dis & Nutr, 151-2,130 W Kingsbridge Rd, Bronx, NY 10468 USA. NR 12 TC 39 Z9 44 U1 0 U2 2 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2002 VL 76 IS 5 BP 1148S EP 1150S PG 3 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 609PE UT WOS:000178913500039 PM 12418492 ER PT J AU Lieber, CS AF Lieber, CS TI S-adenosyl-L-methionine: its role in the treatment of liver disorders SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article; Proceedings Paper CT Symposium on S-Adenosylmethionine (SAMe) - From Molecular Mechanism to Clinical Implications CY MAR 07-10, 2001 CL SANTA BARBARA, CALIFORNIA SP Abbott Labs, Ross Prod Div DE S-adenosyl-L-methionine; SAMe; alcoholic liver injury; baboons; cholestasis; fibrosis; mitochondria; oxidative stress; liver disorders ID HEPATIC GLUTATHIONE; INTRAHEPATIC CHOLESTASIS; AMINO-ACIDS; ETHANOL; DISEASE; CIRRHOSIS; ALCOHOL; PATHOGENESIS; PLASMA; INJURY AB S-Adenosyl-L-methionine (SAMe) exerts many key functions in the liver, including serving as a precursor for cysteine, 1 of 3 amino acids of glutathione-the major physiologic defense mechanism against oxidative stress. SAMe is particularly important in opposing the toxicity of free oxygen radicals generated by various pathogens, including alcohol, which cause oxidative stress largely by the induction of cytochrome P4502E1 (CYP2E1) and by its metabolite acetaldehyde. SAMe also acts as the main methylating agent in the liver. The precursor of SAMe is methionine, one of the essential amino acids, which is activated by SAMe-synthetase (EC 2.5.1.6). Unfortunately, the activity of this enzyme is significantly decreased as a consequence of liver disease. Because of decreased utilization, methionine accumulates and, simultaneously, there is a decrease in SAMe that acquires the status of an essential nutrient and therefore must be provided exogenously as a supernutrient to compensate for its deficiency. Administration of this innocuous supernutrient results in many beneficial effects in various tissues, mainly in the liver, and especially in the mitochondria. This was shown in alcohol-fed baboons and in other experimental models of liver injury and in clinical trials, some of which are reviewed in other articles in this issue. C1 Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. Bronx Vet Affairs Med Ctr, Alcohol Res Ctr, Sect Liver Dis & Nutr, Bronx, NY 10468 USA. RP Lieber, CS (reprint author), Bronx Vet Affairs Med Ctr, Mt Sinai Sch Med, Sect Liver Dis & Nutr, 151-2,130 W Kingsbridge Rd, Bronx, NY 10468 USA. FU NIAAA NIH HHS [AA11115, AA12867] NR 50 TC 72 Z9 80 U1 2 U2 6 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2002 VL 76 IS 5 BP 1183S EP 1187S PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 609PE UT WOS:000178913500045 PM 12418503 ER PT J AU Ramirez, FC Padda, S Medlin, S Tarbell, H Leung, FW AF Ramirez, FC Padda, S Medlin, S Tarbell, H Leung, FW TI Reflectance spectrophotometry in the gastrointestinal tract: Limitations and new applications SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID MUCOSAL BLOOD-FLOW; PORTAL HYPERTENSIVE GASTROPATHY; ENDOSCOPIC ASSESSMENT; CIRRHOTIC-PATIENTS; GASTRIC-ULCER; HEMODYNAMICS; PERFUSION; INJURY; RESPONSES; HYPOXIA AB OBJECTIVES: Reflectance spectrophotometry (RS) assesses blood flow changes by measuring an index of Hb concentration (IHB) and index of Hb oxygen saturation (ISO2). We tested the following hypotheses: 1) endoscopic RS measurements obtained by two observers and with the aid of fiber optic and video endoscopes are similar, and 2) the method is suitable for documenting mesenteric venoconstriction associated with systemic hypoxia and blood flow autoregulation associated with hemorrhagic hypotension. METHODS: Study 1: two investigators obtained baseline gastric mucosal RS measurements in anesthetized rats (n = 3) before and after stepwise reduction of blood pressure induced by arterial hemorrhage. Study 2: subjects were examined by both fiber optic and video endoscopes. Endoscopic RS measurements were obtained at 20 cm from the anal verge. Study 3: video endoscope was used to obtain RS measurements in oxygen-dependent patients on and off oxygen treatment. Study 4: the procedures in study I were repeated in five additional rats by one of the investigators. RESULTS: Study 1: there was good agreement between the measurements of IHB and ISO2 between the two investigators. Study 2: video endoscope-assisted measurements were consistently lower. Study 3: cessation of oxygen treatment produced a significant drop in oxygen saturation (pulse oximetry), decline in ISO2, and rise in IHB. Study 4: when blood pressure varied between 90% and 40% of baseline, gastric mucosal blood flow (IHB) was maintained at similar to70% of baseline level. CONCLUSIONS: We confirmed that reproducible measurement can be obtained by different investigators using standardized techniques. Standardization of endoscopic equipment is also necessary to overcome the significant limitation of endoscopic equipment on RS measurements. RS measurements can document mesenteric venoconstriction associated with systemic hypoxia and blood flow autoregulation associated with hemorrhagic hypotension. (C) 2002 by Am. Coll. of Gastroenterology. C1 Carl T Hayden VA Med Ctr, Res Serv, Phoenix, AZ 85012 USA. Carl T Hayden VA Med Ctr, Med Serv, Phoenix, AZ 85012 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Nursing Home, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Ramirez, FC (reprint author), Carl T Hayden VA Med Ctr, Res Serv, 650 E Indian Sch Rd, Phoenix, AZ 85012 USA. NR 31 TC 13 Z9 13 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2002 VL 97 IS 11 BP 2780 EP 2784 AR PII S0002-9270(02)05439-4 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 613DH UT WOS:000179116100021 PM 12425548 ER PT J AU Oslin, DW Pettinati, H Volpicelli, JR AF Oslin, DW Pettinati, H Volpicelli, JR TI Alcoholism treatment adherence - Older age predicts better adherence and drinking outcomes SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID ADDICTION SEVERITY INDEX; BEHAVIORAL TREATMENT; TREATMENT PROGRAMS; NALTREXONE; DEPENDENCE; RELIABILITY; ABUSE; DRINKERS; TRIAL AB Objective: Adherence to treatment has been demonstrated to be an important factor for remission from alcohol dependence. The authors compared therapy and medication adherence for treatment of alcohol dependence in older adults with adherence in younger adults. Methods: All subjects were participants in a randomized, double-blind, placebo-controlled efficacy trial of naltrexone for the treatment of alcohol dependence. All subjects received a medically-based psychosocial intervention focused on motivating patients to change and on adherence to treatment The therapy is non-confrontational and is delivered by a nurse-practitioner Results: Compared with younger adults, older adults bad greater attendance at therapy sessions and greater adherence to the medication. Age-group was the only pretreatment factor associated with adherence. The greater adherence in older adults translated to less relapse than in younger adults. Conclusion: Treatment for alcohol dependence can be effective for older adults. Older adults appear to respond well to a medically-oriented program that is supportive and individualized. In fact, findings from this study suggest that older adults can be treated in mixed-age treatment settings when psychotherapeutic strategies are used that are age-appropriate and delivered on an individual basis. C1 Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Ctr Study Addict, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Oslin, DW (reprint author), Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, 3535 Market St,Room 3002, Philadelphia, PA 19104 USA. FU NIAAA NIH HHS [AA 07517] NR 34 TC 32 Z9 33 U1 5 U2 7 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV-DEC PY 2002 VL 10 IS 6 BP 740 EP 747 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 614DC UT WOS:000179172200013 PM 12427583 ER PT J AU Suchin, EJ Cizman, B Connolly, BR DiBattista, WJ Agus, ZS AF Suchin, EJ Cizman, B Connolly, BR DiBattista, WJ Agus, ZS TI Pseudohyperphosphatemia in a hyperphosphatemic hemodialysis patient SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE phosphorus; hyperphosphatemia; pseudohyperphosphaternia; hemodialysis (HD); analytical methods ID ROUTINE PHOTOMETRIC ANALYSIS; MULTIPLE-MYELOMA; INTERFERENCE; PHOSPHORUS AB Hyperphosphatemia is a predictable consequence of end-stage renal disease. Pseudohyperphosphatemia is a spurious elevation of serum phosphate in samples containing a substance that interferes with the laboratory assay for phosphate. The most common cause is a paraprotein in disorders such as Waldenstrom's macroglobulinemia and multiple myeloma. We report here a case of pseudohyperphosphatemia in a hyperphosphatemic patient with end-stage renal disease on long-term hemodialysis caused by a saline solution containing phosphorus used to dilute the patient's serum sample in the clinical chemistry laboratory. Investigations showed that the phosphorus most likely was introduced at the time of saline manufacture. Pseudohyperphosphatemia resulting from the manufacture and distribution of saline-containing phosphorus could be a cause of abnormally high serum phosphate measurements in hyperphosphatemic dialysis patients whose serum samples must be diluted in the laboratory. Such spuriously elevated results can lead to inappropriate changes in medications and subject patients to additional hemodialysis treatments. C1 Hosp Univ Penn, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Med, Renal Sect, Philadelphia, PA USA. Philadelphia Vet Affairs Med Ctr, Dept Lab Med, Philadelphia, PA USA. RP Agus, ZS (reprint author), Hosp Univ Penn, Renal Electrolyte & Hypertens Div, 700 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA. NR 22 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2002 VL 40 IS 5 AR E18 DI 10.1053/ajkd.2002.36351 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 611ZA UT WOS:000179047100036 PM 12407666 ER PT J AU Peabody, JW Luck, J AF Peabody, JW Luck, J TI When do developing countries adopt managed care policies and technologies? Part I: Policies, experience, and a framework of preconditions SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID HEALTH-CARE; LATIN-AMERICA; REFORM; PROSPECTS; SERVICES; COLOMBIA; SYSTEM; SECTOR; CHINA; HMOS AB Objective: For developing countries with constrained economic resources, managed care holds out the promise of,being able to control healthcare costs and reduce unnecessary utilization. However, little empirical evidence has been gathered about when managed care techniques can be applied to these countries and no framework considers the macroeconomic context. We propose. a, straightforward method to evaluate the economic and policy environment of a developing country to assess when managed care might be introduced. Study Design and, Methods: Analysis of available developing country health system and healthcare spending data, review of the available literature, and authors' experience evaluating healthcare reforms in developing,countries. Results: Many countries have implemented managed care techniques, which are driven by-policy efforts to increase quality or to control costs. Successful implementation of managed care, however, appears to depend on five major preconditions. One precondition is an adequately developed formal wage sector in which patients have a sufficient ability to pay for healthcare services. Another is an adequate labor supply of trained professionals to support managed care administration, foster competition, and use available information technology. Conclusions: Although managed care encompasses a range of incentives and arrangements, implementation in developing countries appears to depend on attaining macroeconomic preconditions. C1 Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, San Francisco, CA 94105 USA. RAND Corp, Santa Monica, CA 90407 USA. Univ Calif Los Angeles, Sch Publ Hlth, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90024 USA. RP Peabody, JW (reprint author), Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, 74 New Montgomery St,Suite 508, San Francisco, CA 94105 USA. NR 63 TC 3 Z9 3 U1 0 U2 1 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2002 VL 8 IS 11 BP 997 EP 1007 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 614LE UT WOS:000179190100008 PM 12437314 ER PT J AU Grady, D Yaffe, K Kristof, M Lin, F Richards, C Barrett-Connor, E AF Grady, D Yaffe, K Kristof, M Lin, F Richards, C Barrett-Connor, E TI Effect of postmenopausal hormone therapy on cognitive function: The heart and estrogen/progestin replacement study SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID ALZHEIMERS-DISEASE; ESTROGEN-TREATMENT; WORKING-MEMORY; WOMEN; DEMENTIA; TRIAL; HEALTH; APOE AB PURPOSE: To determine if hormone therapy results in better cognitive function in older postmenopausal women. SUBJECTS AND METHODS: The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized, placebo-controlled trial involving 2763 women with coronary disease. Women were assigned randomly to conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) in one tablet daily or identical placebo; they were followed for a mean (+/-SD) of 4.2 +/- 0.4 years. Participants at 10 of the 20 HERS centers were invited to enroll in the cognitive function substudy. At the end of the trial, we measured cognitive function in 517 women in the hormone group and 546 in the placebo group using six standard tests: the modified Mini-Mental Status Examination, Verbal Fluency, Boston Naming, Word List Memory, Word List Recall, and Trails B. Cognitive function was not measured at baseline. RESULTS: The mean age of participants at the time of cognitive function testing was 71 +/- 6 years. There were no differences in age-adjusted cognitive function test scores between the two treatment groups, except that women assigned to hormones scored worse on the Verbal Fluency test than women assigned to placebo (15.9 +/- 4.8 vs. 16.6 +/- 4.8, P = 0.02). Adjustment for other potential confounders and restriction of the analyses to women who had been adherent to study medication did not change the results. CONCLUSION: Among older postmenopausal women with coronary disease, 4 years of treatment with postmenopausal hormone therapy did not result in better cognitive function as measured on six standardized tests. Whether these results also apply to elderly women without coronary disease cannot be determined from this study. (C) 2002 by Excerpta Medica, Inc. C1 Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94115 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94115 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Wyeth Ayerst Res, Radnor, PA USA. Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. RP Grady, D (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 1635 Divisidero St,Suite 600, San Francisco, CA 94115 USA. NR 34 TC 132 Z9 139 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD NOV PY 2002 VL 113 IS 7 BP 543 EP 548 AR PII S0002-9343(02)01270-6 DI 10.1016/S0002-9343(02)01270-6 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 619BR UT WOS:000179453900002 PM 12459399 ER PT J AU Mangrulkar, RS Saint, S Chu, S Tierney, LM AF Mangrulkar, RS Saint, S Chu, S Tierney, LM TI What is the role of the clinical "pearl"? SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID EVIDENCE-BASED MEDICINE; EPIDEMIOLOGY C1 Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA. Ann Arbor VA Med Ctr, Ann Arbor, MI USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Mangrulkar, RS (reprint author), Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA. NR 14 TC 5 Z9 5 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD NOV PY 2002 VL 113 IS 7 BP 617 EP 624 AR PII S0002-9343(02)01353-0 DI 10.1016/S0002-9343(02)01353-0 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 619BR UT WOS:000179453900019 PM 12459416 ER PT J AU Berg, AO AF Berg, AO CA US Preventive Services Task Force TI Newborn hearing screening: Recommendations and rationale SO AMERICAN JOURNAL OF NURSING LA English DT Article ID IDENTIFICATION; IMPAIRMENT C1 Univ Washington, Dept Family Med, Seattle, WA 98195 USA. Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX 78285 USA. Tri Cty Family Med, Cohocton, NY USA. Univ Rochester, Sch Med, Rochester, NY USA. Natl Initiat Childrens Healthcare Qual, Boston, MA USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Family Med, Newark, NJ 07103 USA. Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78285 USA. Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA. Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. CUNY Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Med Serv Care Ctr, New York, NY 10029 USA. Mt Sinai Med Ctr, New York, NY 10029 USA. Merck & Co Inc, Outcomes Res & Management, W Point, PA USA. Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY USA. Virginia Commonwealth Univ, Dept Family Practice, Fairfax, VA USA. RP Berg, AO (reprint author), Care of Atkins D, US Prevent Serv Task Force, Ctr Practice & Technol Assessment, Agcy Healthcare Res & Qual, 6010 Execut Blvd,Suite 300, Rockville, MD 20852 USA. NR 18 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD NOV PY 2002 VL 102 IS 11 BP 83 EP + PG 4 WC Nursing SC Nursing GA 615DZ UT WOS:000179231700033 PM 12436079 ER PT J AU Cunha, IT Lim, PAC Henson, H Monga, T Qureshy, H Protas, EJ AF Cunha, IT Lim, PAC Henson, H Monga, T Qureshy, H Protas, EJ TI Performance-based gait tests for acute stroke patients SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE physical performance; gait; qualitative measures; stroke survivors ID REHABILITATION; RECOVERY; SCALE; TRIAL AB Objective: Qualitative measures may not differentiate severity of deficits after an acute or subacute stroke. The aim of this study was to contrast the utility of performance-based gait tests with qualitative measures in a sample of acute stroke patients. Design: Twenty acute stroke subjects had their performance-based gait measured by gait speed, walking distance, gait energy expenditure, and gait energy cost. They were also qualitatively evaluated for cognition, functional outcomes, motor impairment, and Functional Ambulation Category. Results: Strong and significant correlations were observed among performance-based gait tests. Qualitative scales indicated moderate to minimal deficits in each domain evaluated although they were not, correlated among themselves, except for Functional Ambulation Category and FIM(TM) and FIM and Mini-Mental State Exam. Functional Ambulation Category correlated with performance-based gait tests. Conclusions: Performance-based gait tests are feasible to conduct during early recovery after a stroke and allow better discrimination among the patients than qualitative measures. C1 Texas Womans Univ, Sch Phys Therapy, Houston, TX USA. Houston Vet Affairs Med Ctr, Phys Med & Rehabil Dept, Houston, TX USA. Houston Vet Affairs Med Ctr, Rehabil Res & Dev Ctr Healthy Aging & Disabil, Houston, TX USA. Singapore Gen Hosp, Singapore 0316, Singapore. RP Protas, EJ (reprint author), 1130 John Freeman Blvd, Houston, TX 77030 USA. NR 29 TC 62 Z9 66 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2002 VL 81 IS 11 BP 848 EP 856 DI 10.1097/01.PHM.0000027423.96462.CF PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 607FP UT WOS:000178781700008 PM 12394997 ER PT J AU Chen, MC Solomon, TE Kui, R Soll, AH AF Chen, MC Solomon, TE Kui, R Soll, AH TI Apical EGF receptors regulate epithelial barrier to gastric acid: endogenous TGF-alpha is an essential facilitator SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE peptic ulcer; paracellular pathway; tight junctions; cell polarity ID EPIDERMAL GROWTH-FACTOR; CHIEF CELL MONOLAYERS; MOLECULAR PHYSIOLOGY; TIGHT JUNCTIONS; CULTURE; JUICE; PATHOPHYSIOLOGY; SURFACE; PERMEABILITY; PROTEINS AB In previous studies, we found that apical and basolateral EGF receptors (EGFR) on primary canine gastric monolayers decreased paracellular permeability, evident by increased transepithelial electrical resistance (TER) and decreased flux of [H-3]mannitol (MF). After studying monolayers in Ussing chambers, we now report that treatment with apical, but not basolateral, EGF enhanced tolerance to apical H+, evident by a slower decay in TER and an attenuated rise in MF. Enhanced tolerance to apical acid was evident within 10 min of treatment with apical EGF. Immunoneutralization of endogenous transforming growth factor (TGF)-alpha accelerated the drop in TER and the rise in MF in response to apical acidification; apical EGF reversed these effects. Study of monolayers cultured in Transwell inserts showed that immunoblockade of basolateral, but not apical, EGFR also impaired the resistance to apical acidification and enhanced MF. We conclude that apical EGFR regulates the barrier to apical acidification via effects on paracellular resistance. Although exogenous basolateral EGF has a less apparent effect on the barrier to acid, endogenous ligand active at basolateral EGFR plays an important role in maintaining the barrier to apical acid. Our data implicate a role for an apical EGFR ligand, which may be EGF or another member of the EGF family. C1 Univ Calif Los Angeles, Sch Med, Greater Los Angeles Vet Affairs Hlth Care Syst, CURE,Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Greater Los Angeles Vet Affairs Hlth Care Syst, Med & Res Serv, Los Angeles, CA 90073 USA. RP Soll, AH (reprint author), Vet Affairs Wadsworth Hosp Ctr, Bldg 115,Rm 215,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-19984, DK-30444] NR 35 TC 15 Z9 15 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV PY 2002 VL 283 IS 5 BP G1098 EP G1106 DI 10.1152/ajpgi.00507.2001 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 604CX UT WOS:000178599100011 PM 12381523 ER PT J AU Okolo, C Wong, T Moody, MW Nguyen, TD AF Okolo, C Wong, T Moody, MW Nguyen, TD TI Effects of bile acids on dog pancreatic duct epithelial cell secretion and monolayer resistance SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE taurocholate; iodide and rubidium efflux; pancreatitis; Ussing chamber; transepithelial resistance ID TAUROURSODEOXYCHOLIC ACID; CALCIUM; LINE; CONDUCTANCES; MORPHOLOGY; POTASSIUM; TRANSPORT; CURRENTS; SALTS; COLON AB Pancreatic duct epithelial cells (PDEC) mediate the secretion of fluid and electrolytes and are exposed to refluxed bile. In nontransformed cultured dog PDEC, which express many ion transport pathways of PDEC, 1 mM taurodeoxycholic acid (TDCA) stimulated an I-125(-) efflux inhibited by DIDS and 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) and a Rb-86(+) efflux inhibited by charybdotoxin. Inhibition by 1,2-bis(2-aminophenoxy)-ethane- N,N,N',N'-tetraacetic acid (BAPTA)-AM suggests mediation via increased intracellular Ca2+ concentration, whereas the absence of lactate dehydrogenase release excludes cellular toxicity. At 1 mM, TDCA stimulated a larger I-125(-) efflux than glycodeoxycholate; two dihydroxy bile acids, taurochenodeoxycholate and TDCA, were similarly effective, whereas a trihydroxy bile acid, taurocholate, was ineffective. In Ussing chambers, 1 mM serosal or 2 mM luminal TDCA stimulated an I-sc increase from confluent PDEC monolayers. TDCA also stimulated 1) a short-circuit current (I-sc) increase from basolaterally permeabilized PDEC subject to a serosal-to-luminal Cl- gradient that was inhibited by BAPTA-AM, DIDS, and NPPB and 2) an I-sc increase from apically permeabilized PDEC subject to a luminal-to-serosal K+ gradient inhibited by BAPTA-AM and charybdotoxin. Along with the efflux studies, these findings suggest that TDCA interacts directly with PDEC to stimulate Ca2+-activated apical Cl- channels and basolateral K+ channels. Monolayer transepithelial resistance was only minimally affected by 1 mM serosal and 2 mM luminal TDCA but decreased after exposure to higher TDCA concentrations (2 mM serosal and 4 mM luminal). A secretory role for bile acids should be considered in pancreatic diseases associated with bile reflux. C1 Univ Washington, Div Gastroenterol, Dept Med, VA Med Ctr,GI Sect, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Nguyen, TD (reprint author), Univ Washington, Div Gastroenterol, Dept Med, VA Med Ctr,GI Sect, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK-07742, R01-DK-55885] NR 23 TC 5 Z9 5 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV PY 2002 VL 283 IS 5 BP G1042 EP G1050 DI 10.1152/ajpgi.00436.2001 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 604CX UT WOS:000178599100005 PM 12381517 ER PT J AU Wu, MF John, J Maidment, N Lam, HA Siegel, JM AF Wu, MF John, J Maidment, N Lam, HA Siegel, JM TI Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE cerebrospinal fluid; locomotor activity; feeding; orexin ID LOCUS-COERULEUS NEURONS; LATERAL HYPOTHALAMIC AREA; OREXIN MESSENGER-RNA; RETICULAR-FORMATION; BEHAVIORAL ORGANIZATION; UNRESTRAINED CAT; CONSCIOUS RATS; EXPRESSION; MICE; SECRETION AB Hypocretins (orexins) are recently discovered hypothalamic neuropeptides that have been implicated in the etiology of narcolepsy. The normal behavioral functions of these peptides are unclear, although a role in feeding has been suggested. We measured hypocretin-1 (Hcrt-1) in the cerebrospinal fluid of dogs during a variety of behaviors. We found that 48 h without food (24 h beyond normal 24-h fasting period) produced no significant change in Hcrt-1 levels nor did feeding after the deprivation. In contrast, 24 h of sleep deprivation produced on average a 70% increase in Hcrt-1 level compared with baseline levels. The amount of increase was correlated with the level of motor activity during the sleep-deprivation procedure. A 2-h period of exercise in the same dogs produced a 57% increase in Hcrt-1 levels relative to quiet waking levels, with the magnitude of the increase being highly correlated with the level of motor activity. The strong correlation between motor activity and Hcrt-1 release may explain some of the previously reported behavioral, physiological, and pathological phenomena ascribed to the Hcrt system. C1 Vet Affairs Greater Los Angeles Healthcare Syst S, North Hills, CA 91343 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. RP Wu, MF (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst S, North Hills, CA 91343 USA. FU NIMH NIH HHS [MH-64109]; NINDS NIH HHS [NS-14610] NR 64 TC 90 Z9 92 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD NOV PY 2002 VL 283 IS 5 BP R1079 EP R1086 DI 10.1152/ajpregu.00207.2002 PG 8 WC Physiology SC Physiology GA 604HP UT WOS:000178613500012 PM 12376401 ER PT J AU Kern, RS Liberman, RP Kopelowicz, A Mintz, J Green, MF AF Kern, RS Liberman, RP Kopelowicz, A Mintz, J Green, MF TI Applications of errorless learning for improving work performance in persons with schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the Society-for-Research-in-Psychopathology CY NOV 01-04, 2001 CL MADISON, WISCONSIN SP Soc Res Psychopathol ID SEVERE MENTAL-ILLNESS; SUPPORTED EMPLOYMENT; CONTROLLED TRIAL; MEMORY; REHABILITATION; DISORDERS; OUTPATIENTS; INDIVIDUALS; REMEDIATION; DEFICITS AB Objective: Until recently, few training methods used in the psychosocial rehabilitation of persons with schizophrenia have taken into account the neurocognitive deficits common to this illness. The present study tested a training method called errorless learning (which theoretically compensates for neurocognitive impairments) for efficacy at teaching entry-level job tasks to persons with serious and persistent mental illness. Method: Sixty-five unemployed, clinically stable outpatients with schizophrenia or schizoaffective disorder were randomly assigned to training by means of either errorless learning or conventional instruction for two entry-level job tasks (index card filing and toilet tank assembly). Training was conducted in small groups of four subjects for 90-120 minutes in a simulated workshop. Efficacy-as measured by accuracy, speed, and overall productivity-was assessed immediately after training and at a 3-month follow-up evaluation. Results: Significant group differences in accuracy that favored errorless learning were found on both job tasks. In terms of productivity, the errorless learning group was superior to the conventional instruction group on the card filing task, and differences for the tank assembly task approached significance. There were no significant group differences in speed. Both groups showed significant drops in accuracy and productivity on the tank assembly task from immediately after training to the 3-month follow-up evaluation; performance levels were more stable for both groups on the card filing task. Conclusions. Errorless learning appears to be a useful training method for establishing introductory high levels of performance in the work rehabilitation of persons with schizophrenia. Future studies may wish to test its long-term durability by embedding it within supported employment programs. C1 VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Mental Illness Res Educ & Clin Ctr, MIRECC, Dept Vet Affairs, VISN 22, Los Angeles, CA USA. San Fernando Mental Hlth Ctr, San Fernando, CA USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC, 210 A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI kopelowicz, alex/0000-0002-1728-4105 FU NIMH NIH HHS [MH-30911] NR 54 TC 52 Z9 53 U1 5 U2 8 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD NOV PY 2002 VL 159 IS 11 BP 1921 EP 1926 DI 10.1176/appi.ajp.159.11.1921 PG 6 WC Psychiatry SC Psychiatry GA 613EY UT WOS:000179120300020 PM 12411229 ER PT J AU Washington, DL Bird, CE AF Washington, DL Bird, CE TI Sex differences in disease presentation in the emergency department SO ANNALS OF EMERGENCY MEDICINE LA English DT Editorial Material ID ACUTE MYOCARDIAL-INFARCTION; GENDER DIFFERENCES; CHEST PAIN; PERSPECTIVE C1 VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RAND Hlth, Santa Monica, CA USA. RP Washington, DL (reprint author), 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. RI Bird, Chloe/C-7107-2008 NR 12 TC 3 Z9 3 U1 1 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD NOV PY 2002 VL 40 IS 5 BP 461 EP 463 DI 10.1067/mem.2002.128859 PG 3 WC Emergency Medicine SC Emergency Medicine GA 609DX UT WOS:000178889300002 PM 12399787 ER PT J AU Weinberg, A Li, SB Palmer, M Tyler, KL AF Weinberg, A Li, SB Palmer, M Tyler, KL TI Quantitative CSFPCR in Epstein-Barr virus infections of the central nervous system SO ANNALS OF NEUROLOGY LA English DT Article ID POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; NEUROLOGIC COMPLICATIONS; MONONUCLEOSIS; ENCEPHALITIS; DISEASES; PCR; MENINGOENCEPHALITIS; ANTIBODIES; DIAGNOSIS AB Acute Epstein-Barr virus (EBV) infection of the central nervous system (CNS) is associated with meningoencephalitis and other neurological syndromes and with CNS lymphomas (CNSLs). Diagnosis is based on serological studies and more recently on detection of EBV DNA in cerebrospinal fluid (CSF) by polymerase chain reaction (PCR). We measured EBV DNA toy quantitative PCR and EBV mRNA by RT-PCR in the CSF in patients with EBV-associated neurological disorders. EBV was identified as the cause of CNS infection in 28 patients: 14 with CNSL, 10 with encephalitis, and 4 with postinfectious neurological complications. CSF analysis showed that patients with CNSL had high EBV load (mean +/- standard error of 4.8 +/- 0.2 log(10) DNA copies/ml) and low leukocyte counts (22 +/- 7 cells/mul); encephalitis was characterized by high EBV load (4.2 +/- 0.3 log(10) DNA copies/ml) and high leukocyte counts (143 62 cells/mul); and patients with postinfectious complications showed low EBV load (3.0 +/- 0.2 log(10) DNA copies/ml) with high leukocyte counts (88 +/- 57 cells/mul). Lytic cycle EBV mRNA, a marker of viral replication, was identified in 10 CSF samples from patients with CNSL and encephalitis. These studies demonstrate the utility of quantitative CSF PCR and establish the presence of lyric cycle EBV mRNA in CSF of patients with EBV-associated neurological disease. C1 Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol & Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Weinberg, A (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Campus Box C227, Denver, CO 80262 USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NIAID NIH HHS [U01 AI 38858]; NICHD NIH HHS [N01HD 33162] NR 29 TC 73 Z9 76 U1 0 U2 3 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD NOV PY 2002 VL 52 IS 5 BP 543 EP 548 DI 10.1002/ana.10321 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 609PK UT WOS:000178914000005 PM 12402250 ER PT J AU Suzuki, T Bless, DM Connor, NP Ford, CN Lee, K Inagi, K AF Suzuki, T Bless, DM Connor, NP Ford, CN Lee, K Inagi, K TI Age-related alterations in myosin heavy chain isoforms in rat intrinsic laryngeal muscles SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article; Proceedings Paper CT Meeting of the American-Broncho-Esophagological-Association CY MAY 14-15, 2001 CL PALM DESERT, CALIFORNIA SP Amer Broncho Esophagolog Assoc DE aging; lateral cricoarytenoid muscle; myosin heavy chain; posterior cricoarytenoid muscle; thyroarytenoid muscle ID SKELETAL-MUSCLE; FIBER-TYPE; EXPRESSION; MODULATION; VELOCITY; ATROPHY AB Deficits in voice and swallowing are found in the elderly, but the underlying neuromuscular mechanisms are unclear. A potential mechanism may be denervation-induced muscle fiber transformation to a slower-contracting type of muscle fiber. This study examined young, old, and denervated rat laryngeal muscles (lateral thyroarytenoid, lateral cricoarytenoid, and posterior cricoarytenoid) to examine differences in myosin heavy chain (MHC) composition. Results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses indicated that all muscles were composed predominately of type IIB MHC. With aging and denervation, type IIB was reduced and type IIX, a slower-contracting isoform, was increased in the lateral thyroarytenoid and lateral cricoarytenoid muscles. In the posterior cricoarytenoid muscle, the MHC composition was relatively unchanged. These findings suggest that aging may affect laryngeal adductory function by altering muscle fiber type composition to a slower-contracting isoform, in a manner similar to that observed with denervation. C1 Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. Kitasato Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kanagawa, Japan. Med Ctr Hosp, Kitasato Inst, Dept Otolaryngol Head & Neck Surg, Saitama, Japan. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. NR 35 TC 25 Z9 28 U1 1 U2 4 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD NOV PY 2002 VL 111 IS 11 BP 962 EP 967 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 614EM UT WOS:000179175400002 PM 12450167 ER PT J AU Wexler, HM Molitoris, D St John, S Vu, A Read, EK Finegold, SM AF Wexler, HM Molitoris, D St John, S Vu, A Read, EK Finegold, SM TI In vitro activities of faropenem against 579 strains of anaerobic bacteria SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CARBAPENEMASE GENE CFIA; BACTEROIDES-FRAGILIS; PSEUDOMONAS-AERUGINOSA; HYDROLYZING ENZYME; BETA-LACTAMASE; ORAL PENEM; IMIPENEM; RESISTANCE; EXPRESSION; OPRD AB The activity of faropenem, a new oral penem, was tested against 579 strains of anaerobic bacteria by using the NCCLS-approved reference method. Drugs tested included amoxicillin-clavulanate, cefoxitin, clindamycin, faropenem, imipenem, and metronidazole. Of the 176 strains of Bacteroides fragilis group isolates tested, two isolates had faropenem MICs of 64 mug/ml and imipenem MICs of >32 mug/ml. Faropenem had an MIC of 16 mug/ml for an additional isolate of B. fragilis; this strain was sensitive to imipenem (MIC of 1 mug/ml). Both faropenem and imipenem had MICs of less than or equal to4 mug/ml for all isolates of Bacteroides capillosus (10 isolates), Bacteroides splanchnicus (13 isolates), Bacteroides ureolyticus (11 isolates), Bilophila wadsworthia (11 isolates), Porphyromonas species (42 isolates), Prevotella species (78 isolates), Campylobacter species (25 isolates), Sutterella wadsworthensis (11 isolates), Fusobacterium nucleatum (19 isolates), Fusobacterium mortiferum/varium (20 isolates), and other Fusobacterium species (9 isolates). Faropenem and imipenem had MICs of 16 to 32 mug/ml for two strains of Clostridium difficile; the MICs for all other strains of Clostridium tested (69 isolates) were less than or equal to4 mug/ml. Faropenem had MICs of 8 and 16 mug/ml, respectively, for two strains of Peptostreptococcus anaerobius (MICs of imipenem were 2 mug/ml). MICs were less than or equal to4 mug/ml for all other strains of gram-positive anaerobic cocci (53 isolates) and non-spore-forming gram-positive rods (28 isolates). Other results were as expected and reported in previous studies. No metronidazole resistance was seen in gram-negative anaerobes other than S. wadsworthensis (18% resistant); 63% of gram-positive non-spore-forming rods were resistant. Some degree of clindamycin resistance was seen in most of the groups tested. C1 Vet Adm Greater Los Angeles Healthcare Syst, Med Serv, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA. RP Wexler, HM (reprint author), Wadsworth Anaerobe Lab, Bldg 304,Room E3-224,VAGLAHS 692-151J, Los Angeles, CA 90073 USA. NR 19 TC 20 Z9 22 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2002 VL 46 IS 11 BP 3669 EP 3675 DI 10.1128/AAC.46.11.3669-3675.2002 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 606BK UT WOS:000178712800057 PM 12384389 ER PT J AU Namjou, B Nath, SK Kilpatrick, J Kelly, JA Reid, J James, JA Harley, JB AF Namjou, B Nath, SK Kilpatrick, J Kelly, JA Reid, J James, JA Harley, JB TI Stratification of pedigrees multiplex for systemic lupus erythematosus and for self-reported rheumatoid arthritis detects a systemic lupus erythematosus susceptibility gene (SLER1) at 5p15.3 SO ARTHRITIS AND RHEUMATISM LA English DT Article ID AUTOIMMUNE-DISEASES; TELOMERASE ACTIVITY; REVISED CRITERIA; GENOME SCAN; LINKAGE; FAMILIES; CLASSIFICATION; MODELS; LOCUS AB Objective. Arthritis is a common manifestation in systemic lupus erythematosus (SLE), appearing in similar to85% of patients. Often, the polyarthritis at presentation of SLE cannot be distinguished from rheumatoid arthritis (RA) by physical examination or history. Indeed, physicians initially tell many SLE patients that they have RA (one source of "self-reported RA"), only to have SLE established later. In addition, RA aggregates in families with an SLE proband. We predicted that pedigrees multiplex for both SLE and for self-reported RA would better isolate particular genetic effects. If this proved to be true, we would then use the increased genetic homogeneity to more easily reveal genetic linkage. Methods. From a collection of 160 pedigrees multiplex for SLE, we selected 36 pedigrees that also contained greater than or equal to2 members with self-reported RA (19 pedigrees were African American, 14 were European American, and 3 were of other ethnic origin). Data from a genome scan of 307 microsatellite markers were evaluated for SLE linkage by contemporary genetic epidemiologic techniques. Results. The most significant evidence of linkage to SLE was obtained at 5p15.3 in the European American pedigrees by both parametric (logarithm of odds [LOD] score 6.2, P 9.3 X 10(-8)) and nonparametric (LOD score 6.9, P 1.7 X 10(-8)) methods. The bestfitting model for this putative SLE gene in this region was a recessive gene with a population frequency of 5% and with 50% penetrance in females and 15% penetrance in males at virtually 100% homogeneity. Conclusion. For a genetically complex disease phenotype, an unusually powerful linkage has been found with SLE at 5p15.3 in European American pedigrees multiplex for SLE and for self-reported RA. This result predicts the presence of a gene at the top of chromosome 5 in this subset of patients that is important for the pathogenesis of SLE. C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NCRR NIH HHS [RR-15577]; NIAID NIH HHS [AI-31584, AI-24717]; NIAMS NIH HHS [AR-12253, AR-42460, AR-45231] NR 42 TC 25 Z9 26 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD NOV PY 2002 VL 46 IS 11 BP 2937 EP 2945 DI 10.1002/art.10588 PG 9 WC Rheumatology SC Rheumatology GA 615HJ UT WOS:000179239500015 PM 12428235 ER PT J AU Pierre, JM Wirshing, DA Wirshing, WC AF Pierre, JM Wirshing, DA Wirshing, WC TI In response to Furst et al, "Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin" - Reply SO BIOLOGICAL PSYCHIATRY LA English DT Letter ID OVERDOSE C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Pierre, JM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Room 15,B151H, Los Angeles, CA 90073 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD NOV 1 PY 2002 VL 52 IS 9 BP 914 EP 915 AR PII S0006-3223(02)01570-6 DI 10.1016/S0006-3223(02)01494-4 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 606RC UT WOS:000178746100012 ER PT J AU Liu, XB Hill, P Haile, DJ AF Liu, XB Hill, P Haile, DJ TI Role of the ferroportin iron-responsive element in iron and nitric oxide dependent gene regulation SO BLOOD CELLS MOLECULES AND DISEASES LA English DT Article; Proceedings Paper CT Meeting on Molecular and Clinical Aspects of Human Iron Metabolism CY SEP 28-OCT 02, 2002 CL CHIEMESEE, GERMANY SP Deutsch Forsch Gemeinsch, Vifor Fresenium Med Care, Blood Cells Fdn, Schwarz pharma, Innova Med Biotech ID TRANSFERRIN RECEPTOR EXPRESSION; RNA-BINDING ACTIVITY; FERRITIN SYNTHESIS; INTERFERON-GAMMA; ACONITASE ACTIVITY; MOUSE MACROPHAGES; DIVALENT-CATIONS; J774 MACROPHAGES; CANCER-PATIENTS; DOWN-REGULATION AB The newly described iron transporter, ferroportin (MTP1, IREG1), is expressed in a variety of tissues including the duodenum and cells of the mononuclear phagocyte system (MPS). In the MPS, ferroportin is hypothesized to be a major exporter of iron scavenged from senescent erythrocytes. Changes in iron metabolism, including the sequestration of iron in the MPS, are characteristic of both acute and chronic inflammation and these conditions induce changes in ferroportin expression. In a mouse model of acute inflammation, LPS administration is associated with reduced MPS ferroportin protein and mRNA expression. In addition, the ferroportin 5' UTR also has an iron-responsive element that binds to the iron-response proteins, but whether there is a role for this IRE in inflammation induced regulation of ferroportin has been unclear. A luciferase reporter gene under the control of the mouse ferroportin promoter and 5' UTR was used to determine if this 5' UTR conferred IRE-dependent regulation on this reporter gene. Stimulation of reporter gene transfected RAW 264.7 cells (a mouse macrophage cell line) with LPS resulted in IRE-dependent inhibition of luciferase production. Inhibitors of nitric oxide synthase abrogated the IRE-dependent effect of LPS. In addition, direct treatment of RAW 264.7 and with NO donor S-nitroso-N-acetylpenicillamine resulted in IRE-dependent down-regulation of luciferase expression. The effect of NO was consistent with IRP1/IRE mediated translation block. There are most likely both inflammation-mediated transcriptional and post-transcriptional (IRE-dependent) mechanisms for inhibiting ferroportin expression in MPS cells. (C) 2002 Elsevier Science (USA). C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Syst, Audie Murphy Vet Adm Hosp, San Antonio, TX 78229 USA. RP Haile, DJ (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 45 TC 53 Z9 54 U1 5 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1079-9796 J9 BLOOD CELL MOL DIS JI Blood Cells Mol. Dis. PD NOV-DEC PY 2002 VL 29 IS 3 BP 315 EP 326 DI 10.1006/bcmd.2002.0572 PG 12 WC Hematology SC Hematology GA 660FC UT WOS:000181822300009 PM 12547222 ER PT J AU Monnier, J Laken, M Carter, CL AF Monnier, J Laken, M Carter, CL TI Patient and caregiver interest in Internet-based cancer services SO CANCER PRACTICE LA English DT Article DE cancer; caregiver; health information; Internet; online resource ID DIGITAL DIVIDE; BREAST-CANCER; INFORMATION AB PURPOSE: The primary goal of this study was to identify the needs for, the interest in, and the feasibility of the implementation of an Internet-based cancer services web site. Additionally, group differences (racial, patient vs caregiver, or rural vs urban) were identified that might influence the implementation of such a project. DESCRIPTION OF STUDY: Patients with cancer and caregivers (N = 319) in the waiting rooms of a cancer center located within a southeastern medical university completed questionnaires regarding their interest in Internet-based services. Topics included the likelihood of using Internet-based services, interest in home healthcare services delivered via a personal computer, and knowledge about and use of the Internet. RESULTS: Results indicated that most patient and caregiver respondents were interested in Internet-based cancer-related services such as information related to treatment (80%), conversations with physicians via the Internet (70%), and online support groups (65%). In addition, respondents reported that they would be likely to use such services (70%) and were interested in home healthcare services delivered via personal computers (60%). No group differences were found across ethnic groups, geographic settings, and patient status (patient vs caregivers) on these variables. Minorities, older individuals, and less educated individuals were less likely to have knowledge of and to have used the Internet. CLINICAL IMPLICATIONS: Patients with cancer and their caregivers are interested in supplementing in-person services with Internet-based services relating to their cancer treatment. Special efforts need to be made to reach ethnic minorities, the elderly, and those with less education with Internet-based programs. C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. Med Univ S Carolina, Off Special Initiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RP Monnier, J (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA. NR 11 TC 47 Z9 47 U1 2 U2 10 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1065-4704 J9 CANCER PRACT JI Cancer Pract. PD NOV-DEC PY 2002 VL 10 IS 6 BP 305 EP 310 DI 10.1046/j.1523-5394.2002.106005.x PG 6 WC Oncology; Health Care Sciences & Services; Nursing SC Oncology; Health Care Sciences & Services; Nursing GA 608MM UT WOS:000178850100008 PM 12406053 ER PT J AU Perea, S Patterson, TF AF Perea, S Patterson, TF TI Antifungal resistance in pathogenic fungi SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO SUSCEPTIBILITY; MESSENGER-RNA LEVELS; CANDIDA-ALBICANS; AMPHOTERICIN-B; FLUCONAZOLE RESISTANCE; CRYPTOCOCCUS-NEOFORMANS; ASPERGILLUS-FUMIGATUS; INFECTED PATIENTS; OROPHARYNGEAL CANDIDIASIS AB Pathogenic fungi are the cause of life-threatening infections in an increasing number of immunocompromised patients. The intrinsic resistance to antifungal therapy observed in some genera, along with the development of resistance during treatment in others, is becoming a major problem in the management of these diseases. We reviewed the epidemiology of the most common systemic fungal infections for which antifungal resistance is a potential problem, the mechanisms of antifungal resistance, the correlation between in vitro susceptibility testing and clinical outcome, and the clinical implications of antifungal resistance. C1 Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Patterson, TF (reprint author), Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, Mail Code 7881,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 71 TC 114 Z9 127 U1 3 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2002 VL 35 IS 9 BP 1073 EP 1080 DI 10.1086/344058 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 604VF UT WOS:000178641200012 PM 12384841 ER PT J AU Simmons, SF Ferrell, BA Schnelle, JF AF Simmons, SF Ferrell, BA Schnelle, JF TI Effects of a controlled exercise trial on pain in nursing home residents SO CLINICAL JOURNAL OF PAIN LA English DT Article DE assessment; exercise; nursing homes; pain ID RANDOMIZED TRIAL; RELIABILITY AB Objectives: To report preliminary data relevant to the effects of an exercise and toileting intervention on pain among incontinent nursing home (NH) residents. Design: A randomized controlled intervention trial. Setting and Participants: Fifty-one incontinent residents in one skilled NH. Intervention: The intervention was implemented by research staff for a total of 4 times a day (every 2 hours), 5 days a week, for 32 weeks. Residents were provided with incontinence care and assistance to either walk or, if nonambulatory, wheel their chairs, and to repeat sit-to-stand movements. Measurements: Pain was measured in two ways at baseline and again at 32 weeks: (1) a count of the number of verbal expressions and pain behaviors during a standardized physical performance assessment; and (2) a modified Geriatric Pain Measure administered in a one-on-one interview format. Results: There were significant differences between intervention and control groups on all physical performance measures over time, with the intervention group remaining stable and the control group showing a significant decline in sit-to-stand, walking, and wheelchair propulsion endurance. Both groups showed mild to moderate pain at baseline according to each of the two pain measures, while there were no significant changes in pain reports between groups over time based on either measure. There was, however, a trend for pain to increase in the intervention group. Conclusions: No significant changes in pain reports were attributable to exercise despite significant improvements in physical performance. In fact, there was a tendency for pain reports to increase with exercise. These preliminary findings suggest that exercise alone may be ineffective for pain management among incontinent NH residents. Care providers should consider that exercise to improve physical function may increase pain symptoms, requiring preemptive analgesia, other pain control strategies, or modified exercise techniques for this frail segment of the NH population. C1 Univ Calif Los Angeles, Jewish Home Aging, Borun Ctr Gerontol Res, Reseda, CA 91335 USA. Univ Calif Los Angeles, Sch Med, Dept Geriatr, Borun Ctr Gerontol Res, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Speulveda Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Jewish Home Aging, Borun Ctr Gerontol Res, 7150 Tampa Ave, Reseda, CA 91335 USA. FU NIA NIH HHS [AG10415, AG13013] NR 19 TC 18 Z9 18 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-8047 J9 CLIN J PAIN JI Clin. J. Pain PD NOV-DEC PY 2002 VL 18 IS 6 BP 380 EP 385 DI 10.1097/00002508-200211000-00006 PG 6 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 612PM UT WOS:000179084700006 PM 12441832 ER PT J AU Fogarty, CM Cyganowski, M Palo, WA Hom, RC Craig, WA AF Fogarty, CM Cyganowski, M Palo, WA Hom, RC Craig, WA TI A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study SO CLINICAL THERAPEUTICS LA English DT Article DE cefditoren; amoxicillin/clavulanate; CAP; pneumonia ID STREPTOCOCCUS-PNEUMONIAE; ORAL CEPHALOSPORIN; MANAGEMENT; GUIDELINES; CARE; RESISTANCE; ADULTS; AGENTS AB Background: Cefditoren pivoxil is a broad-spectrum cephalosporin that is approved for the treatment of pharyngitis, acute exacerbations of chronic bronchitis, and skin and skin-structure infections. Objective: This study was conducted to examine the efficacy and tolerability of cefditoren in the treatment of community-acquired pneumonia (CAP). Amoxicillin/clavulanate was chosen as a comparator because of its established efficacy and general acceptance as a standard of care in CAP. Methods: This multicenter, prospective, randomized, investigator-blinded, parallel-group trial compared oral cefditoren 200 and 400 mg BID with oral amoxicillin/clavulanate 875/125 mg BID for 14 days in adult outpatients with CAP. Results: Eight hundred two patients (404 men, 398 women; mean age, 50 years; age range, 12-93 years) with CAP were enrolled. Comparable clinical cure rates were observed among evaluable patients in all treatment groups at both the posttreatment and follow-up visits: 88.0% (125/142) for cefditoren 200 mg, 89.9% (143/159) for cefditoren 400 mg, and 90.3% (130/144) for amoxicillin/clavulanate at the posttreatment visit, and 86.5% (128/148), 86.8% (138/159), and 87.8% (129/147) for the respective groups at the follow-up visit. Of 82 Streptococcus pneumoniae strains isolated before treatment, 22 (26.8%) had reduced susceptibility to penicillin, 12 (14.6%) of them penicillin resistant. Overall eradication rates at the posttreatment visit for pathogens isolated from microbiologically evaluable patients were 84.0%, 88.6%, and 82.6% for cefditoren 200 mg, cefditoren 400 mg, and amoxicillin/clavulanate, respectively. In the respective treatmentgroups, 80.6%, 88.6%, and 88.0% of Haemophilus influenzae strains and 95.0%, 96.2%, and 89.5% of S pneumoniae strains were eradicated. The rates of resolution of or improvement in clinical signs and symptoms were comparable between treatment groups. The treatment regimens were well tolerated, with 4.9%, 3.0%, and 5.2% of patients in the respective treatment groups requiring discontinuation of study drug due to an adverse event. Conclusions: In this study in adult outpatients with CAP, both doses of cefditoren demonstrated equivalence to amoxicillin/clavulanate based on rates of clinical and microbiologic cure. All 3 regimens were effective in resolving or improving the clinical signs and symptoms of CAP. Both cefditoren and amoxicillin/clavulanate were well tolerated. C1 Spartanburg Pharmaceut Res, Spartanburg, SC 29307 USA. TAP Pharmaceut Prod Inc, Lake Forest, IL USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Fogarty, CM (reprint author), Spartanburg Pharmaceut Res, 126 Dillon Dr, Spartanburg, SC 29307 USA. NR 22 TC 22 Z9 24 U1 0 U2 2 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD NOV PY 2002 VL 24 IS 11 BP 1854 EP 1870 DI 10.1016/S0149-2918(02)80084-4 PG 17 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 623MJ UT WOS:000179706900011 PM 12501879 ER PT J AU Caroff, SN Rosenberg, H Mann, SC Campbell, EC Sullivan, KA AF Caroff, SN Rosenberg, H Mann, SC Campbell, EC Sullivan, KA TI Neuroleptic malignant syndrome in the critical care unit SO CRITICAL CARE MEDICINE LA English DT Letter C1 Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. St Barnabas Hosp, Dept Med Educ, Livingston, NJ USA. RP Caroff, SN (reprint author), Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. NR 5 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD NOV PY 2002 VL 30 IS 11 BP 2609 EP 2609 DI 10.1097/01.CCM.0000034460.30548.9A PG 1 WC Critical Care Medicine SC General & Internal Medicine GA 616UZ UT WOS:000179322900042 PM 12441787 ER PT J AU Walkes, JCM Earle, N Reardon, MJ Glaeser, DH Wall, MJ Huh, J Jones, JW Soltero, ER AF Walkes, JCM Earle, N Reardon, MJ Glaeser, DH Wall, MJ Huh, J Jones, JW Soltero, ER TI Outcomes in single versus bilateral internal thoracic artery grafting in coronary artery bypass surgery SO CURRENT OPINION IN CARDIOLOGY LA English DT Review ID STERNAL WOUND INFECTIONS; MAMMARY-ARTERY; SURVIVAL AB The authors analyzed the early outcomes in two groups of patients undergoing coronary artery bypass grafting (CABG) with single versus bilateral internal thoracic arteries (ITA) in their institution. One thousand sixty-nine patients underwent CABG with single or bilateral ITAs from 1990 to 2000. Of these patients, 911 (85.2%) had single ITA and 158 had bilateral ITA (14.8%). The incidence of tobacco abuse was 40.3% in the single ITA group and 56.7% in the double ITA group (P = 0.0001). The incidence of perioperative myocardial infarction, renal failure, reoperation for bleeding, stroke, or operative mortality did not differ in the two groups. There was a 4.4% incidence of mediastinitis in the bilateral ITA group versus 2.2% in the single ITA group (P = 0.0602). Early outcomes after bilateral ITA grafting for CABG are similar to single ITA grafting. Careful judgment should be exercised in selecting patients for bilateral ITA grafting, particularly if the patient smokes. (C) 2002 Lippincott Williams Wilkins, Inc. C1 Houston VA Med Ctr, Operat Care Line, Div Cardiothorac Surg, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. Univ Missouri, Dept Surg, Columbia, MO USA. RP Soltero, ER (reprint author), Houston VA Med Ctr, Operat Care Line, Div Cardiothorac Surg, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 18 TC 11 Z9 11 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-4705 J9 CURR OPIN CARDIOL JI Curr. Opin. Cardiol. PD NOV PY 2002 VL 17 IS 6 BP 598 EP 601 DI 10.1097/00001573-200211000-00003 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 635NU UT WOS:000180406300003 PM 12466700 ER PT J AU Guha, S Kaunitz, JD AF Guha, S Kaunitz, JD TI Gastroduodenal mucosal defense: an integrated protective response SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article ID EPIDERMAL GROWTH-FACTOR; ALKALINE SECRETION; HELICOBACTER-PYLORI; RAT DUODENUM; GASTRIC TOXICITY; GEL LAYER; ACID; CELLS; STOMACH; PATHOGENESIS AB The mechanisms by which the gastroducidenal mucosa maintains viability and normal functioning despite its intensely caustic environment have puzzled clinicians and investigators alike for at least 150 years. Protective mechanisms have been divided into three main categories: preepithelial (mucus and bicarbonate secretion), epithelial (cellular buffering, mucosal architecture and permeability), and postepithelial mechanisms (mucosal blood flow). Within each category are many other factors that bear on the ability of the mucosa to withstand constant changes of luminal pH. We will summarize some of the recent findings that pertain to the nature and regulation of these defense mechanisms in the context of a historical overview. Therapeutic implications of these findings will also be presented in the discussion of novel antiinflammatory compounds designed to upregulate simultaneously several defensive mechanisms, with the expectation that gastroduodenal damage will be minimized. (C) 2002 Lippincott Williams Wilkins, C1 W Los Angeles Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, CURE, Digest Dis Res Ctr, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Bldg 114,Suite 217, Los Angeles, CA 90073 USA. NR 53 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2002 VL 18 IS 6 BP 650 EP 657 DI 10.1097/00001574-200211000-00003 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 610ZN UT WOS:000178992100003 PM 17033343 ER PT J AU Feliers, D Frank, MA Riley, DJ AF Feliers, D Frank, MA Riley, DJ TI Activation of cyclin D1-Cdk4 and Cdk4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy SO DIABETES LA English DT Article ID GROWTH-FACTOR-BETA; EPITHELIAL-CELL HYPERTROPHY; RETINOBLASTOMA GENE-PRODUCT; HIGH GLUCOSE; TGF-BETA; FUNCTIONAL INACTIVATION; GLOMERULAR VOLUME; RESTRICTION POINT; DEPENDENT KINASES; IN-VIVO AB To determine the role of cell-cycle proteins in regulating pathological renal hypertrophy, diabetes was induced in mice expressing a human retinoblastoma (RB) transgene and in wild-type littermates. Whole-kidney and glomerular hypertrophy caused by hyperglycemia was associated with specific G1 phase cell-cycle events: early and sustained increase in expression of cyclin D1 and activation of cyclin D1-cdk4 complexes, but no change in expression of cyclin E or cdk2 activity. Overexpression of RB alone likewise caused hypertrophy and increased only cyclin D1-cdk4 activity; these effects were not further augmented by high glucose. Identical observations were made when isolated mesangial cells conditionally overexpressing RB from a tetracycline-repressible system hypertrophied in response to high glucose. A mitogenic signal in the same cell-culture system, in contrast, transiently and sequentially activated both cyclin D1-cdk4 and cyclin E-cdk2. In vivo and in cultured mesangial cells, high glucose resulted in persistent partial phosphorylation of RB, an event catalyzed specifically by cyclin D1-cdk4. These data indicate that mesangial hypertrophy caused by hyperglycemia in diabetes results in sustained cyclin D1-cdk4-dependent phosphorylation of RB and maintenance of mesangial cells in the early-to-middle G1 phase of the cell cycle. C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Med, Div Nephrol, San Antonio, TX USA. RP Riley, DJ (reprint author), Univ Texas, Hlth Sci Ctr, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 45 TC 24 Z9 26 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0012-1797 J9 DIABETES JI Diabetes PD NOV PY 2002 VL 51 IS 11 BP 3290 EP 3299 DI 10.2337/diabetes.51.11.3290 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 609PV UT WOS:000178914900018 PM 12401721 ER PT J AU Willi, SM Kennedy, A Brant, BP Wallace, P Rogers, NL Garvey, WT AF Willi, SM Kennedy, A Brant, BP Wallace, P Rogers, NL Garvey, WT TI Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE type 2 diabetes mellitus; glucocorticoids; thiazolidinedione; troglitazone; glucose tolerance; free fatty acids; leptin ID INDUCED INSULIN-RESISTANCE; RAT SKELETAL-MUSCLE; OB GENE-EXPRESSION; GLUCOSE-TOLERANCE; ADIPOSE-TISSUE; FATTY-ACIDS; TROGLITAZONE; SENSITIVITY; METABOLISM; MELLITUS AB We evaluated the efficacy of a thiazolidinedione in the treatment of diabetes induced by glucocorticoids. We examined the effectiveness of troglitazone in seven patients with long-standing steroid-induced diabetes. Five of the seven subjects were treated with insulin alone, one was treated with both insulin and oral therapy and one was treated with oral therapy alone. The mean insulin dose in six of the seven subjects was 0.66 +/- 0.09 units/kg per day. Diabetes status was assessed by measuring serum fructosamine, HgbAlc, oral glucose and meal tolerance tests (OGTT and MTT) at baseline and after treatment for 5-8 weeks with troglitazone 400 mg/day. Troglitazone caused a significant decrease in fructosamine (274 +/- 32 vs. 217 +/- 22 mmol/l; P < 0.01) and HgbA1C (7.8 +/- 0.4 vs. 7.2 +/- 0.4%; P < 0.01) as well as decrements in the areas under the OGTT 2,308 +/- 156 vs. 1,937 +/- 127 mmol/l; P < 0.05) and MTT glucose curves (4694 +/- 449 vs. 4057 +/- 437 mmol/l; P < 0.05). In addition, the area under the insulin curve for the oral glucose tolerance test showed a significant increase from 27,438 +/- 4,488 to 41,946 +/- 6,048 pmol/l (P < 0.05). Total and LDL cholesterol were also significantly decreased (6.4 +/- 0.9 vs. 5.0 +/- 0.6 mmol/1 and 3.8 +/- 0.7 vs. 2.7 +/- 0.4 mmol/l, respectively, P < 0.05). Fasting leptin values decreased by 23% despite an increase in body weight. Troglitazone is effective in the treatment of glucocorticoid-induced diabetes as manifested by lower measures of glycemia, HgbAlc, and post-prandial glucose values, while the doses of other diabetes medications remained unchanged or were reduced. The insulin-sensitizing drug also produced a marked increase in endogenous insulin secretion in response to glucose, lower total and LDL cholesterol, and decreased fasting leptin despite weight gain. Thiazolidinediones may improve diabetes-related parameters by antagonizing pathways of glucocorticoid-induced insulin resistance and by reversing adverse effects of glucocorticoids on beta cell function. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Gen Clin Res Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Willi, SM (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. FU NCRR NIH HHS [M01 RR-01070-20S3]; NIDDK NIH HHS [DK-38764] NR 45 TC 30 Z9 33 U1 1 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD NOV PY 2002 VL 58 IS 2 BP 87 EP 96 AR PII S0168-8227(02)00127-4 DI 10.1016/S0168-8227(02)00127-4 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 608YJ UT WOS:000178875200002 PM 12213349 ER PT J AU Wheeler, SG Ahroni, JH Boyko, EJ AF Wheeler, SG Ahroni, JH Boyko, EJ TI Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE type 2 diabetes; autonomic neuropathy; heart rate variability; mortality; prospective study ID HEART-RATE-VARIABILITY; INFARCTION; RISK AB Objective: The objective of this study is to evaluate whether autonomic neuropathy predicts short term all-cause mortality in an elderly cohort of veteran patients with diabetes; Research design and methods: All of the diabetic patients receiving primary care at one VA medical center were eligible for participation, between 1990 and 1997. One thousand and fifteen patients were identified, of whom 14% declined to participate, so that a total of 843 diabetic patients were enrolled. Autonomic neuropathy was evaluated by heart rate response to timed deep breathing. One hundred and fifty one patients have died since the onset of the study. Results: Mean follow-up was 42.4 months. Subjects who died had greater diabetes duration compared with survivors (13.1 vs. 11.4 years, P=0.04) but were comparable with regards to type of diabetes and mean glycosylated hemoglobin level. The Cox proportional hazards analysis, adjusting for age, smoking status, creatinine, pack-years of cigarettes smoked, diabetes duration, race, history of ischemic heart disease and hypertension showed that those patients with the lowest quintile of heart rate variability had a significantly increased risk of mortality (hazard ratio = 1.49, 95% confidence limits 1.01-2.19). Conclusions: This study supports the hypothesis that decreased heart rate variability is an independent risk factor for mortality in diabetic patients followed in a primary care setting. (C) 2002 Published by Elsevier Science Ireland Ltd. C1 Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Care Serv, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, ERIC, Seattle Div, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. RP Wheeler, SG (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Primary & Specialty Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X NR 22 TC 52 Z9 54 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD NOV PY 2002 VL 58 IS 2 BP 131 EP 138 AR PII S0168-8227(02)00128-6 DI 10.1016/S0168-8227(02)00128-6 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 608YJ UT WOS:000178875200008 PM 12213355 ER PT J AU Paoletta, M Kahn, SE Halban, PA AF Paoletta, M Kahn, SE Halban, PA TI Truncated (des-[27-31]) C-peptide is not a major secretory product of human islets SO DIABETOLOGIA LA English DT Article DE Type II diabetes; insulinoma; proinsulin; insulin; newborn ID HUMAN CELL-MEMBRANES; K+-ATPASE ACTIVITY; PROINSULIN; BINDING; RAT; NA+ AB Aims/hypothesis. It has been suggested that C-peptide is bioactive and that such bioactivity is lost when the last five amino acids are removed. In rats, C-peptide is truncated in beta-cell granules leading to the loss of these last five residues and secretion of des-[27-31]-C-peptide. The aim of this study was to determine whether this truncated form of C-peptide was also a secretory product of human islets. Methods. Plasma from healthy subjects, patients with Type II (non-insulin-dependent) diabetes mellitus or insulinoma and cord blood was analysed by HPLC and ELISA. This method allows for separation and quantification of intact C-peptide and des-[27-31]-C-peptide. Human islets were pulse-chased and secretion stimulated by a mixture of secretagogues. Radioactive products secreted to the medium were analysed by HPLC and the relative amount of intact and truncated C-peptide measured. Results. The proportion of total C-peptide immunoreactivity comprised of des-[27-31]-C-peptide was 1.5% or less in all plasma samples, except for that from one patient with insulinoma where it was 4.2%. The proportion of radiolabelled des-[27-31]-C-peptide released from isolated islets was less than 1%. Conclusion/interpretation. In contrast to the situation in rats, des-[27-31]-C-peptide is not a major secretory product of human islets and its contribution to total circulating C-peptide is not increased in Type II diabetes or in patients with insulinoma: C1 Univ Geneva, Med Ctr, Louis Jeantet Res Labs, CH-1211 Geneva 4, Switzerland. Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Halban, PA (reprint author), Univ Geneva, Med Ctr, Louis Jeantet Res Labs, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland. OI Kahn, Steven/0000-0001-7307-9002 FU NIDDK NIH HHS [DK-17047, DK-02654] NR 16 TC 5 Z9 5 U1 0 U2 1 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD NOV PY 2002 VL 45 IS 11 BP 1523 EP 1527 DI 10.1007/s00125-002-0938-y PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 624ZV UT WOS:000179792900007 PM 12436335 ER PT J AU Atchley, DH Lopes-Virella, MF Zheng, D Kenny, D Virella, G AF Atchley, DH Lopes-Virella, MF Zheng, D Kenny, D Virella, G TI Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy SO DIABETOLOGIA LA English DT Article DE Type I diabetes; autoimmunity oxidized; LDL; oxidized LDL antibodies; immune complexes ID LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY DISEASE; MALONDIALDEHYDE-MODIFIED LDL; HEART-DISEASE; RISK-FACTORS; PITTSBURGH EPIDEMIOLOGY; IDDM PATIENTS; CAROTID ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION AB Aims/hypothesis. Oxidized LDL is immunogenic and immune complexes formed by oxidized LDL and corresponding antibodies are pro-atherogenic and pro-inflammatory. Considering that macroalbuminuria is a risk factor for coronary heart disease and that common pathogenic factors for atherosclerosis and glomerulosclerosis exist, our aim was to determine whether the amount and/or characteristics of oxidized LDL- anti-oxidized LDL complexes correlated with the degree of albuminuria patients with Type I (insulin-dependent) diabetes mellitus. Methods. We studied 33 macroalbuminuric patients (albumin excretion rate >300 mg/24 h) and 29 microalbuminuric patients (albumin excretion rate greater than or equal to30 mg/24 h and less than or equal to300 mg/24 h) who were matched for age, sex and HbA(1C) concentrations with 43 patients with normal albuminuria. In all patients we isolated. and characterized oxidized LDL-anti-oxidized LDL complexes. A subgroup of 47 patients (22 with normal albuminuria, 11 with microalbuminuria, and 14 with macroalbuminuria) was randomly selected from the. larger group for characterization of the antibody moiety of oxidized LDL immune complexes. Results. The concentrations of oxidized LDL immune complexes were increased in patients with macroalbuminuria (total cholesterol in immune complexes isolated from patients with macroalbuminuria was 272 +/- 20 vs 204 +/- 18 mug/ml in patients with normoalbuminuria, p<0.03). Also, the Kd of oxLDL antibodies isolated from the immune complexes was looter in patients with abnormal albuminuria than in patients with normoalbuminuria (0.86 +/- 0.1x10(-8) vs 1.13+0.1x10(-8) mol/l, p<0.005). Conclusion/interpretation. The data indicate that high concentrations of oxidized LDL-anti-oxidized LDL complexes, particularly when formed with antibodies of higher avidity, are associated with abnormal proteinuria. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. George Washington Univ, DCCT EDIC, Ctr Biostat, Washington, DC USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St,Room 529, Charleston, SC 29425 USA. FU NCRR NIH HHS [M01-RR-1070]; NHLBI NIH HHS [P01-HL55782] NR 71 TC 40 Z9 44 U1 0 U2 0 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD NOV PY 2002 VL 45 IS 11 BP 1562 EP 1571 DI 10.1007/s00125-002-0962-y PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 624ZV UT WOS:000179792900012 PM 12436340 ER PT J AU Kearney, DJ Hubbard, T Putnam, D AF Kearney, DJ Hubbard, T Putnam, D TI Breath ammonia measurement in Helicobacter pylori infection SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Helicobacter pylori; ammonia ID GASTRIC-JUICE AMMONIA; PERFUSED-RAT-LIVER; CAMPYLOBACTER-PYLORI; GLUTAMINE-METABOLISM; UREA; DIAGNOSIS; CIRRHOSIS; HYPERAMMONEMIA; ERADICATION AB Our aim was to define the utility of breath ammonia measurement in assessing Helicobacter pylori infection. Volunteers breathed into a device containing three fiberoptic NH3 sensors at baseline and after ingesting 300 mg of urea. Breath ammonia levels were compared to the [C-14] urea breath test. Thirteen subjects were tested. Before urea ingestion, H. pylori-positive subjects had significantly lower breath ammonia levels than negative subjects (mean +/- SD, 0.04 ppm +/- 0.09 vs 0.49 ppm +/- 0.24, P = 0.002) and had a significantly greater increases in breath ammonia after urea ingestion (range 198-1494% vs 6-98%). One H. pylori-positive subject underwent treatment and breath ammonia levels shifted from the pattern seen in positive subjects to that seen in negative subjects. In conclusion, breath ammonia measurement for H. Pylori-positive and negative subjects showed distinct patterns. Breath ammonia measurement may be feasible as a diagnostic test for H. pylori. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Pacific Technol, Kirkland, WA USA. RP Kearney, DJ (reprint author), Vet Affairs Med Ctr, 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. NR 26 TC 54 Z9 54 U1 1 U2 20 PU KLUWER ACADEMIC/PLENUM PUBL PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2002 VL 47 IS 11 BP 2523 EP 2530 DI 10.1023/A:1020568227868 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 602XE UT WOS:000178529100025 PM 12452390 ER PT J AU Asakawa, JI Kodaira, M Ishikawa, N Hirai, Y Nagataki, S Moatamed, F Sugawara, M AF Asakawa, JI Kodaira, M Ishikawa, N Hirai, Y Nagataki, S Moatamed, F Sugawara, M TI Two-dimensional complementary deoxyribonucleic acid electrophoresis revealing up-regulated human epididymal protein-1 and down-regulated CL-100 in thyroid papillary carcinoma SO ENDOCRINOLOGY LA English DT Article ID MAJOR SECRETORY PROTEIN; GENE-EXPRESSION; HE-1; DISPLAY; CANCER AB Two-dimensional cDNA electrophoresis was used to analyze gene expressions in papillary carcinoma and normal tissue of thyroid glands. Pooled thyroid tissues were used to extract mRNA. Complementary DNAs, synthesized with NotI anchor primers, were digested with three restriction enzymes, NotI, EcoRV, and PvuII. The protruding NotI ends were filled in with P-32 deoxynucleotide triphosphates, and the radiolabeled cDNA fragments were separated in two dimensions. Approximately 500 cDNA fragments were visualized as discrete spots without probes. A total of 20 spots, 9 up-regulated and 11 down-regulated cDNAs in papillary carcinoma, were selected and cloned for sequencing. This experiment lent itself to a novel discovery of up-regulated human epididymal protein 1 (HE-1) and down-regulated CL-100 genes in thyroid papillary carcinomas confirmed by Northern blot analysis. Immunohistochemical stains showed abundant HE-1 protein in the papillary carcinoma, whereas little or no HE-1 protein was detected in other types of thyroid cancers and normal thyroid tissues. The restricted localization of HE-1-protein to the portions of papillary projections suggests an involvement of HE-1 protein for forming papillary shape. Our study showed that two-dimensional cDNA electrophoresis is a useful method of detecting differentially expressed genes in human diseases as demonstrated for HE-1 and CL-100 in papillary carcinoma. C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA. Los Angeles VA Hlth Care Syst, Div Endocrinol & Metab, Dept Med, Los Angeles, CA 90073 USA. Los Angeles VA Hlth Care Syst, Mol Pathol Div, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. RP Asakawa, JI (reprint author), Radiat Effects Res Fdn, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan. OI nagataki, shigenobu/0000-0002-9974-3554 NR 23 TC 3 Z9 3 U1 0 U2 0 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD NOV PY 2002 VL 143 IS 11 BP 4422 EP 4428 DI 10.1210/en.2002-220550 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 608YV UT WOS:000178876700034 PM 12399439 ER PT J AU Cornford, EM Shamsa, K Zeitzer, JM Enriquez, CM Wilson, CL Behnke, EJ Fried, I Engel, J AF Cornford, EM Shamsa, K Zeitzer, JM Enriquez, CM Wilson, CL Behnke, EJ Fried, I Engel, J TI Regional analyses of CNS microdialysate glucose and lactate in seizure patients SO EPILEPSIA LA English DT Article DE brain microdialysate; regional variations; complex partial seizures; glucose; lactate; lactate/lucose ratio ID BLOOD-BRAIN-BARRIER; POSITRON-EMISSION-TOMOGRAPHY; GLUT-1 DEFICIENCY SYNDROME; CEREBRAL METABOLIC-RATE; TEMPORAL-LOBE EPILEPSY; INTRACEREBRAL MICRODIALYSIS; QUANTITATIVE MICRODIALYSIS; EXTRACELLULAR LACTATE; INTENSIVE-CARE; NORMAL VALUES AB Purpose: To correlate glucose (and lactate) results obtained from microdialysate to recent studies suggesting that glucose transporter activity may be significantly altered in seizures. Methods: We used a fluorometric technique to quantify glucose and lactate levels in microdialysates collected from two to four depth electrodes implanted per patient in the temporal and frontal lobes of a series of four patients. Hour-by-hour and day-to-day changes in brain glucose and lactate levels at the same site were recorded. Additionally we compared regional variations in lactate/glucose ratios around the predicted epileptogenic region. Results: Lactate/glucose ratios in the range of 1-2:1 were the most commonly seen. When the lactate/glucose ratio was <1: 1, we typically observed a relative increase in local glucose concentration (rather than decreased lactate), suggesting increased transport, perhaps without increased glycolysis. In some sites, lactate/glucose ratios of 3:1-15: 1 were seen, suggesting that a circumscribed zone of inhibition of tricarboxylic acid cycle activity may have been locally induced. In these dialysates, collected from probes closer to the epileptogenic region, the large increase in lactate/glucose ratios was a result of both increased lactate and reduced glucose levels. Conclusions: We conclude that regional variations in brain extracellular glucose concentrations may be of greater magnitude than previously believed and become even more accentuated in partial seizure patients. Data from concomitant assays of microdialysate lactate and glucose may aid in understanding cerebral metabolism. C1 VA Greater Los Angeles Healthcare Syst, Serv Neurol, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Inst Brain Res, Los Angeles, CA 90024 USA. RP Cornford, EM (reprint author), VA Greater Los Angeles Healthcare Syst, Serv Neurol, W127,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. OI Zeitzer, Jamie/0000-0001-6174-5282 FU NINDS NIH HHS [NS 33310, NS 37360, NS 45292, NS 02808] NR 42 TC 10 Z9 12 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD NOV PY 2002 VL 43 IS 11 BP 1360 EP 1371 DI 10.1046/j.1528-1157.2002.01602.x PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 616MQ UT WOS:000179307900011 PM 12423386 ER PT J AU Houston, HR Harada, N Makinodan, T AF Houston, HR Harada, N Makinodan, T TI Development of a culturally sensitive educational intervention program to reduce the high incidence of tuberculosis among foreign-born Vietnamese SO ETHNICITY & HEALTH LA English DT Article DE tuberculosis (TB); Vietnamese; cultural beliefs; barriers; immigrants ID PACIFIC ISLANDERS; ASIAN-AMERICANS AB Objective. In Los Angeles County and Orange County, 98% of Asians with tuberculosis (TB) were foreign born; newly arrived Vietnamese immigrants had the highest TB risk: i.e.>100 times higher than that of the USA. The study objective was to find ways to reduce the high incidence of tuberculosis among the Vietnamese by: (1) identifying and understanding the cultural health beliefs and barriers among the Vietnamese population of Orange County, California; and (2) developing a partnership between UCLAA/VA/RAND MEDTEP, key Vietnamese community-based organizations, and community leaders in Orange County to develop and implement a comprehensive, culturally sensitive educational intervention program. Design. Vietnamese residing in Orange County were recruited to obtain qualitative and quantitative data in 1998 and 1999, respectively. The study design included focus groups, in-depth interviews, and community surveys. Data were collected via qualitative reports, computer-assisted random telephone interviews, and self-administered questionnaires. Results. A conceptual schema was identified within the Vietnamese health belief system that recognized two different forms of tuberculosis: non-infectious psychological and infectious physical tuberculosis. It was possible to engage community organizations in developing programs to combat TB in the Vietnamese population. Conclusion. The Health beliefs of Vietnamese will be important considerations in developing a culturally sensitive educational intervention program to service this at-risk population. C1 Calif State Univ Los Angeles, COBAE, Dept Mkt, Los Angeles, CA 90032 USA. Univ Calif Los Angeles, Dept Med, UCLA VA RAND MEDTEP Ctr Asians & Pacific Isl, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Houston, HR (reprint author), Calif State Univ Los Angeles, COBAE, Dept Mkt, 5151 State Univ Dr, Los Angeles, CA 90032 USA. EM hhousto@calstatela.edu FU AHRQ HHS [HS-07370] NR 20 TC 16 Z9 16 U1 0 U2 5 PU CARFAX PUBLISHING PI BASINGSTOKE PA RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND SN 1355-7858 J9 ETHNIC HEALTH JI Ethn. Health PD NOV PY 2002 VL 7 IS 4 BP 255 EP 265 DI 10.1080/1355785022000060718 PG 11 WC Ethnic Studies; Public, Environmental & Occupational Health SC Ethnic Studies; Public, Environmental & Occupational Health GA 659FP UT WOS:000181766900004 PM 12772545 ER PT J AU Kroning, R Carter, EA Srivatsan, E Lichtenstein, A Nagami, GT AF Kroning, R Carter, EA Srivatsan, E Lichtenstein, A Nagami, GT TI Cellular accumulation of cisplatin is mediated by the ubiquitously expressed sodium-dependent human ASCT1-amino acid transporter SO EUROPEAN JOURNAL OF CANCER LA English DT Meeting Abstract CT 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics CY NOV 19-22, 2002 CL FRANKFURT, GERMANY C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Hematol & Oncol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Nephrol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD NOV PY 2002 VL 38 SU 7 MA 315 BP S96 EP S96 PG 1 WC Oncology SC Oncology GA 626VZ UT WOS:000179895700317 ER PT J AU Lu, SC Gukovsky I Lugea, A Reyes, CN Huang, ZZ Chen, LX Mato, JM Bottiglieri, T Pandol, SJ AF Lu, SC Gukovsky, I Lugea, A Reyes, CN Huang, ZZ Chen, LX Mato, JM Bottiglieri, T Pandol, SJ TI Role of S-adenosylmethionine in two experimental models of pancreatitis SO FASEB JOURNAL LA English DT Article DE methionine adenosyltransferase 1A; methionine adenosyltransferase 2A; CDE diet; cerulein ID ADENOSYL-L-METHIONINE; KAPPA-B ACTIVATION; RAT-LIVER; ADENOSYLTRANSFERASE GENES; DIFFERENTIAL EXPRESSION; CHOLINE-DEFICIENT; SYNTHETASE; CELLS; HEPATOCYTES; ETHIONINE AB Severe necrotizing pancreatitis occurs in young female mice fed a choline-deficient and ethionine-supplemented (CDE) diet. Although the mechanism of the pancreatitis is unknown, one consequence of this diet is depletion of hepatic S-adenosylmethionine (SAM). SAM formation is catalyzed by methionine adenosyltransferases (MATs), which are encoded by liver-specific (MAT1A) and non-liver-specific (MAT2A) genes. In this work, we examined changes in pancreatic SAM homeostasis in mice receiving the CDE diet and the effect of SAM treatment. We found that both MAT forms are expressed in normal pancreas and pancreatic acini. After 48 h of the CDE diet, SAM levels decreased 50% and MAT1A-encoded protein disappeared via post-translational mechanisms, whereas MAT2A-encoded protein increased via pretranslational mechanisms. CDE-fed mice exhibited extensive necrosis, edema, and acute pancreatic inflammatory infiltration, which were prevented by SAM treatment. However, old female mice consuming the CDE diet that do not develop pancreatitis showed a similar fall in pancreatic SAM level. SAM was also protective in cerulein-induced pancreatitis in the rat, but the protection was limited. Although the pancreatic SAM level fell by more than 80% in the MAT1A knockout mice, no pancreatitis developed. This study thus provides several novel findings. First, the so-called liver-specific MAT1A is highly expressed in the normal pancreas and pancreatic acini. Second, the CDE diet causes dramatic changes in the expression of MAT isozymes by different mechanisms. Third, in contrast to the situation in the liver, where absence of MAT1A and decreased hepatic SAM level can lead to spontaneous tissue injury, in the pancreas the roles of SAM and MAT1A appear more complex and remain to be defined. C1 Univ So Calif, Dept Med, Div Gastrointestinal & Liver Dis, Keck Sch Med,Liver Dis Res Ctr, Los Angeles, CA 90033 USA. Univ Calif Los Angeles, Res Ctr Alcohol Liver & Pancreat Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Navarra, Sch Med, Div Hepatol & Gene Therapy, E-31080 Pamplona, Spain. Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75226 USA. RP Lu, SC (reprint author), Univ So Calif, Dept Med, Div Gastrointestinal & Liver Dis, Keck Sch Med,Liver Dis Res Ctr, HMR Bldg,415,2011 Zonal Ave, Los Angeles, CA 90033 USA. EM Stephen.Pandol@med.va.gov RI MATO, JOSE/A-5187-2011 NR 40 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD NOV PY 2002 VL 16 IS 13 BP 56 EP + DI 10.1096/fj.01-0752fje PG 17 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 632HU UT WOS:000180218500034 ER PT J AU Shin, JM Sachs, G AF Shin, JM Sachs, G TI Restoration of acid secretion following treatment with proton pump inhibitors SO GASTROENTEROLOGY LA English DT Article ID GASTRIC H+,K+-ATPASE ACTIVITY; REFLUX DISEASE; H+/K+-ATPASE; K+-ATPASE; OMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; SITE; RABEPRAZOLE; H,K-ATPASE AB Background & Aims: Proton pump inhibitors (PPIs) are covalent inhibitors of the gastric H+,K+-adenosine triphosphatase (ATPase) forming disulfide bonds. Recovery of acid secretion after PPI inhibition may be due to de novo synthesis of pump protein and/or disulfide reduction and reactivation of inhibited pump. The half-time of recovery of acid secretion in rats following omeprazole treatment is similar to15 hours, whereas pump protein half-life is 54 hours. In humans, the half-life of the inhibitory effect on acid secretion is similar to28 hours for omeprazole and similar to46 hours for pantoprazole. Whereas all PPIs bind to cysteine 813, pantoprazole additionally binds to cysteine 822, deeper in the membrane domain of TM6. Their different durations of action may reflect different rates of pump reactivation due to differing accessibility of the disulfides to glutathione. Methods: Rats were stimulated and treated with 30 mg/kg of each PPI. Gastric ATPase was prepared and reversal of inhibition of the H+,K+-ATPase was measured as the time-dependent restoration of activity by incubation with dithiothreitol or glutathione. Results: One hundred percent reactivation of ATPase following inhibition in vivo by omeprazole or its enantiomers was seen with dithiothreitol and 89% with glutathione. Similar data were found for lansoprazole or rabeprazole. No reactivation by either reducing agent was seen following inhibition by pantoprazole. Conclusions: Recovery of acid secretion following inhibition by all PPIs, other than pantoprazole, may depend on both protein turnover and reversal of the inhibitory disulfide bond. In contrast, recovery of acid secretion after pantoprazole may depend entirely on new protein synthesis. C1 VA Greater Los Andeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA USA. RP W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, 11301 Wilshire Blvd,Bldg 113,Room 324, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu FU NIDDK NIH HHS [DK46917]; PHS HHS [53462, 17294, 41301] NR 40 TC 51 Z9 55 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD NOV PY 2002 VL 123 IS 5 BP 1588 EP 1597 DI 10.1053/gast.2002.36593 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 609UN UT WOS:000178923100023 PM 12404233 ER PT J AU Dobie, DJ Kivlahan, DR Maynard, C Bush, KR McFall, M Epler, AJ Bradley, KA AF Dobie, DJ Kivlahan, DR Maynard, C Bush, KR McFall, M Epler, AJ Bradley, KA TI Screening for post-traumatic stress disorder in female Veteran's Affairs patients: validation of the PTSD checklist SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE stress disorders; post-traumatic; women; veterans; psychiatric status rating scales; quality of life ID QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; CIVILIAN VERSION; VIETNAM VETERANS; SCORING RULES; SEXUAL ABUSE; PRIMARY-CARE; HEALTH; WOMEN; SCALE AB We evaluated the screening validity of a self-report measure for post traumatic stress disorder (PTSD), the PTSD Checklist (PCL), in female Veterans Affairs (VA) patients. All women seen for care at the VA Puget Sound Health Care system from October 1996-January 1999 (n=2,545) were invited to participate in a research interview. Participants (n=282) completed the 17-item PCL, followed by a gold standard diagnostic interview for PTSD, the Clinician Administered PTSD Scale (CAPS). Thirty-six percent of the participants (n=100) met CAPS diagnostic criteria for current PTSD. Receiver Operating Characteristic (ROC) analysis was used to evaluate the screening performance of the PCL. The area under the ROC curve was 0.86 (95% CI 0.82-0.90). A PCL score of 38 optimized the performance of the PCL as a screening test (sensitivity 0.79, specificity 0.79). The PCL performed well as a screening measure for the detection of PTSD in female VA patients. (C) 2002 Elsevier Science Inc. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. Univ Washington, Dept Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Dobie, DJ (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU NIAAA NIH HHS [K23AA00313] NR 57 TC 111 Z9 130 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2002 VL 24 IS 6 BP 367 EP 374 AR PII S0163-8343(02)00207-4 DI 10.1016/S0163-8343(02)00207-4 PG 8 WC Psychiatry SC Psychiatry GA 632FA UT WOS:000180212100002 PM 12490337 ER PT J AU El-Serag, HB AF El-Serag, HB TI Hepatocellular carcinoma and hepatitis C in the United States SO HEPATOLOGY LA English DT Article ID VIRUS-RELATED CIRRHOSIS; PRIMARY LIVER-CANCER; RISK-FACTORS; INTERFERON THERAPY; DIABETES-MELLITUS; SPANISH PATIENTS; NATURAL-HISTORY; HCV INFECTION; PREVALENCE; PROGRESSION AB Chronic infection with hepatitis C virus (HCV) is a major risk factor for development of hepatocellular carcinoma (HCC). In general, HCC develops only after 2 or more decades of HCV infection and the increased risk is restricted largely to patients with cirrhosis or advanced fibrosis. Factors that predispose to HCC among HCV-infected persons include mate sex, older age, hepatitis B virus (HBV) coinfection, heavy alcohol intake, and possibly diabetes and a transfusion-related source of HCV infection. Viral factors play a minor role. The likelihood of development of HCC among HCV-infected persons is difficult to determine because of the paucity of adequate long-term cohort studies; the best estimate is 1% to 3% after 30 years. Once cirrhosis is established, however, HCC develops at an annual rate of 1% to 4%. Successful antiviral therapy of patients with HCV-related cirrhosis may reduce the future risk for HCC. The incidence of and mortality caused by all HCC has doubled in the United States over the past 25 years, an increase that has affected all ethnic groups, both sexes, and younger age groups. Given the current prevalence of HCV infection among persons 30 to 50 years of age, the incidence and mortality rates of HCC are likely to double in the United States over the next 10 to 20 years. Future research should focus on improving understanding of the incidence and risk factors for HCC, causes of HCV-related carcinogenesis, means of early detection, and better treatment for HCC. C1 Houston Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX USA. Houston Dept Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Adm Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. NR 88 TC 283 Z9 286 U1 1 U2 6 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD NOV PY 2002 VL 36 IS 5 SU 1 BP S74 EP S83 DI 10.1053/jhep.2002.36807 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 611VT UT WOS:000179039000009 PM 12407579 ER PT J AU Zhang, Y Yu, J Unni, E Shao, TC Nan, BC Snabboon, T Kasper, S Andriani, F Denner, L Marcelli, M AF Zhang, Y Yu, J Unni, E Shao, TC Nan, BC Snabboon, T Kasper, S Andriani, F Denner, L Marcelli, M TI Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB SO HUMAN GENE THERAPY LA English DT Article ID STAUROSPORINE-INDUCED APOPTOSIS; CHRONIC MYELOID-LEUKEMIA; HUMAN ADENOVIRUS TYPE-5; BCL-2 FAMILY-MEMBERS; CELL-LINE LNCAP; SURVIVAL; OVEREXPRESSION; PHOSPHORYLATION; CASPASE-7; PROTEIN AB We have shown that adenovirus-mediated manipulation of apoptotic genes such as bax could be a therapeutic option for prostate cancer. Unfortunately, the response of experimental prostate tumors to a single therapeutic gene of the apoptotic pathway is short-lived, and most of these tumors relapse after a short period of time. In this investigation we present data generated with adenovirus AvARR(2)PB-Bad, in which the apoptotic gene bad was placed under the control of the dihydrotestosterone (DHT)-inducible third-generation probasin-derived promoter ARR(2)PB. This therapeutic virus was given alone or in combination with other therapeutic viruses to a variety of in vitro and in vivo experimental models of prostate cancer. On infection with AvARR(2)PB-Bad, DHT-induced Bad overexpression occurred specifically in androgen receptor-positive (AR(+)) cells of prostatic derivation. The apoptotic effect of AvARR(2)PB-Bad ( group 1) was compared with that of AvARR(2)PB-Bax ( which overexpresses the apoptotic protein Bax) ( group 2), with that of the combination AvARR(2)PB-Bad plus AvARR(2)PB-Bax ( group 3), and with that of the control virus AvARR(2)PB-CAT ( group 4) in the cell line LNCaP. In addition to identifying the modality of apoptosis induction by overexpressed Bad, the results suggested that group 3 contained more apoptotic cells than any other group. In additional studies, AR1 androgen-dependent LNCaP cells or AR1 and androgen-independent C4-2 cells were injected subcutaneously into nude mice. Four groups of six LNCaP or C4-2 tumors were treated with the same combinations of viruses discussed above for groups 1, 2, 3, and 4. Treatment resulted in decreased tumor size in groups 1, 2, and 3 compared with group 4. There was a better response in group 3 compared with group 2, and in group 2 compared with group 1. A better response in group 3 was confirmed during a 8-week follow-up period, in which no treatment was administered. Two LNCaP and C4-2 tumors of group 3 disappeared at the end of treatment and did not recur after an 8-week follow-up period. The data suggest that polygene therapy with apoptotic molecules is more effective in experimental models of androgen-dependent or - independent prostate cancer than monogene therapy. C1 Baylor Coll Med, VA Med Ctr, Dept Med Mol & Cellular Biol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN 37232 USA. Texas Biotechnol Corp, Apoptosis Program, Houston, TX 77030 USA. RP Marcelli, M (reprint author), Baylor Coll Med, VA Med Ctr, Dept Med Mol & Cellular Biol, 2002 Holcombe Blvd,Bldg 109,Room 217, Houston, TX 77030 USA. EM marcelli@bcm.tmc.edu RI Andriani, Francesca/D-4898-2017 OI Andriani, Francesca/0000-0002-6178-7789 NR 35 TC 17 Z9 18 U1 0 U2 0 PU MARY ANN LIEBERT INC PUBL PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1043-0342 J9 HUM GENE THER JI Hum. Gene Ther. PD NOV PY 2002 VL 13 IS 17 BP 2051 EP 2064 DI 10.1089/10430340260395901 PG 14 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 766CM UT WOS:000188327900005 PM 12490000 ER PT J AU Xu, GL Meyer, JS Thornby, J Chowdhury, M Quach, M AF Xu, GL Meyer, JS Thornby, J Chowdhury, M Quach, M TI Screening for mild cognitive impairment (MCI) utilizing combined mini-mental-cognitive capacity examinations for identifying dementia prodromes SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE MCI screening for dementia prodromes by combined MMSE-CCSE ID AMERICAN-NEUROPSYCHIATRIC-ASSOCIATION; STATE-EXAMINATION; ALZHEIMERS-DISEASE; INTERNATIONAL WORKSHOP; VASCULAR DEMENTIA; DIAGNOSIS; INSTRUMENTS; POPULATION; MMSE; INDIVIDUALS AB Objective To test correctness of results when combining Mini-Mental State Examination (MMSE) and Cognitive Capacity Screening Examination (CCSE) for identifying mild cognitive impairment (MCI) among non-demented elderly subjects at risk for developing dementia. Methods A retrospective study was conducted among consecutively referred volunteers with memory complaints to a research out-patient clinic. Two cognitive screening tests (MMSE and CCSE) were performed according to established protocol. Resulting combined screening test (termed by acronym as CMC) combined the non-overlapping test items derived from both MMSE and CCSE. Conversion to dementia at follow-up served as the 'gold-standard' for evaluating correctness of CMC for identifying MCI. Results Of 351 subjects completing cognitive assessments and meeting requirements for study protocol, 84 (23.9%) developed dementia of different types within 3-6 years (3.89 +/- 2.17) of follow-up. Among these, 47 met criteria for probable Alzheimer disease (AD), 22 for probable vascular dementia (VaD), 12 for mixed AD/VaD and three for probable frontotemporal dementia. When final diagnosis of AD was used as the 'gold standard' for testing correctness of MCI identified by cognitive screening tests, sensitivities of MMSE, CCSE and CMC for identifying MCI were relatively 61.0%, 74.3% and 83.1% with minimum specificity set at 80%. When diagnosis of all types of dementia was used as the standard for testing predictive correctness of MCI, CCSE emerged as an optimal MCI screening test. Conclusion Combining the CCSE and MMSE screening tests resulted in higher sensitivity than was achieved by MMSE alone and maintained specificity at comparable levels for identifying MCI. The results confirmed that CMC has optimal correctness and utility as a brief cognitive test for screening MCI as a prodrome for dementia among non-demented elderly populations. Published in 2002 by John Wiley Sons, Ltd. C1 VA Med Ctr, Cerebrovasc Res Lab, Houston, TX 77030 USA. VA Med Ctr, Biostat Labs, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA. RP Meyer, JS (reprint author), VA Med Ctr, Cerebrovasc Res Lab, Bldg 110 Room 225,2002 Holcombe Blvd, Houston, TX 77030 USA. OI Xu, Gelin/0000-0002-6194-0341 NR 52 TC 56 Z9 61 U1 0 U2 4 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD NOV PY 2002 VL 17 IS 11 BP 1027 EP 1033 DI 10.1002/gps.744 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 614YD UT WOS:000179218300006 PM 12404652 ER PT J AU Kim, N Weeks, DL Shin, JM Scott, DR Young, MK Sachs, G AF Kim, N Weeks, DL Shin, JM Scott, DR Young, MK Sachs, G TI Proteins released by Helicobacter pylori in vitro SO JOURNAL OF BACTERIOLOGY LA English DT Article ID GASTRIC EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; VACUOLATING CYTOTOXIN; IV SECRETION; INFECTION; CAGA; INTERLEUKIN-8; TRANSLOCATION; PATHOGENICITY; PATHOGENESIS AB Secretion of proteins by Helicobacter pylori may contribute to gastric inflammation and epithelial damage. An in vitro analysis was designed to identify proteins released by mechanisms other than nonspecific lysis. The radioactivity of proteins in the supernatant was compared with that of the intact organism by two-dimensional gel phosphorimaging following a 4-h pulse-chase. The ratio of the amount of UreB, a known cytoplasmic protein, in the supernatant to that in the pellet was found to be 0.25, and this was taken as an index of lysis during the experiments (n = 6). Ratios greater than that of UreB were used to distinguish proteins that were selectively released into the medium. Thus, proteins enriched more than 10-fold in the supernatant compared to UreB were identified by mass spectrometry. Sixteen such proteins were present in the supernatant: VacA; a conserved secreted protein (HP1286); putative peptidyl cis-trans isomerase (HP0175); six proteins encoded by HP0305, HP0231, HP0973, HP0721, HP0129, and HP0902; thioredoxin (HP1458); single-stranded-DNA-binding 12RNP2 precursor (HP0827); histone-like DNA-binding protein HU (HP0835); ribosomal protein L11 (HP1202); a putative outer membrane protein (HP1564); and outer membrane proteins Omp21 (HP0913) and Omp20 (HP0912). All except HP0902, thioredoxin, HP0827, HP0835, and HP1202 had a signal peptide. When nalidixic acid, a DNA synthesis inhibitor, was added to inhibit cell division but not protein synthesis, to decrease possible contamination due to outer membrane shedding, two outer membrane proteins (Omp21 and Omp20) disappeared from the supernatant, and the amount of VacA also decreased. Thus, 13 proteins were still enriched greater than 10-fold in the medium after nalidixic acid treatment, suggesting these were released specifically, possibly by secretion. These proteins may be implicated in H. pylori-induced effects on the gastric epithelium. C1 Univ Calif Los Angeles, Digest Dis Ctr, Dept Physiol & Med, Los Angeles, CA 90073 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Spectrometry & Microsequencing Core Facil, Duarte, CA 91010 USA. RP Sachs, G (reprint author), VA Greater Los Angeles Hlth Care Syst, Bldg 113,Room 324,11301 Wilshore Blvd, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu RI Kim, Nayoung/J-5387-2012 FU NIDDK NIH HHS [DK46917, R01 DK046917]; PHS HHS [17294, 41301, 53462] NR 53 TC 52 Z9 58 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD NOV PY 2002 VL 184 IS 22 BP 6155 EP 6162 DI 10.1128/JB.184.22.6155-6162.2002 PG 8 WC Microbiology SC Microbiology GA 609QU UT WOS:000178916700009 PM 12399485 ER PT J AU Saltzman, CL AF Saltzman, CL TI Two types of therapeutic shoes were no better than usual footwear for preventing foot reulceration SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Editorial Material C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Saltzman, CL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD NOV PY 2002 VL 84A IS 11 BP 2107 EP 2107 PG 1 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 612NJ UT WOS:000179082100038 PM 12429781 ER PT J AU El-Serag, HB AF El-Serag, HB TI Hepatocellular carcinoma - An epidemiologic view SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT Yale University Workshop on Hepatocellular Carcinoma CY MAR 15-16, 2002 CL NEW HAVEN, CONNECTICUT SP Yale Sch Med DE hepatocellular carcinoma; epidemiology; hepatitis ID PRIMARY LIVER-CANCER; CHRONIC HEPATITIS-C; UNITED-STATES; DIABETES-MELLITUS; RISK-FACTORS; B VIRUS; CIRRHOSIS; PREVALENCE; ETIOLOGY; SURVIVAL AB Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Because of its high fatality rates, the incidence and mortality rates are almost equal. The major risk factors for HCC are chronic hepatitis B virus infection, chronic hepatitis C virus (HCV) infection, and alcoholic cirrhosis. The epidemiology of HCC is characterized by marked demographic (age, gender; race/ethnicity) and geographic variations. Hepatitis B virus infection, with and without aflatoxin exposure, is responsible for most cases in developing countries; better control of these risk factors has resulted in a recent decline in HCC in some places like Taiwan and China. Recently, however, a trend of rising rates of HCC has been reported from several developed countries in Europe and North America. These new trends are associated with ''new'' risk factors such as HCV and, possibly, diabetes. In the United States, the incidence of HCC has approximately doubled over the past 3 decades. White individuals are two to three times less often affected than African Americans, who in turn are two to three times less often affected than Asians, Pacific Islanders, or Native Americans. Men are two to three times more often affected than women. Concomitant with the rising rates of HCC, there has been a shift of incidence from typically elderly patients to relatively younger patients between ages of 40 to 60 years. An increase in HCV-related HCC accounts for at least half of the witnessed increase in HCC in the United States. Hepatocellular carcinoma continues to carry an overall dismal survival rate (close to 5%); very few patients qualify for and receive potentially curative therapy. The future incidence trends of HCC will be determined to a large extent by the clinical course of HCV-infected people. C1 Houston Vet Affairs Med Ctr 152, Gastroenterol Sect, Houston, TX 77030 USA. Houston Vet Affairs Med Ctr 152, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Houston Vet Affairs Med Ctr 152, Gastroenterol Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. NR 38 TC 361 Z9 374 U1 1 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD NOV-DEC PY 2002 VL 35 IS 5 SU 2 BP S72 EP S78 DI 10.1097/00004836-200211002-00002 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 614AT UT WOS:000179165200002 PM 12394209 ER PT J AU Manire, CA Rhinehart, HL Sutton, DA Thompson, EH Rinaldi, MG Buck, JD Jacobson, E AF Manire, CA Rhinehart, HL Sutton, DA Thompson, EH Rinaldi, MG Buck, JD Jacobson, E TI Disseminated mycotic infection caused by Colletotrichum acutatum in a Kemp's ridley sea turtle (Lepidochelys kempi) SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SUBCUTANEOUS ABSCESS; DRUG-INTERACTIONS; ITRACONAZOLE; RIFAMPIN; GLOEOSPORIOIDES; IDENTIFICATION; BREAKTHROUGH; ANTHRACNOSE; PROPHYLAXIS; FLORIDA AB Colletotrichum acutatum is a cosmopolitan plant pathogen with a wide host range. While the organism's phytopathogenic potential has been well documented, it has never been reported as an etiologic agent of disease in either animals or humans. In this case, a juvenile Kemp's ridley sea turtle, Lepidochelys kempi, probably with immune compromise following cold stunning (extended hypothermia), developed a disseminated mycotic infection in the lungs and kidneys. Prophylactic treatment with oral itraconazole did not prevent or cure the infection. This report of a Colletotrichum acutatum infection in an animal extends the range of disease caused by this organism beyond that of a phytopathogen. C1 Sea Turtle Rehabil Hosp, Mote Marine Lab & Aquarium, Sarasota, FL 34236 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA. RP Manire, CA (reprint author), Sea Turtle Rehabil Hosp, Mote Marine Lab & Aquarium, 1600 Ken Thompson Pkwy, Sarasota, FL 34236 USA. NR 41 TC 19 Z9 21 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2002 VL 40 IS 11 BP 4273 EP 4280 DI 10.1128/JCM.40.11.4273-4280.2002 PG 8 WC Microbiology SC Microbiology GA 612BH UT WOS:000179053200063 PM 12409409 ER PT J AU Komers, R Tian, W Lindsley, JN Oyama, TT Cohen, DM Anderson, S AF Komers, R Tian, W Lindsley, JN Oyama, TT Cohen, DM Anderson, S TI Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes SO JOURNAL OF LABORATORY AND CLINICAL MEDICINE LA English DT Article; Proceedings Paper CT World Congress of Nephrology CY OCT 10-17, 2001 CL SAN FRANCISCO, CALIFORNIA SP ASN, ISN ID MACULA DENSA; RENOVASCULAR HYPERTENSION; BLOOD-FLOW; RAT-KIDNEY; EXPRESSION; PRESSURE; MICE; SUPPRESSION; NEPHROPATHY; SECRETION AB COX-2-derived prostaglandins (PG) have been suggested to be important modulators of renin release and expression. However, the role of COX-2 in various high-renin states is still being debated. In the present studies we explored the role of COX-2-derived PG on basal and angiotensin converting enzyme inhibitor (ACEI)-stimulated plasma and renal renin concentrations (PRC and RRC, RIA), and mRNA expression (RmRNA, RNAse protection assay) in experimental diabetes (DM). Groups of moderately hyperglycemic (n = 5, similar to350 mg/dl), streptozotocin-diabetic rats (D) after 3 weeks of DM were treated with a selective COX-2 inhibitor, MF-tricyclic (MF, 5 mg/kg/day for 10 days in food), the combination of MF and the ACEI enalapril (3 mg/kg/day), enalapril alone, or vehicle (MF-free chow), for 10 days. Non-diabetic control rats, fed MF-free chow, were also studied. All groups of diabetic rats demonstrated similar glycemic control. Treatment with ACEI resulted in significant elevations in PRC, RRC and RmRNA as compared to non-ACEI treated groups of diabetic and control rats. A similar rise in these parameters was observed in the rats treated with the combination of ACEI and MF. Furthermore, in diabetic rats treated with MF alone, PRC and RRC were similar to vehicle-treated animals. Diabetic rats demonstrated higher urinary PG as compared to controls. MF-treated rats demonstrated a significant reduction in urinary PG excretion. In summary, selective COX-2 inhibition influenced neither basal renin status nor ACEI-induced renin release and expression in diabetic rats. These findings do not support a significant role for COX-2 in mediating renin status in diabetes. C1 Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Anderson, S (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. FU NIA NIH HHS [AG 14699]; NIDDK NIH HHS [DK 52494] NR 31 TC 9 Z9 11 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0022-2143 J9 J LAB CLIN MED JI J. Lab. Clin. Med. PD NOV PY 2002 VL 140 IS 5 BP 351 EP 357 DI 10.1067/mlc.2002.128551 PG 7 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 618XJ UT WOS:000179442600008 PM 12434137 ER PT J AU Morihara, T Chu, T Ubeda, O Beech, W Cole, GM AF Morihara, T Chu, T Ubeda, O Beech, W Cole, GM TI Selective inhibition of A beta 42 production by NSAID R-enantiomers SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; beta-amyloid; non-steroidal anti-inflammatory drugs (NSAIDs); nuclear factor-kappa B (NF-kappa B); R-flurbiprofen; R-ibuprofen ID NF-KAPPA-B; ALZHEIMERS-DISEASE; FLURBIPROFEN ENANTIOMERS; CYCLOOXYGENASE; INFLAMMATION; IBUPROFEN; RELEASE; DOMAIN AB Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress beta-amyloid (Abeta) accumulation in vivo and Abeta42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been hampered by dose-limiting toxicity believed to be due to cyclooxygenase (COX)-inhibition that is reportedly not essential for selective Abeta42 reduction. Profens have racemates and R-enantiomers were supposed to be inactive forms. Here we demonstrate that R-ibuprofen and R-flurbiprofen, with poor COX-inhibiting activity, reduce Abeta42 production by human cells. Although these R-enantiomers inhibit nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB can selectively regulate Abeta42, Abetab42 reduction is not mediated by inhibition of NF-kappaB activation. Because of its efficacy at lowering Abeta42 production and low toxicity profile, R-flurbiprofen is a strong candidate for clinical development. C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, GRECC, Sepulveda, CA USA. RP Cole, GM (reprint author), Univ Calif Los Angeles, Dept Med, Greater Los Angeles VA Healthcare Syst GRECC11E, 16111 Plummer St, Sepulveda, CA 91343 USA. FU NIA NIH HHS [AG13471] NR 22 TC 125 Z9 129 U1 0 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD NOV PY 2002 VL 83 IS 4 BP 1009 EP 1012 DI 10.1046/j.1471-4159.2002.01195.x PG 4 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 611YR UT WOS:000179046200029 PM 12421374 ER PT J AU Linseman, DA Phelps, RA Bouchard, RJ Le, SS Laessig, TA McClure, ML Heidenreich, KA AF Linseman, DA Phelps, RA Bouchard, RJ Le, SS Laessig, TA McClure, ML Heidenreich, KA TI Insulin-like growth factor-I blocks Bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signaling in cerebellar granule neurons SO JOURNAL OF NEUROSCIENCE LA English DT Article DE insulin-like growth factor; cerebellar granule neuron; apoptosis; mitochondria; Bim; forkhead transcription factor ID FORKHEAD TRANSCRIPTION FACTOR; CENTRAL-NERVOUS-SYSTEM; CYTOCHROME-C RELEASE; IGF-I; MITOCHONDRIAL DEPOLARIZATION; CASPASE ACTIVATION; FAMILY MEMBERS; PURKINJE-CELLS; MESSENGER-RNA; APOPTOSIS AB Cerebellar granule neurons depend on insulin-like growth factor-I (IGF-I) for their survival. However, the mechanism underlying the neuroprotective effects of IGF-I is presently unclear. Here we show that IGF-I protects granule neurons by suppressing key elements of the intrinsic (mitochondrial) death pathway. IGF-I blocked activation of the executioner caspase-3 and the intrinsic initiator caspase-9 in primary cerebellar granule neurons deprived of serum and depolarizing potassium. IGF-I inhibited cytochrome c release from mitochondria and prevented its redistribution to neuronal processes. The effects of IGF-I on cytochrome c release were not mediated by blockade of the mitochondrial permeability transition pore, because IGF-I failed to inhibit mitochondrial swelling or depolarization. In contrast, IGF-I blocked induction of the BH3- only Bcl-2 family member, Bim (Bcl-2 interacting mediator of cell death), a mediator of Bax-dependent cytochrome c release. The suppression of Bim expression by IGF-I did not involve inhibition of the c-Jun transcription factor. Instead, IGF-I prevented activation of the forkhead family member, FKHRL1, another transcriptional regulator of Bim. Finally, adenoviral-mediated expression of dominant-negative AKT activated FKHRL1 and induced expression of Bim. These data suggest that IGF-I signaling via AKT promotes survival of cerebellar granule neurons by blocking the FKHRL1-dependent transcription of Bim, a principal effector of the intrinsic death-signaling cascade. C1 Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Heidenreich, KA (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E 9th Ave, Denver, CO 80262 USA. FU NINDS NIH HHS [NS38619-01A1] NR 55 TC 116 Z9 125 U1 0 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 1 PY 2002 VL 22 IS 21 BP 9287 EP 9297 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 611RM UT WOS:000179031600019 PM 12417654 ER PT J AU Teter, B Ashford, JW AF Teter, B Ashford, JW TI Neuroplasticity in Alzheimer's disease SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Review DE neuroplasticity; Alzheimer's; genetics; apo-lipoprotein E; therapeutics; pharmacogenetics ID AMYLOID PRECURSOR PROTEIN; NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; APOLIPOPROTEIN-E GENOTYPE; E-DEFICIENT MICE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; DENSITY-LIPOPROTEIN RECEPTOR; ESTROGEN REPLACEMENT THERAPY; HIPPOCAMPAL ORGANOTYPIC CULTURES AB Ramon y Cajal proclaimed in 1928 that "once development was ended, the founts of growth and regeneration of the axons and dendrites dried up irrevocably. In the adult centers the nerve paths are something fixed, ended and immutable. Everything must die, nothing may be regenerated. It is for the science of the future to change, if possible, this harsh decree." (Ramon y Cajal, 1928). In large part, despite the extensive knowledge gained since then, the latter directive has not yet been achieved by 'modern' science. Although we know now that Ramon y Cajal's observation on CNS plasticity is largely true (for lower brain and primary cortical structures), there are mechanisms for recovery from CNS injury. These mechanisms, however, may contribute to the vulnerability to neurodegenerative disease. They may also be exploited therapeutically to help alleviate the suffering from neurodegenerative conditions. Published 2002 Wiley-Liss, Inc. C1 Univ Calif Los Angeles, VA Med Ctr, Dept Med, Sepulveda, CA 91343 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Kentucky, Dept Psychiat, Lexington, KY USA. Univ Kentucky, Dept Neurol, Lexington, KY USA. Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. Vet Affairs Med Ctr, Lexington, KY USA. RP Teter, B (reprint author), Univ Calif Los Angeles, VA Med Ctr, Dept Med, MC151,16111 Plummer St, Sepulveda, CA 91343 USA. FU NIA NIH HHS [K01 AG000962] NR 698 TC 63 Z9 64 U1 6 U2 17 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD NOV 1 PY 2002 VL 70 IS 3 BP 402 EP 437 DI 10.1002/jnr.10441 PG 36 WC Neurosciences SC Neurosciences & Neurology GA 608EL UT WOS:000178832200021 PM 12391603 ER PT J AU Behnam, K Murray, SS Whitelegge, JP Brochmann, EJ AF Behnam, K Murray, SS Whitelegge, JP Brochmann, EJ TI Identification of the molecular chaperone alpha B-crystallin in demineralized bone powder and osteoblast-like cells SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE heat shock protein; osteoblast; crystallin; bone; proteomics; chaperone ID HEAT-SHOCK PROTEINS; MASS-SPECTROMETRY; BETA-CRYSTALLIN; MOUSE EMBRYO; IN-VITRO; STRESS; EXPRESSION; HEAT-SHOCK-PROTEIN-27; CYTOSKELETON; LOCALIZATION AB Bone is subjected to a variety of physiological, as well as cell-deforming biomechanical stresses, including hydrostatic compression and fluid flow. However, little is known about the molecular mechanisms that protect bone cells from mechanical, ischemic, or oxidative damage. Crystallins are 20 kD heat shock proteins that function as molecular chaperones. We tested the hypothesis that alpha B-crystallin (alphaB-crystallin), the most widely expressed vertebrate crystallin, is present in bone and osteoblast-like cells. Noncollagenous proteins (NCPs) were extracted from human demineralized bone matrix with 4 NI guanidine HCl containing 0.5 M CaCl2 and protease inhibitors, defatted, dialyzed against 0.2%, (v/v) Triton X-100 in 100 mM Tris-HCl (pH 7.2) and water, centrifuged, and lyophilized. The NCPs were separated by 2D IEF/SDS-PAGE. The two most abundant 20 kD spots, with apparent pis of 7.85 and 7.42 in urea gels, were excised, subjected to matrix-assisted laser desorption ionization/time-of-flight mass spectrometry, and identified as alphaB-crystallins. Indirect immunofluorescence localized alphaB-crystallin to the interphase nucleus, cytoskeleton and cytoplasm of proliferating MC3T3-El mouse osteoblast-like cells, as well as the cytoskeleton and cytoplasm of confluent cells. In conclusion, alphaB-crystallin is present in bone and osteoblast-like cells. We hypothesize that alphaB-crystallin may play a role in protecting the osteoblast cytoskeleton from mechanical stress and may be important in modulating nuclear or cellular functions, such as transcription or apoptosis, as observed in other tissues. Published by Elsevier Science Ltd. on behalf of Orthopaedic Research Society. C1 VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Pasarow Mass Spectrometry Lab, Chem & Biochem & Neuropsychiat Inst, Los Angeles, CA 90095 USA. RP VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, 16111 Plummer St, Sepulveda, CA 91343 USA. EM murrayes@ucla.edu FU NIAID NIH HHS [AI 12601]; NINDS NIH HHS [NS 31271, NS 07171] NR 38 TC 8 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD NOV PY 2002 VL 20 IS 6 BP 1190 EP 1196 AR PII S0736-0266(02)00071-2 DI 10.1016/S0736-0266(02)00071-2 PG 7 WC Orthopedics SC Orthopedics GA 618CP UT WOS:000179400800009 PM 12472228 ER PT J AU Casarett, D Karlawish, J Sankar, P Hirschman, KB Asch, DA AF Casarett, D Karlawish, J Sankar, P Hirschman, KB Asch, DA TI Obtaining informed consent for cancer pain research: Do patients with advanced cancer and patients with chronic pain have different concerns? SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE pain; research ethics; human subjects; informed consent ID RANDOMIZED CONTROLLED TRIAL; QUALITY-OF-LIFE; PALLIATIVE CARE RESEARCH; TRANSDERMAL FENTANYL; SYMPTOM ASSESSMENT; BREAKTHROUGH PAIN; ORAL MORPHINE; MANAGEMENT; SATISFACTION; GUIDELINES AB To explore the factors that patients with malignant tend nonmalignant pain consider when deciding whether to enroll in pain research studies, determine whether their views are different, and determine whether willingness to enroll in research is associated with pain. severity, semi-structured interviews were conducted with 80 patients (cancer pain: n = 40; chronic nonmalignant pain: n = 40). The risks and potential benefits that were important to patients with cancer were the same as those that were important to patients with chronic pain. Willingness to enroll in, research was associated with pain severity (Spearman p = 0.33; P = 0.041) in patients with chronic pain, but not in patients with cancer pain. Patients with cancer pain do not have different concerns than chronic pain patients do. Although chronic pain patients' willingness to enroll in research was related to pain severity and a desire, for better pain management, cancer patients' willingness to enroll was not. J Pain Symptom Manage 2002;24:506-516. (C) U.S. Cancer Pain Relief Committee, 2002. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA. Leonard Davis Inst Hlth Econ, Wilmington, DE USA. Univ Penn, Sch Social Work, Philadelphia, PA USA. RP Casarett, D (reprint author), Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. NR 47 TC 5 Z9 5 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2002 VL 24 IS 5 BP 506 EP 516 AR PII S0885-3924(02)00527-4 DI 10.1016/S0885-3924(02)00527-4 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 629PY UT WOS:000180059100008 PM 12547050 ER PT J AU O'Connor, TJ Fitzgerald, SG Cooper, RA Thorman, TA Boninger, ML AF O'Connor, TJ Fitzgerald, SG Cooper, RA Thorman, TA Boninger, ML TI Kinetic and physiological analysis of the GAME(wheels) system SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE cardiovascular fitness; computer games; exercise; wheelchair ID SPINAL-CORD INJURIES; WHEELCHAIR PROPULSION; PUSHRIM FORCES; COMPUTER GAMES; VIDEO-GAME AB For individuals with a spinal cord injury or dysfunction (SCI/D), opportunities to exercise are limited and are usually not highly motivating experiences. Exercise programs or extracurricular activities may help increase or maintain the cardiovascular fitness level of individuals with SCI/D. The GAME(Wheels) system, an interface between a portable roller system and a computer, enables an individual to control a video game by propelling his or her wheelchair. The purpose of this study was to investigate whether the propulsive forces used during video play, both with and without the GAME(Wheels) system, were different. A secondary purpose was to examine differences in metabolic parameters during exercise under these two conditions. Ten manual wheelchair users exercised on the GAME(Wheels) system with and without controlling a video game. Physiological and kinetic data were collected six times during two exercise trials. Kinetic data were recorded with the SMART(Wheel) and used to investigate propulsion forces. No significant differences were found in the resultant force, rate of rise, or number of hand contacts with the pushrims. This study showed that propulsion pattern did not change significantly when wheelchair users exercised while playing a computer video game. Oxygen consumption, ventilation, and heart rate were significantly different (p < 0.05) between the two groups during the last three exercise intervals and cooldown. Playing a video game while exercising may help to motivate manual wheelchair users to exercise longer and regularly, something that was reported by this study's subjects; likewise, exercising while playing a video game may not be associated with higher pushrim forces and stroke frequencies. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. Houston VA Med Ctr, Houston, TX USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Fitzgerald, SG (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Ctr Excellence Wheelchairs & Related Technol, 7180 Highland Dr 151R-1, Pittsburgh, PA 15206 USA. FU NICHD NIH HHS [K08 HD01122-01, P01 HD33989-04, P01-HD33989-0151] NR 22 TC 8 Z9 8 U1 2 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD NOV-DEC PY 2002 VL 39 IS 6 BP 627 EP 634 PG 8 WC Rehabilitation SC Rehabilitation GA 667UV UT WOS:000182253200003 PM 17943665 ER PT J AU Ritsher, JB McKellar, JD Finney, JW Otilingam, PG Moos, RH AF Ritsher, JB McKellar, JD Finney, JW Otilingam, PG Moos, RH TI Psychiatric comorbidity, continuing care and mutual help as predictors of five-year remission from substance use disorders SO JOURNAL OF STUDIES ON ALCOHOL LA English DT Article ID COGNITIVE-BEHAVIORAL TREATMENT; ABUSE TREATMENT; TREATMENT OUTCOMES; 1-YEAR OUTCOMES; 12-STEP; INVOLVEMENT; ALCOHOLICS AB Objective: In a cohort of 2,595 male patients in VA intensive treatment programs for substance use disorders (SUD), we tested whether psychiatric comorbidity, outpatient care and mutual help group attendance during the first two follow-up years predicted remission status at Year 5, controlling for covariates. Method: Logistic regression modeling of longitudinal data was used to test the hypotheses. Results: Dual diagnosis patients were less likely to be in remission at Year 5 than SUD only patients. Outpatient care was at best only weakly related to Year 5 remission status. By contrast, mutual help involvement substantially improved the chances of substance use remission at Year 5 for both SUD only and dual diagnosis patients. Mutual help involvement did not, however, offset the poorer prognosis for dual diagnosis patients. Conclusions: Because mutual help groups specifically targeted to individuals with comorbid substance use and psychiatric disorders are currently rare, further research is recommended to investigate whether they are more effective than standard SUD mutual help groups in facilitating the recovery of persons with dual diagnoses. C1 Ctr Hlth Care Evaluat, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. RP Ritsher, JB (reprint author), San Francisco VAMC, No Calif Inst Res & Educ, 4150 Clement St,116A, San Francisco, CA 94121 USA. FU NIAAA NIH HHS [AA12718] NR 31 TC 60 Z9 60 U1 4 U2 7 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 0096-882X J9 J STUD ALCOHOL JI J. Stud. Alcohol PD NOV PY 2002 VL 63 IS 6 BP 709 EP 715 PG 7 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 631ET UT WOS:000180155700009 PM 12529071 ER PT J AU Friedlander, AH Garrett, NR Norman, DC AF Friedlander, AH Garrett, NR Norman, DC TI The prevalence of calcified carotid artery atheromas on the panoramic radiographs of patients with type 2 diabetes mellitus SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article ID INSULIN-RESISTANCE ATHEROSCLEROSIS; IMPAIRED GLUCOSE-TOLERANCE; RISK-FACTORS; CARDIOVASCULAR RISK; CIGARETTE-SMOKING; ISCHEMIC-STROKE; COMPLICATIONS; HYPERTENSION; DISEASE; MORTALITY AB Background. People with type 2 diabetes mellitus are disproportionately at risk of experiencing stroke, because hyper-glycemia and other risk factors associated with diabetes accelerate development of cervical carotid artery atheromas. Removal of these atheromas may reduce the incidence of stroke. The authors conducted a study to ascertain if those treated without insulin (noninsulin-treated, or NIT) would have a lower prevalence of atheromas on their radiographs and a lower prevalence of risk factors than those treated with insulin (insulin-treated, or IT). Methods. The authors evaluated the panoramic radiographs and medical records of 46 neurologically asymtomatic men (n=34) and women (n=12) (age range 62-77 years, mean age 68.5 years) with type 2 diabetes. They used Fisher exact test to perform a statistical comparison of the prevalence of atherogenic atheromas and risk factors between groups. Results. The radiographs showed that 24 percent of the NIT patients had atheromas; this difference was not statistically significant (P=.52). The groups had similar risk factors-that is, high levels of glycsylated hemoglobin A, or HbA(1c); smoking, hyper-tension and obesity (P>.05). When compared with the 4 percent atheroma prevalence rate among healthy people of similar age, the rates were significantly higher in both the NIT (P=.02) and IT (P=.0006) patients. Conclusion. These results demonstrate that people with type 2 diabetes, irrespective of treatment modality, have high rates of atheromas as visualised on their panoramic radiographs. Clinical Implications. Dentists treating patients with type 2 diabetes mellitus must review their panoramic radiographs carefully for evidence of atheroma formation. Patients with atheromatous lesions must be referred to their physicians for further evaluation and treatment because the modification of atherogenic risk factors and the surgical removal of atheromas in certain people have been shown to reduce the likelihood of stroke. C1 Dept Vet Affairs Greater Los Angeles Healthcare S, Oral Biol Res Lab, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov FU NIDCR NIH HHS [DE 09085] NR 56 TC 24 Z9 25 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD NOV PY 2002 VL 133 IS 11 BP 1516 EP 1523 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 618CD UT WOS:000179399800016 PM 12462696 ER PT J AU Latini, DM Penson, DF Colwell, HH Lubeck, DP Mehta, SS Henning, JM Lue, TF AF Latini, DM Penson, DF Colwell, HH Lubeck, DP Mehta, SS Henning, JM Lue, TF TI Psychological impact of erectile dysfunction: Validation of a new health related quality of life measure for patients with erectile dysfunction SO JOURNAL OF UROLOGY LA English DT Article DE penis; impotence; questionnaires; quality of life; psychology, medical ID OF-LIFE; MEN AB Purpose: Male erectile dysfunction has a substantial impact on health related quality of life. We examined the psychometric properties of 2 new scales created to measure the psychological impact of erectile dysfunction. Materials and Methods: Patients enrolled in a long-term study of men with erectile dysfunction completed clinical and health related quality of life information at baseline and at 3 followup points. The questionnaire incorporated a number of standard scales of psychosocial characteristics as well as questions developed from comments made during focus groups of men with erectile dysfunction and of their female partners. Principal components analysis was used to identify underlying constructs in response to the new questions. Results: A total of 168 men completed the baseline quality of life questionnaire. The principal components analysis of the psychological impact of erectile dysfunction questions resulted in 2 new scales. Reliability was good with an internal consistency reliability of 0.91 for scale 1 and 0.72 for scale 2. Test-retest reliability was 0.76 and 0.66, respectively. Men reporting a greater psychological impact of erectile dysfunction also reported greater impairment in functional status, lower sexual self-efficacy, greater depression and anxiety at the last intercourse. Each new scale significantly differentiated men with mild/moderate versus severe erectile dysfunction. Conclusions: We developed 2 new scales to measure the psychological impact of erectile dysfunction and they showed good reliability and validity. These new scales, named the Psychological Impact of Erectile Dysfunction instrument, comprehensively capture the psychological effect of erectile dysfunction on health related quality of life, which is not adequately assessed by existing patient centered measures of erectile function. C1 Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Urol Outcomes Res Grp, San Francisco, CA 94143 USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Urol, Seattle, WA USA. Univ Washington, Dept Urol, Seattle, WA 98195 USA. TAP Pharmaceut Prod, Lake Forest, IL USA. RP Latini, DM (reprint author), Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. OI Latini, David/0000-0002-6161-4861 NR 18 TC 48 Z9 49 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD NOV PY 2002 VL 168 IS 5 BP 2086 EP 2091 DI 10.1097/01.ju.0000034365.57110.b7 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 603LX UT WOS:000178562100052 PM 12394715 ER PT J AU Hegde, NR Tomazin, RA Wisner, TW Dunn, C Boname, JM Lewinsohn, DM Johnson, DC AF Hegde, NR Tomazin, RA Wisner, TW Dunn, C Boname, JM Lewinsohn, DM Johnson, DC TI Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation SO JOURNAL OF VIROLOGY LA English DT Article ID NATURAL-KILLER-CELLS; ENDOPLASMIC-RETICULUM; INVARIANT CHAIN; PEPTIDE TRANSLOCATION; GENE-PRODUCT; HEAVY-CHAINS; INTRACELLULAR-TRANSPORT; SURFACE EXPRESSION; T-CELLS; MOLECULES AB Human cytomegalovirus (HCMV) establishes persistent lifelong infections and replicates slowly. To withstand robust immunity, HCMV utilizes numerous immune evasion strategies. The HCW gene cassette encoding US2 to US11 encodes four homologous glycoproteins, US2, US3, US6, and US11, that inhibit the major histocompatibility complex class I (MHC-I) antigen presentation pathway, probably inhibiting recognition by CD8(+) T lymphocytes. US2 also inhibits the MHC-II antigen presentation pathway, causing degradation of human leukocyte antigen (HLA)-DR-alpha and -DM-alpha and preventing recognition by CD4(+) T cells. We investigated the effects of seven of the US2 to US11 glycoproteins on the MHC-II pathway. Each of the glycoproteins was expressed by using replication-defective adenovirus vectors. In addition to US2, US3 inhibited recognition of antigen by CD4(+) T cells by a novel mechanism. US3 bound to class II alpha/beta complexes in the endoplasmic reticulum (ER), reducing their association with Ii. Class II molecules moved normally from the ER to the Golgi apparatus in US3-expressing cells but were not sorted efficiently to the class II loading compartment. As a consequence, formation of peptide-loaded class II complexes was reduced. We concluded that US3 and US2 can collaborate to inhibit class II-mediated presentation of endogenous HCMV antigens to CD4(+) T cells, allowing virus-infected cells to resist recognition by CD4(+) T cells. C1 Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. Portland Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97207 USA. RP Johnson, DC (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Mail Code L-220,Rm 6383 BCs, Portland, OR 97239 USA. RI Hegde, Nagendra/J-5920-2014; Lewinsohn, David/I-4936-2013 OI Hegde, Nagendra/0000-0001-5260-2159; Lewinsohn, David/0000-0001-9906-9494; Boname, Jessica/0000-0002-5149-5934 FU NEI NIH HHS [EY11245, R01 EY011245] NR 65 TC 67 Z9 72 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD NOV PY 2002 VL 76 IS 21 BP 10929 EP 10941 DI 10.1128/JVI.76.21.10929-10941.2002 PG 13 WC Virology SC Virology GA 602NX UT WOS:000178512300037 PM 12368336 ER PT J AU Kominsky, DJ Bickel, RJ Tyler, KL AF Kominsky, DJ Bickel, RJ Tyler, KL TI Reovirus-induced apoptosis requires mitochondrial release of Smac/DIABLO and involves reduction of cellular inhibitor of apoptosis protein levels SO JOURNAL OF VIROLOGY LA English DT Article ID PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; INFLUENZA-A VIRUS; LYMPHOCYTE APOPTOSIS; MEDIATED APOPTOSIS; FAMILY PROTEINS; MEASLES-VIRUS; T-CELLS; DEATH; IAP AB Many viruses belonging to diverse viral families with differing structure and replication strategies induce apoptosis both in cultured cells in vitro and in tissues in vivo. Despite this fact, little is known about the specific cellular apoptotic pathways induced during viral infection. We have previously shown that reovirus-induced apoptosis of HEK cells is initiated by death receptor activation but requires augmentation by mitochondrial apoptotic pathways for its maximal expression. We now show that reovirus infection of HEK cells is associated with selective cytosollic release of the mitochondrial proapoptotic factors cytochrome c and Smac/DLABLO, but not the release of apoptosis-inducing factor. Release of these factors is not associated with loss of mitochondrial transmembrane potential and is blocked by overexpression of Bcl-2. Stable expression of caspase-9b, a dominant-negative form of caspase-9, blocks reovirus-induced caspase-9 activation but fails to significantly reduce activation of the key effector caspase, caspase-3. Smac/DIABLO enhances apoptosis through its action on cellular inhibitor of apoptosis proteins (IAPs). Reovirus infection is associated with selective downregulation of cellular IAPs, including c-LAP1, XIAP, and survivin, effects that are blocked by Bcl-2 expression, establishing the dependence of IAP down-regulation on mitochondriall events. Taken together, these results are consistent with a model in which Smac/DLABLO-mediated inhibition of 1APs, rather than cytochrome c-mediated activation of caspase-9, is the key event responsible for mitochondrial augmentation of reovirus-induced apoptosis. These studies provide the first evidence for the association of Smac/DIABLO with virus-induced apoptosis. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, B-182,4200 E 9th Ave, Denver, CO 80262 USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NIA NIH HHS [1R01AG14071]; NINDS NIH HHS [T32 NS007321, T32NS07321] NR 63 TC 50 Z9 55 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD NOV PY 2002 VL 76 IS 22 BP 11414 EP 11424 DI 10.1128/JVI.76.22.11414-11424.2002 PG 11 WC Virology SC Virology GA 608AF UT WOS:000178822400026 PM 12388702 ER PT J AU Roman, GC Erkinjuntti, T Wallin, A Pantoni, L Chui, HC AF Roman, GC Erkinjuntti, T Wallin, A Pantoni, L Chui, HC TI Subcortical ischaemic vascular dementia SO LANCET NEUROLOGY LA English DT Review ID WHITE-MATTER LESIONS; AUTOSOMAL-DOMINANT ARTERIOPATHY; CHRONIC CEREBRAL HYPOPERFUSION; ENCEPHALOPATHY BINSWANGERS DISEASE; EXECUTIVE COGNITIVE IMPAIRMENT; CORONARY-ARTERY BYPASS; BRAIN-BARRIER FUNCTION; VISUAL RATING-SCALES; AMYLOID ANGIOPATHY; RISK-FACTORS AB Vascular dementia is the second most common type of dementia. The subcortical ischaemic form (SIVD) frequently causes cognitive impairment and dementia in elderly people. SIVD results from small-vessel disease, which produces either arteriolar occlusion and lacunes or widespread incomplete infarction of white matter due to critical stenosis of medullary arterioles and hypoperfusion (Binswanger's disease). Symptoms include motor and cognitive dysexecutive slowing, forgetfulness, dysarthria, mood changes, urinary symptoms, and short-stepped gait. These manifestations probably result from ischaemic interruption of parallel circuits from the prefrontal cortex to the basal ganglia and corresponding thalamocortical connections. Brain imaging (computed tomography and magnetic resonance imaging) is essential for correct diagnosis. The main risk factors are advanced age, hypertension, diabetes, smoking, hyperhomocysteinaemia, hyperfibrinogenaemia, and other conditions that can cause brain hypoperfusion such as obstructive sleep apnoea, congestive heart failure, cardiac arrhythmias, and orthostatic hypotension. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) and some forms of cerebral amyloid angiopathy have a genetic basis. Treatment is symptomatic and prevention requires control of treatable risk factors. C1 Univ Texas, HSC, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Univ Helsinki, Cent Hosp, Helsinki, Finland. Univ Gothenburg, Molndal, Sweden. Sahlgrens Univ Hosp, Molndal, Sweden. Univ Florence, Florence, Italy. Univ So Calif, Los Angeles, CA USA. Rancho Los Amigos Natl Rehabil Ctr, Downey, CA USA. RP Roman, GC (reprint author), Univ Texas, HSC, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. FU NIA NIH HHS [P01 AG12435] NR 152 TC 505 Z9 556 U1 2 U2 44 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD NOV PY 2002 VL 1 IS 7 BP 426 EP 436 DI 10.1016/S1474-4422(02)00190-4 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 606KC UT WOS:000178732300020 PM 12849365 ER PT J AU Tierney, WM Weinberger, M Ashton, CM McHorney, CA AF Tierney, WM Weinberger, M Ashton, CM McHorney, CA TI A remarkable legacy of science review of AHRQ-funded articles published in Medical Care during John Eisenberg's directorship of AHRQ SO MEDICAL CARE LA English DT Editorial Material ID QUALITY-OF-LIFE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL; PHYSICIAN JOB-SATISFACTION; SELF-MANAGEMENT PROGRAM; OUTCOMES RESEARCH TEAMS; NURSING-HOME RESIDENTS; HEALTH-STATUS; INTRAINDIVIDUAL CHANGES; EDUCATIONAL-PROGRAM C1 Richard L Roudebush VA Med Ctr, HSR&D Serv, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, Indianapolis, IN 46204 USA. Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27515 USA. Durham VA Med Ctr, Durham, NC USA. Houston VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Tierney, WM (reprint author), Richard L Roudebush VA Med Ctr, HSR&D Serv, 11H,1481 W 10th St, Indianapolis, IN 46202 USA. NR 84 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD NOV PY 2002 VL 40 IS 11 BP 1003 EP 1011 DI 10.1097/01.MLR.0000032180.23171.01 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 611DP UT WOS:000179001400001 PM 12409845 ER PT J AU Kovacs, TOG Jensen, DM AF Kovacs, TOG Jensen, DM TI Recent advances in the endoscopic diagnosis and therapy of upper gastrointestinal, small intestinal, and colonic bleeding SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Review ID PROSPECTIVE RANDOMIZED TRIAL; ACUTE VARICEAL HEMORRHAGE; CONTROLLED CLINICAL-TRIAL; ESOPHAGEAL-VARICES; PEPTIC-ULCERS; INJECTION SCLEROTHERAPY; COMPARING SOMATOSTATIN; PORTAL-HYPERTENSION; HEATER PROBE; DOUBLE-BLIND AB Endoscopy has evolved as the first and primary modality to evaluate patients with severe gastrointestinal hemorrhage. Panendoscopy, push enteroscopy, and colonoscopy provide vital diagnostic and prognostic information and the opportunity for therapeutic intervention. Experienced endoscopists who use standardized endoscopic hemostatic techniques can arrest active bleeding from gastrointestinal lesions and improve patient outcome. This article reviews recent advances in the endoscopic diagnosis and treatment of severe gastrointestinal hemorrhage that have resulted in improved patient care. C1 VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Sch Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. RP Kovacs, TOG (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Sch Med, Bldg 115,Room 212,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [M01-RR00865]; NIDDK NIH HHS [R01-DK 33273, DK 41301, 1K24 DK 02650] NR 110 TC 36 Z9 38 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD NOV PY 2002 VL 86 IS 6 BP 1319 EP + AR PII S0025-7125(02)00079-2 DI 10.1016/S0025-7125(02)00079-2 PG 40 WC Medicine, General & Internal SC General & Internal Medicine GA 647UF UT WOS:000181111900006 PM 12510456 ER PT J AU Metlay, JP Shea, JA Asch, DA AF Metlay, JP Shea, JA Asch, DA TI Antibiotic prescribing decisions of generalists and infectious disease specialists: Thresholds for adopting new drug therapies SO MEDICAL DECISION MAKING LA English DT Article DE antibiotics; medical decision making; attitudes of health personnel ID COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; PRIMARY-CARE PHYSICIANS; ANTIMICROBIAL RESISTANCE; UNITED-STATES; PNEUMOCOCCAL PNEUMONIA; RESPONSE RATES; ADULT PATIENTS; MAIL SURVEYS; MANAGEMENT AB The objective of this study was to examine whether physicians are willing to continue to use older antibiotics in the face of drug resistance in order to preserve newer antibiotics for future use. The study was a national sample of 398 generalist physicians and 429 infectious disease (ID) specialists. Clinical vignettes prompted respondents to select the level of resistance to a hypothetical older antibiotic at which they would prefer a newer antibiotic without any current resistance in the treatment of a patient with pneumococcal pneumonia. Vignettes varied in the site of care of the patient as a proxy for variation in disease severity. Respondents significantly reduced their threshold for switching to a newer antibiotic as disease severity increased. Generalists were more responsive to disease severity than ID specialists. Thus, the adoption of recommendations to limit overuse of newer antibiotics maybe variable across clinical settings and providers, reducing the impact of these recommendations on emerging resistance. C1 Univ Penn, Sch Med, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, Philadelphia, PA 19104 USA. Univ Penn, Div Gen Internal Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Metlay, JP (reprint author), Univ Penn, Sch Med, Ctr Hlth Equ Res & Promot, Dept Vet Affairs, 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. OI Asch, David/0000-0002-7970-286X NR 35 TC 10 Z9 10 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2002 VL 22 IS 6 BP 498 EP 505 DI 10.1177/0272989X02238297 PG 8 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 615RQ UT WOS:000179260800005 PM 12458980 ER PT J AU Holmes, WC AF Holmes, WC TI HIV/AIDS, utilities, and cost-effectiveness analysis: Stepping toward the future SO MEDICAL DECISION MAKING LA English DT Editorial Material ID QUALITY-OF-LIFE C1 Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Holmes, WC (reprint author), 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. NR 8 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X J9 MED DECIS MAKING JI Med. Decis. Mak. PD NOV-DEC PY 2002 VL 22 IS 6 BP 522 EP 525 DI 10.1177/0272989X02238584 PG 4 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 615RQ UT WOS:000179260800008 PM 12458983 ER PT J AU Dobashi, K Singh, I Orak, JK Asayama, K Singh, AK AF Dobashi, K Singh, I Orak, JK Asayama, K Singh, AK TI Combination therapy of N-acetylcysteine, sodium nitroprusside and phosphoramidon attenuates ischemia-reperfusion injury in rat kidney SO MOLECULAR AND CELLULAR BIOCHEMISTRY LA English DT Article DE N-acetylcysteine; nitric oxide; endothelin; ischemia-reperfusion injury; antioxidant enzymes; free radicals ID ACUTE-RENAL-FAILURE; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; FREE-RADICALS; TUBULAR-NECROSIS; PROXIMAL TUBULE; RELAXING FACTOR; TISSUE-INJURY; ENDOTHELIUM AB Renal ischemia is of clinical interest because of its role in renal failure and also renal graft rejection. To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. Ninety min of ischemia caused very severe injury and the animals could not survive after 4 days without any treatment. Whereas, animals in the treated groups survived i.e. the NAC group (25%), NAC + SNP group (43%) and in the NAC + SNP + P group (100%), 2 weeks after 90 min of ischemia. A significant increase in the serum levels of creatinine and urea nitrogen was shown in the untreated group and to a much lesser extent in the treated group, especially in the NAC + SNP + P group. The protective effect was also supported by light microscopic studies on renal tissue sections. We also measured the activities of antioxidant enzymes in tissue homogenates. With the exception of Mn-superoxide dismutase, the activities of antioxidant enzymes (catalase, glutathione peroxidase, CuZn-superoxide dismutase) were decreased in the untreated kidney. The administration of NAC alone and NAC + SNP protected against the loss of activities. Treatment with a combination of NAC, SNP and P showed a synergistic effect as evidenced by the best protection. These results suggest that pre-administration of a combination of antioxidant (NAC) with endothelin derived vasodilators (sodium nitroprusside and Phosphoramidon) attenuates renal ischemia-reperfusion injury, e. g. in donor kidney for transplantation, by protecting cells against free radical damage. C1 Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat & Pathol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,316 CSB, Charleston, SC 29425 USA. FU NINDS NIH HHS [NS-34741, NS-40810, NS-37766, NS-22576] NR 48 TC 27 Z9 28 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0300-8177 J9 MOL CELL BIOCHEM JI Mol. Cell. Biochem. PD NOV PY 2002 VL 240 IS 1-2 BP 9 EP 17 DI 10.1023/A:1020629020443 PG 9 WC Cell Biology SC Cell Biology GA 603EH UT WOS:000178545500002 PM 12487367 ER PT J AU Linseman, DA Bartley, CM Meintzer, MK Le, SS Laessig, TA Bouchard, RJ Heidenreich, KA AF Linseman, DA Bartley, CM Meintzer, MK Le, SS Laessig, TA Bouchard, RJ Heidenreich, KA TI Ca2+/calmodulin-dependent protein kinase II promotes neuronal survival by inhibiting HDAC repression of MEF2D SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-for-Cell-Biology CY DEC 14-18, 2002 CL SAN FRANCISCO, CALIFORNIA SP Amer Soc Cell Biol C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver VAMC, Denver, CO USA. RI Bartley, Christopher/G-4226-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD NOV PY 2002 VL 13 MA 923 BP 165A EP 165A PG 1 WC Cell Biology SC Cell Biology GA 621BR UT WOS:000179569100922 ER PT J AU Liu, YY Brent, GA AF Liu, YY Brent, GA TI A complex deoxyribonucleic acid response element in the rat Ca2+/calmodulin-dependent protein kinase IV gene 5 '-flanking region mediates thyroid hormone induction and chicken ovalbumin upstream promoter transcription factor 1 repression SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID RETINOID-X-RECEPTOR; COUP-TF; BINDING PROTEIN; NEURONAL DIFFERENTIATION; SIGNALING PATHWAY; BRAIN-DEVELOPMENT; LATE-PHASE; EXPRESSION; ACTIVATION; CALCIUM AB Ca2+/Calmodulin-dependent protein kinase IV (CaMKIV) is regulated by T-3 in a time- and concentration-dependent manner in the developing rat brain and plays an important role in neuronal-specific gene regulation. T-3 treatment, but not retinoic acid (RA), stimulated endogenous CaMKIV mRNA 5-fold in mouse embryonic stem (ES) cells differentiated into neurons. We localized a region -750 to -700 in the CaMKIV gene 5'-flanking region that conferred T-3 responsiveness and bound thyroid hormone receptor (TR), retinoic acid receptor (RAR), and chicken ovalbumin upstream promoter-transcription factor 1 (COUP-TF1). T-3 and RA treatment stimulated the CaMKIV hormone response element. Cotransfection of a COUP-TF1 expression vector repressed the T-3 response and augmented the RA response. Mutational analysis identified three half-sites arranged in a direct repeat (AB) and overlapping inverted repeat (BC), required for functional induction and receptor binding. TR and RAR bound predominantly to the BC portion of the element and COUP-TF1 to the AB region, with a close correlation of binding and functional studies. COUP-TF1 binding did not influence TR/retinoid X receptor binding but modestly augmented RAR/retinoid X receptor binding. A single element confers T-3 and COUP-TF1 regulation of CaMKIV expression. C1 Univ Calif Los Angeles, Mol Endocrinol Lab, Sch Med,Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Mol Endocrinol Lab, Sch Med,Dept Physiol, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, Mol Endocrinol Lab, Sch Med,Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCI NIH HHS [R01-CA-89364] NR 70 TC 16 Z9 16 U1 0 U2 1 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD NOV PY 2002 VL 16 IS 11 BP 2439 EP 2451 DI 10.1210/me.2001-0324 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 610HG UT WOS:000178954200003 PM 12403833 ER PT J AU Yildiran, ST Fothergill, AW Sutton, DA Rinaldi, MG AF Yildiran, ST Fothergill, AW Sutton, DA Rinaldi, MG TI In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592) SO MYCOSES LA English DT Article DE Cryptococcus neoformans; cerebrospinal fluid; antifungal susceptibility; fluconazole; voriconazole; posaconazole ID IN-VITRO; DIMORPHIC FUNGI; AMPHOTERICIN-B; MENINGITIS; AIDS; ITRACONAZOLE; RESISTANCE; FAILURE; RELAPSE AB We investigated the in vitro susceptibilities of 213 cerebrospinal fluid isolates of Cryptococcus neoformans isolated from 192 patients through a 10-year period, 1990-99, against fluconazole, voriconazole and posaconazole (SCH56592) by using the NCCLS (National Committee for Clinical Laboratory Standards) macrodilution method, M27-A. The overall MICs50 and MICs90 of fluconazole, voriconazole and posaconazole were found to be 2 and 8 mug ml(-1) less than or equal to0.125 mug ml(-1) (both), and less than or equal to 0.015 and 0.06 mug ml(-1), respectively. The MIC ranges, MICs50, and MICs90 of three triazoles were also determined according to the defined year category (1990-94, 1995, 1996, 1997 and 1998-99). The MICs50 and MICs90 of each triazole remained almost unchanged and did not exhibit any sign of an upward shift during a decade (1990-99). However, a tendency for development of possible cross-resistance between the three triazoles was observed only in 1996. Meanwhile, the individual relapsing isolates (n:21) from 20 patients exhibited same, higher or, suprisingly, lower MICs, particularly against fluconazole and posaconazole. C1 Gulhane Mil Med Acad, Div Med Mycol, Dept Microbiol & Clin Microbiol, TR-06018 Ankara, Turkey. Sch Med, TR-06018 Ankara, Turkey. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Yildiran, ST (reprint author), Gulhane Mil Med Acad, Div Med Mycol, Dept Microbiol & Clin Microbiol, TR-06018 Ankara, Turkey. NR 24 TC 26 Z9 28 U1 0 U2 0 PU BLACKWELL VERLAG GMBH PI BERLIN PA KURFURSTENDAMM 57, D-10707 BERLIN, GERMANY SN 0933-7407 J9 MYCOSES JI Mycoses PD NOV PY 2002 VL 45 IS 9-10 BP 378 EP 383 DI 10.1046/j.1439-0507.2002.00765.x PG 6 WC Dermatology; Mycology SC Dermatology; Mycology GA 621WH UT WOS:000179613700007 PM 12421285 ER PT J AU Hyams, KC Scott, K AF Hyams, KC Scott, K TI Adding to our understanding of Gulf War health issues SO PSYCHOLOGICAL MEDICINE LA English DT Editorial Material ID VETERANS C1 US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, VA Cent Off, Washington, DC 20420 USA. Canadian Forces Med Grp Headquarters, Ottawa, ON K1A 0K6, Canada. RP Hyams, KC (reprint author), US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, VA Cent Off, 810 Vermont Ave NW, Washington, DC 20420 USA. NR 6 TC 2 Z9 2 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA SN 0033-2917 J9 PSYCHOL MED JI Psychol. Med. PD NOV PY 2002 VL 32 IS 8 BP 1335 EP 1337 DI 10.1017/S0033291702006669 PG 3 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 621AD UT WOS:000179565600001 PM 12455931 ER PT J AU Cohen, LM Dobscha, SK Hails, KC Pekow, PS Chochinov, HM AF Cohen, LM Dobscha, SK Hails, KC Pekow, PS Chochinov, HM TI Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis SO PSYCHOSOMATIC MEDICINE LA English DT Article ID TERMINALLY ILL; MAJOR DEPRESSION; ASSISTED SUICIDE; RISK-FACTORS; DEATH; DIAGNOSIS; CARE; DECISION; ATTITUDES; WITHDRAWN AB Objective: The objective of this study was to determine the prevalence of major depression and suicidal ideation in patients who stop the life-support treatment of dialysis. Methods: The authors prospectively studied 79 subjects who discontinued maintenance dialysis at eight facilities in North America. Structured interviews were conducted with 23 patients and 76 families. Results: The prevalence of major depression in the sample was between 5% and 25%, and only 1 of 22 patients considered himself to have the illness of depression. Approximately 12% of the respondents were unsure or believed that discontinuing dialysis was the equivalent of suicide. This belief did not correlate with measures of depression. In comparison with the general population there seemed to be an increased prevalence of past suicide attempts. Conclusions: Most patients who decide to stop dialysis do not seem to be influenced by major depression or ordinary suicidal ideation. Although the sample size was small, these results highlight the need to further examine the theoretical framework and terminology of depression and suicide in the context of terminal illness. Key words: dialysis, depression, suicide, life support. C1 Baystate Med Ctr, Dept Psychiat, Springfield, MA 01199 USA. Portland VA Med Ctr, Dept Psychiat, Portland, OR USA. Albert Einstein Med Ctr, Dept Psychiat, Philadelphia, PA 19141 USA. Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA. Univ Manitoba, Dept Psychiat & Family Med, Winnipeg, MB, Canada. CancerCare Manitoba, Winnipeg, MB, Canada. RP Cohen, LM (reprint author), Baystate Med Ctr, Dept Psychiat, S2669, Springfield, MA 01199 USA. NR 51 TC 28 Z9 29 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD NOV-DEC PY 2002 VL 64 IS 6 BP 889 EP 896 DI 10.1097/01.PSY.0000028828.64279.84 PG 8 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 622AB UT WOS:000179622900006 PM 12461194 ER PT J AU Garg, K Keith, RL Byers, T Kelly, K Kerzner, AL Lynch, DA Miller, YE AF Garg, K Keith, RL Byers, T Kelly, K Kerzner, AL Lynch, DA Miller, YE TI Randomized controlled trial with low-dose spiral CT for lung cancer screening: Feasibility study and preliminary results SO RADIOLOGY LA English DT Article DE cancer screening; lung neoplasms, CT; lung neoplasms, diagnosis ID COMPUTED-TOMOGRAPHY; OBSTRUCTION; PULMONARY; SPUTUM; CELLS; RISK AB PURPOSE: To assess the feasibility of conducting a randomized controlled trial for lung cancer screening. MATERIALS AND METHODS: Subjects are being recruited into a randomized controlled trial to undergo either low-dose spiral computed tomography (CT) or observation. Subjects are from a high-risk group with known chronic obstructive pulmonary disease and sputum atypia and a moderate-risk group randomly selected from the general population of a Veterans Affairs Medical Center. All subjects must be 50-80 years of age with 30 or more pack-years of cigarette smoking and must not have undergone chest CT during the previous 3 years. Baseline screening CT is performed with 50 mA, 120 kVp, 5-mm collimation, and a pitch of 2. CT scan interpretation and management of nodules is based on Society of Thoracic Radiology guidelines. The chi(2) test for categoric data was used for statistical analysis. RESULTS: To date, 304 eligible subjects have been contacted, and 239 (79%) have agreed to participate in the trial. One hundred nineteen (88%) of the 136 subjects in the high-risk group and 120 (71%) of the 168 subjects in the moderate-risk group agreed to randomization (P < .001). To date, 190 subjects have been randomized. Of the first 92 subjects examined with CT, 22 (40%) of 55 in the high-risk group and eight (22%) of 37 in the moderate-risk group had one to six noncalcified nodules that required follow-up (P = .07). In all but three subjects, nodules were smaller than 5 mm. Two of the three larger nodules were malignancies. CONCLUSION: Findings of this study indicate that a randomized controlled trial of CT to screen for lung cancer is feasible. (C) RSNA, 2002. C1 Univ Colorado, Ctr Comprehens Canc, Dept Oncol, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Dept Biostat & Epidemiol, Denver, CO USA. Univ Colorado, Denver Vet Affairs Med Ctr, Div Pulm Med, Denver, CO 80202 USA. Univ Colorado, Denver Vet Affairs Med Ctr, Dept Radiol, Denver, CO 80202 USA. RP Garg, K (reprint author), Univ Colorado Hosp, Dept Radiol, Anchutz Outpatient Pavillon,1635 N Ursula St,Camp, Aurora, CO 80010 USA. NR 27 TC 51 Z9 58 U1 0 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD NOV PY 2002 VL 225 IS 2 BP 506 EP 510 DI 10.1148/radiol.2252011851 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 608AG UT WOS:000178822500028 PM 12409588 ER PT J AU Stuber, GD Evans, SB Higgins, MS Pu, YP Figlewicz, DP AF Stuber, GD Evans, SB Higgins, MS Pu, YP Figlewicz, DP TI Food restriction modulates amphetamine-conditioned place preference and nucleus accumbens dopamine release in the rat SO SYNAPSE LA English DT Article ID 6-HYDROXYDOPAMINE LESIONS; INTRAVENOUS COCAINE; LOCOMOTOR-ACTIVITY; MESSENGER-RNA; DEPRIVATION; INCREASES; LEPTIN; REWARD; TRANSPORTER; MORPHINE AB Food restriction has been shown to increase self-administration of psychostimulants, including cocaine and amphetamine (AMPH). Consistent with this, food-restricted rats are more sensitized to the rewarding effects of cocaine as measured by conditioned place preference (CPP). This study investigated whether moderate food restriction in rats (15 g/day) results in an increased CPP, relative to ad libitum-fed controls, to a second psychostimulant, AMPH. Conditioning trials consisted of six alternating injections of i.p. AMPH (0.425-6.8 mg/kg) and i.p. saline, paired with distinct environments. On Day 7, a drug-free 20-min choice test for environment was carried out to assess CPP. 0.85 mg/kg AMPH significantly increased CPP in food-restricted vs. ad libitum-fed rats. At 1.7 and 3.4 mg/kg AMPH, food-restricted rats showed decreased CPP, but increased locomotor activity, relative to ad libitum fed controls. To evaluate whether an alteration in extracellular fluid DA levels in the nucleus accumbens (NAc) core could account for these behavioral alterations, DA release was measured by microdialysis. DA release to a single acute i.p. injection of either 0.85 or 1.7 mg/kg AMPH was comparable in food-restricted and ad libitum fed rats. However, ad libitum fed rats demonstrated conditioned DA release after an AMPH conditioning paradigm analogous to the CPP paradigm, whereas food-restricted rats demonstrated no conditioned DA release. In conclusion, altered DA release in the nucleus accumbens core is not a primary effect of moderate food restriction and cannot completely account for either the altered CPP behavior or enhanced locomotor activity observed in this study. Published 2002 Wiley-Liss, Inc.(dagger). C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Endocrinol Metab 151,1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu RI Stuber, Garret/E-1160-2011 FU NINDS NIH HHS [T32 NS/MH 07431, T32 NS007431]; PHS HHS [R0140963] NR 48 TC 45 Z9 47 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0887-4476 EI 1098-2396 J9 SYNAPSE JI Synapse PD NOV PY 2002 VL 46 IS 2 BP 83 EP 90 DI 10.1002/syn.10120 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 600WA UT WOS:000178413700006 PM 12211086 ER PT J AU Gushiken, FC Le, A Arnett, FC Thiagarajan, P AF Gushiken, FC Le, A Arnett, FC Thiagarajan, P TI Polymorphisms beta 2-glycoprotein I: phospholipid binding and multimeric structure SO THROMBOSIS RESEARCH LA English DT Article DE beta 2-glycoprotein I; anionic phospholipid; vesicle aggregation ID AMINO-ACID-SEQUENCE; BETA(2)-GLYCOPROTEIN I; PARTICLES; VESICLES AB beta2-glycoprotein I is a phospholipid-binding protein of 326 amino acids and is found in plasma at a concentration of similar to 200 mug/ml. It has a sequence of positively charged amino acids located at the carboxy terminus that mediates anionic phospholipid binding. Two polyrnorphisms (306Cys --> Gly and 316Trp --> Set) located at the phospholipid-binding site have been described. Homozygous state for either mutation and a compound heterozygous state show no phospholipid binding. Interestingly, heterozygotes for either 306Cys-->Gly or 316Trp-->Ser mutation have normal cardiolipin binding suggesting that beta2-glycoprotein I may circulate as a multimeric structure where wild-type subunits compensate the defective binding of the mutant ones. We investigated the effect of these mutations on quaternary structure of beta2-glycoprotein I and phospholipid binding. As previously reported, under native conditions, beta2-glycoprotein I shows an apparent molecular weight of similar to 320 kDa and it can be dissociated into subunits of lower molecular weight by boiling in 6 M urea. We show that the multimeric structure is not affected by the presence of mutations in the phospholipid-binding domain. beta2-glycoprotein I induces aggregation of anionic phospholipid vesicles suggesting again a multivalent interaction where at least two binding sites are required to bridge adjacent vesicles. beta2-glycoprotein I-induced aggregation does not cause vesicle fusion or damage as demonstrated by fluorescence resonance energy transfer (FRET) or encapsulated calcein release. In conclusion, the normal cardiolipin binding in heterozygous state for mutations at phospholipid-binding domain may be due to the multimeric structure of beta2-glycoprotein I. (C) 2002 Published by Elsevier Science Ltd. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Thrombosis Res, Houston, TX USA. Univ Texas, Hlth Sci Ctr, Baylor Coll Med, Dept Pathol, Houston, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Rheumatol, Houston, TX USA. RP Thiagarajan, P (reprint author), VA Med Ctr, Mail 113,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NHLBI NIH HHS [HL 65096] NR 18 TC 13 Z9 13 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD NOV 1 PY 2002 VL 108 IS 2-3 BP 175 EP 180 DI 10.1016/S0049-3848(02)00392-4 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 657DZ UT WOS:000181651300012 PM 12590955 ER PT J AU Burgio, KL AF Burgio, KL TI Influence of behavior modification on overactive bladder SO UROLOGY LA English DT Article; Proceedings Paper CT Symposium on New Perspectives on the Overactive Bladder CY MAR 08-09, 2002 CL CAMBRIDGE, MASSACHUSETTS ID URINARY-INCONTINENCE; DETRUSOR INSTABILITY; CONTROLLED TRIAL; OLDER WOMEN; BIOFEEDBACK; DRILL AB Behavioral interventions have been used for decades to treat urge incontinence and other symptoms of overactive bladder. Perhaps the earliest form of treatment was the bladder drill, an intensive intervention designed to increase the interval between voids to establish a normal frequency of urination and normalization of bladder function. Bladder training is a modification of bladder drill that is conducted more gradually on an outpatient basis and has resulted in significant reduction of incontinence in older, community-dwelling women. Multicomponent behavioral training is another form of behavioral treatment that includes pelvic floor muscle training and exercise. This intervention focuses less on voiding habits and more on altering the physiologic responses of the bladder and pelvic floor muscles. Using biofeedback or other teaching methods, patients learn strategies to inhibit bladder contraction using pelvic floor muscle contraction and other urge suppression strategies. Although behavioral and drug therapies are known to be highly effective for reducing urge incontinence, few patients are cured with either treatment alone. Thus, future research should explore ways to enhance the effectiveness of these conservative therapies. Although the mechanisms by which behavioral treatments work have not been established, there is some evidence that behavioral and drug interventions may operate by different mechanisms, suggesting that they may have additive effects and that combining them may result in better outcomes. Future research needs to examine the mechanisms by which these therapies reduce incontinence and whether combining behavioral and drug treatment will result in better outcomes than either therapy alone. (C) 2002, Elsevier Science Inc. C1 Dept Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. Univ Alabama, Sch Med, Birmingham, AL USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, GRECC, 11G,700 19th St S, Birmingham, AL 35233 USA. NR 23 TC 30 Z9 32 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD NOV PY 2002 VL 60 IS 5A SU S BP 72 EP 76 AR PII S0090-4295(02)01800-9 DI 10.1016/S0090-4295(02)01800-9 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 626UY UT WOS:000179893100020 PM 12493360 ER PT J AU Klausner, AP Galea, J Vapnek, JM AF Klausner, AP Galea, J Vapnek, JM TI Effect of catheter size on urodynamic assessment of bladder outlet obstruction SO UROLOGY LA English DT Article ID PRESSURE-FLOW; URETHRAL INSTRUMENTATION AB Objectives. To examine the effect of cross-sectional catheter diameter on urodynamic measurement of bladder outlet obstruction as predicted by the Abrams-Griffiths nomogram. Methods. Thirty-one patients with symptomatic benign prostatic hyperplasia underwent free flow measurements followed by pressure-flow urodynamic evaluation using 5F and I OF urethral catheters in randomly assigned order. The measurements of voided volume, maximal flow rate (Qmax), postvoid residual volume, and detrusor pressure at maximal flow (PdetQmax) were compared. Data points were then plotted on the Abrams-Griffiths nomogram, and categorization of bladder outlet obstruction was assigned for each catheter size. Results. The use of I OF catheters resulted in both a significant decrease in Omax and increase in PdetQmax compared with the use of 5F catheters. Of 31 patients, 10 (32%) were incorrectly categorized as obstructed according to the Abrams-Griffiths nomogram when the larger sized catheter was used, and 17 (55%) experienced migration from a less obstructed to a more obstructed category. Conclusions. The use of 5F catheters allows for more accurate diagnosis of bladder outlet obstruction. In urodynamic evaluations, the larger size I OF catheters should be avoided, especially in patients with borderline symptoms. (C) 2002, Elsevier Science Inc. C1 Mt Sinai Med Ctr, Dept Urol, New York, NY 10029 USA. Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Vapnek, JM (reprint author), Mt Sinai Med Ctr, Dept Urol, Box 1272,1 Gustave L Levy Pl, New York, NY 10029 USA. NR 14 TC 9 Z9 9 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD NOV PY 2002 VL 60 IS 5 BP 875 EP 880 AR PII S0090-4295(02)01873-3 DI 10.1016/S0090-4295(02)01873-3 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 614KU UT WOS:000179188700034 PM 12429319 ER PT J AU Amendola, A Tanzi, E Zappa, A Colzani, D Boschini, A Musher, DM Zanetti, AR AF Amendola, A Tanzi, E Zappa, A Colzani, D Boschini, A Musher, DM Zanetti, AR TI Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users SO VACCINE LA English DT Article DE pneumococcal polysaccharide vaccine; HIV-1 load; CD4+counts ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; STREPTOCOCCUS-PNEUMONIAE; CAPSULAR POLYSACCHARIDES; ANTIBODY-RESPONSES; DISEASE; IMMUNIZATION; INFLUENZA; ADULTS; IMPACT AB The immunogenicity of 23-valent pneumococcal polysaccharide vaccine was assessed in 57 HIV-1 infected former intravenous drug users and in 20 HIV-1 negative controls. The effect of vaccination on HIV-1 infection was studied in a subgroup of 38 patients, 60% of whom under highly active antiretroviral therapy (HAART). Antibody to capsular polysaccharides from Streptococcus pneumoniae serotypes 3, 4, 6B, 19F, 23F, and changes in CD4+ count, HIV-1 RNA, proviral DNA and HIV-1 phenotype were measured in pre- and post-vaccination samples. Vaccinations were well-tolerated. The rate of responders was higher (P < 0.05) in HIV-1 negative than in HIV-1 infected individuals. No difference in antibody response was found within HIV-1 infected patients stratified according to CD4+ counts. Post-vaccination antibody geometric mean concentrations (GMCs) to the five antigens were higher (P < 0.05) than baseline in HIV-1 negative subjects, but not in HIV-1 positive individuals. Those with CD4+ >500 cells/mm(3) showed a significant increase of antibody against type 3 only. Immunisation caused no significant changes in CD4+ counts and in either plasma HIV-1 RNA nor proviral DNA levels. Pneumococcal vaccination does not induce virological or immunological deterioration in HIV infected patients, but the antibody response to a single dose of vaccine is poor. (C) 2002 Elsevier Science Ltd. All rights reserved. C1 Univ Milan, Inst Virol, I-20133 Milan, Italy. San Patrignano Community, Rimini, Italy. Houston Dept Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Houston, TX USA. RP Zanetti, AR (reprint author), Univ Milan, Inst Virol, Via Pascal 38, I-20133 Milan, Italy. RI Amendola, Antonella/M-8980-2016; Tanzi, Elisabetta/M-9066-2016 OI Amendola, Antonella/0000-0002-0499-8977; Tanzi, Elisabetta/0000-0002-4119-701X NR 24 TC 24 Z9 24 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 1 PY 2002 VL 20 IS 31-32 BP 3720 EP 3724 AR PII S0264-410X(02)00357-2 DI 10.1016/S0264-410X(02)00357-2 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 619RA UT WOS:000179489000015 PM 12399200 ER PT J AU Basile, JN AF Basile, JN TI Systolic blood pressure - It is time to focus on systolic hypertension - especially in older people SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID PULSE PRESSURE C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med Geriatr, Charleston, SC 29401 USA. RP Basile, JN (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Div Gen Internal Med Geriatr, Charleston, SC 29401 USA. NR 12 TC 9 Z9 9 U1 0 U2 2 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD OCT 26 PY 2002 VL 325 IS 7370 BP 917 EP 918 DI 10.1136/bmj.325.7370.917 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 610XB UT WOS:000178986300005 PM 12399325 ER PT J AU Okamoto, Y Obeid, LM Hannun, YA AF Okamoto, Y Obeid, LM Hannun, YA TI Bcl-xL interrupts oxidative activation of neutral sphingomyelinase SO FEBS LETTERS LA English DT Article DE Bcl-xL; neutral sphingomyelinase; glutathione; ceramide ID RADIATION-INDUCED APOPTOSIS; BREAST-CARCINOMA CELLS; CERAMIDE FORMATION; GLIOMA-CELLS; HL-60 CELLS; GLUTATHIONE; PATHWAY; DEATH; INHIBITION; GENERATION AB Recent studies demonstrate a role for intracellular oxidation in the regulation of neutral sphingomyelinase (N-SMase). Glutathione (GSH) has been shown to regulate N-SMase in vitro and in cells. However, it has not been established whether the effects of GSH in cells are due to direct action on N-SMase. In this study, treatment of human mammary carcinoma MCF-7 cells with diamide, a thiol-depleting agent, caused a decrease in intracellular GSH and degradation of sphingomyelin (SM) to ceramide. The SM pool hydrolyzed in response to diamide belonged to the bacterial SMase-resistant pool of SM. Importantly, pretreatment of MCF-7 cells with GSH, N-acetylcysteine, an antioxidant, or GW69A, a specific N-SMase inhibitor, prevented diamide-induced degradation of SM to ceramide, suggesting that intracellular levels of GSH regulate the extent to which SM is degraded to ceramide and that this probably involves a GW69A-sensitive N-SMase. Unexpectedly, expression of Bcl-xL prevented tumor necrosis factor-alpha-induced SM hydrolysis and ceramide accumulation but not the decrease in intracellular GSH. Furthermore, Bcl-xL inhibited diamide-induced SM hydrolysis and ceramide accumulation but not the decrease in intracellular GSH. These results suggest that the site of action of Bcl-xL is downstream of GSH depletion and upstream of ceramide accumulation, and that GSH probably does not exert direct physiologic effects on N-SMase. (C) 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved. C1 Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA. RI OKAMOTO, Yasuo/J-8438-2015 OI obeid, lina/0000-0002-0734-0847 FU NIA NIH HHS [AG16583]; NIDDK NIH HHS [DK59340]; NIGMS NIH HHS [GM-43825] NR 49 TC 15 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD OCT 23 PY 2002 VL 530 IS 1-3 BP 104 EP 108 AR PII S0014-5793(02)03435-X DI 10.1016/S0014-5793(02)03435-X PG 5 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 608PZ UT WOS:000178856900020 PM 12387875 ER PT J AU Vagin, O Denevich, S Munson, K Sachs, G AF Vagin, O Denevich, S Munson, K Sachs, G TI SCH28080, a K+-competitive inhibitor of the gastric H,K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain SO BIOCHEMISTRY LA English DT Article ID SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; TRANSMEMBRANE DOMAINS; MEMBRANE TOPOLOGY; H+/K+-ATPASE; BETA-SUBUNIT; H+,K+-ATPASE; NA,K-ATPASE; IDENTIFICATION AB Inhibition of the gastric H,K-ATPase by the imidazo[1,2-alpha]pyridine, SCH28080, is strictly competitive with respect to K+ or its surrogate, NH4+. The inhibitory kinetics [V-max, K-m,K-app(NH4+), K-i(SCH28080), and competitive, mixed, or noncompetitive] of mutants can define the inhibitor binding domain and the route to the ion binding region within M4-6. While mutations Y799F, Y802F, I803L, S806N, V807I (M5), L811V (M5-6), Y928H (M8), and Q905N (M7-8) had no effect on inhibitor kinetics, mutations P798C, Y802L, P810A, P810G, C813A or -S, I814V or -F, F818C, T823V (M5, M5-6, and M6), E914Q, F917Y, G918E, T929L, and F932L (M7-8 and M8) reduced the affinity for SCH28080 up to 10-fold without affecting the nature of the kinetics. In contrast, the L809F substitution in the loop between M5 and M6 resulted in an similar to100-fold decrease in inhibitor affinity, and substitutions L809V, I816L, Y925F, and M937V (M5-6, M6, and M8) reduced the inhibitor affinity by 10-fold, all resulting in noncompetitive kinetics. The mutants L81 IF, Y922I, and I940A also reduced the inhibitor affinity up to 10-fold but resulted in mixed inhibition. The mutations I819L, Q923V, and Y925A also gave mixed inhibition but without a change in inhibitor affinity. These data, and the 9-fold loss of SCH28080 affinity in the C813T mutant, suggest that the binding domain for SCH28080 contains the surface between L809 in the M5-6 loop and C813 at the luminal end of M6, approximately two helical turns down from the ion binding region, where it blocks the normal ion access pathway. On the basis of a model of the Ca-ATPase in the E-2 conformation (PDB entry 1kju), the mutants that change the nature of the kinetics are arranged on one side of M8 and on the adjacent side of the M5-6 loop and M6 itself. This suggests that mutations in this region modify the enzyme structure so that K+ can access the ion binding domain, even with SCH28080 bound. C1 Univ Calif Los Angeles, Dept Physiol & Med, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA 90073 USA. RP VAGLAHS W LA, Bldg 113,Room 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu FU NIDDK NIH HHS [DK46917]; PHS HHS [53462, 17294, 41301] NR 32 TC 50 Z9 50 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD OCT 22 PY 2002 VL 41 IS 42 BP 12755 EP 12762 DI 10.1021/bi025921w PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 605TW UT WOS:000178694000021 PM 12379118 ER PT J AU Yang, FM Liu, XB Quinones, M Melby, PC Ghio, A Haile, DJ AF Yang, FM Liu, XB Quinones, M Melby, PC Ghio, A Haile, DJ TI Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-NECROSIS-FACTOR; AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; RECOMBINANT HUMAN INTERLEUKIN-6; CANCER-PATIENTS; STORAGE IRON; SERUM IRON; TNF-ALPHA; ANEMIA; MICE; METABOLISM AB Acute and chronic inflammation cause many changes in total body iron metabolism including the sequestration of iron in phagocytic cells of the reticuloendothelial system. This change in iron metabolism contributes to the development of the anemia of inflammation. MTP1, the duodenal enterocyte basolateral iron exporter, is also expressed in the cells of the reticuloendothelial system (RES) and is likely to be involved in iron recycling of these cells. In this study, we use a lipopolysaccharide model of the acute inflammation in the mouse and demonstrate that MTP1 expression in RES cells of the spleen, liver, and bone marrow is down-regulated by inflammation. The down-regulation of splenic expression of MTP1 by inflammation was also observed in a Leishmania donovani model of chronic infection. The response of MTP1 to lipopolysaccharide (LPS) requires signaling through the LPS receptor, Toll-like receptor 4 (TLR4). In mice lacking TLR4, MTP1 expression is not altered in response to LPS. In addition, mice lacking tumor necrosis factor-receptor 1a respond appropriately to LPS with down-regulation of MTP1, despite hyporesponsiveness to tumor necrosis factor-alpha signaling, suggesting that this cytokine may not be required for the LPS effect. We hypothesize that the iron sequestration in the RES system that accompanies inflammation is because of down-regulation of MTP1. C1 S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA. US EPA, Natl Hlth & Environm Effect Res Lab, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. RP Haile, DJ (reprint author), S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA. FU NIDDK NIH HHS [R01DK53079] NR 45 TC 141 Z9 145 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 18 PY 2002 VL 277 IS 42 BP 39786 EP 39791 DI 10.1074/jbc.M201485200 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 605EA UT WOS:000178662500093 PM 12161425 ER PT J AU Leung, FW Iwata, F Kao, J Seno, K Itoh, M Leung, JWC AF Leung, FW Iwata, F Kao, J Seno, K Itoh, M Leung, JWC TI Ruthenium red-sensitive cation channels, but not calcitonin gene-related peptide or substance P-mediated mechanisms, protect duodenal villi against acid-induced damage SO LIFE SCIENCES LA English DT Article DE CGRP; substance P; ruthenium red; acid-induced duodenal villous injury ID ALKALINE SECRETION; RABBIT DUODENUM; RAT DUODENUM; BLOOD-FLOW; MESENTERIC HYPEREMIA; SENSORY NEURONS; CAPSAICIN; ANTAGONIST; INJURY; RECEPTOR AB Intestinal mucosal capsaicin-sensitive afferent nerves mediate, in part, the protective mesenteric hyperemia after intraduodenal acidification, Mechanisms associated the sensory neuropeptides, e.g. calcitonin gene-related peptide (CGRP), substance P, and ruthenium red-sensitive cation channels contribute to acid-induced mesenteric hyperemia, but whether they play a role in protection against acid-induced duodenal villous damage is not known. We tested the hypothesis that in doses that attenuate acid-induced hyperemia, inhibitors of these mechanisms will exacerbate acid-induced duodenal villous damage. Intravenous vehicle, specific receptor antagonists of CGRP (CGRP(8-37)), substance P (CP 96345), intraduodenal ruthenium red or vehicle was administered, followed by intraduodenal perfusion with 0.1 N HCl. Duodenal tissue was processed for hematoxylin and eosin staining. Villous damage was scored by blinded observers. Deep villous injury was significantly increased after treatment with ruthenium red, but not with CGRP(8-37) or CP 96345. These findings support the hypothesis that ruthenium red-sensitive cation channels, but not neuropeptides associated with intestinal mucosal afferent nerves, are involved in the acid-sensing mechanism which mediates the protection against acid-induced duodenal villous damage. (C) 2002 Elsevier Science Inc. All rights reserved. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA 91343 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Med Serv, Sepulveda Ambulatory Care Ctr & Nursing Home, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Ctr Ulcer Res & Educ, Los Angeles, CA 90024 USA. Nagoya City Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 467, Japan. Univ Calif Davis, Med Ctr, Div Gastroenterol, Sacramento, CA 95817 USA. Univ Calif Davis, Med Ctr, Vet Affairs No Calif Syst Clin, Sacramento Vet Affairs Med Ctr,Res Serv, Sacramento, CA 95817 USA. Univ Calif Davis, Med Ctr, Vet Affairs No Calif Syst Clin, Sacramento Vet Affairs Med Ctr,Med Serv, Sacramento, CA 95817 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Div GI 111G, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 28 TC 2 Z9 2 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD OCT 18 PY 2002 VL 71 IS 22 BP 2617 EP 2624 AR PII S0024-3205(02)02106-9 DI 10.1016/S0024-3205(02)02106-9 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 603YR UT WOS:000178589300004 PM 12354580 ER PT J AU Jacobs, BP Dennehy, C Ramirez, G Sapp, J Lawrence, VA AF Jacobs, BP Dennehy, C Ramirez, G Sapp, J Lawrence, VA TI Milk thistle for the treatment of liver disease: A systematic review and meta-analysis SO AMERICAN JOURNAL OF MEDICINE LA English DT Review ID CHRONIC HEPATITIS-C; SILYBUM-MARIANUM L; DOUBLE-BLIND; INITIAL TREATMENT; CONTROLLED TRIAL; VIRAL-HEPATITIS; SILYMARIN; CIRRHOSIS; THERAPY; INTERFERON-ALPHA-2B AB PURPOSE: Milk thistle, an herbal compound, is the dietary supplement taken most frequently by patients with chronic liver disease. We performed a systematic review of the literature to determine the efficacy and safety of this herb for the treatment of liver disease. METHODS: We searched English and non-English reports through July 1999 using thirteen databases and reference lists, and contacting manufacturers and technical experts. Reviewers independently screened all reports to identify randomized placebo-controlled trials that evaluated milk thistle for the treatment of liver disease. Outcomes of primary interest included mortality, histological findings on liver biopsy specimens, serum aminotransferase and albumin levels, and prothrombin times. RESULTS: Fourteen trials met inclusion criteria. Four trials reported outcomes for mortality among 433 participants. The overall summary odds ratio for mortality in the milk thistle group compared with placebo was 0.8 (95% confidence interval [CI]: 0.5 to 1.5; P = 0.6). Three trials assessed histology on liver biopsy; study quality was inversely associated with the likelihood of histological benefit for milk thistle compared with placebo. There were no differences in serum alanine aminotransferase, aspartate aminotransferase, or albumin levels, or prothrombin times, among participants assigned to milk thistle compared with those assigned to placebo. The only statistically significant difference was a greater reduction in alanine aminotransferase levels among patients with chronic liver disease assigned to milk thistle (- 9 IU/L, 95% CI: - 18 to - I IU/L; P = 0.05), but this reduction was of negligible clinical importance and no longer statistically significant after limiting analyses to studies of longer duration or of higher quality. The frequency of adverse effects was low and, in clinical trials, indistinguishable from placebo. CONCLUSION: Treatment with milk thistle appears to be safe and well tolerated. We found no reduction in mortality, in improvements in histology at liver biopsy, or in biochemical markers of liver function among patients with chronic liver disease. Data are too limited to exclude a substantial benefit or harm of milk thistle on mortality, and also to support recommending this herbal compound for the treatment of liver disease. C1 Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Osher Ctr, Dept Clin Pharm, San Francisco, CA USA. Univ Texas, Hlth Sci Ctr, San Antonio Evidence Based Practice Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Disseminat & Implementat Ctr, San Antonio, TX USA. RP Jacobs, BP (reprint author), Univ Calif San Francisco, Osher Ctr Integrat Med, Box 1726, San Francisco, CA 94143 USA. NR 84 TC 118 Z9 122 U1 3 U2 17 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD OCT 15 PY 2002 VL 113 IS 6 BP 506 EP 515 AR PII S0002-9343(02)01244-5 DI 10.1016/S0002-9343(02)01244-5 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 613TY UT WOS:000179148600010 PM 12427501 ER PT J AU Yao, JK Stanley, JA Reddy, RD Keshavan, MS Pettegrew, JW AF Yao, JK Stanley, JA Reddy, RD Keshavan, MS Pettegrew, JW TI Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites SO BIOLOGICAL PSYCHIATRY LA English DT Article DE red blood cell; polyunsaturated fatty acids; membranes; in vivo P-31 magnetic resonance spectroscopy; phosphomonoesters; prefrontal; schizophrenia ID MAGNETIC-RESONANCE SPECTROSCOPY; DOCOSAHEXAENOIC ACID; SCHIZOPHRENIC-PATIENTS; EICOSAPENTAENOIC ACID; ERYTHROCYTE-MEMBRANES; ARACHIDONIC-ACID; BRAIN; DEFICIENCY; SUPPLEMENTATION; TURNOVER AB Background: There is evidence for membrane abnormalities in schizophrenia. It is unclear whether the observed membrane deficits in peripheral cells parallel central membrane phospholipid metabolism. To address this question we examined the relations between red blood cell polyunsaturated fatty acids and brain phospholipid metabolites from different regions of interest in schizophrenia and healthy subjects. Methods: Red blood cell membrane fatty acids were measured by capillary gas chromatography and in vivo brain phospholipid metabolite levels were measured using a multi-voxel P-31 Magnetic Resonance Spectroscopy technique on 11 first-episode, neuroleptic-naive schizophrenic subjects and 11 normal control subjects. Results: Both the total polyunsaturated fatty acids and the individual 20:4(n-6) contents were significantly correlated with the freely-mobile phosphomonoester [PME(s-tau(c))] levels (r =.5643, p =.0062 and r =.6729, p =.0006, respectively). The 18:2(n-6) polyunsaturated fatty acids content correlated positively with freely-mobile phosphodiester [PDE(s-tau(c))] levels (r =.5573, p =.0071). The above correlations were present in the combined right and left prefrontal region of the brain, while other regions including the basal ganglia, occipital, inferior parietal, superior temporal and centrum semiovale yielded no significant correlations. Conclusions: Our preliminary data support the association between the decreased red blood cell membrane phospholipid polyunsaturated fatty acids content and the decreased building blocks [PME(s-tau(c))] and breakdown products [PDE(s-tau(c))] of membrane phospholipids in the prefrontal region of first-episode, neuroleptic-naive schizophrenic subjects. Biol Psychiatry 2002;52: 823-830 (C) 2002 Society of Biological Psychiatry. C1 VA Pittsburgh Healthcare Syst, Neurochem & Psychopharmacol Lab, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Neurochem & Psychopharmacol Lab, 7180 Highland Dr,Bldg 13, Pittsburgh, PA 15206 USA. FU NIMH NIH HHS [MH 46614, MH 58141, MH 45203] NR 35 TC 61 Z9 62 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2002 VL 52 IS 8 BP 823 EP 830 AR PII S0006-3223(02)01397-5 DI 10.1016/S0006-3223(02)01397-5 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 601BE UT WOS:000178425600007 PM 12372654 ER PT J AU Maron, DJ Weintraub, WS Hartigan, PM Casperson, P Murphy, A Potter, K Teo, KK Knudtson, ML Kostuk, WJ Boden, WE O'Rourke, RA AF Maron, DJ Weintraub, WS Hartigan, PM Casperson, P Murphy, A Potter, K Teo, KK Knudtson, ML Kostuk, WJ Boden, WE O'Rourke, RA TI Achieving AHA/ACC secondary prevention goals in a clinical trial SO CIRCULATION LA English DT Meeting Abstract CT 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY OCT 13-14, 2002 CL WASHINGTON, D.C. SP Amer Heart Assoc Councils Cardiovasc Dis Young, Cardiovasc Nursing, Cardio Thorac & Vasc Surg, Amer Coll Cardiol Fdn, Dept Vet Affairs C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA. Emory Univ Hosp, Atlanta, GA 30322 USA. VA Connecticut Healthcare Syst, West Haven, CT USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. Hartford Hosp, Hartford, CT 06115 USA. McMaster Univ, Med Ctr, Hamilton, ON, Canada. Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. London Hlth Sci Ctr, London, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 15 PY 2002 VL 106 IS 16 MA P31 BP E82 EP E82 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 605NH UT WOS:000178683600047 ER PT J AU Petersen, LA McNeil, BJ Normand, SLT AF Petersen, LA McNeil, BJ Normand, SLT TI Effect of adjustment for center in multi-center comparisons of AMI quality of care SO CIRCULATION LA English DT Meeting Abstract CT 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke CY OCT 13-14, 2002 CL WASHINGTON, D.C. SP Amer Heart Assoc Councils Cardiovasc Dis Young, Cardiovasc Nursing, Cardio Thorac & Vasc Surg, Amer Coll Cardiol Fdn, Dept Vet Affairs C1 Houston VAMC, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Harvard Med Sch, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 15 PY 2002 VL 106 IS 16 MA P229 BP E116 EP E116 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 605NH UT WOS:000178683600218 ER PT J AU Beall, B Besser, J Bisno, A Chuang, IL Craig, AS Facklam, R Fetter, J Gerber, MA Gray, G Hill, H Lepine, L Levine, O McGeer, A Moore, M Pearson, M O'Brien, K Schuchat, A Sewell, M Shulman, S Siegel, J Stevens, DL Strausbaugh, L Van Beneden, C AF Beall, B Besser, J Bisno, A Chuang, IL Craig, AS Facklam, R Fetter, J Gerber, MA Gray, G Hill, H Lepine, L Levine, O McGeer, A Moore, M Pearson, M O'Brien, K Schuchat, A Sewell, M Shulman, S Siegel, J Stevens, DL Strausbaugh, L Van Beneden, C CA Prevention Invasive Grp A Streptoc TI Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: Recommendations from the Centers for Disease Control and Prevention SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID GROUP-A STREPTOCOCCUS; SURGICAL-WOUND INFECTIONS; HEALTH-CARE WORKERS; PHARYNGEAL CARRIAGE; ERADICATE GROUP; PENICILLIN; OUTBREAK; STRAINS; FAMILY; SUSCEPTIBILITY AB The Centers for Disease Control and Prevention hosted a workshop to formulate recommendations for the control of invasive group A streptococcal (GAS) disease among household contacts of persons with invasive GAS infections and for responding to postpartum and postsurgical invasive GAS infections. Experts reviewed data on the risk of subsequent invasive GAS infection among household contacts of case patients, the effectiveness of chemoprophylactic regimens for eradicating GAS carriage, and the epidemiology of postpartum and postsurgical GAS infection clusters. For household contacts of index patients, routine screening for and chemoprophylaxis against GAS are not recommended. Providers and public health officials may choose to offer chemoprophylaxis to household contacts who are at an increased risk of sporadic disease or mortality due to GAS. One nosocomial postpartum or postsurgical invasive GAS infection should prompt enhanced surveillance and isolate storage, whereas greater than or equal to2 cases caused by the same strain should prompt an epidemiological investigation that includes the culture of specimens from epidemiologically linked health care workers. C1 Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA. Minnesota Dept Hlth, Minneapolis, MN USA. Miami Vet Affairs Med Ctr, Miami, FL USA. Univ Miami, Sch Med, Coral Gables, FL 33124 USA. CDC, Resp Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA. Tennessee Dept Hlth, Nashville, TN USA. CDC, Resp Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA. CDC, Act Bacterial Core Surveillance Program, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA. Northside Hosp, Atlanta, GA USA. Assoc Profess Infect Control & Epidemiol, Washington, DC 20005 USA. Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. Amer Acad Pediat, Elk Grove Village, IL 60007 USA. Univ Iowa, Coll Publ Hlth, Iowa City, IA USA. Univ Utah, Sch Med, Salt Lake City, UT USA. Emory Univ, Sch Med, Atlanta, GA USA. NIAID, Bethesda, MD 20892 USA. Univ Toronto, Lab Med & Publ Hlth Sci, Toronto, ON, Canada. Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. CDC, Epidem Intelligence Serv Program, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA. CDC, Epidem Intelligence Serv Program, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA. CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. New Mexico Dept Hlth, Santa Fe, NM USA. Council State & Terr Epidemiologists, Atlanta, GA 30341 USA. Childrens Mem Hosp, Chicago, IL 60614 USA. Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA. Univ Texas, SW Med Ctr, Dallas, TX USA. Boise VA Med Ctr, Boise, ID USA. Univ Washington, Sch Med, Seattle, WA USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Sch Med, Portland, OR USA. Infect Dis Soc Amer, Alexandria, VA 22314 USA. RP Moore, M (reprint author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd,Mailstop D-63, Atlanta, GA 30333 USA. RI mcgeer, allison /H-7747-2014 OI mcgeer, allison /0000-0001-5647-6137 NR 60 TC 65 Z9 68 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2002 VL 35 IS 8 BP 950 EP 959 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 598YC UT WOS:000178303800006 ER PT J AU Muder, RR Yu, VL AF Muder, RR Yu, VL TI Infection due to Legionella species other than L-pneumophila SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID PITTSBURGH PNEUMONIA AGENT; NOSOCOMIAL LEGIONNAIRES-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; PROSTHETIC-VALVE ENDOCARDITIS; SP-NOV; MICDADEI PNEUMONIA; TRANSPLANT RECIPIENT; PONTIAC FEVER; BOZEMANII PNEUMONIA; GENUS LEGIONELLA AB In addition to Legionella pneumophila, 19 Legionella species have been documented as human pathogens on the basis of their isolation from clinical material. Like L. pneumophila, other Legionella species are inhabitants of natural and man-made aqueous environments. The major clinical manifestation of infection due to Legionella species is pneumonia, although nonpneumonic legionellosis (Pontiac fever) and extrapulmonary infection may occur. The majority of confirmed infections involving non-pneumophila Legionella species have occurred in immunosuppressed patients. Definitive diagnosis requires culture on selective media. Fluoroquinolones and newer macrolides are effective therapy. A number of nosocomial cases have occurred in association with colonization of hospital water systems; elimination of Legionella species from such systems prevents their transmission to susceptible patients. It is likely that many cases of both community-acquired and nosocomial Legionella infection remain undiagnosed. Application of appropriate culture methodology to the etiologic diagnosis of pneumonia is needed to further define the role of these organisms in disease in humans. C1 VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. NR 116 TC 138 Z9 144 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2002 VL 35 IS 8 BP 990 EP 998 DI 10.1086/342884 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 598YC UT WOS:000178303800011 PM 12355387 ER PT J AU Revankar, SG Patterson, J Sutton, DA Rinaldi, MG AF Revankar, SG Patterson, J Sutton, DA Rinaldi, MG TI Central venous catheters as a risk factor for disseminated phaeohyphomycosis? Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID INFECTION C1 Vet Adm Med Ctr, Div Infect Dis 111D, Dallas, TX 75216 USA. Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Revankar, SG (reprint author), Vet Adm Med Ctr, Div Infect Dis 111D, 4500 S Lancaster Rd, Dallas, TX 75216 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2002 VL 35 IS 8 BP 1023 EP 1024 DI 10.1086/342891 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 598YC UT WOS:000178303800019 ER PT J AU Quinn, LS Anderson, BG Drivdahl, RH Alvarez, B Argiles, JM AF Quinn, LS Anderson, BG Drivdahl, RH Alvarez, B Argiles, JM TI Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: Implications for treatment of muscle wasting disorders SO EXPERIMENTAL CELL RESEARCH LA English DT Article DE skeletal muscle; interleukin-15; cachexia; muscle hypertrophy; muscle atrophy; protein synthesis; protein degradation; cytokines ID GROWTH-FACTOR-I; SATELLITE CELL-ACTIVITY; IGF-I; PROTEIN-SYNTHESIS; BODY-COMPOSITION; CANCER CACHEXIA; INSULIN; EXPRESSION; HORMONE; RATS AB Interleukin-15 (IL-15) is a novel anabolic factor for skeletal muscle which inhibits muscle wasting associated with cancer (cachexia) in a rat model. To develop a cell culture system in which the mechanism of the anabolic action of IL-15 on skeletal muscle could be examined, the mouse C2 skeletal myogenic cell line was transduced with a retroviral expression vector for IL-15 and compared to sister cells transduced with a control vector. Overexpression of IL-15 induced fivefold higher levels of sarcomeric myosin heavy chain and a-actin accumulation in differentiated myotubes. Secreted factors from IL-15-overexpressing myogenic cells, but not from control cells, induced increased myofibrillar protein accumulation in cocultured control myotubes. IL-15 overexpression induced a hypertrophic myotube morphology similar to that described for cultured myotubes which overexpressed the well-characterized anabolic factor insulin-like growth factor-I (IGF-I). However, in contrast to IGF-I, the hypertrophic action of IL-15 on skeletal myogenic cells did not involve stimulation of skeletal myoblast proliferation or differentiation. IL-15 induced myotube hypertrophy at both low and high IGF-I concentrations. Furthermore, in contrast to IGF-I, which stimulated only protein synthesis under these culture conditions, IL-15 both stimulated protein synthesis and inhibited protein degradation in cultured skeletal myotubes. These findings indicate that IL-15 action on skeletal myogenic cells is distinct from that of IGF-I. Due to the ability of IGF-I to stimulate cell division and its association with several forms of cancer, controversy exists concerning the advisability of treating cachexia or age-associated muscle wasting with IGF-I. Administration of IL-15 or modulation of the IL-15 signaling pathway may represent an alternative strategy for maintaining skeletal muscle mass under these conditions. (C) 2002 Elsevier Science (USA). C1 VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. VA Puget Sound Hlth Care Syst, Res Serv, Tacoma, WA 98493 USA. Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div 151, Ctr Geriatr Res Educ & Clin, Tacoma, WA 98493 USA. NR 51 TC 94 Z9 100 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD OCT 15 PY 2002 VL 280 IS 1 BP 55 EP 63 DI 10.1006/excr.2002.5624 PG 9 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 603VR UT WOS:000178582000006 PM 12372339 ER PT J AU Liu, HY Buenafe, AC Matejuk, A Ito, A Zamora, A Dwyer, J Vandenbark, AA Offner, H AF Liu, HY Buenafe, AC Matejuk, A Ito, A Zamora, A Dwyer, J Vandenbark, AA Offner, H TI Estrogen inhibition of EAE involves effects on dendritic cell function SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE EAE; estrogen; dendritic cells ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW CULTURES; IN-VIVO; IFN-GAMMA; MULTIPLE-SCLEROSIS; LARGE NUMBERS; FEMALE MICE; T-CELLS; MATURATION AB Estrogen has been found to have suppressive effects on the induction of experimental autoimmune encephalomyelitis (EAE), an animal model for the human disease multiple sclerosis. We have investigated the effects of 17beta-estradiol (E2) treatment on dendritic cells (DCs) in two different mouse models of EAE. The frequency of CD11b(+)/CD11c(+) DCs was significantly decreased in the brain of mice protected from EAE induction by E2 treatment. In addition, the frequency of CD11c(+)/CD8alpha(+) DCs producing tumor necrosis factor (TNF)alpha and interferon (IFN)gamma in the spleen of E2-treated mice was dramatically decreased compared to that in control mice with EAE, demonstrating an effect of E2 on DC function. In order to examine E2 effects on DCs in more detail, splenic DCs were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 to promote maturation. E2 pretreatment was found to suppress the ability of cultured DCs bearing a mature phenotype to present Ag to myelin basic protein (MBP)-specific T cells. Analysis of cytokine production demonstrated that E2 decreased TNFalpha, IFNgamma and IL-12 production in mature DCs. In addition, MBP-specific T cells cocultured with E2-pretreated mature DCs in the presence of antigen demonstrated a shift towards production of Th2 cytokines IL-4 and IL-10 and a concomitant decrease in the production of Th1 cytokines TNFa and IFNgamma. Thus, E2 treatment appears to have multiple effects on the DC population, which may contribute to a down-regulation or block in the activation of Th1 cells involved in the induction of EAE. (C) 2002 Wiley-Liss, Inc. C1 Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D-31,3710 SW US Vets Hosp Rd, Portland, OR 97201 USA. FU NIAID NIH HHS [AI42376]; NINDS NIH HHS [NS23444, NS23221] NR 40 TC 102 Z9 106 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD OCT 15 PY 2002 VL 70 IS 2 BP 238 EP 248 DI 10.1002/jnr.10409 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 600NG UT WOS:000178396700012 PM 12271473 ER PT J AU Lawrence, VA Hilsenbeck, SG Noveck, H Poses, RM Carson, JL AF Lawrence, VA Hilsenbeck, SG Noveck, H Poses, RM Carson, JL TI Medical complications and outcomes after hip fracture repair SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID DISPLACED SUBCAPITAL FRACTURES; MULTIFACTORIAL RISK INDEX; MAJOR NONCARDIAC SURGERY; FEMORAL-NECK; INTERNAL-FIXATION; PULMONARY COMPLICATIONS; FEMUR; HEMIARTHROPLASTY; ARTHROPLASTY; OSTEOSYNTHESIS AB Background: Most evidence guiding perioperative medical risk management of patients undergoing hip fracture repair focuses on cardiac and thromboembolic risk. Little is known of the relative clinical importance of other complications. Objective: To systematically map incidence and outcomes of a broad spectrum of medical complications after hip fracture repair. Methods: Retrospective cohort study of patients 60 years or older in 20 academic, community, and Veterans Affairs hospitals. Data on complications and mortality were abstracted from medical records by trained abstractors using standardized, pretested forms or the National Death Index. Results: Of 8930 patients, 1737 (19%) had postoperative medical complications. Cardiac and pulmonary complications were most frequent (8% and 4% of patients, respectively). Similar numbers of patients had serious cardiac or pulmonary complications (2% and 3%, respectively). Other complications were gastrointestinal tract bleeding (2%), combined cardiopulmonary complications (1%), venous thromboembolism (1%), and transient ischemic attack or stroke (1%). Renal failure and septic shock were rare. After the index complication, 416 patients had 587 additional complications. Mortality was similar for serious cardiac or pulmonary complications (30 day: 22% and 17%, respectively; 1 year: 36% and 44%, respectively) and highest for patients with multiple complications (30 day: 29%-38%; 1 year: 43%-62%). Complications and death occurred significantly earlier for serious cardiac than for serious pulmonary complications (1 vs 4 days, 2 vs 8 days, P<.001); length of stay for patients surviving these complications was similar. Conclusions: Most patients had no medical complications after hip fracture repair. Serious cardiac and pulmonary complications were equally important in frequency, mortality, and survivors' length of stay. Patients with multiple complications had especially poor prognosis. C1 UTHSCSA, Dept Med, Div Gen Med, San Antonio, TX 78229 USA. UTHSCSA, S Texas Vet Hlth Care Syst, Div Gen Med, Audie L Murphy Div, San Antonio, TX 78229 USA. UTHSCSA, Div Med Oncol, San Antonio, TX 78229 USA. Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, New Brunswick, NJ USA. Brown Univ, Sch Med, Dept Med, Div Gen Internal Med, Providence, RI USA. Mem Hosp Rhode Isl, Pawtucket, RI USA. RP Lawrence, VA (reprint author), UTHSCSA, Dept Med, Div Gen Med, 7703 Floyd Curl Dr,Mail Code 7879, San Antonio, TX 78229 USA. FU AHRQ HHS [R01HSO7322] NR 62 TC 111 Z9 138 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 14 PY 2002 VL 162 IS 18 BP 2053 EP 2057 DI 10.1001/archinte.162.18.2053 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 603EP UT WOS:000178546100004 PM 12374513 ER PT J AU El-Serag, HB Graham, DY Richardson, P Inadomi, JM AF El-Serag, HB Graham, DY Richardson, P Inadomi, JM TI Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs - The use of a nomogram in cost-effectiveness analysis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID UPPER GASTROINTESTINAL TOXICITY; ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER; RHEUMATOID-ARTHRITIS; HELICOBACTER-PYLORI; CONTROLLED TRIAL; DUODENAL-ULCERS; ELDERLY PERSONS; HIGH-RISK; MISOPROSTOL AB Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of clinical upper gastrointestinal tract (UGI) events, namely, symptomatic ulcer, perforation, bleeding, and obstruction. Our objective in this study was to compare the cost-effectiveness of several strategies aimed at reducing the risk of clinical UGI events in NSAID users. Methods: A decision tree model was used for patients requiring long-term treatment with NSAIDs to compare conventional NSAID therapy alone with 7 other treatment strategies to reduce the risk of NSAID-related clinical UGI events (cotherapy with proton-pump inhibitor, cotherapy with misoprostol, cyclooxygenase [COX]-2-selective NSAID therapy, or Helicobacter pylori treatment followed by each of the previous strategies, including conventional NSAID treatment, respectively). The outcome measure is the incremental cost per clinical UGI event prevented compared with conventional NSAID treatment over 1 year. Results: The use of a COX-2-selective NSAID and cotherapy with proton-pump inhibitors were the 2 most cost-effective strategies. However, the incremental cost associated with these strategies was high (>$35000) in persons with a low risk of clinical UGI event with conventional NSAIDs (eg, 2.5% per year). If the baseline risk of clinical UGI events is moderately high (eg, 6.5%), using a COX-2-selective NSAID becomes the most effective and least costly (dominant) treatment strategy, followed closely by cotherapy with a daily proton-pump inhibitor. Because small changes in costs or assumed efficacy of these drugs could change the conclusions, the incremental cost-effectiveness ratios between any 2 strategies were presented in a nomogram that allows the flexible use of a wide range of values for costs and rates of clinical UGI events. Conclusions: The risk of clinical UGI events in NSAID users depends on their baseline risk, the added risk associated with the individual NSAID, and the protection conferred by cotherapy. A nomogram can be used to incorporate these factors and derive estimates regarding cost-effectiveness of competing strategies aimed at reducing the risk of clinical UGI events. C1 Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res Sect, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Ann Arbor, MI USA. Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. Univ Michigan, Ann Arbor, MI 48109 USA. RP El-Serag, HB (reprint author), Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res Sect, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. RI Inadomi, John/A-6221-2014 OI Inadomi, John/0000-0001-6776-8661 NR 32 TC 34 Z9 35 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 14 PY 2002 VL 162 IS 18 BP 2105 EP 2110 DI 10.1001/archinte.162.18.2105 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 603EP UT WOS:000178546100010 PM 12374519 ER PT J AU Cichewicz, RH Lim, KC McKerrow, JH Nair, MG AF Cichewicz, RH Lim, KC McKerrow, JH Nair, MG TI Kwanzoquinones A-G and other constituents of Hemerocallis fulva 'Kwanzo' roots and their activity against the human pathogenic trematode Schistosoma mansoni SO TETRAHEDRON LA English DT Article DE anthraquinones; Hemerocallis fulva 'Kwanzo'; natural products; schistosomiasis ID ANTHRAQUINONES; PRAZIQUANTEL AB Schistosomiasis is a debilitating disease caused by parasitic trematodes of the genus Schistosoma that afflicts 200 million people worldwide. Daylilies (Hemerocallis spp.) have been used in Asia for the treatment of schistosomiasis; however, the active principles have not been fully characterized. In our studies of Hemerocallis fulva 'Kwanzo' Kaempfer roots, we have isolated seven new anthraquinones, kwanzoquinones A (1), B (2), C (4), D (5), E (6), F (7), and G (9), two known anthraquinones, 2-hydroxychry sophanol (3) and rhein (8), one new naphthalene glycoside, 5-hydroxydianellin (11), one known naphthalene glycoside, dianellin (10), one known flavone, 6-methylluteolin (12), and a-tocopherol. The structures of the compounds were elucidated by spectroscopic and chemical methods. Compounds 1-11 and the monoacetates of kwanzoquinones A and B, 1a and 2a, respectively, were tested for their activity against multiple life-stages of Schistosoma mansoni. Compound 3 immobilized all cercariae within 15 s at 3.1 mug/mL. However, upon removal of the compound, 20% of the immobilized cercariae recovered after 24 h. In contrast, compound 6 immobilized cercariae within 12-14 min at 25 mug/mL. Following removal of the compound, all cercariae died within 24 h. The adult worms were also immobilized within 16 h by compounds 3 and 6 at 50 mug/mL. None of the compounds had an effect on the schistosomula stage. (C) 2002 Elsevier Science Ltd. All rights reserved. C1 Michigan State Univ, Dept Hort, Bioact Nat Prod & Phytoceut, E Lansing, MI 48824 USA. Michigan State Univ, Natl Food Safety & Toxicol Ctr, E Lansing, MI 48824 USA. Univ Calif San Francisco, Dept Pathol & Cell & Mol Pharmacol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Nair, MG (reprint author), Michigan State Univ, Dept Hort, Bioact Nat Prod & Phytoceut, E Lansing, MI 48824 USA. EM nairm@msu.edu RI Jansen, Nils/G-1835-2011 NR 28 TC 35 Z9 35 U1 1 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0040-4020 J9 TETRAHEDRON JI Tetrahedron PD OCT 14 PY 2002 VL 58 IS 42 BP 8597 EP 8606 AR PII S0040-4020(02)00802-5 DI 10.1016/S0040-4020(02)00802-5 PG 10 WC Chemistry, Organic SC Chemistry GA 604MF UT WOS:000178624700027 ER PT J AU Mazarati, AM Wasterlain, CG AF Mazarati, AM Wasterlain, CG TI Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus SO NEUROSCIENCE LETTERS LA English DT Article DE dynorphin A (1-13); galanin; neuropeptide Y; somatostatin; neuropeptide; hippocampus; status epilepticus ID TEMPORAL-LOBE EPILEPSY; ACID-TREATED RATS; SOMATOSTATIN; RELEASE; RECEPTORS; MODELS AB We compared the anticonvulsant actions of dynorphin A (1-13), galanin, neuropeptide Y and somatostatin in a model of self-sustaining status epilepticus (SSSE). SSSE was induced in adult Wistar rats by 30 min intermittent perforant path stimulation. Peptides or saline were injected into the hilus of the dentate gyrus 10 min after the end of perforant path stimulation. EEG was analyzed using Harmonie software (Stellate systems). While all neuropeptides showed significant seizureprotecting effects, their anticonvulsant profiles followed different patterns: somatostatin and NPY induced strong, but transient suppression of spikes and seizures, while seizure suppression by dynorphin and galanin was more profound and irreversible. (C) 2002 Published by Elsevier Science Ireland Ltd. C1 Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Adm Med Ctr, Dept Neurol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Adm Med Ctr, Brain Res Inst, Los Angeles, CA 90073 USA. RP Mazarati, AM (reprint author), Univ Calif Los Angeles, Sch Med, W Los Angeles Vet Adm Med Ctr, Dept Neurol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NINDS NIH HHS [NS 13515] NR 20 TC 46 Z9 48 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD OCT 11 PY 2002 VL 331 IS 2 BP 123 EP 127 AR PII S0304-3940(02)00847-9 DI 10.1016/S0304-3940(02)00847-9 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 605UW UT WOS:000178696300014 PM 12361856 ER PT J AU Altshuler, L Mintz, J Leight, K AF Altshuler, L Mintz, J Leight, K TI The Life Functioning Questionnaire (LFQ): a brief, gender-neutral scale assessing functional outcome SO PSYCHIATRY RESEARCH LA English DT Article DE role function; functional impairment; bipolar disorder; assessment; quality of life ID CHRONICALLY MENTALLY-ILL; RELIABILITY; VALIDITY; ADJUSTMENT; REHABILITATION; SCHIZOPHRENIA; SCHEDULE; ILLNESS; WORK AB The Life Functioning Questionnaire (LFQ) is a 5-min, 14-item, gender-neutral self-report questionnaire designed to assess role function over the preceding month in four domains: workplace, duties at home, leisure time with family and leisure time with friends. To validate the LFQ for use as an instrument assessing functional outcome in patients with a mood disorder, the LFQ was administered to three different samples of patients (N=87). Fifty-nine concurrently completed the self-report version of the Social Adjustment Scale (SAS-SR) and 32 concurrently had a Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) assessment. The LFQ proved to have high internal consistency reliability, high test-retest reliability, excellent concurrent validity with the SAS-SR, and high validity as a measurement of severity of illness when compared with the CGI-BP The LFQ provides a reliable, consistent and valid assessment of function at work and home in both male and female patients with a mood disorder. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Mood Disorders Res Program, Los Angeles, CA 90095 USA. Vet Adm Med Ctr, W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. RP Altshuler, L (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Mood Disorders Res Program, 300 UCLA Med Plaza, Los Angeles, CA 90095 USA. NR 32 TC 38 Z9 38 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD OCT 10 PY 2002 VL 112 IS 2 BP 161 EP 182 AR PII S0165-1781(02)00180-4 DI 10.1016/S0165-1781(02)00180-4 PG 22 WC Psychiatry SC Psychiatry GA 624PC UT WOS:000179767500007 PM 12429362 ER PT J AU Leonard, S Gault, J Logel, J Short, M Berger, R Drebing, C Olincy, A Ross, RG Adler, LE Freedman, R AF Leonard, S Gault, J Logel, J Short, M Berger, R Drebing, C Olincy, A Ross, RG Adler, LE Freedman, R TI Promoter mutations in the alpha 7 nicotinic acetylcholine receptor subunit gene are associated with an inhibitory deficit found in schizophrenia SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Meeting Abstract CT 10th World Congress of Psychiatric Genetics CY OCT 09-13, 2002 CL BRUSSELS, BELGIUM C1 Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD OCT 8 PY 2002 VL 114 IS 7 MA O96 BP 749 EP 749 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 600WH UT WOS:000178414400139 ER PT J AU Medina, R Escamilla, M Dassori, A Contreras, S Levinson, D Raventos, H Montero, P Balderas, T Ontiveros, A Nicolini, H Mendoza, R Camacho, A Delgado, A AF Medina, R Escamilla, M Dassori, A Contreras, S Levinson, D Raventos, H Montero, P Balderas, T Ontiveros, A Nicolini, H Mendoza, R Camacho, A Delgado, A TI Cluster analysis of schizophrenia patients using lifetime dimensions of psychosis SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Meeting Abstract CT 10th World Congress of Psychiatric Genetics CY OCT 09-13, 2002 CL BRUSSELS, BELGIUM C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S Texas Vet Hlth Syst, San Antonio, TX USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Costa Rica, San Jose, Costa Rica. Univ Nuevo Leon, Monterrey, Mexico. Inst Nacl Psiquiatria, Mexico City, DF, Mexico. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif San Diego, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD OCT 8 PY 2002 VL 114 IS 7 MA P292 BP 859 EP 859 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 600WH UT WOS:000178414400443 ER PT J AU Noel, PH Pugh, JA AF Noel, PH Pugh, JA TI Management of overweight and obese adults SO BRITISH MEDICAL JOURNAL LA English DT Review ID PRIMARY-CARE; WEIGHT AB New treatment strategies have failed to control the global increase in obesity. Here two scientists discuss common barriers that need to be overcome by both healthcare professionals and patients if weight reduction is to be achieved and maintained. C1 S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr Excellence, San Antonio, TX 78229 USA. RP Noel, PH (reprint author), S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr Excellence, San Antonio, TX 78229 USA. OI Pugh, Jacqueline/0000-0003-4933-141X NR 30 TC 35 Z9 37 U1 0 U2 1 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD OCT 5 PY 2002 VL 325 IS 7367 BP 757 EP 761 DI 10.1136/bmj.325.7367.757 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 603AU UT WOS:000178537300021 PM 12364306 ER PT J AU Palevsky, PM Bunchman, T Tetta, C AF Palevsky, PM Bunchman, T Tetta, C TI The Acute Dialysis Quality Initiative - Part V: Operational characteristics of CRRT SO ADVANCES IN RENAL REPLACEMENT THERAPY LA English DT Article DE hemofiltration; hemodialysis; continuous renal replacement therapy ID ACUTE-RENAL-FAILURE; CONTINUOUS VENOVENOUS HEMOFILTRATION; PLATELET-ACTIVATING-FACTOR; CONTINUOUS ARTERIOVENOUS HEMOFILTRATION; CONTINUOUS HEMODIALYSIS; CYTOKINE REMOVAL; DETERMINANTS; CLEARANCE; HEMODIAFILTRATION; INFLAMMATION AB This report represents the consensus statement of the ADQI workgroup addressing the operational characteristics of continuous renal replacement therapy (CRRT). Issues addressed included the specific operational characteristics of continuous hemofiltration (HF), continuous hemodialysis (HD), and continuous hemodiafiltration (HDF) and the impact of these different modalities on solute removal. The relative roles of arteriovenous (AV) and venovenous (VV) modalities of therapy were also evaluated. The workgroup also addressed the optimal components of a CRRT system from an operational standpoint. (C) 2002 by the National Kidney Foundation, Inc. C1 VA Pittsburgh Healthcare Syst, Renal Sect 111FU, Univ Dr Div, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, US Vet Adm, Renal Electrolyte Div, Pittsburgh, PA USA. Univ Alabama, Med Ctr, Dept Pediat Nephrol, Birmingham, AL 35294 USA. Bellco SpA, Clin & Lab Res Dept, Mirandola, Italy. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect 111FU, Univ Dr Div, Pittsburgh, PA 15240 USA. NR 24 TC 7 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 1073-4449 J9 ADV RENAL REPLACE TH JI Adv. Renal Replace. Ther. PD OCT PY 2002 VL 9 IS 4 BP 268 EP 272 DI 10.1053/jarr.2002.35567 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 672HV UT WOS:000182515900009 PM 12382230 ER PT J AU Rukstalis, MR Lynch, KG Oslin, DW Pettinati, HM Anderson, SM Volpicelli, JR Anton, RF AF Rukstalis, MR Lynch, KG Oslin, DW Pettinati, HM Anderson, SM Volpicelli, JR Anton, RF TI Carbohydrate-deficient transferrin levels reflect heavy drinking in alcohol-dependent women seeking treatment SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE carbohydrate-deficient transferrin; gender; estradiol; alcohol dependence ID GAMMA-GLUTAMYL-TRANSFERASE; ADDICTION SEVERITY INDEX; PERCENT-CDT-TIA; OUTPATIENT ALCOHOLICS; BIOLOGICAL MARKERS; CONSUMPTION; POPULATION; SERUM; NALTREXONE; INDICATOR AB Background: Carbohydrate-deficient transferrin (CDT) is a biochemical marker that has been shown to be sensitive in detecting heavy drinking in men, but studies examining CDT in women have been inconsistent because of small sample sizes and failure to consider hormonal status. In healthy female subjects, CDT levels are significantly higher in premenopausal women with higher estradiol (E2) levels (>30 pg/ml) and those taking exogenous estrogens (oral contraceptives, hormone replacement therapy) compared with men and postmenopausal women. This study examined the relationship between drinking behavior and CDT levels in a large sample of alcohol-dependent women and contrasted findings in a comparison group of alcohol-dependent men. The study also examined the extent that E2 levels mediated the relationship between CDT levels and heavy drinking in the alcohol-dependent women. Methods: This study examined the association between CDT level at treatment entry and alcohol consumption the month before initiating treatment in 96 women with a DSM-III-R diagnosis of alcohol dependence, as compared with similar data in 123 male alcoholics. To explore the relationship between E2 and CDT, E2 was measured in women at the time of CDT sampling. Linear regression was used to examine whether patterns of alcohol consumption in the 28 days before the CDT blood sampling predicted the CDT level in women and men presenting for treatment for alcohol dependence. Results: CDT levels were higher in women than men and were related to quantitative alcohol consumption (total standard drinks, percentage of days drinking, percentage of days of heavy drinking) in the month before initiating treatment, irrespective of E2 levels in women. Conclusions: These results suggest that in a larger sample of female alcoholics, the amount of alcohol consumed predicted CDT, similar to what has been reported in male alcoholics. The E2 status did not seem to mediate these results. C1 Univ Penn, Ctr Study Addict, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Med Ctr Vet Affairs, Philadelphia, PA USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Rukstalis, MR (reprint author), Univ Penn, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIAAA NIH HHS [R01AA-09544, R01AA-07517, K23AA-00251]; NIMH NIH HHS [K08MH01599-01, R01-MH55454] NR 37 TC 2 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2002 VL 26 IS 10 BP 1539 EP 1544 DI 10.1097/01.ALC.0000034155.71497.17 PG 6 WC Substance Abuse SC Substance Abuse GA 605AJ UT WOS:000178653000011 PM 12394287 ER PT J AU Limprasert, P Murray, IVJ Tsuang, DW Leverenz, JB Lee, VMY Trojanowski, JQ La Spada, AR AF Limprasert, P Murray, IVJ Tsuang, DW Leverenz, JB Lee, VMY Trojanowski, JQ La Spada, AR TI Beta-synuclein transgenic mice show significant reductions in alpha-synuclein protein expression levels. SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Human-Genetics CY OCT 15-19, 2002 CL BALTIMORE, MARYLAND SP Amer Soc Human Genet, NICHHD, NCI, NIMH, Affymetrix Inc, Gentra Syst, NIDCD C1 Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 NR 0 TC 1 Z9 1 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD OCT PY 2002 VL 71 IS 4 SU S MA 11 BP 165 EP 165 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 594AC UT WOS:000178025800012 ER PT J AU Brose, MS Volpe, P Kumar, M Rishi, I Einhorn, E Gerrero, R Herlyn, M Minna, J Wooster, R Stratton, MR F'utreal, PA AF Brose, MS Volpe, P Kumar, M Rishi, I Einhorn, E Gerrero, R Herlyn, M Minna, J Wooster, R Stratton, MR F'utreal, PA TI BRAF and RAS mutations inhuman lung cancer and melanoma SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Human-Genetics CY OCT 15-19, 2002 CL BALTIMORE, MARYLAND SP Amer Soc Human Genet, NICHHD, NCI, NIMH, Affymetrix Inc, Gentra Syst, NIDCD C1 Hosp Univ Penn, Dept Haematol & Med Oncol, Philadelphia, PA USA. Abramson Family Canc Res Inst, Philadelphia, PA USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA. Univ Texas, SW Med Ctr, Dallas, TX 75235 USA. Wellcome Trust Sanger Inst, Hinxton, England. NR 0 TC 1 Z9 1 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD OCT PY 2002 VL 71 IS 4 SU S MA 432 BP 246 EP 246 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 594AC UT WOS:000178025800433 ER PT J AU Ramos, PS Kelly, JA Meyer, CM Leiran, AN Ortmann, WA Harley, JB Moser, KL AF Ramos, PS Kelly, JA Meyer, CM Leiran, AN Ortmann, WA Harley, JB Moser, KL TI A genome scan for lupus-related autoimmunity genes. SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-of-Human-Genetics CY OCT 15-19, 2002 CL BALTIMORE, MARYLAND SP Amer Soc Human Genet, NICHHD, NCI, NIMH, Affymetrix Inc, Gentra Syst, NIDCD C1 Univ Minnesota, Dept Med, Div Rheumat & Autoimmune Dis, Minneapolis, MN 55455 USA. Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0002-9297 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD OCT PY 2002 VL 71 IS 4 SU S MA 1673 BP 456 EP 456 PG 1 WC Genetics & Heredity SC Genetics & Heredity GA 594AC UT WOS:000178025801673 ER PT J AU Chen, MC Solomon, TE Salazar, EP Kui, R Rozengurt, E Soll, AH AF Chen, MC Solomon, TE Salazar, EP Kui, R Rozengurt, E Soll, AH TI Secretin regulates paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE secretin receptors; epidermal growth factor receptors; gastric mucosal defense; paracellular pathway; regulation of paracellular pathway; apical epidermal growth factor receptors; PP2; tyrosine kinases ID CHIEF CELL MONOLAYERS; GROWTH-FACTOR-ALPHA; TIGHT JUNCTIONS; TYROSINE PHOSPHORYLATION; PEPSINOGEN SECRETION; FAMILY KINASES; PROTECTION; EXPRESSION; RECEPTOR; CULTURE AB Previous studies found that epidermal growth factor (EGF) decreased paracellular permeability in gastric mucosa, but the other physiological regulators and the molecular mechanisms mediating these responses remain undefined. We investigated the role of secretin and Src in regulating paracellular permeability because secretin regulates gastric chief cell function and Src mediates events involving the cytoskeletal-membrane interface, respectively. Confluent monolayers were formed from canine gastric epithelial cells in short-term culture on Transwell filter inserts. Resistance was monitored in the presence of secretin with or without specific kinase inhibitors. Tyrosine phosphorylation of Src at Tyr(416) was measured with a site-specific phosphotyrosine antibody. Basolateral, but not apical, secretin at concentrations from 1 to 100 nM dose dependently increased resistance; this response was rapid and sustained over hours. PP2 (10 muM), a selective Src tyrosine kinase inhibitor, but not the inactive isomer PP3, abolished the increase in resistance by secretin but only modestly attenuated apical EGF effects. AG-1478 (100 nM), a specific EGF receptor tyrosine kinase inhibitor, attenuated the resistance increase to EGF but not secretin. Secretin, but not EGF, induced tyrosine phosphorylation of Src at Tyr(416) in a dose-dependent fashion, with the maximal response observed at 1 min. PP2, but not PP3, dramatically inhibited this tyrosine phosphorylation. Secretin increases paracellular resistance in gastric mucosa through a Src-mediated pathway, while the effect of EGF is Src independent. Src appears to mediate the physiological effects of this G(s)-coupled receptor in primary epithelial cells. C1 Univ Calif Los Angeles, Sch Med, CURE, Div Digest Dis, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Inst Mol Biol, Los Angeles, CA USA. Greater Los Angeles Vet Affairs Hlth Care Syst, Med Serv, Los Angeles, CA USA. Greater Los Angeles Vet Affairs Hlth Care Syst, Res Serv, Los Angeles, CA USA. RP Soll, AH (reprint author), Vet Adm Wadsworth Hosp Ctr, Bldg 115,Rm 215,11301 Wilshire Blvd, Los Angeles, CA USA. FU NIDDK NIH HHS [DK-19984] NR 36 TC 9 Z9 9 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD OCT PY 2002 VL 283 IS 4 BP G893 EP G899 DI 10.1152/ajpgi.00429.2001 PG 7 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 592BJ UT WOS:000177916600009 PM 12223349 ER PT J AU Holschneider, DP Maarek, JMI Harimoto, J Yang, J Scremin, OU AF Holschneider, DP Maarek, JMI Harimoto, J Yang, J Scremin, OU TI An implantable bolus infusion pump for use in freely moving, nontethered rats SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE drug delivery; functional neuroimaging; cerebral blood flow; iodo-antipyrine; autoradiography ID CEREBRAL BLOOD-FLOW; STRESS AB One of the current constraints on functional neuroimaging in animals is that to avoid movement artifacts during data acquisition, subjects need to be immobilized, sedated, or anesthetized. Such measures limit the behaviors that can be examined, and introduce the additional variables of stress or anesthetic agents that may confound meaningful interpretation. This study provides a description of the design and characteristics of a self-contained, implantable microbolus infusion pump (MIP) that allows triggering of a bolus injection at a distance in conscious, behaving rats that are not restrained or tethered. The MIP is externally triggered by a pulse of infrared light and allows in vivo bolus drug delivery. We describe application of this technology to the intravenous bolus delivery of iodo[C-14]antipyrine in a freely moving animal, followed immediately by lethal injection, rapid removal of the brain, and analysis of regional cerebral blood flow tissue radioactivity with the use of autoradiography. The ability to investigate changes in brain activation in nonrestrained animals makes the MIP a powerful tool for evaluation of complex behaviors. C1 Univ So Calif, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. Univ So Calif, Sch Engn, Dept Biomed Engn, Los Angeles, CA 90089 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Holschneider, DP (reprint author), Univ So Calif, Keck Sch Med, LAC USC Hosp, Dept Psychiat, 1200 N State St,Rm 10-621, Los Angeles, CA 90033 USA. RI Kipke, Daryl/A-2167-2009 FU NIBIB NIH HHS [R01 EB000300] NR 18 TC 25 Z9 25 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD OCT PY 2002 VL 283 IS 4 BP H1713 EP H1719 DI 10.1152/ajpheart.00362.2002 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 594DY UT WOS:000178034500052 PM 12234827 ER PT J AU Bagby, SP LeBard, LS Luo, ZM Ogden, BE Corless, C McPherson, ED Speth, RC AF Bagby, SP LeBard, LS Luo, ZM Ogden, BE Corless, C McPherson, ED Speth, RC TI ANG II AT(1) and AT(2) receptors in developing kidney of normal microswine SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE developing kidney; AT(1); AT(2); quantitative autoradiography; swine ID ANGIOTENSIN TYPE-2 RECEPTOR; RAT-KIDNEY; BLOOD-PRESSURE; RENAL-CORTEX; SUBTYPE 2; EXPRESSION; TISSUES; RENIN; FETAL AB To identify an appropriate model of human renin-angiotensin system (RAS) involvement in fetal origins of adult disease, we quantitated renal ANG II AT(1) and AT(2) receptors (AT1R and AT2R, respectively) in fetal (90-day gestation, n = 14), neonatal (3-wk, n = 5), and adult (6-mo, n = 8) microswine by autoradiography ((125)I-labeled [Sar(1)Ile(8)]ANG II+cold CGP-42112 for AT1R, (125)I-CGP-42112 for AT2R) and by whole kidney radioligand binding. The developmental pattern of renal AT1R in microswine, like many species, exhibited a 10-fold increase postnatally (P < 0.001), with maximal postnatal density in glomeruli and lower density AT1R in extraglomerular cortical and outer medullary sites. With aging, postnatal AT1R glomerular profiles increased in size (P < 0.001) and fractional area occupied (P < 0.04), with no change in the number per unit area. Cortical levels of AT2R by autoradiography fell with age from congruent to 5,000 fmol/g in fetal kidneys to congruent to 60 and 20% of fetal levels in neonatal and adult cortex, respectively (P < 0.0001). The pattern of AT2R binding in postnatal pig kidney mimicked that described in human and simian, but not rodent, species: dense AT2R confined to discrete cortical structures, including pre- and juxtaglomerular, but not intraglomerular, vasculature. Our results provide a quantitative assessment of ANG II receptors in developing pig kidney and document the concordance of pigs and primates in developmental regulation of renal AT1R and AT2R. C1 Oregon Hlth Sci Univ, Div Nephrol, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Comparat Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Washington State Univ, Sch Vet Med, Dept Vet & Comparat Anat, Pullman, WA 99164 USA. Washington State Univ, Sch Vet Med, Dept Physiol & Pharmacol, Pullman, WA 99164 USA. RP Bagby, SP (reprint author), Oregon Hlth Sci Univ, Div Nephrol, Dept Med, Suite 262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM bagbys@ohsu.edu FU NICHD NIH HHS [P01-HD-34430] NR 34 TC 17 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD OCT PY 2002 VL 283 IS 4 BP F755 EP F764 DI 10.1152/ajprenal.00313.2001 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 591HH UT WOS:000177873300019 PM 12217867 ER PT J AU Hendrick, V Altshuler, L AF Hendrick, V Altshuler, L TI Management of major depression during pregnancy SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID HUMAN BREAST-MILK; MOTHER-INFANT PAIRS; LOW-BIRTH-WEIGHT; POSTNATAL DEPRESSION; COGNITIVE-DEVELOPMENT; MATERNAL STRESS; NURSING INFANTS; PEDIATRIC PSYCHOPHARMACOLOGY; INTERPERSONAL PSYCHOTHERAPY; POSTPARTUM DEPRESSION C1 W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Hendrick, V (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, Neuropsychiat Inst & Hosp, UCLA Med Plaza,Bldg 300,Suite 2345, Los Angeles, CA 90095 USA. NR 79 TC 23 Z9 23 U1 2 U2 10 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2002 VL 159 IS 10 BP 1667 EP 1673 DI 10.1176/appi.ajp.159.10.1667 PG 7 WC Psychiatry SC Psychiatry GA 600GR UT WOS:000178382700008 PM 12359670 ER PT J AU Golier, JA Yehuda, R Lupien, SJ Harvey, PD Grossman, R Elkin, A AF Golier, JA Yehuda, R Lupien, SJ Harvey, PD Grossman, R Elkin, A TI Memory performance in Holocaust survivors with posttraumatic stress disorder SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CHILDHOOD SEXUAL ABUSE; HIPPOCAMPAL VOLUME; COMBAT VETERANS; EXPLICIT MEMORY; CORTISOL-LEVELS; DEFICITS; DISSOCIATION; IMPLICIT; ATROPHY; PTSD AB Objective: The authors evaluated memory performance in Holocaust survivors and its association with posttraumatic stress disorder (PTSD) and age. Method: Memory performance was measured in Holocaust survivors with PTSD (N= 31) and without PTSD (N=16) and healthy Jewish adults not exposed to the Holocaust (N=35). Explicit and implicit memory were measured by paired-associate recall and word stem completion, respectively. Results: The groups did not differ by age or gender, but the survivors with PTSD had significantly fewer years of education and had lower estimated IQs than the survivors without PTSD and the nonexposed group. There was a significant overall group effect for paired-associate recall but not word stem completion. The survivors with PTSD recalled fewer semantically unrelated words than did the survivors without PTSD and the nonexposed group and fewer semantically related words than the nonexposed group. Of the survivors with PTSD, 36% performed at a level indicative of frank cognitive impairment. older age was significantly associated with poorer paired-associate recall in the survivors with PTSD but not in the other two groups. Conclusions: Markedly poorer explicit but not implicit memory was found in Holocaust survivors with PTSD, which may be a consequence of or a risk factor for chronic PTSD. Accelerated memory decline is one of several explanations for the significantly greater association of older age with poorer explicit memory in survivors with PTSD, which, if present, could increase the cognitive burden of this illness with aging. C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. McGill Univ, Douglas Hosp, Res Ctr, Verdun, PQ, Canada. RP Golier, JA (reprint author), Bronx VAMC, Dept Psychiat 116A, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. FU NIMH NIH HHS [MH 49555] NR 42 TC 88 Z9 89 U1 1 U2 6 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2002 VL 159 IS 10 BP 1682 EP 1688 DI 10.1176/appi.ajp.159.10.1682 PG 7 WC Psychiatry SC Psychiatry GA 600GR UT WOS:000178382700011 PM 12359673 ER PT J AU Kuna, ST Brennick, MJ AF Kuna, ST Brennick, MJ TI Effects of pharyngeal muscle activation on airway pressure-area relationships SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE hypoglossus nerve; glossopharyngeus nerve; vagus nerve; velopharynx; oropharynx ID OBSTRUCTIVE SLEEP-APNEA; HYPOGLOSSAL NERVE-STIMULATION; ELECTRICAL-STIMULATION; FLOW MECHANICS; VOLUME BEHAVIOR; PATENCY; RAT AB Fiberoptic imaging in an isolated, sealed upper airway was performed in 10 decerebrate cats to determine the effect of pharyngeal muscle activation on airway pressure-area relationships. Bilateral cuff electrodes stimulated the distal cut ends of the following nerves: medial and lateral hypoglossus, glossopharyngeus, and pharyngeal branch of vagus. At given intraluminal pressures ranging from +6 to -6 cm H2O, cross-sectional area was measured in the rostral oropharynx, velopharynx, and caudal oropharynx, with and without nerve stimulation. A mixed model analysis of variance indicated a relatively constant increase in area across the pressure range with glossopharyngeal stimulation at any given level. Significant interactions between pressure and stimulation were present in the rostral oropharynx with medial hypoglossus stimulation and in the caudal oropharynx with independent and combined hypoglossal branch stimulation and pharyngeal branch of vagus stimulation. With stimulation of the hypoglossal nerves, greater increases in area in these regions occurred in the lower pressure ranges. Stimulation of the pharyngeal branch of the vagus caused a greater decrease in area at the higher pressure ranges in the caudal oropharynx and velopharynx. The results indicate that the mechanical effects of pharyngeal muscle activation depend not only on the region and muscles activated but also on the intraluminal pressure. C1 Philadelphia Vet Affairs Med Ctr, Primary Care & Consultat Med Serv, Philadelphia, PA 19104 USA. Univ Penn, Pulm Allergy & Crit Care Div, Dept Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. RP Kuna, ST (reprint author), Philadelphia Vet Affairs Med Ctr, Primary Care & Consultat Med Serv, 111P,Univ & Woodland Ave, Philadelphia, PA 19104 USA. FU NHLBI NIH HHS [HL-27520] NR 24 TC 27 Z9 29 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 1 PY 2002 VL 166 IS 7 BP 972 EP 977 DI 10.1164/rccm.200203-214OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 599YJ UT WOS:000178362600016 PM 12359656 ER PT J AU Lin, PH Kulbaski, MJ Terramani, TT Bush, RL Brinkman, WT Chen, CY Conklin, B Lumsden, AB AF Lin, PH Kulbaski, MJ Terramani, TT Bush, RL Brinkman, WT Chen, CY Conklin, B Lumsden, AB TI The regained referral ground and clinical practice of vena cava filter placement in vascular surgery SO AMERICAN SURGEON LA English DT Article; Proceedings Paper CT Annual Meeting of the Southeastern-Surgical-Congress CY FEB 01-05, 2002 CL NASHVILLE, TENNESSEE ID INSERTION; PATTERNS; TRAUMA AB Interventional. radiologist rather than vascular surgeons have become the predominant clinicians placing inferior vena cava (IVC) filters since the percutaneous device was introduced more than a decade ago. We conducted a retrospective analysis of 592 patients treated at a single institution between 1987 and 2000 to determine the indications, referral pattern, and clinical outcome of IVC filter placement between the radiologist and surgeon groups. Before 1989 all filters were placed by surgeons in the operating room. The adoption of the percutaneous delivery method by radiologists in 1989 led to a dramatic increase in its practice volume accounting for 99 per cent of all filters placed from 1991 to 1993 (P < 0.001). The development of an endovascular program by the vascular surgeons in 1994 led to a steady increase in its IVC filter practice annually (P < 0.05) and accounted for 42 per cent of all filter placements in 2000. A distinct referral pattern also emerged as 74 per cent of all filter placements by surgeons were referred by surgical services. The proportion of filter placement for strict indications remained constant over time between the two groups (P = 0.86). The complications and survival rates were not significantly different between the two groups (P = 0.24). Percutaneous devices have dramatically increased the clinical volume of IVC filter placement by interventional radiologists. Vascular surgeons with endovascular interest are well suited to perform the procedure and can regain referral ground of IVC filter placement. C1 Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. Emory Univ, Sch Med, Dept Surg, Div Vasc Surg, Atlanta, GA 30322 USA. RP Lin, PH (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcomb Blvd,112-OCL, Houston, TX 77030 USA. NR 13 TC 3 Z9 3 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI ATLANTA PA 141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA SN 0003-1348 J9 AM SURGEON JI Am. Surg. PD OCT PY 2002 VL 68 IS 10 BP 865 EP 870 PG 6 WC Surgery SC Surgery GA 605TG UT WOS:000178692700009 PM 12412712 ER PT J AU Ho, PM Rumsfeld, JS Lyons, E Every, NR Magid, DJ AF Ho, PM Rumsfeld, JS Lyons, E Every, NR Magid, DJ TI Lack of an association between medicare supplemental insurance and delay in seeking emergency care for patients with myocardial infarction SO ANNALS OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-Academic-Emergency-Medicine CY MAY 20-23, 1999 CL BOSTON, MASSACHUSETTS SP Soc Amer Emergency Med ID PRIVATE HEALTH-INSURANCE; THROMBOLYTIC THERAPY; COVERAGE; SERVICES; ACCESS; DEFIBRILLATION; ENROLLEES; AMERICANS; IMPACT; TRIAGE AB Study objective: Previous studies have shown that Medicare patients without supplemental insurance are less likely to receive preventive services, such as mammography. The effect of supplemental insurance on the appropriate use of emergency services is unknown. We sought to determine whether the absence of supplemental Medicare coverage is associated with increased delay in seeking care for acute myocardial infarction. Methods: In this retrospective cohort study, we compared the time from symptom onset to hospital arrival (the time-delay interval) in Medicare patients with and without supplemental insurance coverage who presented with an acute myocardial infarction to 1 of 19 hospitals in King County, WA, from 1989 to 1993. There were 1,373 patients with Medicare-only coverage and 2,050 patients with Medicare plus supplemental insurance coverage. Results: The age-, sex-, and race-adjusted median time delay was 135 minutes for the Medicare-only group and 130 minutes for the Medicare plus supplemental insurance group (P=.34; 95% confidence interval for median time-delay difference in minutes -5 to 10). There was no significant association between the presence of Medicare supplemental insurance coverage and time delay in Cox regression models, which also adjusted for event year, income, education, past cardiac history, and clinical symptoms. Conclusion: For this cohort of Medicare patients, the absence of supplemental insurance coverage did not lead to significantly increased delays in seeking care for myocardial infarction. Lack of supplemental insurance for Medicare patients might not have as great an effect on the use of emergency services as it has on other health care services. C1 Denver VA Med Ctr, Cardiol & Hlth Serv Res, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO USA. Colorado Permanente Med Grp, Clin Res Unit, Denver, CO USA. Univ Washington, Cardiovasc Outcomes Res Ctr, Seattle, WA 98195 USA. VA Puget Sound Healtcare Syst, Seattle, WA USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO USA. RP Ho, PM (reprint author), 1055 Clermont St 111B, Denver, CO 80220 USA. NR 23 TC 3 Z9 3 U1 1 U2 4 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD OCT PY 2002 VL 40 IS 4 BP 381 EP 387 DI 10.1067/mem.2002.125717 PG 7 WC Emergency Medicine SC Emergency Medicine GA 596ZP UT WOS:000178197400001 PM 12239492 ER PT J AU Cowper, DC Kubal, JD Maynard, C Hynes, DM AF Cowper, DC Kubal, JD Maynard, C Hynes, DM TI A primer and comparative review of major US mortality databases SO ANNALS OF EPIDEMIOLOGY LA English DT Review DE MeSH headings; databases; mortality; vital statistics; veterans ID NATIONAL-DEATH-INDEX; VETERAN POPULATION; VITAL STATUS; ASCERTAINMENT AB PURPOSE: Mortality data are important tools for research requiring vital status information. We reviewed the major mortality databases and mortality ascertainment services available in the United States, including the National Death Index (NDI), the Social Security Administration (SSA) files, and the Department of Veterans Affairs databases. METHODS: The content, reliability, and accuracy of mortality sources are described and compared. We also describe how investigators can gain access to these resources and provide further contact information. RESULTS: We reviewed the accuracy of major mortality sources. The sensitivity (i.e., the proportion of the true number of deaths) of the NDI ranged from 87.0% to 97.9%, whereas the sensitivity for the VA Beneficiary Identification and Records Locator System (BIRLS) ranged between 80.0% and 94.5%. The sensitivity of SSA files ranged between 83.0% and 83.6%. Sensitivity for the VA Patient Treatment File (PTF) was 33%. CONCLUSIONS: While several national mortality ascertainment services are available for vital status (i.e., death) analyses, the NDI information demonstrated the highest sensitivity and, currently, it is the only source at the national level with a cause of death field useful for research purposes. Researchers must consider methods used to ascertain vital status as well as the quality of the information in mortality databases. (C) 2002 Elsevier Science Inc. All rights reserved. C1 Hines VA Hosp, VA Informat Resource Ctr, VIReC 578 151V, Dept Vet Affairs Hlth Serv Res, Hines, IL 60141 USA. Hines VA Hosp, Dev Serv Resource Ctr, Hines, IL 60141 USA. Vet Affairs Edward Hines Jr Hosp, Midw Ctr Hlth Serv & Policy Res, Hlth Serv Res & Dev Serv Ctr Excellence, Hines, IL USA. Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA. Epidemiol Res & Informat Ctr, Seattle, WA USA. NW Ctr Outcomes Res Older Adults, Seattle, WA USA. Loyola Univ, Dept Med, Maywood, IL 60153 USA. RP Cowper, DC (reprint author), Hines VA Hosp, VA Informat Resource Ctr, VIReC 578 151V, Dept Vet Affairs Hlth Serv Res, POB 5000, Hines, IL 60141 USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 16 TC 304 Z9 305 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2002 VL 12 IS 7 BP 462 EP 468 AR PII S1047-2797(01)00285-X DI 10.1016/S1047-2797(01)00285-X PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 594GN UT WOS:000178041400004 PM 12377423 ER PT J AU Abbruzzese, C Porrini, SC Mariani, B Gould, FK Mcabney, JP Monckton, DG Ashizawa, T Giacanelli, M AF Abbruzzese, C Porrini, SC Mariani, B Gould, FK Mcabney, JP Monckton, DG Ashizawa, T Giacanelli, M TI Instability of a premutation allele in homozygous patients with myotonic dystrophy type 1 SO ANNALS OF NEUROLOGY LA English DT Article ID CTG REPEAT; SOMATIC INSTABILITY; CAG REPEAT; EXPANSIONS; MOSAICISM; HETEROGENEITY; STABILITY; MUSCLE; EVENTS; GENE AB Myotonic dystrophy type I (DM1) is caused by the expansion of an unstable CTG repeat in the DMPK gene on chromosome 19q13.3. We present two siblings with DM1 who each inherited a premutation allele, (CTG)(43), stably transmitted from the mother and a full-mutation allele, either (CTG)(500) or (CTG)(180), derived from a paternal protomutation allele, (CTG)(52). Small-pool polymerase chain reaction analysis showed that the (CTG)(52) repeat allele was relatively stable in somatic tissues but was highly unstable in the male germline and extremely biased toward further expansion, consistent with the high levels of anticipation observed in DM1 families. The (CTG)(43) allele showed subtle somatic instability in the mother, with maximum additions of two repeats and deletions of one repeat. Conversely, in the younger affected siblings the (CTG)(43) allele showed a high degree of somatic instability (approximately 70% mutation load), resulting in deletions reverting to the high end of the normal range (down to [CTG](33)) and additions up to the proto-mutation range (up to [CTG](64)). The difference in the somatic stability of the (CTG)(43) allele between the mother and her offspring suggests that interallelic interactions or other mechanisms in trans regulate the stability of the (CTG)(43) premutation allele. C1 Univ Texas, Dept Neurol, Med Branch, Galveston, TX 77555 USA. Azienda Osped San Camillo Forlanini, Dipartimento Medicochirurg Neurosci, Lab Istopatol Neurogenet Mol, Rome, Italy. Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. RP Ashizawa, T (reprint author), Univ Texas, Dept Neurol, Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA. NR 23 TC 13 Z9 13 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD OCT PY 2002 VL 52 IS 4 BP 435 EP 441 DI 10.1002/ana.10304 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 600GG UT WOS:000178381800008 PM 12325072 ER PT J AU Poorkaj, P Muma, NA Zhukareva, V Cochran, EJ Shannon, KM Hurtig, H Koller, WC Bird, TD Trojanowski, JQ Lee, VMY Schellenberg, GD AF Poorkaj, P Muma, NA Zhukareva, V Cochran, EJ Shannon, KM Hurtig, H Koller, WC Bird, TD Trojanowski, JQ Lee, VMY Schellenberg, GD TI An (R)5(L) tau mutation in a subject with a progressive supranuclear palsy phenotype SO ANNALS OF NEUROLOGY LA English DT Article ID NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PRESENILE-DEMENTIA; GENE; ISOFORMS; PATHOLOGY; MISSENSE; CRITERIA; FTDP-17; EXON-10 AB MAPT, the gene encoding tau, was screened for mutations in 96 progressive supranuclear palsy subjects. A point mutation ((R)5(L)) was identified in a single progressive supranuclear palsy subject that was not in the other progressive supranuclear palsy subjects or in 96 controls. Functionally, this mutation alters the ability of tau to promote microtubule assembly. Analysis of soluble tau from different brain regions indicates that the mutation does not affect the ratio of tau isoforms synthesized. Aggregated insoluble tau from subcortical regions was predominantly four-repeat tau with no or one amino terminal insert (0N4R and 1N4R). Insoluble tau from cortical regions also contained 1N3R tau. Thus, the (R)5(L) mutation causes a progressive supranuclear palsy phenotype, presumably by a gain-of-function mechanism. C1 GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA. Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA. Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. Univ Miami, Dept Neurol, Miami, FL 33152 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Schellenberg, GD (reprint author), GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, 182-B,1660 S Columbian Way, Seattle, WA 98195 USA. OI Muma, Nancy/0000-0001-8272-3138 FU NIA NIH HHS [AG10124, AG11762, AG17583] NR 20 TC 110 Z9 115 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD OCT PY 2002 VL 52 IS 4 BP 511 EP 516 DI 10.1002/ana.10340 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 600GG UT WOS:000178381800019 PM 12325083 ER PT J AU Inagi, K Connor, NP Suzuki, T Ford, CN Bless, DM Nakajima, M AF Inagi, K Connor, NP Suzuki, T Ford, CN Bless, DM Nakajima, M TI Glottal configuration, acoustic, and aerodynamic changes induced by variation in suture direction in arytenoid adduction procedures SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article; Proceedings Paper CT Meeting of the American-Broncho-Esophagological-Association CY MAY 14-16, 2001 CL PALM DESERT, CALIFORNIA SP Amer Broncho Esophagol Assoc DE arytenoid adduction; lateral cricoarytenoid muscle; thyroarytenoid muscle ID VIVO CANINE MODEL; VOCAL CORD PARALYSIS; MEDIALIZATION; BIOMECHANICS; FOLD AB Arytenoid adduction is a phonosurgical procedure in which the arytenoid cartilages are approximated to reduce posterior glottal gap size and improve voice. Voice outcomes following arytenoid adduction are not always optimal. The goal of this study was to systematically vary suture direction and force of pull on the arytenoid cartilages in a human excised laryngeal model to determine the optimal combination of factors for reducing glottal gap and improving voice. Several factors demonstrated significant effects. Changes in suture direction and force of pull affected glottal configuration in both the horizontal and vertical planes. Increased force of pull on the muscular process resulted in increased adduction of the vocal process for all suture directions. Changes in suture direction and force of pull also affected acoustic and aerodynamic measures of induced voice. Therefore, voice outcomes can be optimized with arytenoid adduction if the vocal fold plane is accurately adjusted. C1 Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg,Sch Med, Madison, WI 53792 USA. Kitasato Inst, Med Ctr Hosp, Dept Otolaryngol Head & Neck Surg, Saitama, Japan. William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg,Sch Med, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. FU NIDCD NIH HHS [P6DC000976] NR 19 TC 13 Z9 13 U1 0 U2 1 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 USA SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD OCT PY 2002 VL 111 IS 10 BP 861 EP 870 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA 604GR UT WOS:000178609200001 PM 12389852 ER PT J AU Tsukamoto, H AF Tsukamoto, H TI Redox regulation of cytokine expression in Kupffer cells SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID NF-KAPPA-B; ISCHEMIA-REPERFUSION INJURY; NECROSIS-FACTOR-ALPHA; DNA-BINDING ACTIVITY; INDUCED LIVER-INJURY; TRANSCRIPTION FACTOR; RAT-LIVER; SIGNAL-TRANSDUCTION; ALCOHOLIC HEPATITIS; GENE-EXPRESSION AB Kupffer cells, resident macrophages in the liver, play a central role in the homeostatic response to liver injury. Ironically, this defensive mechanism, if dysregulated, also works against the liver in acute and chronic liver damage. Central to this response is activation of nuclear factor-kappaB (NF-kappaB), a redox-sensitive transcription factor that transactivates promoters of many inflammatory genes, including cytokines. Much research has been devoted to identification of upstream signaling for activation of NF-kappaB, but the precise mechanism by which oxidant stress participates in this signaling is yet to be determined. Clues to this key question may be attained through studies on the mechanisms of sustained and/or accentuated NF-kappaB activation in hepatic macrophages in chronic liver diseases. This article reviews the literature on redox regulation of cytokine gene expression by Kupffer cells. C1 Univ So Calif, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, USC Res Ctr Liver Dis, Los Angeles, CA 90033 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90033 USA. RP Univ So Calif, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, 1333 San Pablo St,MMR-402, Los Angeles, CA 90033 USA. EM htsukamo@hsc.usc.edu FU NIAAA NIH HHS [P50AA11999, R37AA06603]; NIDDK NIH HHS [P30DK48522] NR 66 TC 57 Z9 59 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD OCT PY 2002 VL 4 IS 5 BP 741 EP 748 DI 10.1089/152308602760598882 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 607NP UT WOS:000178797900006 PM 12470501 ER PT J AU Tsuang, DW Dalan, AM Eugenio, CJ Poorkaj, P Limprasert, P La Spada, AR Steinbart, E Bird, TD Leverenz, JB AF Tsuang, DW Dalan, AM Eugenio, CJ Poorkaj, P Limprasert, P La Spada, AR Steinbart, E Bird, TD Leverenz, JB TI Familial dementia with Lewy bodies - A clinical and neuropathological study of 2 families SO ARCHIVES OF NEUROLOGY LA English DT Article ID E EPSILON-4 ALLELE; APOLIPOPROTEIN-E GENE; HUMAN PARKIN GENE; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; BODY-DISEASE; HUNTINGTONS-DISEASE; PSYCHOTIC SYMPTOMS; SENILE DEMENTIA; POLYMORPHISMS AB Background: Dementia with Lewy bodies (DLB) is characterized by early dementia and associated visual hallucinations, parkinsonism, and fluctuations in cognition. Few families with DLB have been described with detailed clinical, pathological, and genetic assessments. Objective: To investigate the clinical, neuropathological, and genetic characteristics of families with 2 or more autopsy-proven cases of DLB. Design: Consecutive cases with the neuropathological diagnosis of DLB were reviewed as part of a case series. Families included in this study have 2 or more autopsy-proven cases of DLB available and a positive family history of dementia. We obtained clinical and neuropathological data on all first-degree relatives. Neuropathological evaluations included alpha-synuclein immunostaining for Lewy body detection. We conducted apolipoprotein E genotyping and sequenced the alpha-, beta-, gamma-synuclein, and parkin genes. Setting: Subjects were selected from the neuropathology core of the University of Washington's Alzheimer's Disease Research Center. Patients: The study investigated 2 families. Clinical information was obtained from 10 individuals in family 1 and 7 individuals in family 2. Neuropathological examinations were conducted in 3 individuals in family 1 and 2 individuals in family 2. Main Outcome Measures: Each subject was examined for the presence of clinical symptoms and neuropathological findings consistent with DLB. Results: While all affected individuals presented with dementia in both families, only individuals in family 1 developed visual hallucinations and delusions. Parkinsonism, if present, occurred later in the course of illness. Neuropathological examination revealed Lewy bodies in all patients, while 1 patient from each family also met the neuropathological criteria for Alzheimer disease. All affected individuals carried at least 1 APOE (apolipoprotein E) epsilon4 allele, while there were no nucleotide alterations in the synuclein or parkin genes. Conclusions: Familial DLB exists, although there is substantial clinical and neuropathological heterogeneity within and between families. Additional clinicopathologic and genetic studies are necessary to further our understanding of DLB. C1 Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. RP Tsuang, DW (reprint author), Dept Vet Affairs, NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 NR 59 TC 41 Z9 41 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD OCT PY 2002 VL 59 IS 10 BP 1622 EP 1630 DI 10.1001/archneur.59.10.1622 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 603LC UT WOS:000178560100014 PM 12374501 ER PT J AU Neuzil, KM Hohlbein, C Zhu, YW AF Neuzil, KM Hohlbein, C Zhu, YW TI Illness among schoolchildren during influenza season - Effect on school absenteeism, parental absenteeism from work, and secondary illness in families SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID PANDEMIC INFLUENZA; VIRUS-INFECTIONS; CHILDREN; IMPACT; MORTALITY; YOUNG; AGE; HOSPITALIZATIONS; VACCINATION; MORBIDITY AB Background: High attack rates of Influenzavirus among school-aged children tend to be expected to cause significant disruption of usual activities at school and at home. Objective: To quantify the effect of influenza season on illness episodes, school absenteeism, medication use, parental absenteeism from work, and the occurrence of secondary illness in families among a cohort of children enrolled in an elementary school during the 2000-2001 influenza season. Design: Prospective survey study. Setting: Kindergarten through eighth grade elementary school in Seattle, Wash. Patients or Other Participants: All children enrolled in the school were eligible for the study. Study participants were 313 children in 216 families. Main Outcome Measures: The primary outcome measure was missed school days. Secondary outcomes measures included total illness episodes, febrile illness episodes, medication usage, physician visits, parental workdays missed, and secondary illnesses among family members of children in the study cohort. Differences between the rates of study events among participants when influenza was circulating and the event rates during the winter season when influenza was not circulating were used to calculate influenza-attributable excess events. Results: Total illness episodes, febrile illness episodes, analgesic use, school absenteeism, parental industrial absenteeism, and secondary illness among family members were significantly higher during influenza season compared with the noninfluenza winter season. For every 100 children followed up for this influenza season, which included 37 school days, an excess 28 illness episodes and 63 missed school days occurred. Similarly, for every 100 children followed up, influenza accounted for an estimated 20 days of work missed by the parents and 22 secondary illness episodes among family members. Conclusion: Influenza season has significant adverse effects on the quality of life of school-aged children and their families. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA. Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. RP Neuzil, KM (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 36 TC 174 Z9 180 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD OCT PY 2002 VL 156 IS 10 BP 986 EP 991 PG 6 WC Pediatrics SC Pediatrics GA 602EY UT WOS:000178493900007 PM 12361443 ER PT J AU Calverley, DC Brass, E Hacker, MR Tsao-Wei, DD Espina, BM Pullarkat, VA Hodis, HN Groshen, S AF Calverley, DC Brass, E Hacker, MR Tsao-Wei, DD Espina, BM Pullarkat, VA Hodis, HN Groshen, S TI Potential role of platelet Fc gamma RIIA in collagen-mediated platelet activation associated with atherothrombosis SO ATHEROSCLEROSIS LA English DT Article DE blood platelets; diabetes mellitus; cardiovascular disease; collagen; platelet activation; receptors, Fc ID STIMULATES TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-2; RECEPTOR; EXPRESSION; SYK; INTEGRIN; PROTEIN; DISEASE; ALPHA(2)BETA(1); INTERACTS AB Collagen-mediated platelet activation contributes significantly to coronary and cerebrovascular thrombus formation associated with atherosclerotic plaque destabilization. Recent clinical and laboratory observations support a potential role for the platelet Fc receptor (FcgammaRIIA) in this process. The purpose of this study was to elucidate any association between platelet Fc receptor (FcR) expression levels and both atherosclerosis risk factors (ARFs) along with collagen-dependent platelet activation. Age and gender-independent variation has been described in the expression of this receptor that is stable over time. Platelet Fc surface expression was compared between patients experiencing an acute coronary or cerebrovascular event, healthy patients with two or more ARFs, and healthy patients with fewer than two ARFs. Platelet FcR expression was significantly and stably (6-52 weeks, mean 20 weeks) increased in 101 patients with acute myocardial infarction, unstable angina, or ischemic stroke syndrome (P < 0.001) and 38 healthy patients with two or more ARFs (P = 0.027) compared with 109 healthy patients with fewer than two ARFs. Patients with diabetes mellitus from all groups had significantly increased platelet FcR expression over those without diabetes (P < 0.0001). Platelet aggregation studies suggested a correlation between number of ARFs per patient, platelet Fc expression levels, and relative sensitivity to collagen stimulation. Platelet FcR surface expression is increased in patients with an acute coronary or cerebrovascular event, non-acutely ill patients with two or more ARFs, and in patients with diabetes mellitus. Increased platelet FcR expression may therefore contribute towards risk for atherothrombotic events. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Mt States Reg Hemophilia & Thrombosis Ctr, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Med Serv, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80262 USA. Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA. Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. RP Calverley, DC (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B171, Denver, CO 80262 USA. FU NCI NIH HHS [P30 CA 14089]; NIA NIH HHS [R01AG13860] NR 35 TC 23 Z9 24 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD OCT PY 2002 VL 164 IS 2 BP 261 EP 267 AR PII S0021-9150(02)00179-X DI 10.1016/S0021-9150(02)00179-X PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 594TY UT WOS:000178068100007 PM 12204796 ER PT J AU Patchornik, G Munson, K Goldshleger, R Shainskaya, A Sachs, G Karlish, SJD AF Patchornik, G Munson, K Goldshleger, R Shainskaya, A Sachs, G Karlish, SJD TI The ATP-Mg2+ binding site and cytoplasmic domain interactions of Na+,K+-ATPase investigated with Fe2+-catalyzed oxidative cleavage and molecular modeling SO BIOCHEMISTRY LA English DT Article ID P-TYPE ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; ENERGY TRANSDUCTION MECHANISM; ALPHA-BETA PROTOMERS; (NA+ + K+)-ATPASE; NA+/K+-ATPASE; HIGH-AFFINITY; AMINO-ACID; FLUORESCEIN ISOTHIOCYANATE; CONFORMATIONAL-CHANGES AB This work utilizes Fe2+-catalyzed cleavages and molecular modeling to obtain insight into conformations of cytoplasmic domains and ATP-Mg2+ binding sites of Na+,K+-ATPasc. In E-1 conformations the ATP-Fe2+ Complex mediates specific cleavages at 712VNDS (P domain) and near 440VAGDA (N domain). In E-2(K), ATP-Fe2+ mediates cleavages near 212TGES (A domain), near 440VAGDA, and between residues 460-490 (N domain). Cleavages at high ATP-Fe2+ concentrations do not support suggestions for two ATP sites. A new reagent, fluorescein-DTPA, has been synthesized. The fluorescein-DTPA-Fe2+ Complex mediates cleavages similar to those mediated by ATP-Fe2+. The data suggest the existence of N to P domain interactions in E1Na, with bound ATP-Fe2+ or fluorescein-DPTA-Fe2+, A-N, and A-P interactions in E-2(K), and provide testable constraints for model building. Molecular models based on the Ca2+-ATPase structure are consistent with the predictions. Specifically, high-affinity ATP-Mg2+ binding in E-1 is explained with the N domain tilted ca. 80degrees toward the P domain, by comparison with well-separated N and P domains in the Ca-ATPase crystal structure. With ATP-Mg2+ docked, bound Mg2+ is close to both D710 (in 710DGVNDS) and D443 (in 440VAGDASE). D710 is known to be crucial for Mg2+ binding. The cleavage and modeling data imply that D443 could also be a candidate for Mg2+ binding. Comparison of E-1.ATP,Mg2+ and E-2 models suggests an explanation of the high or low ATP affinities, respectively. We propose a scheme of ATP-Mg2+ and Mg2+ binding and N, P, and A domain interactions in the different conformations of the catalytic cycle. C1 Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel. Weizmann Inst Sci, Biol Mass Spectrometry Facil, IL-76100 Rehovot, Israel. Univ Calif Los Angeles, Dept Physiol, Membrane Biol Lab, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Karlish, SJD (reprint author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel. FU NIDDK NIH HHS [DK 17294, DK 46971, DK 53462, DK 41301] NR 59 TC 21 Z9 21 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD OCT 1 PY 2002 VL 41 IS 39 BP 11740 EP 11749 DI 10.1021/bi026334d PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 598DP UT WOS:000178260400022 PM 12269816 ER PT J AU Park, GH McNeil, MR Doyle, PJ AF Park, GH McNeil, MR Doyle, PJ TI Effects of increased inter-word intervals following prepositions on auditory sentence comprehension in agrammatic and normal comprehenders SO BRAIN AND LANGUAGE LA English DT Meeting Abstract C1 Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Aphasia Rehabil Res Lab & Clin, Pittsburgh, PA USA. Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X J9 BRAIN LANG JI Brain Lang. PD OCT PY 2002 VL 83 IS 1 BP 220 EP 222 AR PII S0093-934X(02)00142-6 PG 3 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA 601EP UT WOS:000178433800086 ER PT J AU Casarett, DJ Karlawish, JHT Henry, MI Hirschman, KB AF Casarett, DJ Karlawish, JHT Henry, MI Hirschman, KB TI Must patients with advanced cancer choose between a Phase I trial and hospice? SO CANCER LA English DT Article DE Phase I trials; ethics; research ethics; hospice; palliative care; informed consent ID MOTIVATION AB BACKGROUND. Phase I oncology trials offer no meaningful chance for direct medical benefit and they may prevent patients with advanced cancer from receiving palliative care in a hospice program. however, it is not known whether dual enrollment in a Phase I trial and hospice is feasible. METHODS. Five hundred thirty-four Phase I trials were identified in a national online database, of which 179 (34%) accepted patients with a life expectancy of less than 6 months. Of these, 50 were selected randomly. Their principal investigators were surveyed by fax, with follow-up telephone calls and e-mails. Ninety-two hospices were selected randomly from a national database. Surveys were conducted by telephone with intake coordinators. Principal investigators were asked whether patients enrolled in hospice could also enroll in their trials if they were eligible in all other respects. hospice intake coordinators were asked whether a patient with advanced cancer who met hospice eligibility criteria could also enroll in a Phase I trial. RESULTS. Surveys were completed by 45 of 50 principal investigators (90%) and by 89 of 92 hospices (97%). Although both groups were in favor of dual enrollment, principal investigators (41 of 45; 91%) were more likely to support dual enrollment than hospices (60 of 89; 67%; chi-square test, P = 0.004). Most hospices that did not support dual enrollment cited reasons that were based on concerns about payment or misunderstandings about the nature of Phase I trials. CONCLUSIONS. Most hospices and Phase I principal investigators believe that eligible patients should be allowed to enroll simultaneously in hospice and Phase I trials. These results suggest that the choice between hospice and a Phase I trial is a false dilemma and that greater collaboration in this area is needed. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA. Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Sch Social Work, Philadelphia, PA 19104 USA. RP Casarett, DJ (reprint author), Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. FU PHS HHS [K01-00931] NR 14 TC 9 Z9 9 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD OCT 1 PY 2002 VL 95 IS 7 BP 1601 EP 1604 DI 10.1002/cncr.10820 PG 4 WC Oncology SC Oncology GA 595VE UT WOS:000178128600025 PM 12237931 ER PT J AU Gariti, P Rosenthal, DI Lindell, K Hansen-Flaschen, J Shrager, J Lipkin, C Alterman, AI Kaiser, LR AF Gariti, P Rosenthal, DI Lindell, K Hansen-Flaschen, J Shrager, J Lipkin, C Alterman, AI Kaiser, LR TI Validating a dipstick method for detecting recent smoking SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CELL LUNG-CANCER; CESSATION; SURVIVORS; EXPOSURE; VALIDITY AB This report evaluates the validity of a new method for verifying self-reported smoking status in patients presenting for pulmonary medicine treatment. A prospective comparison was made between self-reports of smoking status and a new semiquantitative, enzyme-linked, immunosorbent assay-based method testing for the presence of a prime nicotine metabolite, cotinine. Results were validated by gas chromatography/mass spectrometry. Data were collected in an urban, academic, tertiary health care setting. The study included 76 consecutive new patients presenting to participating clinical practices at the Pulmonology or Thoracic Surgery Services. Before taking a smoking history, patients were informed that their urine would be tested onsite for the presence of nicotine using a new method, the NicoMeter, for determining tobacco product exposure, followed by more standard laboratory testing. The level of agreement between the biochemical measurement types was excellent, kappa = 0.777. The new biochemical measurement type used was easy to use. Self-reported smoking status corresponded closely to biochemical testing. However, there was a 5.3-9.5% misclassification of smoking status among the group studied, depending upon the measurement type used. Among 32 lung cancer patients, 15.6%, most likely misrepresented their current smoking status. The NicoMeter appears to be a valid and useful method for confirming self-reported smoking status. Lung cancer patients had a higher rate of inaccurate nonsmoking compared with patients with nonmalignant pulmonary disease. The findings have implications for investigators who accept self-reported smoking status without biochemical verification. C1 Univ Penn, Canc Ctr Grp, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Univ Pittsburgh, Pittsburgh, PA 15238 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Gariti, P (reprint author), Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. OI Hansen-Flaschen, John/0000-0003-1989-7244 NR 18 TC 31 Z9 32 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2002 VL 11 IS 10 BP 1123 EP 1125 PN 1 PG 3 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 604RD UT WOS:000178634100028 PM 12376520 ER PT J AU Levine, SM AF Levine, SM TI Lung transplantation and bronchiolitis obliterans syndrome - Are two lungs better than one? SO CHEST LA English DT Editorial Material ID VOLUME REDUCTION; EMPHYSEMA; SINGLE; DYSFUNCTION; REJECTION C1 Univ Texas, Hlth Sci Ctr, Div Pulm Dis Crit Care Med, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Levine, SM (reprint author), Univ Texas, Hlth Sci Ctr, Div Pulm Dis Crit Care Med, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 15 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2002 VL 122 IS 4 BP 1112 EP 1114 DI 10.1378/chest.122.4.1112 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 605PA UT WOS:000178685200002 PM 12377826 ER PT J AU Virella, G Atchley, D Koskinen, S Lopes-Virella, MF AF Virella, G Atchley, D Koskinen, S Lopes-Virella, MF CA DCCT EDIC Res Grp TI Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL SO CLINICAL IMMUNOLOGY LA English DT Article DE arteriosclerosis; diabetes; autoimmunity; human oxidized LDL antibodies; immune complexes; immunological factors in atherosclerosis ID LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY DISEASE; MONOCYTE-DERIVED MACROPHAGES; HUMAN-ENDOTHELIAL-CELLS; MODIFIED LDL ANTIBODIES; OXIDIZED LDL; CAROTID ATHEROSCLEROSIS; METABOLIC CONTROL; HEART-DISEASE; IN-VITRO AB Immune complexes (IC) prepared with human low density lipoprotein (LDL) and rabbit LDL antibodies induce foam cell transformation of human macrophages and activate the release of proinflammatory mediators by human macrophages and THP-1 cells. Because the affinity of human oxidized LDL (oxLDL) antibodies is lower than that of rabbit antibodies, IC formed with human antibodies could have limited pathogenic potential. Immune complexes prepared with human oxidized LDL (oxLDL) and purified human oxLDL antibodies (predominantly of the IgG1 and IgG3 isotypes) were presented to THP-1 cells using two protocols previously described in studies of the properties of LDL-IC prepared with rabbit antibodies. OxLDL/human oxLDL antibody IC immobilized by adsorption to red blood cells (RBC) induced the release of significantly higher levels of TNF from THP-1 cells (872-313 pg/ml) than oxLDL adsorbed to RBC (461-75.6 pg/ml) and caused a higher degree of cholesterol ester accumulation in the same cells (5.4-0.77 in cells incubated with IC-coated RBC vs 1.99-1.16 in oxLDL-coated RBC). Insoluble IC prepared with oxLDL/human oxLDL antibody were even more effective in promoting intracellular accumulation of cholesterol in THP-1 cells (total cholesterol = 53.8-13.5 and cholesterol esters = 24.0-7.2 mg/l in THP-1 cells incubated with insoluble IC (200 jig) vs total cholesterol = 32.4-8.2 and cholesterol esters = 7.7 +/- 2.8 mug/l in THP-1 cells incubated with an identical concentration of oxLDL) and also induced the release of TNF. Thus we have demonstrated that IC prepared with human oxLDL and human oxLDL antibodies have the same atherogenic and proinflammatory properties as IC prepared with human LDL and rabbit LDL antibodies. This strongly supports the concept that modified LDL-IC present in circulation and/or tissues play an important pathogenic role in arteriosclerosis. (C) 2002 Elsevier Science (USA). C1 Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29403 USA. RP Lopes-Virella, MF (reprint author), Ralph H Johnson VA Med Ctr, Strom Thrumond Res Bldg,114 Doughty St, Charleston, SC 29425 USA. FU NCRR NIH HHS [M01-RR-1070]; NHLBI NIH HHS [P01-HL55782] NR 51 TC 74 Z9 86 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD OCT PY 2002 VL 105 IS 1 BP 81 EP 92 DI 10.1006/clim.2002.5269 PG 12 WC Immunology SC Immunology GA 607RT UT WOS:000178805100010 PM 12483997 ER PT J AU Willi, SM Kennedy, A Wallace, P Ganaway, E Rogers, NL Garvey, WT AF Willi, SM Kennedy, A Wallace, P Ganaway, E Rogers, NL Garvey, WT TI Troglitazone antagonizes metabolic effects of glucocorticoids in humans - Effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin SO DIABETES LA English DT Article ID ACTIVATED RECEPTOR-GAMMA; RAT SKELETAL-MUSCLE; OB GENE-EXPRESSION; PRIMARY CULTURED ADIPOCYTES; II DIABETES-MELLITUS; OBESE ZUCKER RATS; ADIPOSE-TISSUE; ENERGY-EXPENDITURE; 3T3-L1 ADIPOCYTES; HEALTHY-SUBJECTS AB Glucocorticoids induce insulin resistance in humans, whereas thiazolidinediones enhance insulin sensitivity. Although the effects of glucocorticoids and thiazolidinediones have been assessed in isolation, interaction between these drugs, which both act as ligands for nuclear receptors, has been less Well studied. Therefore, we examined the metabolic effects of dexamethasone and troglitazone, alone and in combination, for the first time in humans. A total of 10 healthy individuals with normal glucose tolerance (age 40 +/- 11 years, BMI 31 +/- 6.1 kg/m(2)) were sequentially studied at baseline, after 4 days of dexamethasone (4 mg/day), after 4-6 weeks on troglitazone alone (400 mg/day), and again after 4 days of dexamethasone added to troglitazone. Key metabolic variables included glucose tolerance assessed by blood glucose and insulin responses to an oral glucose tolerance test (OGTT), insulin sensitivity evaluated via hyperinsulinemic-euglycemic clamp, free fatty acids (FFAs) and FFA suppressibility by insulin during the clamp study, and fasting serum leptin. Dexamethasone drastically impaired glucose tolerance, with fasting and 2-h OGTT insulin values increasing by 2.3-fold (P < 0.001) and 4.4-fold (P < 0.001) over baseline values, respectively. The glucocorticoid also induced a profound state of insulin resistance, with a 34% reduction in maximal glucose disposal rates (GDRs; P < 0.001). Troglitazone alone increased GDRs by 20% over baseline (P = 0.007) and completely prevented the deleterious effects of dexamethasone on glucose tolerance and insulin sensitivity, as illustrated by a return of OGTT glucose and insulin values and maximal GDR to near-baseline levels. Insulin-mediated FFA suppressibility (FFA decline at 30 min during clamp/FFA at time 0) was also markedly reduced by dexamethasone (P 0.002). Troglitazone had no effect per se, but it was able to normalize FFA suppressibility in subjects co-administered dexamethasone. Futhermore, the magnitudes of response of FFA suppressibility and GDR to dexamethasone were proportionate. The same was true for the reversal of dexamethasone-induced insulin resistance by troglitazone, but not in response to troglitazone alone. Leptin levels were increased 2.2-fold above baseline by dexamethasone. Again, troglitazone had no effect per se but blocked the dexamethasone-induced increase in leptin. Subjects experienced a 1.7-kg weight gain while taking troglitazone but no other untoward effects. We conclude that in healthy humans, thiazolidinediones antagonize the action of dexamethasone with respect to multiple metabolic effects. Specifically, troglitazone reverses both glucocorticoid-induced insulin resistance and impairment of glucose tolerance, prevents dexamethasone from impairing the antilipolytic action of insulin, and blocks the increase in leptin levels induced by dexamethasone. Even though changes in FFA suppressibility were correlated with dexamethasone-induced insulin resistance and its reversal by troglitazone, a cause-and-effect relationship cannot be established. However, the data suggest that glucocorticoids and thiazolidinediones exert fundamentally antagonistic effects on human metabolism in both adipose and muscle tissues. By preventing or reversing insulin resistance, troglitazone may prove to be a valuable therapeutic agent in the difficult clinical task of controlling diabetes in patients receiving glucocorticoids. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Willi, SM (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. FU NCRR NIH HHS [M01 RR-01070-20S3]; NIDDK NIH HHS [DK-38764] NR 63 TC 52 Z9 60 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2002 VL 51 IS 10 BP 2895 EP 2902 DI 10.2337/diabetes.51.10.2895 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 599LT UT WOS:000178336600003 PM 12351424 ER PT J AU Mei, Q Mundinger, TO Lernmark, A Taborsky, GJ AF Mei, Q Mundinger, TO Lernmark, A Taborsky, GJ TI Early, selective, and marked loss of sympathetic nerves from the islets of BioBreeder diabetic rats SO DIABETES LA English DT Article ID AUTONOMIC NEUROPATHY; GROWTH-FACTOR; BB RAT; NERVOUS-SYSTEM; BETA-CELLS; ALPHA; GLUCAGON; PANCREAS; INSULIN; NOREPINEPHRINE AB To discover whether islet sympathetic nerves are damaged during the autoimmune destruction of islet B-cells, we immunostained sections of pancreas from Bio-Breeder (BB) diabetic rats, using antibodies against vesicular monoamine transporter 2 (VMAT2), a marker of sympathetic nerve terminals. We found a marked decrease in the VMAT2-positive fiber area in the islets of BB rats that had been diabetic for only 1-2 weeks compared with their nondiabetic controls. In contrast, there was no significant decrease in the VMAT2-positive fiber area in the exocrine pancreas in these early diabetic BB rats. Furthermore, streptozotocin-diabetic rats showed no decrease in VMAT2-positive fiber area in their islets compared with controls. The classical diabetic autonomic neuropathy (DAN) that eventually occurs in the heart was not present in BB diabetic rats at this early stage as evidenced by normal cardiac VMAT2 immunostaining and normal cardiac norepinephrine content. Also, in contrast to DAN, this islet neuropathy did not worsen with duration of diabetes. These data provide evidence of a heretofore unrecognized early sympathetic islet neuropathy (eSIN). Because eSIN occurs selectively in the islet, is rapid in onset, and is associated with autoimmune but not chemically induced diabetes, it is distinct from DAN in location, time course, and mechanism. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Dept Med, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Mei, Q (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol & Metab 151, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK-12047, DK-50154, DK-12829] NR 32 TC 60 Z9 61 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1660 DUKE ST, ALEXANDRIA, VA 22314 USA SN 0012-1797 J9 DIABETES JI Diabetes PD OCT PY 2002 VL 51 IS 10 BP 2997 EP 3002 DI 10.2337/diabetes.51.10.2997 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 599LT UT WOS:000178336600018 PM 12351439 ER PT J AU Nelson, KM Reiber, G Boyko, EJ AF Nelson, KM Reiber, G Boyko, EJ TI Diet and exercise among adults with type Z diabetes SO DIABETES CARE LA English DT Article; Proceedings Paper CT 62nd Annual Meeting of the American-Diabetes-Association CY JUN 14-18, 2002 CL SAN FRANCISCO, CALIFORNIA SP Amer Diabet Assoc ID FOOD-FREQUENCY QUESTIONNAIRE; NUTRITION EXAMINATION SURVEY; MEXICAN-AMERICAN WOMEN; 3RD NATIONAL-HEALTH; PHYSICAL-ACTIVITY; SELF-MANAGEMENT; MELLITUS; PREVENTION; RECOMMENDATIONS; COMPLICATIONS AB OBJECTIVE - To describe diet and exercise practices from a nationally representative sample of U.S. adults with type 2 diabetes. METHODS- We analyzed data from 1,480 adults older than 17 years with a self-reported diagnosis of type 2 diabetes in the Third National Health and Nutrition Examination Survey (NHANES III). Fruit and vegetable consumption was obtained from a food frequency questionnaire; the percentages of total calories from fat and saturated fat were obtained from a 24-h food recall. Physical activity was based on self report during the month before the survey. RESULTS- Of individuals with-type 2 diabetes, 31% reported no regular physical activity and another 38% reported less than recommended levels of physical activity. Sixty-two percent of respondents ate fewer than five servings of fruits and vegetables per day. Almost two thirds of the respondents consumed >30% of their daily calories from fat and >10% of total calories from saturated fat: Mexican Americans and individuals over the age of 65 years ate a higher number of fruits and vegetables and a lower percentage of total calories from fat. Lower income and increasing age were associated with physical inactivity. Thirty-six percent of the sample were overweight an another 46% were obese. CONCLUSIONS- The majority of individuals with type 2 diabetes were overweight, did pot engage in recommended levels of physical activity, and did not follow dietary guidelines for fat and fruit and vegetable consumption. Additional measures are needed to encourage regular physical activity and improve dietary habits in this population. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA 98108 USA. Univ Washington, Dept Epidemiol & Hlth Serv, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Serv, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Nelson, KM (reprint author), VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, 1660 S Columbian Way,S-111-GIMC, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X NR 45 TC 193 Z9 205 U1 5 U2 13 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2002 VL 25 IS 10 BP 1722 EP 1728 DI 10.2337/diacare.25.10.1722 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 724UF UT WOS:000185504500009 PM 12351468 ER PT J AU Boyko, EJ Fihn, SD Scholes, D Chen, CL Normand, EH Yarbro, P AF Boyko, EJ Fihn, SD Scholes, D Chen, CL Normand, EH Yarbro, P TI Diabetes and the risk of acute urinary tract infection among postmenopausal women SO DIABETES CARE LA English DT Article ID ASYMPTOMATIC BACTERIURIA; MELLITUS; PREVALENCE; DIAGNOSIS; NIDDM AB OBJECTIVE - To examine whether the presence of diabetes alters the risk of acute urinary tract infection (UTI) in postmenopausal women. RESEARCH DESIGN AND METHODS - A case-control study of the Group Health Cooperative of Puget Sound (GHC), a staff-model nonprofit health maintenance organization in Washington State, was conducted. Subjects were women aged 55-75 years who had been members of GHC for at least 1 year and who had had an acute symptomatic UTI within the preceding month. Laboratory files were used to identify women with a urine culture that grew greater than or equal to 10(5) colonies of a urinary pathogen. Medical records were reviewed to confirm the presence of acute, clinically symptomatic UTI. Control subjects were randomly selected from the GHC enrollment file, screened to remove women with recent UTI, and frequency matched to cases by age within 2 years. An interviewer ascertained self-reported clinician-diagnosed diabetes. Diagnosis of diabetes was confirmed by the GHC diabetes registry. A subsample of women underwent measurement of postvoid residual bladder volume (n = 748) and culture of vaginal flora (n = 454). RESULTS- Of the 901 case and 913 control subjects; diabetes was reported in 13.1 and 6.8%, respectively. The health plan diabetes registry confirmed the diagnosis in 92% of women who self-reported the condition. The age-adjusted odds ratio (OR) for UTI in relation to self-reported clinician-diagnosed diabetes was 2.2 (95% CI 1.6=3.0). Adjustment for frequency of sexual intercourse and history of UTI had little effect on this estimate. Compared with nondiabetic women, higher UTI odds were seen in subjects who used oral hypoglycemic agents (OR 2.9 [95% CI 1.7-5.1]) and insulin (2.6 [1.5-4.6]) but not,in subjects with untreated diabetes or diabetes treated by lifestyle changes.(1.3 [0.7-2.3]). No significant difference was seen in the OR for UTI in diabetic women with disease of shorter duration (<10 years, OR 1.9) or longer duration (>=10 years, OR 2.6) or in relation to HbA(1c) level. Similar microbiologic pathogens were seen in diabetic and nondiabetic women. No significant differences were seen by diabetes status in mean postvoid residual bladder volume or vaginal flora. CONCLUSIONS- Diabetes under pharmacologic treatment is associated with increased risk of clinically apparent UTI in postmenopausal women. C1 Seattle ERIC, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound, NW Hlth Serv Res & Dev Program, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. RP Boyko, EJ (reprint author), Seattle ERIC, VA Puget Sound 152E,1660 S Columbian Way, Seattle, WA 98108 USA. OI Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [R01-DK-43134] NR 27 TC 75 Z9 78 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2002 VL 25 IS 10 BP 1778 EP 1783 DI 10.2337/diacare.25.10.1778 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 724UF UT WOS:000185504500018 PM 12351477 ER PT J AU Taborsky, GJ Ahren, B Mundinger, TO Mei, Q Havel, PJ AF Taborsky, GJ Ahren, B Mundinger, TO Mei, Q Havel, PJ TI Autonomic mechanism and defects in the glucagon response to insulin-induced hypoglycaemia SO DIABETES NUTRITION & METABOLISM LA English DT Article; Proceedings Paper CT Symposium on Hypoglycaemia 2001 - From Research to Practice CY MAY 26-29, 2001 CL ASSISI, ITALY DE sympathetic; type 1 diabetes; parasympathetic ID PANCREATIC-POLYPEPTIDE; INDUCED HYPOGLYCEMIA; SYMPATHETIC-NERVES; SECRETION; STIMULATION; CELL; ACTIVATION; RELEASE; RATS C1 Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Lund Univ, Dept Med, Lund, Sweden. Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. RP Taborsky, GJ (reprint author), VA Puget Sound Hlth Care Syst, MS 151,Bldg 1,Room 501,1660 Columbian Way S, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK-50154, DK-12829, DK-12047] NR 27 TC 18 Z9 18 U1 0 U2 1 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 0394-3402 J9 DIABETES NUTR METAB JI Diabetes Nutr. Metab. PD OCT PY 2002 VL 15 IS 5 BP 318 EP 322 PG 5 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 645QZ UT WOS:000180991000023 PM 12625478 ER PT J AU Eisenberg, JNS Wade, TJ Hubbard, A Abrams, DI Leiser, RJ Charles, S Vu, M Saha, S Wright, CC Levy, DA Jensen, P Colford, JM AF Eisenberg, JNS Wade, TJ Hubbard, A Abrams, DI Leiser, RJ Charles, S Vu, M Saha, S Wright, CC Levy, DA Jensen, P Colford, JM TI Associations between water-treatment methods and diarrhoea in HIV-positive individuals SO EPIDEMIOLOGY AND INFECTION LA English DT Article ID DRINKING-WATER; CRYPTOSPORIDIUM INFECTION; RISK; CONSUMPTION; OUTBREAK AB This manuscript extends our previously published work (based on data from one clinic) on the association between three drinking water-treatment modalities (boiling, filtering, and bottling) and diarrhoeal disease in HIV-positive persons by incorporating data from two additional clinics collected in the following year. We conducted a cross-sectional survey of drinking water patterns, medication usage, and episodes of diarrhoea among HIV-positive persons attending clinics associated with the San Francisco Community Consortium. We present combined results from our previously published work in one clinic (n = 226) with data from these two additional clinics (n = 458). In this combined analysis we employed logistic regression and marginal structural modelling of the data. The relative risk of diarrhoea for 'always' vs. 'never' drinking boiled water was 0.68 (95% CI 0.45-1.04) and for 'always' vs. 'never' drinking bottled water was 1.22 (95 % CI 0.82-1.82). Drinking filtered water was unrelated to diarrhoea [1.03 (95 % CI 0.78, 1.35) for 'always' vs. 'never' drinking filtered water]. Adjustment for confounding did not have any notable effect on the point estimates (0.61, 1.35 and 0.98 for boiled, bottled, and filtered water respectively, as defined above). The risk of diarrhoea was lower among those consuming boiled water but this finding was not statistically significant. Because of these findings, the importance of diarrhoea in immunocompromised individuals, and the limitations of cross-sectional data further prospective investigations of water consumption and diarrhoea among HIV-positive individuals are needed. C1 Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. Univ Calif San Francisco, Community Consortium, San Francisco, CA 94143 USA. San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Parasit Dis, Atlanta, GA USA. RP Eisenberg, JNS (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 140 Warren Hall,MC 7360, Berkeley, CA 94720 USA. FU ODCDC CDC HHS [UR2/CCU916252-02] NR 17 TC 4 Z9 4 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2002 VL 129 IS 2 BP 315 EP 323 DI 10.1017/S0950268802007422 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 608YW UT WOS:000178876800010 PM 12405100 ER PT J AU Hu, J Fink, D Mata, M AF Hu, J Fink, D Mata, M TI Microarray analysis suggests the involvement of proteasomes, lysosomes, and matrix metalloproteinases in the response of motor neurons to root avulsion SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE apoptosis; degeneration; rat; regeneration ID SPINAL-CORD INJURY; SCIATIC-NERVE TRANSECTION; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; CYCLIN D1; INDEPENDENT APOPTOSIS; MESSENGER-RNA; EXPRESSION; INDUCTION; RECEPTOR AB We used microarray analysis of RNA expression from punch samples from ventral horn of spinal cord to identify alterations in gene expression in motor neurons 3 days after proximal spinal root avulsion, a traumatic injury that results in the death of 80% of the motor neurons. This analysis identified the anticipated increases in expression of genes coding for proteins involved in the apoptosis cascades and abortive cell cycle re-entry, as well as decreases in expression of genes coding for proteins related to neuronal functional activity, including groups of genes related to energy metabolism, transporter proteins, ion channels, and receptors. It was also found that cathepsins, metalloproteinases, and proteasome-related protein products were highly upregulated in motor neurons following axotomy. Each of these products represent pathways that have been implicated in other models of neuronal damage, but which have not previously been described as a response to axotomy. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA. GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Mata, M (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-520 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. NR 45 TC 23 Z9 25 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD OCT PY 2002 VL 16 IS 8 BP 1409 EP 1416 DI 10.1046/j.1460-9568.2002.02218.x PG 8 WC Neurosciences SC Neurosciences & Neurology GA 609UL UT WOS:000178922900001 PM 12405953 ER PT J AU Baldus, S Eiserich, JP Brennan, ML Jackson, RM Alexander, CB Freeman, BA AF Baldus, S Eiserich, JP Brennan, ML Jackson, RM Alexander, CB Freeman, BA TI Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE myeloperoxidase; peroxynitrite; nitric oxide; nitrotyrosine; free radical; inflammation ID NITRIC-OXIDE PRODUCTION; ALVEOLAR MACROPHAGES; HYDROGEN-PEROXIDE; HYPERTENSIVE RATS; REACTIVE OXYGEN; PEROXYNITRITE; PROTEINS; ATHEROSCLEROSIS; BRONCHIOLITIS; DEGRANULATION AB Nitrotyrosine (NO(2)Tyr) formation is a hallmark of acute and chronic inflammation and has been detected in a wide variety of human pathologies. However, the mechanisms responsible for this posttranslational protein modification remain elusive. While NO(2)Tyr has been considered a marker of peroxynitrite (ONOO-) formation previously, there is growing evidence that heme-protein peroxidase activity, in particular neutrophil-derived myeloperoxidase (MPO), significantly contributes to NO(2)Tyr formation in vivo via the oxidation of nitrite (NO2-) to nitrogen dioxide ((NO2)-N-.). Coronary arteries from a patient with coronary artery disease, liver and lung tissues from a sickle cell disease patient, and an open lung biopsy from a lung transplant patient undergoing rejection were analyzed immunohistochemically to map relative tissue distributions of MPO and NO(2)Tyr. MPO immunodistribution was concentrated along the subendothelium in coronary tissue and hepatic veins as well as in the alveolar epithelial compartment of lung tissue from patients with sickle cell disease or acute rejection. MPO immunoreactivity strongly colocalized with NO(2)Tyr formation, which was similarly distributed in the subendothelial and epithelial regions of these tissues. The extracellular matrix protein fibronectin (FN), previously identified as a primary site of MPO association in vascular inflammatory reactions, proved to be a major target protein for tyrosine nitration, with a strong colocalization of MPO, NO(2)Tyr, and tissue FN occurring. Finally, lung tissue from MPO-/- mice, having tissue inflammatory responses Stimulated by intraperitoneal zymosan administration, revealed less subendothelial NO(2)Tyr immunoreactivity than tissue from wild-type mice, confirming the significant role that MPO plays in catalyzing tissue nitration reactions. These observations reveal that (i) sequestration of neutrophil-derived MPO in vascular endothelial and alveolar epithelial compartments is an important aspect of MPO distribution and action in vivo, (ii) MPO-catalyzed NO(2)Tyr formation occurs in diverse vascular and pulmonary inflammatory pathologies, and (iii) extracellular matrix FN is an important target of tyrosine nitration in these inflammatory processes. (C) 2002 Elsevier Science Inc. C1 Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA. Univ Alabama, Dept Pulm Allergy & Crit Care Med, Birmingham, AL 35233 USA. Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA. Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA. Birmingham VAMC, Birmingham, AL USA. Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35233 USA. Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA. Univ Hamburg, Hosp Eppendorf, Dept Cardiol, D-20246 Hamburg, Germany. RP Freeman, BA (reprint author), Univ Alabama, Dept Anesthesiol, 946 Tinsley Harrison Tower,619 19th St S, Birmingham, AL 35233 USA. RI Freeman, Bruce/H-9342-2012 NR 43 TC 116 Z9 119 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD OCT 1 PY 2002 VL 33 IS 7 BP 1010 EP 1019 DI 10.1016/S0891-5849(02)00993-0 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 598NN UT WOS:000178282700012 PM 12361810 ER PT J AU Schneider, A Suman, A Rossi, L Barmada, MM Beglinger, C Parvin, S Sattar, S Ali, L Khan, AKA Gyr, N Whitcomb, DC AF Schneider, A Suman, A Rossi, L Barmada, MM Beglinger, C Parvin, S Sattar, S Ali, L Khan, AKA Gyr, N Whitcomb, DC TI SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh SO GASTROENTEROLOGY LA English DT Article ID SECRETORY TRYPSIN-INHIBITOR; GENOME SCAN; GENE; HEREDITARY AB Background & Aims: Tropical pancreatitis, including tropical calcific pancreatitis and fibrocalculous pancreatic diabetes, is endemic in parts of Asia and Africa. In a preliminary study, we found serine protease inhibitor, Kazal type 1 (SPINK1) mutations in 6 of 8 patients with fibrocalculous pancreatic diabetes in Bangladesh. A more extensive investigation of patients with pancreatic diseases in Bangladesh, including non-insulin-dependent diabetes mellitus, was undertaken. Methods: Patients with fibrocalculous pancreatic diabetes (n = 22), tropical calcific pancreatitis (n = 15), and non-insulin-dependent diabetes mellitus (n = 43) and controls (n = 76) from Bangladesh were studied. DNA was extracted, and the SPINK1 gene was sequenced in all patients and 50 controls. Exon 3 was sequenced in an additional 26 controls. Results: SPINK1 N34S mutations appeared in 1 of 76 controls (13%), 12 of 22 patients with fibrocalculous pancreatic diabetes (55%; odds ratio, 83; P < 0.00001), 3 of :15 with tropical calcific pancreatitis (20%; odds ratio, 11.2; P = 0.04), and 6 of 43 with non-insulin-dependent diabetes mellitus (14%; odds ratio, 11.9; P = 0.009). P55S was present in 2 of 76 controls (3%) and in I of 22 patients with fibrocalculous pancreatic diabetes (5%; P = not significant). A novel Y54H (160T>C) mutation was identified in 1 of 15 tropical calcific pancreatitis patients. Conclusions: In Bangladesh, the SPINK1 N34S mutation increases the risk of several forms of pancreatic disease, including fibrocalculous pancreatic diabetes, tropical calcific pancreatitis, and non-insulin-dependent diabetes mellitus. C1 Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA. Kantonsspital, Dept Gastroenterol, Luzern, Switzerland. Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. Univ Basel Hosp, Dept Med, CH-4031 Basel, Switzerland. Bangladesh Inst Res & Rehabil Diabet Endocrine &, Dhaka, Bangladesh. Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Suman, A (reprint author), Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Room 571,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. RI Beglinger, Christoph/D-2247-2010 OI Barmada, M Michael/0000-0002-3604-6460 FU NIDDK NIH HHS [DK54709] NR 33 TC 91 Z9 92 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2002 VL 123 IS 4 BP 1026 EP 1030 DI 10.1053/gast.2002.36059 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 600WY UT WOS:000178415800014 PM 12360464 ER PT J AU Faigel, DO Hunt, GC Gopal, D AF Faigel, DO Hunt, GC Gopal, D TI Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and follow-up of esophageal cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT 13th International Symposium on Endoscopic Ultrasonography CY OCT 04-06, 2002 CL NEW YORK, NEW YORK C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD OCT PY 2002 VL 56 IS 4 SU S MA 36 BP S109 EP S109 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 600WP UT WOS:000178415000057 ER PT J AU Harley, JB AF Harley, JB TI The genetic etiology of systemic lupus erythematosus: a short dispatch from the combat zone SO GENES AND IMMUNITY LA English DT Editorial Material DE SLE; lupus; genetics; review; linkage ID SUSCEPTIBILITY LOCUS; AUTOIMMUNITY; LINKAGE C1 Univ Oklahoma, Oklahoma Med Res Fdn, Med Ctr, US Dept Vet Affairs,Dept Med, Oklahoma City, OK 73104 USA. RP Harley, JB (reprint author), Univ Oklahoma, Oklahoma Med Res Fdn, Med Ctr, US Dept Vet Affairs,Dept Med, 825 NE 13th St, Oklahoma City, OK 73104 USA. NR 31 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S1 EP S4 DI 10.1038/sj.gene.6363908 PG 4 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300001 PM 12215895 ER PT J AU Kelly, JA Moser, KL Harley, JB AF Kelly, JA Moser, KL Harley, JB TI The genetics of systemic lupus erythematosus: putting the pieces together SO GENES AND IMMUNITY LA English DT Article; Proceedings Paper CT Lupus Genetics Conference CY SEP 07-09, 2001 CL OKLAHOMA CITY, OKLAHOMA SP Oklahoma Med Res Fdn, Amgen Corp DE genetics; systemic lupus erythematosus; genome scan; linkage ID MAJOR HISTOCOMPATIBILITY COMPLEX; MANNOSE-BINDING-PROTEIN; FC-RECEPTOR-III; GAMMA-RIIA POLYMORPHISM; NECROSIS-FACTOR-ALPHA; NATURAL-KILLER CELLS; SIB-PAIR FAMILIES; LYMPHOPROLIFERATIVE DISEASE; SUSCEPTIBILITY LOCUS; AUTOIMMUNE-DISEASE AB With A,, estimates of 10 to 20 and other evidence of familial aggregation, as well as a monozygotic twin concordance rate >20, systemic lupus erythematosus (SLE) would appear to be a very promising phenotype using modem genetic approaches. Indeed, genetic associations are already known at numerous candidate loci including various HLA alleles, complement component genes, Fcgamma receptors, and others, and murine genetic studies of lupus models have provided additional candidate genes and potential syntenic linkages to evaluate in man. The completed genetic linkage studies performed on various collections of pedigrees multiplex for SLE have identified 60 susceptibility loci with varying degrees of evidence for linkage in man. Seven of these meet or exceed the threshold for significant linkage (LOD greater than or equal to 3.3 or P less than or equal to 0.00005) at 1q22-23, 1q41, 2q37, 4p16, 6p21-11, 16q13 and 17p13. In addition, these linkages usually dominate in one ethnicity or another, suggesting that the responsible polymorphisms, once identified, will also vary by ethnicity. Evidence that these linkages can be reproduced range from outright independent confirmation (1q41, 4p16 and 6p21) to additional suggestive evidence in the genomic region of the purported linkage (1q22-23 and 2q37). The results now available suggest that human lupus genetics are robust and that gene identification should be possible using existing genetic approaches and technologies. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NCRR NIH HHS [RR03655]; NHGRI NIH HHS [HG01577]; NIAID NIH HHS [AI31585, AI24717]; NIAMS NIH HHS [AR42460, AR45231] NR 145 TC 70 Z9 73 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S71 EP S85 DI 10.1038/sj.gene.6363885 PG 15 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300013 PM 12215907 ER PT J AU Namjou, B Nath, SK Kilpatrick, J Kelly, JA Reid, J Reichlin, M James, JA Harley, JB AF Namjou, B Nath, SK Kilpatrick, J Kelly, JA Reid, J Reichlin, M James, JA Harley, JB TI Genome scan stratified by the presence of anti-double-stranded DNA (dsDNA) autoantibody in pedigrees multiplex for systemic lupus erythematosus (SLE) establishes linkages at 19p13.2 (SLED1)and 18q21.1 (SLED2) SO GENES AND IMMUNITY LA English DT Article; Proceedings Paper CT Lupus Genetics Conference CY SEP 07-09, 2001 CL OKLAHOMA CITY, OKLAHOMA SP Oklahoma Med Res Fdn, Amgen Corp DE SLE; linkage analysis; anti-double stranded DNA; Crithidia luciliae ID DEOXYRIBONUCLEASE-II; ANTIBODIES; NEPHRITIS; IMMUNOFLUORESCENCE; CALRETICULIN; ASSOCIATION; DIAGNOSIS; FAMILIES; HOMOLOGS; DISEASE AB Anti-double-stranded DNA (anti-dsDNA) is arguably one of the most specific autoantibodies in systemic lupus erythematosus (SLE). This antibody is associated with more severe SLE and with glomerulonephritis. From 196 pedigrees multiplex for SLE, we selected those that had any SLE affected positive for anti-dsDNA by the Crithidia luciliae kinetoplast imunofluorescence assay. This stratification strategy tested the hypothesis that anti-dsDNA would identify a more genetically homogeneous group of pedigrees, in which previously undetected linkage effects could be established. A genome screen data for linkage to SLE was available at 307 microsatellite markers for this selected group of 71 pedigrees: 37 European-American, 29 African-American, and five others. The most significant results were obtained at 19p13.2 (LODEmax = 4.93), named SLED1, in the 37 European-American pedigrees using a dominant model with mixed penetrances (92% for females and 49% for males) at 100% homogeneity (theta = 0). A second linkage effect, SLED2, was established in the 29 African-American pedigrees at 18q21.1 (LODmax = 3.40) using a recessive model with 100% penetrance (theta = 0.1). Parametric and non-parametric multipoint analyses were performed, which provided further evidence and support of susceptibility genes residing in these regions. In conclusion, two powerful linkages have been detected with SLE based on the presence of anti-dsDNA. These findings show SLE to be a richly complicated disease phenotype that is now ripe for important new discovery through a genetic approach. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, JB (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NCRR NIH HHS [RR15577]; NIAID NIH HHS [AI24717, AI31584]; NIAMS NIH HHS [AR45231, AR42460, AR12253] NR 43 TC 22 Z9 23 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S35 EP S41 DI 10.1038/sj.gene.6363905 PG 7 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300006 PM 12215900 ER PT J AU Olson, JM Song, Y Dudek, DM Moser, KL Kelly, JA Bruner, GR Downing, KJ Berry, CK James, JA Harley, JB AF Olson, JM Song, Y Dudek, DM Moser, KL Kelly, JA Bruner, GR Downing, KJ Berry, CK James, JA Harley, JB TI A genome screen of systemic lupus erythematosus using affected-relative-pair linkage analysis with covariates demonstrates genetic heterogeneity SO GENES AND IMMUNITY LA English DT Article; Proceedings Paper CT Lupus Genetics Conference CY SEP 07-09, 2001 CL OKLAHOMA CITY, OKLAHOMA SP Oklahoma Med Res Fdn, Amgen Corp DE systemic lupus erythematosus; genetic linkage analysis; affected relative pairs ID SUSCEPTIBILITY LOCUS; REVISED CRITERIA; FAMILIES; SCAN; CLASSIFICATION; MANIFESTATIONS; PSORIASIS AB Systemic lupus erythematosus (SLE) appears to be the consequence of complex genetics and of only partly understood environmental contributions. Previous work by ourselves and by others has established genetic effects on 1q, 2q, 4p, 6p, and 16p using SLE as the phenotype. However, individual SLE affecteds are extraordinarily different from one another by clinical and laboratory measures. This variation may have a genetic basis; if so, it is advantageous to incorporate measures of between-family clinical variability as covariates in a genetic linkage analysis of affected relative pairs (ARPs) to allow for locus heterogeneity. This approach was applied to genome scan marker data from 160 pedigrees multiplex for SLE and containing 202 ARPs. Because the number of potential covariates was large, we used both ad hoc methods and formal principal components analysis to construct four composite covariates using the SLE classification criteria plus age of onset, ethnicity, and sex. Linkage analysis without covariates has detected evidence for linkage at 1q22-24, 2q37, 4p16, 12p12-11, and 17p13. Linkage analysis with these covariates uncovered linkage at 13p11, 17q11-25, and 20q12 and greatly improved evidence for linkage at 1q22-24, 2q37, 12p12-11, and 17p13. Follow-up analysis identified the original variables contributing to locus heterogeneity in each of these locations. In conclusion, allowing for locus heterogeneity through the incorporation of covariates in linkage analysis is a useful way to dissect the genetic contributions to SLE and uncover new genetic effects. C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA. Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA. Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Olson, JM (reprint author), Case Western Reserve Univ, Dept Epidemiol & Biostat, Rammelkamp Ctr Educ & Res, 2500 MetroHlth Dr,R258,MetroHlth Campus, Cleveland, OH 44109 USA. FU NCRR NIH HHS [RR15577, RR03655]; NHGRI NIH HHS [HG01577]; NIAID NIH HHS [AI31584, AI24717]; NIAMS NIH HHS [AR42460, AR45231, AR52221] NR 30 TC 23 Z9 23 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S5 EP S12 DI 10.1038/sj.gene.6363860 PG 8 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300002 PM 12215896 ER PT J AU Quintero-Del-Rio, AI Kelly, JA Kilpatrick, J James, JA Harley, JB AF Quintero-Del-Rio, AI Kelly, JA Kilpatrick, J James, JA Harley, JB TI The genetics of systemic lupus erythematosus stratified by renal disease: linkage at 10q22.3 (SLEN1), 2q34-35 (SLEN2), and 11p 15.6 (SLEN3) SO GENES AND IMMUNITY LA English DT Article; Proceedings Paper CT Lupus Genetics Conference CY SEP 07-09, 2001 CL OKLAHOMA CITY, OKLAHOMA SP Oklahoma Med Res Fdn, Amgen Corp DE proteinuria; cellular casts; lupus; ethnicity; linkage ID LYMPHOPROLIFERATIVE SYNDROME; AFRICAN-AMERICANS; GENOME SCAN; NEPHRITIS; AUTOANTIBODIES; EXPRESSION; FAMILIES AB Renal disease occurs in 40-75% of systemic lupus erythematosus (SLE) patients and significantly contributes to morbidity and mortality. We used two pedigree stratification strategies to explore the impact of the ACR renal criterion for SLE classification upon genetic linkage with SLE In both we used SLE as the phenotype. First, we evaluated genome scan data from >300 microsatellite markers in the 75 pedigrees that had at least one SLE affected with the SLE renal criterion. A maximum-likehood parametric model approach produced a maximum screening LOD score of 3.16 at 10q22.3 in the European-American (EA) pedigrees. The African-American (AA) pedigrees obtained a maximum screening LOD score of 2.58 at 11p15.6. A multipoint sib-pair regression analysis produced P = 0.0000008 in EA at 10q22.3 (SLEN1) and P = 0.000001 in AA at 2q34-35 (SLEN2). A second stratification strategy explored the renal criterion in 35 pedigrees with two or more SLE patients with renal disease and produced a LOD score of 3.34 at 11p 15.6 in AA (SLEN3). Sib-pair analysis in these 35 pedigrees revealed P = 0.00003 at 4q13.1 in EA, P = 0.00003 at 11p13 and 0.00007 at 3q23 in AA. Thus, multiple genetic linkages are related to the renal criterion in SLE. Of the significant genetic linkages with SLE described herein, those at 10q22.3 in the EA pedigrees (SLEN1) and at 2q34-35 in the AA pedigrees (SLEN2) have not been previously described. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Quintero-Del-Rio, AI (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NIAID NIH HHS [AI31584, AI42460]; NIAMS NIH HHS [AR52221, AR45231, AR24717, AR-1-2253] NR 30 TC 50 Z9 52 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S57 EP S62 DI 10.1038/sj.gene.6363901 PG 6 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300010 PM 12215904 ER PT J AU Sawalha, AH Namjou, B Nath, SK Kilpatrick, J Germundson, A Kelly, JA Hutchings, D James, J Harley, J AF Sawalha, AH Namjou, B Nath, SK Kilpatrick, J Germundson, A Kelly, JA Hutchings, D James, J Harley, J TI Genetic linkage of systemic lupus erythematosus with chromosome 11q14 (SLEH1) in African-American families stratified by a nucleolar antinuclear antibody pattern SO GENES AND IMMUNITY LA English DT Article; Proceedings Paper CT Lupus Genetics Conference CY SEP 07-09, 2001 CL OKLAHOMA CITY, OKLAHOMA SP Oklahoma Med Res Fdn, Amgen Corp DE SLE; genetics; antinucleolar pattern; linkage analysis ID SIB-PAIR FAMILIES; SUSCEPTIBILITY GENES; GENOME SCAN; MODELS AB Systemic lupus erythematosus (SLE) is an autoimmune disease with complex genetics. We evaluated pedigrees multiplex for SLE that had an affected with antinucleolar antibodies to increase the homogeneity for genetic linkage analysis. We found a significant linkage effect on chromosome 11q14 at marker D11S2002 in African-American Pedigrees. This effect produced a maximum LOD score of 5.62 using a dominant inheritance model with 95% penetrance in males and 99% penetrance in females. The results were supported by multipoint linkage analysis. Fine mapping of the region with two additional markers within 6 cM of D11S2002 further provided evidence of linkage in this region. Linkage at D11S2002, named SLEW, was previously found in some of these same African-American pedigrees multiplex for SLE, but who were stratified by hemolytic anemia (Kelly et al, submitted).(1) In conclusion, an important SLE susceptibility gene, SLEH1 at 11q14, is identified in African-Americans when stratifying pedigrees by antinucleolar autoantibodies. C1 Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Med, Norman, OK 73019 USA. Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Harley, J (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NCRR NIH HHS [RR03655]; NHGRI NIH HHS [HG01577]; NIAID NIH HHS [AI31584, AI45231, AI24717]; NIAMS NIH HHS [AR12253, AR42460] NR 23 TC 15 Z9 15 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD OCT PY 2002 VL 3 SU 1 BP S31 EP S34 DI 10.1038/sj.gene.6363904 PG 4 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 601BB UT WOS:000178425300005 PM 12215899 ER PT J AU Burton, L Leff, B Clark, B Guido, S Greenough, W Burton, J Steinwachs, D Burl, J Naughton, B Mader, S Donius, M Saltzman, S Delano, C AF Burton, L Leff, B Clark, B Guido, S Greenough, W Burton, J Steinwachs, D Burl, J Naughton, B Mader, S Donius, M Saltzman, S Delano, C TI Comparison of caregiver stress between caregivers of patients treated in hospital or a home hospital SO GERONTOLOGIST LA English DT Meeting Abstract C1 Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Johns Hopkins Bayview Med Ctr, Baltimore, MD USA. Johns Hopkins Sch Med, Baltimore, MD USA. Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. Buffalo Gen Hosp, Buffalo, NY 14203 USA. Fallon Healthcare, Worcester, MA USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 13 EP 14 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400053 ER PT J AU Whitmer, R Haan, M Jagust, W AF Whitmer, R Haan, M Jagust, W TI Does hormone replacement therapy modify the effect of homocysteine on cognitive decline? SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Ctr, GRECC, Sepulveda, CA 91343 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 33 EP 33 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400121 ER PT J AU Valcour, V Goodkin, K Shiramizu, B Shikuma, C Asthana, D Shapshak, P Concha, M Wilkie, F Khamis, I Lee, D Ardila, A Lecusay, R Suarez, P Rigg, D Zheng, W O'Mellan, S Neundorfer, M Camp, C Lee, M Malone, M Carr, J Skrajner, M Justice, A McGinnis, K Wagner, J Conigliaro, J Rabeneck, L Stoff, D Linsk, N AF Valcour, V Goodkin, K Shiramizu, B Shikuma, C Asthana, D Shapshak, P Concha, M Wilkie, F Khamis, I Lee, D Ardila, A Lecusay, R Suarez, P Rigg, D Zheng, W O'Mellan, S Neundorfer, M Camp, C Lee, M Malone, M Carr, J Skrajner, M Justice, A McGinnis, K Wagner, J Conigliaro, J Rabeneck, L Stoff, D Linsk, N TI Aging, HIV-1 infection and neurocognitive function: Clinical correlates SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Hawaii, Sch Med, Honolulu, HI 96816 USA. Univ Miami, Sch Med, Miami, FL 33136 USA. Myers Res Inst, Beachwood, OH USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Ctr Mental Hlth Res, Bethesda, MD USA. Univ Illinois, Chicago, IL USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 81 EP 82 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400279 ER PT J AU Baumgarten, M Margolis, D Lowe, R Localio, R Kagan, S Kavesh, W Kinosian, B Abbuhl, S Holmes, J AF Baumgarten, M Margolis, D Lowe, R Localio, R Kagan, S Kavesh, W Kinosian, B Abbuhl, S Holmes, J TI Extrinsic risk factors for pressure ulcers in elderly hospital patients SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Maryland, Baltimore, MD 21201 USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Emergency Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 153 EP 154 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400541 ER PT J AU Teri, L Hedrick, S Tornatore, J Logsdon, R McCurry, S Kane, R AF Teri, L Hedrick, S Tornatore, J Logsdon, R McCurry, S Kane, R TI Dementia patients in assisted living facilities: Innovations on clinical care and research SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, NW Res Grp Aging, Seattle, WA 98115 USA. Screen Inc, Seattle, WA USA. Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 159 EP 160 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400561 ER PT J AU Murray, E Rubenstein, L Perry, H Murray, S Fink, H AF Murray, E Rubenstein, L Perry, H Murray, S Fink, H TI VA GRECC symposium: Osteoporosis and falls prevention: New developments SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Ctr, GRECC 11E, Sepulveda, CA 91343 USA. Vet Adm Med Ctr, St Louis, MO USA. Minneapolis GRECC, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 187 EP 188 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400669 ER PT J AU Aiken, J Joseph, J Van Remmen, H Cadenas, E AF Aiken, J Joseph, J Van Remmen, H Cadenas, E TI Oxidative stress and aging SO GERONTOLOGIST LA English DT Meeting Abstract C1 Univ Wisconsin, Madison, WI 53706 USA. Tufts Univ, USDA,HNRCA, Boston, MA USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. Univ Wisconsin, Madison, WI USA. Univ So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 204 EP 204 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400724 ER PT J AU Rodriguez, K Young, A Granieri, E AF Rodriguez, K Young, A Granieri, E TI Patient and provider understanding of the VA advance directive: A matched pair, mixed methods analysis SO GERONTOLOGIST LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 225 EP 225 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541400794 ER PT J AU Braun, U Beyth, R AF Braun, U Beyth, R TI Racial disparities in tube feeding practices for patients with dementia SO GERONTOLOGIST LA English DT Meeting Abstract C1 Baylor Coll Med, Houston VAMC, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 300 EP 300 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541401071 ER PT J AU Talerico, K Miller, L Harvath, T Ganzini, L Ersek, M Norton, S Quinn, J Baggs, J Catwright, J Tilden, V AF Talerico, K Miller, L Harvath, T Ganzini, L Ersek, M Norton, S Quinn, J Baggs, J Catwright, J Tilden, V TI Issues and challenges in end-of-life care SO GERONTOLOGIST LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Swedish Med Ctr, Seattle, WA USA. Univ Rochester, Sch Nursing, Rochester, NY 14627 USA. Oregon Hlth Sci Univ, Son Ashland, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 329 EP 329 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541401160 ER PT J AU Rubenstein, L Cole, G Schellenberg, G Kraemer, B Poorkaj, P Turner, R Griffin, S Frautschy, S Morley, J Asthana, S AF Rubenstein, L Cole, G Schellenberg, G Kraemer, B Poorkaj, P Turner, R Griffin, S Frautschy, S Morley, J Asthana, S TI VA GRECC symposium: From molecular biology and animal models to future treatments for Alzheimer's disease SO GERONTOLOGIST LA English DT Meeting Abstract C1 Vet Affairs Greater Los Angeles GRECC, Sepulveda, CA 91343 USA. VA Greater Los Angeles Healthcare Ctr, GRECC, Sepulveda, CA 91343 USA. Seattle VA Med Ctr, Seattle, WA USA. Vet Affairs Med Ctr, GRECC, Seattle, WA USA. Ann Arbor VA Med Ctr, Ann Arbor, MI USA. Little Rock VA Med Ctr, Little Rock, AR USA. VAGLA, GRECC, North Hills, CA USA. VAGLA, Dept Med, North Hills, CA USA. VAMC, GRECC, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 402 EP 402 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541401423 ER PT J AU Harvath, T Caley, J Wanlass, W Ralls, W Schulling, J AF Harvath, T Caley, J Wanlass, W Ralls, W Schulling, J TI The nursing home resident with a history of pedophilia: Issues and challenges SO GERONTOLOGIST LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Sch Nursing, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2002 VL 42 SI 1 BP 411 EP 411 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 620PH UT WOS:000179541401448 ER PT J AU Kanwal, F Kilbourne, A Hays, RD Gralnek, IM AF Kanwal, F Kilbourne, A Hays, RD Gralnek, IM TI Does model for end-stage liver disease (MELD) predict health related quality of life (HRQOL) in patients with advanced, chronic liver disease?. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Calif Los Angeles, Sch Med,VA Greater Los Angeles Hlth Care Syst, CURE Digest Dis Res, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. RI Hays, Ronald/D-5629-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 87 BP 188A EP 188A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700087 ER PT J AU Merriman, N Brensinger, C Reddy, KR Chang, KM AF Merriman, N Brensinger, C Reddy, KR Chang, KM TI Increased morbidity and mortality with HCV/HIV coinfection relative to HCV or HIV monoinfection among US veterans. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 409 BP 265A EP 265A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700391 ER PT J AU Ikeda, F Sugimoto, K Standanlick, J Valiga, M Dhopesh, V Weinrieb, R Chang, KM AF Ikeda, F Sugimoto, K Standanlick, J Valiga, M Dhopesh, V Weinrieb, R Chang, KM TI Influence of alcohol and HIV coinfection on HCV-specific CD4 T cell response. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philidelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 431 BP 271A EP 271A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700417 ER PT J AU Sugimoto, K Ikeda, F Stadanlick, J Valiga, M Chang, KM AF Sugimoto, K Ikeda, F Stadanlick, J Valiga, M Chang, KM TI CD4 and CD8 T cell response to the entire HCV core and NS3-NS5 antigens in HCV persistence and clearance. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 443 BP 274A EP 274A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700426 ER PT J AU Xu, YQ Leo, MA Lieber, CS AF Xu, YQ Leo, MA Lieber, CS TI Lycopene attenuates arachidonic acid-induced toxicity in Hepg2 cells transfected with CYPE21. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Bronx Vet Adm Med Ctr, Sect Liver dis & Nutr, Bronx, NY USA. Mt Sinai Sch Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 658 BP 327A EP 327A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700641 ER PT J AU Cao, Q Mak, KM Lieber, CS AF Cao, Q Mak, KM Lieber, CS TI Lipopolysaccharide signaling cascades mediate TNF-alpha overproduction in raw 264.7 macrophages transfected with cytochrome P4502E1 (CYP2E1). SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 666 BP 329A EP 329A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700649 ER PT J AU Arora, S Lau, D Gish, R Rossi, S Lin, CC Lau, JY Fang, JW AF Arora, S Lau, D Gish, R Rossi, S Lin, CC Lau, JY Fang, JW TI Phase I clinical studies of viramidine - A liver-targeting prodrug of ribavirin. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ New Mexico, Albuquerque, NM 87131 USA. Univ Texas, Med Branch, Galveston, TX 77550 USA. Calif Pacific Med Ctr, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. Ribapharm Inc, Costa Mesa, CA USA. NR 0 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 773 BP 356A EP 356A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700755 ER PT J AU Lieber, CS Weiss, DG Groszmann, R Paronetto, F Schenker, S Fye, CL Lowe, N Feinman, L Leo, MA Fimmel, CJ Lissoos, TW Anand, BS Morgan, TR Bloor, JH Simon, F Mendenhall, CL Linscheer, WG Iber, FL Schiff, ER Jeffers, L Gebhard, RL Bond, J Foust, RT Knapple, W Willner, I Tamburro, C Cecil, B Bay, M Marsano, L McClain, CJ Trotter, JF Muir, A Sninsky, CA Mishra, G Lumeng, L Born, LJ AF Lieber, CS Weiss, DG Groszmann, R Paronetto, F Schenker, S Fye, CL Lowe, N Feinman, L Leo, MA Fimmel, CJ Lissoos, TW Anand, BS Morgan, TR Bloor, JH Simon, F Mendenhall, CL Linscheer, WG Iber, FL Schiff, ER Jeffers, L Gebhard, RL Bond, J Foust, RT Knapple, W Willner, I Tamburro, C Cecil, B Bay, M Marsano, L McClain, CJ Trotter, JF Muir, A Sninsky, CA Mishra, G Lumeng, L Born, LJ TI Effect of moderation of ethanol consumption combined with PPC administration on liver injury in alcoholics: Prospective, randomized, placebo-controlled, multicenter va trial (CSP 391). SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Perry Point VA Med Ctr, Perry Point, MD USA. W Haven VA Med Ctr, West Haven, CT USA. San Antonio VA Med Ctr, San Antonio, TX USA. Albuquerque VA Med Ctr, Albuquerque, NM USA. St Louis VA Med Ctr, St Louis, MO USA. Houston VA Med Ctr, Houston, TX USA. Long Beach VA Med Ctr, Long Beach, CA USA. Denver VA Med Ctr, Denver, CO USA. Cincinatii VA Med Ctr, Cincinnati, OH USA. Syracuse VA Med Ctr, Syracuse, NY USA. Hines VA Med Ctr, Hines, IL USA. Miami VA Med Ctr, Miami, FL USA. Minneapolis VA Med Ctr, Minneapolis, MN USA. Charleston VA Med Ctr, Charleston, SC USA. Louisville VA Med Ctr, Louisville, KY USA. San Antonio VA Med Ctr, San Antonio, TX USA. Lexington VA Med Ctr, Lexington, KY USA. Durham VA Med Ctr, Durham, NC USA. Gainesville VA Med Ctr, Gainesville, FL USA. Indianapolis VA Med Ctr, Indianapolis, IN USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 874 BP 381A EP 381A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700856 ER PT J AU Piasecki, B Reddy, R Lewis, JD Brensinger, CM Stieritz, DD Chang, KM AF Piasecki, B Reddy, R Lewis, JD Brensinger, CM Stieritz, DD Chang, KM TI Heavy alcohol consumption and spontaneous clearance of hepatitis C virus infection. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 887 BP 385A EP 385A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301700869 ER PT J AU Karsan, HA Morton, SC Suttorp, MJ Shekelle, PG Edelstein, M Gralnek, IM AF Karsan, HA Morton, SC Suttorp, MJ Shekelle, PG Edelstein, M Gralnek, IM TI Combination endoscopic band ligation and sclerotherapy compared with band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: A meta-analysis. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. RAND Corp, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, CURS,Digest Dis Res Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1399 BP 513A EP 513A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701381 ER PT J AU Nieto, JM Saab, S AF Nieto, JM Saab, S TI Medical versus surgical and radiological treatment of refractory ascites: A meta-analysis of randomized controlled trials. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Dumont UCLA, Liver Transplant Program, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1465 BP 529A EP 529A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701446 ER PT J AU El-Serag, HB Rabeneck, L AF El-Serag, HB Rabeneck, L TI HCV coinfection increases the risk of clinically relevant liver disease in HIV-infected patients. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Houston VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1581 BP 558A EP 558A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701562 ER PT J AU Hu, KQ Cheung, R Rossi, S Bini, EJ Jeffers, L Wright, T AF Hu, KQ Cheung, R Rossi, S Bini, EJ Jeffers, L Wright, T TI Risk factors for hepatitis C virus (HCV) infection in US veterans: A large VA multicenter study. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Loma Linda VAMC, Loma Linda, CA USA. Palo Valto VAMC, Palo Alto, CA USA. San Francisco VAMC, San Francisco, CA USA. New York Harbor VAMC, New York, NY USA. Miami VAMC, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1595 BP 562A EP 562A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701577 ER PT J AU Anand, BS Mendenhall, CL Bini, EJ Wright, T Rossi, SJ Jeffers, L AF Anand, BS Mendenhall, CL Bini, EJ Wright, T Rossi, SJ Jeffers, L CA VA HVC 001 Study Grp TI Alcohol consumption decreases overtime in US veterans with HCV infection. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 VA Med Ctr, Houston, TX USA. VA Med Ctr, Cincinnati, OH USA. VA Med Ctr, New York, NY USA. VA Med Ctr, San Francisco, CA USA. VA Med Ctr, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1610 BP 565A EP 565A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701592 ER PT J AU Ruimy, SS Jazrawi, S Zucker, BL Sasaki, AW AF Ruimy, SS Jazrawi, S Zucker, BL Sasaki, AW TI Hepatitis C and veterans: An evaluation of patient education at the Portland, Oregon VA medical center SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1616 BP 567A EP 567A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701599 ER PT J AU Rodriquez-Torres, M Gonzalez-Garcia, J Mendes-Correa, M Katlama, C Nelson, M Cooper, D Staszewski, S Carosi, G Smaill, F Brau, N AF Rodriquez-Torres, M Gonzalez-Garcia, J Mendes-Correa, M Katlama, C Nelson, M Cooper, D Staszewski, S Carosi, G Smaill, F Brau, N TI Prevalence of occult hepatitis B in a large multinational trial of the treatment of HCV with peginterferon alfa 2a (40KD) (Pegasis (R)) in patients coinfected with HIV. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Fundac Gastroenterol Diego, Santurce, PR USA. Hop La Paz, Madrid, Spain. Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil. Grp Hosp Pitie Salpetriere, F-75634 Paris, France. Chelsea & Westminster Hosp, London, England. St Vincents Hosp, Sydney, NSW 2010, Australia. Klin III Infectionsambulanz, Frankfurt, Germany. Clin Infect & Trop Dis, Brescia, Italy. Chedoke McMaster Hosp, Hamilton, ON, Canada. Bronx Vet Adm Med Ctr, Bronx, NY USA. RI mendes correa, maria cassia /A-6779-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1659 BP 578A EP 578A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701641 ER PT J AU Schiffman, ML Goncales, FL Bronowicki, JP Fried, MW Wright, T Hadziyannis, SJ Brouwer, J Zeuzem, S Hoffmann, J AF Schiffman, ML Goncales, FL Bronowicki, JP Fried, MW Wright, T Hadziyannis, SJ Brouwer, J Zeuzem, S Hoffmann, J TI Hepatitis C virus genotype 2 and 3 infection: A curable disease?. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA. UNICAMP, Hosp Clin, Sao Paulo, Brazil. CHU Nancy, Nancy, France. Univ N Carolina, Chapel Hill, NC USA. San Francisco VA Med Ctr, San Francisco, CA USA. Henry Dunant Hosp, Athens, Greece. Univ Rotterdam, Rotterdam, Netherlands. Univ Saarlandes Kliniken, Frankfurt, Germany. Hoffmann La Roche Inc, Nutley, NJ 07110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1677 BP 582A EP 582A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701658 ER PT J AU Anand, BS Yoffe, B Tavakoli-Tabasi, S AF Anand, BS Yoffe, B Tavakoli-Tabasi, S TI Effect of previous hepatitis B infection on hepatitis C virus infection. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 VA Med Ctr, Digest Dis Sect, Houston, TX USA. VA Med Ctr, Infect Dis Sect, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1703 BP 589A EP 589A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701685 ER PT J AU Kulig, CC Martin, BK Bialkowski, DB Clapp, LK Goldberg, JL Mangum, LE Everson, GT Beresford, TP AF Kulig, CC Martin, BK Bialkowski, DB Clapp, LK Goldberg, JL Mangum, LE Everson, GT Beresford, TP TI Absence of liver injury in hepatitis C positive alcoholics prescribed disulfiram (Antabuse (R)) for up to one year, a pilot toxicity study. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1737 BP 597A EP 597A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701718 ER PT J AU Sulkowski, MS Rossi, SJ Arora, S Lamb, MW Modi, M AF Sulkowski, MS Rossi, SJ Arora, S Lamb, MW Modi, M TI Peginterferon alfa-2a (40KD) monotherapy induces early antiviral response in CHC patients on methadone maintenance therapy. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Johns Hopkins Univ, Baltimore, MD USA. San Francisco VA Med Ctr, San Francisco, CA USA. Univ New Mexico Albuquerque Hlth, Albuquerque, NM USA. Hoffmann La Roche Inc, Nutley, NJ 07110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1765 BP 604A EP 604A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701746 ER PT J AU Loftis, JM Thornton, AJ Schultz, RL Hill, JA Howell, CD Hauser, P AF Loftis, JM Thornton, AJ Schultz, RL Hill, JA Howell, CD Hauser, P TI Interferon-induced depression and end-of-treatment response rates in patients with hepatitis C. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Univ Maryland, Baltimore VA Med Ctr, Coll Med, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 1773 BP 606A EP 606A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301701754 ER PT J AU Nguyen, MH Wright, TL Garcia, RT Mahood, G Bacchetti, P Keeffe, EB AF Nguyen, MH Wright, TL Garcia, RT Mahood, G Bacchetti, P Keeffe, EB TI Effects of ethnicity on risk for hepatocelluiar carcinoma (HCC) in US patients with hepatitis C cirrhosis. SO HEPATOLOGY LA English DT Meeting Abstract CT 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 01-05, 2002 CL BOSTON, MASSACHUSETTS SP Amer Assoc Study Liver Dis C1 Stanford Univ, Palo Alto, CA 94304 USA. Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA. Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2002 VL 36 IS 4 SU S MA 2099 BP 688A EP 688A PN 2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598XK UT WOS:000178301702081 ER PT J AU Drinka, PJ Krause, P Nest, L Gravenstein, S Goodman, B Shult, P AF Drinka, PJ Krause, P Nest, L Gravenstein, S Goodman, B Shult, P TI Delays in the application of outbreak control prophylaxis for influenza A in a nursing home SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID OSELTAMIVIR; PREVENTION AB OBJECTIVE: To identify delayed prophylaxis from a preexisting database and strategies to improve performance. SETTING: A skilled nursing facility with 14 floors (4 buildings). The "outbreak unit" was a 50- to 60-bed floor. METHODS: We performed surveillance during six seasons using one protocol. Prophylaxis was started when influenza was cultured in the building and 10% of residents on the floor had a new respiratory illness within 7 days. We defined delayed prophylaxis as four or more residents on a floor with positive cultures whose specimens had been collected within 5 days before the application of prophylaxis. RESULTS: We identified 14 examples of delayed prophylaxis. In three, delayed prophylaxis was related to the 3.9-day delay between culture collection and culture report There was a high degree of commonality among building attack rates within a season. During six seasons, the first case in the last building occurred 27 to 64 days after the first case in the facility The two seasons with the greatest activity (68 and 154 cases, respectively) began with explosive, multi-floor outbreaks in a single building. The match between the circulating strain and the vaccine was good, except in 1997-1998 when there were seven examples of delayed prophylaxis. CONCLUSIONS: Influenza may involve buildings sequentially with a commonality of building attack rates. Explosive, multi-floor outbreaks early in the season could lead to a lower threshold for prophylaxis within a larger area when initial cases are encountered later in the season. This strategy could have prevented five examples of delayed prophylaxis. Rapid testing of multiple specimens while waiting for culture confirmation could have prevented three examples of delayed prophylaxis. C1 Wisconsin Vet Home, King, WI 54946 USA. Univ Wisconsin, Madison, WI USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Eastern Virginia Med Sch, Norfolk, VA 23501 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. State Lab Hyg, Communicable Dis Div, Madison, WI USA. RP Drinka, PJ (reprint author), Wisconsin Vet Home, N2665 Cty Rd QQ, King, WI 54946 USA. FU NIA NIH HHS [AG 09632] NR 14 TC 11 Z9 11 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2002 VL 23 IS 10 BP 600 EP 603 DI 10.1086/501978 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 604FE UT WOS:000178605200011 PM 12400890 ER PT J AU Gatzke-Kopp, LM Raine, A Loeber, R Stouthamer-Loeber, M Steinhauer, SR AF Gatzke-Kopp, LM Raine, A Loeber, R Stouthamer-Loeber, M Steinhauer, SR TI Serious delinquent behavior, sensation seeking, and electrodermal arousal SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE recidivists; skin conductance; antisocial; stimulation-seeking; arousal ID STIMULATION-SEEKING; ORIENTING RESPONSE; AUTONOMIC MEASURES; HIGH-RISK; ADOLESCENTS; PERSONALITY; AGE; IQ; PSYCHOPATHY; IMPULSIVITY AB Low tonic skin conductance level (SCL) has been related, inconsistently, to both delinquency and sensation-seeking. This study tests the hypothesis that there is an interaction such that high sensation seeking delinquents, in particular, have low SCLs. Participants consisted of 335 boys from the Pittsburgh Youth Study classified as serious delinquents or controls based upon 10 years of prospectively collected self-report delinquency data. Participants' skin conductance was evaluated at age 16 along with several personality and neuropsychological measures. Both delinquency and sensation seeking were characterized by low SCL. However, there was no evidence to suggest that the presence of both of these factors together lead to especially low skin conductance levels. This finding is not explained by differences between the groups on measures of negative emotionality, IQ, socioeconomic status, or impulsivity. C1 Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Life Hist Studies Program, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gatzke-Kopp, LM (reprint author), Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. EM gatzke@usc.edu NR 55 TC 51 Z9 54 U1 1 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD OCT PY 2002 VL 30 IS 5 BP 477 EP 486 AR UNSP 0091-0627/02/1000-0477/0 DI 10.1023/A:1019816930615 PG 10 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA 585UB UT WOS:000177542000004 PM 12403151 ER PT J AU Kellogg, DL Liu, Y McAllister, K Friel, C Pergola, PE AF Kellogg, DL Liu, Y McAllister, K Friel, C Pergola, PE TI Bradykinin does not mediate cutaneous active vasodilation during heat stress in humans SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE microdialysis; laser-Doppler flowmetry ID SKIN BLOOD-FLOW; NITRIC-OXIDE; RESPONSES; EXERCISE AB To test the hypothesis that bradykinin effects cutaneous active vasodilation during hyperthermia, we examined whether the increase in skin blood flow (SkBF) during heat stress was affected by blockade of bradykinin B-2 receptors with the receptor antagonist HOE-140. Two adjacent sites on the forearm were instrumented with intradermal microdialysis probes for local delivery of drugs in eight healthy subjects. HOE-140 was dissolved in Ringer solution (40 muM) and perfused at one site, whereas the second site was perfused with Ringer alone. SkBF was monitored by laser-Doppler flowmetry (LDF) at both sites. Mean arterial pressure (MAP) was monitored from a finger, and cutaneous vascular conductance (CVC) was calculated (CVC = LDF/MAP). Water-perfused suits were used to control body temperature and evoke hyperthermia. After hyperthermia, both microdialysis sites were perfused with 28 mM nitroprusside to effect maximal vasodilation. During hyperthermia, CVC increased at HOE-140 (69 +/- 2% maximal CVC, P < 0.01) and untreated sites (65 +/- 2% maximal CVC, P < 0.01). These responses did not differ between sites (P > 0.05). Because the bradykinin B-2-receptor antagonist HOE-140 did not alter SkBF responses to heat stress, we conclude that bradykinin does not mediate cutaneous active vasodilation. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. RP Kellogg, DL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. FU NHLBI NIH HHS [HL-65599] NR 32 TC 13 Z9 14 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD OCT PY 2002 VL 93 IS 4 BP 1215 EP 1221 DI 10.1152/japplphysiol.01142.2001 PG 7 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 594DZ UT WOS:000178034600006 PM 12235017 ER PT J AU Klein, RF Turner, RJ Skinner, LD Vartanian, KA Serang, M Carlos, AS Shea, M Belknap, JK Orwoll, ES AF Klein, RF Turner, RJ Skinner, LD Vartanian, KA Serang, M Carlos, AS Shea, M Belknap, JK Orwoll, ES TI Mapping quantitative trait loci that influence femoral cross-sectional area in mice SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE femoral cross-sectional area; osteoporosis; heredity; quantitative trait; quantitative trait locus analysis ID BONE-MINERAL DENSITY; X-RAY ABSORPTIOMETRY; STRESS-FRACTURE; GENOME SCREEN; HIP FRACTURE; OSTEOPOROTIC FRACTURES; GENETIC-DETERMINANTS; INBRED STRAINS; MOUSE STRAINS; MASS AB Size and shape are critical determinants of the mechanical properties of skeletal elements and can be anticipated to be highly heritable. Moreover, the genes responsible may be independent of those that regulate bone mineral density (BMD). To begin to identify the heritable determinants of skeletal geometry, we have examined femoral cross-sectional area (FCSA) in male and female mice from two inbred strains of mice with divergent FCSA (C57BL/6 [B6] and DBA/2 [D2]), a large genetically heterogeneous population (n = 964) of B6D2F(2) mice and 18 BXD recombinant inbred (RI) strains derived from their F-2 cross. Femora were harvested from 16-week-old mice and FCSA (bone and marrow space enclosed within the periosteum) was measured at the midshaft by digital image analysis. In all mouse populations examined, FCSA was positively correlated with body weight and weight-corrected FCSA (WC-FCSA) values were normally distributed in the BXD-RI and F-2 populations, suggesting polygenic control of this trait. Genome-wide quantitative trait locus (QTL) analysis of the B6D2F(2) population revealed regions on four different chromosomes that were very strongly linked to WC-FCSA (chromosomes 6, 8, 10, and X) in both genders. Evidence of gender-specific genetic influences on femoral geometry was also identified at three other chromosomal sites (chromosomes 2, 7, and 12). Supporting evidence for the WC-FCSA QTLs on chromosomes 2, 7, 8, 10, and 12 also was present in the RI strains. Interestingly, none of these WC-FCSA QTLs were identified in our previous QTL analysis of whole body BMD in the same B6D2F(2) population. Thus, the genetic determinants of bone size appear to be largely, if not entirely, distinct from those that regulate BMD attainment. The identification of the genes responsible for geometric differences in bone development should reveal fundamentally important processes in the control of skeletal integrity. C1 Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Res Unit, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Dept Orthoped, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Klein, RF (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit CR113, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. OI Orwoll, Eric/0000-0002-8520-7355 FU NIAAA NIH HHS [AA 10760]; NIAMS NIH HHS [R01 AR044659, R01 AR044659-07, AR 44659] NR 51 TC 76 Z9 77 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD OCT PY 2002 VL 17 IS 10 BP 1752 EP 1760 DI 10.1359/jbmr.2002.17.10.1752 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 595GU UT WOS:000178100900003 PM 12369778 ER PT J AU Hardy, DJ Hinkin, CH AF Hardy, DJ Hinkin, CH TI Reaction time performance in adults with HIV/AIDS SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED INDIVIDUALS; AIDS DEMENTIA COMPLEX; WORKING-MEMORY; ANTIRETROVIRAL THERAPY; NEUROPSYCHOLOGICAL PERFORMANCE; DECISION-MAKING; STROOP TASK; HUMAN-BRAIN; ABNORMALITIES AB Infection with the Human Immunodeficiency Virus-Type 1 (HIV-1) has been shown to lead to cognitive decline in a substantial proportion of infected adults. The characteristic neuropsychological symptomatology includes memory dysfunction, higher order attentional disturbance, executive dysfunction and, most relevant to this manuscript, cognitive slowing. This paper reviews the extant literature on reaction time (RT) performance in HIV-infected adults with an emphasis on mental chronometry. In addition to discussing studies of simple and choice RT, we also examine the utility of RT paradigms in the assessment of selective attention, covert orienting, sustained attention, divided attention, working memory, and implicit memory. Studies documenting the utility of RT tasks to track treatment response are also introduced. In aggregate, research to date that has employed RT tasks in the evaluation of HIV-infected patients has found that HIV infection leads to a mild degree of cognitive slowing that tends to worsen with increasing disease severity. It needs to be noted, however, that a significant percentage of studies failed to find HIV infection to lead to RT slowing. Results of Brinley plot analyses, a technique that shares commonalities with meta-analysis, reveal that HIV-infected patients diagnosed with AIDS are on an average 22% slower than uninfected controls. This paper also reviews data that has shown that HIV associated cognitive slowing, as indexed by single and dual choice RT, is amenable to pharmacologic intervention using the psychostimulant methylphenidate. Given the demonstrated sensitivity of RT tasks to the neuropsychological effects of HIV infection, it is recommended that RT tasks be included whenever possible in the routine clinical evaluation of HIV-infected patients. C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Psychol Serv, Los Angeles, CA USA. RP Hardy, DJ (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 760 Westwood Plaza,Room C-8747, Los Angeles, CA 90024 USA. FU NIA NIH HHS [R03 AG18549]; NIDA NIH HHS [R01 DA13799]; NIMH NIH HHS [R01 MH058552, R01 MH58552] NR 78 TC 32 Z9 33 U1 0 U2 0 PU SWETS ZEITLINGER PUBLISHERS PI LISSE PA P O BOX 825, 2160 SZ LISSE, NETHERLANDS SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD OCT PY 2002 VL 24 IS 7 BP 912 EP 929 DI 10.1076/jcen.24.7.912.8391 PG 18 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 642GY UT WOS:000180796900005 PM 12647768 ER PT J AU Long, JA Ickovics, JR Gill, TM Horwitz, RI AF Long, JA Ickovics, JR Gill, TM Horwitz, RI TI Social class and mortality in older women SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE social class; mortality; clinical covariates; women; occupations ID SOCIOECONOMIC-STATUS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; CIVIL-SERVANTS; FOLLOW-UP; HEALTH; INEQUALITIES; PREDICTORS; INCOME; EMPLOYMENT AB In middle-aged people, social class is one of the strongest predictors of mortality. However. to date, research prospectively evaluating the relationship between social class and mortality in the older persons has produced conflicting results. This may be due to the lack of clinical covariates in many analyses. The objective of this study was to determine the relationship between social class markers-education, income, husband's work history, and personal work history-and mortality in a cohort of older women, after adjusting for clinical and behavioral factors. The participants were 737 ambulatory, community-living women, age 72 and older, followed from 1989 to 1993. In addition to education attained, present income, husband's work history, and personal work history, proportional hazard models adjusted for age, race, marital status, number of chronic conditions, number of medications used, Activities of Daily Living status, Mini-Mental State Exam score, physical activity, and alcohol use. In multivariable models personal work history was the only social class marker that remained significantly associated with mortality. Compared with managers and professionals, women who never worked outside the home had a 3.5 greater risk of death (95% CI, 1.6-7.5), while women who had worked in partly/unskilled or skilled professions were over two and a half times more likely to die; the adjusted hazard ratios were 2.7 (95% CI, 1.2-6.4) and 2.7 (95% CI, 1.3-5.7), respectively. In this population of older women, personal work history was the only social class marker predictive of mortality. (C) 2002 Elsevier Science Inc. All rights reserved. C1 Ctr Hlth Equ Res & Promot, Philadelphia Vet Adm, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. RP Long, JA (reprint author), Ctr Hlth Equ Res & Promot, Philadelphia Vet Adm, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. FU NIA NIH HHS [R01 AG 07449, K32 AG 00759] NR 45 TC 4 Z9 4 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD OCT PY 2002 VL 55 IS 10 BP 952 EP 958 AR PII S0895-4356(02)00464-X DI 10.1016/S0895-4356(02)00464-X PG 7 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 615JE UT WOS:000179241400001 PM 12464370 ER PT J AU Cooper, GS Dooley, MA Treadwell, EL Clair, EWS Gilkeson, GS AF Cooper, GS Dooley, MA Treadwell, EL Clair, EWS Gilkeson, GS TI Risk factors for development of systemic lupus erythematosus: Allergies, infections, and family history SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE systemic lupus erythematosus; autoimmune disease; sulfa drug; herpes zoster; infections ID BARR-VIRUS INFECTION; AUTOIMMUNE-DISEASES; MULTIPLE-SCLEROSIS; REVISED CRITERIA; UNITED-STATES; HERPES-ZOSTER; EPIDEMIOLOGY; ENGLAND; CLASSIFICATION; ANTIBODIES AB We examined risk factors for systemic lupus erythematosus (SLE) in 265 recently diagnosed patients in North Carolina and South Carolina and 355 control subjects identified through driver's license records and frequency matched to patients by age, sex, and state. Analyses were limited to exposures before diagnosis (cases) or reference year (control subjects). SLE patients were more likely than control subjects to report a history of allergy to medications (odds ratio [OR] 3.1, 95% confidence interval [CI], 2.1-4.5), particularly to antibiotics. SLE risk increased with history of shingles (OR 2.5, 95 % CI 1.1-5.9) and with frequent (more than once per year) cold sores in the 3 years before diagnosis (OR 2.8, 95 % CI 1.4-5.4). There was little association with history of mononucleosis, a marker of late infection with Epstein-Barr virus, implanted medical devices, or hepatitis B vaccination. History of lupus in parents or siblings was associated with an increased risk (OR 3.3, 95% CI 1.2-8.6). Further research is needed to clarify whether medication allergies and specific infectious agents are involved in the etiology of SLE. Published by Elsevier Science Inc. C1 NIEHS, Epidemiol Branch, Durham, NC 27709 USA. Univ N Carolina, Div Rheumatol, Chapel Hill, NC USA. E Carolina Univ, Sch Med, Div Rheumatol, Greenville, NC USA. Duke Univ, Med Ctr, Div Rheumatol Allergy & Clin Immunol, Durham, NC USA. Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC USA. Med Univ S Carolina, Charleston, SC 29425 USA. RP Cooper, GS (reprint author), NIEHS, Epidemiol Branch, A3-05,POB 12233, Durham, NC 27709 USA. NR 35 TC 50 Z9 52 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD OCT PY 2002 VL 55 IS 10 BP 982 EP 989 AR PII S0895-4356(02)00429-8 DI 10.1016/S0895-4356(02)00429-8 PG 8 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 615JE UT WOS:000179241400005 PM 12464374 ER PT J AU Singer, EJ Aronow, HA Lee, SY Hinkin, CH Lazarus, T AF Singer, EJ Aronow, HA Lee, SY Hinkin, CH Lazarus, T TI Stability of human immunodeficiency virus type 1 RNA in cerebrospinal fluid determined with the AMPLICOR HIV-1 MONITOR test, version 1.5 (Ultrasensitive) SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VIRAL LOAD; PLASMA; QUANTITATION; ASSAY; DEMENTIA; DISEASE; PCR AB We evaluated the effects of time, temperature, freezing, and thawing on the cerebrospinal fluid viral load by using the Roche AMPLICOR HIV-1 MONITOR test, version 1.5 (ultrasensitive). While a statistically significant decrease from the baseline was observed at 24 h, but not at 6 or 12 h, and with one freeze-thaw cycle, all changes were within the range of intra-assay variability. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Dept Neurol, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA USA. Univ So Calif, Keck Sch Med, Dept Internal Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, AIDS Healthcare Fdn, Dept Res, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Consolidated Lab, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Psychol Serv, Los Angeles, CA USA. New York Med Coll, Dept Internal Med, New York, NY USA. Roche Diagnost Corp, Indianapolis, IN USA. RP Singer, EJ (reprint author), 11645 Wilshire Blvd,Suite 770, Los Angeles, CA 90025 USA. FU NINDS NIH HHS [R24 NS038841, NS-38841] NR 16 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2002 VL 40 IS 10 BP 3863 EP 3864 DI 10.1128/JCM.40.10.3863-3864.2002 PG 2 WC Microbiology SC Microbiology GA 600MP UT WOS:000178394800058 PM 12354902 ER PT J AU Wirshing, DA Boyd, JA Meng, LR Ballon, JS Marder, SR Wirshing, WC AF Wirshing, DA Boyd, JA Meng, LR Ballon, JS Marder, SR Wirshing, WC TI The effects of novel antipsychotics on glucose and lipid levels SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SERUM TRIGLYCERIDE LEVELS; ONSET DIABETES-MELLITUS; WEIGHT-GAIN; CLOZAPINE TREATMENT; OLANZAPINE TREATMENT; PSYCHOTROPIC-DRUGS; PLASMA-LEVELS; KETOACIDOSIS; HYPERGLYCEMIA; RISPERIDONE AB Background. The novel antipsychotics are extensively used based on their favorable extrapyramidal side effect profiles. However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels. The goal of this study is to compare the effects of novel antipsychotics clozapine, olanzapine, risperidone, and quetiapine and typical antipsychotics haloperidol and fluphenazine on glucose and lipid levels. Method: The charts of 590 patients were retrospectively reviewed. Of those, 215 patients had adequate laboratory data for inclusion. Glucose and lipid level data from 2 1/2 years before and after initiation of the target antipsychotic were included. Covariates, including patients' age, the duration of antipsychotic treatment, other medications that may affect glucose or lipid levels, and the initial laboratory values, were controlled for in the analyses. Results: Glucose levels were increased from baseline for patients treated with clozapine, olanzapine, and haloperidol. There were statistically and clinically significant differences among the medications' effects on lipid profiles (p < .05). Those receiving clozapine and olanzapine demonstrated statistically significant increases in triglyceride levels compared with the other groups. Over one third of patients treated with any of the novel antipsychotics had clinically meaningful triglyceride elevations. Conclusion: It has been shown that novel antipsychotics are associated with weight gain. This risk factor along with others, such as elevated glucose and triglyceride levels, compounds the risk for coronary artery disease. Routine monitoring of glucose and lipid levels during treatment with novel antipsychotics should be advocated. C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Mental Illness Res Educ & Clin Ctr, MIRECC, VA VISN 22, Los Angeles, CA USA. RP Wirshing, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychiat, 11301 Wilshire Blvd,B151-H, Los Angeles, CA 90073 USA. OI Ballon, Jacob/0000-0002-6157-4847 NR 61 TC 217 Z9 228 U1 2 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2002 VL 63 IS 10 BP 856 EP 865 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 608VA UT WOS:000178866700002 PM 12416594 ER PT J AU Joo, JH Lenze, EJ Mulsant, BH Begley, AE Weber, EM Stack, JA Mazumdar, S Reynolds, CF Pollock, BG AF Joo, JH Lenze, EJ Mulsant, BH Begley, AE Weber, EM Stack, JA Mazumdar, S Reynolds, CF Pollock, BG TI Risk factors for falls during treatment of late-life depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID OLDER-PEOPLE; ANTIDEPRESSANTS; FRACTURES AB Background. Prior studies have found that antidepressant medications are associated with an increased risk of falling in elderly persons. However, little is known about the prevention of falls during treatment for depression in elderly persons. This study evaluated the time course and potential risk factors for falls in a treatment protocol for late-life depression to identify specific at-risk periods and risk factors for falls in this population. Method: One hundred four subjects aged 69 years and over were treated in a protocolized manner using paroxetine and interpersonal psychotherapy. Those who did not respond received augmentation therapy with bupropion, nortriptyline, or lithium. Subjects were assessed at baseline and weekly during treatment; demographic and clinical characteristics of those who experienced a fall during treatment were compared with those who did not fall. Cox proportional hazards models were used to define risk factors for falls in univariate and multivariate models. Results: During a mean of 21 weeks of treatment, 40 subjects (38%) fell. About half (53%) of the subjects fell during the first 6 weeks of treatment. In the multivariate model, memory impairment and orthostatic changes in blood pressure during treatment were risk factors for failing. Additionally, augmentation with bupropion appeared to be a risk factor for falls in univariate analysis, but this result is preliminary due to the small number of subjects who took bupropion. Conclusion: Increased monitoring for falls is warranted during the acute treatment of late-life depression. When treating such patients, clinicians should be especially watchful of those with memory impairments or those who develop orthostatic blood pressure changes; orthostatic blood pressure should be measured throughout acute treatment. Additionally, augmenting paroxetine with bupropion may also increase the risk of falls, and this medication combination should be used with caution in elderly patients. C1 Univ Pittsburgh, Sch Med, Intervent Res Ctr Late Life Mood Disorders, Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, GRECC, Pittsburgh, PA USA. RP Lenze, EJ (reprint author), Western Psychiat Inst & Clin, Room E1124,3811 OHara St, Pittsburgh, PA 15213 USA. FU NIMH NIH HHS [P30 MH 52247, T32 MH19986, K02 MH01509, K23 MH64196, K01 MH01613, R01 MH37869, K05 MH00295, R37 MH43832] NR 25 TC 28 Z9 28 U1 0 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2002 VL 63 IS 10 BP 936 EP 941 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 608VA UT WOS:000178866700012 PM 12416604 ER PT J AU Solai, LK Pollock, BG Mulsant, BH Frye, RF Miller, MD Sweet, RA Kirshner, M Sorisio, D Begley, A Reynolds, CF AF Solai, LK Pollock, BG Mulsant, BH Frye, RF Miller, MD Sweet, RA Kirshner, M Sorisio, D Begley, A Reynolds, CF TI Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; DEXTROMETHORPHAN IN-VITRO; EXTENSIVE METABOLIZERS; DEBRISOQUINE OXIDATION; SPARTEINE OXIDATION; RATING-SCALE; RISK-FACTORS; HUMAN-LIVER; SERTRALINE; INHIBITION AB This study was performed in elderly patients (1) to assess in vivo the degree to which CYP2D6-mediated metabolism of debrisoquine at baseline determines plasma concentration to dose quotients for nortriptyline or paroxetine after 4 weeks of treatment, and (2) to compare the effects of nortriptyline and paroxetine on debrisoquine metabolism after 6 weeks of treatment. CYP2D6 activity was estimated in 66 subjects (71.4 +/- 7.2 years) before initiating treatment and again after 6 weeks of treatment with either nortriptyline or paroxetine under randomized, double-blind conditions according to a standard protocol. CYP2D6 activity was estimated by the debrisoquine recovery ratio in a 6- to 8-hour urine sample collected after oral administration of 10 mg debrisoquine sulfate. Nortriptyline and paroxetine plasma concentrations were obtained weekly. Baseline debrisoquine recovery ratio values were significantly correlated with the plasma concentration to dose quotient at 4 weeks for both nortriptyline (r = -0.75, p = 0.0001, N = 29) and paroxetine (r = -0.50,p = 0.003, N = 33). Treatment with either nortriptyline or paroxetine was associated with a significant decrease in the median debrisoquine recovery ratio, reflecting inhibition of CYP2D6 metabolism. The percent decrease associated with nortriptyline was significantly smaller than that with paroxetine (p < 0.0001). None of the patients treated with nortriptyline but 19 of the 32 extensive metabolizers treated with paroxetine were converted to phenotypic poor metabolic status. Our observations of CYP2D6 inhibition are consistent with in vitro data and results obtained in younger healthy volunteers. The significant correlations between baseline debrisoquine recovery ratio and the plasma concentrations to dose quotients at 4 weeks for both nortriptyline and paroxetine are consistent with CYP2D6 playing a major role in the metabolism of both drugs. CYP2D6 inhibition by paroxetine, which effectively converted 59% of patients to phenotypic PMs, may be especially relevant for elderly patients given their generally higher concentration of paroxetine. C1 Univ Pittsburgh, Sch Med, Mental Hlth Intervent Res Ctr Study Late Life Moo, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. RP Solai, LK (reprint author), Western Psychiat Inst & Clin, Beaver Valley Mental Hlth Serv, 176 Virginia Ave, Rochester, PA 15074 USA. OI Frye, Reginald/0000-0002-1841-1401 FU NIMH NIH HHS [MH64173, MH 00295, MH 01613, MH 37869, MH 43832, MH 52247, MH 65416, MH59666] NR 31 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD OCT PY 2002 VL 22 IS 5 BP 481 EP 486 DI 10.1097/01.jcp.0000033398.43191.6a PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 597EW UT WOS:000178210100007 PM 12352271 ER PT J AU Hussein, MR Wood, GS AF Hussein, MR Wood, GS TI Melanomas, dysplastic nevi and benign nevi: is dysplastic nevus a non-benign neoplasm? Reply SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Letter C1 Univ Wisconsin, William S Middleton Mem Vet Hosp, Dept Med Dermatol, Madison, WI 53706 USA. RP Hussein, MR (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, Dept Med Dermatol, Madison, WI 53706 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD OCT PY 2002 VL 29 IS 9 BP 570 EP 571 DI 10.1034/j.1600-0560.2002.290911_2.x PG 2 WC Dermatology; Pathology SC Dermatology; Pathology GA 599PU UT WOS:000178345000012 ER PT J AU Dresselhaus, TR Luck, J Peabody, JW AF Dresselhaus, TR Luck, J Peabody, JW TI The ethical problem of false positives: a prospective evaluation of physician reporting in the medical record SO JOURNAL OF MEDICAL ETHICS LA English DT Article ID STANDARDIZED PATIENTS; CHART ABSTRACTION; QUALITY; RESIDENTS; DECEPTION; CARE; WELL AB Objective: To determine if the medical record might overestimate the quality of care through false, and potentially unethical, documentation by physicians. Design: Prospective trial comparing two methods for measuring the quality of care for four common outpatient conditions: (1) structured reports by standardised patients (SPs) who presented unannounced to the physicians' clinics, and (2) abstraction of the medical records generated during these visits. Setting: The general medicine clinics of two veterans affairs medical centres. Participants: Twenty randomly selected physicians (10 at each site) from among eligible second and third year internal medicine residents and attending physicians. Main measurements: Explicit criteria were used to score the medical records of physicians and the reports of SPs generated during 160 visits (8 cases x 20 physicians). Individual scoring items were categorised into four domains of clinical performance: history, physical examination, treatment, and diagnosis. To determine the false positive rate, physician entries were classified as false positive (documented in the record but not reported by the SP), false negative, true positive, and true negative. Results: False positives were identified in the medical record for 6.4% of measured items. The false positive rate was higher for physical examination (0.330) and diagnosis (0.304) than for history (0.166) and treatment (0.082). For individual physician subjects, the false positive rate ranged from 0.098 to 0.397. Conclusions: These data indicate that the medical record falsely overestimates the quality of important dimensions of care such as the physical examination. Though it is doubtful that most subjects in our study participated in regular, intentional falsification, we cannot exclude the possibility that false positives were in some instances intentional, and therefore fraudulent, misrepresentations. Further research is needed to explore the questions raised but incompletely answered by this research. C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, San Francisco, CA 94105 USA. Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, San Diego, CA 92103 USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Peabody, JW (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Inst Global Hlth, 74 New Montgomery St,Ste 508, San Francisco, CA 94105 USA. NR 24 TC 1 Z9 1 U1 0 U2 4 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0306-6800 J9 J MED ETHICS JI J. Med. Ethics PD OCT PY 2002 VL 28 IS 5 BP 293 EP 296 PG 4 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 603BC UT WOS:000178538100007 ER PT J AU Wang, F Trial, J Diwan, A Gao, F Birdsall, HH Entman, ML Hornsby, PJ Sivasubramaniam, N Mann, DL AF Wang, F Trial, J Diwan, A Gao, F Birdsall, HH Entman, ML Hornsby, PJ Sivasubramaniam, N Mann, DL TI Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE cytokine; leukemia inhibitory factor; cardiac fibroblast; proliferation; differentiation; collagen content; MMP activity ID SMOOTH MUSCLE ACTIN; GENE-EXPRESSION; DIFFERENTIATION; MYOFIBROBLASTS; COLLAGEN; PROLIFERATION; MYOBLAST; MYOCYTES; GP130; CELLS AB Background: Previous studies have shown that leukemia inhibitory factor (LIF) provokes hypertrophic and cytoprotective effects in cardiac myocytes. However, the effects of LIF in cardiac fibroblasts are not known. Given that the cardiac fibroblast is the most abundant cell type in the heart, we sought to examine the functional effects of LIF on cardiac fibroblasts in vitro. Results: Short-term LIF stimulation (24 h) had no effect on fibroblast proliferation and/or cell differentiation. However. longer-term LIT stimulation (48-72 h) increased fibroblast proliferation, and significantly inhibited cardiac fibroblast differentiation into myofibroblasts. Moreover, 72 It of LIF stimulation significantly reduced collagen content in cardiac fibroblasts cultures, as well as decreased MMP activity in fibroblast culture supernatants. Conclusion: The results of this study suggest that LIF stimulation down-regulates several key components of the remodeling process, including collagen content and matrix metalloproteinase (MMP) activation, and thus suggest that LIF may play an important autocrine/paracrine role in preventing excessive extracellular matrix remodeling following acute myocardial injury. (C) 2002 Published by Elsevier Science Ltd. C1 Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Baylor Coll Med, Houston VAMC, Huffington Ctr Aging, Houston, TX 77030 USA. Baylor Coll Med, Houston VAMC, Dept Otorhinolaryngol, Houston, TX 77030 USA. Baylor Coll Med, Houston VAMC, Dept Med, Houston, TX 77030 USA. Methodist Hosp, DeBakey Heart Ctr, Program Cardiovasc Sci, Houston, TX 77030 USA. RP Mann, DL (reprint author), Winters Ctr Heart Failure Res, MS 524 6565 Fannin St, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [HL 42250-10/10, R01 HL 58081-01, R01 HL 61543-01] NR 28 TC 32 Z9 33 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD OCT PY 2002 VL 34 IS 10 BP 1309 EP 1316 DI 10.1006/jmcc.2002.2059 PG 8 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 613HE UT WOS:000179126200012 PM 12392991 ER PT J AU Richardson-Burns, SM Kominsky, DJ Tyler, KL AF Richardson-Burns, SM Kominsky, DJ Tyler, KL TI Reovirus-induced neuronal apoptosis is mediated by caspase 3 and is associated with the activation of death receptors SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE apoptosis; caspases; CNS; neuroblastoma; neuronal cultures; virus ID CENTRAL-NERVOUS-SYSTEM; ENCEPHALITIS-VIRUS INFECTION; NECROSIS-FACTOR-ALPHA; CELL-DEATH; DNA FRAGMENTATION; BRAIN INJURY; EXPRESSION; INHIBITION; RAT; ISCHEMIA AB Reovirus infection of the central nervous system (CNS) is an important experimental system for understanding the pathogenesis of neurotropic viral infection. Infection of neonatal mice with T3 reoviruses causes lethal encephalitis in which injury results from virus-induced apoptosis. We now show that this apoptosis in vivo is associated with activation of caspase 3, and use neuroblastoma and primary neuronal cultures to identify the cellular pathways involved. Reovirus-induced apoptosis in neuronal cultures is initiated by activation of the tumor necrosis factor (TNF) receptor superfamily death receptors and is inhibited by treatment with soluble death receptors (DRs). The DR-associated initiator caspase, caspase 8, is activated following infection, this activation is inhibited by a cell-permeable peptide inhibitor (IETD-CHO). In contrast to our previous findings in non-neuronal cell lines, reovirus-induced neuronal apoptosis is not accompanied by significant release of cytochrome c from the mitochondria or with caspase 9 activation following infection. This suggests that in neuronal cells, unlike their non-neuronal counterparts, the mitochondria-mediated apoptotic pathway associated with cytochrome c release and caspase 9 activation does not play a significant role in augmenting reovirus-induced apoptosis. Consistent with these results, peptide caspase inhibitors show a hierarchy of efficacy in inhibiting reovirus-induced apoptosis, with inhibitors of caspase 3 > caspase 8 >>> caspase 9. These studies provide a comprehensive profile of the pattern of virus-induced apoptotic pathway activation in neuronal culture. C1 Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B182, 4200 E 9th Ave, Denver, CO 80262 USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NIA NIH HHS [1R01AG14071] NR 65 TC 42 Z9 42 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2002 VL 8 IS 5 BP 365 EP 380 DI 10.1080/13550280290100806 PG 16 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 626FL UT WOS:000179861500002 PM 12402163 ER PT J AU Amory, JK Chansky, HA Chansky, KL Camuso, MR Hoey, CT Anawalt, BD Matsumoto, AM Bremner, WJ AF Amory, JK Chansky, HA Chansky, KL Camuso, MR Hoey, CT Anawalt, BD Matsumoto, AM Bremner, WJ TI Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE arthritis; arthroplasty; FIM; rehabilitation ID RANDOMIZED CONTROLLED TRIAL; TOTAL HIP; ELECTIVE HIP; ARTHROPLASTY; FRACTURE AB Objectives: Older patients undergoing knee replacement surgery can recover more slowly than younger patients and require extended rehabilitation. Because administration of supraphysiological testosterone (T) dramatically increases strength, we hypothesized that preoperative T therapy would improve functional recovery and reduce hospital stay in older men undergoing knee replacement surgery. Design: Double-blinded, placebo-controlled pilot trial. Setting: A Veterans Affairs orthopedics clinic and inpatient postoperative unit. Participants: Twenty-five men, mean age 70, undergoing elective knee replacement. Intervention: Preoperative, supraphysiological T administration (600 mg T enanthate intramuscularly weekly for 4 weeks) or sesame oil placebo. Measurements: Length of hospital stay and functional ability by Functional Independence Measure (FIM) score. Results: Mean length of hospital stay +/- standard deviation was nonsignificantly reduced in the T group (5.9+/-2.4 days vs 6.8+/-2.5 days; P=.15). At postoperative Day 3, there was a significant improvement in ability to stand (mean FIM score 5.2+/-1.0 vs 4.0+/-1.1; P=.04) and trends towards improvements in walking and stair climbing in the T group. There were no complications attributable to T therapy. Conclusions: In older men undergoing knee replacement surgery, preoperative supraphysiological T administration may confer some clinical benefit. Future studies using longer courses of preoperative T administration in larger numbers of older men undergoing knee replacement surgery are warranted. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Dept Orthoped, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Dept Pharm, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Geriatr Clin Res Ctr, Seattle, WA USA. RP Amory, JK (reprint author), Univ Washington, Dept Med, Box 356429,1959 NE Pacific St, Seattle, WA 98195 USA. NR 16 TC 42 Z9 43 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD OCT PY 2002 VL 50 IS 10 BP 1698 EP 1701 DI 10.1046/j.1532-5415.2002.50462.x PG 4 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 602AP UT WOS:000178482800011 PM 12366624 ER PT J AU Sanicola, SM Arnold, TB Osher, L AF Sanicola, SM Arnold, TB Osher, L TI Is the radiographic appearance of the hallucal tarsometatarsal joint representative of its true anatomical structure? SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Article ID AUSTRALOPITHECUS-AFARENSIS; EVOLVING FOOT AB The medial cuneiforms and first metatarsals were identified in 515 randomly selected specimens at the Hamman-Todd osteology collection in the Cleveland Museum of Natural History in Cleveland, Ohio, and the transverse plane angulation of the hallucal tarsometatarsal joint was determined by direct measurement of the selected bones. Medial cuneiforms were subsequently separated into three categories corresponding to the amount of measured obliquity. The first tarsometatarsal joint was reassembled, and the paired medial cuneiforms and first metatarsals were radiographed at different declination angles in inverted, everted, and rectus positions. Radiographic evaluation revealed discordance between the appearance of atavism and true atavism in the cuneiform. Specifically, it was determined that the position of the hallucal tarsometatarsal joint significantly influenced the appearance of atavism in the cuneiform. It is concluded that the position of the first ray in an anteroposterior radiograph can produce the appearance of an increased obliquity angle of the medial cuneiform, resulting in an inaccurate representation of the hallucal tarsometatarsal joint. C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Sanicola, SM (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. NR 35 TC 4 Z9 4 U1 0 U2 0 PU AMER PODIATRIC MED ASSN PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD OCT PY 2002 VL 92 IS 9 BP 491 EP 498 PG 8 WC Orthopedics SC Orthopedics GA 607PZ UT WOS:000178801100003 PM 12381798 ER PT J AU Simmons, SF Babineau, S Garcia, E Schnelle, JF AF Simmons, SF Babineau, S Garcia, E Schnelle, JF TI Quality assessment in nursing homes by systematic direct observation: Feeding assistance SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID LONG-TERM-CARE; WEIGHT-LOSS; RESIDENTS; DIFFICULTIES; MEALTIME; STAFF AB Background. Direct observation of care is an important data source for nursing home (NH) quality assessment, especially in light of evidence that chart information is inaccurate or incomplete for many daily care areas. The purpose of this study was to describe a standardized feeding assistance observational protocol that is designed for routine use by external (survey teams) and internal (licensed NH staff) quality assurance personnel to (i) maximize the amount Of useful information gained from relatively brief observational periods; (ii) provide specific rules of measurement, which allow for replication and valid comparisons between NHs; and (iii) provide specific scoring rules that allow defensible categorical statements to be made about feeding assistance care quality within the NH. Methods. Four feeding assistance care quality indicators (QIs) were defined and operationalized in this study for 302 long-term residents in 10 skilled NHs: (i) Staff ability to accurately identify residents with clinically significant low oral food and fluid intake during mealtime; (ii) Staff ability to provide feeding assistance to at-risk residents during mealtime; (iii) Staff ability to provide feeding assistance to residents identified by the Minimum Data Set as requiring staff assistance to eat; and (iv) Staff ability to provide a verbal prompt to residents who receive physical assistance at mealtimes. Results. There were significant differences between facilities for three of the four QIs. The proportion of participants in each facility where staff "failed" the QIs ranged as follows: (Quality Indicator i) 42% to 91%; (ii) 25% to 73%; (iii) 11% to 82%; and (iv) 0% to 100%. Conclusions. A standardized observational protocol can be used to accurately measure the quality of feeding assistance care in NHs. This protocol is replicable and shows significant differences between facilities with respect to accuracy of oral intake documentation and the adequacy and quality of feeding assistance during mealtimes. C1 Univ Calif Los Angeles, Borun Ctr Gerontol Res, Sch Med, Dept Geriatr, Los Angeles, CA USA. Jewish Home Aging, Reseda, CA USA. Brown Univ, Sch Med, Providence, RI USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Sepulveda Geriatr Res, Educ & Clin Ctr, Sepulveda, CA USA. RP Simmons, SF (reprint author), Univ Calif Los Angeles, Borun Ctr Gerontol Res, Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. NR 26 TC 52 Z9 53 U1 1 U2 6 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2002 VL 57 IS 10 BP M665 EP M671 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 598TB UT WOS:000178291600013 PM 12242322 ER PT J AU Berfield, AK Andress, DL Abrass, CK AF Berfield, AK Andress, DL Abrass, CK TI IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function SO KIDNEY INTERNATIONAL LA English DT Article DE mesangial cell; IGF-1; IGFBP-5; contraction; migration; atherosclerosis; lipids; glomerulosclerosis ID LOW-DENSITY-LIPOPROTEIN; GROWTH-FACTOR-I; MONOCYTE CHEMOATTRACTANT PROTEIN-1; EXTRACELLULAR-MATRIX; GLOMERULAR INJURY; ANGIOTENSIN-II; MESSENGER-RNA; INSULIN; GLOMERULOSCLEROSIS; EXPRESSION AB Background. Chronic treatment of mesangial cells with insulin-like growth factor-1 (IGF-1) results in intracellular lipid accumulation. These mesangial cells resemble foam cells. Methods. To determine whether this phenotype affects cell function, lipid-laden mesangial cells were tested for their ability to migrate in response to IGF-binding protein-5 (IGFBP-5) and to contract in response to angiotensin II (Ang II). IGFBP-5 binding and subsequent activation of the signal transduction cascade for migration were examined. To confirm that lipid accumulation was responsible for impaired contractility, lipid was removed from lipid-laden mesangial cells and the cells were re-tested for contractile response to Ang II. Results. In comparison to control mesangial cells, lipid-laden cells failed to migrate in response to IGFBP-5. Although cellular binding of IGFBP-5 was not altered by lipid accumulation, IGFBP-5 failed to activate cdc42, a Rho GTPase required for IGFBP-5-mediated mesangial cell migration. These data indicate that lipid accumulation within the mesangial cell interferes with the signal transduction response to IGFBP-5. In addition, mesangial cells treated with IGF-1 had reduced contraction to Ang II. When lipid accumulation was exaggerated by adding cholesteryl esters to the culture medium, mesangial cells failed to contract in response to Ang II. Following removal of excess lipid from these mesangial cells, the contractile response to Ang II was restored. Conclusions. IGF-1 induces lipid accumulation in mesangial cells, which impairs their ability to respond to specific migratory and contractile stimuli. These observations are relevant to understanding functional abnormalities in diseases where mesangial foam cells occur, such as focal and segmental glomerulosclerosis and diabetic nephropathy. C1 Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, Seattle, WA 98108 USA. Univ Washington, Sch Med, Seattle, WA USA. RP Abrass, CK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nephrol, 111A,1660 S Columbian Way, Seattle, WA 98108 USA. FU NIAMS NIH HHS [R01 AR-44911]; NIDDK NIH HHS [R01 DK-49771] NR 45 TC 24 Z9 26 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD OCT PY 2002 VL 62 IS 4 BP 1229 EP 1237 DI 10.1046/j.1523-1755.2002.00578.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 594GV UT WOS:000178042000013 PM 12234293 ER PT J AU Rosen, HR AF Rosen, HR TI Hepatitis C in the liver transplant recipient: current understanding and treatment SO MICROBES AND INFECTION LA English DT Article DE liver transplantation; immunosuppression; recurrent disease; outcomes; rejection ID INTERFERON-ALPHA; RECURRENCE; CIRRHOSIS; IMMUNOSUPPRESSION; CYCLOSPORINE; TACROLIMUS; REJECTION; RIBAVIRIN; INFECTION; OKT3 AB Hepatitis C virus (HCV)-related liver disease is the leading indication for orthotopic liver transplantation worldwide. Recurrent HCV infection as defined by viremia after transplantation is nearly universal, with histologic evidence of recurrent hepatitis present in the majority. Although short-term survival appears to be similar to that in other causes of liver failure, it has recently been demonstrated that approximately 20-30% of HCV-positive patients develop allograft cirrhosis by 5 years. Therefore, it is possible to define disease outcomes within a relatively short period of follow-up. Identification of patients who are likely to develop progressive HCV-related allograft injury is important to optimize results of current antiviral therapy. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved. C1 Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Liver Transplantat Program, Portland, OR 97207 USA. RP Rosen, HR (reprint author), Oregon Hlth Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, POB 1034,P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. NR 36 TC 12 Z9 12 U1 0 U2 0 PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS CEDEX 15 PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE SN 1286-4579 J9 MICROBES INFECT JI Microbes Infect. PD OCT PY 2002 VL 4 IS 12 BP 1253 EP 1258 AR PII S1286-4579(02)01653-2 DI 10.1016/S1286-4579(02)01653-2 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 618GL UT WOS:000179410300008 PM 12467767 ER PT J AU Taki, K Kogai, T Kanamoto, Y Hershman, JM Brent, GA AF Taki, K Kogai, T Kanamoto, Y Hershman, JM Brent, GA TI A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3 ',5 '-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID SODIUM-IODIDE SYMPORTER; TRANSCRIPTION FACTOR-I; TISSUE-SPECIFIC EXPRESSION; THYROTROPIN RECEPTOR GENE; POLYMERASE-CHAIN-REACTION; TUMOR-NECROSIS-FACTOR; NA+/I SYMPORTER; KINASE-A; FRTL-5 CELLS; THYROGLOBULIN PROMOTER AB The sodium/iodide symporter (NIS) gene is highly expressed in the thyroid gland and is important for the diagnosis and radioiodide therapy of differentiated thyroid cancers. We investigated a human NIS (hNIS) gene 5'-far-upstream enhancer (hNUE) (-9847 to -8968). The hNUE is TSH responsive in both FRTL-5 cells and primary normal thyroid cells, but not in human papillary thyroid cancer cells (BHP cells). The hNUE enhanced expression of the basal hNIS promoter 15-fold and required both a Pax-8 binding site and a cAMP response element (CRE)-like sequence for full activity. The hNUE activated transcription in a thyroid-selective and cAMP-dependent manner, mediated by both protein kinase A (PKA)-dependent and PKA-independent pathways. Pax-8 and two CRE-like sequence binding proteins bind to the hNUE. Supershift binding assay indicated that one of the CRE-like sequence binding protein(s) was CRE-binding protein-1, activation transcription factor-1, and/or CRE modulator, and the other was an unknown factor(s) that is absent in BHP 2-7 cells. A far-upstream enhancer is important for hNIS regulation in the thyroid. Deficient CRE-like sequence binding protein(s) that bind to the hNUE in normal thyroid cells may be responsible for reduced NIS gene expression in some thyroid carcinomas. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Div Endocrinol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Div Endocrinol, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCI NIH HHS [R01 CA-89364] NR 66 TC 65 Z9 67 U1 0 U2 0 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD OCT PY 2002 VL 16 IS 10 BP 2266 EP 2282 DI 10.1210/me.2002-0109 PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 598GC UT WOS:000178266700008 PM 12351692 ER PT J AU Street, VA Meekins, G Lipe, HP Seltzer, WK Carter, GT Kraft, GH Bird, TD AF Street, VA Meekins, G Lipe, HP Seltzer, WK Carter, GT Kraft, GH Bird, TD TI Charcot-Marie-Tooth neuropathy: clinical phenotypes of four novel mutations in the MPZ and Cx 32 genes SO NEUROMUSCULAR DISORDERS LA English DT Article DE neuropathy; Charcot-Marie-Tooth; myelin pzero; comnexin 32 ID MYELIN PROTEIN ZERO; UNUSUAL ELECTROPHYSIOLOGICAL FINDINGS; DISEASE TYPE-1A; FAMILY; P-0; IDENTIFICATION; POLYNEUROPATHY; DUPLICATION; RECOGNITION; ASSOCIATION AB Charcot-Marie-Tooth Hereditary Neuropathy is a heterogeneous syndrome associated with mutations in several different genes including peripheral myelin protein 22, myelin P0, connexin 32, and early growth response 2. There is considerable variability in the phenotypic expression of this syndrome and the relationship of this variability to mutation genotypes requires extensive analysis. Here we describe the phenotypes and genotypes of four new mutations underlying the Charcot-Marie-Tooth syndrome and document segregation with disease. Four families with Charcot-Marie-Tooth were ascertained, examined, and evaluated electrophysiologically. Each family had peripheral blood DNA screened for mutations in myelin protein 22, myelin P0, and connexin 32. Two families were found with new mutations in the myelin P0 gene: S140T in the extracellular domain and K236del in the cytoplasmic domain. All families showed segregation of the mutations with the Charcot-Marie-Tooth phenotype as did a new family with the rare G163R mutation in the membrane domain. A 49-year-old man with the S140T mutation demonstrated conduction block on electrophysiological testing. A family with a novel S49P mutation in the connexin 32 gene had a neuropathy with very slow nerve conduction. These new mutations in the myelin P0 and connexin 32 genes help to clarify the pathophysiology of the clinical Charcot-Marie-Tooth syndrome. The S140T mutation in myelin P0 can be associated with conduction block and Charcot-Marie-Tooth should be part of the differential diagnosis of that phenomenon. Mutations in the cytoplasmic domain of myelin P0 can cause clinical neuropathy. The S49P mutation in the connexin 32 gene can produce aspects of a demyelinating type of X-linked hereditary neuropathy. (C) 2002 Elsevier Science B.V. All rights reserved. C1 Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Bloedel Hearing Ctr, Seattle, WA 98195 USA. VA Med Ctr, GRECC S 182, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Athena Diagnost Inc, Worcester, MA 01605 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Bird, TD (reprint author), Univ Washington, Dept Neurol, Seattle, WA 98195 USA. NR 34 TC 22 Z9 24 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2002 VL 12 IS 7-8 BP 643 EP 650 AR PII S0960-8966(02)00021-4 DI 10.1016/S0960-8966(02)00021-4 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 602HA UT WOS:000178498800005 PM 12207932 ER PT J AU Bartzokis, G AF Bartzokis, G TI Schizophrenia: Breakdown in the well-regulated lifelong development and SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE schizophrenia; brain; development; myelin; white matter; connectivity; neural networks; frontal; temporal; association regions ID MAGNETIC-RESONANCE SPECTROSCOPY; AGE-RELATED-CHANGES; CHILDHOOD-ONSET SCHIZOPHRENIA; FIRST-EPISODE SCHIZOPHRENIA; 22Q11 DELETION SYNDROME; PREFRONTAL GRAY-MATTER; HUMAN CEREBRAL-CORTEX; WHITE-MATTER; APOLIPOPROTEIN-D; IN-VIVO AB Recent evidence suggests that the temporal extent of brain development/maturation can be expanded into middle age when maximal white matter volume and myelination are reached in frontal lobes and association areas. This temporally expanded view of brain development underlies a more comprehensive conceptual model of schizophrenia that incorporates both the reduction of gray matter volume and the complementary expansion of white matter volume occurring from adolescence until middle age. The model posits that the brain is in a constant state of well-regulated structural and functional change roughly defined as periods of development continuing into middle age followed by degeneration. Multiple genetic and environmental factors can interfere with the developmental processes resulting in a dysregulation of the complementary changes occurring in gray and white matter. This dysregulation in development results in an insufficient capacity to maintain temporal synchrony of widely distributed neural networks and is manifested in the heterogeneity of symptoms and cognitive impairments of schizophrenia. The model highlights the contributory role of myelination to synchronous brain function, provides explanations for inconsistencies in the existing literature, and suggests testable hypotheses and novel approaches for intervention efforts. C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. Cent Arkansas Vet Hlthcare Syst, Little Rock, AR USA. Greater Los Angeles VA Hlthcare Syst, Los Angeles, CA USA. RP Bartzokis, G (reprint author), 710 Westwood Plaza,Room 2-238, Los Angeles, CA 90095 USA. RI Bartzokis, George/K-2409-2013 FU NIMH NIH HHS [MH-51928] NR 144 TC 120 Z9 121 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD OCT PY 2002 VL 27 IS 4 BP 672 EP 683 AR PII S0893-133X(02)00364-0 DI 10.1016/S0893-133X(02)00364-0 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 593GY UT WOS:000177983700017 PM 12377404 ER PT J AU Porte, D Baskin, DG Schwartz, MW AF Porte, D Baskin, DG Schwartz, MW TI Leptin and insulin action in the central nervous system SO NUTRITION REVIEWS LA English DT Article; Proceedings Paper CT 19th Marabou Symposium Leptin - A Key Regulator in Nutrition CY JUN 15-17, 2001 CL SUNDBYBERG, SWEDEN SP 4 DE adiposity; insulin; leptin; ventral hypothalamus; anabolic; catabolic signaling; satiety system ID PROOPIOMELANOCORTIN MESSENGER-RNA; MELANIN-CONCENTRATING-HORMONE; REDUCES FOOD-INTAKE; BODY-WEIGHT; GENE-EXPRESSION; ARCUATE NUCLEUS; BRAIN INSULIN; OB/OB MICE; MELANOCORTIN RECEPTORS; HYPOTHALAMIC NEURONS AB Body adiposity is known to be carefully regulated and to remain relatively stable for long periods of time in most mammalian species. This review summarizes old and recent data implicating insulin and leptin as key circulating signals to the central nervous system, particularly the ventral hypothalamus, in communicating the size and the distribution of body fat stores. This input ultimately alters food intake and energy expenditure to maintain constancy of the adipose depot The key primary neurons in the arcuate nucleus containing NPY/AgRP and POMC/CART appear be critical constituents of the CNS regulating system, and are shown to contribute to anabolic and catabolic signaling systems to complete the feedback loop. New data to indicate shared intracellular signaling from leptin and insulin is provided. The satiety system for meals, consisting of neural afferents to the hind-brain from the gastrointestinal tract, is described and its effectiveness is shown to vary with the strength of the insulin and leptin signals. This provides an efferent mechanism that plays a key role in a complex feedback system that allows intermittent meals to vary from day to day, but provides appropriate long-term adjustment to need. Recently described contributions of this system to obesity are described and potential therapeutic implications are discussed. C1 Univ Calif San Diego, Div Metab Diabet & Endocrinol, San Diego, CA 92161 USA. VA San Diego Healthcare Syst, San Diego, CA 92161 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Harborview Med Ctr, Div Endocrine, Seattle, WA 98104 USA. RP Porte, D (reprint author), Univ Calif San Diego, Div Metab Diabet & Endocrinol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. RI Schwartz, Michael/H-9950-2012 FU NIDDK NIH HHS [DK 52989, DK12829]; NINDS NIH HHS [NS 32273] NR 93 TC 106 Z9 109 U1 2 U2 12 PU INT LIFE SCIENCES INST PI LAWRENCE PA 810 EAST 10TH ST SUBSCRIPTION OFFICE, LAWRENCE, KS 66044 USA SN 0029-6643 J9 NUTR REV JI Nutr. Rev. PD OCT PY 2002 VL 60 IS 10 BP S20 EP S29 PN 2 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 602VB UT WOS:000178524200003 PM 12403080 ER PT J AU Friedlander, AH Norman, DC AF Friedlander, AH Norman, DC TI Late-life depression: Psychopathology, medical interventions, and dental implications SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS LA English DT Article ID SEROTONIN REUPTAKE INHIBITORS; BURNING MOUTH SYNDROME; NURSING-HOME RESIDENTS; ELECTROCONVULSIVE-THERAPY; GERIATRIC DEPRESSION; MAJOR DEPRESSION; OLDER ADULTS; TRICYCLIC ANTIDEPRESSANTS; PSYCHOLOGICAL-ASPECTS; DRUG-INTERACTIONS AB Background. Late-life depression (LLD) initially occurs after age 65 years and is a major public health concern because the elderly who are at high risk constitute an ever-expanding segment of the population. LLD is a mental illness in which mood, thought content, and behavioral patterns are impaired, causing the individual distress, compromising social function; and impairing self-maintenance skills (eg, bathing, dressing, hygiene). LLD characterized by marked sadness or a loss of interest or pleasure in daily activities and maybe accompanied by weight change, sleep disturbance, fatigue, difficulty in concentration, and a high suicide rate. Diagnosis of LLD is sometimes complicated by a denial of mood change and an inability to distinguish symptoms of a concurrent physical illness from those of a depressive etiology. The disorder is most frequently treated with antidepressant medications, and although older individuals have a recovery rate that is comparable with younger adults, they often take longer to recover, have more frequent relapses, and are more sensitive to the side effects of the drugs. Clinical implications. Individuals undergoing treatment for LLD and those whose illness has not been diagnosed or treated often are seen with significant oral disease by the dentist. Dentists need to be cognizant of how to safely and compassionately provide care to those already receiving mental health services. They must also be familiar with the psychiatric symptoms of the disorder to effectuate a timely referral to a physician of those with occult or relapsing disease. LLD is frequently associated with a disinterest in oral hygiene, a cariogenic diet, diminished salivary flow, rampant dental decay, advanced periodontal disease, and oral dysesthesias. Many medications used to treat the disease magnify the xerostomia and increase the incidence of dental disease. Appropriate dental management necessitates a vigorous preventive dental education program, the use of artificial salivary products, antiseptic mouthwash, daily fluoride mouth rinse, and special precautions in administration of local anesthetics with vasoconstrictors and prescription of analgesics. Conclusion. Dentists who invoke appropriate precautions can usually provide a full range of services to individuals with LLD, thereby enhancing patient self-esteem and contributing to the psychotherapeutic aspect of management. C1 VA Greater Los Angeles Healthcare Syst 14, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Med, Hosp Dent Serv, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst 14, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 96 TC 23 Z9 25 U1 0 U2 7 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 1079-2104 J9 ORAL SURG ORAL MED O JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. PD OCT PY 2002 VL 94 IS 4 BP 404 EP 412 DI 10.1067/moe.2002.122434 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 602KF UT WOS:000178503900004 PM 12374911 ER PT J AU Yang, H Tache, Y Ohning, G Go, VLW AF Yang, H Tache, Y Ohning, G Go, VLW TI Activation of raphe pallidus neurons increases insulin through medullary thyrotropin-releasing hormone (TRH)-vagal pathways SO PANCREAS LA English DT Article DE dorsal motor nucleus (DMN); kainic acid; pancreas; serum insulin levels; TRH antibody; vagus ID DORSAL VAGAL COMPLEX; GASTRIC-ACID SECRETION; WISTAR FATTY RATS; OBESE FA/FA RATS; VAGUS NERVE; MOTOR NUCLEUS; SUBSTANCE-P; PREGANGLIONIC NEURONS; ENDOCRINE PANCREAS; GENE-EXPRESSION AB Introduction: Pancreatic insulin secretion is regulated by the vagus nerve. Medullary thyrotropin-releasing hormone (TRH) containing projections from the raphe pallidus (Rpa) neurons innervate vagal preganglionic motor neurons in the dorsal vagal complex (DVC) and are involved in vagal regulation of gastric functions, Aim: To investigate whether chemical stimulation of Rpa neurons influences circulating insulin levels through brain medullary TRH-vagal pathways. Methodology: In fasted, pentobarbital-anesthetized rats, kainic acid (10 ng/50 nL) was microinjected into the Rpa, and serum insulin levels were measured. Gastric acid secretion was monitored as a control of vagally mediated visceral response. Results: Chemical stimulation of Rpa neuronal cell bodies significantly increased serum insulin levels. Values before and at 30, 60, and 90 minutes after the microinjection of kainic acid were 0.34 +/- 0.02, 0.54 +/- 0.06, 0.60 +/- 0.06, and 0.99 +/- 0.13 ng/mL, respectively. In the same rats, gastric acid secretion was stimulated (basal, 2.3 +/- 0.6, versus 26.1 +/- 8.6 mumol/15 min at 30 minutes). Microinjections outside of the Rpa had no effect. The Rpa stimulation-induced increase in serum insulin could be mimicked by DVC microinjection of TRH analog, completely prevented by bilateral cervical vagotomy, and significantly reduced by bilateral microinjection of TRH antibody into the DVC. Conclusion: Chemical activation of Rpa neurons increases pancreatic insulin release through medullary TRH and vagal-mediated pathways. C1 Univ Calif Los Angeles, CURE,Digest Dis Res Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med,Div Digest Dis, Los Angeles, CA USA. Brain Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA USA. RP Yang, H (reprint author), W Los Angeles VA Med Ctr, DDRC, CURE, Bldg 115,Room 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-41301, DK-30110, DK-50255] NR 50 TC 15 Z9 15 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD OCT PY 2002 VL 25 IS 3 BP 301 EP 307 DI 10.1097/01.MPA.0000016985.11229.48 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 598DE UT WOS:000178259400014 PM 12370543 ER PT J AU Belperio, PS Glassman, PA Simon, B Lanto, A AF Belperio, PS Glassman, PA Simon, B Lanto, A TI Role of pharmacists in improving provider recognition of drug interactions. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 20-23, 2002 CL ALBUQUERQUE, NEW MEXICO SP Amer Coll Clin Pharmacy C1 VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2002 VL 22 IS 10 MA 10 BP 1325 EP 1325 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 601GN UT WOS:000178438300021 ER PT J AU Hamm, JW Washington, DM Cobb, TH Herndon, KC AF Hamm, JW Washington, DM Cobb, TH Herndon, KC TI Evaluation of a proton pump inhibitor step-down initiative in a Veterans Affairs medical center. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Annual Meeting of the American-College-of-Clinical-Pharmacy CY OCT 20-23, 2002 CL ALBUQUERQUE, NEW MEXICO SP Amer Coll Clin Pharmacy C1 Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Pfizer Inc, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD OCT PY 2002 VL 22 IS 10 MA 92 BP 1339 EP 1339 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 601GN UT WOS:000178438300088 ER PT J AU Eladoumikdachi, F Valkov, PL Thomas, J Netscher, DT AF Eladoumikdachi, F Valkov, PL Thomas, J Netscher, DT TI Anatomy of the intrinsic hand muscles revisited: Part I. Interossei SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB In this article, the anatomic variations in interosseous muscle insertions are described based on a review of the literature and 14 fresh cadaver hand dissections. The findings are correlated and compared with those of a number of other investigators, and the clinical implications are discussed (i.e., in the correction of ulnar deviation in arthritis patients and in the treatment of congenital anomalies of the hand). It is concluded that descriptions of insertion sites of the intrinsic muscles have been oversimplified by previous researchers, and a number of variations are identified through the cadaver dissections. The differing and confusing nomenclature used by other investigators is discussed and simplified. The results of this study indicate that not only are there important distal insertions onto bone and the extensor apparatus, but there is also an additional insertion onto the volar plate ("assemblage nucleus"), as Zancolli reported. It was found that the palmar interossei, generally thought to insert only onto the extensor apparatus, could also insert onto bone and onto the volar plate. Classic teaching is that all dorsal interossei (except the third) have two heads and that all palmar interossei have only one head. In this study, however, 38 percent of the palmar interossei and 75 percent of the dorsal interossei had more than one head. The complexity of the interossei is apparent when as many as three different muscle heads are present, each with a different distal destination. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. RP Netscher, DT (reprint author), 6560 Fannin,Suite 800, Houston, TX 77030 USA. NR 11 TC 15 Z9 17 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD OCT PY 2002 VL 110 IS 5 BP 1211 EP 1224 DI 10.1097/01.PRS.0000024442.72140.56 PG 14 WC Surgery SC Surgery GA 596WJ UT WOS:000178189200001 PM 12360058 ER PT J AU Eladoumikdachi, F Valkov, PL Thomas, J Netscher, DT AF Eladoumikdachi, F Valkov, PL Thomas, J Netscher, DT TI Anatomy of the intrinsic hand muscles revisited: Part II. Lumbricals SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article AB The authors discuss the anatomic variations and the precise origins and insertions of the lumbrical muscles, after dissecting 14 fresh cadavers (56 lumbrical muscles) and reviewing the scant published literature. They compare the findings with those of other investigators, and they describe the lumbrical muscle insertions discovered during the dissections. The authors conclude that descriptions of the origins and insertions of the lumbrical muscles have been oversimplified or not investigated at all, that lumbricals originate variably from the flexor digitorum profundus tendon and may even be bipinnate, and that three different major destinations exist for distal insertion of these intrinsic muscles: bone, volar plate, and extensor apparatus. Previous descriptions have focused only on the lumbrical continuation to the lateral band of the extensor mechanism. C1 Baylor Coll Med, Div Plast Surg, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. RP Netscher, DT (reprint author), 6560 Fannin,Suite 800, Houston, TX 77030 USA. NR 9 TC 21 Z9 23 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD OCT PY 2002 VL 110 IS 5 BP 1225 EP 1231 DI 10.1097/01.PRS.0000024443.27141.1D PG 7 WC Surgery SC Surgery GA 596WJ UT WOS:000178189200002 PM 12360059 ER PT J AU Garb, HN Wood, JM Lilienfeld, SO Nezworski, MT AF Garb, HN Wood, JM Lilienfeld, SO Nezworski, MT TI Effective use of projective techniques in clinical practice: Let the data help with selection and interpretation SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article ID COMPREHENSIVE SYSTEM; PERSONALITY-DISORDER; DEPRESSION INDEXES; RORSCHACH; VALIDITY; NORMS; CHILDREN; DRAWINGS; MMPI-2; TAT AB By learning about the validity of individual test scores, psychologists can avoid using scores that are invalid and making judgments that are potentially harmful to their clients. This is important not only for improving clinical and forensic practice but also for avoiding lawsuits. In this article, the effective use of projective techniques is described, with attention to the overperception of psychopathology, diagnosis and the description of symptoms, and the detection of child abuse. Guidelines are offered for using the Rorschach, Thematic Apperception Test, human figure drawings, and the Washington University Sentence Completion Test. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. Emory Univ, Atlanta, GA 30322 USA. Univ Texas, El Paso, TX 79968 USA. Univ Texas, Dallas, TX 75230 USA. RP Garb, HN (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr, Pittsburgh, PA 15206 USA. NR 79 TC 26 Z9 27 U1 4 U2 20 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD OCT PY 2002 VL 33 IS 5 BP 454 EP 463 DI 10.1037//0735-7028.33.5.454 PG 10 WC Psychology, Multidisciplinary SC Psychology GA 596VT UT WOS:000178187700004 ER PT J AU McClain, MT Scofield, RH Kurien, BT Gross, TF James, JA AF McClain, MT Scofield, RH Kurien, BT Gross, TF James, JA TI Selective small antigenic structures are capable of inducing widespread autoimmunity which closely mimics the humoral fine specificity of human SLE SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMMUNE-RESPONSE; 60-KDA RO; SM B/B'; IMMUNIZATION; PEPTIDES; ANTIBODIES; DISEASE; PROTEIN; MICE AB Recent data have suggested that autoantibodies in lupus can progress from simple immunity against a few antigenic structures to a complex response against multiple autoantigens. Our aim was to determine whether these diverse epitope patterns can indeed be generated by antigenic challenge with a single, small structure. Rabbits were immunized with either a 60 kDa Ro peptide commonly antigenic in human system lupus erythematosus (SLE) (Ro 274-289) or one which is rarely a humoral target (Ro 500-515). Rabbits immunized with the antigenic peptide (Ro 287-289) not only developed antibodies to multiple epitopes of 60 kDa Ro and La, as has been described, but also produced non-cross-reactive antibodies to the common spliceosomal proteins Sm B' and D1, and nRNP A and C. Rabbits immunized with the Ro 274-289 peptide also mount a progressive, diversified immune response to the sequential antigenic regions of these proteins (60 kDa Ro, Sm B' and D1, nRNP A and C), which is nearly identical to that seen in human SLE. Animals immunized with the nonantigenic peptide Ro 500-515 develop antibodies only to 60 kDa Ro. These results demonstrate that loss of tolerance to select single, small antigenic structures can begin a cascade which virtually recreates, at the epitope level, the humoral autoimmune specificity seen in human SLE. C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73114 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP James, JA (reprint author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73114 USA. RI Kurien, Biji/C-2392-2008 FU NIAID NIH HHS [AI31584]; NIAMS NIH HHS [AR01981, AR45084, AR45451] NR 33 TC 13 Z9 14 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0300-9475 J9 SCAND J IMMUNOL JI Scand. J. Immunol. PD OCT PY 2002 VL 56 IS 4 BP 399 EP 407 DI 10.1046/j.1365-3083.2002.01141.x PG 9 WC Immunology SC Immunology GA 594HP UT WOS:000178044100008 PM 12234261 ER PT J AU Mazarati, AM Sofia, RD Wasterlain, CG AF Mazarati, AM Sofia, RD Wasterlain, CG TI Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE fluorofelbamate; self-sustaining status epilepticus; spontaneous seizures; rat; hippocampus; antiepileptic drugs ID METHYL-D-ASPARTATE; SUSTAINING STATUS EPILEPTICUS; TEMPORAL-LOBE EPILEPSY; IN-VITRO REACTIVITY; RAT MODEL; FELBAMATE; RECEPTORS; SEIZURES; METABOLITE; MECHANISM AB Purpose: To examine the seizure-protective properties of fluorofelbamate, a felbamate analog, on acute and chronic seizures in an experimental model of self-sustaining status epilepticus (SSSE). Methods: SSSE was induced by stimulation of the perforant path for 30 min (PPS) through chronically implanted electrodes in free-running adult male Wistar rats. Fluorofelbamate was injected intravenously (i.v.) either 10 min, or 40 min after SSSE induction. Seizure and spike profiles were analyzed off-line. Results: Fluorofelbamate injected during the early stages of SSSE (10 min after the end of PPS), shortened the duration of seizures in a dose-dependent manner. While a dose of 50 mg kg(-1) was ineffective, 100 and 200 mg kg(-1) reduced cumulative seizure time from 393 +/- 10 min to 15 +/- 8 min and 2.4 +/- 0.5 min respectively. Administration of fluorofelbamate (200 and 300 mg kg-1) at a late stage of SSSE, which is refractory to treatment with conventional anticonvulsants, also significantly attenuated seizures. Acute fluorofelbamate treatment (200 mg kg-1 10 min after PPS) significantly decreased the frequency of spontaneous seizures which follow SSSE after a 'latent' interval. Moreover, in contrast to control animals, fluorofelbamate-treated rats showed regression of spontaneous seizures, and an apparent remission of epilepsy within 2 months after SSSE. Conclusions: Acute treatment of SSSE with fluorofelbamate showed strong anticonvulsant effects even during the late stages of SSSE. In this model, it also displayed antiepileptogenic properties: it reduced the severity of chronic epilepsy after SSSE and lead to apparent remissions of that epilepsy. (C) 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. Wallace Pharmaceut, Cranbury, NJ USA. RP Wasterlain, CG (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. FU NINDS NIH HHS [NS13515] NR 32 TC 22 Z9 22 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD OCT PY 2002 VL 11 IS 7 BP 423 EP 430 DI 10.1053/seiz.2002.0677 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 609BF UT WOS:000178882200003 PM 12237067 ER PT J AU Freedland, SJ Amling, CL Dorey, F Kane, CJ Presti, JC Terris, MK Aronson, WJ AF Freedland, SJ Amling, CL Dorey, F Kane, CJ Presti, JC Terris, MK Aronson, WJ CA Search Database Study Grp TI Race as an outcome predictor after radical prostatectomy: Results from the shared equal access regional cancer hospital (search) database SO UROLOGY LA English DT Article ID SEXTANT BIOPSIES; INDEPENDENT PREDICTOR; DISEASE RECURRENCE; SURVIVAL; IMPACT; RISK; MEN AB Objectives. Whether race is an independent predictor of prostate-specific antigen (PSA) recurrence after RP is controversial. To compare racial differences in clinical and pathologic features and biochemical recurrence in men undergoing radical prostatectomy (RP), we used a newly established multicenter database of patients from four equal-access healthcare centers in California, the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Methods. A retrospective survey of 1547 patients treated with RP at four different equal-access medical centers in California between 1988 and 2001 was undertaken. Race was categorized as white (n = 10 14), black (n = 338), or nonwhite-nonblack (n = 195). Patients were analyzed for racial differences in preoperative variables (age at surgery, clinical stage, PSA, and biopsy Gleason score) and surgical variables (pathologic stage, surgical Gleason score, incidence of seminal vesicle invasion, positive surgical margins, capsular penetration, and pelvic lymph node involvement). Patients were followed up for PSA recurrence. Multivariate analysis was used to determine whether race was an independent predictor of biochemical failure. Results. Significant differences were found among the races in the preoperative factors of clinical stage, age, serum PSA, and biopsy Gleason score, although the absolute differences were small. No differences were found among the races in the pathologic features of the RP specimens, including Gleason score, pathologic stage, and incidence of positive surgical margins, capsular penetration, seminal vesicle invasion, or lymph node involvement. In both univariate and multivariate analyses, only serum PSA (P <0.001) and biopsy Gleason score (P <0.001) were significant independent predictors of time to biochemical recurrence. Conclusions. In a large multicenter cohort of patients from four equal-access medical care facilities in California, although racial differences were found in clinical stage, age, biopsy Gleason score, and serum PSA level at diagnosis, we found race was not an independent predictor of biochemical recurrence after RP. Race should not be used in models or nomograms predicting PSA failure after RP. The current study represents the largest series of black patients and the first large series of nonwhite-nonblack patients treated with RP reported to date. The Shared Equal Access Regional Cancer Hospital database is a valuable resource for studying patients treated with RP. (C) 2002, Elsevier Science Inc. C1 Univ Calif Los Angeles, Dept Urol, Sch Med, Los Angeles, CA 90095 USA. San Diego Naval Hosp, Dept Urol, San Diego, CA USA. Univ Calif Los Angeles, Dept Biostat, Sch Med, Los Angeles, CA USA. Vet Affairs Med Ctr, Dept Surg, Urol Sect, San Francisco, CA 94121 USA. Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA. Palo Alto Vet Affairs Med Ctr, Dept Surg, Palo Alto, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Aronson, WJ (reprint author), Univ Calif Los Angeles, Dept Urol, Sch Med, Box 951738, Los Angeles, CA 90095 USA. NR 16 TC 84 Z9 87 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD OCT PY 2002 VL 60 IS 4 BP 670 EP 674 AR PII S0090-4295(02)01847-2 DI 10.1016/S0090-4295(02)01847-2 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 603UK UT WOS:000178578700026 PM 12385931 ER PT J AU Luck, J Peabody, JW AF Luck, J Peabody, JW TI Using standardised patients to measure physicians' practice: validation study using audio recordings SO BRITISH MEDICAL JOURNAL LA English DT Article ID SIMULATED PATIENTS; CHART ABSTRACTION; PERFORMANCE; QUALITY; SKILLS AB Objective To assess the validity of standardised patients to measure the quality of physicians' practice. Design Validation study of standardised patients' assessments. Physicians saw unannounced standardised patients presenting with common outpatient conditions. The standardised patients covertly tape recorded their visit and completed a checklist of quality criteria immediately afterwards. Their assessments were compared against independent assessments of the recordings by a trained medical records abstractor. Setting Four general internal medicine primary care clinics in California. Participants 144 randomly selected consenting physicians. Main outcome measures Rates of agreement between the patients' assessments and independent assessment. Results 40 visits, one per standardised patient, were recorded. The overall rate of agreement between the standardised patients' checklists and the independent assessment of the audio transcripts was 91% (K=0.81). Disaggregating the data by medical condition, site, level of physicians' training, and domain (stage of the consultation) gave similar rates of agreement. Sensitivity of the standardised patients' assessments was 95%, and specificity was 85%. The area under the receiver operator characteristic curve was 90%. Conclusions Standardised patients' assessments seem to be a valid measure of the quality of physicians' care for a variety of common medical conditions in actual outpatient settings. Properly trained standardised. patients compare well with independent assessment of recordings of the consultations and may justify their use as a "gold standard" in comparing the quality of care across sites or evaluating data obtained from other sources, such as medical records and clinical vignettes. C1 Inst Global Hlth, San Francisco, CA 94105 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Peabody, JW (reprint author), Inst Global Hlth, 74 New Montgomery St, San Francisco, CA 94105 USA. NR 30 TC 90 Z9 91 U1 1 U2 2 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD SEP 28 PY 2002 VL 325 IS 7366 BP 679 EP + DI 10.1136/bmj.325.7366.679 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 600JV UT WOS:000178387600018 PM 12351358 ER PT J AU Zandi, PP Anthony, JC Hayden, KM Mehta, K Mayer, L Breitner, JCS AF Zandi, PP Anthony, JC Hayden, KM Mehta, K Mayer, L Breitner, JCS CA Cache County Study Investigators TI Reduced incidence of AD with NSAID but not H-2 receptor antagonists - The Cache County Study SO NEUROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HISTAMINE-H2 BLOCKING-DRUGS; ALZHEIMERS-DISEASE; RHEUMATOID-ARTHRITIS; COGNITIVE DECLINE; CONTROLLED TRIAL; DOUBLE-BLIND; DEMENTIA; RISK; INFLAMMATION AB Background: Previous analyses from the Cache County (UT) Study showed inverse associations between the prevalence of AD and the use of nonsteroidal anti-inflammatory drugs (NSAID), aspirin compounds, or histamine H, receptor antagonists (H,RA). The authors re-examined these associations using data on incident AD. Methods: In 1995 to 1996, elderly (aged 65+) county residents were assessed for dementia, with current and former use of NSAID, aspirin, and H,RA as well as three other "control" medication classes also noted. Three years later, interval medication histories were obtained and 104 participants with incident AD were identified among 3,227 living participants. Discrete time survival analyses estimated the risk of incident AD in relation to medication use. Results: AD incidence was marginally reduced in those reporting NSAID use at any time. Increased duration of use was associated with greater risk reduction, and the estimated hazard ratio was 0.45 with greater than or equal to2 years of exposure. Users of NSAID at baseline showed little reduction in AD incidence, regardless of use thereafter. By contrast, former NSAID users showed substantially reduced incidence (estimated hazard ratio = 0.42), with a trend toward greatest risk reduction among those with extended exposure. Similar patterns appeared with aspirin but not with any other medicines examined. Conclusions: Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. More recent exposure seems to offer little protection. Recently initiated randomized trials of NSAID for primary prevention of AD are therefore unlikely to show effects with treatment until participants have been followed for several years. C1 VA Puget Sound Hlth Care Syst, GRECC S182, Seattle, WA 98108 USA. Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hyg, Baltimore, MD USA. Banner Hlth Syst, Phoenix, AZ USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Breitner, JCS (reprint author), VA Puget Sound Hlth Care Syst, GRECC S182, 1660 S Columbian Way, Seattle, WA 98108 USA. RI Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [AG-11380]; NIMH NIH HHS [MH-14592] NR 48 TC 218 Z9 224 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 24 PY 2002 VL 59 IS 6 BP 880 EP 886 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 596JH UT WOS:000178161100015 PM 12297571 ER PT J AU Johnson, KR Becker, KP Facchinetti, MM Hannun, YA Obeid, LM AF Johnson, KR Becker, KP Facchinetti, MM Hannun, YA Obeid, LM TI PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane - Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA) SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID 2ND MESSENGER; CELL-GROWTH; 1-PHOSPHATE; CERAMIDASE; EXPRESSION; STRESS; SPHINGOMYELINASE; DIFFERENTIATION; PROLIFERATION; SURVIVAL AB Sphingosine-1-phosphate (S1P) is a highly bioactive sphingolipid involved in diverse biological processes leading to changes in cell growth, differentiation, motility, and survival. S1P generation is regulated via sphingosine kinase (SK), and many of its effects are mediated through extracelluar action on G-protein-coupled receptors. In this study, we have investigated the mechanisms regulating SK, where this occurs in the cell, and whether this leads to release of S1P extracellularly. The protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), induced early activation of SK in HEK 293 cells, and this activation was more specific to the membrane-associated SK. Therefore, we next investigated whether PMA induced translocation of SK to the plasma membrane. PMA induced translocation of both endogenous and green fluorescent protein (GFP)-tagged human SKI (hSK1) to the plasma membrane. PMA also induced phosphorylation of GFP-hSK1. The PMA-induced translocation was abrogated by preincubation with known PKC inhibitors (bisindoylmaleimide and calphostin-c) as well as by the indirect inhibitor of PKC, C-6-ceramide, supporting a role for PKC in mediating translocation of SK to the plasma membrane. SK activity was not necessary for translocation, because a dominant negative G82D mutation also translocated in response to PMA. Importantly, PKC regulation of SK was accompanied by a 4-fold increase in S1P in the media. These results demonstrate a novel mechanism by which PKC regulates SK and increases secretion of S1P, allowing for autocrine/paracrine signaling. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Dept Vet Affairs, Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Univ Buenos Aires, Fac Farm & Bioquim, Dept Biol Sci, RA-1113 Buenos Aires, DF, Argentina. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. OI obeid, lina/0000-0002-0734-0847 FU NHLBI NIH HHS [HL07260, HL43707]; NIGMS NIH HHS [GM62887] NR 30 TC 202 Z9 209 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 20 PY 2002 VL 277 IS 38 BP 35257 EP 35262 DI 10.1074/jbc.M203033200 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 595PB UT WOS:000178117000077 PM 12124383 ER PT J AU Jatana, M Giri, S Singh, AK AF Jatana, M Giri, S Singh, AK TI Apoptotic positive cells in Krabbe brain and induction of apoptosis in rat C6 glial cells by psychosine SO NEUROSCIENCE LETTERS LA English DT Article DE Krabbe brain; terminal dUTP nick-end labeling; apoptosis; psychosine; C6 glial cells; annexin-V ID MURINE MODEL; OLIGODENDROCYTES; LEUKODYSTROPHY; LOCALIZATION; ACCUMULATION; METABOLITE; TWITCHER; DISEASE; DEATH AB Globoid cell leukodystrophy (GILD) is an autosomal recessive disorder of infants, caused by deficient activity of cerebroside-beta-galactosidase resulting in loss of myelin accompanied by loss of oligodendrocytes. The loss of oligodendrocyte population is accompanied by accumulation of psychosine, which is considered as the molecule responsible for the observed pathophysiology of GLD. We were able to detect apoptotic cells by terminal dUTP nick-end labeling assay and nuclear localization of p53 in postmortem brain tissue of Krabbe's disease patients, which were not detected in the control brain. To study the role of psychosine in cell death, we investigated the effect of psychosine on C6 glial cell survival by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Similar to ceramide (43.8% loss) the galactopsychosine and glucopsychosine treatment killed up to 46.3 and 48.75% of cells, respectively. On the other hand, sphingosine had no effect. DNA laddering assay confirmed these results. Moreover, psychosine-induced detection of annexin-V positive cells supports a role for psychosine in C6 glial cell death via the apoptotic pathway. These results indicate that psychosine may play a role in apoptotic cell loss observed in GILD brain. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Pathol & Pediat, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Pediat, 316 Clin Sci Bldg,POB 250160, Charleston, SC 29425 USA. FU NINDS NIH HHS [NS-37766] NR 20 TC 54 Z9 55 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD SEP 20 PY 2002 VL 330 IS 2 BP 183 EP 187 AR PII S0304-3940(02)00655-9 DI 10.1016/S0304-3940(02)00655-9 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 606GC UT WOS:000178725400015 PM 12231442 ER PT J AU Ratcliffe, MB AF Ratcliffe, MB TI Non-ischemic infarct extension - A new type of infarct enlargement and a potential therapeutic target SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID LEFT-VENTRICULAR ANEURYSM; ACUTE MYOCARDIAL-INFARCTION; MATRIX-METALLOPROTEINASE; MECHANICAL DYSFUNCTION; VOLUME REDUCTION; PATCH REPAIR; BORDER ZONE; CELL-DEATH; MODEL; MYOCYTES C1 San Francisco Vet Affairs Med Ctr, VAMC Surg 112D, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Dept Surg, Div Cardiothorac Surg, San Francisco, CA 94143 USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, VAMC Surg 112D, 4150 Clement St, San Francisco, CA 94121 USA. NR 31 TC 33 Z9 35 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 18 PY 2002 VL 40 IS 6 BP 1168 EP 1171 AR PII S0735-1097(02)02113-7 DI 10.1016/S0735-1097(02)02113-7 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 593TQ UT WOS:000178009900023 ER PT J AU Berg, AO Allan, JD Frame, PS Homer, CJ Johnson, MS Klein, JD Lieu, TA Mulrow, CD Orleans, CT Peipert, JF Pender, NJ Siu, AL Teutsch, SM Westhoff, C Woolf, SH AF Berg, AO Allan, JD Frame, PS Homer, CJ Johnson, MS Klein, JD Lieu, TA Mulrow, CD Orleans, CT Peipert, JF Pender, NJ Siu, AL Teutsch, SM Westhoff, C Woolf, SH CA US Preventive Serv Task Force TI Screening for osteoporosis in postmenopausal women: Recommendations and rationale SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID BONE DENSITOMETRY AB This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for osteoporosis and the supporting scientific evidence and updates the 1996 USPSTF recommendations on this topic. The complete USPSTF recommendation and rationale statement on this topic, which includes a brief review of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and the systematic evidence review on the Web sites already mentioned. C1 Univ Washington, Seattle, WA 98195 USA. Univ Maryland, Baltimore, MD 21201 USA. Univ Rochester, Rochester, NY 14627 USA. Natl Initiat Childrens Healthcare Qual, Boston, MA USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Univ Rochester, Sch Med, Rochester, NY 14642 USA. Harvard Pilgrim Hlth Care, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78284 USA. Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Mt Sinai Sch Med, New York, NY USA. Merck & Co Inc, W Point, PA USA. Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. Virginia Commonwealth Univ, Fairfax, VA USA. RP Berg, AO (reprint author), Univ Washington, Seattle, WA 98195 USA. NR 5 TC 217 Z9 221 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 17 PY 2002 VL 137 IS 6 BP 526 EP 528 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 594UJ UT WOS:000178069100008 ER PT J AU Fihn, SD Williams, SV Gibbons, RJ AF Fihn, SD Williams, SV Gibbons, RJ TI Guidelines for the management of patients with chronic stable angina - In response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID THERAPY C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Penn, Philadelphia, PA 19104 USA. Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. RP Fihn, SD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 17 PY 2002 VL 137 IS 6 BP 549 EP 549 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 594UJ UT WOS:000178069100022 ER PT J AU Lawrence, VA AF Lawrence, VA TI Postoperative pulmonary complications - In response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID OXYGEN C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Lawrence, VA (reprint author), Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 17 PY 2002 VL 137 IS 6 BP 551 EP 551 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 594UJ UT WOS:000178069100026 ER PT J AU Ly, J Percy, L Dhanani, S AF Ly, J Percy, L Dhanani, S TI Use of dietary supplements and their interactions with prescription drugs in the elderly SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 10, 2001 CL CHICAGO, ILLINOIS SP Amer Geriatr Soc ID ALTERNATIVE MEDICINE USE; GINKGO-BILOBA; CLINICAL CONSIDERATIONS; HERBAL MEDICINALS; SAFETY ISSUES; INGESTION; THERAPIES AB The Notes section welcomes the following types of contributions: (1) practical innovations or solutions to everyday practice problems, (2) substantial updates or elaborations on work previously published by the same authors, (3) important confirmations of research findings previously published by others, and (4) short research reports, including practice surveys, of modest scope or interest. Notes should be submitted with AJHP's manuscript checklist. The text should be concise, and the number of references, tables, and figures should be limited. C1 Vet Affairs Greater Los Angeles Healthcare Syst, GRECC 11 G, Los Angeles, CA 90073 USA. San Gabriel Med Ctr, San Gabriel, CA USA. Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. Univ So Calif, Los Angeles, CA USA. Univ Pacific, Stockton, CA 95211 USA. Western Univ Hlth Sci, Pomona, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Evaluat & Management Unit, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med Geriatr Med, Los Angeles, CA USA. RP Dhanani, S (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, GRECC 11 G, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 33 TC 11 Z9 11 U1 2 U2 2 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD SEP 15 PY 2002 VL 59 IS 18 BP 1759 EP 1762 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 597PY UT WOS:000178231000014 PM 12298114 ER PT J AU Lewinsohn, DA Lines, RA Lewinsohn, DM AF Lewinsohn, DA Lines, RA Lewinsohn, DM TI Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis-specific CD8(+) T cells SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE CD8-positive T lymphocytes; dendritic cells; tuberculosis ID PULMONARY TUBERCULOSIS; IMMUNE-RESPONSES; INFECTION; MICE; VACCINATION; CD4(+); LYMPHOCYTES; PROTEINS; EPITOPE; MODELS AB Previous studies in murine and human models have suggested an important role for CD8(+) T cells in host defense to Mycobacterium tuberculosis (Mtb). Consequently, a successful tuberculosis vaccine may require the elicitation of sustained CD4(+) and CD8(+) T cell responses. We tested the hypothesis that the potent CD4(+) T cell antigen Mtb39 is also a CD8(+) T cell antigen. A recombinant adenovirus-expressing Mtb39 (adenoMtb39) was used to infect monocyte-derived dendritic cells. Using interferon-gamma enzyme-linked immunospot, Mtb39-specific CD8(+) T lymphocytes were detected in three healthy individuals with latent tuberculosis infection who also had strong anti-Mtb39-specific CD4(+) T cell responses. An Mtb39-specific CD8(+) T cell line was generated using Mtb39-expressing dendritic cells. Mtb39-specific T cell clones were obtained by limiting dilution cloning. All seven T cell clones obtained were HLA-B44 restricted. Using a panel of synthetic overlapping peptides representative of Mtb39, the peptide epitope was identified for two clones. Furthermore, all T cell clones recognized Mtb-infected dendritic cells and were cytolytic. We conclude that infection of dendritic cells with adenoviral vectors expressing Mtb proteins allows for measurement of antigen-specific CD8(+) T cell responses from peripheral blood mononuclear cells. The technique will be useful in defining CD8(+) T cell antigens and in measuring immunogenicity of tuberculosis vaccines. C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Pediat Infect Dis, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Pediat Infect Dis, Dept Mol Microbiol & Immunol, 3710 SW US Vet Rd,R&D 11, Portland, OR 97201 USA. RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU NIAID NIH HHS [1K08AI01644, 1KO8AI01645-03]; NICHD NIH HHS [HD33703] NR 32 TC 25 Z9 26 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2002 VL 166 IS 6 BP 843 EP 848 DI 10.1164/rccm.2110094 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 594AU UT WOS:000178027300014 PM 12231495 ER PT J AU Butt, AA AF Butt, AA TI Hepatitis C information on the World Wide Web SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; INITIAL TREATMENT; VIRUS-INFECTION; NON-A; INTERFERON-ALPHA-2B; TRIAL AB World Wide Web sites about hepatitis C vary from simple Web sites that provide basic information to the layperson to regularly updated medical-information portals. Medical professionals can use these Web sites to obtain up-to-date information on the epidemiological characteristics of hepatitis C and treatment of and information materials for their patients. For researchers in this field, there are Web sites that provide bibliographies, conference summaries and updates, and continuing medical education credits. This review provides an overview of selected Web sites for health care providers and researchers, sites of professional societies, sites created by patients, and sites created by the pharmaceutical industry. C1 Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Butt, AA (reprint author), Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Healthcare Syst, 3601 5th Ave,Ste 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. NR 7 TC 2 Z9 2 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2002 VL 35 IS 6 BP 754 EP 759 DI 10.1086/342204 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 589MQ UT WOS:000177763200017 PM 12203174 ER PT J AU Bent, S Nallamothu, BK Fihn, SD Saint, S AF Bent, S Nallamothu, BK Fihn, SD Saint, S TI Clinical diagnosis of urinary tract infection - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID WOMEN C1 Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Ann Arbor VA Med Ctr, Dept Med, Ann Arbor, MI USA. RP Bent, S (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 11 PY 2002 VL 288 IS 10 BP 1230 EP 1231 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 592BW UT WOS:000177917700016 ER PT J AU Reiber, GE Smith, DG Heagerty, PJ LeMaster, J Wallace, C Hayes, SG Sullivan, K Maciejewski, M Yu, O AF Reiber, GE Smith, DG Heagerty, PJ LeMaster, J Wallace, C Hayes, SG Sullivan, K Maciejewski, M Yu, O TI Therapeutic footwear in patients with diabetes - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID RISK; ULCERATION C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Shanes Foot Comfort Ctr, Seattle, WA USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. RP Reiber, GE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 5 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 11 PY 2002 VL 288 IS 10 BP 1232 EP 1233 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 592BW UT WOS:000177917700019 ER PT J AU Cai, JM Hastukami, TS Ferguson, MS Small, R Polissar, NL Yuan, C AF Cai, JM Hastukami, TS Ferguson, MS Small, R Polissar, NL Yuan, C TI Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging SO CIRCULATION LA English DT Article DE magnetic resonance imaging; atherosclerosis; carotid arteries ID HIGH-RESOLUTION MRI; ARTERY STENOSIS; IN-VIVO; PLAQUE; HEMORRHAGE; THROMBOSIS; ACCURACY; RUPTURE AB Background-Recent studies demonstrated that in vivo and ex vivo MRI can characterize the components of the carotid atherosclerotic plaque, such as fibrous tissue, lipid/necrotic core, calcium, hemorrhage, and thrombus. The purpose of this study was to determine whether in vivo high-resolution multicontrast MRI could accurately classify human carotid atherosclerotic plaque according to the American Heart Association classification. Methods and Results-Sixty consecutive patients (mean age 70 years; 54 males) scheduled for carotid endarterectomy were imaged with a 1.5-T scanner after informed consent was obtained. A standardized protocol was used to obtain 4 different contrast-weighted images (time of flight and T1-, PD-, and T2-weighted) of the carotid arteries. Best voxel size was 0.25 x 0.25 x 1 mm(3). Carotid plaques were removed intact and processed for histological examination. Both MR images and histological sections were independently reviewed, categorized, and compared. Overall, the classification obtained by MRI and the American Heart Association classifications showed good agreement, with Cohen's kappa (95% CI) of 0.74 (0.67 to 0.82) and weighted kappa of 0.79. The sensitivity and specificity, respectively, of MRI classification were as follows: type I-II lesions, 67% and 100%; type III lesions, 81% and 98%; type IV-V lesions, 84% and 90%; type VI lesions, 82% and 91%; type VII lesions, 80% and 94%; and type VIII lesions, 56% and 100%. Conclusions-In vivo high-resolution multicontrast MRI is capable of classifying intermediate to advanced atherosclerotic lesions in the human carotid artery and is also capable of distinguishing advanced lesions from early and intermediate atherosclerotic plaque. C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. Mt Whisper Light Stat Consulting, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yuan, C (reprint author), Univ Washington, Dept Radiol, Box 357115, Seattle, WA 98195 USA. FU NHLBI NIH HHS [R01 HL60213, R01 HL56874] NR 23 TC 377 Z9 419 U1 2 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD SEP 10 PY 2002 VL 106 IS 11 BP 1368 EP 1373 DI 10.1161/01.CIR.0000028591.44554.F9 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 593LN UT WOS:000177993100021 PM 12221054 ER PT J AU Montgomery, RB AF Montgomery, RB TI Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE EGFR; dimerization; quinazoline; tyrphostin; mutant; tyrosine kinase ID EPIDERMAL GROWTH-FACTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; TYRPHOSTINS; PATHWAY; PHOSPHORYLATION; PROLIFERATION; DIMERIZATION AB A mutated form of the EGF receptor (EGFRvIII), resulting from deletion of exons 2-7, is an oncogenic protein that is expressed in multiple human tumors. This mutation induces ligand-independent activation of the EGFR tyrosine kinase and thereby can initiate unregulated cell growth and tumorigenesis. Thus, inhibition of the kinase activity of EGFRvIII is a potential means of suppressing its oncogenic properties. Certain tyrosine kinase inhibitors (tyrphostins) specifically inhibit the wild-type EGFR and thereby inhibit tumor growth both in vitro and in vivo. We demonstrate that the quinazoline tyrphostins AG 1478 and AG 15 17 can suppress morphologic transformation of cell lines by EGFRvIII. Quinazolines were found to inhibit receptor autophosphorylation and signaling through MAP kinase, but had minimal effects on association of EGFRvIII with Grb2/SOS. Low concentrations of quinazoline also increased receptor dimerization and phosphotyrosine content. This was associated with increases in colony formation in soft agar and increased invasion through matrigel for AG 1478. Thus, both AG 1478 and AG 15 17 can inhibit multiple EGFRvIII signaling pathways, but at low concentrations AG 1478 can enhance colony formation, presumably related to augmented homodimerization of the receptor and activation of downstream signaling. (C) 2002 Wiley-Liss, Inc. C1 VA Puget Sound HCS, Seattle, WA 98108 USA. Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. RP Montgomery, RB (reprint author), VA Puget Sound HCS, 111ONC,1660 S Columbian Way, Seattle, WA 98108 USA. FU NCI NIH HHS [CA60782] NR 36 TC 18 Z9 19 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD SEP 10 PY 2002 VL 101 IS 2 BP 111 EP 117 DI 10.1002/ijc.10560 PG 7 WC Oncology SC Oncology GA 587CH UT WOS:000177622600002 PM 12209987 ER PT J AU Goldstein, IB Bartzokis, G Guthrie, D Shapiro, D AF Goldstein, IB Bartzokis, G Guthrie, D Shapiro, D TI Ambulatory blood pressure and brain atrophy in the healthy elderly SO NEUROLOGY LA English DT Article ID CARDIOVASCULAR HEALTH; HYPERTENSION; PEOPLE; DISEASE; VOLUMES; MATTER; MRI; AGE AB Background: Brain lesions and atrophy increase with age and hypertension. Objective: To evaluate the relationship of age and ambulatory blood pressure (BP) to brain atrophy in healthy elderly individuals. Methods: MRI volume measurements (normalized to intracranial volume) were taken of total brain and lateral and third ventricles in 155 healthy men and women who went through extensive medical examinations. Younger (56 to 66 years old) and older (67 to 80 years old) subgroups were compared on casual and 24-hour ambulatory BP values and MRI volume measurements. Results: Older subjects had smaller brain volumes and larger lateral and third ventricles. Compared with women, men had larger lateral and third ventricles. With age controlled for, greater sleep systolic BP (SBP) variability was associated with smaller brain volumes; greater waking and sleep SBP variability were associated with larger lateral and third ventricles. Subjects with higher casual and waking SBP and waking diastolic BP had larger lateral ventricles. Among older subjects, only those with elevated SBP had smaller brain volumes and larger lateral ventricles. Conclusions: These results indicate that if BP levels are within the upper normal range, even healthy individuals with no prior diagnosis of hypertension are more likely to have brain atrophy than those with lower BP. Moreover, not only do BP level and variability relate to brain atrophy, but the combination of high level and greater variability shows an even stronger relationship to brain atrophy than either one of these variables alone. C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA 90095 USA. Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. RP Goldstein, IB (reprint author), Univ Calif Los Angeles, Dept Psychiat, 760 Westwood Plaza, Los Angeles, CA 90095 USA. RI Bartzokis, George/K-2409-2013 FU NIA NIH HHS [AG-11595] NR 30 TC 38 Z9 39 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD SEP 10 PY 2002 VL 59 IS 5 BP 713 EP 719 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 591TU UT WOS:000177897000012 PM 12221162 ER PT J AU Wong, M Staszewsky, L Latini, R Barlera, S Volpi, A Chiang, YT Benza, RL Gottlieb, SO Kleemann, TD Rosconi, F Vandervoort, PM Cohn, JN AF Wong, M Staszewsky, L Latini, R Barlera, S Volpi, A Chiang, YT Benza, RL Gottlieb, SO Kleemann, TD Rosconi, F Vandervoort, PM Cohn, JN CA Val-HeFT Heart Failure Trial Inves TI Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID DYSFUNCTION; HYPERTROPHY; CARVEDILOL; MORTALITY; ENALAPRIL; BLOCKADE; THERAPY; ENZYME; TRIAL AB OBJECTIVES The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to prescribed heart failure therapy. BACKGROUND The clinical benefit derived from heart failure therapy is attributed to the regression of LV remodeling. METHODS At 302 multinational sites, 5,010 patients in New York Heart Association (NYHA) classification II to IV heart failure taking angiotensin-converting enzyme inhibitor (ACEI) and/or beta-blocker (BB) were randomized into valsartan and placebo groups and followed for a mean of 22.4 months. Serial echocardiographic measurements of left ventricular internal diastolic diameter (LVIDd) and ejection fraction (EF) were recorded. Total study reproducibility calculated to 90% power at 5% significance defined detectable differences of 0.09 cm for LVIDd and 0.86% for EF. RESULTS Baseline LVIDd and EF for valsartan and placebo groups were similar: 3.6 +/- 0.5 versus 3.7 +/- 0.5 (cm/m(2)) and 26.6 +/- 7.3 versus 26.9 +/- 7.0 (%). Mean group changes from baseline over time were compared. Significant decrease in LVIDd and increase in EF began by four months, reached plateau by one year, and persisted to two years in valsartan compared with placebo patients, irrespective of age, gender, race, etiology, NYHA classification, and co-treatment therapy. Changes at 18 months were -0.12 +/- 0.4 versus -0.05 +/- 0.4 (cm/m(2)), p < 0.00001 for LVIDd, and +4.5 +/- 8.9 versus +3.2 +/- 8.6 (%), p < 0.00001 for EF. The exception occurred in patients taking both ACEI and BB as co-treatment, in whom the decrease in LVIDd and increase in EF were no different between valsartan and placebo groups. CONCLUSIONS The Val-HeFT echocardiographic substudy of 5,010 patients with moderate heart failure demonstrated that valsartan therapy taken with either ACEI or BB reversed LV remodeling. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Ist Mario Negri, Milan, Italy. C Borella Hosp, Milan, Italy. Novartis Pharmaceut, E Orange, NJ USA. Univ Alabama, Birmingham, AL USA. Mid Atlantic Cardiovasc Associates, Baltimore, MD USA. Herzzentrum Ludwigshafen, Ludwigshafen, Germany. Osped Passirana Rho, Milan, Italy. Hartctr Limburg, Genk, Belgium. Univ Minnesota, Minneapolis, MN USA. RP Wong, M (reprint author), VA Greater Los Angeles Healthcare Syst, 00QM,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 22 TC 114 Z9 128 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 4 PY 2002 VL 40 IS 5 BP 970 EP 975 AR PII S0735-1097(02)02063-6 DI 10.1016/S0735-1097(02)02063-6 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 589ND UT WOS:000177765200020 PM 12225725 ER PT J AU Humphrey, LL Helfand, M Chan, BKS Woolf, SH AF Humphrey, LL Helfand, M Chan, BKS Woolf, SH TI Breast cancer screening: A summary of the evidence for the US Preventive Services Task Force SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED TRIALS; POSITIVE PREDICTIVE VALUE; SWEDISH 2-COUNTY TRIAL; FAMILY HISTORY; FOLLOW-UP; REPLACEMENT THERAPY; SELF-EXAMINATION; SOJOURN TIME; RISK-FACTORS; DEATH RATES AB Purpose: To synthesize new data on breast cancer screening for the U.S. Preventive Services Task Force. Data Sources: MEDLINE; the Cochrane Controlled Trials Registry; and reference lists of reviews, editorials, and original studies. Study Selection: Eight randomized, controlled trials of mammography and 2 trials evaluating breast self-examination were included. One hundred fifty-four publications of the results of these trials, as well as selected articles about the test characteristics and harms associated with screening, were examined. Data Extraction: Predefined criteria were used to assess the quality of each study. Meta-analyses using a Bayesian random-effects model were conducted to provide summary relative risk estimates and credible intervals (CrIs) for the effectiveness of screening with mammography in reducing death from breast cancer. Data Synthesis: For studies of fair quality or better, the summary relative risk was 0.84 (95% CrI, 0.77 to 0.91) and the number needed to screen to prevent one death from breast cancer after approximately 14 years of observation was 1224 (CrI, 665 to 2564). Among women younger than 50 years of age, the summary relative risk associated with mammography was 0.85 (CrI, 0.73 to 0.99) and the number needed to screen to prevent one death from breast cancer after 14 years of observation was 1792 (CrI, 764 to 10 540). For clinical breast examination and breast self-examination, evidence from randomized trials is inconclusive. Conclusions: in the randomized, controlled trials, mammography reduced breast cancer mortality rates among women 40 to 74 years of age. Greater absolute risk reduction was seen among older women. Because these results incorporate several rounds of screening, the actual number of mammograms needed to prevent one death from breast cancer is higher. In addition, each screening has associated risks and costs. C1 Oregon Hlth & Sci Univ, Portland, OR USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Virginia Commonwealth Univ, Med Coll Virginia, Fairfax, VA USA. RP Humphrey, LL (reprint author), Agcy Healthcare Res & Qual, Publicat Clearinghouse, Rockville, MD 20852 USA. FU PHS HHS [290-97-0018] NR 99 TC 666 Z9 690 U1 2 U2 34 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 3 PY 2002 VL 137 IS 5 BP 347 EP 360 PN 1 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 591DZ UT WOS:000177865600007 PM 12204020 ER PT J AU Kelly, JA Thompson, K Kilpatrick, J Lam, T Nath, SK Gray-McGuire, C Reid, J Namjou, B Aston, CE Bruner, GR Scofield, RH Harley, JB AF Kelly, JA Thompson, K Kilpatrick, J Lam, T Nath, SK Gray-McGuire, C Reid, J Namjou, B Aston, CE Bruner, GR Scofield, RH Harley, JB TI Evidence for a susceptibility gene (SLEH1) on chromosome 11q14 for systemic lupus erythematosus (SLE) families with hemolytic anemia SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID SIB-PAIR FAMILIES; AUTOIMMUNE-DISEASE; REVISED CRITERIA; UNITED-STATES; GENOME SCAN; BXSB MICE; LINKAGE; NEPHRITIS; LOCUS; PREVALENCE AB Hemolytic anemia is a forme fruste of systemic lupus erythematosus (SLE), being observed months or even years before the onset of other clinical manifestations in some patients. We hypothesized that hemolytic anemia in those SLE-affected patients would identify a group of SLE pedigrees that share a high degree of genetic homogeneity. From 160 multiplex SLE pedigrees, we sought evidence for linkage in 35 (16 African-American, 17 European-American, and 2 Hispanic) who had at least one SLE-affected patient with hemolytic anemia. Significant linkage was present at 11q14 in the 16 African-American pedigrees, yielding a maximum two-point logarithm of odds (LOD) score of 4.5 at D11S2002. The segregation pattern of SLE in these African-American pedigrees suggested a dominant mode of inheritance and, when maximized across penetrance and disease allele frequencies, produced a multipoint LOD of 4.7. Multipoint analysis yielded a multipoint heterogeneity LOD score of 3.6 (alpha = 0.63), again with maximum LOD at D11S2002. Finally, markerstyped 7 centimorgans to either side of D11S2002 achieved LOD scores of 3 or better by using the maximized model, supporting linkage to 11q14. Clearly, pedigree ascertainment based on select clinical manifestations is an important tool, capable of revealing otherwise cryptic genetic linkages in complex genetic diseases. Thus, we show strong evidence for an SLE susceptibility gene, SLEH1, near D11S2002 in African-American pedigrees multiplex for SLE that have at least one SLE-affected patient with hemolytic anemia. C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Case Western Reserve Univ, Cleveland, OH 44106 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. RP Harley, JB (reprint author), 825 NE 13th St, Oklahoma City, OK 73104 USA. FU NCRR NIH HHS [RR15577, P20 RR015577, P41 RR003655, 1 P41 RR03655]; NIAID NIH HHS [AI31584, AI24717, R01 AI031584, R37 AI024717, R01 AI024717]; NIAMS NIH HHS [AR42460, N01AR12253, R01 AR042460] NR 62 TC 29 Z9 30 U1 0 U2 0 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD SEP 3 PY 2002 VL 99 IS 18 BP 11766 EP 11771 DI 10.1073/pnas.182162399 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 590UW UT WOS:000177843100043 PM 12192084 ER PT J AU Israel, JA Lee, K AF Israel, JA Lee, K TI Amphetamine usage and genital self-mutilation SO ADDICTION LA English DT Article DE amphetamine; self-mutilation; self-injurious; substance abuse ID INJURIOUS-BEHAVIOR; RATS; AMPUTATION AB Amphetamine usage has been associated with addiction, psychosis and self-injurious behavior. We report on two patients who severely and repeatedly mutilated their own genitalia while intoxicated on amphetamines and consider possible diagnostic etiologies. C1 Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, Consultat Liason Psychiat Serv, San Francisco, CA 94121 USA. RP Israel, JA (reprint author), Vet Affairs Med Ctr, Acute Psychiat Serv, 4150 Clement St 116N, San Francisco, CA 94121 USA. NR 27 TC 13 Z9 13 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0965-2140 J9 ADDICTION JI Addiction PD SEP PY 2002 VL 97 IS 9 BP 1215 EP 1218 DI 10.1046/j.1360-0443.2002.00230.x PG 4 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 593GB UT WOS:000177981700019 PM 12199837 ER PT J AU Teichner, G Horner, MD Roitzsch, JC Herron, J Thevos, A AF Teichner, G Horner, MD Roitzsch, JC Herron, J Thevos, A TI Substance abuse treatment outcomes for cognitively impaired and intact outpatients SO ADDICTIVE BEHAVIORS LA English DT Article DE cognitive impairment; treatment outcome; substance abuse; treatment dropouts ID MEN ALCOHOLICS; COCAINE; RELAPSE; ACQUISITION; PERSONALITY; PREDICTION; LENGTH; MEMORY; STAY AB The purpose of this research was to examine the effects of cognitive impairment on the efficacy of substance abuse treatment outcome. Alcohol, drug, medical, legal, psychological, employment, and family functioning related treatment outcomes were examined for 26 cognitively impaired and 68 cognitively intact abusing outpatients. Subjects were enrolled in an intensive, 3-week, outpatient program for the treatment of their substance abuse. Subjects were administered a battery of neuropsychological tests prior to treatment onset, and outcome data were obtained at 1, 3, 6, and 12 months posttreatment entry. No significant between-group differences were found on any of the outcome measures, and significant treatment gains were observed across all problem domains in both groups. Subjects' largest improvements were made in the first month of treatment for alcohol, drug, legal, family, and psychological problems. Improvements for employment and medical problems were not observed until 6 months posttreatment. Success across domains was maintained through 12 months follow-up, with the exception of psychological problems; 12-month data indicated a return to the level observed at 30 days posttreatment for psychological problems, a level that reflected significant improvement from baseline functioning. A greater proportion of treatment dropouts (i.e., no follow-up data obtained after 30 days) were cognitively impaired as compared to treatment completers. These results suggest that this method of intensive substance abuse outpatient treatment is effective for cognitively impaired patients, an important finding given that research evaluating the efficacy of interventions for such patients is limited. Additionally, neuropsychological evaluation may be important in reducing treatment dropouts, as the present findings indicated that greater cognitive impairment was related to an increased likelihood of treatment dropout. (C) 2002 Elsevier Science Ltd. All rights reserved. C1 Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. RP Teichner, G (reprint author), Med Univ S Carolina, Dept Neurol, 96 Jonathan Lucas St,CSB 3,POB 280606, Charleston, SC 29425 USA. NR 42 TC 62 Z9 62 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD SEP-OCT PY 2002 VL 27 IS 5 BP 751 EP 763 AR PII S0306-4603(01)00207-6 DI 10.1016/S0306-4603(01)00207-6 PG 13 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 584WZ UT WOS:000177492900008 PM 12201382 ER PT J AU Every, N Hallstrom, A McDonald, KM Parsons, L Thom, D Weaver, D Hlatky, MA AF Every, N Hallstrom, A McDonald, KM Parsons, L Thom, D Weaver, D Hlatky, MA TI Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; HEART-RATE-VARIABILITY; STRATIFICATION; METAANALYSIS; ANGIOPLASTY; SURVIVORS; SURGERY; ARREST AB Background Patients at high risk of sudden cardiac death, yet at low risk of nonsudden death, might be ideal candidates for antiarrhythmic drugs or devices. Most previous studies of prognostic markers for sudden cardiac death have ignored the competitive risk of nonsudden cardiac death. The goal of the present study was to evaluate the ability of clinical factors to distinguish the risks of sudden and nonsudden cardiac death. Methods We identified all deaths during a 3.3-year follow-up of 30,680 patients discharged alive after admission to the cardiac care unit of a Seattle hospital. Detailed chart reviews were conducted on 1093 subsequent out-of-hospital sudden deaths, 973 nonsudden cardiac deaths, and 442 randomly selected control patients. Results Patients who died in follow-up (suddenly or nonsuddenly) were significantly different for many clinical factors from control patients. In contrast, patients with sudden cardiac death were insignificantly different for most clinical characteristics from patients with nonsudden cardiac death. The mode of death was 20% to 30% less likely to be sudden in women, patients who had angioplasty or bypass surgery, and patients prescribed beta-blockers. The mode of death was 20% to 30% more likely to be sudden in patients with heart failure, frequent ventricular ectopy, or a discharge diagnosis of acute myocardial infarction. A multivariable model had only modest predictive capacity for mode of death (c-index of 0.62). Conclusion Standard clinical evaluation is much better at predicting overall risk of death than at predicting the mode of death as sudden or nonsudden. C1 Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. Univ Washington, VA Puget Sound Healthcare Syst, NW Hlth Serv Res & Dev Ctr Excellence, Dept Biostat, Seattle, WA 98195 USA. Henry Ford Healthcare, Div Cardiol, Detroit, MI USA. RP Hlatky, MA (reprint author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, HRP Redwood Bldg,Room 150, Stanford, CA 94305 USA. FU AHRQ HHS [HS08362] NR 23 TC 23 Z9 28 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD SEP PY 2002 VL 144 IS 3 BP 390 EP 396 DI 10.1067/mhj.2002.125495 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 595BK UT WOS:000178086800005 PM 12228774 ER PT J AU Oei, TT Dulai, GS Gralnek, IM Chang, D Kilbourne, AM Sale, GA AF Oei, TT Dulai, GS Gralnek, IM Chang, D Kilbourne, AM Sale, GA TI Hospital care for low-risk patients with acute, nonvariceal upper GI hemorrhage: A comparison of neighboring community and tertiary care centers SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the American-College-of-Gastroenterology CY OCT 16-18, 2000 CL NEW YORK, NEW YORK SP Amer Coll Gastroenterol ID UPPER GASTROINTESTINAL HEMORRHAGE; PEPTIC-ULCER HEMORRHAGE; OUTPATIENT MANAGEMENT; TRACT HEMORRHAGE; EARLY DISCHARGE; SCORING SYSTEM; MORTALITY; ENDOSCOPY; COST; ANTAGONISTS AB Objectives: The proportion of patients admitted to the hospital with acute upper GI hemorrhage (UGIH) who are at low risk for adverse outcomes may be substantial. The process of care for this low risk population likely varies across practice settings but has not been extensively studied. Use of the Rockall Risk score, a simple validated scoring index that predicts outcomes in UGIH, may help to identify these low risk patients. Methods: We evaluated and compared the incidence of low risk UGIH admissions, adverse outcomes, and level of healthcare resource use in a community hospital (SMH) and a neighboring tertiary care university hospital (CHS). Cases of UGIH were identified from administrative databases during 1997 and 1998. Medical record data were abstracted in a standardized manner. Cases were defined as low risk on the basis of Rockall risk scores of less than or equal to2. Results: The low risk study groups consisted of 49 of 187 (26%) SMH cases and 53/175 (30%) CHS cases (p=0.40). Rebleeding was uncommon (6% at SMH; 4% at CHS) (p=0.64). No deaths occurred; 71% at SMH versus 49% at CHS were admitted to a monitored bed (p=0.04); and 92% at SMH versus 57% at CHS were prescribed i.v. H2 blockers for the acute bleeding event (p<0.001). Low risk patients had a mean hospital length of stay of 3.3+2.4 days at SMH versus 2.6+2.1 days at CHS (p=0.15). Conclusions: In this study, the proportion of acute, low risk, nonvariceal, upper GI hemorrhage admissions to neighboring community and tertiary care medical centers was high, whereas adverse clinical outcomes in this group of patients was low. Use of healthcare resources seemed to be greater in the community hospital. This observed variation in the process of care for populations with similar disease severity and outcomes suggests an opportunity for evidence-based interventions aimed at improving the efficiency of care. C1 VA Greater Los Angeles Hlth Care Syst, CURE Digest Dis Res Ctr, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90024 USA. Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Ctr Hlth Serv Res, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA. Harbor UCLA Med Ctr, Los Angeles, CA USA. RP Gralnek, IM (reprint author), VA Greater Los Angeles Hlth Care Syst, CURE Digest Dis Res Ctr, Ctr Study Digest Healthcare Qual & Outcomes, Bldg 115,Room 215B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 45 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 BP 2271 EP 2278 AR PII S0002-9270(02)04338-1 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PJ UT WOS:000178229700020 PM 12358244 ER PT J AU El-Serag, HB Garewel, H Sampliner, RE AF El-Serag, HB Garewel, H Sampliner, RE TI Where did the long Barrett's esophagus go? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 So Arizona VA Healthcare Syst, Tucson, AZ USA. Univ Arizona, Tucson, AZ 85724 USA. Houston VA Med Ctr, Gastroenterol & Hlth Serv Res, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 18 BP S6 EP S6 DI 10.1016/S0002-9270(02)04451-9 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400019 ER PT J AU Gralnek, IM Dulai, GS Coulter, ID Maida, CA AF Gralnek, IM Dulai, GS Coulter, ID Maida, CA TI What constitutes exemplary care for "low-risk" patients with acute, non-variceal upper gastrointestinal hemorrhage (NVUGIH)? A stakeholder analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RAND Corp, Hlth Sci Program, Los Angeles, CA USA. NR 2 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 705 BP S231 EP S231 DI 10.1016/S0002-9270(02)05187-0 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400706 ER PT J AU Littner, MR Leung, FW Ballard, ED Huang, BD Samra, NK AF Littner, MR Leung, FW Ballard, ED Huang, BD Samra, NK TI Lansoprazole for 24 weeks reduces asthma exacerbations and improves quality of life in subjects with symptoms of acid reflux - A multicenter, randomized, double-blind, placebo controlled trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. TAP Pharmaceut Inc, Lake Forest, IL USA. Abbott Labs, Abbott Pk, IL 60064 USA. NR 0 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 39 BP S13 EP S13 DI 10.1016/S0002-9270(02)04472-6 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400040 ER PT J AU Malaty, HM Wilsey, MJ Abudayyeh, S Graham, DY Wristers, K Rabeneck, LR AF Malaty, HM Wilsey, MJ Abudayyeh, S Graham, DY Wristers, K Rabeneck, LR TI Soda (severity of dyspepsia assessment) in children: A new outcome measure in relation to Helicobacter pylori infection in children with recurrent abdominal SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. VA Med Ctr, Digest Dis Sect, Houston, TX 77030 USA. Texas Childrens Hosp, Digest Dis Sect, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 695 BP S227 EP S228 DI 10.1016/S0002-9270(02)05177-8 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400696 ER PT J AU Nieto, JM Ashook, M Farrell, JJ AF Nieto, JM Ashook, M Farrell, JJ TI Intraductal papillary mucinous tumor: A new extraintestinal manifestation of Peutz-Jegher syndrome SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 551 BP S181 EP S181 DI 10.1016/S0002-9270(02)05033-5 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400552 ER PT J AU Nieto, JM DeRosa, VP DeGuzman, LJ AF Nieto, JM DeRosa, VP DeGuzman, LJ TI Vulvular Crohns antedating gastrointestinal involvment: Case report and review of the literature SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Arrowhead Reg Med Ctr, Colton, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 542 BP S178 EP S179 DI 10.1016/S0002-9270(02)05024-4 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400543 ER PT J AU Qureshi, WA Heiser, M Abudayyeh, S Anand, BS AF Qureshi, WA Heiser, M Abudayyeh, S Anand, BS TI Selecting the right patient for PEG/PEJ placement: Do clinical and laboratory parameters help? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 712 BP S233 EP S233 DI 10.1016/S0002-9270(02)05194-8 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400713 ER PT J AU Yamaguchi, DJ Tachiki, K Germano, P Oh, D Pisegna, JR AF Yamaguchi, DJ Tachiki, K Germano, P Oh, D Pisegna, JR TI Description of a technique to isolate and purify ECL cells by FACS analysis: Investigations of the expression and proliferative effects of the PAC1 receptor expressed on isolated ECL cells SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Digest Dis Res Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, CURE, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2002 VL 97 IS 9 SU S MA 163 BP S54 EP S54 DI 10.1016/S0002-9270(02)04635-X PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 597PR UT WOS:000178230400164 ER PT J AU Natarajan, S Clyburn, EB Brown, RT AF Natarajan, S Clyburn, EB Brown, RT TI Association of exercise stages of change with glycemic control in individuals with type 2 diabetes SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article ID PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; POPULATION; PATTERNS; DISEASE; SMOKING C1 Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Ctr Hlth Care Res, Charleston, SC 29425 USA. Med Univ S Carolina, Div Gen Internal Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Natarajan, S (reprint author), 135 Cannon St,Suite 403,PO 250837, Charleston, SC 29425 USA. NR 10 TC 7 Z9 7 U1 0 U2 0 PU AMER J HEALTH PROMOTION INC PI KEEGO HARBOR PA 1660 CASS LAKE RD, STE 104, KEEGO HARBOR, MI 48320 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD SEP-OCT PY 2002 VL 17 IS 1 BP 72 EP 75 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 593ZD UT WOS:000178023600004 PM 12271755 ER PT J AU Ioannou, GN Rockey, DC Bryson, CL Weiss, NS AF Ioannou, GN Rockey, DC Bryson, CL Weiss, NS TI Iron deficiency and gastrointestinal malignancy: a population-based cohort study SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID PREMENOPAUSAL WOMEN; ANEMIA; TRACT; CANCER AB PURPOSE: We investigated whether iron deficiency, with or without anemia, is associated with an increased likelihood of gastrointestinal malignancy. SUBJECTS AND METHODS: Data were obtained from the first National Health and Nutrition Examination Survey and Epidemiologic Followup Study, a nationally representative, prospective cohort study that measured hemoglobin levels and iron saturation and recorded follow-up diagnoses. We included persons 25 to 74 years of age with no previous gastrointestinal malignancy. Anemia was defined as a hemoglobin value below the fifth percentile for each age group and sex. Iron deficiency was defined as an iron saturation below 15%. RESULTS: Eighteen (0.2%) gastrointestinal malignancies were identified among the 9024 participants during the first 2 years of follow-up. None of the 442 premenopausal women with iron deficiency (92 with anemia and 350 without anemia) were diagnosed with gastrointestinal malignancy. Among men and postmenopausal women, the proportion diagnosed with gastrointestinal malignancy was 31 times greater (95% confidence interval [CI]: 9 to 107) in those with iron deficiency anemia (3/51 [6%]) and five times greater (95% Cl: 1 to 21) in those with iron deficiency without anemia (2/223 [1%]), compared with those with normal hemoglobin levels and iron saturation (11/5733 [0.2%]). CONCLUSION: Gastrointestinal malignancy is uncommon in iron-deficient premenopausal women with or without anemia, Among men and postmenopausal Women, gastrointestinal malignancy is significantly more common in those with iron deficiency than in persons with normal serum iron saturation and hemoglobin levels. C1 Univ Washington, Ctr Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Ctr Med, Div Gastroenterol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Duke Univ, Ctr Med, Div Gastroenterol, Dept Med, Durham, NC USA. Duke Univ, Ctr Med, Duke Liver Ctr, Durham, NC USA. RP Ioannou, GN (reprint author), Vet Adm Med Ctr, Hlth Serv Res & Dev, 1660 S Columbian Way,MS 152,Bldg 1,Room 422, Seattle, WA 98108 USA. NR 21 TC 52 Z9 57 U1 0 U2 2 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD SEP PY 2002 VL 113 IS 4 BP 276 EP 280 DI 10.1016/S0002-9343(02)01214-7 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 599DU UT WOS:000178319500002 PM 12361812 ER PT J AU Stehman-Breen, CO Levine, RJ Qian, C Morris, CD Catalano, PM Curet, LB Sibai, BM AF Stehman-Breen, CO Levine, RJ Qian, C Morris, CD Catalano, PM Curet, LB Sibai, BM TI Increased risk of preeclampsia among nulliparous pregnant women with idiopathic hematuria SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE preeclampsia; gestational hypertension; pregnancy; hematuria ID RENAL-DISEASE; HYPERTENSION; CALCIUM; TRIAL AB OBJECTIVE: Our purpose was to determine the risk of preeclampsia and gestational hypertension among nulliparous pregnant women with idiopathic hematuria. STUDY DESIGN: We conducted a prospective cohort study using data from the trial of Calcium for Preeclampsia Prevention (CPEP). Participants were followed up from screening and enrollment (gestational weeks 11-21) throughout pregnancy. Our analysis was limited to women who had been followed up to at least 20 weeks' gestation, had outcome information available, and were not suspected to have had urolithiasis. Surveillance for hematuria was conducted with dipsticks on clean-catch urine specimens obtained at research clinic visits. Idiopathic hematuria was defined as hematuria identified at regularly scheduled clinic visits in the absence of urinary tract infection and before the onset of labor. Logistic regression was used to estimate the risk of preeclampsia among women with hematuria compared with women without hematuria. RESULTS: Among the 4307 women available for analysis, 132 (3%) had idiopathic hematuria during pregnancy. Idiopathic hematuria was associated with an almost 2-fold increased odds for development of preeclampsia (adjusted odds ratio [aOR] = 1.89, 95% Cl 1.12-3.18) but not with increased odds of gestational hypertension (aOR = 0.78, 95% Cl 0.46-1.32). CONCLUSIONS: Idiopathic hematuria identified during pregnancy is associated with greater risk of preeclampsia but not gestational hypertension. C1 Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA 98108 USA. NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA. Allied Technol Grp, Rockville, MD USA. Oregon Hlth Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA. Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. Metrohlth Med Ctr, Dept Obstet & Gynecol, Cleveland, OH USA. Univ Cincinnati, Coll Med, Cincinnati, OH USA. RP Stehman-Breen, CO (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, 1660 S Columbian Way,Mailstop 111A, Seattle, WA 98108 USA. FU NICHD NIH HHS [N01-HD-1-3121, N01-HD-2-3154, N01-HD-1-3123, N01-HD-1-3125, N01-HD-1-3122, N01-HD-1-3124, N01-HD-1-3126, N01-HD-5-3246] NR 23 TC 8 Z9 8 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2002 VL 187 IS 3 BP 703 EP 708 DI 10.1067/mob.2002.125768 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 598BZ UT WOS:000178256400031 PM 12237651 ER PT J AU Zhu, WH MacIntyre, A Nicosia, RF AF Zhu, WH MacIntyre, A Nicosia, RF TI Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model - Distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; CELL-SURVIVAL; TRANSDUCTION PATHWAY; TIE2 RECEPTOR; ACTIN REORGANIZATION; BLOOD-VESSEL; AKT; MIGRATION; GENE AB Vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) promote the spontaneous angiogenic response of freshly cut rat aortic rings. When VEGF and Ang-1 were tested in cultures of 14-day-old rings, which are quiescent and unable to spontaneously produce neovessels, only VEGF was capable of inducing an angiogenic response. Ang-1 failed to initiate angiogenesis in this system, but significantly potentiated VEGF-induced neovessel sprouting. Potential differences in cell signaling triggered by VEGF and Ang-1 were evaluated in cultures of quiescent rings. VEGF induced biphasic and prolonged (15 minutes and 4 to 24 hours) phosphorylation of p44/42 MAPK and Akt, while the effect of Ang-1 was transient and monophasic (15 minutes). Both VEGF and Ang-1 induced rapid, monophasic (15 minutes) phosphorylation of p38 MAPK. When VEGF and Ang-1 were administered together, the second peak of VEGF-induced p44/42 MAPK phosphorylation was markedly reduced. The effect of the VEGF/Ang-1 combination on AKT phosphorylation was, instead, additive over time, and sustained over a 24-hour period. The VEGF/ Ang-1 combination caused an additive effect also on p38 MAPK phosphorylation at 1 hour. Confocal microscopy of VEGF-, Ang-1, or VEGF/Ang-1-stimulated aortic rings double stained at time points of maximal phosphorylation for cell markers and signal transduction proteins demonstrated phosphorylated p44/42 MAPK, p38 MAPK, and Akt predominantly in endothelial cells. Experiments with specific inhibitors demonstrated that p44/42 MAPK and Akt, but not p38 MAPK, are necessary for neovessel sprouting. These results identify p44/42 MAPK and Akt as critical intracellular mediators of angiogenesis, whose transient phosphorylation is, however, not sufficient for the initiation of this process. The observation that sustained phosphorylation of these signaling pathways, particularly of Akt, correlates with induction of angiogenesis suggests that the duration of phosphorylation signals influences critical cellular events required for the induction of angiogenic sprouting. C1 VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, S113 Lab, Seattle, WA 98108 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Philadelphia Coll Osteopath Med, Dept Pathol Microbiol & Immunol, Philadelphia, PA USA. RP Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Div Pathol & Lab Med, S113 Lab, 1660 S Columbian Way, Seattle, WA 98108 USA. FU NHLBI NIH HHS [HL52585, R01 HL052585] NR 42 TC 72 Z9 74 U1 0 U2 3 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD SEP PY 2002 VL 161 IS 3 BP 823 EP 830 DI 10.1016/S0002-9440(10)64242-3 PG 8 WC Pathology SC Pathology GA 591BJ UT WOS:000177859600011 PM 12213710 ER PT J AU Yuan, PQ Yang, H AF Yuan, PQ Yang, H TI Neuronal activation of brain vagal-regulatory pathways and upper gut enteric plexuses by insulin hypoglycemia SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE dorsal motor nucleus of the vagus; nucleus tractus solitarii; glucose; vagus; stomach ID NITRIC-OXIDE SYNTHASE; NUCLEUS-TRACTUS-SOLITARII; GASTRIC MYENTERIC NEURONS; DORSAL MOTOR NUCLEUS; PORTAL-VEIN AREA; FOS EXPRESSION; NERVOUS-SYSTEM; VAGUS NERVE; GUINEA-PIG; HYPOTHALAMIC NEURONS AB Neuronal activation of brain vagal-regulatory nuclei and gastric/duodenal enteric plexuses in response to insulin (2 U/kg, 2 h) hypoglycemia was studied in rats. Insulin hypoglycemia significantly induced Fos expression in the paraventricular nucleus of the hypothalamus, locus coeruleus, dorsal motor nucleus of the vagus (DMN), and nucleus tractus solitarii (NTS), as well as in the gastric/duodenal myenteric/ submucosal plexuses. A substantial number of insulin hypoglycemia-activated DMN and NTS neurons were choline acetyltransferase and tyrosine hydroxylase positive, respectively, whereas the activated enteric neurons included NADPH- and vasoactive intestinal peptide neurons. The numbers of Fos-positive cells in each above-named brain nucleus or in the gastric/duodenal myenteric plexus of insulin-treated rats were negatively correlated with serum glucose levels and significantly increased when glucose levels were lower than 80 mg/dl. Acute bilateral cervical vagotomy did not influence insulin hypoglycemia-induced Fos induction in the brain vagal-regulatory nuclei but completely and partially prevented this response in the gastric and duodenal enteric plexuses, respectively. These results revealed that brain-gut neurons regulating vagal outflow to the stomach/duodenum are sensitively responsive to insulin hypoglycemia. C1 VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Yang, H (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Dept Med,Div Digest Dis, Bldg 115,Rm 203,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK-41301, DK-50255] NR 77 TC 27 Z9 28 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD SEP PY 2002 VL 283 IS 3 BP E436 EP E448 DI 10.1152/ajpendo.00538.2001 PG 13 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 582LT UT WOS:000177353000005 PM 12169436 ER PT J AU Simon, FR Fortune, J Iwahashi, M Sutherland, E AF Simon, FR Fortune, J Iwahashi, M Sutherland, E TI Sexual dimorphic expression of ADH in rat liver: importance of the hypothalamic-pituitary-liver axis SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE growth hormone; thyroxine; hypophysectomy; estrogen; testosterone ID GROWTH-HORMONE SECRETION; ALCOHOL-DEHYDROGENASE ACTIVITY; GENE-EXPRESSION; HYPOPHYSECTOMIZED RATS; HEPATOCYTE CULTURE; TESTOSTERONE; METABOLISM; ESTRADIOL; TURNOVER; ENZYMES AB Hepatic alcohol dehydrogenase (ADH) activity is higher in female than in male rats. Although sex steroids, thyroid, and growth hormone (GH) have been shown to regulate hepatic ADH, the mechanism(s) for sexual dimorphic expression is unclear. We tested the possibility that the GH secretory pattern determined differential expression of ADH. Gonadectomized and hypophysectomized male and female rats were examined. Hepatic ADH activity was 2.1-fold greater in females. Because protein and mRNA content were also 1.7- and 2.4-fold greater, results indicated that activity differences were due to pretranslational mechanisms. Estradiol increased ADH selectively in males, and testosterone selectively decreased activity and mRNA levels in females. Effect of sex steroids on ADH was lost after hypophysectomy; infusion of GH in males increased ADH to basal female levels, supporting a role of the pituitary-liver axis. However, GH and L-thyroxine (T-4) replacements alone in hypophysectomized rats did not restore dimorphic differences for either ADH activity or mRNA levels. On the other hand, T-4 in combination with intermittent administration of GH reduced ADH activity and mRNA to basal male values, whereas T-4 plus GH infusion replicated female levels. These results indicate that the intermittent male pattern of GH secretion combined with T-4 is the principal determinant of low ADH activity in male liver. C1 Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver Vet Affairs Hosp, Denver, CO 80262 USA. RP Simon, FR (reprint author), Univ Colorado, Sch Med, Dept Med B145, Hepatobiliary Res Ctr, 4200 E 9th Ave, Denver, CO 80262 USA. FU NIDDK NIH HHS [R01-DK-15851] NR 63 TC 18 Z9 19 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP PY 2002 VL 283 IS 3 BP G646 EP G655 DI 10.1152/ajpgi.00438.2001 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 585AY UT WOS:000177502000019 PM 12181179 ER PT J AU Tian, W Cohen, DM AF Tian, W Cohen, DM TI Urea stress is more akin to EGF exposure than to hypertonic stress in renal medullary cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE expression array; tonicity enhancer binding protein; hypertonicity; cytoprotection; activating transcription factor 3; mIMCD3 cells; epidermal growth factor ID DUCT MIMCD3 CELLS; EPITHELIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; RESPONSE ELEMENT; KIDNEY-CELLS; MDCK CELLS; C-FOS; ACTIVATION; PROTEIN; GENE AB Although urea is considered to be a cell stressor even in renal medullary cells perpetually exposed to this solute in vivo by virtue of the renal concentrating mechanism, aspects of urea signaling resemble that of a peptide mitogen. Urea was compared with epidermal growth factor and hypertonic NaCl or hypertonic mannitol using a large-scale expression array-based approach. The expression profile in response to urea stress more closely resembled that of EGF treatment than hypertonic stress, as determined by hierarchical cluster analysis; the effect of urea+NaCl was equidistant from that of either solute applied individually. Among the most highly urea- and hypertonicity-responsive transcripts were genes that had previously been shown to be responsive to these solutes, validating this approach. Increased expression of the activating transcription factor 3 by urea was newly detected via expression array and confirmed via immunoblot analysis. Earlier, we noted an abrogation of tonicity-dependent gene regulation by urea, primarily in a transient transfection-based model (Tian W and Cohen DM. Am J Physiol Renal Physiol 280: F904-F912, 2001). Here we applied K-means cluster analysis to demonstrate that the genes most profoundly up- or downregulated by hypertonic stress were partially restored toward basal levels in the presence of urea pretreatment. These global expression data are consistent with our earlier biochemical studies suggesting that urea affords cytoprotection in this context. In the aggregate, these data strongly support the hypothesis that the urea effect in renal medullary cells resembles that of a peptide mitogen in terms of the adaptive program of gene expression and in terms of cytoprotection from hypertonicity. C1 Oregon Hlth Sci Univ, Dept Med, Div Nephrol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Cohen, DM (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Nephrol, Mailcode PP262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM cohend@ohsu.edu FU NCI NIH HHS [5P30 CA69533-04]; NIDDK NIH HHS [DK-52494] NR 41 TC 15 Z9 15 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD SEP PY 2002 VL 283 IS 3 BP F388 EP F398 DI 10.1152/ajprenal.00031.2002 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 581VV UT WOS:000177315600003 PM 12167588 ER PT J AU Silverman, DHS Small, GW AF Silverman, DHS Small, GW TI Prompt identification of Alzheimer's disease with brain PET imaging of a woman with multiple previous diagnoses of other neuropsychiatric conditions SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; DIFFERENTIAL-DIAGNOSIS; LEWY BODIES; FDG PET; DEMENTIA; PATTERNS; RISK C1 Univ Calif Los Angeles, Sch Med, Ahmanson Biol Imaging Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Silverman, DHS (reprint author), Univ Calif Los Angeles, Sch Med, Ahmanson Biol Imaging Ctr, Dept Mol & Med Pharmacol, CHS AR-144,MC694215, Los Angeles, CA 90095 USA. FU NIA NIH HHS [AG-10123, AG-13308]; NIMH NIH HHS [MH-52453] NR 28 TC 4 Z9 4 U1 1 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2002 VL 159 IS 9 BP 1482 EP 1488 DI 10.1176/appi.ajp.159.9.1482 PG 7 WC Psychiatry SC Psychiatry GA 591EQ UT WOS:000177867100004 PM 12202266 ER PT J AU Mulsant, BH Kastango, KB Rosen, J Stone, RA Mazumdar, S Pollock, BG AF Mulsant, BH Kastango, KB Rosen, J Stone, RA Mazumdar, S Pollock, BG TI Interrater reliability in clinical trials of depressive disorders SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article AB Objective: The goal of this study was to review the reported methods of rater training, assessment of interrater reliability, and rater drift in clinical trials of treatments for depressive disorders. Method: Two psychiatrists independently identified all original reports of clinical trials relevant to depressive disorders published between 1996 and 2000 in the American Journal of Psychiatry and the Archives of General Psychiatry, Reported methods of rater training, assessment of interrater reliability, and rater drift were systematically summarized. Results: Sixty-three original papers met criteria for inclusion. Only 11 (17%) of the studies reported the number of raters. Only two (9%) of the 22 multicenter and four (10%) of the 41 single-center trials documented rater training. Only nine (22%) of the single-center trials and three (14%) of the multicenter trials reported interrater reliability, despite a median number of five raters (range=2-20). Only three (5%) of the 63 articles reported rater drift. Conclusions: Few published reports of clinical trials of treatments for depressive disorders document adequately the number of raters, rater training, assessment of interrater reliability, and rater drift. C1 Univ Pittsburgh, Western Psychiat Inst & Clin, Intervent Res Ctr Study Late Life Mood Disorders, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Mulsant, BH (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Intervent Res Ctr Study Late Life Mood Disorders, 3811 Ohara St, Pittsburgh, PA 15213 USA. FU NIMH NIH HHS [MH-52247, MH-59566, MH-01613, MH-65416, MH-61639] NR 6 TC 23 Z9 23 U1 0 U2 1 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD SEP PY 2002 VL 159 IS 9 BP 1598 EP 1600 DI 10.1176/appi.ajp.159.9.1598 PG 3 WC Psychiatry SC Psychiatry GA 591EQ UT WOS:000177867100023 PM 12202285 ER PT J AU Perea, S Gonzalez, G Fothergill, AW Kirkpatrick, WR Rinaldi, MG Patterson, TF AF Perea, S Gonzalez, G Fothergill, AW Kirkpatrick, WR Rinaldi, MG Patterson, TF TI In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ANTIFUNGAL MK-0991 L-743,872; DIMORPHIC FUNGI; CANDIDIASIS; TERBINAFINE; FUSARIUM; LY303366 AB The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of < 1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole. C1 Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. Audie Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Perea, S (reprint author), Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, 7703 Floyd Curl Dr,Mail Code 7881, San Antonio, TX 78229 USA. FU NCRR NIH HHS [M01 RR001346, M01-RR-01346]; NIDCR NIH HHS [5 R01 DE11381, R01 DE011381] NR 17 TC 132 Z9 137 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2002 VL 46 IS 9 BP 3039 EP 3041 DI 10.1128/AAC.46.9.3039-3041.2002 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 585FQ UT WOS:000177515000045 PM 12183266 ER PT J AU Justice, AC McGinnis, KA Skanderson, M Conigliaro, J Kilbourne, A Good, C Fultz, SL Rabenenck, L Rodriguez-Barradas, M Weissman, S AF Justice, AC McGinnis, KA Skanderson, M Conigliaro, J Kilbourne, A Good, C Fultz, SL Rabenenck, L Rodriguez-Barradas, M Weissman, S CA VACS 3 Project Team TI Comorbid disease is a major determinant of patient outcomes in HIV infection SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International HIV Workshop on Management of Treatment-Experienced Patients CY SEP 26-27, 2002 CL SAN DIEGO, CALIFORNIA C1 VA Pittsburgh Healthcare Syst, Vet Aging Cohort Study Ctr, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Res Hlth Care, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. Excellence VA Med Ctr, VA Hlth Serv Res & Dev Ctr, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PD SEP PY 2002 VL 7 IS 3 MA 108 BP L69 EP L70 PG 2 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 619WY UT WOS:000179501500118 ER PT J AU Rhew, D Kim, M Bernal, M Aguilar, D Iloeje, U Goetz, MB AF Rhew, D Kim, M Bernal, M Aguilar, D Iloeje, U Goetz, MB TI Association between protease inhibitors and increased cardiovascular risk: a systematic review SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV CY SEP 22-25, 2002 CL SAN DIEGO, CALIFORNIA C1 Zynx Hlth, Beverly Hills, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PD SEP PY 2002 VL 7 IS 3 MA 56 BP L38 EP L38 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 619WY UT WOS:000179501500066 ER PT J AU Zarbo, RJ Jones, BA Friedberg, RC Valenstein, PN Renner, SW Schifman, RB Walsh, MK Howanitz, PJ AF Zarbo, RJ Jones, BA Friedberg, RC Valenstein, PN Renner, SW Schifman, RB Walsh, MK Howanitz, PJ CA Coll Amer Pathologists TI Q-Tracks - A College of American Pathologists program of continuous laboratory monitoring and longitudinal performance tracking SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID BLOOD CULTURE CONTAMINATION; FROZEN-SECTION CONSULTATION; Q-PROBES; DIAGNOSTIC REPRODUCIBILITY; SPECIMEN ACCEPTABILITY; QUALITY IMPROVEMENT; SMALL HOSPITALS; INSTITUTIONS; CYTOLOGY; IDENTIFICATION AB Context.-Continuous monitoring of key laboratory indicators of quality by hundreds of laboratories in a standardized measurement program affords an opportunity to document the influence of longitudinal tracking on performance improvement by participants focused on that outcome. Objective.-To describe the results of the first 2 years of participation in a unique continuous performance assessment program for pathology and laboratory medicine. Design.-Participants in any of 6 modules in the 1999 and 2000 College of American Pathologists (CAP) Q-Tracks program collected data according to defined methods and sampling intervals on standardized input forms. Data were submitted quarterly to CAP for statistical analysis. Inter-institutional comparison reports returned in 6 weeks provided each laboratory with its performance profile of key indicators and its percentile ranking compared with all participants in that quarter. This also included longitudinal comparisons of performance during previous cumulative quarters. Control charts graphically displayed data with flags identifying performance points that were out of statistical control. Setting.-Hospital-based laboratories in the United States (98%), Canada, and Australia. Participants.-Voluntary subscriber laboratories in the CAP Q-Tracks performance measurement program: roughly 70% from hospitals of 300 occupied beds or fewer, 65% from private, nonprofit institutions, slightly more than half located in cities, one third from teaching hospitals, and 20% with pathology residency training programs. Main Outcome Measures.-Each module measured several major and additional minor quality indicators and unbenchmarked individualized data for internal use. Results.-Participants in 4 of 6 Q-Tracks continuous monitors demonstrated statistically significant performance improvement trends in 1999 and 2000, which were most marked for laboratories that continued participation throughout both years. These monitors were wristband patient identification, laboratory specimen acceptability, blood product wastage, and intraoperative frozen section consultation. Conclusions.-Key continuous indicators chosen on the basis of a decade's experience in the CAP Q-Probes quality improvement program are useful measurement and benchmarking tools for laboratories to improve performance. In general, measures in which there is a broad range of demonstrable performance initially are most optimal for subsequent improvement using continuous monitoring. These studies have shown that quality is not static, but rather is a moving benchmark of performance as seen in the redefinition of benchmarks over time by participants in the first 2 years of the CAP Q-Tracks program. C1 Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA. St John Hosp & Med Ctr, Dept Pathol, Detroit, MI USA. Baystate Med Ctr, Dept Pathol, Springfield, MA USA. St Joseph Mercy Hlth Syst, Dept Pathol, Ann Arbor, MI USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. Vet Adm Med Ctr, Dept Diagnost, Tucson, AZ 85723 USA. Coll Amer Pathologists, Northfield, IL USA. SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA. RP Renner, SW (reprint author), Henry Ford Hosp, Dept Pathol, 2799 W Grand Blvd, Detroit, MI 48202 USA. NR 29 TC 65 Z9 73 U1 1 U2 5 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD SEP PY 2002 VL 126 IS 9 BP 1036 EP 1044 PG 9 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 594UA UT WOS:000178068300006 PM 12204052 ER PT J AU da Cunha, IT Lim, PA Qureshy, H Henson, H Monga, T Protas, EJ AF da Cunha, IT Lim, PA Qureshy, H Henson, H Monga, T Protas, EJ TI Gait outcomes after acute stroke rehabilitation with supported treadmill ambulation training: A randomized controlled pilot study SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE ambulation; cerebrovascular accident; gait; rehabilitation; treadmill test ID BODY-WEIGHT SUPPORT; NONAMBULATORY HEMIPARETIC PATIENTS; MENTAL-STATE-EXAMINATION; ENERGY-EXPENDITURE; RECOVERY; WALKING; RELIABILITY; LOCOMOTION; THERAPY; SCALE AB Objective: To investigate gait outcomes with supported treadmill ambulation training (STAT) associated with regular rehabilitation in acute stroke survivors. Design: Randomized controlled trial, pilot study. Setting: Rehabilitation medicine service at a Veterans Affairs medical center. Participants: Seven acute stroke survivors assigned to regular intervention group and 6 patients assigned to STAT intervention. Interventions: Regular intervention consisted of 3 hours daily of physical therapy, kinesiotherapy, and occupational therapy. STAT group received regular rehabilitation with STAT substituted for usual gait training. Participants were tested at baseline, treated for an average of 3 weeks, and retested on discharge. The analysis of covariance procedure was used to test for differences between the 2 approaches. Main Outcome Measures: Functional Ambulation Category Scale, gait speed, walking distance, gait energy expenditure, and gait energy cost. Results: The small sample size did not generate enough power to detect significant differences in any variable. However, medium to large effect sizes of 0.7 and 1.16 standard deviation units were observed for gait energy cost and walk distance, respectively. Conclusions: This pilot study indicated that STAT is a safe, feasible, and promising intervention for acute stroke survivors. A larger trial is warranted for statistical relevance. C1 Texas Womans Univ, Sch Phys Therapy, Houston, TX USA. Houston Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Houston, TX USA. Houston Vet Affairs Med Ctr, Rehabil Res & Dev Ctr Excellenve Healthy Aging &, Houston, TX USA. Singapore Gen Hosp, Singapore 0316, Singapore. RP Protas, EJ (reprint author), 1130 John Freeman Blvd, Houston, TX 77030 USA. NR 45 TC 87 Z9 91 U1 2 U2 18 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD SEP PY 2002 VL 83 IS 9 BP 1258 EP 1265 DI 10.1053/apmr.2002.34267 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 591AE UT WOS:000177856500011 PM 12235606 ER PT J AU Ibrahim, SA Siminoff, LA Burant, CJ Kwoh, CK AF Ibrahim, SA Siminoff, LA Burant, CJ Kwoh, CK TI Differences in expectations of outcome mediate African American/white patient differences in "willingness" to consider joint replacement SO ARTHRITIS AND RHEUMATISM LA English DT Article ID TOTAL HIP-ARTHROPLASTY; RACIAL-DIFFERENCES; OSTEOARTHRITIS; PREFERENCES; KNEE; VALIDATION; DEPRESSION; POPULATION; ARTHRITIS; HEALTH AB Objective. Joint replacement therapy is an effective treatment option for end-stage osteoarthritis (OA) of the knee and/or hip. There are marked racial/ethnic disparities in the utilization of this procedure. The reasons for these disparities are not known. We sought to determine whether African American patients differ from white patients in their "willingness" to consider joint replacement and to determine the factors that influence this relationship. Methods. We performed a cross-sectional survey of 596 elderly, male, African American or white patients with moderate-to-severe symptomatic knee or hip OA who were receiving primary care at the Department of Veterans Affairs outpatient clinics. Results. The groups were similar with respect to age, severity of arthritis measured by the Lequesne Scale and the Western Ontario and McMaster Universities Osteoarthritis-Index, and scores on the Charlson Comorbidity Index and Geriatric Depression Scale. Compared with whites, African Americans were less likely to be employed or married or to have attained a high school education, but were more likely to report a median annual household income of <$10,000. They were also less likely than whites to be familiar with joint replacement and more likely to expect a longer duration of hospital course, pain, and functional disability following replacement surgery. African American patients were less "willing" than white patients to consider joint replacement (odds ratio 0.50, 95% confidence interval 0.30-0.84). However, this difference was explained by the between-group differences in expectations. Conclusion. African American patients were less likely than white patients to express "willingness" to consider joint replacement if the procedure was needed and recommended. This difference was explained by differences between the groups in their expectations of hospital course, pain, and function following replacement surgery. C1 VA Pittsburgh HealthCare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Ibrahim, SA (reprint author), VA Pittsburgh HealthCare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,11-E,130 A-U, Pittsburgh, PA 15240 USA. RI Siminoff, Laura /H-6277-2012 NR 34 TC 110 Z9 110 U1 0 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2002 VL 46 IS 9 BP 2429 EP 2435 DI 10.1002/art.10494 PG 7 WC Rheumatology SC Rheumatology GA 600ZK UT WOS:000178421500019 PM 12355491 ER PT J AU Byrne, M O'Malley, K Suarez-Almazor, ME AF Byrne, M O'Malley, K Suarez-Almazor, ME TI Ethnic differences in arthritis health preferences: Analysis using willingness-to-pay. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2002 CL NEW ORLEANS, LOUISIANA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Univ Pittsburgh, Pittsburgh, PA USA. Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2002 VL 46 IS 9 SU S BP S73 EP S73 PG 1 WC Rheumatology SC Rheumatology GA 600ZN UT WOS:000178421800122 ER PT J AU Namjou, B Kilpatrick, J Kelly, JA Aberle, T Lam, T Reid, J Wilson, J Kimberly, RP Provost, TT James, JA Harley, JB AF Namjou, B Kilpatrick, J Kelly, JA Aberle, T Lam, T Reid, J Wilson, J Kimberly, RP Provost, TT James, JA Harley, JB TI Biopsy-proven vasculitis is related to genetic linkages at 1p36 and 3p14-12 in systemic lupus erythematosus (SLE) SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2002 CL NEW ORLEANS, LOUISIANA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Univ Mississippi, US Dept Vet Affairs, Jackson, MS 39216 USA. Univ Alabama, Birmingham, AL USA. Johns Hopkins Univ, Baltimore, MD USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, US Dept Vet Affairs Med Ctr, Oklahoma City, OK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2002 VL 46 IS 9 SU S BP S37 EP S37 PG 1 WC Rheumatology SC Rheumatology GA 600ZN UT WOS:000178421800016 ER PT J AU Singh, J Pando, J Tomaszewski, J Schumacher, R AF Singh, J Pando, J Tomaszewski, J Schumacher, R TI Quantitative immunobistochemistry of synovium in very early rheumatoid arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2002 CL NEW ORLEANS, LOUISIANA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Minneapolis VA Med Ctr, Minneapolis, MN USA. None, Rehoboth Beach, DE USA. Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2002 VL 46 IS 9 SU S BP S102 EP S102 PG 1 WC Rheumatology SC Rheumatology GA 600ZN UT WOS:000178421800203 ER PT J AU Wong, AL Mittman, BS Aiso, J Beardmore, TD Louie, JS Kitridou, RC Harker, JO Paulus, HE AF Wong, AL Mittman, BS Aiso, J Beardmore, TD Louie, JS Kitridou, RC Harker, JO Paulus, HE TI A data driven approach to pharmacy policy for management of RA in a county healthcare system. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2002 CL NEW ORLEANS, LOUISIANA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ So Calif, Sch Pharm, Los Angeles, CA USA. Rancho Los Amigos Natl Rehabil Ctr, Downey, CA USA. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. LAC, Los Angeles, CA USA. USC, Med Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD SEP PY 2002 VL 46 IS 9 SU S BP S88 EP S89 PG 2 WC Rheumatology SC Rheumatology GA 600ZN UT WOS:000178421800169 ER PT J AU Quarterman, RL Moonly, S Wallace, AW Guccione, J Ratcliffe, MB AF Quarterman, RL Moonly, S Wallace, AW Guccione, J Ratcliffe, MB TI A finite element model of left ventricular cellular transplantation in dilated cardiomyopathy SO ASAIO JOURNAL LA English DT Article ID VOLUME REDUCTION SURGERY; IMPROVED HEART FUNCTION; STRESS; MECHANICS; MUSCLE; CARDIOMYOCYTES; MYOCARDIUM; ANEURYSM; GRAFTS; TISSUE AB Surgical therapies for heart failure that reduce left ventricular (LV) size have failed to improve LV function. Recent reports describe the direct injection of myocytes into the LV wall and suggest that myocyte transplantation improves regional contractile ability and improves LV function. Using a previously described finite element model, we simulated myocyte transplantation in the failing LV and tested the hypothesis that myocyte transplantation improves LV function (Starling relationship). An elastance model for active fiber stress was incorporated in an axisymmetric geometric model of the dilated, poorly contractile LV (dilated cardiomyopathy [DCM]). The nonlinear stress-strain relationship for the diastolic myocardium was anisotropic with respect to the local muscle fiber direction. Systolic material properties were depressed by assigning a peak intracellular calcium concentration (Ca2+) of 1.8 mumoL (normal value: 4.2 mumoL). Six different simulations of myocyte transplantation were performed in which transplanted areas were assigned a peak intracellular calcium concentration (Ca2+) of 4.2 mumoL. The pattern of myocyte engraftment was varied (transmural versus subepicardial; confluent versus heterogeneous), as was the amount of the LV free wall that was transplanted (17% vs 33%). Models were created and loaded with a range of physiologic LV pressures. Simulated myocyte transplantation increased the slope of the end-systolic elastance curve, improved the Starling relationship, and improved stroke volume and ejection fraction compared with DCM. This study demonstrated an improvement in LV function after myocyte transplantation. C1 San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Sch Med, Div Cardiothorac Surg, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Sch Med, Dept Anesthesia, San Francisco, CA 94143 USA. RP Ratcliffe, MB (reprint author), San Francisco Vet Affairs Med Ctr, 112D,4150 Clement St, San Francisco, CA 94121 USA. FU NHLBI NIH HHS [R01-HL-58759, R01-HL-63348] NR 36 TC 11 Z9 11 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1058-2916 J9 ASAIO J JI Asaio J. PD SEP-OCT PY 2002 VL 48 IS 5 BP 508 EP 513 DI 10.1097/01.MAT.0000026353.66193.6B PG 6 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 594GG UT WOS:000178040500012 PM 12296571 ER PT J AU Hegel, MT Barrett, JE Cornell, JE Oxman, TE AF Hegel, MT Barrett, JE Cornell, JE Oxman, TE TI Predictors of response to problem-solving treatment of depression in primary care SO BEHAVIOR THERAPY LA English DT Article ID RANDOMIZED CONTROLLED TRIAL; COGNITIVE-BEHAVIORAL-THERAPY; MINOR DEPRESSION; EMOTIONAL DISORDERS; HOMEWORK COMPLIANCE; MAJOR DEPRESSION; OLDER ADULTS; PSYCHOTHERAPY; DYSTHYMIA; IMPACT AB Problem-solving treatment of depression is a brief intervention specifically designed for primary care (PST-PC). To date, predictors of an optimal response to PST-PC have not been studied. In primary care, knowing such factors is essential for proper triage decisions. Patient, therapist, and process variables were evaluated for their ability to predict remission of minor depression or dysthymia in patients treated with PST PC. The most salient predictors of remission were the ability to understand the PST-PC rationale and to apply the PST-PC procedure in early treatment sessions, having a cognitive-behavioral therapist, and, for dysthymia, having a lower depression severity level at baseline. These results provide preliminary evidence of some factors associated with an optimal response to PST-PC and also present challenges for the ability to broadly disseminate the intervention. Modifications to the existing PST PC training program and directions for future research are discussed. C1 Dartmouth Coll Sch Med, Lebanon, NH 03756 USA. Univ Texas, Hlth Sci Ctr, S Texas Vet Affairs Hlth Care Syst, San Antonio, TX 78284 USA. RP Hegel, MT (reprint author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA. NR 53 TC 25 Z9 25 U1 2 U2 4 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD FAL PY 2002 VL 33 IS 4 BP 511 EP 527 DI 10.1016/S0005-7894(02)80014-4 PG 17 WC Psychology, Clinical SC Psychology GA 607CZ UT WOS:000178774900003 ER PT J AU Suri, R Stowe, ZN Hendrick, V Hostetter, A Widawski, M Altshuler, LL AF Suri, R Stowe, ZN Hendrick, V Hostetter, A Widawski, M Altshuler, LL TI Estimates of nursing infant daily dose of fluoxetine through breast milk SO BIOLOGICAL PSYCHIATRY LA English DT Article DE breastfeeding; postpartum; depression; fluoxetine; collection; infant ID POSTNATAL DEPRESSION; POSTPARTUM DEPRESSION; EXCRETION; DESMETHYLSERTRALINE; NORFLUOXETINE; SERTRALINE; PAROXETINE; CITALOPRAM AB Background: This study compared three methods of estimating the daily dose of fluoxetine to nursing infants and the relationship between these estimates and infant serum concentrations. Methods: Breast milk and infant serum concentrations of fluoxetine and norfluoxetine were obtained from 10 nursing mother-infant pairs. Quantification of daily infant dose was determined by three methods: 1) collection of the total volume of breast milk over 24 hours and determination of the average breast milk concentration (Baby's Total Daily Dose); 2) determination of the maximum and minimum breast milk concentrations during 24 hours and an estimated milk consumption of 150 mL/kg/day (Atkinson Model); and 3) determination of the gradient of excretion of medication into breast milk at a specified time after the maternal dose, applying this gradient to each nursing collection and summing the values over 24 hours (Mathematical Model). The relationship between the 24-hour medication dose, obtained from each method, and the infant serum concentrations was examined. Results: A total of 177 breast milk and 10 infant serum samples were collected. An estimate of the infant daily medication dose obtained by the Mathematical Model was the best predictor of total infant serum concentration. Conclusions: Breast milk analysis may allow one to determine whether medication concentrations will be detectable in an infant, eliminating the need for an infant serum concentration. Although the Mathematical Model seems to reflect infant serum concentration most accurately, all three methods suggest that the maximum dose that a nursing child receives over the course of a year equals as much as 120 mg, or 160 +/- 47% of the maternal daily dose. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Los Angeles, CA 90095 USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. RP Suri, R (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, 300 UCLA Med Plaza,Suite 2339, Los Angeles, CA 90095 USA. NR 18 TC 40 Z9 40 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 1 PY 2002 VL 52 IS 5 BP 446 EP 451 AR PII S0006-3223(02)01368-9 DI 10.1016/S0006-3223(02)01368-9 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 593HN UT WOS:000177985100009 PM 12242061 ER PT J AU Deng, HY Chu, JT Rettig, MB Martinez-Maza, O Sun, R AF Deng, HY Chu, JT Rettig, MB Martinez-Maza, O Sun, R TI Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression SO BLOOD LA English DT Article ID MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; NF-KAPPA-B; EPSTEIN-BARR-VIRUS; KAPOSIS-SARCOMA; VIRAL INTERLEUKIN-6; DNA-SEQUENCES; CELLS; LYMPHOCYTES; ACTIVATION AB Human herpesvirus 8 (HHV-8)/Kaposi sarcoma-associated herpesvirus (KSHV) is linked to a number of malignancies thought to be driven by cytokines, including interieukin-6 (IL-6). Rta, a transcriptional activator encoded by HHV-8/KSHV, activates the viral lytic cycle leading to the expression of several viral genes implicated in viral pathogenesis. However, the effect of HHV-8/KSHV Rta on cellular genes has not been reported. We present.. evidence that the human IL-6 (hIL-6) gene is up-regulated by Rta. Rta potently activated (up to 164-fold) the hIL-6 promoter in a dose-dependent manner in a transient transfection reporter system. Rta also induced expression of the endogenous hIL-6 gene, as shown by enzyme-linked immunosorbent assays. Activation of the hIL-6 gene by HHV-8/KSHV supports the role of hIL-6 in the development of these malignancies. (C) 2002 by The American Society of Hematology. C1 Univ Calif Los Angeles, Dent Res Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm Med Ctr, Dept Med, Los Angeles, CA USA. W Los Angeles Vet Adm Med Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP Sun, R (reprint author), Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. RI Martinez-Maza, Otoniel/B-2667-2009 OI Martinez-Maza, Otoniel/0000-0003-1364-0675 FU NCI NIH HHS [CA57152, CA83525, CA91791]; NIDCR NIH HHS [DE14153] NR 25 TC 47 Z9 48 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD SEP 1 PY 2002 VL 100 IS 5 BP 1919 EP 1921 DI 10.1182/blood-2002-01-0015 PG 3 WC Hematology SC Hematology GA 587WU UT WOS:000177667700058 PM 12176919 ER PT J AU Restrepo, A Devore, P Encarnacion, CE Wholey, MH Schneider, D Callander, NS Ferral, H Postoak, D Anderson, JE Walsh, T Padayao, G Gokmen, E Ehsan, A Ochoa, L Neumon, B West, G Restrepo, MI Przykucki, J Patterson, J Freytes, CO AF Restrepo, A Devore, P Encarnacion, CE Wholey, MH Schneider, D Callander, NS Ferral, H Postoak, D Anderson, JE Walsh, T Padayao, G Gokmen, E Ehsan, A Ochoa, L Neumon, B West, G Restrepo, MI Przykucki, J Patterson, J Freytes, CO TI Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation SO BONE MARROW TRANSPLANTATION LA English DT Article DE catheters; indwelling; infection; hematopoietic stem cell transplantation ID PROGENITOR CELLS; CANCER-PATIENTS; RISK-FACTORS; COMPLICATIONS; INFECTIONS; MARROW; CHEMOTHERAPY; COLLECTION; HICKMAN; DEVICES AB Patients undergoing autologous peripheral blood stem cell transplantation (PBSC) frequently require the sequential insertion of two central venous catheters, one for leukapheresis and one for transplant support. Hybrid catheters suitable for leukapheresis and long-term use have been increasingly used, but there is limited information regarding their performance and complication rate. The purpose of this study was to determine the performance of the Pheres-Flow hybrid catheter when utilized for both leukapheresis and transplant support, with particular emphasis on the incidence of infectious and occlusive complications. We prospectively analyzed the performance of 92 catheters in 82 consecutive patients who underwent autologous peripheral blood stem cell (PBSC) transplantation. Occlusion was the most frequent complication of this catheter with 29% of the patients experiencing difficulty drawing blood or infusing fluids. Infection was another frequent complication. Twenty-two percent of patients developed catheter-related bloodstream infections and 15 catheters had to be removed because of proven or suspected infection that did not respond to antibiotic therapy. Nevertheless, 77% of patients were able to complete leukapheresis and transplant support with only one catheter. We conclude that the utilization of the Pheres-Flow catheter for both leukapheresis and transplant support is feasible, but that new strategies need to be developed to decrease the incidence of occlusive and infectious complications of hybrid catheters. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Freytes, CO (reprint author), Mail Code 7880,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 15 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD SEP PY 2002 VL 30 IS 6 BP 389 EP 395 DI 10.1038/sj.bmt.1703647 PG 7 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 603EK UT WOS:000178545700009 PM 12235524 ER PT J AU Rao, PK Pergola, PE Habiba, NM Liu, Y Kellogg, DL AF Rao, PK Pergola, PE Habiba, NM Liu, Y Kellogg, DL TI Double injection vs skin microdialysis technique in minimally invasive in vivo pharmacology SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Letter C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. RP Pergola, PE (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0306-5251 J9 BRIT J CLIN PHARMACO JI Br. J. Clin. Pharmacol. PD SEP PY 2002 VL 54 IS 3 BP 333 EP 334 DI 10.1046/j.1365-2125.2002.01655.x PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 594ZA UT WOS:000178081300014 PM 12236855 ER PT J AU Shi, YJ Gera, J Hu, LP Hsu, JH Bookstein, R Li, WQ Lichtenstein, A AF Shi, YJ Gera, J Hu, LP Hsu, JH Bookstein, R Li, WQ Lichtenstein, A TI Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 SO CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR-I; PLASMA-CELLS; AKT KINASE; RAPAMYCIN; EXPRESSION; ACTIVATION; SURVIVAL; P70(S6K); PATHWAY AB Recent work identifies the AKT kinase as a potential mediator of tumor expansion in multiple myeloma. The finding of PTEN mutations in several myeloma cell lines suggests that loss of PTEN function may be one mechanism by which AKT activity is increased in this disease. Because PTEN-deficient myeloma cells may have up-regulated activity of the mammalian target of rapamycin (mTOR), downstream of AKT. they may, be particularly sensitive to mTOR inhibition. To test this hypothesis, we challenged myeloma cell lines with CCI-779, a newly developed analogue of rapamycin and an efficient inhibitor of mTOR. Three of four PTEN-deficient cell lines with constitutively active AKT were remarkably sensitive to cytoreduction and G(1) arrest induced by CCI-779 with ID50 concentrations of <1 nM. In contrast, myeloma cells expressing wild-type PTEN were >1000-fold more resistant. Acute expression of a constitutively active AKT gene in CCI-779-resistant myeloma cells containing wild-type PTEN and quiescent AKT did not convert them to the CCI-779-sensitive phenotype. Conversely, expression of wild-type PTEN in CCI-779-sensitive, PTEN-deficient myeloma cells did not induce resistance. Differential sensitivity did not appear to be due to differences in the ability of CCI-779 to inhibit mTOR and induce dephosphorylation of p70S6kinase or 4E-BP1. However, CCI-779 inhibited expression of c-myc in CCI-sensitive PTEN-null myeloma cells but had no effect on expression in CCI-resistant cells. In contrast, cyclin D1 expression was not altered in either sensitive or resistant cells. These results indicate that PTEN-deficient myeloma cells are remarkably sensitive to mTOR inhibition. Although the results of transfection studies suggest that the level of PTEN and AKT function per se does not regulate sensitivity, PTEN/AKT status may be a good predictive marker of sensitivity. C1 Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Div Hematol Oncol, Los Angeles, CA 90073 USA. Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. Georgetown Univ, Med Ctr, Washington, DC 20007 USA. Canji Inc, San Diego, CA 92121 USA. RP Lichtenstein, A (reprint author), VA W Los Angeles Hosp, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCI NIH HHS [CA 96920-01] NR 29 TC 205 Z9 216 U1 1 U2 6 PU AMER ASSOC CANCER RESEARCH PI BIRMINGHAM PA PO BOX 11806, BIRMINGHAM, AL 35202 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD SEP 1 PY 2002 VL 62 IS 17 BP 5027 EP 5034 PG 8 WC Oncology SC Oncology GA 591TW UT WOS:000177897200030 PM 12208757 ER PT J AU Kominsky, DJ Bickel, RJ Tyler, KL AF Kominsky, DJ Bickel, RJ Tyler, KL TI Reovirus-induced apoptosis requires both death receptor- and mitochondrial-mediated caspase-dependent pathways of cell death SO CELL DEATH AND DIFFERENTIATION LA English DT Article DE apoptosis; reovirus; caspase; death receptor; mitochondria ID CYTOCHROME-C RELEASE; PROTEIN; ACTIVATION; FAMILY; BCL-2; INHIBITION; INFECTION; COMPLEX; SPECIFICITIES; MODULATION AB Apoptosis plays an important role in the pathogenesis of many viral infections. Despite this fact, the apoptotic pathways triggered during viral infections are incompletely understood. We now provide the first detailed characterization of the pattern of caspase activation following infection with a cytoplasmically replicating RNA virus. Reovirus infection of HEK293 cells results in the activation of caspase-8 followed by cleavage of the pro-apoptotic protein Bid. This initiates the activation of the mitochondrial apoptotic pathway leading to release of cytochrome c and activation of caspase-9. Combined activation of death receptor and mitochondrial pathways results in downstream activation of effector caspases including caspase-3 and caspase-7 and cleavage of cellular substrates including PARP. Apoptosis is initiated by death receptor pathways but requires mitochondrial amplification producing a biphasic pattern of caspase-8, Bid, and caspase-3 activation. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave,B-182, Denver, CO 80262 USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NIA NIH HHS [1R01AG14071] NR 40 TC 62 Z9 65 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 J9 CELL DEATH DIFFER JI Cell Death Differ. PD SEP PY 2002 VL 9 IS 9 BP 926 EP 933 DI 10.1038/sj.cdd.4401045 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 586KN UT WOS:000177583300008 PM 12181743 ER PT J AU Vielma, S Virella, G Gorod, AJ Lopes-Virella, MF AF Vielma, S Virella, G Gorod, AJ Lopes-Virella, MF TI Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (Fc gamma RII) SO CLINICAL IMMUNOLOGY LA English DT Article DE Chlamydophila pneumoniae; Fc gamma receptors; atherosclerosis; endothelial dysfunction ID CORONARY HEART-DISEASE; CIRCULATING IMMUNE-COMPLEXES; ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; ATHEROSCLEROTIC PLAQUES; RESPIRATORY-TRACT; ARTERY DISEASE; RISK-FACTORS; IN-VITRO; T-CELLS AB Chronic endothelial infection is believed to be one of the factors able to cause endothelial cell damage and trigger the onset of human atherosclerosis. Chlamydophila pneumoniae infects endothelial cells and has received special attention because of both epidemiological and experimental evidence supporting its role as a risk factor for atherosclerosis. It is also possible that otherwise independent risk factors for atherosclerosis may have synergistic effects. Immune phenomena, such as the formation of circulating immune complexes (IC) containing modified LDL and corresponding antibodies, have been linked to the development of coronary artery disease. The antibodies involved in the immune response to modified lipoproteins are predominantly of the pro-inflammatory IgG1 and IgG3 subclasses. However, it is difficult to understand how circulating IC could cause endothelial damage and initiate the atherosclerotic process, unless they were formed in the subendothelial space or immobilized by endothelial cells. The last hypothesis would be possible if endothelial cells expressed Fcgamma receptors. Healthy endothelial cells do not express Fcgamma receptors, but endothelial cells infected by a variety of infectious agents do. Thus we decided to investigate whether infection of endothelial cells with C. pneumoniae is also able to cause the expression of Fcgamma receptors. The expression of Fcgamma receptors (CD64, 32, and 16) on human aortic endothelial cells infected with C. pneumoniae for 4, 24, 36, and 48 h was studied by flow cytometry. Twenty-four hours after infection 30-40% of the endothelial cells had detectable inclusion bodies, 8-9% of the total number of cells (approximately 25% of the infected cells) expressed FcgammaRII, and about 1.5-2% (5% of infected cells) expressed FcgammaRI and FcgammaRIII. Double-staining studies confirmed that the expression of FcgammaRII was limited to C. pneumoniae-infected endothelial cells. We conclude that C. pneumoniae infection induces primarily the expression of FcgammaRII by endothelial cells and this may be a significant link between two proposed pathogenic mechanisms involved in the pathogenesis of human atherosclerosis. (C) 2002 Elsevier Science (USA). C1 Med Univ S Carolina, Dept Med, Div Endocrinol Metab Nutr, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Vielma, S (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Metab Nutr, Charleston, SC 29425 USA. NR 48 TC 20 Z9 21 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD SEP PY 2002 VL 104 IS 3 BP 265 EP 273 DI 10.1006/clim.2002.5237 PG 9 WC Immunology SC Immunology GA 603FW UT WOS:000178549100010 PM 12217337 ER PT J AU Finegold, SM Molitoris, D Song, YL Liu, CX Vaisanen, ML Bolte, E McTeague, M Sandler, R Wexler, H Marlowe, EM Collins, MD Lawson, PA Summanen, P Baysallar, M Tomzynski, TJ Read, E Johnson, E Rolfe, R Nasir, P Shah, H Haake, DA Manning, P Kaul, A AF Finegold, SM Molitoris, D Song, YL Liu, CX Vaisanen, ML Bolte, E McTeague, M Sandler, R Wexler, H Marlowe, EM Collins, MD Lawson, PA Summanen, P Baysallar, M Tomzynski, TJ Read, E Johnson, E Rolfe, R Nasir, P Shah, H Haake, DA Manning, P Kaul, A TI Gastrointestinal microflora studies in late-onset autism SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Anaerobe Odyssey Symposium held in honor of Sydney M Finegolds 80th Birthday CY AUG 12, 2001 CL UNIV CALIF LOS ANGELES, FAC CLUB, LOS ANGELES, CALIFORNIA HO UNIV CALIF LOS ANGELES, FAC CLUB ID MYELIN BASIC-PROTEIN; AMINO-ACIDS; CHILDREN; BACTERIA; DEGRADATION; ANTIBODIES; INTESTINE; PRODUCTS; DISORDER; STRAINS AB Some cases of late-onset (regressive) autism may involve abnormal flora because oral vancomycin, which is poorly absorbed, may lead to significant improvement in these children. Fecal flora of children with regressive autism was compared with that of control children, and clostridial counts were higher. The number of clostridial species found in the stools of children with autism was greater than in the stools of control children. Children with autism had 9 species of Clostridium not found in controls, whereas controls yielded only 3 species not found in children with autism. In all, there were 25 different clostridial species found. In gastric and duodenal specimens, the most striking finding was total absence of non-spore-forming anaerobes and microaerophilic bacteria from control children and significant numbers of such bacteria from children with autism. These studies demonstrate significant alterations in the upper and lower intestinal flora of children with late-onset autism and may provide insights into the nature of this disorder. C1 W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111 F, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Clin Microbiol Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Rush Childrens Hosp, Chicago, IL USA. Univ Wisconsin, Dept Food Microbiol & Toxicol & Bacteriol, Madison, WI USA. Texas Tech Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Lubbock, TX 79430 USA. Childrens Hosp, Med Ctr, Div Pediat Gastroenterol & Nutr, Cincinnati, OH 45229 USA. Univ Reading, Sch Food Biosci, Dept Microbiol, Reading, Berks, England. Cent Publ Hlth Lab, Publ Hlth Lab Serv, Identificat Serv Unit, London NW9 5HT, England. RP Finegold, SM (reprint author), W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111 F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RI Lawson, Paul/E-3760-2012 NR 47 TC 194 Z9 214 U1 3 U2 38 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2002 VL 35 SU 1 BP S6 EP S16 DI 10.1086/341914 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 585PH UT WOS:000177533400002 PM 12173102 ER PT J AU Wexler, HM AF Wexler, HM TI Outer-membrane pore-forming proteins in gram-negative anaerobic bacteria SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Anaerobe Odyssey Symposium held in honor of Sydney M Finegolds 80th Birthday CY AUG 12, 2001 CL UNIV CALIF LOS ANGELES, FAC CLUB, LOS ANGELES, CALIFORNIA HO UNIV CALIF LOS ANGELES, FAC CLUB ID PORPHYROMONAS-GINGIVALIS W50; ESCHERICHIA-COLI K-12; BACTEROIDES-FRAGILIS; FUSOBACTERIUM-NUCLEATUM; PSEUDOMONAS-AERUGINOSA; ACTIVE EFFLUX; CELL-SURFACE; IDENTIFICATION; PORINS; GENE AB The outer-membrane proteins (OMPs) of bacteria function as the dynamic interface between the bacterium and its surroundings and are involved in maintenance of cell structure, binding a variety of substances, adhesion to other cells, and regulation of transport of both nutrients and bactericidal agents. There is a vast amount of information about aerobic OMPs and their roles in immunogenicity, virulence, and antimicrobial resistance. Knowledge about OMPs in anaerobic bacteria is much sparser. Genetic data present in data banks regarding aerobic porins are not readily helpful in identifying or analyzing anaerobic porins because of the large phylogenetic distance between the aerobic and anaerobic organisms. We recently identified and sequenced the genes for both a porin protein complex and an OmpA protein in Bacteroides fragilis, and the data are summarized here. Also, recent information is presented about similar OMPs found in other gram-negative anaerobic bacteria, including Bacteroides thetaiotaomicron, Bacteroides distasonis, Porphyromonas, and Fusobacterium. C1 VA Greater Los Angeles Healthcare Syst, Microbial Dis Res Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. RP Wexler, HM (reprint author), VA Greater Los Angeles Healthcare Syst, Microbial Dis Res Lab, Bldg 304,Rm E3-224,691-151J, Los Angeles, CA 90073 USA. NR 43 TC 16 Z9 17 U1 2 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2002 VL 35 SU 1 BP S65 EP S71 DI 10.1086/341923 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 585PH UT WOS:000177533400011 PM 12173111 ER PT J AU Liao, D Asberry, PJ Shofer, JB Callahan, H Matthys, C Boyko, EJ Leonetti, D Kahn, SE Austin, M Newell, L Schwartz, RS Fujimoto, WY AF Liao, D Asberry, PJ Shofer, JB Callahan, H Matthys, C Boyko, EJ Leonetti, D Kahn, SE Austin, M Newell, L Schwartz, RS Fujimoto, WY TI Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance SO DIABETES CARE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; FASTING PLASMA-INSULIN; CORONARY-HEART-DISEASE; VISCERAL ADIPOSITY; RISK-FACTORS; WEIGHT-LOSS; FOLLOW-UP; MEN; PREVENTION; NIDDM AB OBJECTIVE- To determine whether diet and endurance exercise improved adiposity-related measurements in Japanese Americans with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS- This study compared the effects of an American Heart Association (AHA) step 2 diet (< 30% of total calories as fat, < 7% saturated fat, 55% carbohydrate, and < 200 mg cholesterol daily) plus endurance exercise for I h three times a week (treatment group) with an AHA step I diet (30% of total calories as fat, 10% saturated fat, 50% carbohydrate, and < 300 mg cholesterol) plus stretching exercise three times a week (control group) on BMI, body composition (% fat), and body fat distribution at 6 and 24 months of follow-up in 64 Japanese American men and women with IGT, 58 of whom completed the study. RESULTS- At 6 months, the treatment group showed significantly greater reduction in percent, body fat (-1.4 +/- 0.4 vs. -0.3 +/- 0.3%); BMI (-1.1 +/- 0.2 vs. -0.4 +/- 0.1 kg/m(2)); subcutaneous fat by computed tomography at the abdomen (-29.3 +/- 4.2 vs. -5.7 +/- 5.9 cm(2)), thigh (-13.2 +/- 3.6 vs. -3.6 +/- 3.0 cm(2)), and thorax (-19.6 +/- 3.6 vs. -8.9 +/- 2.6 cm(2)); and skinfold thickness at the bicep (-2.0 +/- 0.6 vs. 1.1 +/- 0.6 mm) and tricep (-3.7 +/- 0.8 vs. -0.9 +/- 0.6 MITI), which continued despite moving to home-based exercise for the last 18 months. CONCLUSIONS- Diet and endurance exercise improved BMI, body composition, and body fat distribution and, thus, may delay or prevent type 2 diabetes in Japanese Americans with IGT. C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Gen Clin Res Ctr, Seattle, WA 98195 USA. Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Liao, D (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Box 356426, Seattle, WA 98195 USA. OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [RR-00037]; NIDDK NIH HHS [DK-02654, DK-1707, DK-35816, DK-48152] NR 32 TC 47 Z9 49 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2002 VL 25 IS 9 BP 1504 EP 1510 DI 10.2337/diacare.25.9.1504 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 724UE UT WOS:000185504400002 PM 12196418 ER PT J AU Franceschi, F Genta, RM Gasbarrini, A Silveri, NG Gasbarrini, G Sepulveda, AR AF Franceschi, F Genta, RM Gasbarrini, A Silveri, NG Gasbarrini, G Sepulveda, AR TI Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE angiogenic factors; gastric cancer; Helicobacter pylori; platelet-derived endothelial cell growth factor ID THYMIDINE PHOSPHORYLASE; PROGNOSTIC-SIGNIFICANCE; CANCER; LECTURE AB Background. Expression of the angiogenic factor platelet-derived endothelial cell growth factor is induced in some gastric carcinomas. Whether angiogenesis is induced early in the development of gastric pre-neoplastic lesions and whether Helicobacter pylori infection affects platelet-derived endothelial cell growth factor expression is not known. Aim. To assess whether chronic gastritis, intestinal metaplasia, gastric dysplasia and gastric carcinomas express platelet-derived endothelial cell growth factor and whether Helicobacter pylori infection might affect the expression of platelet-derived endothelial cell growth factor in these lesions. Patients and Methods. Patients with gastric carcinomas, atrophic gastritis with associated intestinal metaplasia, dysplasia and controls without infection or carcinoma were studied. Results. Platelet-derived endothelial cell growth factor was detected by immunohistochemistry in 9 out 19 gastric carcinomas (459,D). Only focal immunostaining was detected in intestinal metaplasia adjacent to dysplasia and in dysplastic cells. Of the tumours, 90% contained platelet-derived endothelial cell growth factor-positive interstitial cells. A significant correlation was found between active Helicobacter pylori infection and a larger number of platelet-derived endothelial cell growth factor-positive interstitial cells in areas of intestinal metaplasia (p<0.05). Conclusion. Helicobacter pylori infection does not influence the expression of platelet-derived endothelial cell growth factor once gastric cancer has developed. However Helicobacter pylori infection may increase the extension of expression of platelet-derived endothelial cell growth factor by infiltrating interstitial cells in premalignant lesions, such as intestinal metaplasia, which may help create a favourable environment for tumour development. This may possibly be due to nonspecific increase in recruitment of inflammatory cells caused by Heli cobacter pylori infection. Further studies, with a larger number of samples, are now needed in order to confirm this finding. C1 Univ Sacred Heart, Policlin Gemelli, Dept Internal Med, I-00168 Rome, Italy. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX USA. Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA. RP Gasbarrini, G (reprint author), Univ Sacred Heart, Policlin Gemelli, Dept Internal Med, Largo A Gemelli 8, I-00168 Rome, Italy. NR 25 TC 9 Z9 10 U1 0 U2 0 PU PACINI EDITORE PI PISA PA VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY SN 1590-8658 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD SEP PY 2002 VL 34 IS 9 BP 621 EP 625 DI 10.1016/S1590-8658(02)80203-1 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 600KE UT WOS:000178388500004 PM 12405247 ER PT J AU Licht, EA Fujikawa, DG AF Licht, EA Fujikawa, DG TI Nonconvulsive status epilepticus with frontal features: quantitating severity of subclinical epileptiform discharges provides a marker for treatment efficacy, recurrence and outcome SO EPILEPSY RESEARCH LA English DT Article DE nonconvulsive status epilepticus; subclinical epileptiform discharges; subclinical seizures; frontal lobe seizures; cognitive deficits ID CONVULSIVE STATUS EPILEPTICUS; CONFUSION; SEIZURES AB Nonconvulsive status epilepticus (NCSE) is difficult to diagnose but is an important cause of cognitive impairment. Electroencephalogram (EEG) monitoring is required for diagnosis and treatment. Little is known regarding the stability of subclinical epileptiform discharges (SEDs) preceding NCSE nor what strategies may optimize patient outcomes. We report extended follow-up of patients with recurrent frontal SEDs, integrating EEG and cognitive findings before and following treatment of NCSE, and show that quantitating SED severity provides an objective marker of treatment efficacy and recurrence. (C) 2002 Elsevier Science B.V. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. Nursing Home Care Unit, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90024 USA. RP Licht, EA (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 17 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 J9 EPILEPSY RES JI Epilepsy Res. PD SEP PY 2002 VL 51 IS 1-2 BP 13 EP 21 AR PII S0920-1211(02)00107-9 DI 10.1016/S0920-1211(02)00107-9 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 605VE UT WOS:000178697100003 PM 12350380 ER PT J AU Rowan, AJ AF Rowan, AJ TI Seizure - Fundamentals of drug management of epilepsy in the older patient SO GERIATRICS LA English DT Article AB Although commonly perceived as a condition of the young, epilepsy has a significant presence in the geriatric population. The most common seizure types in older persons are complex partial, simple partial, and secondarily generalized tonic clonic. Patient assessment and management objectives include determining the seizure type, calculating the risk of seizure recurrence, and determining whether to initiate anticonvulsant therapy. These objectives are pursued using clinical, electroencephalographic (EEG), and neuroimaging findings. Treatment can reduce the risk of recurrence and prevent injuries likely to occur among older persons experiencing seizures. C1 CUNY Mt Sinai Sch Med, New York, NY 10029 USA. Bronx Vet Adm Med Ctr, Dept Neurol, Bronx, NY USA. RP Rowan, AJ (reprint author), CUNY Mt Sinai Sch Med, New York, NY 10029 USA. NR 13 TC 3 Z9 3 U1 0 U2 0 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD SEP PY 2002 VL 57 IS 9 BP 33 EP 37 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 595VP UT WOS:000178129500009 PM 12271827 ER PT J AU Franceschi, F Sepulveda, AR Penland, R Fukui, H Osato, M Gasbarrini, A Gasbarrini, G Graham, DY Genta, RM AF Franceschi, F Sepulveda, AR Penland, R Fukui, H Osato, M Gasbarrini, A Gasbarrini, G Graham, DY Genta, RM TI Pathological changes in the gastric mucosa of Mongolian gerbils infected by different strains of Helicobacter pylori SO GUT LA English DT Meeting Abstract CT 15th International Workshop on Gastrointestinal Pathology and Helicobacter CY SEP 11-14, 2002 CL ATHENS, GREECE C1 Univ Sacred Heart, I-00168 Rome, Italy. Univ Pittsburgh, Pittsburgh, PA USA. VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD SEP PY 2002 VL 51 SU 2 MA 813 BP A49 EP A50 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 599PJ UT WOS:000178344100176 ER PT J AU Franceschi, F Penland, R Fukui, H Osato, M Gasbarrini, A Gasbarrini, G Graham, DY Sepulveda, AR Genta, RM AF Franceschi, F Penland, R Fukui, H Osato, M Gasbarrini, A Gasbarrini, G Graham, DY Sepulveda, AR Genta, RM TI Helicobacter pylori infection affects growth rate in Mongolian gerbils SO GUT LA English DT Meeting Abstract CT 15th International Workshop on Gastrointestinal Pathology and Helicobacter CY SEP 11-14, 2002 CL ATHENS, GREECE C1 Univ Sacred Heart, I-00168 Rome, Italy. VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD SEP PY 2002 VL 51 SU 2 MA 810 BP A49 EP A49 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 599PJ UT WOS:000178344100173 ER PT J AU Kwon, DH Dore, MP Kim, JJ Lee, M Kato, M Graham, DY AF Kwon, DH Dore, MP Kim, JJ Lee, M Kato, M Graham, DY TI Mechanism of acquired-multidrug resistance in Helicobacter pylori: Alterations of outer membrane proteins and lipopolysaccharide SO GUT LA English DT Meeting Abstract CT 15th International Workshop on Gastrointestinal Pathology and Helicobacter CY SEP 11-14, 2002 CL ATHENS, GREECE C1 VA Med Ctr, Houston, TX USA. Univ Sassari, Dept Med, I-07100 Sassari, Italy. Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Seoul, South Korea. Ewha Womans Univ, Dept Clin Pathol, Seoul, South Korea. Hokkaido Univ, Sch Med, Dept Endoscopy, Sapporo, Hokkaido 060, Japan. RI Kato, Mototsugu/A-6736-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD SEP PY 2002 VL 51 SU 2 MA 107 BP A2 EP A2 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 599PJ UT WOS:000178344100009 ER PT J AU Vakil, N Kovacs, T Ignatowitz, W Hahne, W Barth, J AF Vakil, N Kovacs, T Ignatowitz, W Hahne, W Barth, J TI Presence or absence of peptic ulcer disease does not affect H-pylori eradication rates with rabeprazole-based triple therapy SO GUT LA English DT Meeting Abstract CT 15th International Workshop on Gastrointestinal Pathology and Helicobacter CY SEP 11-14, 2002 CL ATHENS, GREECE C1 Univ Wisconsin, Sch Med, Milwaukee, WI 53201 USA. Univ Calif Los Angeles, W Los Angeles VAMC, CURE Clin, Los Angeles, CA USA. Pharma Trials Inc, Brooklyn, NY USA. Eisai Inc, Teaneck, NJ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD SEP PY 2002 VL 51 SU 2 MA 1509 BP A93 EP A93 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 599PJ UT WOS:000178344100321 ER PT J AU Ostrow, JD AF Ostrow, JD TI Hemolysis in Gilbert's syndrome SO HEPATOLOGY LA English DT Letter ID LIVER C1 Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Ostrow, JD (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD SEP PY 2002 VL 36 IS 3 BP 764 EP 764 DI 10.1053/jhep.2002.34438 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 588VL UT WOS:000177722500029 PM 12198673 ER PT J AU Sharma, R Bhatti, S Gomez, M Clark, RM Murray, C Ashizawa, T Bidichandani, SI AF Sharma, R Bhatti, S Gomez, M Clark, RM Murray, C Ashizawa, T Bidichandani, SI TI The GAA triplet-repeat sequence in Friedreich ataxia shows a high level of somatic instability in vivo, with a significant predilection for large contractions SO HUMAN MOLECULAR GENETICS LA English DT Article ID LYMPHOBLASTOID CELL-LINES; SMALL POOL PCR; REPLICATION PROTEIN-A; SINGLE SPERM ANALYSIS; DOT-TTC REPEATS; MYOTONIC-DYSTROPHY; TRINUCLEOTIDE REPEATS; INTERGENERATIONAL INSTABILITY; DIAGNOSTIC-CRITERIA; CLINICAL-FEATURES AB Friedreich ataxia is commonly caused by large expansions of a GAA triplet-repeat (GAA-TR) sequence in the first intron of the FRDA gene. We used small-pool PCR to analyze somatic variability among 7190 individual FRDA molecules from peripheral blood DNA of subjects carrying 12 different expanded alleles, ranging in size from 241 to 1105 triplets. Expanded alleles showed a length-dependent increase in somatic variability, with mutation loads ranging from 47% to 78%. We noted a strong contraction bias among long alleles (>500 triplets), which showed a 4-fold higher frequency of large contractions versus expansions. Some contractions were very large; of all somatic mutations scored, similar to5% involved contractions of >50% of the original allele length, and 0.29% involved complete reversion to the normal/premutation length (less than or equal to60 triplets). These observations contrast sharply with the strong expansion bias seen in expanded CTG triplet repeats in myotonic dystrophy. No somatic variability was detected in >6000 individual FRDA molecules analyzed from 15 normal alleles (8-25 triplets). A premutation allele with 44 uninterrupted GAA repeats was found to be unstable, ranging in size from 6 to 113 triplets, thus establishing the threshold for somatic instability between 26 and 44 GAA triplets. Analysis of an additional 7850 FRDA molecules from serially passaged lymphoblastoid cell lines carrying nine expanded alleles (132-933 triplets) showed very low mutation loads, ranging from 0% to 6.2%. Our data indicate that expanded GAA-TR alleles in Friedreich ataxia are highly mutable and have a natural tendency to contract in vivo, and that these properties depend on multiple factors, including DNA sequence, triplet-repeat length and unknown cell-type-specific factors. C1 Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA. Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73104 USA. Univ Cent Oklahoma, Dept Math & Stat, Edmond, OK USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. RP Bidichandani, SI (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE,10th,BRC458, Oklahoma City, OK 73104 USA. NR 62 TC 43 Z9 45 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD SEP 1 PY 2002 VL 11 IS 18 BP 2175 EP 2187 DI 10.1093/hmg/11.18.2175 PG 13 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 586NU UT WOS:000177590700011 PM 12189170 ER PT J AU Eslami, P Nyby, MD Corry, D Eggena, P Tuck, ML AF Eslami, P Nyby, MD Corry, D Eggena, P Tuck, ML TI Angiotensin II AT1 receptor blocker decreases insulin-stimulated intracellular angiotensin II in vascular smooth muscle cells SO HYPERTENSION LA English DT Meeting Abstract CT 56th Annual Fall Conference and Scientific Sessions of the Council-for-High-Blood-Pressure-Research in Associaton with the Council-on-Kidney-in-Cardiovascular-Disease CY SEP 25-28, 2002 CL ORLANDO, FLORIDA SP Council High Blood Pressure, Council Kidney Cardiovas Dis, Council Nutrition Phys Activ & Metab C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif, Sepulveda, CA USA. Sepulveda VA Med Ctr, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD SEP PY 2002 VL 40 IS 3 MA P19 BP 398 EP 398 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 594LY UT WOS:000178052900132 ER PT J AU Haake, DA Matsunaga, J AF Haake, DA Matsunaga, J TI Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins SO INFECTION AND IMMUNITY LA English DT Article ID TWO-DIMENSIONAL ELECTROPHORESIS; IMMOBILIZED PH GRADIENTS; TREPONEMA-PALLIDUM; PATHOGENIC LEPTOSPIRA; BORRELIA-BURGDORFERI; ESCHERICHIA-COLI; MAMMALIAN INFECTION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; SIGNAL PEPTIDES AB The outer membrane (OM) of the mammalian pathogen Leptospira kirschneri was isolated in the form of membrane vesicles by alkaline plasmolysis and separated from the protoplasmic cylinder by sucrose density gradient ultracentrifugation. All four components of the alkaline plasmolysis buffer, including 1.0 M NaCl, 27% sucrose (wt/vol), 2 mM EDTA, and 10 mM Tris (pH 9), were required for efficient OM release, as judged by recovery of leptospiral lipopolysaccharide. Two populations of OM vesicles (OMVs) were recovered, with peak concentrations found in the sucrose gradient at densities of 1.16 and 1.18 g/ml. Transmission electron microscopy revealed that the more buoyant OMV population was smaller (<0.1 μm,m in diameter) than the denser OMV population (0.2 to 0.3 μm in diameter). The densities of both populations of OMVs were distinct from that of the protoplasmic-cylinder material, which was found in the sucrose gradient at a density of 1.20 g/ml. The OMV fractions were free of protoplasmic-cylinder material, as judged by immunoblotting with antibodies to the endoflagellar sheath protein, heat shock protein GroEL, and two novel cytoplasmic membrane proteins, lipoprotein LipL31 and transmembrane protein ImpL63. The protein components of the OMVs were characterized by one- and two-dimensional immunoblotting and found to include previously described OM proteins (OMPs), including the porin OmpL1; the lipoproteins LipL32, LipL36, and LipL41; and the peripheral membrane protein P31(LipL45). A number of less well-characterized OMPs were also identified, including those with molecular masses of 16, 21, 21.5, 22, 31, 36, 44, 48, 90, and 116 kDa. The 48-kDa OMP was identified as a novel OM lipoprotein designated LipL48. The use of membrane-specific markers in OM isolation techniques facilitates an accurate description of the leptospiral OM and its components. C1 VA Greater LA Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. FU NIAID NIH HHS [R01 AI034431, AI-34431, R01 AI034431-06A2, R21 AI034431, R29 AI034431] NR 45 TC 71 Z9 85 U1 2 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD SEP PY 2002 VL 70 IS 9 BP 4936 EP 4945 DI 10.1128/IAI.70.9.4936-4945.2002 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 584WE UT WOS:000177491100024 PM 12183539 ER PT J AU Cotton, A Farley, M Baron, R AF Cotton, A Farley, M Baron, R TI Attitudes toward prostitution and acceptance of rape myths SO JOURNAL OF APPLIED SOCIAL PSYCHOLOGY LA English DT Article ID COLLEGE-STUDENTS; VIOLENCE; RAPISTS; WOMEN AB Rape myths and prostitution myths are a component of culturally supported attitudes that normalize violence against women. Prostitution myths justify the existence of prostitution, promote misinformation about prostitution, and contribute to a social climate that exploits and harms not only prostituted women, but all women. This study investigated the relationship between prostitution myth acceptance and rape myth acceptance in a sample of university undergraduates. Rape myth acceptance was positively correlated with prostitution myth acceptance among 783 university undergraduates from California, Iowa, Oregon, and Texas. College men were significantly more accepting of prostitution myths than were college women. Results suggest that acceptance of prostitution myths are a component of attitudes that justify violence against women. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Prostitut Res & Educ, San Francisco, CA USA. Univ Iowa, Iowa City, IA USA. RP Farley, M (reprint author), Box 16254, San Francisco, CA 94116 USA. NR 21 TC 18 Z9 19 U1 2 U2 15 PU V H WINSTON & SON INC PI PALM BEACH PA 360 SOUTH OCEAN BLVD, PH-B, PALM BEACH, FL 33480 USA SN 0021-9029 J9 J APPL SOC PSYCHOL JI J. Appl. Soc. Psychol. PD SEP PY 2002 VL 32 IS 9 BP 1790 EP 1796 DI 10.1111/j.1559-1816.2002.tb00259.x PG 7 WC Psychology, Social SC Psychology GA 636RV UT WOS:000180471400002 ER PT J AU Lopez, I Aguilera-Tejero, E Felsenfeld, AJ Estepa, JC Rodriguez, M AF Lopez, I Aguilera-Tejero, E Felsenfeld, AJ Estepa, JC Rodriguez, M TI Direct effect of acute metabolic and respiratory acidosis on parathyroid hormone secretion in the dog SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE acidosis; calcium; metabolic acidosis; parathyroid hormone; respiratory acidosis ID CHRONIC-RENAL-FAILURE; PTH-CALCIUM CURVE; IONIZED CALCIUM; HYPOCALCEMIA; PHOSPHATE; MAGNESIUM; DISEASE; HUMANS; CELLS; RAT AB Because both metabolic (Met Acid) and respiratory acidosis (Resp Acid) have diverse effects on mineral metabolism, it has been difficult to establish whether acidosis directly affects parathyroid hormone (PTH) secretion. Our goal was to determine whether acute Met Acid and Resp Acid directly affected PTH secretion. Three groups of dogs were studied: control, acute Met Acid induced by HCl infusion, and acute Resp Acid induced by hypoventilation. EDTA was infused to prevent acidosis-induced increases in ionized calcium, but more EDTA was needed in Met Acid than in Resp Acid. The PTH response to EDTA-induced hypocalcemia was evaluated also. Magnesium needed to be infused in groups receiving EDTA to prevent hypomagnesemia. The half-life of intact PTH (iPTH) was determined during hypocalcemia when PTH was measured after parathyroidectomy. During normocalcemia, PTH values were greater (p < 0.05) in Met Acid (92 +/- 19 pg/ml) and Resp Acid (77 h 22 pg/ml) than in controls (27 +/- 5 pg/ml); the respective pH values were 7.23 +/- 0.01, 7.24 +/- 0.01, and 7.39 +/- 0.02. The maximal PTH response to hypocalcemia was greater (p < 0.05) in Met Acid (443 54 pg/ml) than in Resp Acid (267 +/- 37 pg/ml) and controls (262 +/- 48 pg/ml). The half-life of PTH was greater (p < 0.05) in Met Acid than in controls, but the PTH secretion rate also was greater (p < 0.05) in Met Acid than in the other two groups. In conclusion, (1) both acute Met Acid and Resp Acid increase PTH secretion when the ionized calcium concentration is normal; (2) acute Met Acid may increase the bone efflux of calcium more than Resp Acid; (3) acute Met Acid acts as a secretogogue for PTH secretion because it enhances the maximal PTH response to hypocalcemia. C1 Hosp Univ Reina Sofia, Unidad Invest, Cordoba 14004, Spain. Hosp Univ Reina Sofia, Dept Nefrol, Cordoba 14004, Spain. Univ Cordoba, Dept Med & Cirugia Anim, E-14071 Cordoba, Spain. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. RP Rodriguez, M (reprint author), Hosp Univ Reina Sofia, Unidad Invest, Avda Menendez Pidal SN, Cordoba 14004, Spain. RI Rodriguez, teresa/H-5452-2011 NR 52 TC 22 Z9 22 U1 0 U2 4 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 IS 9 BP 1691 EP 1700 DI 10.1359/jbmr.2002.17.9.1691 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 586ZN UT WOS:000177616200016 PM 12211440 ER PT J AU Abboud, SL Woodruff, K Ghosh-Choudhury, N AF Abboud, SL Woodruff, K Ghosh-Choudhury, N TI Rescue of the osteopetrotic defect in op/op mice by osteoblast-specific targeting of membrane-bound CSF-1. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA 1122 BP S154 EP S154 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952800123 ER PT J AU Bischoff, DS Zhu, JH Makhijani, NS Yamaguchi, DT AF Bischoff, DS Zhu, JH Makhijani, NS Yamaguchi, DT TI TGF-beta 3 regulation of KC chemokine expression in mouse mesenchymal C3H10T1/2 and pre-osteoblast MC3T3-E1 cells. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA M153 BP S430 EP S430 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952801327 ER PT J AU Ghosh-Choudhury, N Abboud, SL Choudhury, GG AF Ghosh-Choudhury, N Abboud, SL Choudhury, GG TI BMP-2-induced phosphatidylinositol 3 kinase (PI 3-K) regulates GATA-4 and MEF2 ttranscription factors during cardiomyocyte differentiation. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA SU45 BP S303 EP S303 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952800758 ER PT J AU Kammerer, CM Mitchell, BD Schneider, JL Cole, SA Hixson, JE Perez, R Bauer, RL AF Kammerer, CM Mitchell, BD Schneider, JL Cole, SA Hixson, JE Perez, R Bauer, RL TI Quantitative trait loci for spine bone mineral density are linked to chromosome 19q in men and women and to 21q in women less than 50 years old. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Houston, TX USA. SW Fdn Biomed Res, San Antonio, TX 78284 USA. Univ Maryland, Sch Med, Baltimore, MD 21201 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA 1079 BP S144 EP S144 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952800080 ER PT J AU Makhijani, NS Bischoff, DS Yamaguchi, DT AF Makhijani, NS Bischoff, DS Yamaguchi, DT TI TGF-beta isoforms stimulate chemotaxis but not cell proliferation in the pluripotent mesenchymal stem cell line C3H10T1/2. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA M154 BP S430 EP S430 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952801328 ER PT J AU Vallarta-Ast, N Krueger, D Binkley, N AF Vallarta-Ast, N Krueger, D Binkley, N TI Clinical utility of combining calcaneal bone mass measurement with central DXA in men. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT 24th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 20-24, 2002 CL SAN ANTONIO, TEXAS SP American-Soc-Bone-Mineral-Res C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD SEP PY 2002 VL 17 SU 1 MA M78 BP S413 EP S413 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592TK UT WOS:000177952801253 ER PT J AU Martinez, M Lopez-Ribot, JL Kirkpatrick, WR Coco, BJ Bachmann, SP Patterson, TF AF Martinez, M Lopez-Ribot, JL Kirkpatrick, WR Coco, BJ Bachmann, SP Patterson, TF TI Replacement of Candida albicans with C-dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IN-VITRO; ANTIFUNGAL AGENTS; CHROMOGENIC AGAR; UNITED-STATES; IDENTIFICATION; SUSCEPTIBILITY; INDIVIDUALS; RESISTANCE; RADIATION AB Candida dubliniensis is an opportunistic yeast that has been increasingly implicated in oropharyngeal candidiasis (OPC) in human Immunodeficiency virus (HIV)-infected patients but may be underreported due to its similarity with Candida albicans. Although most C. dubliniensis isolates are susceptible to fluconazole, the inducibility of azole resistance in vitro has been reported. Thus, the use of fluconazole prophylaxis in the treatment of these patients may have contributed to the increasing rates of isolation of C dubliniensis. In this study, yeast strains were collected from the oral cavities of HIV-infected patients enrolled in a longitudinal study of OPC. Patients received fluconazole for the suppression or treatment of OPC, and isolates collected at both study entry and end of study were chosen for analysis. Samples were plated on CHROMagar Candida medium for initial isolation and further identified by Southern blot analysis with the species-specific probes Ca3 (for C. albicans) and Cd25 (for C. dubliniensis). Fluconazole MICs were determined by using NCCLS methods. At study entry, susceptible C. albicans isolates were recovered from oral samples in 42 patients who were followed longitudinally (1 to 36 months). C. albicans strains from 12 of these patients developed fluconazole resistance (fluconazole MIC, greater than or equal to64 mug/ml). C. dubliniensis was not detected at end of study in any of these patients. Of the remaining 30 patients, eight (27%) demonstrated a replacement of C. albicans by C. dubliniensis when a comparison of isolates obtained at baseline and those from the last culture was done. For the 22 of these 30 patients in whom no switch in species was detected, the fluconazole MICs for initial and end-of-study C. albicans isolates ranged from 0.125 to 2.0 mug/ml. For the eight patients in whom a switch to C. dubliniensis was detected, the fluconazole MICs for C. dubliniensis isolates at end of study ranged from 0.25 to 64 mug/ml: the fluconazole MICs for isolates from six patients were 0.25 to 2.0 mug/ml and those for the other two were 32 and 64 mug/ml, respectively. In conclusion, a considerable number of patients initially infected with C. albicans strains that failed to develop fluconazole resistance demonstrated a switch to C. dubliniensis. C. dubliniensis in this setting may be underestimated due to lack of identification and may occur due to the impact of fluconazole on the ecology of oral yeast species. C1 Univ Texas, Hlth Sci Ctr San antonio, S Texas Ctr Biol Med, Dept Med,Div Infect Dis, San Antonio, TX 78245 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. RP Lopez-Ribot, JL (reprint author), Univ Texas, Hlth Sci Ctr San antonio, S Texas Ctr Biol Med, Dept Med,Div Infect Dis, 15355 Lambda Dr, San Antonio, TX 78245 USA. RI Lopez-Ribot, Jose/D-2048-2010 FU NCRR NIH HHS [M01 RR001346, M01-RR-01346]; NIAID NIH HHS [R29 AI42401]; NIDCR NIH HHS [5 R01 DE11381-04A2, R01 DE011381] NR 35 TC 63 Z9 65 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2002 VL 40 IS 9 BP 3135 EP 3139 DI 10.1128/JCM.40.9.3135-3139.2002 PG 5 WC Microbiology SC Microbiology GA 590NX UT WOS:000177829900004 PM 12202543 ER PT J AU Chen, HI Hulten, K Clarridge, JE AF Chen, HI Hulten, K Clarridge, JE TI Taxonomic subgroups of Pasteurella multocida correlate with clinical presentation SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PNEUMONIA; CAT AB Pasteurella multocida is a small nonmotile gram-negative coccobacillus that is found in the nasopharynx and gastrointestinal tract of many wild and domesticated animals. In humans it most commonly causes cellulitis and localized superficial skin abscesses following an animal bite or scratch. The respiratory tract is the second most common site of infection for Pasteurella. Of the more than 17 species of Pasteurella known, Pasteurella multocida subsp. multocida and Pasteurella multocida subsp. septica are among the most common pathogens in humans. With the use of molecular techniques, distinction between different subspecies of P. multocida can be made more easily and accurately. We used the sequence of the 16S ribosomal DNA (rDNA) and repetitive extragenic palindromic sequence-PCR (REP-PCR) to characterize 20 strains (14 of P. multocida subsp. multocida and 6 of P. multocida subsp. septica; the 16S rDNA is identical for P. multocida subsp. multocida and Pasteurella multocida subsp. gallicida but differs from that of P. multocida subsp. septica) isolated from various anatomic sites. We found excellent correlation between the 16S rDNA sequence (a marker for a small conserved region of the genome), REP-PCR (a marker for a large portion of the genome), and biochemical tests (trehalose and sorbitol). We also found a correlation between the clinical presentation and the taxonomic group, with P. multocida subsp. septica more often associated with wounds than with respiratory infections (67 versus 17%, respectively) (P < 0.05, Z test) and P. multocida subsp. multocida more often associated with respiratory infections than with wounds (71 versus 14%, respectively) (P < 0.05, Z test). C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Vet Affairs Med Ctr, Pathol & Lab Med Serv, Houston, TX 77030 USA. RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98102 USA. OI Hulten, Kristina/0000-0001-7446-157X NR 12 TC 21 Z9 21 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2002 VL 40 IS 9 BP 3438 EP 3441 DI 10.1128/JCM.40.9.3438-3441.2002 PG 4 WC Microbiology SC Microbiology GA 590NX UT WOS:000177829900051 PM 12202590 ER PT J AU Clarridge, JE Zhang, Q AF Clarridge, JE Zhang, Q TI Genotypic diversity of clinical Actinomyces species: Phenotype, source, and disease correlation among genospecies SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DNA RESTRICTION ANALYSIS; RAPID ANA-II; SP-NOV; IDENTIFICATION; SPECIMENS; TURICENSIS; EUROPAEUS; RADINGAE; SYSTEMS AB We determined the frequency distribution of Actinomyces spp. recovered in a routine clinical laboratory and investigated the clinical significance of accurate identification to the species level. We identified 92 clinical strains of Actinomyces, including 13 strains in the related Arcanobacterium-Actinobaculum taxon, by 16S rRNA gene sequence analysis and recorded their biotypes, sources, and disease associations. The clinical isolates clustered into 21 genogroups. Twelve genogroups (74 strains) correlated with a known species, and nine genogroups (17 strains) did not. The individual species had source and disease correlates. Actinomyces turicensis was the most frequently isolated species and was associated with genitourinary tract specimens, often with other organisms and rarely with inflammatory cells. Actinomyces radingae was most often associated with serious, chronic soft tissue abscesses of the breast, chest, and back. Actinomyces curopaeus was associated with skin abscesses of the neck and genital areas. Actinomyces lingnae, Actinomyces gravenitzii, Actinomyces odontolyticus, and Actinomyces meyeri were isolated from respiratory specimens, while A. odontolyticus-like strains were isolated from diverse sources. Several of the species were commonly eoisolated with a particular bacterium:Actinomyces israelii was the only Actinomyces spp. coisolated with Actinobacillus (Haemophilus) actinomycetemcomitans; Actinomyces meyeri was coisolated with Peptostreptococcus micros and was the only species other than A. israelii associated with sulfur granules in histological specimens. Most genogroups had consistent biotypes (as determined with the RapID ANA II system); however, strains were misidentified, and many codes were not in the database. One biotype was common to several genogroups, with all of these isolates being identified as A. meyeri. Despite the recent description of new Actinomyces spp., 19% of the isolates recovered in our routine laboratory belonged to novel genospecies. One novel group with three strains, Actinomyces houstonensis sp. nov., was phenotypically similar to A. meyeri and A. turicensis but was genotypically closest to Actinomyces neuii. A. houstonensis sp. nov. was associated with abscesses. Our data documented consistent site and disease associations for 21 genogroups of Actinomyces spp. that provide greater insights into appropriate treatments. However, we also demonstrated a complexity within the Actinomyces genus that compromises the biochemical identification of Actinomyces that can be performed in most clinical laboratories. It is our hope that this large group of well-defined strains will be used to find a simple and accurate biochemical test for differentiation of the species in routine laboratories. C1 Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Vet Affairs Med Ctr, Pathol & Lab Med Serv, Houston, TX 77030 USA. RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98102 USA. NR 14 TC 50 Z9 51 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2002 VL 40 IS 9 BP 3442 EP 3448 DI 10.1128/JCM.40.9.3442-3448.2002 PG 7 WC Microbiology SC Microbiology GA 590NX UT WOS:000177829900052 PM 12202591 ER PT J AU Matzke, GR Palevsky, PM Frye, RF AF Matzke, GR Palevsky, PM Frye, RF TI In-vitro assessment of influence of molecular weight on drug clearance by conventional and synthetic dialyzers. SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Sch Pharm & Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2700 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD SEP PY 2002 VL 42 IS 9 MA 85 BP 1070 EP 1070 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 586HR UT WOS:000177579000088 ER PT J AU Altshuler, LL Gitlin, MJ Mintz, J Leight, KL Frye, MA AF Altshuler, LL Gitlin, MJ Mintz, J Leight, KL Frye, MA TI Subsyndromal depression is associated with functional impairment in patients with bipolar disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PROSPECTIVE FOLLOW-UP; MAJOR DEPRESSION; MEDICAL OUTCOMES; MANIA; SYMPTOMS; ILLNESS; DISABILITY; VALIDITY; LITHIUM; SCALE AB Background: The purpose of this study was to assess whether a relationship exists between mild depressive symptoms and overall functioning in subjects with bipolar disorder. Method: Twenty-five male subjects with bipolar I disorder (DSM-III-R criteria), who had not experienced a DSM-III-R episode of mania, hypomania, or major depression for 3 months as determined using, the Structured Clinical Interview for DSM-III-R, were evaluated for degree of depressive symptoms using the Hamilton Rating Scale for Depression (HAM-D) and for overall functional status using the Global Assessment of Functioning (GAF, DSM-IV Axis V). Results: GAF scores were significantly negatively correlated with HAM-D scores (r = -0.61, df = 23, p = .001), despite the fact that no patient had a HAM-D score high enough to be considered clinically depressed. Conclusion: The results of this study support a relationship between subsyndromal depressive symptoms and functional impairment in bipolar subjects, despite their not meeting threshold criteria for a major depressive episode. These findings raise the possibility that in some patients with bipolar disorder subsyndromal depressive symptoms might contribute to ongoing functional impairment. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Altshuler, LL (reprint author), Vet Adm Med Ctr, B116AA,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 38 TC 137 Z9 139 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD SEP PY 2002 VL 63 IS 9 BP 807 EP 811 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 599PP UT WOS:000178344600010 PM 12363122 ER PT J AU Datto, C Rai, AK Ilivicky, HJ Caroff, SN AF Datto, C Rai, AK Ilivicky, HJ Caroff, SN TI Augmentation of seizure induction in electroconvulsive therapy: A clinical reappraisal SO JOURNAL OF ECT LA English DT Review DE electroconvulsive therapy; proconvulsant agents; caffeine; theophylline; etomidate; ketamine; hyperventilation; seizures ID ELECTRICALLY INDUCED SEIZURES; ECT-SEIZURE; STIMULUS-INTENSITY; CAFFEINE AUGMENTATION; INTRAVENOUS CAFFEINE; COMBINED CLOZAPINE; STATUS EPILEPTICUS; PROLONGED SEIZURE; ANESTHETIC AGENTS; DURATION AB Objective: Missed or abortive seizures during electroconvulsive therapy (ECT) may preclude completion of an effective course of treatment in some cases. Seizure augmentation, using proconvulsant agents, has been used to overcome resistance to the induction and continuation of seizure activity. In this review, we analyze published clinical data on the effects and safety of seizure augmentation techniques. Method: Clinical studies and case reports were obtained through a MEDLINE literature search from 1966 to 2001, cross-referencing ECT and proconvulsant agents. Article references were also scanned for relevant studies. Results and Conclusions: Data from clinical trials indicate that augmentation facilitates seizure induction when maximal electrical stimuli fail. Anesthetic modifications, including hyperventilation and substitution with etomidate, ketamine, or other agents, often are successful in overcoming seizure resistance and compare favorably with the use of caffeine. In a few studies, augmentation enabled the use of lower stimulus intensities and fewer treatments without loss of efficacy, even in patients not resistant to seizure induction. However, effects of proconvulsants must be reconciled with increasing evidence of the importance of stimulus dosing relative to seizure threshold and other parameters, now considered key to the efficacy of ECT. Further investigations of pharmacologic augmentation could facilitate the administration of ECT and could provide further insights concerning parameters of seizure efficacy and the mechanism of action underlying convulsive therapies. C1 Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. New Hope Penn Inc, Wyoming, PA USA. St Charles Psychiat Associates, St Charles, MO USA. RP Caroff, SN (reprint author), Dept Vet Affairs Med Ctr, 116A,Univ Ave, Philadelphia, PA 19104 USA. NR 105 TC 30 Z9 30 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1095-0680 J9 J ECT JI J. ECT PD SEP PY 2002 VL 18 IS 3 BP 118 EP 125 DI 10.1097/00124509-200209000-00002 PG 8 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA 605KX UT WOS:000178678000002 PM 12394529 ER PT J AU Holmes, WC Pace, JL AF Holmes, WC Pace, JL TI HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV; AIDS; prognosis; patient compliance; sex behavior ID TRIPLE-DRUG THERAPY; ANTIRETROVIRAL THERAPY; UNITED-STATES; INFECTION; DISEASE; CARE; AIDS; ZIDOVUDINE; ADULTS; MEN AB OBJECTIVE: The study objective was to characterize respondents' prognostic perceptions of HIV infection and to explore how perceptions might affect medication and safe sex nonadherence. METHODS: Surveys were mailed to 295 clients of an HIV-specific case management organization. Participants were asked to describe experience with HIV/AIDS right after serostatus knowledge and currently, using provided word lists, after which they were asked to assess current life expectancy. Self-reported information on antiretroviral medication and safe sex nonadherence was obtained. RESULTS: A total of 220 (75%) clients (66% nonwhite, 73% male, 63% gay/bisexual, 50% educated >12 years, and 53% with incomes <$10,000/year) returned surveys. Negative descriptors from word lists were significantly less common and positive descriptors significantly more common now compared to right after serostatus knowledge. Current perceptions about life expectancy indicated that most respondents thought they would live many years, many believing they would live well into old age. Whites (odds ratio [OR], 0.34; P = .01) were less likely and those with >12 years education (OR, 2.76; P = .02) and with CD4 cell counts >200 (OR, 2.70; P = .01) were more likely to have optimistic prognostic beliefs. The optimistic subgroup, when compared with the pessimistic subgroup, was more likely to report medication (26% vs 13%, P = .04) and safe sex (57% vs 29%, P = .004) nonadherence. CONCLUSIONS: Seropositive individuals, including persons of color (adjusted) as well as women and drug users (unadjusted), self-reported optimistic beliefs about their prognosis. Those with more optimism about their prognosis were significantly more likely to report medication and safe sex nonadherence. A better understanding of seropositive patients' prognostic beliefs and the factors determining them is warranted. C1 Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Holmes, WC (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. FU NIAID NIH HHS [AI01482] NR 29 TC 21 Z9 23 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2002 VL 17 IS 9 BP 677 EP 683 DI 10.1046/j.1525-1497.2002.00746.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 594AF UT WOS:000178026100003 PM 12220363 ER PT J AU Halpern, SD Ubel, PA Berlin, JA Townsend, RR Asch, DA AF Halpern, SD Ubel, PA Berlin, JA Townsend, RR Asch, DA TI Physicians' preferences for active-controlled versus placebo-controlled trials of new anti hypertensive drugs SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE clinical trials; placebo-controlled trials; antihypertensive drugs; physicians' preferences; ethics ID RANDOMIZED CLINICAL-TRIALS; BLOOD-PRESSURE; BREAST-CANCER; PARTICIPATION; ISSUES; MORBIDITY; MORTALITY AB OBJECTIVE: To evaluate physicians' preferences for referring patients to, and using information from, active-controlled trials (ACTs) versus placebo-controlled trials (PCTs) of new antihypertensive drugs. DESIGN AND SETTING: Nationwide mailed survey, with telephone contact of nonresponders to assess nonresponse bias. PARTICIPANTS: One thousand two hundred primary care physicians randomly selected from the American Medical Association's Master File. Of 1, 154 physicians eligible to respond, 651 (56.4%) returned completed questionnaires. MEASUREMENTS AND MAIN RESULTS: We measured physicians' stated willingness to encourage hypertensive patients to enroll in ACTs and PCTs of new antihypertensive drugs, their views of the relative merits of ACTs versus PCTs, their stated willingness to prescribe new drugs tested in ACTs or PCTs, and their views regarding the overall justifiability of the 2 designs. Physicians were significantly more likely to indicate they would encourage their patients to enroll in ACTs than in PCTs (P < .0001). Physicians thought ACTs provided more valuable information for their practices, were more likely to lead to a public health benefit, offered enrolled patients greater opportunity for personal benefit, and were less likely to expose enrolled patients to unnecessary risks (all P < .0001). Physicians were more likely to prescribe new drugs that had been compared in ACTs (P < .0001). and viewed ACTs as a more justifiable method for testing new antihypertensive drugs (P < .0001). There was no evidence of nonresponse bias for these main results. CONCLUSIONS: Although PCTs remain the standard method for testing new antihypertensive drugs, physicians strongly prefer ACTs. Using ACTs to test new antihypertensive drugs may enhance the efficiency of patient recruitment and more strongly influence physicians' prescribing practices. C1 Univ Penn, Leonard Davis Inst Hlth Econ, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Michigan, Sch Med, Div Gen Internal Med, Ann Arbor, MI USA. Univ Michigan, Sch Med, Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA. RP Halpern, SD (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, Sch Med, 3641 Locust Walk, Philadelphia, PA 19104 USA. NR 38 TC 18 Z9 18 U1 1 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2002 VL 17 IS 9 BP 689 EP 695 DI 10.1046/j.1525-1497.2002.11024.x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 594AF UT WOS:000178026100005 PM 12220365 ER PT J AU Nelson, K Geiger, AM Mangione, CM AF Nelson, K Geiger, AM Mangione, CM TI Effect of health beliefs on delays in care for abnormal cervical cytology in a multiethnic population SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-05, 2001 CL SAN DIEGO, CALIFORNIA SP Soc Gen Internal Med DE Papanicolaou smear; health beliefs; patient adherence ID FOLLOW-UP RECOMMENDATIONS; INCOME MINORITY WOMEN; PAPANICOLAOU SMEARS; PAP SMEARS; RACIAL-DIFFERENCES; AMERICAN WOMEN; ANGLO WOMEN; CANCER; BREAST; KNOWLEDGE AB CONTEXT. Women from racial and ethnic minorities in the United States have higher rates of cervical cancer and present with later stage disease compared to whites. Delays in care for abnormal Papanicolaou (Pap) smears can lead to missed cases of cervical cancer or late-stage presentation and may be one explanation for these differences. about cancer, but not race and ethnicity, were independently associated with delays in care. OBJECTIVE: To determine if race and ethnicity, health beliefs, and cancer knowledge are associated with delays in care for abnormal Pap smears. DESIGN, PARTICIPANTS, AND SETTING: We conducted a mailed survey with telephone follow-up of all women with an abnormal Pap smear who received care at Kaiser Permanente Los Angeles Medical Center between October 1998 and October 1999 (n = 1,049). MEASUREMENTS AND MAIN RESULTS: A delay in care was defined as not attending the first scheduled clinic visit to follow up on an abnormal Pap smear, or requiring multiple contact attempts, including a certified letter, to schedule a follow-up visit. Our response rate was 70% (n = 733) and the sample was 51% Latina. Spanish-speaking Latinas and women of Asian descent were more likely to endorse fatalistic beliefs and misconceptions about cancer. Thirteen percent of the sample delayed follow-up on their abnormal Pap smear. Women who delayed care were more fatalistic and endorsed more misconceptions about cervical cancer. Delays in care were not independently associated with race and ethnicity. CONCLUSIONS: Health beliefs and cancer knowledge differed by race and ethnicity among women in a large managed care organization. Fatalistic health beliefs and misconceptions about cancer, but not race and ethnicity, were independently associated with delays in care. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA USA. So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA USA. Univ Calif Los Angeles, Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RP Nelson, K (reprint author), VA Puget Sound Med Ctr, S-111-GIMC,1660 S Columbian Way, Seattle, WA 98108 USA. FU NCI NIH HHS [1F32 CA 88495-01, F32 CA088495] NR 54 TC 43 Z9 43 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2002 VL 17 IS 9 BP 709 EP 716 DI 10.1046/j.1525-1497.2002.11231.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 594AF UT WOS:000178026100008 PM 12220368 ER PT J AU Datto, CJ Oslin, DW Streim, JE Scheinthal, SM DiFilippo, S Katz, IR AF Datto, CJ Oslin, DW Streim, JE Scheinthal, SM DiFilippo, S Katz, IR TI Pharmacologic treatment of depression in nursing home residents: A mental health services perspective SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article ID LATE-LIFE DEPRESSION; CLINICAL-TRIAL; SERTRALINE; CARE AB Over the past 10 to 15 years, there has been marked progress in clinical research on depression in nursing home residents. There have also been significant changes in federal regulations designed to improve the quality of care. In 1987, only 10% of nursing home residents diagnosed with depression were receiving treatment, but by 1999, 25% of all residents were receiving antidepressants. We report on two studies: one demonstrating that treatment for depression has a substantial, ecologically relevant impact in the nursing home and another demonstrating that profound changes have occurred in the clinical epidemiology of depression and its treatment in the nursing home. Although the numbers of nursing home residents receiving antidepressants have increased dramatically, there are now second-generation problems that must be addressed to ensure the delivery of effective treatment. Developing models to ensure quality of care will require focused mental health services research. C1 Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA. RP Oslin, DW (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Rm 3055, Philadelphia, PA 19104 USA. FU NIMH NIH HHS [R37-MH51247, P30-MH52129] NR 25 TC 27 Z9 27 U1 0 U2 2 PU B C DECKER INC PI HAMILTON PA 20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD FAL PY 2002 VL 15 IS 3 BP 141 EP 146 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 592XA UT WOS:000177961100005 PM 12230084 ER PT J AU Werth, VP Callen, JP Ang, G Sullivan, KE AF Werth, VP Callen, JP Ang, G Sullivan, KE TI Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: Implications for a unique pathogenesis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article DE ultraviolet light ID CUTANEOUS LUPUS-ERYTHEMATOSUS; TNF-ALPHA; PROMOTER POLYMORPHISM; JUVENILE DERMATOMYOSITIS; KERATINOCYTE APOPTOSIS; TNF-ALPHA-308A ALLELE; GENE POLYMORPHISM; SUSCEPTIBILITY; CELLS; TRANSCRIPTION AB We recently reported that the -308A tumor necrosis factor alpha promoter polymorphism is associated with the photosensitive disorder subacute cutaneous lupus erythematosus and mediates an exaggerated tumor necrosis factor alpha response to ultraviolet B. We now sought to examine the association of this polymorphism with adult dermatomyositis, a photosensitive disease that exhibits some features in common with subacute cutaneous lupus erythematosus. Fifty adult patients with dermatomyositis and 239 healthy, race-matched controls were examined for the -308A tumor necrosis factor alpha polymorphism and the more common -308G allele. The frequency of the -308A allele was 0.27 in the entire dermatomyositis group, versus 0.14 in the controls (p = 0.003, chi(2) 2 x 2 table). Caucasians were the only racial/ethnic group in our study large enough to allow separate statistical analysis (47 dermatomyositis, 223 controls). The frequency of the -308A allele was 0.26 for dermatomyositis and 0.14 for controls (p = 0.014). Caucasians are known to exhibit a linkage disequilibrium between -308A and HLA-DR3, which we previously found to be significantly enhanced in subacute cutaneous lupus erythematosus patients. In contrast, we now found no increase in the association of -308A and HLA-DR3 in Caucasians with dermatomyositis compared to controls. Consistent with this observation, the association of these two genes in dermatomyositis was significantly less than we previously reported in Caucasians with subacute cutaneous lupus erythematosus (p = 0.016). We conclude that the tumor necrosis factor -308A polymorphism is associated with dermatomyositis, which suggests a pathophysiologic contribution from ultraviolet-induced production of tumor necrosis factor alpha, similar to subacute cutaneous lupus erythematosus. The differences in linkage with HLA-DR3, as well as several divergent clinical features, indicate that there are also fundamental mechanistic differences between dermatomyositis and subacute cutaneous lupus erythematosus. C1 Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Louisville, Dept Dermatol, Louisville, KY 40292 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, 2 Rhoads Pavil,36th & Spruce St, Philadelphia, PA 19104 USA. FU NIAMS NIH HHS [1K24AR002207-01] NR 37 TC 52 Z9 57 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD SEP PY 2002 VL 119 IS 3 BP 617 EP 620 DI 10.1046/j.1523-1747.2002.01869.x PG 4 WC Dermatology SC Dermatology GA 592RV UT WOS:000177951400011 PM 12230503 ER PT J AU Mann, DL AF Mann, DL TI Endothelin antagonism and the failing heart: An unfilled promise, an unmet need, or an unanswered question? SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Editorial Material ID MYOCARDIAL ENDOTHELIN; RECEPTORS; FAILURE; EXPRESSION; SYSTEM C1 Baylor Coll Med, Winters Ctr Heart Failure Res, Dept Med, Houston, TX 77030 USA. Houston Vet Adm Med Ctr, Med Serv Care Line, Houston, TX 77030 USA. RP Mann, DL (reprint author), Baylor Coll Med, Winters Ctr Heart Failure Res, Dept Med, MS 524,6565 Fannin, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 NR 13 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD SEP PY 2002 VL 34 IS 9 BP 1131 EP 1133 DI 10.1006/jmcc.2002.2054 PG 3 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 604LL UT WOS:000178622500008 PM 12392886 ER PT J AU Offner, H Zamora, A Drought, H Matejuk, A Auci, DL Morgan, EE Vandenbark, AA Reading, CL AF Offner, H Zamora, A Drought, H Matejuk, A Auci, DL Morgan, EE Vandenbark, AA Reading, CL TI A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE EAE; MS; androstene; DHEA; cytokines ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; MULTIPLE-SCLEROSIS; IN-VITRO; CYTOKINE PRODUCTION; TNF-ALPHA; IMMUNE-RESPONSE; T-LYMPHOCYTES; DEHYDROEPIANDROSTERONE AB Experimental allergic encephalomyelitis (EAE), a Th1 polarized demyelinating disease of the central nervous system (CNS), shares many pathological and clinical similarities with multiple sclerosis (MS), and thus represents an attractive animal model for this disease. The goal of this study was to evaluate the suppressive effects of fluasterone (HE2500), a synthetic androstene derivative, and androstenetriol (HE2200), a natural androstene hormone on EAE. SJL mice were immunized with proteolipid protein (PLP) 139-151 peptide/CFA to induce EAE. Starting on day -7, animals were given daily injections (s.c.) of derivatives (3.0 mg) in vehicle, or vehicle alone for 33 days. Both HE2500 and HE2200 significantly delayed the onset, reduced the peak clinical score and cumulative disease index of EAE, and prevented or significantly attenuated relapses. Lower doses or other routes of administration were less effective. Moreover, T cells from treated mice had significantly reduced PLP 139-151-specific T cell proliferation responses and reduced numbers of TNF-alpha- and IFN-gamma-producing cells in the CNS. Daily treatment of B10.PL mice with HE2500, starting on day 0, completely prevented the development of disease in these animals. Finally, SJL mice treated with HE2500 at EAE onset showed significantly reduced mean clinical scores. Thus, these compounds, which have been reported to have a few androgenic or estrogenic side effects, appear to have a potent inhibitory activity in EAE. These observations suggest that HE2500, and/or HE2200 limit the production of autoimmune Th1 associated cytokines, and ultimately may be beneficial for patients with MS or other autoimmune diseases. (C) 2002 Elsevier Science B.V. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. Vet Affairs Med Ctr, Portland, OR 97201 USA. Hollis Eden Pharmaceut Inc, San Diego, CA 92121 USA. Polish Acad Sci, L Hirszfeld lnst Immunol & Expt Therapy, Wroclaw, Poland. RP Offner, H (reprint author), Portland VA Med Ctr, R&D-31,3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. FU NIAID NIH HHS [AI42376]; NINDS NIH HHS [NS23444] NR 51 TC 35 Z9 36 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD SEP PY 2002 VL 130 IS 1-2 BP 128 EP 139 AR PII S0165-5728(02)00214-X DI 10.1016/S0165-5728(02)00214-X PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 599HX UT WOS:000178329200013 PM 12225895 ER PT J AU Mendez, MF Perryman, KM AF Mendez, MF Perryman, KM TI Neuropsychiatric features of frontotemporal dementia: Evaluation of consensus criteria and review SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Review ID CLINICAL DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; PICKS-DISEASE; LOBAR DEGENERATION; BEHAVIOR; DIFFERENTIATION; NEUROPATHOLOGY; NOSOLOGY; SYMPTOMS AB Neuropsychiatric features characterize frontotemporal dementia (FTD). The authors evaluated the neuropsychiatric features of 53 FTD patients and retrospectively applied the Consensus Criteria for this disorder. Only one-third of the patients met Consensus Criteria for FTD on presentation. Most had early disengagement with poor insight; however, more than half retained socially appropriate interpersonal conduct and emotional expression. Supportive features, including compulsive-like acts and speech changes, were common presenting features, and 20% developed the Kluver-Bucy syndrome on 2-year follow-up. Consensus Criteria for FTD offer guidelines for diagnosis, but further refinement is needed, particularly for patients who lack early changes in social interpersonal conduct. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 38 TC 69 Z9 74 U1 0 U2 2 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2002 VL 14 IS 4 BP 424 EP 429 DI 10.1176/appi.neuropsych.14.4.424 PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 611ZB UT WOS:000179047300005 PM 12426410 ER PT J AU Cooley, ME Short, TH Moriarty, HJ AF Cooley, ME Short, TH Moriarty, HJ TI Patterns of symptom distress in adults receiving treatment for lung cancer SO JOURNAL OF PALLIATIVE CARE LA English DT Article ID QUALITY-OF-LIFE; PALLIATIVE CARE; HEALTH; DISEASE; TRIAL; AGE; CHEMOTHERAPY; PREVALENCE; EXPERIENCE; DIAGNOSIS AB Knowledge of the patterns of symptom distress in adults receiving treatment for lung cancer is an important first step in developing interventions that can potentially lessen symptom distress. The purposes of this secondary analysis were to describe the changes in patterns of symptom distress over time in adults receiving treatment for lung cancer, and to examine the relationship of selected demographic and clinical characteristics to symptom distress. Complete data were available for 117 patients. The patterns of symptom distress in adults receiving treatment for lung cancer varied between treatment groups and over time. Symptom distress scores were moderate to high on entry into the study, indicating that symptom management in newly diagnosed lung cancer patients is essential and should begin early in the course of illness. Moreover, clinical interventions should be tailored to the type of treatment. Various demographic and clinical variables were weak and inconsistent predictors of symptom distress, underscoring the importance of examining the role of psychosocial factors in mediating symptom distress. C1 Harvard Univ, Sch Med, Sch Dent Med, Smoking Cessat Res Program, Boston, MA 02115 USA. Indiana Univ Penn, Dept Math, Indiana, PA USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Cooley, ME (reprint author), Harvard Univ, Sch Med, Sch Dent Med, Smoking Cessat Res Program, Boston, MA 02115 USA. FU NINR NIH HHS [T32 NR07035] NR 58 TC 30 Z9 30 U1 0 U2 2 PU CENTER BIOETHICS CLIN RES INST MONTREAL PI MONTREAL PA 110 PINE AVE W, MONTREAL, QUEBEC H2W 1R7, CANADA SN 0825-8597 J9 J PALLIATIVE CARE JI J. Palliative Care PD FAL PY 2002 VL 18 IS 3 BP 150 EP 159 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 612AD UT WOS:000179050100003 PM 12418365 ER PT J AU Suntsova, N Szymusiak, R Alam, MN Guzman-Marin, R McGinty, D AF Suntsova, N Szymusiak, R Alam, MN Guzman-Marin, R McGinty, D TI Sleep-waking discharge patterns of median preoptic nucleus neurons in rats SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID SLOW-WAVE SLEEP; MONOAMINERGIC CELL GROUPS; LOCUS COERULEUS NEURONS; DORSAL RAPHE NEURONS; POSTERIOR HYPOTHALAMUS; POSSIBLE INVOLVEMENT; PROSTAGLANDIN D-2; PROMOTING ZONE; REM-SLEEP; IN-VITRO AB Several lines of evidence show that the preoptic area (POA) of the hypothalamus is critically implicated in the regulation of sleep. Functionally heterogeneous cell groups with sleep-related discharge patterns are located both in the medial and lateral POA. Recently a cluster of neurons showing sleep-related c-Fos immunoreactivity was found in the median preoptic nucleus (MnPN). To determine the specificity of the state-related behaviour of MnPN neurons we have undertaken the first study of their discharge patterns across the sleep-waking cycle. Nearly 76 % of recorded cells exhibited elevated discharge rates during sleep. Sleep-related units showed several distinct types of activity changes across sleep stages. Two populations included cells displaying selective activation during either non-rapid eye movement (NREM) sleep (10 %) or REM sleep (8 %). Neurons belonging to the predominant population (58 %) exhibited activation during both phases of sleep compared to wakefulness. Most of these cells showed a gradual increase in their firing rates prior to sleep onset, elevated discharge during NREM sleep and a further increase during REM sleep. This specific sleep-waking discharge profile is opposite to that demonstrated by wake-promoting monoaminergic cell groups and was previously found in cells localized in the ventrolateral preoptic area (vlPOA). We hypothesize that these vlPOA and MnPN neuronal populations act as parts of a GABAergic/galaninergic sleep-promoting ('anti-waking') network which exercises inhibitory control over waking-promoting systems. MnPN neurons that progressively increase activity during sustained waking and decrease activity during sustained sleep states may be involved in homeostatic regulation of sleep. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med & Neurobiol, Los Angeles, CA 90024 USA. Rostov State Univ, AB Kogan Res Inst Neurocybernet, Rostov Na Donu 344090, Russia. RP McGinty, D (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. FU NHLBI NIH HHS [P50 HL060296, HL 60296]; NIMH NIH HHS [MH 47480, R01 MH047480, MH 04708] NR 74 TC 95 Z9 98 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD SEP 1 PY 2002 VL 543 IS 2 BP 665 EP 677 DI 10.1113/jphsiol.2002.023085 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 596VB UT WOS:000178186200023 PM 12205198 ER PT J AU Thompson, RL Brossart, DF Carlozzi, AF Miville, ML AF Thompson, RL Brossart, DF Carlozzi, AF Miville, ML TI Five-factor model (Big Five) personality traits and universal-diverse orientation in counselor trainees SO JOURNAL OF PSYCHOLOGY LA English DT Article DE counselor training; diversity; five-factor model of personality; NEO-PI; universal-diverse orientation ID 5-FACTOR MODEL; PERCEPTIONS; OPENNESS AB In this study the authors explored the relationship between five-factor model (FFM: Big Five) personality traits (J. M. Digman, 1990; R. R. McCrae & O. P John, 1992; J. S, Wiggins & P. D. Trappnell, 1997) and universal-diverse orientation (UDO; M. L. Miville et al., 1999) in counselor trainees. FFM traits were measured using the NEO-Personality Inventory-Revised (P. T Costa & R. R. McCrae, 1992). Statistically significant relationships were found between UDO and one of the Big Five personality traits (Openness to Experience) in Counselor trainees. Further regression analysis suggested a relationship between UDO and a particular facet of Openness to Experience, Openness to Aesthetics. This finding suggests that counselor trainees who are open to the creative expressions of others may be comfortable working with a wide variety of clients. These results suggest that counselor training that encourages experiences of aesthetic diversity in addition to an exploration of values may promote trainees' ability to work with diverse clients. C1 Texas A&M Univ, S Texas Vet Hlth Care Syst, College Stn, TX 77843 USA. Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA. Oklahoma State Univ, Sch Appl Hlth & Educ Psychol, Stillwater, OK 74078 USA. RP Thompson, RL (reprint author), Texas A&M Univ, S Texas Vet Hlth Care Syst, College Stn, TX 77843 USA. NR 42 TC 19 Z9 19 U1 0 U2 4 PU HELDREF PUBLICATIONS PI WASHINGTON PA 1319 EIGHTEENTH ST NW, WASHINGTON, DC 20036-1802 USA SN 0022-3980 J9 J PSYCHOL JI J. Psychol. PD SEP PY 2002 VL 136 IS 5 BP 561 EP 572 PG 12 WC Psychology, Multidisciplinary SC Psychology GA 613AR UT WOS:000179108600007 PM 12431039 ER PT J AU Marder, SR Saba, AR Kaplita, SB Archibald, DG McQuade, RD AF Marder, SR Saba, AR Kaplita, SB Archibald, DG McQuade, RD TI Safety and tolerability meta-analysis of aripiprazole in schizophrenia SO JOURNAL OF PSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT Summer Meeting of the British-Association-for-Psychopharmacology CY JUL 21-24, 2002 CL HARROGATE, ENGLAND C1 Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Otsuka Maryland Res Inst LLC, Rockville, MD USA. Bristol Myers Squibb Co, Lawrenceville, NJ USA. Bristol Myers Squibb Co, Plainsboro, NJ USA. Otsuka Pharmaceut Co Ltd, Tokyo, Japan. Univ Calif Los Angeles, Sch Med, W LA VA Med Ctr, VA Greater LA Healthcare Syst,Psychiat Serv 116A, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 6 BONHILL STREET, LONDON EC2A 4PU, ENGLAND SN 0269-8811 J9 J PSYCHOPHARMACOL JI J. Psychopharmacol. PD SEP PY 2002 VL 16 IS 3 SU S MA A31 BP A17 EP A17 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 595EN UT WOS:000178094000067 ER PT J AU Vaughan, NE Fausti, SA Chelius, S Phillips, D Helt, W Henry, JA AF Vaughan, NE Fausti, SA Chelius, S Phillips, D Helt, W Henry, JA TI An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE ototoxicity; rapid identification protocol; sensitive range of ototoxicity (SRO); uppermost target frequency ID OTOACOUSTIC EMISSIONS; CISPLATIN OTOTOXICITY AB A primary focus of research at the National Center for Rehabilitative Auditory Research (NCRAR) has been to develop methodology for rapid and efficient early detection of ototoxicity. It has been shown that an individualized, limited frequency range can be identified, which is sensitive to early ototoxic changes in the auditory system. In this study, a rapid identification protocol for identifying the uppermost target frequency within this sensitive range of ototoxicity (SRO) was investigated. In 36 of 42 ears, the target frequency found with the rapid identification protocol was the same as that found with the full-frequency baseline testing. Where differences occurred, target frequencies obtained by the two methods did not differ by more than one-half octave. This rapid identification protocol results in considerable time savings in ototoxicity monitoring, which will result in the capability to include more patients in a monitoring program. C1 Portland VA Med Ctr, RR&D Natl Ctr Rehab Auditory Res, Dept Vet Affairs, Portland, OR 97207 USA. RP Vaughan, NE (reprint author), Portland VA Med Ctr, RR&D Natl Ctr Rehab Auditory Res, Dept Vet Affairs, POB 1034, Portland, OR 97207 USA. NR 14 TC 10 Z9 10 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD SEP-OCT PY 2002 VL 39 IS 5 BP 567 EP 573 PG 7 WC Rehabilitation SC Rehabilitation GA 667UY UT WOS:000182253500005 PM 17642021 ER PT J AU Friedlander, AH Friedlander, IK Marder, SR AF Friedlander, AH Friedlander, IK Marder, SR TI Bipolar I disorder - Psychopathology, medical management and dental implications SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article ID SEROTONIN REUPTAKE INHIBITORS; ADVERSE DRUG-INTERACTIONS; PSYCHOSOCIAL FACTORS; MAINTENANCE TREATMENT; DEPRESSIVE SYMPTOMS; CIGARETTE-SMOKING; INDUCED BRUXISM; VALPROATE; LITHIUM; SERIES AB Background. The authors review the clinical features, epidemiology, pathophysiology, medical management, dental findings and dental management of patients who have bipolar I disorder, or BD, previously known as manic-depressive disorder. Types of Studies Reviewed. The authors conducted a MEDLINE search for the period 1995 through 2001 using the key terms "bipolar disorder," "epidemiology," " pathophysiology," "treatment" and "dentistry." The articles they selected for further review included those published in English in peer-reviewed journals; they gave preference to articles reporting randomized, controlled trials. Results. BD is a psychiatric illness characterized by extreme mood swings. Mania is accompanied by euphoria, grandiosity, racing thoughts and lack of insight. Depression is characterized by marked sadness or loss of interest or pleasure in daily activities. The unpredictable mood swings can distress the person, can impair social function and quality of life and are associated with a significant increase in the risk for substance abuse and suicide. BD is common in the United States, with a lifetime prevalence rate of 1.6 percent and recurrence rate of more than 50 percent. Clinical Implications. The prevalence of dental disease usually is extensive because of poor oral hygiene and medication-induced xerostomia. Preventive dental education, saliva substitutes and anticaries agents are indicated. To avoid adverse drug interactions with the usually prescribed psychiatric medications, special precautions should be taken when administering certain antibiotics, analgesics and sedatives. C1 W Valley Los Angeles Cty Dept Hlth, Van Nuys, CA USA. Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr VISN22, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 84 TC 23 Z9 23 U1 3 U2 6 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD SEP PY 2002 VL 133 IS 9 BP 1209 EP 1217 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 595KK UT WOS:000178107900017 PM 12356252 ER PT J AU Schnelle, JF Alessi, CA Simmons, SF Al-Samarrai, NR Beck, JC Ouslander, JG AF Schnelle, JF Alessi, CA Simmons, SF Al-Samarrai, NR Beck, JC Ouslander, JG TI Translating clinical research into practice: A randomized controlled trial of exercise and incontinence care with nursing home residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE practice guidelines; dissemination barriers; labor requirements ID ILLNESS RATING-SCALE; INTERVENTION; TECHNOLOGY; RISK AB OBJECTIVES: To examine clinical outcomes and describe the staffing requirements of an incontinence and exercise intervention. DESIGN: Randomized controlled trial with blinded assessments of outcomes at three points over 8 months. SETTING: Four nursing homes. PARTICIPANTS: Two hundred fifty-six incontinent residents. INTERVENTION: Research staff provided the intervention, which integrated incontinence care and exercise every 2 hours from 8:00 a.m. to 4:00 p.m. 5 days a week. MEASUREMENTS: Average and maximum distance walked or wheeled, level of assistance required to stand, maximum pounds lifted by arms, fecal and urinary incontinence frequency, and time required to implement intervention. RESULTS: Intervention residents maintained or improved performance whereas the control group's performance declined on 14 of 15 outcome measures. Repeated measures analysis of variance group-by-time significance levels ranged from P <.0001 to.05. The mean time required to implement the intervention each time care was provided was 20.7 +/- 7.2 minutes. We estimate that a work assignment of approximately five residents to one aide would be necessary to provide this intervention. CONCLUSIONS: The incontinence care and exercise intervention resulted in significant improvement for most residents, and most who could be reliably interviewed expressed a preference for such care. Fundamental changes in the staffing of most nursing homes will be necessary to translate efficacious clinical interventions into everyday practice. C1 Borun Ctr, UCLA Los Angeles Jewish Home Aging, Reseda, CA 91335 USA. Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. Emory Univ, Div Geriatr Med & Gerontol, Wesley Woods Ctr, Atlanta, GA 30322 USA. Atlanta VA Rehabil Res & Dev Ctr, Atlanta, GA USA. RP Schnelle, JF (reprint author), Borun Ctr, UCLA Los Angeles Jewish Home Aging, 7150 Tampa Ave, Reseda, CA 91335 USA. FU NIA NIH HHS [AG10415, AG13013] NR 30 TC 145 Z9 145 U1 2 U2 4 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2002 VL 50 IS 9 BP 1476 EP 1483 DI 10.1046/j.1532-5415.2002.50401.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 593AE UT WOS:000177968400001 PM 12383143 ER PT J AU Vig, EK Davenport, NA Pearlman, RA AF Vig, EK Davenport, NA Pearlman, RA TI Good deaths, bad deaths, and preferences for the end of life: A qualitative study of geriatric outpatients SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT 1st International Geriatric Palliative Care Congress CY OCT, 2000 CL NEW YORK, NEW YORK DE older; end of life; attitude to death; terminal care; patient-centered care ID MENTAL STATUS QUESTIONNAIRE; OF-LIFE; ELDERLY PATIENTS; SUSTAINING TREATMENTS; TERMINAL ILLNESS; FAMILY MEMBERS; OLDER ADULTS; CARE; STABILITY; VIEWS AB OBJECTIVES: Patient involvement in decision-making has been advocated to improve the quality of life at the end of life. Although the size of the oldest segment of the population is growing, with greater numbers of older adults facing the end of life, little is known about their preferences for the end of life. This study aimed to explore the attitudes of older adults with medical illness about the end of life, and to investigate whether current values could be extended to end-of-life preferences. DESIGN: Descriptive study with interviews using open- and closed-ended questions. SETTING: Patients attending two university-affiliated geriatric clinics were interviewed in a private conference room near the clinic they attended or in their homes. PARTICIPANTS: Sixteen older men and women identified by their physicians as having nonterminal heart disease or cancer. MEASUREMENTS: The interview contained open-ended questions such as: "What are the most important things in your life right now?" and "What would you consider a good/bad death?" The interview also contained closed-ended questions about symptoms, quality of life, and health status. Additional questions elicited preferences for the end of life, such as location of death and the presence of others. The open-ended questions were tape-recorded, transcribed, and analyzed using qualitative methods. The closed-ended questions were analyzed using descriptive statistics. RESULTS: Patients with heart disease and cancer provided similar responses. Participants' views about good deaths, bad deaths, and end-of-life scenarios were heterogeneous. Each participant voiced a unique combination of themes in describing good and bad deaths. Because each participant described a multifaceted view of a good death, for instance, no theme was mentioned by even half of the participants. Participants provided differing explanations for why given themes contributed to good deaths. Currently valued aspects of life were not easily translated into end-of-life preferences. For example, although the majority of participants identified their family as being important, many gave reasons why they did not want their family members present when they died. CONCLUSIONS: Because of the heterogeneity of views and the difficulty in inferring end-of-life preferences from current values, older adults should be asked not only questions about general values, but also specific questions about their end-of-life choices and the reasons for these choices. A thorough understanding of an individual's end-of-life preferences may help health professionals working with older adults develop patient-centered care plans for the end of life. C1 Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Vig, EK (reprint author), Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, 325 9th Ave,Box 359755, Seattle, WA 98104 USA. NR 38 TC 53 Z9 54 U1 1 U2 8 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2002 VL 50 IS 9 BP 1541 EP 1548 DI 10.1046/j.1532-5415.2002.50410.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 593AE UT WOS:000177968400010 PM 12383152 ER PT J AU Yukawa, M McCormick, WC Rajan, S Matsumoto, AM Wallace, JI Pearlman, RA Weigle, DS AF Yukawa, M McCormick, WC Rajan, S Matsumoto, AM Wallace, JI Pearlman, RA Weigle, DS TI Leptin levels are appropriate for body mass index in older men who experience involuntary weight SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE serum leptin levels; involuntary weight loss; body mass index ID STAGE RENAL-DISEASE; SERUM LEPTIN; CIRCULATING LEPTIN; NUTRITIONAL-STATUS; ANOREXIA-NERVOSA; FAT-CONTENT; WOMEN; TESTOSTERONE; HYPERINSULINEMIA; ASSOCIATION AB OBJECTIVES: To determine the relationship between leptin and unintentional weight loss In older adults. DESIGN: Prospective cohort study over 2 years. SETTING: University-affiliated Veterans Affairs Medical Center. PARTICIPANTS: The subjects were 105 community-dwelling male veterans aged 65 and older who had participated in a prospective cohort study on nutrition and health conducted at the Veterans Affairs Puget Sound Health Care System from 1986 to 1989. MEASUREMENTS: Anthropometric data and fasting blood specimens were collected at baseline and annually for the subsequent 2 years. Stored blood specimens were analyzed for leptin, insulin, glucose, C-reactive protein, sex hormone binding globulin, and testosterone levels. RESULTS: Over 2 years, 75 men were weight stable (weight loss <4% of baseline) and 30 men had unintentional weight loss (weight loss >4% of baseline). The baseline body mass index (BMI) and leptin levels for the two groups were not statistically different. Positive correlations existed between leptin level and BMI at each time point for weight-stable and weight-loss subjects. Furthermore, a significant relationship existed between changes ill leptin and changes in BMI over 1 year in multiple regression analysis (r =.436, P <.001 after the first year; and r =.630, P =.027 after the second year). CONCLUSIONS: Like in younger adults, plasma leptin levels remained proportional to BMI, and changes in BMI were accurately reflected by changes in leptin levels in older individuals. Fasting leptin levels did not predict involuntary weight loss over 2 years of follow-up. C1 Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. Univ Washington, Div Endocrinol, Seattle, WA 98104 USA. VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Univ Colorado, Hlth Sci Ctr, Div Geriatr, Denver, CO USA. RP Yukawa, M (reprint author), Univ Washington, Harborview Med Ctr, Div Gerontol & Geriatr Med, 325 9th Ave,Box 359755, Seattle, WA 98104 USA. FU NIDDK NIH HHS [DK02860] NR 46 TC 5 Z9 5 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2002 VL 50 IS 9 BP 1566 EP 1571 DI 10.1046/j.1532-5415.2002.50414.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 593AE UT WOS:000177968400014 PM 12383156 ER PT J AU Friedlander, AH Jones, LJ AF Friedlander, AH Jones, LJ TI The biology, medical management, and podiatric implications of menopause SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Article ID HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR MODULATORS; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOPOROTIC FRACTURES; RISK-FACTORS; ELDERLY WOMEN; HIP FRACTURE; POPULATION; PREVENTION AB Approximately 36 million women in the United States are in the postmenopausal phase of life, creating unique challenges for the provision of compassionate, comprehensive podiatric medical treatment. Longterm estrogen deprivation arising from menopause in association with age-related factors disproportionately increases the risk of ischemic heart disease, osteoporosis, and concomitant podiatric complications. This article discusses the physiologic basis of menopause, hormone replacement therapy and its effects on osteoporosis, and other podiatric implications of menopause. Podiatric physicians caring for larger numbers of peri- and postmenopausal women must formulate a comprehensive management plan for treating fractures that arise from a combination of estrogen-deprivation osteoporosis and abnormal foot biomechanics. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA USA. NR 67 TC 1 Z9 1 U1 0 U2 2 PU AMER PODIATRIC MED ASSN PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD SEP PY 2002 VL 92 IS 8 BP 437 EP 443 PG 7 WC Orthopedics SC Orthopedics GA 595KM UT WOS:000178108200003 PM 12237264 ER PT J AU Senthil, D Choudhury, GG Bhandari, BK Kasinath, BS AF Senthil, D Choudhury, GG Bhandari, BK Kasinath, BS TI Requirement of IRS-I for regulation of protein synthesis by VEGF in proximal tubular epithelial (PTE) cells. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 16A EP 16A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757500076 ER PT J AU O'Hare, AM Navarro, D Hynes, D Colin, P Dudley, A Stroupe, K McCulloch, C Rapp, J Johansen, KL AF O'Hare, AM Navarro, D Hynes, D Colin, P Dudley, A Stroupe, K McCulloch, C Rapp, J Johansen, KL TI High percentage of autogenous AV-fistula placement in the VA Healthcare System nationally. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 San Francisco VAMC, San Francisco, CA USA. UCSF, San Francisco, CA USA. Hines VAMC, VIREC, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 37A EP 37A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757500183 ER PT J AU Gooch, JL Gorin, Y Zhang, B Abboud, HE AF Gooch, JL Gorin, Y Zhang, B Abboud, HE TI Calcineurin is activated by mobilization of extracellular calcium in mesangial cells and is required for accumulation of matrix proteins by TGFb beta. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 86A EP 86A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757500422 ER PT J AU Riley, DJ Feliers, D AF Riley, DJ Feliers, D TI Rb and AP-1 positively regulate transcription of the cyclin D1 gene during renal and mesangial hypertrophy. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 S Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 91A EP 91A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757500446 ER PT J AU Li, SX Daniel, CD Balkovetz, DF AF Li, SX Daniel, CD Balkovetz, DF TI Hepatocyte growth factor increases cyclin D1 in contact inhibited renal epithelial cells. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 92A EP 92A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757500449 ER PT J AU Tian, W Cohen, DM AF Tian, W Cohen, DM TI Urea stress resembles EGF treatment more than it resembles hypertonic stress. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 275A EP 276A PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757501352 ER PT J AU Jara, A Chacon, C Valdivieso, A Ibaceta, M Felsenfeld, A AF Jara, A Chacon, C Valdivieso, A Ibaceta, M Felsenfeld, A TI Effect of chronic metabolic acidosis on renal function and mineral metabolism in 5/6 nephrectomized rats on low and high phosphate diets. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Pontificia Univ, Nephrol Dept, Rio De Janeiro, Brazil. Santiago Chile & Dept Med, W Los Angeles VA, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 281A EP 281A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757501379 ER PT J AU O'Hare, AM Navarro, D McCulloch, C Hynes, D Colin, P Stroupe, K Dudley, A Rapp, J Johansen, KL AF O'Hare, AM Navarro, D McCulloch, C Hynes, D Colin, P Stroupe, K Dudley, A Rapp, J Johansen, KL TI Surgeon practice pattern and center procedure volume are associated with choice of initial permanent hemodialysis access in the VA Healthcare System. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 San Francisco VAMC, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. VIREC, Hines VAMC, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 402A EP 403A PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757501982 ER PT J AU Kestenbaum, B Seliger, S Wasse, H Ball, A Gillen, D Sherrard, D Stehman-Breen, C AF Kestenbaum, B Seliger, S Wasse, H Ball, A Gillen, D Sherrard, D Stehman-Breen, C TI Parathyroid hormone levels and the risk of left ventricular hypertrophy at the onset of dialysis. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Washington, Div Nephrol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA USA. RI Wasse, Haimanot/A-5726-2013 OI Wasse, Haimanot/0000-0001-5756-0242 NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 434A EP 434A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502127 ER PT J AU Hung, AM Qureishy, O Wetmore, JB Lovett, DH Johansen, KL AF Hung, AM Qureishy, O Wetmore, JB Lovett, DH Johansen, KL TI Role of IL 1RA gene polymorphism in ESRD and cardiovascular disease. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 435A EP 436A PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502135 ER PT J AU Weisbord, SD Bruns, FJ Saul, MI Chang, CH Palevsky, PM AF Weisbord, SD Bruns, FJ Saul, MI Chang, CH Palevsky, PM TI The high costs of acute renal failure following the administration of intravenous contrast media in hospitalized patients. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 447A EP 447A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502188 ER PT J AU Weisbord, SD Bruns, FJ Saul, MI Palevsky, PM AF Weisbord, SD Bruns, FJ Saul, MI Palevsky, PM TI Are intravenous fluids used to limit the risk of contrast nephropathy? SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 6 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 447A EP 447A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502187 ER PT J AU Fried, L Naydeck, B Edmundowicz, D Sutton-Tyrrell, K Kuller, L Newman, A AF Fried, L Naydeck, B Edmundowicz, D Sutton-Tyrrell, K Kuller, L Newman, A TI Coronary calcification and mild-moderate renal insufficiency in elderly individuals SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 465A EP 466A PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502279 ER PT J AU Nagami, GT Warech, EM AF Nagami, GT Warech, EM TI AT1 receptor blockade prevents the enhancement of AT1 receptor cell surface expression by low pH in cultured proximal tubule cells SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 VA Greater LA Healthcare Syst, Nephrol Sect, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 474A EP 475A PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502323 ER PT J AU Nagami, GT Warech, EM AF Nagami, GT Warech, EM TI Low pH increases AT1a receptor promoter-driven reporter gene expression in cultured proximal tubule cells SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 VA Greater LA Healthcare Syst, Nephrol Sect, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 475A EP 475A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502324 ER PT J AU Yamamoto, K Eslami, P Nyby, MD Tuck, ML Corry, DB AF Yamamoto, K Eslami, P Nyby, MD Tuck, ML Corry, DB TI Uric acid stimulate's vascular smooth muscle cell proliferation by increasing angiotensin II production. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Olive View Med Ctr, Sylmar, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 495A EP 495A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502425 ER PT J AU Senthil, D Choudhury, GG Bhandari, BK Kasinath, BS AF Senthil, D Choudhury, GG Bhandari, BK Kasinath, BS TI Angiotensin II (Ang II) regulates expression of vascular endothelial growth factor (VEGF) and type 2 VEGF receptor (VEGFR2) in proximal tubular epithelial (PTE) cells. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 496A EP 496A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502433 ER PT J AU Gorin, YC Simon, M Bhandari, B Choudhury, GG Abboud, HE AF Gorin, YC Simon, M Bhandari, B Choudhury, GG Abboud, HE TI Tumor necrosis factor-alpha modulates the apoptotic effect of Thy 1.1 antibody. Role of PI3-K/Akt/PKB-dependent NF-kB activation. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Audie L Murphy Hosp Div, S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 502A EP 502A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502462 ER PT J AU Komers, R John, RF Jessie, LN Terry, OT Scott, MM Anderson, S AF Komers, R John, RF Jessie, LN Terry, OT Scott, MM Anderson, S TI Functional expression of endothelial nitric oxide (NO) synthase (eNOS, NOS3) and caveolin-1 (CAV-1) in diabetic kidney cortex. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Res Serv, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 532A EP 532A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502610 ER PT J AU Bhandari, BK Senthil, D Choudhury, GG Kasinath, BS AF Bhandari, BK Senthil, D Choudhury, GG Kasinath, BS TI Regulation or renal cortical protein tyrosine phosphatases (PTP) in mice with type 2 diabetes. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Texas, Hlth Sci Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78285 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 535A EP 535A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757502626 ER PT J AU Campoy, S Spiegel, DM Chonchol, MB AF Campoy, S Spiegel, DM Chonchol, MB TI Pre-end stage renal disease care improves outcomes at the start of hemodialysis. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Denver Vet Affairs Med Ctr, Sect Renal Dis & Hypertens, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 673A EP 673A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757503288 ER PT J AU Cizman, B Waldman, M Tomaszewski, JE AF Cizman, B Waldman, M Tomaszewski, JE TI Collapsing glomerulopathy with acute renal failure (ARF) associated with interferon-alpha treatment for chronic hepatitis B. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 Univ Penn, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Renal Sect, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 679A EP 679A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757503317 ER PT J AU Johansen, KL Doyle, J Shubert, T Sakkas, GK Kent-Braun, JA AF Johansen, KL Doyle, J Shubert, T Sakkas, GK Kent-Braun, JA TI Mechanisms of skeletal muscle fatigue in patients on dialysis. SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Meeting Abstract C1 San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. No Calif Inst Res & Educ, San Francisco, CA USA. Univ Massachusetts, Dept Exercise Sci, Amherst, MA 01003 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2002 VL 13 SU S BP 700A EP 700A PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 589KL UT WOS:000177757503421 ER PT J AU Lin, PH Bush, RL Chaikof, EL Chen, CY Conklin, B Terramani, TT Brinkman, WT Lumsden, AB AF Lin, PH Bush, RL Chaikof, EL Chen, CY Conklin, B Terramani, TT Brinkman, WT Lumsden, AB TI A prospective evaluation of hypogastric artery embolization in endovascular aortoiliac aneurysm repair SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Southern-Association-for-Vascular-Surgery CY JAN 16-19, 2002 CL MIAMI BEACH, FLORIDA SP SO Assoc Vasc Surg ID INTERNAL ILIAC ARTERY; ABDOMINAL AORTIC-ANEURYSMS; COIL EMBOLIZATION; REVASCULARIZATION; IMPOTENCE; SURGERY AB Purpose. Hypogastric artery embolization (HAE) is often performed in endovascular aortoiliac aneurysm repair to prevent potential endoleak, and this can be associated with pelvic ischemic sequelae. This prospective study was performed to evaluate the clinical outcome of HAE in patients who underwent endovascular aortoiliac aneurysm repair. Methods: During a 15-month period, 12 patients who underwent either unilateral or bilateral HAE for endovascular aortoiliac aneurysm repair were prospectively evaluated. All patients underwent preoperative and postoperative penile pressure measurement and pulse-volume recording evaluation. Angiographic features relating to pelvic collaterals and clinical outcomes relating to pelvic ischemia were evaluated. Results. Unilateral HA-E was performed in eight patients (67%), and bilateral HAE was performed in four patients (33%). Mean reductions in penile brachial index (PBI) after unilateral and bilateral HAE were 13 +/- 6% (not significant) and 39 +/- 14% (P < .05), respectively. Erectile dysfunction occurred in three patients for unilateral HAE (38%) and in two patients for bilateral HAE (50%), with an overall PBI reduction of 36 &PLUSMN; 12% (P < .01). No significant change in thigh brachial or ankle brachial index occurred after HAE. Hip and buttock claudication occurred in four patients for unilateral HAE (50%) and in two patients for bilateral HAE (50%), with an overall PBI reduction of 18 +/- 9% (P < .05). Other associated pelvic ischemic complications after bilateral HAE included one scrotal skin sloughing (25%) that occurred 3 days after aortic endografting and one sacral decubitus (25%) that occurred 4 months after aortic endografting. With analysis of angiographic collateral patterns, diseased profunda femoral artery (PFA; >50% stenosis) was noted in four patients, all in whom post-HAE pelvic ischemic symptoms developed (P < .05). In contrast, only four of the remaining eight patients with normal or mild PFA disease had pelvic ischemic sequelae after HAE. Conclusion: Erectile dysfunction after HAE correlates with significant reduction in PBI. Severe pelvic ischemic symptoms are more likely to occur after bilateral HAE, which should be avoided if possible. Moreover, patients with diseased PFA are at risk of development of pelvic ischemia after HAE. Our data suggest a potential role of concomitant profundapalsty at the time of aortic endografting to improve pelvic collateral flow and reduce pelvic ischemia in this subset of patients with HAE. C1 Baylor Coll Med, Houston VAMC, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. RP Lin, PH (reprint author), Baylor Coll Med, Houston VAMC, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcomb Blvd 112, Houston, TX 77030 USA. NR 21 TC 69 Z9 77 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD SEP PY 2002 VL 36 IS 3 BP 500 EP 505 DI 10.1067/mva.2002.127350 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 595GE UT WOS:000178099600021 PM 12218973 ER PT J AU Hooker, K Bowman, SR Coehlo, DP Lim, SR Kaye, J Guariglia, R Li, FZ AF Hooker, K Bowman, SR Coehlo, DP Lim, SR Kaye, J Guariglia, R Li, FZ TI Behavioral change in persons with dementia: Relationships with mental and physical health of caregivers SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article ID ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC INVENTORY; FAMILY CAREGIVERS; SPOUSE-CAREGIVERS; STRESS; INSTITUTIONALIZATION; PSYCHOPATHOLOGY; PREDICTORS; DEPRESSION; MORTALITY AB The purpose of this study was to examine the effects that changes in behavioral and psychological symptoms of dementia of persons with Alzheimer's disease have on their caregivers' mental health and physical health. The research design was a prospective, longitudinal follow-up study conducted in a major medical center and in participants' homes. Longitudinal analysis linking change in behavior to caregiver outcomes was based on 64 cases. Care recipients were assessed at the time of diagnosis with the Mini-Mental State Examination (MMSE). To provide information on the care recipient's behaviors, caregivers participated in an interview with the Modified Neuropsychiatric Inventory at diagnosis and at follow-up. Caregivers also completed a battery of established instruments to measure stress appraisal, mental health, and perceptions of their physical health at follow-up. Results showed that increases in problem behaviors among persons living with dementia, along with residence status, were significant predictors of caregivers' mental health and also their physical health. However, these relationships were mediated through stress appraisal. Variables such as MMSE score of the person with dementia, number of years caregiving, relationship status, and education level were not significant predictors of caregivers' health when behavior change was in the model. C1 Oregon State Univ, Dept Human Dev & Family Sci, Corvallis, OR 97331 USA. Oregon Hlth & Sci Univ, Oregon Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Res Inst, Eugene, OR 97403 USA. RP Hooker, K (reprint author), Oregon State Univ, Dept Human Dev & Family Sci, Milam 322, Corvallis, OR 97331 USA. EM hookerk@orst.edu FU NIA NIH HHS [P30 AG 08017] NR 52 TC 34 Z9 34 U1 3 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD SEP PY 2002 VL 57 IS 5 BP P453 EP P460 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA 589NU UT WOS:000177766800008 PM 12198104 ER PT J AU Shlipak, MG Fried, LF Crump, C Bleyer, AJ Manolio, TA Tracy, RP Furberg, CD Psaty, BM AF Shlipak, MG Fried, LF Crump, C Bleyer, AJ Manolio, TA Tracy, RP Furberg, CD Psaty, BM TI Cardiovascular disease risk status in elderly persons with renal insufficiency SO KIDNEY INTERNATIONAL LA English DT Article DE coronary heart disease; stroke; age and cardiovascular disease; risk predictors; serum creatinine; subclinical heart disease; kidney insufficiency; chronic renal disease ID NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE INDEX; 3RD NATIONAL-HEALTH; SERUM CREATININE; KIDNEY-DISEASE; OLDER ADULTS; MORTALITY; HYPERTENSION; DYSFUNCTION; PREDICTION AB Background. Renal insufficiency has been independently associated with incident cardiovascular disease events in some, but not all, prospective studies. We determined the prevalence of elevated cardiovascular disease risk status among elderly persons with renal insufficiency. Methods. This study is a cross-sectional analysis using data collected at the baseline visit of the Cardiovascular Health Study, which enrolled 5888 community dwelling adults aged 65 years or older from four clinical centers in the United States. Renal insufficiency was defined as a serum creatinine level greater than or equal to1.3 mg/dL in women and greater than or equal to1.5 mg/dL in men. The outcomes of this study included prevalent cardiovascular disease [prior coronary heart disease (CHD) or stroke], subclinical cardiovascular disease (abnormal values of ankle-arm index, carotid ultrasound, and echocardiography) and elevated cardiovascular risk based upon a diagnosis of diabetes and the Framingham equations. The association between renal insufficiency and cardiovascular risk status was estimated with and without adjustment for other cardiovascular predictors. Results. Among the 5808 participants with creatinine levels measured at entry, 15.9% of men (N = 394), and 7.6% of women (N = 254) had renal insufficiency. The prevalence of either clinical or subclinical cardiovascular disease was 64% in persons with renal insufficiency compared with 43% in those without it [odds ratio (OR) 2.34; 95 % confidence interval (95 % CI), 1.96, 2.80]. After adjustment for other cardiovascular risk factors, renal insufficiency remained significantly associated with clinical and subclinical cardiovascular disease (adjusted OR 1.43; 95% CI, 1.18,1.75), but the magnitude of association was substantially reduced. After combining clinical and subclinical cardiovascular disease, diabetes, and an estimated risk >20% by the Framingham equations, 78% of men and 61% of women with renal insufficiency had elevated cardiovascular risk status. Conclusions. Renal insufficiency is a marker for elevated cardiovascular disease risk in community dwelling elderly adults. C1 Vet Affairs Med Ctr, Med Serv, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Winston Salem, NC USA. Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Univ Vermont, Coll Med, Dept Pathol & Biochem, Burlington, VT USA. RP Shlipak, MG (reprint author), Vet Affairs Med Ctr, Med Serv, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. FU NHLBI NIH HHS [N01 HC 35129, N01 HC 15103, N01 HC 85079, N01 HC 85086, R03 HL 68099-01] NR 30 TC 120 Z9 126 U1 0 U2 3 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD SEP PY 2002 VL 62 IS 3 BP 997 EP 1004 DI 10.1046/j.1523-1755.2002.00522.x PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 584WR UT WOS:000177492200030 PM 12164883 ER PT J AU Karlawish, JHT Fox, E Pearlman, R AF Karlawish, JHT Fox, E Pearlman, R TI How changes in health care practices, systems, and research challenge the practice of informed consent SO MEDICAL CARE LA English DT Article DE informed consent; autonomy; evidence-based medicine ID OVARIAN-CANCER; MANAGED CARE; DECISIONS; CHOICE AB Informed consent has been the central model for ethical decision making in clinical care and research. The goal of informed consent is to protect the right of a competent person to make his or her own health care decisions based on personal values and goals. But changes in health care practices, systems, and research have challenged this well-established goal. This paper examines these changes to show that decisions about care and research directed to individual patients rely more and more upon a population perspective. As a result, efforts to promote patient choice should attend to the ethical decision-making processes of institutions that create and sustain this perspective. C1 Univ Penn, Hlth Syst, Dept Med, Div Geriatr Med,Ralston Penn Ctr, Philadelphia, PA 19104 USA. Univ Penn, Hlth Syst, Dept Med, Div Geriatr Med,Alzheimers Dis Ctr, Philadelphia, PA 19104 USA. Univ Penn, Hlth Syst, Dept Med, Div Geriatr Med,Ctr Bioeth, Philadelphia, PA 19104 USA. Vet Hlth Adm, Natl Ctr Eth, White River Jct, VT USA. George Washington Univ, Washington, DC USA. Univ Washington, Div Gerontol & Geriat Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Div Gerontol & Geriat Med, Dept Med, Seattle, WA 98195 USA. RP Karlawish, JHT (reprint author), Univ Penn, Hlth Syst, Dept Med, Div Geriatr Med,Ralston Penn Ctr, 3615 Chestnut St, Philadelphia, PA 19104 USA. NR 38 TC 2 Z9 2 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2002 VL 40 IS 9 SU S BP 12 EP 19 DI 10.1097/01.MLR.0000023951.75030.51 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 591HU UT WOS:000177874300003 ER PT J AU Lee, ML Yano, EM Wang, MM Simon, BF Rubenstein, LV AF Lee, ML Yano, EM Wang, MM Simon, BF Rubenstein, LV TI What patient population does visit-based sampling in primary care settings represent? SO MEDICAL CARE LA English DT Article DE sampling; health surveys; process and outcomes assessment; primary care ID RANDOMIZED CONTROLLED TRIAL; MEDICAL-CARE; SCREENING INSTRUMENT; AMBULATORY CARE; HEALTH-CARE; OUTCOMES; QUESTIONNAIRE; RELIABILITY; EDUCATION; EMERGENCY AB BACKGROUND. Evaluations of outpatient interventions often rely on consecutive sampling of clinic visitors, and assume that study results generalize to the population of patients cared for. OBJECTIVE. The representativeness of such visit-based sampling compared with the population of patients seen during the same year, in terms of sociodemographic and clinical characteristics of the user groups that visit-based sampling yielded were assessed. METHODS. One thousand five hundred forty-six continuing patients visiting the primary care firms in an urban VA medical center were consecutively sampled, and visit frequencies were compared for these patients with subsets of the patient population. Administrative and survey data was then used to describe the types of patients visit-based sampling most represented compared with the types of patients sampled less frequently. RESULTS. The average sampled patient visited the firms significantly more often than patients in the reference population (18.7 vs. 9.5). Sampled patients were significantly older (>55 years), in poorer health (higher prevalence of cancer, stroke, hypertension), less likely to smoke, and more likely to be single than the average patient visiting the firms (P <0.05). Adjusting for age and sickness, frequent visitors were more apt to have experienced continuity of care during the prior year, to prefer VA care, and to be unemployed. CONCLUSIONS. Consecutive visit-based sampling actually selected patients with a visit pattern more typical of the patient population visiting four or more times a year. Studies using sampling of consecutive visitors will typically under-represent low users of care and should account for the degree to which results may not generalize to the broader practice population. C1 VA Greater Los Angeles HSR&D Ctr Excellence, Ctr Study Healthcare Provider Behav, VA Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. VA Greater Los Angeles Healthcare Syst, Nursing Home, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA. RAND Corp, Dept Social Policy, Santa Monica, CA 90406 USA. RP Lee, ML (reprint author), VA Greater Los Angeles HSR&D Ctr Excellence, Ctr Study Healthcare Provider Behav, VA Sepulveda Ambulatory Care Ctr, 152,16111 Plummer St, Sepulveda, CA 91343 USA. NR 50 TC 28 Z9 28 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2002 VL 40 IS 9 BP 761 EP 770 DI 10.1097/01.MLR.0000024720.87446.41 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 589ZD UT WOS:000177790900006 PM 12218767 ER PT J AU Halpern, SD Ubel, PA Berlin, JA Asch, DA AF Halpern, SD Ubel, PA Berlin, JA Asch, DA TI Randomized trial of $5 versus $10 monetary incentives, envelope size, and candy to increase physician response rates to mailed questionnaires SO MEDICAL CARE LA English DT Article DE response rate; surveys; mailed questionnaire; bias; cost-effectiveness ID CONFIDENCE-INTERVALS; COST-EFFECTIVENESS AB BACKGROUND. The validity of the results of mailed surveys is often threatened by nonresponse bias, which is made more likely when response rates are low. However, the effectiveness and cost-effectiveness of several strategies to increase response rates are uncertain. OBJECTIVES. To assess three strategies to increase response rates to mailed physician surveys: including a $10 versus a $5 cash incentive in the initial mailing, including a mint candy or not, and using a large versus small outgoing envelope. RESEARCH DESIGN AND SUBJECTS. Using a 2 X 2 X 2 factorial design, a randomized trial of these strategies was conducted in a survey of 1200 physicians randomly selected from the American Medical Association's Master File. RESULTS. Including a $10 incentive yielded a significantly higher response rate (60.5% vs. 52.8%) (P = 0.009). The mailing and incentive costs per completed response were $12.24 (95% Cl, $11.75, $13.64) in the $5 group and $18.48 (95% Cl, $17.77, $20.69) in the $10 group. Each additional response obtained in the $10 group came at an incremental cost of $61.26 (95% Cl, $36.98, $200.80). Neither inclusion of a mint nor use of a large envelope influenced the response rate. CONCLUSIONS. Investigators may increase response rates by including more money in the initial questionnaire packet, but there may be diminishing returns to serial increments in incentives greater than $5. Including smaller incentives in more questionnaires may maximize total responses. C1 Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA. Univ Michigan, Sch Med, Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Asch, DA (reprint author), Univ Penn, Leonard Davis Inst Hlth Econ, 3644 Locust Walk, Philadelphia, PA 19104 USA. NR 18 TC 63 Z9 62 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD SEP PY 2002 VL 40 IS 9 BP 834 EP 839 DI 10.1097/01.MLR.0000024722.29926.3D PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 589ZD UT WOS:000177790900012 PM 12218773 ER PT J AU Bush, RK AF Bush, RK TI Asthma - Preface SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, Madison, WI 53705 USA. RP Bush, RK (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2002 VL 86 IS 5 BP XI EP XII AR PII S0025-7125(02)00027-5 DI 10.1016/S0025-7125(02)00027-5 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 612RF UT WOS:000179088700001 ER PT J AU Bush, RK AF Bush, RK TI Environmental controls in the management of allergic asthma SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID HOUSE-DUST-MITE; REDUCING RELATIVE-HUMIDITY; FEL-D-I; INDOOR ALLERGENS; MECHANICAL VENTILATION; CHILDHOOD ASTHMA; CAT ALLERGEN; DOUBLE-BLIND; MANCHESTER ASTHMA; RANDOMIZED TRIAL AB Sensitization to aeroallergens is a risk factor for the development of asthma in children and adults and ongoing exposure perpetuates the symptoms. Sensitivity to indoor allergens (house dust mites, pet dander, and cockroaches) and to the fungus Alternaria is most closely linked to these processes. Exposure avoidance and reduction have been shown significantly to improve asthma symptoms. Implementation of methods to achieve these results is an important part of asthma therapy. C1 William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, Madison, WI 53705 USA. RP Bush, RK (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 78 TC 2 Z9 2 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2002 VL 86 IS 5 BP 973 EP + AR PII S0025-7125(02)00029-9 DI 10.1016/S0025-7125(02)00029-9 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 612RF UT WOS:000179088700005 PM 12428541 ER PT J AU Bush, RK AF Bush, RK TI The use of anti-IgE in the treatment of allergic asthma SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID HUMANIZED MONOCLONAL-ANTIBODY; SERUM IGE; AIRWAY RESPONSIVENESS; IMMUNE-RESPONSE; OMALIZUMAB; DISEASE; RHINITIS; THERAPY; COSTIMULATION; CHILDHOOD AB Allergic sensitization plays a significant role in the pathogenesis of asthma in many patients. Immunotherapy of allergic asthma is controversial. Large-scale trials in patients aged 6 to 76 years with moderate-to-severe allergic asthma have shown that anti-IgE (omalizumab) therapy is safe and effective in reducing corticosteroid dosages and preventing exacerbations. C1 William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Sect Allergy & Immunol, Madison, WI 53792 USA. RP Bush, RK (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Allergy, 2500 Overlook Terrace, Madison, WI 53705 USA. NR 41 TC 8 Z9 8 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD SEP PY 2002 VL 86 IS 5 BP 1113 EP + AR PII S0025-7125(02)00036-6 DI 10.1016/S0025-7125(02)00036-6 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 612RF UT WOS:000179088700012 PM 12428547 ER PT J AU Castiglioni, B Sutton, DA Rinaldi, MG Fung, J Kusne, S AF Castiglioni, B Sutton, DA Rinaldi, MG Fung, J Kusne, S TI Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature SO MEDICINE LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; BONE-MARROW TRANSPLANTATION; IN-VITRO ACTIVITY; AMPHOTERICIN-B; BRAIN-ABSCESS; ALLESCHERIA-BOYDII; PULMONARY PSEUDALLESCHERIASIS; CLINICAL-SIGNIFICANCE; PETRIELLIDIUM-BOYDII; ASPERGILLUS-TERREUS AB Scedosporium apiospermum (Sca) is a ubiquitous filamentous fungus capable of causing invasive disease. We reviewed our electronic microbiology records and the English-language literature. Between 1976 and December 1999 we identified 23 solid organ transplant recipients with Sca infection, 7 of which occurred between December 1987 and December 1999 at our institution. Overall incidence was 1 per 1,000 patients, with a trend of higher incidence in patients receiving lung transplants compared with other transplant organs (p = 0.06). The 23 patients included liver (4), kidney (8), heart (8), lung (2), and heart/lung (1) recipients. Male to female ratio was 19:4, and the mean age was 46 +/- 12 (SD) years. Fungal infection was diagnosed at a median of 4 months (range, 0.4-156 mo) after transplant. The clinical presentation included disseminated disease (8), skin lesions (3), lung disease (5), endophthalmitis (1), meningitis (1), brain abscess with or without extension to eye (3), fungal mycotic aneurysm (1), and sinusitis (1). Seven (30%) patients had intravascular infection, and 11 (48%) patients had central nervous system involvement. Antifungal therapy was accompanied by surgical debridement in 9 cases. Three additional patients were found to have an-way colonization only and received itraconazole prophylaxis, without evidence of disease. Of 22 patients with known outcome, 16 (72.7%) died. Five of 6 patients who survived had localized infections: skin lesions (n = 3), sinus fungus ball (n = 1), and solitary lung nodule (n = 1). All patients with disseminated disease and 10 of 11 patients with central nervous system disease died. An exception was I patient with a brain abscess, successfully treated with voriconazole and surgical drainage. Sca infection is rare but. is associated with high mortality. Early diagnosis by,culture is important because Sca is resistant to amphotericin B, routinely used in the empiric therapy of invasive fungal infections. Treatment with the combination of an antifungal and surgery may have a better outcome. Voriconazole promises to be an effective antifungal agent. Cultures positive for Sca should not be ignored, and long-term antifungal prophylaxis in candidates, and transplant recipients should he considered. C1 Univ Pittsburgh, Ctr Med, Thomas E Starzl Transplantat Inst, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Ctr Med, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Kusne, S (reprint author), Univ Pittsburgh, Ctr Med, Div Infect Dis, Falk Med Bldg,Suite 3A,3601 5th Ave, Pittsburgh, PA 15213 USA. NR 70 TC 105 Z9 108 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7974 J9 MEDICINE JI Medicine (Baltimore) PD SEP PY 2002 VL 81 IS 5 BP 333 EP 348 DI 10.1097/01.md.0000030341.26556.e8 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 595WH UT WOS:000178131200001 PM 12352630 ER PT J AU Matsuda, M DeFronzo, RA Glass, L Consoli, A Giordano, M Bressler, P DelPrato, S AF Matsuda, M DeFronzo, RA Glass, L Consoli, A Giordano, M Bressler, P DelPrato, S TI Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID POSTPRANDIAL HYPERGLYCEMIA; INSULIN; METABOLISM; MELLITUS; HYPERGLUCAGONEMIA; SUPPRESSION; HUMANS; NIDDM; GLUCONEOGENESIS; HORMONE AB This study sought to examine whether enhanced hepatic sensitivity to glucagon contributes to impaired glucose homeostasis in subjects with type 2 diabetes mellitus (T2DM). Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects received a 4-hour glucagon infusion at the rates of 0.2, 0.5, 2, 6, and 8 ng . kg(-1) . min(-1) while maintaining the plasma insulin concentration constant at the basal level with exogenous infusions of somatostatin and insulin, On the evening prior to study, diabetic subjects received a low-dose insulin infusion at a rate designed to maintain euglycemia and this infusion rate was continued until the end of the glucagon infusion study on the following day. Each glucagon infusion study was performed on a separate day and in random order. 3-H-3-glucose was infused in all studies to measure endogenous glucose production (EGP) and the rate of whole body glucose disposal. During the first 2 hours (0 to 120 minutes) of glucagon infusion, EGP increased sharply in both groups, and the initial rate of rise in EGP was higher in control versus diabetic subjects. During the last 2 hours (120 to 240 minutes) of glucagon infusion, EGP in the diabetics tended to be higher than controls during the 3 lower glucagon infusion rates and this difference reached statistical significance (P<.05 to .01) during the 6 and 8 ng . kg(-1 .) min(-1) infusions. During the 2 hours following cessation of glucagon (240- to 360-minute time period), the stimulation of glucose disappearance from plasma was impaired (P<.05) during all 5 glucagon infusion rates in the diabetics compared to controls. We conclude that in T2DM patients, the initial (0 to 120 minutes) stimulation of hepatic glucose output (which primarily reflects glycogenolysis) by glucagon is not enhanced in T2DM patients. The late (120 to 240 minutes) stimulation of hepatic glucose output (which primarily reflects gluconeogenesis) by glucagon tends to be increased, especially at supraphysiologic plasma glucagon concentrations, Copyright 2002, Elsevier Science (USA). All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Diabet Div, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. RP Univ Texas, Hlth Sci Ctr, Dept Med, Diabet Div, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. OI Matsuda, Masafumi/0000-0001-8543-1616 FU NCRR NIH HHS [RR01346]; NIDDK NIH HHS [DK24092] NR 47 TC 39 Z9 40 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 EI 1532-8600 J9 METABOLISM JI Metab.-Clin. Exp. PD SEP PY 2002 VL 51 IS 9 BP 1111 EP 1119 DI 10.1053/meta.2002.34700 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592HA UT WOS:000177930000006 PM 12200754 ER PT J AU Murray, SS Tu, KN Young, KL Murray, EJB AF Murray, SS Tu, KN Young, KL Murray, EJB TI The effects of Lovastatin on proteasome activities in highly purified rabbit 20 S proteasome preparations and mouse MC3T3-E1 osteoblastic cells SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID COA REDUCTASE INHIBITORS; IN-VITRO; DIFFERENTIATION; PROLIFERATION; SIMVASTATIN; COMPACTIN; RISK; OSTEOCLASTS; ACTIVATION; UBIQUITIN AB A number of clinical studies suggest that the use of the lipid-lowering agents collectively referred to as statins (hydroxymethyl glutaryl coenzyme A [HMG-CoA] reductase inhibitors) is associated with increased bone density, reduced fracture risk, and net bone anabolism. Statins ( less than or equal to5 mumol/L) stimulate rodent bone formation, but the mechanistic basis remains unclear. Since statins and the proteasome inhibitor lactacystin are structurally similar, and high doses (greater than or equal to40 mumol/L) of statins can inhibit the chymotryptic activity of the proteasome, it has been hypothesized that statins exert their anabolic effects on bone, in part, by inhibiting the proteasome, the major eukaryotic intracellular regulatory protease. This hypothesis conflicts with reports that statins stimulate proteasome activity and that proteasome-catalyzed degradation of specific substrates is required for cell proliferation, differentiation, and survival. Our chief objective was to determine the effects of statins (less than or equal to10 mumol/L) on the chymotryptic activity of the proteasome in the 20 S proteasome and intact murine MC3T3-E1 cells cultured to low density (preosteoblasts) or high density (differentiated osteoblasts). Lovastatin (0.001 mumol/L to 5.0 mumol/L) stimulated the chymotryptic activity of the highly purified 20 S proteasome. Preosteoblasts and differentiated osteoblasts treated with 1, 5, or 10 mumol/L lovastatin for 1 hour exhibited morphologic abnormalities that were ameliorated by preincubation and treatment with 20 mumol/L mevalonate. The chymotryptic activity of the preosteoblast proteasome increased after 2 days of 1.0 mumol/L or 5.0 mumol/L lovastatin treatment. In addition, the DNA and protein contents of 1.0 mumol/L or 5.0 mumol/L lovastatin-treated preosteoblast cultures were lower those that observed in vehicle-, 0.01 mumol/L lovastatin-, or 0.10 mumol/L lovastatin-treated cultures, The chymotryptic activity of the proteasome was much lower in differentiated osteoblasts than in preosteoblasts. Two days of treatment with 1 mumol/L lovastatin modestly stimulated the chymotryptic activity of the proteasome in differentiated osteoblasts, but had no effects on total protein or DNA, compared to cultures treated with vehicle or lower doses of lovastatin. Thus, the data support the hypothesis that statins stimulate proteasome activities in highly purified proteasome preparations and preosteoblastic cells. Treating preosteoblastic or differentiated MC3T3-E1 cells with lovastatin concentrations greater than or equal to 1 mumol/L resulted in abnormal morphology and reduced the DNA and protein levels in preosteoblastic cultures, confirming the adverse effects of statins previously reported for other cells. In conclusion, the hypothesis that lovastatin exerts its anabolic effects on bone by inhibiting the proteasome activity of the osteoblast was refuted, and the effects of lovastatin on MC3T3-E1 cells were found to be highly dose- and development-dependent. Copyright 2002, Elsevier Science (USA). All rights reserved. C1 VA Greater Los angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr & Nursing Home, Serv Pharm, Sepulveda, CA 91343 USA. VA Greater Los angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Murray, SS (reprint author), VA Greater Los angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr & Nursing Home, Serv Pharm, Mail Code 11-E,16111 Plummer St, Sepulveda, CA 91343 USA. NR 35 TC 14 Z9 14 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD SEP PY 2002 VL 51 IS 9 BP 1153 EP 1160 DI 10.1053/meta.2002.34706 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 592HA UT WOS:000177930000012 PM 12200760 ER PT J AU Villa, VM Harada, ND Washington, D Damron-Rodriguez, J AF Villa, VM Harada, ND Washington, D Damron-Rodriguez, J TI Health and functioning among four war eras of US veterans: Examining the impact of war cohort membership, socioeconomic status, mental health, and disease prevalence SO MILITARY MEDICINE LA English DT Article ID QUALITY-OF-LIFE; MILITARY SERVICE; VIETNAM EXPERIENCE; CONSEQUENCES; STRESSORS AB This analysis examines the self-rated health and functioning of World War II, Vietnam era, Korean Conflict, and Persian Gulf War veterans participating in the Veteran Identity Program Survey 2001. The results indicate that although World War II veterans are more likely to report poor health status and functioning, Vietnam-era veterans report more difficulty with specific activities of daily living and instrumental activities of daily living than any other era of veterans. These relationships remain when controlling for race/ethnicity, socioeconomic status, disease prevalence, and mental health status. These findings suggest that there are characteristics unique to the Vietnam experience that negatively affect this cohort of veterans. We suggest that further analysis examine the specific pathways through which the experience of being a Vietnam veteran affects health. In the meantime, health and social service planning within the Department of Veterans Affairs should explore the services that should be developed and targeted to this cohort of veterans so that they may remain independent in the community. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Policy & Social Res, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA USA. Calif State Polytech Univ Pomona, Pomona, CA 91768 USA. RP Villa, VM (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 25 TC 12 Z9 12 U1 0 U2 2 PU ASSN MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD SEP PY 2002 VL 167 IS 9 BP 783 EP 789 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 653EA UT WOS:000181421200018 PM 12363172 ER PT J AU Taylor, AN Tritt, SH Tio, DL Romeo, HE Yirmiya, R AF Taylor, AN Tritt, SH Tio, DL Romeo, HE Yirmiya, R TI Maternal adrenalectomy abrogates the effect of fetal alcohol exposure on the interleukin-1 beta-induced febrile response: Gender differences SO NEUROENDOCRINOLOGY LA English DT Article DE adrenalectomy; body temperature; interleukins; thermoregulation; sex dimorphism; stress; fever; fetal differentiation; alcohol exposure ID PRENATAL ALCOHOL; INDUCED FEVER; RATS; CYTOKINES; IMMUNE; DAMS; CORTICOSTERONE; THERMOGENESIS; SECRETION; PREGNANCY AB Fetal alcohol exposure (FAE) has been shown to blunt the febrile component of the primary host-defense response to infection induced experimentally by systemic administration of interleukin (IL)-1beta. Given that maternal adrenalectomy (ADX) can prevent various postnatal effects of FAE, the present experiments were designed to determine whether maternal ADX would prevent the blunted IL-1beta-induced febrile response of fetal alcohol-exposed offspring and whether the effects of maternal ADX would be gender related. Timed-pregnant rats underwent ADX or were sham-operated on gestation day (GD) 7, or remained intact (without any surgery), and were fed ethanol-containing (E) or pair-fed (PF) liquid diets or normal (N) rat chow and water from GD 8 to GD 21. As adults, male and female E, PF and N offspring were injected with saline on day 1 and with IL-1beta (2 mug/ kg, i.p.) on day 2 at 09.00 h and the body temperature was recorded biotelemetrically for 8.5 h. IL-1beta produced significantly lower febrile responses in female than in male offspring of intact dams, irrespective of prenatal diet. Furthermore, prenatal surgical stress differentially affected the IL-1beta-induced febrile response of male and female normally fed offspring. Additionally, in both male and female offspring of intact dams, FAE significantly attenuated the IL-1beta-induced febrile response. In males, FAE also attenuated the febrile response in the offspring of maternal sham-operated dams, and this effect was completely reversed by maternal ADX In females, both maternal sham surgery and ADX reversed the effect of FAE on the febrile response. These findings suggest that maternal adrenal mediators are essential for the longterm effect of FAE on the febrile response in male offspring. In females, early prenatal surgical stress is sufficient to reverse the effects of FAE, possibly via adrenalin-dependent mechanisms that affect the thermoregulatory system. Copyright (C) 2002 S. KargerAG, Basel. C1 Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Hebrew Univ Jerusalem, Dept Psychol, Jerusalem, Israel. RP Taylor, AN (reprint author), Univ Calif Los Angeles, Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. FU NIAAA NIH HHS [AA09850] NR 25 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PD SEP PY 2002 VL 76 IS 3 BP 185 EP 192 DI 10.1159/000064524 PG 8 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 596PY UT WOS:000178174300006 PM 12218351 ER PT J AU Ehrhart, J Gluck, M Mieyal, J Zeevalk, GD AF Ehrhart, J Gluck, M Mieyal, J Zeevalk, GD TI Functional glutaredoxin (thioltransferase) activity in rat brain and liver mitochondria SO PARKINSONISM & RELATED DISORDERS LA English DT Article; Proceedings Paper CT 14th International Congress on Parkinsons Disease CY JUL 28-31, 2001 CL HELSINKI, FINLAND DE glutathione; mitochondria; Parkinson's disease; protein-glutathione mixed disulfide; brain ID PROTEIN DISULFIDE-ISOMERASE; GLUTATHIONE MIXED DISULFIDE; IN-SITU HYBRIDIZATION; DNA-BINDING ACTIVITY; IMMUNOLOGICAL CHARACTERIZATION; THIOREDOXIN REDUCTASE; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; THIOL HOMEOSTASIS; S-THIOLATION AB Glutaredoxin (Grx) is a specific and efficient catalyst of glutathione-dependent deglutathionylation of protein-SS-glutathione mixed disulfides. Grx has been identified in brain cytosol, but the presence of activity in subcellular organelles has not been reported. Increases in protein glutathionylation are likely to occur in mitochondria during oxidative stress and it is, therefore, important to know if this organelle contains the enzyme activity needed to reverse such protein thiolation. Grx-like activity in the PI supernatant from rat brain and liver was doubled in the presence of Triton-X 100 suggesting a releasable pool of Grx. Brain and liver homogenates were subfractionated into cytosolic, mitochondrial and microsomal fraction, their purity determined by biochemical assay and EM and assayed for Grx-like activity. The data presented demonstrate that mitochondria contain functional Grx-like activity. (C) 2002 Elsevier Science Ltd. All rights reserved. C1 UMDNJ, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA. Bronx Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA. RP Ehrhart, J (reprint author), UMDNJ, Robert Wood Johnson Med Sch, Dept Neurol, Bldg UBHC,Room D-437-E-675 Hoes Lane, Piscataway, NJ 08854 USA. FU NIA NIH HHS [AG15885]; NINDS NIH HHS [NS36157] NR 50 TC 17 Z9 17 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD SEP PY 2002 VL 8 IS 6 BP 395 EP 400 AR PII S1353-8020(02)00020-2 DI 10.1016/S1353-8020(02)00020-2 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 593MK UT WOS:000177995100004 PM 12217626 ER PT J AU Levin, LA Gordon, LK AF Levin, LA Gordon, LK TI Retinal ganglion cell disorders: types and treatments SO PROGRESS IN RETINAL AND EYE RESEARCH LA English DT Review ID OPTIC-NERVE HEAD; OPEN-ANGLE GLAUCOMA; NITRIC-OXIDE SYNTHASE; LATERAL GENICULATE-NUCLEUS; NORMAL-TENSION GLAUCOMA; METABOTROPIC GLUTAMATE-RECEPTOR; ELEVATED INTRAOCULAR-PRESSURE; RETROGRADE AXONAL-TRANSPORT; NEUROTROPHIC FACTOR BDNF; CALCIUM-BINDING PROTEIN C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA. Jules Stein Eye Inst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA. RP Levin, LA (reprint author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 600 Highland Ave, Madison, WI 53792 USA. FU NEI NIH HHS [EY12492, EY13708] NR 268 TC 32 Z9 32 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1350-9462 J9 PROG RETIN EYE RES JI Prog. Retin. Eye Res. PD SEP PY 2002 VL 21 IS 5 BP 465 EP 484 AR PII S1350-9462(02)00012-5 DI 10.1016/S1350-9462(02)00012-5 PG 20 WC Ophthalmology SC Ophthalmology GA 601HK UT WOS:000178440300003 PM 12207946 ER PT J AU Klein, CE Tangen, CM Braun, TJ Hussain, MHA Peereboom, DM Nichols, CR Rivkin, SE Dakhil, SR Crawford, ED AF Klein, CE Tangen, CM Braun, TJ Hussain, MHA Peereboom, DM Nichols, CR Rivkin, SE Dakhil, SR Crawford, ED TI SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: A Southwest Oncology Group Study SO PROSTATE LA English DT Article DE hormone refractory prostate cancer; topotecan; clinical trial ID PHASE-II TRIAL; ORAL ESTRAMUSTINE; SOLID TUMORS; CHEMOTHERAPY; PACLITAXEL AB BACKGROUND. Prostate cancer is the most common malignancy in American men, and as many as 70%, of those initially treated for localized disease will ultimately progress and be considered candidates to receive therapy for metastatic cancer [1,2]. Although most will respond initially to hormone manipulation, essentially all will fail and require additional therapy. No standard chemotherapy approach has been shown to prolong survival significantly, and new agents are desperately needed. Topotecan is a now topoisomerase-1 inhibitor whose early investigation suggested possible activity in hormone-refractory prostate cancer. METHODS. In this phase II trial, patients having failed one or two prior androgen ablative therapies were treated with 21-day continuous intravenous infusions of topotecan at a dose of 0.5 mg/m(2) per day every 28 days. RESULTS. Twenty-six eligible patients were entered on the study. There were no confirmed tumor responses. Median survival was 9 months. The most common toxicities were hematologic, with 8 of 24 assessable patients experiencing grade 4 toxicity. CONCLUSION. Topotecan infusions at this dose are ineffective in the management of hormone-refractory prostate cancer. C1 Univ Colorado, Denver, CO 80202 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA. Wayne State Univ, Med Ctr, Detroit, MI 48202 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Puget Sound Oncol Consortium, Seattle, WA USA. Wichita Community Clin Oncol Program, Wichita, KS USA. RP Klein, CE (reprint author), Denver VAMC, 1055 Clermont St, Denver, CO 80220 USA. FU NCI NIH HHS [CA37981, CA58861, CA63844, CA04919, CA12213, CA45807, CA32102, CA45560, CA35281, CA14028, CA38296, CA76462, CA35431, CA46113, CA96429, CA20319] NR 19 TC 6 Z9 6 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0270-4137 J9 PROSTATE JI Prostate PD SEP 1 PY 2002 VL 52 IS 4 BP 264 EP 268 DI 10.1002/pros.10118 PG 5 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA 585TT UT WOS:000177541200002 PM 12210486 ER PT J AU McKay, JR Pettinati, HM Morrison, R Feeley, M Mulvaney, FD Gallop, R AF McKay, JR Pettinati, HM Morrison, R Feeley, M Mulvaney, FD Gallop, R TI Relation of depression diagnoses to 2-year outcomes in cocaine-dependent patients in a randomized continuing care study SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article ID ADDICTION SEVERITY INDEX; SUBSTANCE USE; FOLLOW-UP; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; COPING SKILLS; ALCOHOLIC MEN; RELIABILITY; ABUSERS; DRINKING AB This study examined the relation between depression diagnoses and outcomes in 132 cocaine-dependent patients who were randomized to relapse prevention (RP) or standard 12-step focused group continuing care and followed for 2 years. Depressed patients attended more treatment sessions and had more cocaine-free urines during treatment than participants without depression, but they drank alcohol more frequently before treatment and during the 18-month posttreatment follow-up. Cocaine outcomes in depressed patients deteriorated to a greater degree after treatment than did cocaine outcomes in patients without depression, particularly in patients in RP who had a current depressive disorder at baseline. The best alcohol outcomes were obtained in nondepressed patients who received RP. The results suggest that extended continuing care treatment may be warranted for cocaine-dependent patients with co-occurring depressive disorders. C1 Univ Penn, Treatment Res Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP McKay, JR (reprint author), Univ Penn, Treatment Res Ctr, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [K02 DA00361, P50 DA05186, R01 DA10262] NR 59 TC 63 Z9 63 U1 1 U2 4 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD SEP PY 2002 VL 16 IS 3 BP 225 EP 235 DI 10.1037//0893-164X.16.3.225 PG 11 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 592AC UT WOS:000177913700006 PM 12236457 ER PT J AU Alterman, AI Gariti, P Niedbala, RS AF Alterman, AI Gariti, P Niedbala, RS TI Varying results for immunoassay screening kits for cotinine level SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article ID SMOKING AB Our earlier study found that although enzyme-linked immunosorbent analysis (ELISA) screening assays for urine cotinine indicated use in former smoking treatment patients who reported abstinence, this finding was sometimes incorrect when validated against gas chromatography/mass spectrometry (GC/MS; P. Gariti, A. I. Alterman, R. Ehrmann, F. D. Mulvaney, & C. P, O'Brien, 2002). In the current validation study, separate urine samples of 71 of these same patients were reanalyzed by an independent laboratory in blinded fashion using a screening enzyme immunoassay (EIA) analysis and GC/MS confirmation. EIA results showed almost total agreement with confirmatory testing. The findings indicate that use of screening ELISA/EIA for urine cotinine can detect unreported cases of smoking in former patients, but that care is needed in selecting a laboratory for conducting these tests. C1 Univ Penn, Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. OraSure Technol Inc, Bethlehem, PA USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Alterman, AI (reprint author), Univ Penn, Sch Med, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. FU NIDA NIH HHS [DA 10070] NR 9 TC 5 Z9 6 U1 1 U2 2 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD SEP PY 2002 VL 16 IS 3 BP 256 EP 259 DI 10.1037//0893-164X.16.3.256 PG 4 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 592AC UT WOS:000177913700010 PM 12236461 ER PT J AU Rehman, SU Cope, DW Basile, JN AF Rehman, SU Cope, DW Basile, JN TI Metastatic gastroesophageal adenocarcinoma to skeletal muscle: A unique event SO SOUTHERN MEDICAL JOURNAL LA English DT Article ID CARCINOMA; CANCER; INFILTRATION; THIGH; COLON; TUMOR AB Skeletal muscle is rarely the site of metastatic cancer, though a few such cases have been reported. Esophageal adenocarcinoma metastasic to skeletal muscle has not previously been reported in the literature. We describe the case of 71-year-old African American male with stage IV adenocarcinoma of die gastroesophageal junction. He had severe and disabling pain in the right thigh, which was tender to palpation. The pain was unresponsive to nonsteroidal anti-inflammatory drugs and full-close narcotics. Plain x-ray films and bone scan were nondiagnostic. Magnetic resonance imaging showed a soft tissue mass involving the thigh muscles, anterior and medial to the right femur. Computed tomography (CT)-guided biopsy revealed that the thigh mass was metastatic adenocarcinoma consistent with the primary gastroesophageal cancer. Metastasis to muscle is rare, but physicians should be aware of the possibility because detection requires specific tests. We discuss the role of these tests, as well as available treatment options. C1 Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Rehman, SU (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA. NR 35 TC 12 Z9 12 U1 0 U2 0 PU SOUTHERN MEDICAL ASSN PI BIRMINGHAM PA 35 LAKESHORE DR PO BOX 190088, BIRMINGHAM, AL 35219 USA SN 0038-4348 J9 SOUTHERN MED J JI South.Med.J. PD SEP PY 2002 VL 95 IS 9 BP 1076 EP 1078 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 596KR UT WOS:000178164500031 PM 12356116 ER PT J AU Clark, RA Li, SL Pearson, DW Leidal, KG Clark, JR Denning, GM Reddick, R Krause, KH Valente, AJ AF Clark, RA Li, SL Pearson, DW Leidal, KG Clark, JR Denning, GM Reddick, R Krause, KH Valente, AJ TI Regulation of calreticulin expression during induction of differentiation in human myeloid cells - Evidence for remodeling of the endoplasmic reticulum SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROTEIN DISULFIDE-ISOMERASE; RESPIRATORY BURST OXIDASE; CALCIUM-PUMP ISOFORMS; HEAT-SHOCK; CA2+ STORE; INTRACELLULAR-DISTRIBUTION; TRANSCRIPTIONAL REGULATION; FUNCTIONAL EXPRESSION; MOLECULAR CHAPERONE; CARDIAC DEVELOPMENT AB Induction of differentiation of HL-60 human myeloid cells profoundly affected expression of calreticulin, a Ca2+-binding endoplasmic reticulum chaperone. Induction with Me2SO or retinoic acid reduced levels of calreticulin protein by similar to60% within 4 days. Pulse-chase studies indicated that labeled calreticulin decayed at similar rates in differentiated and undifferentiated cells (t(1/2) similar to4.6 days), but the biosynthetic rate was <10% of control after 4 days. Differentiation also induced a rapid decline in calreticulin mRNA levels (90% reduction after 1 day) without a decrease in transcript stability (t(1/2) similar to5 h). Nuclear run-on analysis demonstrated rapid down-regulation of gene transcription (21% of control at 2 h). Differentiation also greatly reduced the Ca2+ content of the cells (25% of control), although residual Ca2+ pools remained sensitive to thapsigargin, ionomycin, and inositol trisphosphate. Progressive decreases were also observed in levels of calnexin and ERp57, whereas BiP/GRP78 and protein disulfide isomerase were only modestly affected. Ultrastructural studies showed a substantial reduction in endoplasmic reticulum content of the cells. Thus, terminal differentiation of myeloid cells was associated with decreased endoplasmic reticulum content, selective reductions in molecular chaperones, and diminished intracellular Ca2+ stores, perhaps reflecting an endoplasmic reticulum remodeling program as a prominent feature of granulocytic differentiation. C1 Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Pathol, San Antonio, TX 78229 USA. Iowa City Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA. Univ Iowa, Iowa City, IA 52242 USA. Univ Geneva, Dept Med, CH-1225 Geneva, Switzerland. RP Clark, RA (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. RI Krause, Karl-Heinz/E-8030-2011 NR 65 TC 16 Z9 16 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 30 PY 2002 VL 277 IS 35 BP 32369 EP 32378 DI 10.1074/jbc.M205269200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 588UB UT WOS:000177718700133 PM 12065601 ER PT J AU Young, JM Bennett, C Gilhooly, P Wessells, H Ramos, DE AF Young, JM Bennett, C Gilhooly, P Wessells, H Ramos, DE TI Efficacy and safety of sildenafil citrate (Viagra((R))) in black and Hispanic American men SO UROLOGY LA English DT Article ID ERECTILE DYSFUNCTION; ORAL SILDENAFIL; INTERNATIONAL INDEX; DOUBLE-BLIND; RISK-FACTORS; PREVALENCE AB The objective of this study was to assess the efficacy and safety of sildenafil citrate (Viagra) in black American and Hispanic American men with erectile dysfunction (ED) of broad-spectrum etiology. A total of 246 black American and 197 Hispanic American men were randomized to sildenafil (50 mg, adjustable to 25 mg or 100 mg, depending on efficacy and tolerability; n = 124 and n = 99, respectively) or matching placebo (n = 122 and n = 98, respectively). After 6 weeks, patients were given the option of switching to the other blinded treatment for the following 6 weeks. The 12 weeks of double-blind treatment were followed by 12 weeks of open-label extension. Despite differences in prevalence of hypertension, diabetes mellitus, hyperlipidemia, and use of concomitant anti hypertensive agents between the 2 study groups, sildenafil was efficacious and well tolerated. After 6 weeks, scores for questions 3 and 4 from the International Index of Erectile Function (IIEF) were significantly higher among sildenafil-treated black and Hispanic patients than in placebo-treated patients. In addition, compared with placebo, a significantly larger proportion of sildenafil patients reported improved erections and improved ability to have sexual intercourse. When efficacy results were stratified by ED severity or number of risk factors, scores for IIEF questions 3 and 4 were lower in men with severe ED versus mild-to-moderate ED. Similarly, the percentage of patients reporting improved erections decreased with ED severity and number of risk factors. The proportion of patients switching to the other treatment after 6 weeks was significantly higher in the placebo group (71% to 85%) than in the sildenafil group (27% to 28%). The most common adverse events included headache and vasodilation, which were mild to moderate in nature and were comparable between groups. These data demonstrate that despite differences in prevalence rates of comorbidities, efficacy and safety of sildenafil is maintained across different ethnic groups. C1 S Orange Cty Urol Med Associates, Laguna Woods, CA 92653 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Dept Vet Affairs, New Jersey Healthcare Syst, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. Univ Washington, Seattle, WA 98195 USA. Pfizer Inc, New York, NY USA. RP Young, JM (reprint author), S Orange Cty Urol Med Associates, 24301 Paseo Valencia, Laguna Woods, CA 92653 USA. NR 25 TC 27 Z9 27 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI UROLOGY PD AUG 30 PY 2002 VL 60 IS 2B SU S BP 39 EP 48 AR PII S0090-4295(02)01689-8 DI 10.1016/S0090-4295(02)01689-8 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 597HW UT WOS:000178217000005 PM 12414332 ER PT J AU Pham, T Guerrini, S Wong, H Reeve, J Sternini, C AF Pham, T Guerrini, S Wong, H Reeve, J Sternini, C TI Distribution of galanin receptor 1 - Immunoreactivity in the rat stomach and small intestine SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE enteric neurons; excitatory neurons; inhibitory neurons; enterochromaffin-like cells; interstitial cells of Cajal; gastrointestinal motility ID ENTEROCHROMAFFIN-LIKE CELLS; SMOOTH-MUSCLE CELLS; PIG SMALL-INTESTINE; GUINEA-PIG; GASTROINTESTINAL-TRACT; INTERSTITIAL-CELLS; PHARMACOLOGICAL CHARACTERIZATION; CONTAINING NEURONS; MOLECULAR-CLONING; ENTERIC NEURONS AB Galanin affects gastrointestinal functions by activating different G protein-coupled receptors. Here, we identified the sites of expression of the galanin receptor 1 (GAL-R1) subtype in the rat stomach and small intestine by using immunohistochemistry with an antibody raised to the third intracellular loop of rat GAL-R1 (GAL-R1(Y225-238)) and confocal microscopy. Antibody specificity was confirmed by (1) the detection of a band at approximately 70 kDa in Western blot of membranes from GAL-R1 transfected cells, (2) the cell surface staining of GAL-R1 transfected cells, which was not detected in control cells, and (3) the abolition of Western signal and tissue immunostaining by preadsorbing the antibody with the peptide used for immunization. GAL-R1 immunoreactivity was localized to the cell surface of enterochromaffin-like cells, and of myenteric and submucous neurons, and to fibers distributed to the plexuses, interconnecting strands, muscle layers, vasculature, and mucosa. A dense network of GAL-R1 immunoreactivity was observed in the deep muscular plexus in very close association with interstitial cells of Cajal visualized by c-kit immunostaining. In the ileum, 81.6% of GAL-R1 myenteric neurons and 70.7% of GAL-R1 submucosal neurons were substance P immunoreactive. Vasoactive intestinal polypeptide immunoreactivity was found in 48.3% of GAL-R1 submucosal neurons, but not in GAL-R1 myenteric neurons. These findings support the hypothesis that GAL-R1 mediates galanin actions on gastrointestinal motility and secretion by modulating the release of other neurotransmitters and contributes to galanin-induced inhibition of gastric acid secretion by means of the suppression of endogenous histamine release. (C) 2002 Wiley-Liss, Inc. C1 Univ Calif Los Angeles, Div Digest Dis, Digest Dis Res Ctr, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Sternini, C (reprint author), Univ Calif Los Angeles, Div Digest Dis, Digest Dis Res Ctr, CURE, Bldg 115,Room 224,VAGLAHS,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [DK35740, DK41301, DK57073] NR 49 TC 36 Z9 37 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD AUG 26 PY 2002 VL 450 IS 3 BP 292 EP 302 DI 10.1002/cne.10311 PG 11 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 577UQ UT WOS:000177080900007 PM 12209857 ER PT J AU Casarett, D Inouye, S AF Casarett, D Inouye, S TI Delirium at the end of life - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Yale Univ, New Haven, CT 06520 USA. RP Casarett, D (reprint author), Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 20 PY 2002 VL 137 IS 4 BP 295 EP 295 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 585BB UT WOS:000177502300013 ER PT J AU Bartsch, P Maggiorini, M Mairbaurl, H Vock, P Swenson, ER AF Bartsch, P Maggiorini, M Mairbaurl, H Vock, P Swenson, ER TI Pulmonary extravascular fluid accumulation in climbers SO LANCET LA English DT Letter ID MOUNTAIN-SICKNESS C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Clin, Dept Med, Div Sports Med, Heidelberg, Germany. Univ Hosp, Dept Internal Med, Med Intens Care Unit, Zurich, Switzerland. Univ Bern, Inselspital, Dept Radiol, CH-3010 Bern, Switzerland. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, S-11-Pulm,1660 S Columbian Way, Seattle, WA 98108 USA. NR 5 TC 32 Z9 35 U1 0 U2 3 PU LANCET LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0140-6736 J9 LANCET JI Lancet PD AUG 17 PY 2002 VL 360 IS 9332 BP 571 EP 571 DI 10.1016/S0140-6736(02)09723-4 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 585EZ UT WOS:000177512800039 PM 12241685 ER PT J AU Plotnick, MI Rubin, H Schechter, NM AF Plotnick, MI Rubin, H Schechter, NM TI The effects of reactive site location on the inhibitory properties of the serpin alpha(1)-antichymotrypsin SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-SHEET-A; PLASMA PROTEINASE-INHIBITORS; HUMAN NEUTROPHIL ELASTASE; CENTER LOOP; ALPHA(1)-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR; HUMAN CHYMASE; COMPLEX; CHYMOTRYPSIN; INSERTION AB The large size of the serpin reactive site loop (RSL) suggests that the role of the RSL in protease inhibition is more complex than that of presenting the reactive site (P1 residue) to the protease. This study examines the effect on inhibition of relocating the reactive site (Leu-358) of the serpin alpha(1)-antichymotrypsin either one residue closer (P2) or further (P1') from the base of the RSL (Glu-342). alpha(1)-Antichymotrypsin variants were produced by mutation within the P4-P2' region; the sequence ITLLSA was changed to ITLSSA to relocate the reactive site to P2 (Leu-357) and to ITITLS to relocate it to P1' (Leu-359). Inhibition of the chymotrypsin-like proteases human chymase and chymotrypsin and the non-target protease human neutrophil elastase (HNE) were analyzed. The P2 variant inhibited chymase and chymotrypsin but not HNE. Relative to P1, interaction at P2 was characterized by greater complex stability, lower inhibition rate constants, and increased stoichiometry of inhibition values. In contrast, the P1' variant inhibited HNE (stoichiometry of inhibition = 4) but not chymase or chymotrypsin. However, inhibition of HNE was by interaction with Ile-357, the P2 residue. The P1' site was recognized by all proteases as a cleavage site. Covalent-complexes resistant to SDS-PAGE were observed in all inhibitory reactions, consistent with the trapping of the protease as a serpin-acyl protease complex. The complete loss in inhibitory activity associated with lengthening the Glu-342-reactive site distance by a single residue and the enhanced stability of complexes associated with shortening this distance by a single residue are compatible with the distorted-protease model of inhibition requiring full insertion of the RSL into the body of the serpin and translocation of the linked protease to the pole opposite from that of encounter. C1 Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA. Philadelphia Vet Affais Med Ctr, Philadelphia, PA 19104 USA. RP Plotnick, MI (reprint author), Hosp Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Maloney Bldg 8th Fl,36th & Spruce Sts, Philadelphia, PA 19104 USA. FU NHLBI NIH HHS [HL03495, HL50523]; NIAMS NIH HHS [AR39674] NR 51 TC 10 Z9 10 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 16 PY 2002 VL 277 IS 33 BP 29927 EP 29935 DI 10.1074/jbc.M202374200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 585DW UT WOS:000177509300073 PM 12055188 ER PT J AU Finegold, SM Flynn, MJ Rose, FV Jousimies-Somer, H Jakielaszek, C McTeague, M Wexler, HM Berkowitz, E Wynne, B AF Finegold, SM Flynn, MJ Rose, FV Jousimies-Somer, H Jakielaszek, C McTeague, M Wexler, HM Berkowitz, E Wynne, B TI Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ANAEROBIC-BACTERIA; MICROBIOLOGY; SPECIMENS AB An open-label, multicenter study was performed to assess bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Seventy aerobic (52.2%) and 64 anaerobic (47.8%) pathogens were recovered from clinically evaluable patients at baseline (before therapy). The most commonly isolated anaerobes were Prevotella species (31.1%), anaerobic streptococci (21.9%), and Fusobacterium species (15.6%). The aerobes most frequently recovered included Streptococcus species (21.4%), Haemophilus influenzae (15.7%), Pseudomonas aeruginosa (15.7%), and Staphylococcus aureus and Moraxella catarrhalis (10.0% each). Recurrences of signs or symptoms of bacterial maxillary sinusitis associated with anaerobes were twice as frequent as were those associated with aerobes when counts of anaerobes were greater than or equal to10(3) cfu/mL. A pathogenic role for Granulicatella species in cases of chronic sinusitis was documented for the first time. C1 W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111 F, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. GlaxoSmithKline Pharmaceut, Collegeville, PA USA. RP Finegold, SM (reprint author), W Los Angeles Vet Affairs Med Ctr, Infect Dis Sect 111 F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 15 TC 62 Z9 69 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2002 VL 35 IS 4 BP 428 EP 433 DI 10.1086/341899 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 578HQ UT WOS:000177111700013 PM 12145727 ER PT J AU Tyor, WR Avgeropoulos, N Ohlandt, G Hogan, EL AF Tyor, WR Avgeropoulos, N Ohlandt, G Hogan, EL TI Treatment of spinal cord impact injury in the rat with transforming growth factor-beta SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE spinal cord injury; rats; mononuclear phagocytes; cytokines; transforming growth factor-beta ID TUMOR-NECROSIS-FACTOR; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRAUMATIC INJURY; FACTOR-ALPHA; TNF-ALPHA; TGF-BETA; BRAIN; EXPRESSION; GROWTH-FACTOR-BETA-1; CYTOKINES AB To investigate the contribution of cytokines, proinflammatory TNF-alpha and inhibitory TGF-beta, to spinal cord injury (SCI) in a rat model, two studies were performed using adult Sprague-Dawley rats which were injured at T9/T10. In the first study, rats were sacrificed at 1, 6, 24, 96 and 168 h after SCI for immunocytochemistry of coronal sections for the presence of mononuclear phagocytes, astrocytes, TNF-alpha and TGF-beta, among other markers. From intervening frozen sections, RNA was extracted for semiquantitative polymerase chain reaction (RTPCR) analysis of TNF-alpha and TGF-beta. In the second experiment, rats were treated with intravenous TGF-beta 30 min after injury and sacrificed at 6 and 48 h after injury. Spinal cord sections were immunocytochemically stained and RNA extracted for semiquantitative PCR as mentioned above, as well as quantitation of lesion volume. There were increases in mononuclear phagocytes and astrocytes, as early as 1 h after SCI, with steady progression over 168 h after injury. TNF-alpha and TGF-beta was produced locally by mononuclear phagocytes and astrocytes. There was an 18-h delay in peak mRNA production of TGF-beta compared to TNF-alpha. The treatment of SCI rats with TGF-beta reduced lesion volume by 50% at 48 h and this was associated with decreased accumulation of mononuclear phagocytes in and around the injury site. This reduction of mononuclear phagocyte numbers around the site of trauma would reduce their contribution to secondary injury. Published by Elsevier Science B.V. C1 Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Tyor, WR (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. FU NINDS NIH HHS [NS 31767] NR 28 TC 54 Z9 63 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD AUG 15 PY 2002 VL 200 IS 1-2 BP 33 EP 41 AR PII S0022-510X(02)00113-2 DI 10.1016/S0022-510X(02)00113-2 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 584FY UT WOS:000177457600005 PM 12127673 ER PT J AU Yaffe, K Covinsky, KE AF Yaffe, K Covinsky, KE TI Nursing home placement and dementia - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 14 PY 2002 VL 288 IS 6 BP 697 EP 697 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 583KY UT WOS:000177408100025 ER PT J AU Ganzini, L Johnston, WS Silveira, MJ AF Ganzini, L Johnston, WS Silveira, MJ TI The final month of life in patients with ALS SO NEUROLOGY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; PRACTICE PARAMETER; TERMINAL PHASE; CARE DATABASE; GOOD DEATH; QUALITY AB Objective: To study the health care experiences and palliative care needs of patients with ALS in their final month of life. Methods: Caregivers of decedent patients with ALS completed a single survey focused on the final month of life. They reported the patients' physical and emotional symptoms, preferences for end-of-life care, completion of advance directives, and preparation for death. The caregiver reported which life-sustaining treatments were administered, withheld, or withdrawn; whether the patient was enrolled in hospice; and their own satisfaction with the patient's medical care. Results: Fifty caregivers completed the survey. Caregivers reported that the most common symptoms in the last month of life included difficulty communicating (62%), dyspnea (56%), insomnia (42%), and discomfort other than pain (48%). Pain was both frequent and severe. One-third of caregivers were dissatisfied with some aspect of symptom management. Caregivers reported an advance directive was completed by 88% of patients and the patients' goals of care were honored by 88% of health care practitioners. Two-thirds of patients were enrolled in hospice. Compared to nonhospice patients, hospice patients were significantly more likely to: 1) die in their preferred location; 2) die outside the hospital; and 3) receive morphine. Most caregivers reported that their loved one was at peace, and prepared for and was accepting of death. Conclusions: Caregivers report that many patients with ALS still experience distressing physical symptoms in the last month of life, despite enrollment in hospice. Most patients with ALS, however, anticipate and plan for their deaths and have their wishes respected. C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97207 USA. Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR USA. Univ Alberta, Div Neurol, Edmonton, AB, Canada. Univ Michigan, Sch Med, VA Hlth Serv Res & Dev Serv, VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. Univ Michigan, Sch Med, Bioeth Program, Ann Arbor, MI USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, POB 1034, Portland, OR 97207 USA. RI Silveira, Maria/E-9802-2013; Johnston, Wendy/E-2491-2013 OI Johnston, Wendy/0000-0002-4330-5563 NR 20 TC 61 Z9 62 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD AUG 13 PY 2002 VL 59 IS 3 BP 428 EP 431 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 582EB UT WOS:000177335800021 PM 12177378 ER PT J AU Wu, AG Fujikawa, DG AF Wu, AG Fujikawa, DG TI Effects of AMPA-receptor and voltage-sensitive sodium channel blockade on high potassium-induced glutamate release and neuronal death in vivo SO BRAIN RESEARCH LA English DT Article DE high potassium; microdialysis; cell death; sodium channel; AMPA receptor; tetrodotoxin ID EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; EXTRACELLULAR POTASSIUM; SPREADING DEPRESSION; RAT-BRAIN; HIPPOCAMPAL CA1; GLOBAL-ISCHEMIA; CELL-CULTURE; NEUROTOXICITY; ASPARTATE AB High extracellular potassium induces spreading depression-like depolarizations and elevations of extracellular glutamate. Both occur in the penumbra of a focal ischemic infarct, and may be responsible for the spread of cell death from the infarct core to the penumbra. We have modeled this situation with microdialysis of an isotonic high-potassium solution into the normal rat amygdala for 70 min. This elevates extracellular glutamate up to 8-fold or more and produces irreversibly damaged, acidophilic neurons. NMDA-receptor blockade protects neurons and reduces the elevation of extracellular glutamate. Here we investigated the effects of sodium channel blockade with the voltage-sensitive sodium channel blocker tetrodotoxin and the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide disodium (NBQX disodium) on high potassium-induced neuronal death and extracellular glutamate elevations. The acidophilic neurons produced are necrotic by ultrastructural examination. Tetrodotoxin, at dialysate concentrations of 33, 330 and 3300 muM (only a small fraction is extracted by tissue), markedly reduced the elevations of glutamate in rat amygdala at nearly all time points during high-potassium perfusion, but it reduced tissue edema only at the highest concentration, and it was neuroprotective only if dialyzed prior to high-potassium microdialysis (at 330 muM concentration). Although both 250 muM (6.2% is extracted by tissue) and 500 muM NBQX reduced elevations of glutamate, neither was neuroprotective, and neuropil edema was not reduced by either concentration. Our results suggest that in vivo, sodium influx through voltage-sensitive sodium channels but not through ligand-gated AMPA receptor channels contributes to high potassium-induced neuronal necrosis. Published by Elsevier Science B.V. C1 VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab, Sepulveda Ambulatory Care Ctr, Sepulveda, CA 91343 USA. Nursing Home Care Unit, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Fujikawa, DG (reprint author), VA Greater Los Angeles Healthcare Syst, Expt Neurol Lab 151B4, Sepulveda Ambulatory Care Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. NR 43 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD AUG 9 PY 2002 VL 946 IS 1 BP 119 EP 129 AR PII S0006-8993(02)02869-X DI 10.1016/S0006-8993(02)02869-X PG 11 WC Neurosciences SC Neurosciences & Neurology GA 591NH UT WOS:000177886500013 PM 12133601 ER PT J AU Faraone, SV Skol, AD Tsuang, DW Bingham, S Young, KA Prabhudesai, S Haverstock, SL Mena, F Menon, ASK Bisset, D Pepple, J Sautter, F Baldwin, C Weiss, D Collins, J Keith, T Boehnke, M Tsuang, MT Schellenberg, GD AF Faraone, SV Skol, AD Tsuang, DW Bingham, S Young, KA Prabhudesai, S Haverstock, SL Mena, F Menon, ASK Bisset, D Pepple, J Sautter, F Baldwin, C Weiss, D Collins, J Keith, T Boehnke, M Tsuang, MT Schellenberg, GD TI Linkage of chromosome 13q32 to schizophrenia in a large veterans affairs cooperative study sample SO AMERICAN JOURNAL OF MEDICAL GENETICS LA English DT Article DE chromosome 13; schizophrenia; linkage; genetics ID SUSCEPTIBILITY LOCI; GENOME SCAN; DIAGNOSTIC INTERVIEW; BIPOLAR-DISORDER; 13Q14.1-Q32; CONSORTIUM; PEDIGREES; FAMILIES; REGIONS; PROGRAM AB Several prior reports have suggested that chromosomal region 13q32 may harbor a schizophrenia susceptibility gene. In an attempt to replicate this finding, we assessed linkage between chromosome 13 markers and schizophrenia in 166 families, each with two or more affected members. The families, assembled from multiple centers by the Department of Veterans Affairs Cooperative Studies Program, included 392 sampled affected subjects and 216 affected sib pairs. By DSM-III-R criteria, 360 subjects (91.8%) had a diagnosis of schizophrenia and 32 (8.2%) were classified as schizoaffective disorder, depressed. The families had mixed ethnic backgrounds. The majority were northern European-American families (n = 62, 37%), but a substantial proportion were African-American kindreds (n = 60, 36%). Chromosome 13 markers, spaced at intervals of approximately 10 cM over the entire chromosome and 2-5 cM for the 13q32 region were genotyped and the data analyzed using semiparametric affected only linkage analysis. For the combined sample (with race broadly defined and schizophrenia narrowly defined) the maximum LOD score was 1.43 (Z-score of 2.57; P = 0.01) at 79.0 cM between markers D13S1241 (76.3 cM) and D13S159 (79.5 cM). Both ethnic groups showed a peak in this region. The peak is within 3 cM of the peak reported by Brzustowicz et al. Published 2002 Wiley-Liss, Inc. C1 Brockton W Roxbury Vet Affairs Med Ctr, Brockton, MA USA. Harvard Univ, Massachusetts Mental Hlth Ctr, Dept Psychiat, Sch Med, Boston, MA USA. Inst Psychiat Epidemiol & Genet, Boston, MA USA. Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA. Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. Vet Affairs Med Ctr, Waco, TX USA. Vet Affairs Med Ctr, Danville, IL USA. Vet Affairs Med Ctr, Augusta, GA USA. Vet Affairs Med Ctr, Tuskegee, AL USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Vet Affairs Med Ctr, New Orleans, LA USA. Vet Affairs Med Ctr, Northport, NY USA. Genome Therapeut Corp, Waltham, MA USA. RP Faraone, SV (reprint author), Harvard Univ, Suite 255,750 Washington St, S Easton, MA 02375 USA. RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Faraone, Stephen/0000-0002-9217-3982 NR 26 TC 28 Z9 30 U1 1 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0148-7299 J9 AM J MED GENET JI Am. J. Med. Genet. PD AUG 8 PY 2002 VL 114 IS 6 BP 598 EP 604 DI 10.1002/ajmg.10601 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 579NU UT WOS:000177185400002 PM 12210272 ER PT J AU Bamshad, MJ Mummidi, S Gonzalez, E Ahuja, SS Dunn, DM Watkins, WS Wooding, S Stone, AC Jorde, LB Weiss, RB Ahuja, SK AF Bamshad, MJ Mummidi, S Gonzalez, E Ahuja, SS Dunn, DM Watkins, WS Wooding, S Stone, AC Jorde, LB Weiss, RB Ahuja, SK TI A strong signature of balancing selection in the 5 ' cis-regulatory region of CCR5 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID DNA-SEQUENCE VARIATION; MODERN HUMANS; HIV-1 INFECTION; STATISTICAL TESTS; POPULATION-GROWTH; GENETIC-VARIATION; EVOLUTION; POLYMORPHISMS; HAPLOTYPE; DIVERSITY AB CCR5 encodes a cell surface chemokine receptor molecule that serves as the principal coreceptor, with CD4, for HIV-type 1 (HIV-1). Varied HIV-1 susceptibility and time to progression to AIDS have been associated with polymorphisms in CCR5. Many of these polymorphisms are located in the 5' cis-regulatory region of CCR5, suggesting that it may have been a target of natural selection. We characterized CCR5 sequence variation in this region in 400 chromosomes from worldwide populations and compared it to a genome-wide analysis of 100 AN polymorphisms typed in the same populations. Variation was substantially higher than expected and characterized by an excess of intermediate-frequency alleles. A genealogy of CCR5 haplotypes had deep branch lengths despite markedly little differentiation among populations. This finding suggested a deviation from neutrality not accounted for by population structure, which was confirmed by tests for natural selection. These results are strong evidence that balancing selection has shaped the pattern of variation in CCR5 and suggest that HIV-1 resistance afforded by CCR5 5' cis-regulatory region haplotypes may be the consequence of adaptive changes to older pathogens. C1 Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA. Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Ctr AIDS & HIV 1 Infect, Vet Adm, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. Univ New Mexico, Dept Anthropol, Albuquerque, NM 87131 USA. RP Bamshad, MJ (reprint author), Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA. RI Mummidi, Srinivas/C-1004-2008; Stone, Anne/B-5719-2009 OI Mummidi, Srinivas/0000-0002-4068-6380; FU NCRR NIH HHS [RR-00064, M01 RR000064]; NIAID NIH HHS [AI43279, AI46326, R01 AI043279, R01 AI046326, R21 AI046326, R37 AI046326]; NIGMS NIH HHS [GM-59290, R01 GM059290] NR 49 TC 136 Z9 139 U1 0 U2 14 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 6 PY 2002 VL 99 IS 16 BP 10539 EP 10544 DI 10.1073/pnas.162046399 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 582HC UT WOS:000177343200059 PM 12149450 ER PT J AU Anton, RF Lieber, C Tabakoff, B AF Anton, RF Lieber, C Tabakoff, B CA CDTect Study Grp TI Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article; Proceedings Paper CT 22nd Annual Meeting of the Research-Society-on-Alcoholism CY JUN 26-JUL 01, 1999 CL SANTA BARBARA, CALIFORNIA SP Res Soc Alcoholism DE alcohol; markers; carbohydrate-deficient transferrin; gamma-glutamyltransferase; relapse ID ANION-EXCHANGE CHROMATOGRAPHY; GLUTAMYL-TRANSFERASE; LABORATORY MARKERS; OUTPATIENT ALCOHOLICS; BIOLOGICAL MARKERS; SERUM; CONSUMPTION; DRINKING; DEPENDENCE; ABUSE AB Background: The purpose of this article is to evaluate the biological marker of heavy alcohol use, carbohydrate-deficient transferrin (CDT), in contrast to the older and more widely used gamma-glutamyltransferase (GGT) for the detection and monitoring of heavy alcohol use. Methods: In this report, CDT and GGT sensitivity and specificity for heavy alcohol intake are examined in a large multisite study in which 444 recently admitted inpatient alcoholics were compared with 204 matched social drinker controls. In addition, changes in these biomarkers were evaluated during an initial abstinence period and biweekly over 14 weeks of monitoring to compare changes in CDT and GGT during continued abstinence or relapse. Results: CDT and GGT were comparable in identifying heavy alcohol consumption in men, but GGT appeared to be better for women, For both genders, when these markers were combined, there was better sensitivity than when used alone. CDT and GGT both decreased during 4 weeks of abstinence. When we used a 30% increase from baseline abstinent levels as an indicator, CDT appeared marginally better than GGT at indicating relapse in men but not in women. For men in particular, relapse over the course of the study was best identified by evaluating changes (30% increase) in both markers simultaneously. Conclusions: These results support the utility, of CDT, especially when used in conjunction with GGT. as an aid in detecting and monitoring heavy alcohol consumption. C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Univ Colorado, Dept Pharmacol, Sch Med, Denver, CO 80202 USA. RP Anton, RF (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861,POB 250861, Charleston, SC 29425 USA. NR 59 TC 100 Z9 102 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD AUG PY 2002 VL 26 IS 8 BP 1215 EP 1222 DI 10.1097/01.ALC.0000023986.42254.F5 PG 8 WC Substance Abuse SC Substance Abuse GA 586BC UT WOS:000177561400012 PM 12198396 ER PT J AU Watanabe, CT Maynard, C Ritchie, JL AF Watanabe, CT Maynard, C Ritchie, JL TI Short-term outcomes after percutaneous coronary intervention: Effects of stenting and institutional volume shifts SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; BALLOON ANGIOPLASTY; ARTERY DISEASE; ASSOCIATION; PLACEMENT; HOSPITALS; IMPLANTATION; MORTALITY AB Background This study examines how the dissemination of stenting and procedural shifts to high-volume facilities have affected short-term outcomes after percutaneous coronary intervention (PCI). Methods Discharge information from the 1994 and 1997 US Nationwide Inpatient Sample was used. Data from 1994 involved 84,036 angioplasties, 27.3% of which were performed for acute myocardial infarction (AMI), at a time when stents were generally unavailable. Data from 1997 included 118,548 angioplasties, 30.2% of which were performed for AMI and 59% of which involved stenting. Outcomes included same-admission mortality and same-admission bypass grafting surgery (CABG). Results Compared with 1994, in 1997 stents were in widespread use, and there was a significant shift in PCI procedures to high-volume facilities. There was no significant difference in overall mortality rates between 1994 and 1997. However, same-admission CABG rates were lower in 1997 than in 1994 for the AMI group (2.9% vs,4.7%, P < .0001) and for the no-AMI group (1.8% vs 3.0%, P < .0001), which was attributable almost entirely to stenting. For 1997 only, patients receiving stents had a lower mortality rate than patients undergoing PCI without stenting (AMI 2.7% vs 4.7%, P < .0001, no AMI 0.7% vs 0.9%, P = .004). Conclusions Despite the dissemination of stenting and shifts to high-volume facilities, overall mortality rates after PCI have not significantly changed. However, patients undergoing stenting in 1997 had a significantly lower mortality rate than patients who did not undergo stenting, suggesting that stents may prevent inhospital deaths. Furthermore, same-admission CABG rates have decreased dramatically, an association seen with the introduction of stenting, but not with volume shifts. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Sci, Seattle, WA 98195 USA. Hlth Serv Res & Dev, Seattle, WA USA. Dept Vet Affairs, Dept Med, Seattle, WA USA. RP Maynard, C (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 NR 18 TC 2 Z9 2 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD AUG PY 2002 VL 144 IS 2 BP 309 EP 314 DI 10.1067/mhj.2002.123845 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 585AR UT WOS:000177501400020 ER PT J AU Huerta, S Rogers, LM Li, ZP Heber, D Liu, C Livingston, EH AF Huerta, S Rogers, LM Li, ZP Heber, D Liu, C Livingston, EH TI Vitamin A deficiency in a newborn resulting from maternal hypovitaminosis A after biliopancreatic diversion for the treatment of morbid obesity SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE vitamin A deficiency; biliopancreatic diversion; night blindness; malabsorption; morbid obesity; neonatal nutrition; hypovitaminosis A ID RETINOL-BINDING PROTEIN; NUTRITIONAL-STATUS; GASTRIC BYPASS; GESTATIONAL-AGE; A STATUS; PREGNANCY AB Background: Biliopancreatic diversion (BPD) has been advocated for the treatment of morbid obesity. This procedure has the theoretical advantage that patients retain normal eating capacity and lose weight irrespective of their eating habits. However, vitamin deficiencies may develop because BPD causes malabsorption. Objective: This report describes a 40-y-old mother and her newborn infant, who developed vitamin A deficiency as a result of iatrogenic maternal malabsorption after BPD. Our primary objective is to show that BPD patients need close follow-up and lifelong micronutrient supplementation to prevent nutrient deficiencies in themselves and their offspring. Design: The medical records of the mother and infant were reviewed, and their clinical course was followed until 10 mo postpartum. The mother was also interviewed on several occasions about her medical care, follow-up, and supplemental vitamin use. Results: The mother developed night blindness with undetectable serum vitamin A concentrations in the third trimester of her pregnancy. Her vitamin A deficiency was untreated until she delivered her infant. At delivery, the infant also had vitamin A deficiency. He may have permanent retinal damage, but this is still unclear because the ophthalmologic examination performed at 2 mo of age was inconclusive. Conclusions: Complications of BPD may take many years to develop, and the signs and symptoms may be subtle. Because of the malabsorption that results from BPD, patients need lifelong follow-up and appropriate vitamin supplementation to prevent deficiencies. These nutrient deficiencies can also affect the offspring of female BPD patients. C1 Univ Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA USA. RP Huerta, S (reprint author), Univ Calif Los Angeles, Ctr Human Nutr, 900 Vet Ave,12-217 Warren Hall,Box 951742, Los Angeles, CA 90095 USA. FU NIDDK NIH HHS [DK07688] NR 22 TC 52 Z9 55 U1 0 U2 3 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD AUG PY 2002 VL 76 IS 2 BP 426 EP 429 PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 577CV UT WOS:000177044900021 PM 12145017 ER PT J AU Straus, WL Ofman, JJ MacLean, C Morton, S Berger, ML Roth, EA Shekelle, P AF Straus, WL Ofman, JJ MacLean, C Morton, S Berger, ML Roth, EA Shekelle, P TI Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; HEALTHY-VOLUNTEERS; GASTROINTESTINAL COMPLICATIONS; COLLABORATIVE METAANALYSIS; GASTRODUODENAL MUCOSA; RHEUMATOID-ARTHRITIS; HELICOBACTER-PYLORI; GASTRIC-MUCOSA AB OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with dyspepsia, but the relationship is obscured by variations in the terminology used to report GI symptoms. Using alternative definitions, we assessed the relationship between NSAID use and dyspepsia. METHODS: We searched MEDLINE, EMBASE, HEALTH-STAR, and BIOSIS databases (1966-1997) and New Drug Application reviews, identifying randomized, placebo-controlled trials (5 days or more duration) of any NSAID, reporting original data on GI complications. Based upon reported terms describing upper GI symptoms, we derived three definitions: strict, using terms synonymous with epigastric pain/discomfort; loose, (containing the strict definition plus terms for heartburn, nausea, bloating, anorexia, and vomiting); and a loose definition without heartburn terms (the loose-less-heartburn definition). Using each definition, we performed a random-effects model meta-analysis of the relationship between NSAID exposure and dyspepsia. RESULTS: Fifty-five published and 37 unpublished controlled NSAID trials met our inclusion criteria. The mean duration of the trials was 33.2 days (SD 40 days). Application of the strict definition resulted in a pooled risk ratio of dyspepsia for NSAIDs compared with placebo of 1.36 (95% CI = 1.11-1.67). For the loose definition, the pooled risk ratio was 1.13 (95% CI = 0.98-1.32). The loose-less-heartburn definition yielded a pooled risk ratio of 1.19 (95% CI = 1.03-1.39). In the placebo-treated control groups, the percent of patients reporting dyspepsia ranged from 2.3% (strict definition) to 4.2% (loose and loose-less-heartburn definitions). CONCLUSIONS: Using the strict definition, based solely on epigastric pain-related symptoms, NSAIDs increased the risk of dyspepsia by 36% (p < 0.05). These findings may be useful in creating a standardized definition of NSAID-related dyspepsia. C1 Merck & Co Inc, Outcomes Res & Management, W Point, PA 19486 USA. AHCPR So Calif Evidence Based Practice Ctr, Los Angeles, CA USA. Cedars Sinai Hlth Syst, Dept Med, Div Gastroenterol, Los Angeles, CA USA. Cedars Sinai Hlth Syst, Dept Hlth Serv Res, Div Gastroenterol, Los Angeles, CA USA. Cedars Sinai Hlth Syst, Zynx Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. W Los Angeles Vet Adm Med Ctr, Dept Med, Los Angeles, CA USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Straus, WL (reprint author), Merck & Co Inc, Outcomes Res & Management, Box 4,WP39-160, W Point, PA 19486 USA. NR 80 TC 46 Z9 47 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD AUG PY 2002 VL 97 IS 8 BP 1951 EP 1958 AR PII S0002-9270(02)04262-4 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 584GV UT WOS:000177459600020 PM 12190159 ER PT J AU Fung, F Sherrard, DJ Gillen, DL Wong, C Kestenbaum, B Seliger, S Ball, A Stehman-Breen, C AF Fung, F Sherrard, DJ Gillen, DL Wong, C Kestenbaum, B Seliger, S Ball, A Stehman-Breen, C TI Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE nutrition; cardiovascular disease (CVD); mortality; epidemiology ID C-REACTIVE PROTEIN; HEMODIALYSIS-PATIENTS; SERUM-ALBUMIN; DIALYSIS PATIENTS; HEART-DISEASE; INFLAMMATION; INTERLEUKIN-6; FAILURE; DEATH; HYPOALBUMINEMIA AB Background: Studies have shown that protein-energy malnutrition (PEM) is a strong predictor of total mortality among patients with end-stage renal disease (ESRD). The aim of this study is to assess the relationship between nutritional indices and cardiovascular (CV) mortality among patients with ESRD by using data from the US Renal Data System (USRDS) Dialysis Morbidity and Mortality Study Wave I (DMMS-1). Methods: Demographic and medical data were abstracted from 5,058 patients who participated in the USRDS DMMS-1. Nutritional measurements of interest included subjective assessment of malnutrition, serum albumin level, body mass index (BMI), and cholesterol level. The USRDS provided follow-up data on mortality through July 1998. The Cox proportional hazard model was used to estimate the risk for CV death associated with nutritional markers. Results: The risk for CV death was 39% greater for each 1-g/dL (10-g/L) decrement in serum albumin level (95% confidence interval [Cl], 1.20 to 1.60; P < 0.001). A care provider's assessment of malnutrition was associated with a 27% greater risk for CV mortality (95% Cl, 1.08 to 1.50; P < 0.004). For each one-unit decrement in BMI, the risk for CV disease (CVD) was 6% greater (95% Cl, 1.00 to 1.13; P < 0.046). Among patients without CVD at the study start, serum albumin level remained a significant risk factor for CV death (adjusted relative risk = 1.39 per 1-g/dL (10-g/L) increment; P = 0.026). In addition, change in albumin levels over time was significantly associated with CV mortality. For each 0.1-g/dL (1-g/L) decrement in albumin level per month, the risk for CV death was 2.24-fold greater (95% Cl, 1.65 to 3.02; P < 0.001) among the entire cohort and 3.86-fold greater (95% Cl, 1.96 to 7.60; P < 0.010) among those without a known history of CVD at the study start. Conclusion: Both PEM at baseline and worsening PEM over time are associated with a greater risk for CV death. This finding persists among dialysis patients without preexisting CVD at baseline. (C) 2002 by the National Kidney Foundation, Inc. C1 Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Div Nephrol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA 98108 USA. RP Stehman-Breen, C (reprint author), VA Puget Sound Hlth Care Syst, Div Nephrol, 1660 S Columbian Way,Mailstop 111A, Seattle, WA 98108 USA. FU NIDDK NIH HHS [DK07721-06] NR 34 TC 85 Z9 100 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2002 VL 40 IS 2 BP 307 EP 314 DI 10.1053/ajkd.2002.34509 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 578QN UT WOS:000177129800011 PM 12148103 ER PT J AU Berg, AO Allan, JD Frame, PS Homer, CJ Lieu, TA Mulrow, CD Peipert, JF Pender, NJ Sox, HC Teutsch, SM Westhoff, C Woolf, SH AF Berg, AO Allan, JD Frame, PS Homer, CJ Lieu, TA Mulrow, CD Peipert, JF Pender, NJ Sox, HC Teutsch, SM Westhoff, C Woolf, SH CA Preventive Services Task Force TI Screening for bacterial vaginosis in pregnancy: Recommendations and rationale SO AMERICAN JOURNAL OF NURSING LA English DT Article C1 Univ Washington, Dept Family Med, Seattle, WA 98195 USA. Univ Texas, Hlth Sci Ctr, Sch Nursing, San Antonio, TX USA. Univ Rochester, Cohocton, NY USA. Natl Initiat Childrens Healthcare Qual, Boston, MA USA. Natl Initiat Childrens Healthcare Qual, Boston, MA USA. Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Texas, Hlth Sci Ctr, Audie L Murphy Mem Vet Hosp, San Antonio, TX USA. Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. Brown Univ, Women & Infants Hosp, Providence, RI USA. Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA. Merck & Co Inc, Outcomes Res & Management, W Point, PA USA. Columbia Univ, Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY USA. Virginia Commonwealth Univ Med Coll Virginia, Dept Family Practice, Fairfax, VA USA. RP Berg, AO (reprint author), Care of Atkins D, Agcy Healthcare Res & Qual, Ctr Practice & Technol Assessment, 6010 Execut Blvd,Suite 300, Rockville, MD 20852 USA. NR 5 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD AUG PY 2002 VL 102 IS 8 BP 91 EP 93 PG 3 WC Nursing SC Nursing GA 585TH UT WOS:000177540300044 PM 12394084 ER PT J AU Fletcher, JA Fletcher, CDM Rubin, BP Ashman, LK Corless, CL Heinrich, MC AF Fletcher, JA Fletcher, CDM Rubin, BP Ashman, LK Corless, CL Heinrich, MC TI KIT gene mutations in gastrointestinal stromal tumors - More complex than previously recognized? SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Letter ID C-KIT; PROGNOSIS; DOMAIN C1 Harvard Univ, Sch Med, Boston, MA 02115 USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. Univ Newcastle, Sch Biomed Sci, Callaghan, NSW, Australia. Oregon Hlth Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Fletcher, JA (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. RI ASHMAN, LEONIE/G-7631-2013 OI ASHMAN, LEONIE/0000-0003-3559-3611 NR 11 TC 15 Z9 16 U1 0 U2 0 PU AMER SOC INVESTIGATIVE PATHOLOGY, INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD AUG PY 2002 VL 161 IS 2 BP 737 EP 738 DI 10.1016/S0002-9440(10)64229-0 PG 2 WC Pathology SC Pathology GA 582DQ UT WOS:000177334800042 PM 12163398 ER PT J AU Pagel, KJ Kaul, MP Dryden, JD AF Pagel, KJ Kaul, MP Dryden, JD TI Lack of utility of Semmes-Weinstein monofilament testing in suspected carpal tunnel syndrome SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE carpal tunnel syndrome; Semmes-Weinstein monofilaments; electrodiagnosis; veteran AB Objective: To investigate the value of Semmes-Weinstein monofilament (SWM) testing in patients with electrodiagnostically confirmed carpal tunnel syndrome in a group of patients with symptoms compatible with carpal tunnel syndrome. Design: A total of 119 consecutive patients with symptoms compatible with carpal tunnel syndrome were assessed. Blinded comparison of two Semmes-Weinstein monofilament testing protocols with orthodromic midpalm electrodiagnostic testing was performed. The electrodiagnostic test was considered the standard to which the results of the Semmes-Weinstein monofilament testing were measured. Results: Fifty three percent of our patients had electrodiagnostically confirmed carpal tunnel syndrome. Using a conservative Semmes-Weinstein monofilament testing protocol the sensitivity was 98% and the specificity was 15%. The positive predictive value was 56% and the negative predictive value was 88%. Using a liberal Semmes-Weinstein monofilament testing protocol the sensitivity was 13% and the specificity was 88%. The positive predictive value was 53% and the negative predictive value was 47%. Conclusion: Semmes-Weinstein monofilament testing was not shown to have utility in diagnosing electrodiagnostically confirmed carpal tunnel syndrome in our population of predominantly male veterans. C1 Portland Vet Affairs Med Ctr, Rehabil Med Serv, Portland, OR 97207 USA. RP Kaul, MP (reprint author), Portland Vet Affairs Med Ctr, Rehabil Med Serv, 3710 US Vet Hosp Rd, Portland, OR 97207 USA. NR 12 TC 11 Z9 11 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD AUG PY 2002 VL 81 IS 8 BP 597 EP 600 AR UNSP 0894-9115/02/8108-0597/0 DI 10.1097/00002060-200208000-00007 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 577EE UT WOS:000177047900007 PM 12172069 ER PT J AU Nurgalieva, ZZ Malaty, HM Graham, DY Almuchambetova, R Machmudova, A Kapsultanova, D Osato, MS Hollinger, FB Zhangabylov, A AF Nurgalieva, ZZ Malaty, HM Graham, DY Almuchambetova, R Machmudova, A Kapsultanova, D Osato, MS Hollinger, FB Zhangabylov, A TI Helicobacter pylori infection in Kazakhstan: Effect of water source and household hygiene SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID LIVING-CONDITIONS; RISK-FACTORS; HEPATITIS-A; CHILDREN; TRANSMISSION; SEROPREVALENCE; PREVALENCE; COMMUNITY; SEROEPIDEMIOLOGY; EPIDEMIOLOGY AB The epidemiology of Helicobacter pylori infection and risk factors associated with its transmission are not well understood. Kazakhstan is country with two ethnic groups, Asian (Kazakhs) and Western (Russians), living under similar socioeconomic conditions. The aim of this study was to examine the seroepidemiologic pattern of H. pylori and hepatitis A among the same individuals from both ethnic groups, with emphasis on water source and household sanitation practices. This was a cross-sectional seroepidemiologic study conducted among unrelated healthy individuals in Kazakhstan. From May through August 1999, individuals between the ages of 10 and 60 years from Almaty, Kazakhstan, were invited to participate. Demographic information, socioeconomic factors, living conditions, and various aspects of the local household environment including access to water were collected. A clean water index (CWI) was created based on combined factors, consistency of boiling water before drinking, frequency of storing and reusing water, and frequency of bathing and showering. H. pylori and hepatitis A antibodies were assessed by enzyme-linked immunosorbent assay. Two hundred eighty-eight individuals between the ages of 10 and 60 years participated. The prevalence of H. pylori infection was almost identical among the two ethnic groups (Russians 79% and Kazakhs 80%). H. pylori infection was inversely correlated with the CWI (i.e., 56%, 79%, and 95% for high, middle, and low, respectively (P<.05). Drinking river water had highest risk of H. pylori infection (OR = 13.6, 95% CI = 1.8- 102.4; P<.01, compared with tap water). Crowding showed no significant effect on H. pylori prevalence. Anti-HAV antibodies were found in 86% of the population, 90% among the Russians versus 82% among the Kazakhs (OR = 1.8, 95 % CI = 1.1-3.8, P=.05). Although the two infections were highly correlated (P<.001), antibody to both infections were present simultaneously in only 74%. The prevalence of H. pylori infection in Kazakhstan is very high. The data suggest that transmission of H. pylori can be water borne, related to poor sanitary practices, or both. The high prevalence of antibodies to H. pylori and HAV among this population is a marker for poor sanitation and hygienic practices. Reducing the rate of H. pylori transmission will require improvements in overall sanitation including clean water, waste disposal, as well as in household hygienic practices. C1 VA Med Ctr, Dept Med, Houston, TX 77030 USA. Almaty State Med Univ, Dept Fac Therapy, Almaty, Kazakhstan. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Nurgalieva, ZZ (reprint author), VA Med Ctr, Dept Med, Rm 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIDDK NIH HHS [DK-53659, DK56338] NR 39 TC 62 Z9 65 U1 3 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2002 VL 67 IS 2 BP 201 EP 206 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 601ZN UT WOS:000178479700015 PM 12389948 ER PT J AU Yu, FC Gibbon, GW Klaustermeyer, WB AF Yu, FC Gibbon, GW Klaustermeyer, WB TI Refractory atopic dermatitis treated with low dose cyclosporin SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Editorial Material ID DOUBLE-BLIND; THERAPEUTIC AGENT; CONTROLLED TRIAL; ECZEMA; ADULTS; COLONIZATION; COMPLEXES; DISEASE C1 Greater Los Angeles VA Med Ctr, Allergy & Immunol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Klaustermeyer, WB (reprint author), VA Greater Los Angeles Healthcare Syst, Allergy & Immunol Sect 111R, 11301 Wilshire Blvd,Bldg 500, Los Angeles, CA 90073 USA. NR 34 TC 1 Z9 1 U1 0 U2 1 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD AUG PY 2002 VL 89 IS 2 BP 127 EP 131 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA 585VL UT WOS:000177545200006 PM 12197567 ER PT J AU Montine, TJ Quinn, JF Milatovic, D Silbert, LC Dang, T Sanchez, S Terry, E Roberts, LJ Kaye, JA Morrow, JD AF Montine, TJ Quinn, JF Milatovic, D Silbert, LC Dang, T Sanchez, S Terry, E Roberts, LJ Kaye, JA Morrow, JD TI Peripheral F-2-isoprostanes and F-4-neuroprostanes are not increased in Alzheimer's disease SO ANNALS OF NEUROLOGY LA English DT Article ID RADICAL-CATALYZED MECHANISM; LIPID-PEROXIDATION; IN-VIVO; OXIDATIVE STRESS; PLASMA; NONCYCLOOXYGENASE; NEUROPROSTANES; ISOPROSTANES; PRODUCTS; ACID AB Quantitative biomarkers of oxidative damage, such as the F-2-isoprostanes (IsoPs) and F-4-neuroprostanes (F-4-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F-2-IsoPs and F-4-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F-2-IsoPs and F-4-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F-2-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F-2-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F-2-IsoPs and F-4-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F-2-IsoPs and F-4-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease. C1 Vanderbilt Univ, Med Ctr N, Dept Pathol, Nashville, TN 37232 USA. Vanderbilt Univ, Med Ctr N, Dept Pharmacol, Nashville, TN 37232 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Neurol Serv, Portland, OR USA. Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. RP Montine, TJ (reprint author), Vanderbilt Univ, Med Ctr N, Dept Pathol, C-3321A, Nashville, TN 37232 USA. OI Silbert, Lisa/0000-0002-4525-0068; Kaye, Jeffrey/0000-0002-9971-3478 FU NCI NIH HHS [CA77839]; NIA NIH HHS [AG05144, AG08017, AG16835]; NIDDK NIH HHS [DK48831]; NIGMS NIH HHS [GM15431] NR 22 TC 110 Z9 112 U1 0 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD AUG PY 2002 VL 52 IS 2 BP 175 EP 179 DI 10.1002/ana.10272 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 578UX UT WOS:000177140000007 PM 12210787 ER PT J AU Kirkpatrick, WR Perea, S Coco, BJ Patterson, TF AF Kirkpatrick, WR Perea, S Coco, BJ Patterson, TF TI Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ANTIFUNGAL MK-0991 L-743,872; IN-VITRO; AMPHOTERICIN-B; ECHINOCANDIN CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; FUMIGATUS; CANDIDA; TERBINAFINE; SUSCEPTIBILITY AB The antifungal activity of caspofungin acetate (CAS) alone and in combination with voriconazole (VRC) was evaluated in an immunosuppressed transiently neutropenic guinea pig model of invasive aspergillosis. Guinea pigs were immunosuppressed with triamcinolone at 20 mg/kg of body weight/day subcutaneously beginning 4 days prior to lethal intravenous challenge with Aspergillus fumigatus and were made temporarily neutropenic with cyclophosphamide administered at 150 mg/kg intraperitoneally (i.p.) 1 day prior to challenge. Therapy with i.p. CAS at 1 and 2.5 mg/kg/day (with and without oral VRC at 5 mg/kg/day), oral VRC at 5 mg/kg/day, or i.p. amphotericin B (AMB) at 1.25 mg/kg/day was begun 24 h after challenge and was continued for 5 days. Mortality occurred in 12 of 12 untreated controls, whereas mortality occurred in 4 of 12 and 6 of 12 guinea pigs treated with CAS at 1 and 2.5 mg/kg/day, respectively, and in 3 of 12 guinea pigs treated with AMB. No mortality occurred among animals treated with CAS at 1 mg/kg/day plus VRC at 5 mg/kg/day, CAS at 2.5 mg/kg/day plus VRC at 5 mg/kg/day, or VRC at 5 mg/kg/day alone. Both CAS regimens increased the survival times and reduced the colony counts in tissue compared with those for the controls. Treatment with VRC and AMB significantly reduced the colony counts in the tissues of selected animals compared with those in the tissues of the controls. Treatment with VRC and AMB also resulted in reductions in colony counts in tissues compared with those in the tissues of animals treated with CAS (the difference was not statistically significant) and improved the survival times but did not sterilize tissues. Combination therapies with CAS plus VRC at either dose reduced colony counts in tissues 1,000-fold over those for the controls and were the only regimens that significantly reduced the numbers of positive cultures. The combinations of CAS plus VRC were highly effective in this model and should be further evaluated for use against invasive aspergillosis. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX 78284 USA. RP Kirkpatrick, WR (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,Mail Code 7881, San Antonio, TX 78229 USA. NR 29 TC 195 Z9 204 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD AUG PY 2002 VL 46 IS 8 BP 2564 EP 2568 DI 10.1128/AAC.46.8.2564-2568.2002 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 575VG UT WOS:000176968700036 PM 12121933 ER PT J AU Finegold, SM Molitoris, D Phan, VT Vaisanen, ML Wexler, HM AF Finegold, SM Molitoris, D Phan, VT Vaisanen, ML Wexler, HM TI Activities of ABT-773 against microaerophilic and fastidious organisms SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID IN-VITRO ACTIVITIES; ANAEROBIC-BACTERIA AB ABT-773 was tested against 317 fastidious isolates; it inhibited 99% of organisms at a concentration of 4.0 mug/ml. With ampicillin-sulbactam and levofloxacin, only 2 and 6% of these strains, respectively, were resistant at the breakpoint. With clindamycin, penicillin G, and metronidazole, 22, 26, and 58% of the strains, respectively, were resistant. C1 VA Greater Los Angeles Healthcare Syst, W Los Angeles Div, Infect Dis Sect 111 F, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, W Los Angeles Div, Res Serv, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA. RP Finegold, SM (reprint author), VA Greater Los Angeles Healthcare Syst, W Los Angeles Div, Infect Dis Sect 111 F, Los Angeles, CA 90073 USA. NR 7 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD AUG PY 2002 VL 46 IS 8 BP 2716 EP 2719 DI 10.1128/AAC.46.8.2716-2719.2002 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 575VG UT WOS:000176968700068 PM 12121965 ER PT J AU Park, GH McNeil, MR Doyle, PJ AF Park, GH McNeil, MR Doyle, PJ TI Lexical access rate of closed-class elements during auditory sentence comprehension in adults with aphasia SO APHASIOLOGY LA English DT Article ID CLASS WORDS; TIME; COMPLEXITY; LANGUAGE; CONTEXT; MODEL AB Background: One hypothesis regarding the underlying impairment in agrammatic comprehension suggests that individuals with this disorder suffer from a reduction in lexical activation of closed-class words and therefore cannot appropriately construct a syntactic frame on which lexical semantic information can be applied (Friederici, 1988). Aims: Given the temporally based hypothesis, this investigation examined the effects of increased inter-word intervals (IWI) following closed-class words on auditory comprehension of various sentence types by individuals with agrammatic comprehension. It was hypothesised that providing a longer temporal window for access and processing of closed-class words would improve sentence structure comprehension. Methods & Procedures: Twelve adults with aphasia participated in an agent identification task given varying auditory sentence stimuli. Six sentence types and six IWI durations served as independent variable while accuracy and response times were measured. Outcomes & Results: Results indicated that auditory sentence comprehension performance improves when IWIs are increased. However, differences exist among individuals in response to specific IWI durations. Conclusions: Implications of delayed access rates of closed-class words in agrammatic comprehension are discussed. C1 Univ Pittsburgh, Pittsburgh, PA 15260 USA. Va Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Univ Pittsburgh, Passavant Hosp, Pittsburgh, PA 15260 USA. RP Park, GH (reprint author), NIDCD, NIH, Language Sect, Bldg 10,Room 3C-716, Bethesda, MD 20892 USA. NR 40 TC 3 Z9 3 U1 1 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD AUG PY 2002 VL 16 IS 8 BP 801 EP 814 DI 10.1080/02687030244000158 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA 581LQ UT WOS:000177294200003 ER PT J AU McNeil, MR Doyle, PJ Park, GH Fossett, TRD Brodsky, MB AF McNeil, MR Doyle, PJ Park, GH Fossett, TRD Brodsky, MB TI Increasing the sensitivity of the Story Retell Procedure for the discrimination of normal elderly subjects from persons with aphasia SO APHASIOLOGY LA English DT Article ID CONNECTED SPEECH; MEMORY; ADULTS; INFORMATION AB Background: Clinicians have long recognised the need for assessing language production at multiple levels of complexity and at impairment, participation, and activity levels. Methods for the elicitation of connected spoken language have taken many forms, typically selected with a balance between validly sampling linguistic performance, and reliability and economy of the sampling and scoring procedures. A Story Retell Procedure (SRP) has been proposed as a preferred method for achieving valid, reliable, and economic assessment of connected language (Doyle et al., 2000), and an information unit (IU) metric has been developed for validly and economically capturing important linguistic aspects of the retelling (McNeil, Doyle, Fossett, Park & Goda, 2001). Aims: In keeping with the goal of making assessment procedures as efficient and economic as possible, a study was undertaken to investigate the refinement of the IU metric for increasing the sensitivity of the SRP as an instrument for the detection of connected paragraph-level language production deficits in persons with aphasia. This metric involved the calculation of the percentage of lUs (%IU) produced relative to the time taken to produce them (%IU/Min). Methods & Procedures: A total of 15 persons with aphasia, and 31 normal control individuals without a communication disorder served as participants for this study. Subjects heard, and immediately retold each of 12 stories originally taken from the Discourse Comprehension Test (Brookshire & Nicholas, 1997). The retellings were scored using the procedures outlined by McNeil et al. (2001) with the addition of the %IU calculated over the time of the retelling. Comparisons between subject groups and groups stratified by age, among SRP forms, between scoring methods (%IU vs %IU/Min.), and group misclassification by scoring method were made. Outcome & Results: Application of the %IU/Min with the SRP yielded equivalence among alternate forms as evidenced by non-significant differences and high correlation coefficients among the SRP forms for persons with aphasia. The %IU/Min also decreased the percentage of misclassified aphasic and normal individuals compared to the %IU measure. Older normal subjects were misclassified as aphasic with greater frequency compared to the younger normal subjects. Conclusions: The %IU/Min is a more sensitive metric than the %IU in differentiating individuals with aphasia from older normal controls. C1 Univ Pittsburgh, Passavants Hosp, Pittsburgh, PA 15260 USA. Va Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorder, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. NR 24 TC 9 Z9 9 U1 1 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD AUG PY 2002 VL 16 IS 8 BP 815 EP 822 DI 10.1080/02687030244000284 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 581LQ UT WOS:000177294200004 ER PT J AU Brkanac, Z Bylenok, L Fernandez, M Matsushita, M Lipe, H Wolff, J Nochlin, D Raskind, WH Bird, TD AF Brkanac, Z Bylenok, L Fernandez, M Matsushita, M Lipe, H Wolff, J Nochlin, D Raskind, WH Bird, TD TI A new dominant spinocerebellar ataxia linked to chromosome 19q13.4-qter SO ARCHIVES OF NEUROLOGY LA English DT Article ID CEREBELLAR-ATAXIA; LINKAGE ANALYSIS; FAMILIES; CHANNEL; MAPS AB Background: The autosomal dominant spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of neurodegenerative disorders. Although molecular genetic studies have so far implicated 16 loci in the etiology of these diseases, approximately 30% of families with SCAs remain unlinked. Objectives: To report the location of a gene causing a "pure" autosomal dominant cerebellar ataxia in one family and to describe the clinical phenotype. Patients: We have identified a 4-generation American family of English and Dutch ethnicity with a pure cerebellar ataxia displaying an autosomal dominant pattern of inheritance. The disease typically has its onset in the third and fourth decades of life, shows no evidence of anticipation, progresses slowly, and does not appear to decrease life expectancy. Clinical DNA testing excluded SCA1, 2, 3, 6, 7, and 8. Methods: A genome-wide linkage analysis at a 10 centimorgan (cM) level was performed with samples from 26 family members (11 affected, 10 clinically unaffected at risk, and 5 spouses) Results: Assuming 90% penetrance, we found suggestive evidence of linkage to chromosome 19, with a lod score of 2.49 for D19S571. More detailed mapping in this region provided a maximum 2-point led score of 2.57 at theta = 0 for D19S254 and a maximum multipoint lod score of 4.72 at D19S926. By haplotype construction a 22-cM critical region from D19S601 to the q telomere was defined. Conclusions: We have mapped a gene for an autosomal dominant SCA to chromosome 19q13.4-qter in one family. The critical region overlaps with the locus for SCA14, a disease described in a single Japanese family and characterized by axial myoclonus. Myoclonus was not seen in the family we studied, but it remains possible that the 2 disorders are allelic variants. C1 Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Ohio State Univ, Dept Med, Columbus, OH 43210 USA. Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. RP Raskind, WH (reprint author), Univ Washington, Sch Med, Dept Med, Box 35-7720, Seattle, WA 98195 USA. NR 17 TC 30 Z9 32 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD AUG PY 2002 VL 59 IS 8 BP 1291 EP 1295 DI 10.1001/archneur.59.8.1291 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 583DQ UT WOS:000177391000010 PM 12164726 ER PT J AU Novis, DA Friedberg, RC Renner, SW Meier, FA Walsh, MK AF Novis, DA Friedberg, RC Renner, SW Meier, FA Walsh, MK TI Operating room blood delivery turnaround time - A College of American Pathologists Q-Probes study of 12 647 units of blood components in 466 institutions SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID SMALL HOSPITALS; LABORATORIES; TIMELINESS; EMERGENCY; PERFORMANCE; BIOPSIES AB Objectives.-To determine the normative distribution of time elapsed for blood bank personnel to fill nonscheduled operating room (OR) blood component orders in hospital communities throughout the United States, and to examine hospital blood bank practices associated with faster blood component delivery times. Design-Participants in the College of American Pathologists Q-Probes laboratory quality improvement program collected data prospectively on the times elapsed for blood bank personnel to fill nonscheduled emergent orders from hospital ORs for red blood cell (RBC) products, fresh frozen plasma (FFP), and platelets (PLTs). Participants also completed questionnaires describing their hospitals' and blood banks' laboratory and transfusion practices. Setting and Participants.-Four hundred sixty-six public and private institutions located in 48 states in the United States (n = 444), Canada (n = 9), Australia (n = 8), the United Kingdom (n = 4), and Spain (n = 1). Main Outcome Measures.-The median time elapsed between requests for blood components by OR personnel and the retrieval of those components by blood component transport personnel, and the median time elapsed between requests for blood components by OR personnel and the arrival of those components in ORs. Results.-Participants submitted data on 12 647 units of RBCs, FFP, and PLTs. The median aggregate request-to-retrieval turnaround times (TATs) for RBCs, FFP, and PLTs ranged from 30 to 35 minutes, and the median aggregate request-to-arrival TATs for RBCs, FFP, and PLTs ranged from 33 to 39 minutes. Most of the TAT was consumed by events occurring prior to, rather than after release of components from blood banks. Shorter prerelease TATs were associated with having surgical schedules that listed patients' names and procedures available to blood bank personnel prior to surgeries, and having adequate clotted specimens in the blood bank and completed type-and-screen procedures performed before requests for blood components were submitted to blood banks. Among the fastest-performing 10% of participants (90th percentile and above), request-to-retrieval TATs ranged from 12 to 24 minutes for the 3 blood components, whereas among the slowest-performing 10% of participants (loth percentile and below), request-to-retrieval TATs ranged from 63 to 115 minutes for the 3 components. Median TATs ranged from 33 to 37 minutes for the 3 components. Institutions with TATs in the fastest-performing 25th percentile more frequently stored cross-matched RBCs in the OR daily, stocked PLTs for unexpected surgical use, stored PLTs in or near the OR, and had laboratory rather than nonlaboratory personnel deliver components to the OR than did those institutions with TATs in the slowest-performing 25th percentile. Conclusions.-Hospital blood bank personnel can deliver blood components to the OR in slightly longer than 30 minutes, measured from the time that those units are requested by OR personnel. Practices aimed at saving time before components are released from blood banks will be more efficient in reducing overall TAT than those practices aimed at saving time after components are released from blood banks. Specific practices associated with shorter blood delivery TATs included providing blood bank personnel with access to the names of surgical patients potentially requiring blood components, having pretransfusion testing completed on those patients prior to surgery, having ample blood products on hand, and having laboratory personnel control blood product delivery. C1 Wentworth Douglass Hosp, Dept Pathol, Dover, NH 03820 USA. Baystate Med Ctr, Dept Pathol, Springfield, MA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Alfred I DuPont Hosp Children, Dept Pathol, Wilmington, DE USA. Coll Amer Pathologists, Northfield, IL USA. RP Novis, DA (reprint author), Wentworth Douglass Hosp, Dept Pathol, Dover, NH 03820 USA. NR 20 TC 15 Z9 17 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD AUG PY 2002 VL 126 IS 8 BP 909 EP 914 PG 6 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 585AE UT WOS:000177500300003 PM 12171488 ER PT J AU Whyte, EM Mulsant, BH AF Whyte, EM Mulsant, BH TI Post stroke depression: Epidemiology, pathophysiology, and biological treatment SO BIOLOGICAL PSYCHIATRY LA English DT Review DE stroke; depression; prevalence; etiology; treatment; review ID POSTSTROKE MOOD DISORDERS; GENERALIZED ANXIETY DISORDER; SILENT CEREBRAL INFARCTION; LATE-LIFE DEPRESSION; DOUBLE-BLIND TRIAL; MAJOR DEPRESSION; RISK-FACTORS; FOLLOW-UP; CEREBROVASCULAR LESIONS; ELECTROCONVULSIVE-THERAPY AB Depression is a common occurrence after stroke and is associated with excess disability, cognitive impairment, and mortality. The authors undertook a systematic review of the English language literature to review several aspects of this illness, including the prevalence of this disorder, the debate on its etiology, and the current understanding of the biological treatment of poststroke depression. Methodological problems encountered in the study of poststroke depression are highlighted throughout the manuscript. The authors conclude that the available evidence supports poststroke depression as being multifactorial in origin and consistent with the biopsychosocial model of mental illness. (C) 2002 Society of Biological Psychiatry. C1 Univ Pittsburgh, Sch Med, Dept Psychiat, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA. Pittsburgh VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Mulsant, BH (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, VA Pittsburgh Hlth Care Syst, 3811 O Hara St,TDH,WPID,Room E-837, Pittsburgh, PA 15213 USA. RI crona, malin/B-7085-2012 FU NIMH NIH HHS [MH01613, T32 MH19986] NR 122 TC 219 Z9 253 U1 7 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD AUG 1 PY 2002 VL 52 IS 3 BP 253 EP 264 AR PII S0006-3223(02)01424-5 DI 10.1016/S0006-3223(02)01424-5 PG 12 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 584TG UT WOS:000177484400013 PM 12182931 ER PT J AU Kay, JH Altshuler, LL Ventura, J Mintz, J AF Kay, JH Altshuler, LL Ventura, J Mintz, J TI Impact of axis II comorbidity on the course of bipolar illness in men: a retrospective chart review SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; illness course; personality disorder ID PERSONALITY-DISORDERS; DEPRESSION AB Objectives: The purpose of this study was to investigate whether the presence of comorbid personality disorder influences the course of bipolar illness. Methods: Fifty-two euthymic male bipolar I out-patients were assessed using the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID II). Bipolar patients with an axis II diagnosis were compared with those without an axis II diagnosis on retrospectively obtained demographic, clinical and course of illness variables. Results: Thirty-eight percent of the bipolar patients met criteria for an axis II diagnosis. Two (4%) met criteria for (only) a Cluster A disorder, four (8%) for (only) a Cluster B, and six (12%) for (only) a Cluster C disorder. One (2%) bipolar patient met criteria a disorder in both Clusters A and B, and one (2%) for a disorder in Clusters B and C. Five (10%) met criteria for at least one disorder in Clusters A and C, and one met criteria for disorders in Clusters A, B, and C. The presence of a personality disorder was significantly associated with a lower rate of current employment, a higher number of currently prescribed psychiatric medications, and a higher incidence of a history of both alcohol and substance use disorders compared with the bipolar patients without axis II pathology. Conclusions: Our results extend previous findings of an association between comorbid personality disorder in bipolar I patients and factors that suggest a more difficult course of bipolar illness. C1 Greater Los Angeles VA Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Psychiat, Los Angeles, CA USA. RP Altshuler, LL (reprint author), 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. NR 21 TC 38 Z9 38 U1 0 U2 1 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD AUG PY 2002 VL 4 IS 4 BP 237 EP 242 DI 10.1034/j.1399-5618.2002.01165.x PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 571JK UT WOS:000176714100003 PM 12190712 ER PT J AU Liu, XM Chapman, GB Peyton, KJ Schafer, AI Durante, W AF Liu, XM Chapman, GB Peyton, KJ Schafer, AI Durante, W TI Carbon monoxide inhibits apoptosis in vascular smooth muscle cells SO CARDIOVASCULAR RESEARCH LA English DT Article DE apoptosis; arteries; cell culture/isolation; cytokines; smooth muscle ID SPONTANEOUSLY HYPERTENSIVE RATS; NECROSIS-FACTOR-ALPHA; HEME OXYGENASE; EXPRESSION; PROTEIN; MECHANISMS; INTERLEUKIN-1-BETA; ATHEROSCLEROSIS; INDUCTION; ENZYME AB Objective: Carbon monoxide (CO) is generated from vascular smooth muscle cells via the degradation of heme by the enzyme heme oxygenase-1. Since smooth muscle cell apoptosis is associated with numerous vascular disorders, we investigated whether CO regulates apoptosis in vascular smooth muscle. Methods and Results: Treatment of cultured rat aortic smooth muscle cells with a combination of cytokines (interleukin-1beta, 5 ng/ml; tumor necrosis factor-alpha, 20 ng/ml; interferon-gamma, 200 U/ml) for 48 h stimulated apoptosis, as demonstrated by DNA laddering, annexin V binding, and caspase-3 activation. However, the exogenous administration of CO inhibited cytokine-mediated apoptosis. The antiapoptotic action of CO was partially dependent on the activation of soluble guanylate cyclase and was associated with the inhibition of mitochondrial cytochrome c release and with the suppression of p53 expression. Incubation of smooth muscle cells with the cytokines also resulted in a pronounced increase in heme oxygenase-1 protein after 24 h of stimulation. The addition of the heme oxygenase inhibitor, zinc protoporphyrin-IX, or the CO scavenger, hemoglobin, stimulated apoptosis following 24 h of cytokine exposure. Conclusions: These results demonstrate that CO, either administered exogenously or endogenously derived from heme oxygenase-1 activity, inhibits vascular smooth muscle cell apoptosis. The ability of CO to block smooth muscle cell apoptosis may play an important role in blocking lesion formation at sites of vascular injury. (C) 2002 Elsevier Science B.V. All rights reserved. C1 Houston VA Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. RP Durante, W (reprint author), Houston VA Med Ctr, Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NHLBI NIH HHS [HL36045, HL59976, HL62467] NR 42 TC 122 Z9 128 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0008-6363 J9 CARDIOVASC RES JI Cardiovasc. Res. PD AUG 1 PY 2002 VL 55 IS 2 BP 396 EP 405 AR PII S0008-6363(02)00410-8 DI 10.1016/S0008-6363(02)00410-8 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 582MQ UT WOS:000177355500024 PM 12123779 ER PT J AU Fan, VS Curtis, JR Tu, SP McDonell, MB Fihn, SD AF Fan, VS Curtis, JR Tu, SP McDonell, MB Fihn, SD CA Ambulatory Care Qual Improvement TI Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases SO CHEST LA English DT Article DE hospitalization; mortality; obstructive lung diseases; quality of life ID PULMONARY-DISEASE; OF-LIFE; CO-MORBIDITY; PROGNOSIS; OUTCOMES; EXACERBATION; ASTHMA; CARE AB Study objectives: Condition-specific nreasures of quality of life (QOL) for patients with COPD have been demonstrated to be highly reliable and valid, but they have not conclusively been shown to predict hospitalization or death. Objective: We sought to determine whether a brief, self-administered, COPD-specific QOL measure, the Seattle Obstructive Lung Disease Questionnaire (SOLDQ), could accurately predict hospitalizations and death. Design: Prospective cohort study. Setting. Patients enrolled in the primary care clinics at seven Department of Veterans Affairs (VA) medical centers participating in the Ambulatory Care Quality Improvement Project. Patients: Of 24,458 patients who completed a health inventory, 5,503 reported having chronic lung disease. The 3,282 patients who completed the baseline SOLDQ were followed for 12 months. Measurements: Hospitalization and all-cause mortality during the 1-year follow-up period. Results: During the follow-up period, 601 patients (18.3%) were hospitalized, 141 (4.3%) for COPD exacerbations, and 167 patients (5.1%) died. After adjusting for age, VA. hospital site, distance to die VA hospital, employment status, and smoking status, die relative risk of any hospitalization among patients with scores on the emotional, physical, and coping skills scales of the SOLDQ that were in the lowest quartile, when compared to the highest quartile, were 2.0 (95% confidence interval [CI], 1.5 to 2.6), 2.5 (95% CI, 1.9 to 3.4), and 1.9 (95% CI, 1.5 to 2.5), respectively. When hospitalizations were restricted to those specifically for COPD, the odds ratio (OR) for the lowest quartile of physical function was 6.0 (95% CI, 3.1 to 11.5). Similarly, patients in the lowest quartile of physical function also had an increased risk of death (OR, 6.8; 95% CI, 3.3 to 13.8). When adjusted for comorbidity (OR, 0.8; 95% CI, 0.5 to 1.2), long-term steroid use (OR, 2.8; 95% CI, 1.6 to 4.9), and prior hospitalization for COPD (OR, 4.5; 95% CI, 2.2 to 9.2), patients having baseline SOLDQ physical function scores in the lowest quartile had an odds of hospitalization for COPD that was fivefold higher than patients with scores in the highest quartile (OR, 5.0; 95% CI, 2.6 to 9.7). Conclusions: Lower QOL is a powerful predictor of hospitalization and an-cause mortality. Brief, self-administered instruments such as the SOLDQ may provide an opportunity to identify patients who could benefit from preventive interventions. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. NR 25 TC 124 Z9 127 U1 1 U2 5 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD AUG PY 2002 VL 122 IS 2 BP 429 EP 436 DI 10.1378/chest.122.2.429 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 584CJ UT WOS:000177449400012 PM 12171813 ER PT J AU Kleerup, EC Koyal, SN Marques-Magallanes, JA Goldman, MD Tashkin, DP AF Kleerup, EC Koyal, SN Marques-Magallanes, JA Goldman, MD Tashkin, DP TI Chronic and acute effects of "crack" cocaine on diffusing capacity, membrane diffusion, and pulmonary capillary blood volume in the lung SO CHEST LA English DT Article DE capillary blood volume; cocaine base; cocaine hydrochloride; diffusing capacity; membrane diffusion; tobacco; transfer factor ID CARBON-MONOXIDE; NORMAL VALUES; SMOKERS; USERS; PERMEABILITY; DYSFUNCTION; MARIJUANA; ABUSERS; SMOKING; TOBACCO AB Study objectives: To evaluate possible alterations in the diffusing capacity of the lung for carbon monoxide (DLCO) or its components, membrane diffusing capacity of the lung for carbon monoxide (DMCO) and pulmonary capillary blood volume (Vc), in habitual smokers of "crack" cocaine (with or without tobacco) and following the short-term administration of inhaled cocaine base or IV cocaine HCl. Design: Cross-sectional and longitudinal evaluation of DLCO and its components in smokers of cocaine alone, tobacco alone, and cocaine plus tobacco, and in nonsmokers and ex-smokers. Measurement of possible acute effects on DLCO and its components after experimental short-term administration of IV and smoked cocaine. Setting: University and Veterans Affairs hospital research laboratories. Participants: Convenience sample of habitual smokers of crack cocaine with or without tobacco and matched control nonsmokers and ex-smokers, and smokers of tobacco only. Measurements: DLCO, DMCO, and Vc. Conclusions: Neither habitual cocaine smoking in cross-sectional or longitudinal analysis nor the short-term administration of inhaled alkaloidal cocaine significantly affected DLCO or its component parts. In contrast, a clear cross-sectional effect of regular tobacco smoking was demonstrated. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Kleerup, EC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care, CHS 37-131,Box 951690, Los Angeles, CA 90095 USA. FU NIDA NIH HHS [R01 DA08254, R01 DA008254] NR 41 TC 7 Z9 8 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD AUG PY 2002 VL 122 IS 2 BP 629 EP 638 DI 10.1378/chest.122.2.629 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 584CJ UT WOS:000177449400042 PM 12171843 ER PT J AU Dore, MP Malaty, HM Graham, DY Fanciulli, G Delitala, G Realdi, G AF Dore, MP Malaty, HM Graham, DY Fanciulli, G Delitala, G Realdi, G TI Risk factors associated with Helicobacter pylori infection among children in a defined geographic area SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SOCIOECONOMIC-STATUS; DIAGNOSTIC-TESTS; CHILDHOOD; AGE; EPIDEMIOLOGY; COMMUNITY; COHORT; SEROEPIDEMIOLOGY; TRANSMISSION; PREVALENCE AB Factors influencing the pattern of Helicobacter pylori infection among children living in adjacent urban and rural areas of northern Sardinia, Italy, were compared. The seroprevalence of H. pylori infection was 22% (625 of 2810 children) in the study population and was significantly higher among children in rural areas (37%) than in urban areas (13%) (odds ratio [OR], 3. 8; 95% confidence interval [CI], 3.2- 4.7; P < .005). This difference was consistent within each age group. In rural areas, children who had dogs were at greatest risk for H. pylori infection (OR, 1.8; 95% CI, 1.3-2.6; P < .05). No association was seen between H. pylori seropositivity and a history of breast-feeding. Urban children attending day care centers had a higher prevalence of infection (17%) than did those who never attended (12%) (OR, 1.5; 95% CI, 1.1-2.0; P < .05). The epidemiology of H. pylori infection is complex; even within the same geographic area, different factors influence acquisition of H. pylori infection. C1 Univ Sassari, Ist Clin Med, I-07100 Sassari, Italy. Univ Sassari, Inst Patol Med, I-07100 Sassari, Italy. VA Med Ctr, Gastrointestinal Sect, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Dore, MP (reprint author), Univ Sassari, Ist Clin Med, Viale San Pietro 8, I-07100 Sassari, Italy. NR 34 TC 45 Z9 46 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2002 VL 35 IS 3 BP 240 EP 245 DI 10.1086/341415 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 573QA UT WOS:000176841300004 PM 12115088 ER PT J AU Lipsky, BA Driver, VR Edmiston, CE Thomas, J Wage, JM AF Lipsky, BA Driver, VR Edmiston, CE Thomas, J Wage, JM TI Delivering antibiotics to the lower limb by localized venous perfusion with a novel catheter device SO DIABETOLOGIA LA English DT Meeting Abstract CT 38th EASD Annual Meeting of the European-Association-for-the-Study-of-Diabetes CY SEP 01-05, 2002 CL BUDAPEST, HUNGARY SP European Assoc Study Diabetes (EASD) C1 Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. Madigan Army Med Ctr, Tacoma, WA 98431 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. PharmaSpec Corp, Clin Affairs, Redmond, WA USA. PharmaSpec Corp, Regulatory Affairs, Redmond, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD AUG PY 2002 VL 45 SU 2 MA 1061 BP A343 EP A343 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 590HM UT WOS:000177813601059 ER PT J AU Brady, KT Myrick, H Henderson, S Coffey, SF AF Brady, KT Myrick, H Henderson, S Coffey, SF TI The use of divalproex in alcohol relapse prevention: a pilot study SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE divalproex; alcoholism; withdrawal; hostility; irritability ID DOUBLE-BLIND; GABAPENTIN TREATMENT; CONTROLLED TRIAL; SUBSTANCE USE; DEPENDENCE; WITHDRAWAL; CARBAMAZEPINE; PHARMACOTHERAPY; FLUOXETINE; VALPROATE AB Anticonvulsant agents show promise in the treatment of the acute symptoms of alcohol withdrawal and may also treat some symptoms associated with the protracted abstinence syndrome. Impulsivity, hostility and irritability are common characteristics of alcohol-dependent individuals, and there is some evidence that anticonvulsant agents decrease these traits in individuals with a number of different psychiatric disorders. This pilot study is a 12-week, double-blind, placebo-controlled trial of an anticonvulsant agent, divalproex (DVPX), in alcohol-dependent individuals. Alcohol use (Timeline Follow Back), impulsivity (Barratt Impulsivity Scale), irritability and aggression (Buss-Durkee Hostility Index; and Anger, Irritability, Aggression Scale) were measured at baseline and throughout the 12-week treatment period. Drinking decreased significantly in both the placebo and the DVPX-treated groups. In the DVPX group, a significantly smaller percentage of individuals relapsed to heavy drinking, but there were no significant differences in other alcohol-related outcomes. There were significantly greater decreases in irritability in the DVPX-treated group and a trend towards greater decreases on measures of lability and verbal assault. There were no significant between-group differences on measures of impulsivity. While DVPX did not have a robust effect on alcohol-related outcomes, it did have modest impact on a measure of irritability. This is consistent with the findings of other investigators exploring the use of DVPX in schizophrenia, personality disorder and a number of other psychiatric disorders. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Ctr Drugs & Alcohol Programs, Inst Psychiat & Behav Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. SUNY Buffalo, Buffalo Gen Hosp, Dept Psychiat, Buffalo, NY 14203 USA. RP Brady, KT (reprint author), Med Univ S Carolina, Ctr Drugs & Alcohol Programs, Inst Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA. NR 42 TC 66 Z9 67 U1 1 U2 3 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD AUG 1 PY 2002 VL 67 IS 3 BP 323 EP 330 AR PII S0376-8716(02)00105-9 DI 10.1016/S0376-8716(02)00105-9 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 580EC UT WOS:000177221200011 PM 12127203 ER PT J AU Rosen, MI Rosenheck, RA Shaner, AL Eckman, TA Gamache, GR Krebs, CW AF Rosen, MI Rosenheck, RA Shaner, AL Eckman, TA Gamache, GR Krebs, CW TI Substance abuse and the need for money management assistance among psychiatric inpatients SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE payee; case management; dual diagnosis; substance abuse; social services AB Patients who mismanage their funds may benefit from financial advice, case management or the involuntary assignment of a payee who restricts direct access to funds. Data from a survey of psychiatric inpatients at four VA hospitals (N = 236) was used to evaluate the relationship between substance abuse and clinician-rated need for money management assistance. Multivariate analytic techniques were used to control for sociodemographic factors and psychopathology. Alcohol and drug use severity both were modestly associated with need for assistance. The effect of substance use severity was greater in patients who were also diagnosed with a major mental illness. Clinicians indicated that 27 patients (11% of the sample) required an involuntary payee and 21 of the 27 (78%) had a Substance Abuse diagnosis. Only drug use severity was significantly associated with need for a payee. These data describe a substantial unmet need for money management assistance in psychiatric inpatients, particularly among those with substance abuse disorders. There is a need to examine the process by which the Social Security and Veterans Benefits Administrations assign payees to determine whether patients with co-morbid substance abuse are not being assigned a payee in spite of their discernible need for one. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. C1 VA Connecticut Healthcare Syst, Dept Psychiat 116A, West Haven, CT 06516 USA. W Los Angeles Vet Affairs Med Ctr, Dept Mental Hlth, Los Angeles, CA 90073 USA. Northampton VA Med Ctr, Mental Illness Res Educ & Clin Care Ctr, Leeds, MA 01053 USA. VA Bedford Med Ctr, Mental Illness Res Educ & Clin Care Ctr, Bedford, MA 01730 USA. RP Rosen, MI (reprint author), VA Connecticut Healthcare Syst, Dept Psychiat 116A, Bldg 1,Rm 953-M,950 Campbell Ave, West Haven, CT 06516 USA. FU NIDA NIH HHS [P50-DA09241, R01-DA12952] NR 8 TC 17 Z9 17 U1 1 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD AUG 1 PY 2002 VL 67 IS 3 BP 331 EP 334 AR PII S0376-8716(02)00080-7 DI 10.1016/S0376-8716(02)00080-7 PG 4 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 580EC UT WOS:000177221200012 PM 12127204 ER PT J AU Larson, VD Williams, DW Henderson, WG Luethke, LE Beck, LB Noffsinger, D Bratt, GW Dobie, RA Fausti, SA Haskell, GB Rappaport, BZ Shanks, JE Wilson, RH AF Larson, VD Williams, DW Henderson, WG Luethke, LE Beck, LB Noffsinger, D Bratt, GW Dobie, RA Fausti, SA Haskell, GB Rappaport, BZ Shanks, JE Wilson, RH TI A multi-center, double blind clinical trial comparing benefit from three commonly used hearing aid circuits SO EAR AND HEARING LA English DT Article AB Objective: Although numerous studies have demonstrated that hearing aids provide significant benefit, carefully controlled, multi-center clinical trials have not been conducted. A multi-center clinical trial was conducted to compare the efficacy of three commonly used hearing aid circuits: peak clipping, compression limiting, and wide dynamic range compression. Conclusions: The three hearing aid circuits studied provide significant benefit both in quiet and in noisy listening situations. The two compression hearing aids appear to provide superior benefits compared to the linear circuit, although the differences between the hearing aids were smaller than the differences between unaided and aided conditions. Design: Patients (N = 360) with bilateral, sensorineural hearing loss were studied using a double blind, three-period, three-treatment crossover design. The patients were fit with each of three programmable hearing aid circuits. Outcome tests were administered in the unaided condition at baseline and then after 3 mo usage of each circuit, the tests were administered in both aided and unaided conditions. The outcome test battery included tests of speech recognition, sound quality and subjective scales of hearing aid benefit, including patients' overall rank-order rating of the three circuits. Results: Each hearing aid circuit improved speech recognition markedly, with greater improvement observed for soft and conversationally loud speech in both quiet and noisy listening conditions. In addition, a significant reduction in the problems encountered in communication was observed. Some tests suggested that the two compression hearing aids provided a better listening experience than the peak clipping hearing aid. In the rank-order ratings, patients preferred the compression limiting hearing aid more frequently than the other two hearing aids. Conclusions: The three hearing aid circuits studied provide significant benefit both in quiet and in noisy listening situations. The two compression hearing aids appear to provide superior benefits compared to the linear circuit, although the differences between the hearing aids were smaller than the differences between unaided and aided conditions. C1 Howard Leight Ind, San Diego, CA 92154 USA. Hines VA Cooperat Studies Program Coordinating Ct, Hines, IL USA. Natl Inst Deafness & Other Commun Dis, Bethesda, MD USA. Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Dept Vet Affairs Med Ctr, Washington, DC USA. Dept Vet Affairs Med Ctr, Nashville, TN USA. Dept Vet Affairs Med Ctr, Portland, OR USA. Dept Vet Affairs Med Ctr, Iowa City, IA USA. Dept Vet Affairs Med Ctr, Albuquerque, NM USA. Dept Vet Affairs Med Ctr, Long Beach, CA USA. Dept Vet Affairs Med Ctr, Mountain Home, TN USA. RP Larson, VD (reprint author), Howard Leight Ind, 7828 Waterville Rd, San Diego, CA 92154 USA. OI dobie, robert/0000-0003-3833-1772 NR 22 TC 20 Z9 22 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD AUG PY 2002 VL 23 IS 4 BP 269 EP 276 DI 10.1097/01.AUD.0000027409.90397.E4 PG 8 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 586CN UT WOS:000177566400001 PM 12195168 ER EF